## NIAâ€AA Research Framework: Toward a biological def

Alzheimer's and Dementia 14, 535-562 DOI: 10.1016/j.jalz.2018.02.018

Citation Report

#	Article	IF	CITATIONS
1	Alzheimer disease biomarkers and synucleinopathy. Neurology, 2018, 90, 537-538.	1.1	0
2	NIA commentary on the NIAâ€AA Research Framework: Towards a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 576-578.	0.8	63
3	The End of the Beginning of the Alzheimer's Disease Nightmare: A Devil's Advocate's View. Journal of Alzheimer's Disease, 2018, 64, S41-S46.	2.6	12
4	FDA Guidance and New Drug Approvals. Hospital Pharmacy, 2018, 53, 360-362.	1.0	1
5	Evaluation of the Feasibility of Screening Tau Radiotracers Using an Amyloid Biomathematical Screening Methodology. Computational and Mathematical Methods in Medicine, 2018, 2018, 1-13.	1.3	0
6	Antemortem CSF A <i>β</i> 42/A <i>β</i> 40 ratio predicts Alzheimer's disease pathology better than A <i>β</i> 42 in rapidly progressive dementias. Annals of Clinical and Translational Neurology, 2019, 6, 263-273.	3.7	31
8	Neuropsychiatric Symptoms Complicating the Diagnosis of Alzheimer's Disease: A Case Report. Journal of Alzheimer's Disease, 2018, 66, 1363-1369.	2.6	5
9	Non-Phosphorylated Tau in Cerebrospinal Fluid is a Marker of Alzheimer's Disease Continuum in Young Urbanites Exposed to Air Pollution. Journal of Alzheimer's Disease, 2018, 66, 1437-1451.	2.6	18
10	Blood-Based Kinase Assessments in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 338.	3.4	11
11	Population Health Solutions for Assessing Cognitive Impairment in Geriatric Patients. Innovation in Aging, 2018, 2, igy025.	0.1	15
12	<scp>CSF</scp> progranulin increases in the course of Alzheimer's disease and is associated with <scp>sTREM</scp> 2, neurodegeneration and cognitive decline. EMBO Molecular Medicine, 2018, 10, .	6.9	64
13	Degenerative Amnesia for Past Public Events: An Attempt to Measure Storage and Retrieval. Journal of Alzheimer's Disease, 2018, 66, 1083-1094.	2.6	2
14	Imaging and Molecular Mechanisms of Alzheimer's Disease: A Review. International Journal of Molecular Sciences, 2018, 19, 3702.	4.1	45
15	Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead. Frontiers in Neuroscience, 2018, 12, 798.	2.8	67
16	Disrupted Functional Connectivity of Cornu Ammonis Subregions in Amnestic Mild Cognitive Impairment: A Longitudinal Resting-State fMRI Study. Frontiers in Human Neuroscience, 2018, 12, 413.	2.0	18
17	Functional Decline in Alzheimer's Disease: A Continuum. Journal of the American Geriatrics Society, 2018, 66, 2239-2240.	2.6	0
18	The clinical practice of risk reduction for Alzheimer's disease: A precision medicine approach. Alzheimer's and Dementia, 2018, 14, 1663-1673.	0.8	61
19	Population Health Solutions for Assessing Cognitive Impairment in Geriatric Patients. Clinical Neuropsychologist, 2018, 32, 1193-1225.	2.3	10

ιτλτιώνι Ρερώ

#	Article	IF	CITATIONS
21	Vestibular Function and Beta-Amyloid Deposition in the Baltimore Longitudinal Study of Aging. Frontiers in Aging Neuroscience, 2018, 10, 408.	3.4	6
22	Gradual Disturbances of the Amplitude of Low-Frequency Fluctuations (ALFF) and Fractional ALFF in Alzheimer Spectrum. Frontiers in Neuroscience, 2018, 12, 975.	2.8	135
23	Regional tau pathology and loneliness in cognitively normal older adults. Translational Psychiatry, 2018, 8, 282.	4.8	46
24	Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease –conformist, nonconformist, and realistic prospects for AD pathogenesis. Translational Neurodegeneration, 2018, 7, 34.	8.0	77
25	Efficacy and mechanisms of combined aerobic exercise and cognitive training in mild cognitive impairment: study protocol of the ACT trial. Trials, 2018, 19, 700.	1.6	18
26	The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 124.	6.2	273
27	Advances in Resting State Neuroimaging of Mild Cognitive Impairment. Frontiers in Psychiatry, 2018, 9, 671.	2.6	14
28	Alzheimer's disease in Down syndrome: An overlooked population for prevention trials. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 703-713.	3.7	63
29	Ethical Arguments Concerning the Use of Alzheimer's Disease Biomarkers in Individuals with No or Mild Cognitive Impairment: A Systematic Review and Framework for Discussion. Journal of Alzheimer's Disease, 2018, 66, 1309-1322.	2.6	27
30	Cerebrospinal fluid neurogranin/βâ€site APPâ€cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 617-627.	3.7	24
31	Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 563-572.	2.4	52
32	Amyloid and FDG PET of Successful Cognitive Aging: Global and Cingulate-Specific Differences. Journal of Alzheimer's Disease, 2018, 66, 307-318.	2.6	20
33	Amyloidâ€associated increases in longitudinal report of subjective cognitive complaints. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 444-449.	3.7	51
34	In vivo Brainstem Imaging in Alzheimer's Disease: Potential for Biomarker Development. Frontiers in Aging Neuroscience, 2018, 10, 266.	3.4	12
35	Association between white matter lesions and cerebral $A\hat{I}^2$ burden. PLoS ONE, 2018, 13, e0204313.	2.5	14
36	Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 98.	6.2	25
37	Critical role of mitosis in spontaneous late-onset Alzheimer's disease; from a Shugoshin 1 cohesinopathy mouse model. Cell Cycle, 2018, 17, 2321-2334.	2.6	7
38	Study partners: essential collaborators in discovering treatments for Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 101.	6.2	29

#	Article	IF	CITATIONS
39	Alzheimer's disease (AD) therapeutics – 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality. Biochemical Pharmacology, 2018, 158, 359-375.	4.4	59
40	Alzheimer's disease (AD) therapeutics – 2: Beyond amyloid – Re-defining AD and its causality to discover effective therapeutics. Biochemical Pharmacology, 2018, 158, 376-401.	4.4	24
41	Vitamin D3 as a potentially modifiable factor in mild cognitive impairment. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1236-1236.	1.9	0
42	The role of brain vasculature in neurodegenerative disorders. Nature Neuroscience, 2018, 21, 1318-1331.	14.8	612
43	Aβ and the dementia syndrome: Simple versus complex perspectives. European Journal of Clinical Investigation, 2018, 48, e13025.	3.4	11
44	Primary prevention of dementia: from modifiable risk factors to a public brain health agenda?. Social Psychiatry and Psychiatric Epidemiology, 2018, 53, 1289-1301.	3.1	47
45	Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. Brain, 2018, 141, 3233-3248.	7.6	24
46	Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1505-1521.	0.8	163
47	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. Alzheimer's Research and Therapy, 2018, 10, 112.	6.2	46
48	Aberrant functional connectivity network in subjective memory complaint individuals relates to pathological biomarkers. Translational Neurodegeneration, 2018, 7, 27.	8.0	34
49	Systematic Review on Resting-State EEG for Alzheimer's Disease Diagnosis and Progression Assessment. Disease Markers, 2018, 2018, 1-26.	1.3	195
50	Tau PET imaging evidence in patients with cognitive impairment: preparing for clinical use. Clinical and Translational Imaging, 2018, 6, 471-482.	2.1	3
51	CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 782-790.	2.4	26
52	Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease. Acta Neuropathologica, 2018, 136, 663-689.	7.7	151
54	Diagnosis of neurodegenerative dementia: where do we stand, now?. Annals of Translational Medicine, 2018, 6, 340-340.	1.7	24
55	Atrophy, metabolism and cognition in the posterior cortical atrophy spectrum based on Alzheimer's disease cerebrospinal fluid biomarkers. NeuroImage: Clinical, 2018, 20, 1018-1025.	2.7	21
56	Population Health Solutions for Assessing Cognitive Impairment in Geriatric Patients. Archives of Clinical Neuropsychology, 2018, 33, 655-675.	0.5	5
57	Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-Î <sup>2</sup> 42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Molecular Neurodegeneration, 2018, 13, 57.	10.8	164

#	ARTICLE	IF	CITATIONS
58	An MRI biomarker of mixed pathology. Neurology, 2018, 91, 682-683.	1.1	3
59	Automation vs. Experience: Measuring Alzheimer's Beta-Amyloid 1–42 Peptide in the CSF. Frontiers in Aging Neuroscience, 2018, 10, 253.	3.4	25
60	Combination therapy for Alzheimer's disease: Are we ready?. Alzheimer's and Dementia, 2018, 14, 1232-1233.	0.8	1
61	Discriminative Accuracy of [ <sup>18</sup> F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2018, 320, 1151.	7.4	298
62	A standard model of Alzheimer's disease?. Prion, 2018, 12, 261-265.	1.8	20
63	Neuropathologic Correlates of Psychiatric Symptoms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 66, 115-126.	2.6	133
64	Diagnostic challenges in rapidly progressive dementia. Expert Review of Neurotherapeutics, 2018, 18, 761-772.	2.8	29
65	Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias. Proteomes, 2018, 6, 32.	3.5	52
66	Plasma Amyloid as Prescreener for the Earliest <scp>A</scp> lzheimer Pathological Changes. Annals of Neurology, 2018, 84, 648-658.	5.3	230
67	Widespread distribution of tauopathy in preclinical Alzheimer's disease. Neurobiology of Aging, 2018, 72, 177-185.	3.1	42
68	Antioxidants and risk of dementia. Current Opinion in Lipidology, 2018, 29, 424-425.	2.7	1
69	Relationship Between Amyloid-Î <sup>2</sup> Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1313-1325.	2.6	19
70	Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 413-420.	2.4	9
71	PET/CT of Dementia. American Journal of Roentgenology, 2018, 211, 246-259.	2.2	18
72	Broadening the scope of epidemiologic dementia research. European Journal of Epidemiology, 2018, 33, 617-620.	5.7	2
73	Biomarkers of agitation and aggression in Alzheimer's disease: A systematic review. , 2018, 14, 1344-1376.		31
74	Not all, but specific types of cognitive complaints predict decline to MCI. Neurology, 2018, 91, 153-154.	1.1	6
75	A new era for dementia epidemiology: Alzheimer's disease, hardening of arteries, or just old age?. European Journal of Epidemiology, 2018, 33, 613-616.	5.7	5

#	ARTICLE	IF	CITATIONS
76	The contribution of small vessel disease to subtypes of Alzheimer's disease: a study on cerebrospinal fluid and imaging biomarkers. Neurobiology of Aging, 2018, 70, 18-29.	3.1	48
77	Distinct Cognitive and Brain Morphological Features in Healthy Subjects Unaware of Informant-Reported Cognitive Decline. Journal of Alzheimer's Disease, 2018, 65, 181-191.	2.6	15
78	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. Alzheimer's Research and Therapy, 2018, 10, 72.	6.2	34
79	Phenotypic Heterogeneity in Dementia: A Challenge for Epidemiology and Biomarker Studies. Frontiers in Public Health, 2018, 6, 181.	2.7	55
80	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology, 2018, 91, e867-e877.	1.1	207
81	Biomarkers for Alzheimer's disease: current status and prospects for the future. Journal of Internal Medicine, 2018, 284, 643-663.	6.0	550
82	Levels of ADAM10 are reduced in Alzheimer's disease CSF. Journal of Neuroinflammation, 2018, 15, 213.	7.2	39
83	Subjective Cognitive Decline and APOE ɛ4: A Systematic Review. Journal of Alzheimer's Disease, 2018, 65, 303-320.	2.6	32
84	Alzheimer's disease is getting easier to spot. Nature, 2018, 559, S10-S12.	27.8	14
85	Which is to blame for cognitive decline in ageing: amyloid deposition, neurodegeneration or both?. Brain, 2018, 141, 2237-2241.	7.6	5
86	Role of FABP3 as biomarker in Alzheimer's disease and synucleinopathies. Future Neurology, 2018, 13, 199-207.	0.5	25
87	Editorial: Dementia, Frailty and Aging. Frontiers in Medicine, 2018, 5, 168.	2.6	13
88	Using the A/T/N Framework to Examine Driving in Preclinical Alzheimer's Disease. Geriatrics (Switzerland), 2018, 3, 23.	1.7	6
89	Recent advancements toward therapeutic vaccines against Alzheimer's disease. Expert Review of Vaccines, 2018, 17, 707-721.	4.4	46
90	The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults. Intelligence, 2018, 70, 22-29.	3.0	13
91	Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 609.	2.8	59
92	InÂvivo mapping of brainstem nuclei functional connectivity disruption in Alzheimer's disease. Neurobiology of Aging, 2018, 72, 72-82.	3.1	58
93	The genetic risk of Alzheimer's disease beyond APOE ε4: systematic review of Alzheimer's genetic risk scores. Translational Psychiatry, 2018, 8, 166.	4.8	76

#	Article	IF	CITATIONS
94	Left lateralized cerebral glucose metabolism declines in amyloid-Î <sup>2</sup> positive persons with mild cognitive impairment. Neurolmage: Clinical, 2018, 20, 286-296.	2.7	64
95	Common Variant in PLD3 Influencing Cerebrospinal Fluid Total Tau Levels and Hippocampal Volumes in Mild Cognitive Impairment Patients from the ADNI Cohort. Journal of Alzheimer's Disease, 2018, 65, 871-876.	2.6	7
96	Biomarkers of dementia in obstructive sleep apnea. Sleep Medicine Reviews, 2018, 42, 139-148.	8.5	63
97	How early can we diagnose Alzheimer disease (and is it sufficient)?. Neurology, 2018, 91, 395-402.	1.1	60
98	A simple and clinically relevant combination of neuroimaging and functional indexes for the identification of those at highest risk of Alzheimer's disease. Neurobiology of Aging, 2018, 69, 102-110.	3.1	8
99	Will biomarker-based diagnosis of Alzheimer's disease maximize scientific progress? Evaluating proposed diagnostic criteria. European Journal of Epidemiology, 2018, 33, 607-612.	5.7	31
100	Stopping Cognitive Decline in Patients With Late-Life Depression: A New Front in the Fight Against Dementia. American Journal of Geriatric Psychiatry, 2018, 26, 828-834.	1.2	5
101	A systemsâ€based model of Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 168-171.	0.8	26
102	Evaluation of Cerebrospinal Fluid Neurofilament Light Chain as a Routine Biomarker in a Memory Clinic. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 442-445.	3.6	17
103	Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI. Alzheimer's Research and Therapy, 2019, 11, 72.	6.2	23
104	Novel Pharmacologic Strategies for Treating Behavioral Disturbances in Alzheimer's Disease. Current Behavioral Neuroscience Reports, 2019, 6, 72-87.	1.3	1
105	Visualizing Alzheimer's disease progression in low dimensional manifolds. Heliyon, 2019, 5, e02216.	3.2	6
106	Increased Gain in the Auditory Pathway, Alzheimer's Disease Continuum, and Air Pollution: Peripheral and Central Auditory System Dysfunction Evolves Across Pediatric and Adult Urbanites. Journal of Alzheimer's Disease, 2019, 70, 1275-1286.	2.6	15
107	Lipid and Lipid Raft Alteration in Aging and Neurodegenerative Diseases: A Window for the Development of New Biomarkers. International Journal of Molecular Sciences, 2019, 20, 3810.	4.1	108
108	Bloodâ€based biomarkers for Down syndrome and Alzheimer's disease: A systematic review. Developmental Neurobiology, 2019, 79, 699-710.	3.0	16
109	The basis of cellular and regional vulnerability in Alzheimer's disease. Acta Neuropathologica, 2019, 138, 729-749.	7.7	73
110	Dementia Around the World and the Latin America and Mexican Scenarios. Journal of Alzheimer's Disease, 2019, 71, 1-5.	2.6	14
111	Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults. JAMA Network Open, 2019, 2, e198964.	5.9	72

ARTICLE IF CITATIONS Alzheimer's disease and other neurodegenerative dementias in comorbidity: A clinical and 1.9 84 112 neuropathological overview. Clinical Biochemistry, 2019, 73, 26-31. Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal 0.8 study. Alzheimer's and Dementia, 2019, 15, 1208-1217. Cerebral changes improved by physical activity during cognitive decline: A systematic review on MRI 114 2.7 68 studies. NeuroImage: Clinical, 2019, 23, 101933. Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease. NeuroImage: Clinical, 2019, 24, 101949.  $\hat{l}^2$ -amyloid pathology and hippocampal atrophy are independently associated with memory function in 116 3.3 28 cognitively healthy elderly. Scientific Reports, 2019, 9, 11180. Advances in screening instruments for Alzheimer's disease. Aging Medicine (Milton (N S W)), 2019, 2, 2.1 88-93. Depression, subjective cognitive decline, and the risk of neurocognitive disorders. Alzheimer's 118 6.2 61 Research and Therapy, 2019, 11, 70. Safranal, an active ingredient of saffron, attenuates cognitive deficits in amyloid 12-induced rat model 119 2.9 46 of Alzheimer's disease: underlying mechanisms. Metabolic Brain Disease, 2019, 34, 1747-1759. Added value of amyloid PET in individualized risk predictions for MCI patients. Alzheimer's and 120 2.4 8 Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 529-537. Assessing costâ€effectiveness of early intervention in Alzheimer's disease: An openâ€source modeling 0.8 38 framework. Alzheimer's and Dementia, 2019, 15, 1309-1321. Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior 122 3.142 white matter regions. Neurobiology of Aging, 2019, 84, 225-234. Default Mode Network Connectivity Moderates the Relationship Between the APOE Genotype and Cognition and Individualizes Identification Across the Alzheimer's Disease Spectrum. Journal of 2.6 Alzheimer's Disease, 2019, 70, 843-860. Linking Molecular Pathways and Large-Scale Computational Modeling to Assess Candidate Disease 124 Mechanisms and Pharmacodynamics in Alzheimer's Disease. Frontiers in Computational Neuroscience, 2.1 83 2019, 13, 54. Validation of the RUDAS in Patients With a Middle-Level Education in Lima, Peru. American Journal of Alzheimer's Disease and Other Dementias, 2019, 34, 513-522. Which features of subjective cognitive decline are related to amyloid pathology? Findings from the 127 6.2 74 DELCODE study. Alzheimer's Research and Therapy, 2019, 11, 66. Role of Resveratrol and Selenium on Oxidative Stress and Expression of Antioxidant and Anti-Aging 69 Genes in Immortalized Lymphocytes from Alzheimer's Disease Patients. Nutrients, 2019, 11, 1764. Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers 129 0.8 45 and cognition in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 1149-1159. The neuropathological diagnosis of Alzheimer's disease. Molecular Neurodegeneration, 2019, 14, 32. 1,497

#	Article	IF	CITATIONS
131	European Ultrahighâ€Field Imaging Network for Neurodegenerative Diseases (EUFIND). Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 538-549.	2.4	17
132	Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Journal of Neuroscience, 2019, 39, 7428-7437.	3.6	19
133	A Multimodal Approach to Stratification of Patients with Dementia: Selection of Mixed Dementia Patients Prior to Autopsy. Brain Sciences, 2019, 9, 187.	2.3	7
134	Diagnosing and Treating Depression in Patients with Alzheimer's Disease. Neurology and Therapy, 2019, 8, 325-350.	3.2	67
135	Diagnostic performance of regional cerebral blood flow images derived from dynamic PIB scans in Alzheimer's disease. EJNMMI Research, 2019, 9, 59.	2.5	19
136	Current radiotracers to image neurodegenerative diseases. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 17.	3.9	28
137	Reduction of Glycolysis Intermediate Concentrations in the Cerebrospinal Fluid of Alzheimer's Disease Patients. Frontiers in Neuroscience, 2019, 13, 871.	2.8	24
138	Insights into Computational Drug Repurposing for Neurodegenerative Disease. Trends in Pharmacological Sciences, 2019, 40, 565-576.	8.7	70
139	Assessment of lipid peroxidation and artificial neural network models in early Alzheimer Disease diagnosis. Clinical Biochemistry, 2019, 72, 64-70.	1.9	14
140	Early Prediction Of Alzheimer's Disease Dementia Based On Baseline Hippocampal MRI and 1-Year Follow-Up Cognitive Measures Using Deep Recurrent Neural Networks. , 2019, 2019, 368-371.		40
141	Brain Molecular Connectivity in Neurodegenerative Diseases: Recent Advances and New Perspectives Using Positron Emission Tomography. Frontiers in Neuroscience, 2019, 13, 617.	2.8	54
142	Detecting Alzheimer's Disease from Continuous Speech Using Language Models. Journal of Alzheimer's Disease, 2019, 70, 1163-1174.	2.6	19
143	Highly Elevated Cerebrospinal Fluid Total Tau Level Reflects Higher Likelihood of Non-Amnestic Subtype of Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 70, 1051-1058.	2.6	21
144	The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease. Journal of Parkinson's Disease, 2019, 9, 553-563.	2.8	29
145	Clinical utility of 18F-FDG-PET/MRI brain in dementia: Preliminary experience from a geriatric clinic in South India. Asian Journal of Psychiatry, 2019, 44, 99-105.	2.0	10
146	The Challenge of Defining Alzheimer Disease Based on Biomarkers in the Absence of Symptoms. JAMA Neurology, 2019, 76, 1143.	9.0	4
147	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer's Association Research Framework. JAMA Neurology, 2019, 76, 1174.	9.0	182
148	Associations of Physical Activity and β-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. JAMA Neurology, 2019, 76, 1203.	9.0	97

#	Article	IF	CITATIONS
149	Air Pollution, Combustion and Friction Derived Nanoparticles, and Alzheimer's Disease in Urban Children and Young Adults. Journal of Alzheimer's Disease, 2019, 70, 343-360.	2.6	23
150	Preclinical Alzheimer Disease—Early Diagnosis or Overdiagnosis?. JAMA Internal Medicine, 2019, 179, 1161.	5.1	19
151	Current and emerging avenues for Alzheimer's disease drug targets. Journal of Internal Medicine, 2019, 286, 398-437.	6.0	102
152	Which Episodic Memory Performance is Associated with Alzheimer's Disease Biomarkers in Elderly Cognitive Complainers? Evidence from a Longitudinal Observational Study with Four Episodic Memory Tests (Insight-PreAD). Journal of Alzheimer's Disease, 2019, 70, 811-824.	2.6	16
153	Combustion and friction-derived nanoparticles and industrial-sourced nanoparticles: The culprit of Alzheimer and Parkinson's diseases Environmental Research, 2019, 176, 108574.	7.5	55
154	Alzheimer's disease drug development pipeline: 2019. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 272-293.	3.7	546
155	Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time. Alzheimer's Research and Therapy, 2019, 11, 61.	6.2	30
156	ANTI-TAU TRIALS FOR ALZHEIMER'S DISEASE: A REPORT FROM THE EU/US/CTAD TASK FORCE. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-7.	2.7	48
157	Relationships Between Diffusion Tensor Imaging and Cerebrospinal Fluid Metrics in Early Stages of the Alzheimer's Disease Continuum. Journal of Alzheimer's Disease, 2019, 70, 965-981.	2.6	20
158	Can Subjective Memory Complaints Identify Aβ Positive and Aβ Negative Amnestic Mild Cognitive Impairment Patients?. Journal of Alzheimer's Disease, 2019, 70, 1103-1111.	2.6	4
159	Trends in Glycolipid Biomarker Discovery in Neurodegenerative Disorders by Mass Spectrometry. Advances in Experimental Medicine and Biology, 2019, 1140, 703-729.	1.6	13
160	Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression. Acta Neuropathologica Communications, 2019, 7, 120.	5.2	64
161	Sulcal morphology in Alzheimer's disease: an effective marker of diagnosis and cognition. Neurobiology of Aging, 2019, 84, 41-49.	3.1	23
162	Tau and atrophy: domain-specific relationships with cognition. Alzheimer's Research and Therapy, 2019, 11, 65.	6.2	37
163	Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set. Alzheimer's Research and Therapy, 2019, 11, 64.	6.2	47
164	Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. JAMA Network Open, 2019, 2, e197978.	5.9	142
165	Staging the cognitive continuum in prodromal Alzheimer's disease with episodic memory. Neurobiology of Aging, 2019, 84, 1-8.	3.1	22
166	How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years. BMJ Open, 2019, 9, e029663.	1.9	16

#	Article	IF	CITATIONS
167	Linked CSF reduction of phosphorylated tau and IL-8 in HIV associated neurocognitive disorder. Scientific Reports, 2019, 9, 8733.	3.3	14
168	Retinal thickness as a potential biomarker in patients with amyloidâ€proven early―and lateâ€onset Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 463-471.	2.4	25
169	Development of a transcallosal tractography template and its application to dementia. NeuroImage, 2019, 200, 302-312.	4.2	28
170	Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum. NeuroImage: Clinical, 2019, 23, 101895.	2.7	28
171	The Multilingual Naming Test (MINT) as a Measure of Picture Naming Ability in Alzheimer's Disease. Journal of the International Neuropsychological Society, 2019, 25, 821-833.	1.8	26
172	Predicting Risk for Dementia: Is It Ready for the Clinic?. American Journal of Psychiatry, 2019, 176, 501-502.	7.2	3
173	A Birth Cohort Analysis of Amnestic Mild Cognitive Impairment Incidence in the Einstein Aging Study (EAS) Cohort. Journal of Alzheimer's Disease, 2019, 70, S271-S281.	2.6	6
174	Alzheimer's disease: Key developments support promising perspectives for therapy. Pharmacological Research, 2019, 146, 104316.	7.1	17
175	FDC-PET as an independent biomarker for Alzheimer's biological diagnosis: a longitudinal study. Alzheimer's Research and Therapy, 2019, 11, 57.	6.2	90
176	Plasma totalâ€ŧau as a biomarker of stroke risk in the community. Annals of Neurology, 2019, 86, 463-467.	5.3	15
177	Consequences of Metabolic Disruption in Alzheimer's Disease Pathology. Neurotherapeutics, 2019, 16, 600-610.	4.4	51
178	Alzheimer's disease frequency peaks in the tenth decade and is lower afterwards. Acta Neuropathologica Communications, 2019, 7, 104.	5.2	26
179	Das Demenzsyndrom und KomorbiditÃ <b>z</b> en. , 2019, , 13-31.		1
180	Applying the ATN scheme in a memory clinic population. Neurology, 2019, 93, e1635-e1646.	1.1	51
181	Reformulating Pro-Oxidant Microglia in Neurodegeneration. Journal of Clinical Medicine, 2019, 8, 1719.	2.4	47
182	Developments and debates on latent variable modeling in diagnostic studies when there is no gold standard. Biostatistics and Epidemiology, 2019, , 1-18.	0.4	0
183	Association of Acquired and Heritable Factors With Intergenerational Differences in Age at Symptomatic Onset of Alzheimer Disease Between Offspring and Parents With Dementia. JAMA Network Open, 2019, 2, e1913491.	5.9	11
184	Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. Alzheimer's Research and Therapy, 2019, 11, 84.	6.2	28

ARTICLE IF CITATIONS # Transcriptional Networks of Microglia in Alzheimer's Disease and Insights into Pathogenesis. Genes, 185 2.4 19 2019, 10, 798. VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. International Journal 4.1 of Molecular Sciences, 2019, 20, 4674. Blood Pressure Variability and Progression of Clinical Alzheimer Disease. Hypertension, 2019, 74, 187 2.7 60 1172-1180. Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The 188 ABIDE project. Alzheimer's and Dementia, 2019, 15, 1458-1467. A combined miRNA–piRNA signature to detect Alzheimer's disease. Translational Psychiatry, 2019, 9, 250. 189 4.8 74 The Role of Physical Fitness in Cognitive-Related Biomarkers in Persons at Genetic Risk of Familial Alzheimer's Disease. Journal of Clinical Medicine, 2019, 8, 1639. 2.4 Associating Cognition With Amyloid Status Using Partially Ordered Set Analysis. Frontiers in 191 2.4 3 Neurology, 2019, 10, 976. The dawn of robust individualised risk models for dementia. Lancet Neurology, The, 2019, 18, 985-987. 10.2 Amyloid-Î<sup>2</sup> peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. Alzheimer's 193 6.2 23 Research and Therapy, 2019, 11, 83. Inter-method and anatomical correlates of episodic memory tests in the Alzheimer's Disease spectrum. 194 2.5 PLoS ONE, 2019, 14, e0223731. Recognition Memory Performance as a Cognitive Marker of Prodromal Alzheimer's Disease. Journal of 195 17 2.6 Alzheimer's Disease, 2019, 72, 507-514. Clinical Characteristics in Subjective Cognitive Decline with and without Worry: Baseline 2.6 Investigation of the SILCODE Study. Journal of Alzheimer's Disease, 2019, 72, 443-454. Association of Apolipoprotein E É>4, Educational Level, and Sex With Tau Deposition and Tau-Mediated 197 5.9 41 Metabolic Dysfunction in Older Adults. JAMA Network Open, 2019, 2, e1913909. Subjective Cognitive Decline and Biomarkers of Preclinical Alzheimer's Disease. Current Behavioral 198 1.3 Neuroscience Reports, 2019, 6, 219-226. Brain Amyloid-l<sup>2</sup> Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's 199 2.6 28 Disease. Journal of Alzheimer's Disease, 2019, 69, 169-178. Amyloid PET, FDG-PET or MRI? - the power of different imaging biomarkers to detect progression of 1.8 early Alzheimer's disease. BMC Neurology, 2019, 19, 264. Cognition at age 70. Neurology, 2019, 93, e2144-e2156. 201 1.1 37 Association between enrollment factors and incident cognitive impairment in Blacks and Whites: Data 64 from the Alzheimer's Disease Center. Alzheimer's and Dementia, 2019, 15, 1533-1545.

#	Article	IF	CITATIONS
203	Comparison of variables associated with cerebrospinal fluid neurofilament, totalâ€ŧau, and neurogranin. Alzheimer's and Dementia, 2019, 15, 1437-1447.	0.8	38
204	Individualized clinical management of patients at risk for Alzheimer's dementia. Alzheimer's and Dementia, 2019, 15, 1588-1602.	0.8	49
205	Extracellular vesicles as an emerging tool for the early detection of Alzheimer's disease. Mechanisms of Ageing and Development, 2019, 184, 111175.	4.6	47
206	The Cortical Neuroanatomy Related to Specific Neuropsychological Deficits in Alzheimer's Continuum. Dementia and Neurocognitive Disorders, 2019, 18, 77.	1.4	85
207	When Does Alzheimer′s Disease Really Start? The Role of Biomarkers. International Journal of Molecular Sciences, 2019, 20, 5536.	4.1	57
208	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Molecular Medicine, 2019, 11, e11170.	6.9	228
209	Methodological Issues in the Clinical Validation of Biomarkers for Alzheimer's Disease: The Paradigmatic Example of CSF. Frontiers in Aging Neuroscience, 2019, 11, 282.	3.4	8
210	Meta-Analysis of Gene Expression Changes in the Blood of Patients with Mild Cognitive Impairment and Alzheimer's Disease Dementia. International Journal of Molecular Sciences, 2019, 20, 5403.	4.1	29
211	AD molecular: Imaging tau aggregates with positron emissions tomography. Progress in Molecular Biology and Translational Science, 2019, 165, 107-138.	1.7	10
212	Practical algorithms for amyloid β probability in subjective or mild cognitive impairment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 710-720.	2.4	8
213	Impaired tau–microtubule interactions are prevalent among pathogenic tau variants arising from missense mutations. Journal of Biological Chemistry, 2019, 294, 18488-18503.	3.4	23
214	Somatostatin Receptor Subtype-4 Regulates mRNA Expression of Amyloid-Beta Degrading Enzymes and Microglia Mediators of Phagocytosis in Brains of 3xTg-AD Mice. Neurochemical Research, 2019, 44, 2670-2680.	3.3	15
215	Proteins and microRNAs are differentially expressed in tear fluid from patients with Alzheimer's disease. Scientific Reports, 2019, 9, 15437.	3.3	63
216	Diagnosis and Management of Dementia: Review. JAMA - Journal of the American Medical Association, 2019, 322, 1589.	7.4	675
217	Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. Annals of Clinical and Translational Neurology, 2019, 6, 1815-1824.	3.7	104
218	Tauopathy in veterans with long-term posttraumatic stress disorder and traumatic brain injury. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1139-1151.	6.4	51
219	"Alzheimer's disease―is neither "Alzheimer's clinical syndrome―nor "dementia― Alzheimer's and Dementia, 2019, 15, 153-157.	0.8	23
220	Biomarker Localization, Analysis, Visualization, Extraction, and Registration (BLAzER) Methodology for Research and Clinical Brain PET Applications. Journal of Alzheimer's Disease, 2019, 70, 1241-1257.	2.6	4

#	Article	IF	CITATIONS
221	Two distinct pathological substrates associated with MMSE-pentagons item deficit in DLB and AD. Neuropsychologia, 2019, 133, 107174.	1.6	12
222	Guidelines for CSF Processing and Biobanking: Impact on the Identification and Development of Optimal CSF Protein Biomarkers. Methods in Molecular Biology, 2019, 2044, 27-50.	0.9	19
223	Large-Artery Stiffness in Health andÂDisease. Journal of the American College of Cardiology, 2019, 74, 1237-1263.	2.8	512
224	Genomeâ€wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. Alzheimer's and Dementia, 2019, 15, 1333-1347.	0.8	111
225	Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 364-373.	3.7	11
226	Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. Science Translational Medicine, 2019, 11, .	12.4	192
227	Biomarker-Based Signature of Alzheimer's Disease in Pre-MCI Individuals. Brain Sciences, 2019, 9, 213.	2.3	15
228	Optimizing Machine Learning Methods to Improve Predictive Models of Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 71, 1027-1036.	2.6	26
229	APPLICATION OF THE NIA-AA RESEARCH FRAMEWORK: TOWARDS A BIOLOGICAL DEFINITION OF ALZHEIMER' DISEASE USING CEREBROSPINAL FLUID BIOMARKERS IN THE AIBL STUDY. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-8.	™S 2.7	20
230	Cerebrospinal fluid amyloid levels are associated with delayed memory retention in cognitively normal biomarker-negative older adults. Neurobiology of Aging, 2019, 84, 90-97.	3.1	4
231	Overview of Transgenic Mouse Models for Alzheimer's Disease. Current Protocols in Neuroscience, 2019, 89, e81.	2.6	78
233	Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. Alzheimer's Research and Therapy, 2019, 11, 74.	6.2	28
234	Amyloid-β PET—Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic. PLoS ONE, 2019, 14, e0221365.	2.5	37
235	Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer's disease and associated with CSF-TAU and FDG-PET. Translational Neurodegeneration, 2019, 8, 25.	8.0	11
236	The Future of Nuclear Medicine as an Independent Specialty. Journal of Nuclear Medicine, 2019, 60, 3S-12S.	5.0	47
237	AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention. Progress in Molecular Biology and Translational Science, 2019, 165, 63-106.	1.7	10
238	InÂvivo measures of tau burden are associated with atrophy in early Braak stage medial temporal lobe regions in amyloidâ€negative individuals. Alzheimer's and Dementia, 2019, 15, 1286-1295.	0.8	24
239	The search for meaning in preclinical Alzheimer disease clinical trials. Neurology, 2019, 93, 139-140.	1.1	1

#	Article	IF	CITATIONS
240	Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer's disease. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1875-1881.	2.3	20
241	The "rights―of precision drug development for Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 76.	6.2	148
242	Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 382-387.	3.7	34
243	Ageing as a risk factor for neurodegenerative disease. Nature Reviews Neurology, 2019, 15, 565-581.	10.1	1,578
244	Application of T1-/T2-Weighted Ratio Mapping to Elucidate Intracortical Demyelination Process in the Alzheimer's Disease Continuum. Frontiers in Neuroscience, 2019, 13, 904.	2.8	23
245	Conceptual, Regulatory and Strategic Imperatives in the Early Days of EEG-Based Biomarker Validation for Neurodevelopmental Disabilities. Frontiers in Integrative Neuroscience, 2019, 13, 45.	2.1	48
246	Refining the understanding of typical Alzheimer disease. Nature Reviews Neurology, 2019, 15, 623-624.	10.1	3
247	The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	7.6	129
248	Depletion of Caveolin-1 in Type 2 Diabetes Model Induces Alzheimer's Disease Pathology Precursors. Journal of Neuroscience, 2019, 39, 8576-8583.	3.6	37
249	The Alzheimer's Disease Exposome. Alzheimer's and Dementia, 2019, 15, 1123-1132.	0.8	58
250	Exercise Training in Amnestic Mild Cognitive Impairment: A One-Year Randomized Controlled Trial. Journal of Alzheimer's Disease, 2019, 71, 421-433.	2.6	51
251	Memorability of photographs in subjective cognitive decline and mild cognitive impairment: Implications for cognitive assessment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 610-618.	2.4	17
252	Interaction between the progression of Alzheimer's disease and fractal degradation. Neurobiology of Aging, 2019, 83, 21-30.	3.1	22
253	Perceptions of precision medicine among diverse dementia caregivers and professional providers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 468-474.	3.7	6
254	Plasma lipocalinâ€2 levels in the preclinical stage of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 646-653.	2.4	22
255	Discordant amyloid-β PET and CSF biomarkers and its clinical consequences. Alzheimer's Research and Therapy, 2019, 11, 78.	6.2	40
256	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	10.2	85
257	Affective symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer's disease: A systematic literature review. Neuroscience and Biobehavioral Reviews, 2019, 107, 346-359.	6.1	29

#	Article	IF	CITATIONS
258	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. Neurobiology of Aging, 2019, 83, 42-53.	3.1	48
259	Braak neurofibrillary tangle staging prediction from in vivo MRI metrics. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 599-609.	2.4	5
260	Vitegnoside Mitigates Neuronal Injury, Mitochondrial Apoptosis, and Inflammation in an Alzheimer's Disease Cell Model via the p38 MAPK/JNK Pathway. Journal of Alzheimer's Disease, 2019, 72, 199-214.	2.6	23
261	Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a "gray zone�. Alzheimer's and Dementia, 2019, 15, 1348-1356.	0.8	20
262	Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloidâ€positive individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 679-689.	2.4	48
263	Stress granules and neurodegeneration. Nature Reviews Neuroscience, 2019, 20, 649-666.	10.2	452
264	Sex Differences in Cardiovascular Disease and Cognitive Impairment: Another Health Disparity for Women?. Journal of the American Heart Association, 2019, 8, e013154.	3.7	39
265	Face-to-Face and Digital Multidomain Lifestyle Interventions to Enhance Cognitive Reserve and Reduce Risk of Alzheimer's Disease and Related Dementias: A Review of Completed and Prospective Studies. Nutrients, 2019, 11, 2258.	4.1	35
266	Plasma Aβ42 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment. Scientific Reports, 2019, 9, 13984.	3.3	38
267	Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell, 2019, 179, 312-339.	28.9	1,675
268	Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid-β positivity. Cortex, 2019, 121, 117-124.	2.4	12
269	Multicenter Tract-Based Analysis of Microstructural Lesions within the Alzheimer's Disease Spectrum: Association with Amyloid Pathology and Diagnostic Usefulness. Journal of Alzheimer's Disease, 2019, 72, 455-465.	2.6	15
270	New screening approach for Alzheimer's disease risk assessment from urine lipid peroxidation compounds. Scientific Reports, 2019, 9, 14244.	3.3	25
271	3D mapping reveals network-specific amyloid progression and subcortical susceptibility in mice. Communications Biology, 2019, 2, 360.	4.4	42
272	Regional brain atrophy predicts time to conversion to Alzheimer's disease, dependent on baseline volume. Neurobiology of Aging, 2019, 83, 86-94.	3.1	20
273	Cerebral Amyloid Angiopathy, Alzheimer's Disease and MicroRNA: miRNA as Diagnostic Biomarkers and Potential Therapeutic Targets. NeuroMolecular Medicine, 2019, 21, 369-390. 	3.4	18
274	MRI Volumetric Quantification in Persons with a History of Traumatic Brain Injury and Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 72, 293-300.	2.6	9
275	Using subjective cognitive decline to identify high global amyloid in communityâ€based samples: A crossâ€cohort study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 670-678.	2.4	19

#	RTICLE		CITATIONS
276	Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects. Frontiers in Aging Neuroscience, 2019, 11, 222.		29
277	Prediction and Classification of Alzheimer's Disease Based on Combined Features From Apolipoprotein-E Genotype, Cerebrospinal Fluid, MR, and FDG-PET Imaging Biomarkers. Frontiers in Computational Neuroscience, 2019, 13, 72.	2.1	97
278	Higher CSF Tau Levels Are Related to Hippocampal Hyperactivity and Object Mnemonic Discrimination in Older Adults. Journal of Neuroscience, 2019, 39, 8788-8797.	3.6	64
279	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nature Medicine, 2019, 25, 277-283.	30.7	610
280	Coded Prevalence of Mild Cognitive Impairment in General and Neuropsychiatrists Practices in Germany Between 2007 and 2017. Journal of Alzheimer's Disease, 2019, 67, 1313-1318.	2.6	6
281	The Incremental Diagnostic Value of [18F]Florbetaben PET and the Pivotal Role of the Neuropsychological Assessment in Clinical Practice. Journal of Alzheimer's Disease, 2019, 67, 1235-1244.	2.6	5
282	Polygenic hazard score, amyloid deposition and Alzheimer's neurodegeneration. Brain, 2019, 142, 460-470.	7.6	63
283	Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders?. Clinica Chimica Acta, 2019, 491, 81-84.	1.1	18
284	Is there a specific memory signature associated with Aβ-PET positivity in patients with amnestic mild cognitive impairment?. Neurobiology of Aging, 2019, 77, 94-103.	3.1	9
285	A Case with Early Onset Alzheimer's Disease, Frontotemporal Hypometabolism, ApoE Genotype ɛ4/ɛ4 and C9ORF72 Intermediate Expansion: A Treviso Dementia (TREDEM) Registry Case Report. Journal of Alzheimer's Disease, 2019, 67, 985-993.	2.6	3
286	The 2018 NIAâ€AA research framework: Recommendation and comments. Alzheimer's and Dementia, 2019, 15, 182-183.	0.8	2
287	Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. Alzheimer's Research and Therapy, 2019, 11, 8.	6.2	23
288	Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clinical Biochemistry, 2019, 72, 30-38.	1.9	60
289	Method comparison study of the Elecsys® β-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS. Clinical Biochemistry, 2019, 72, 7-14.	1.9	30
290	Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. Scientific Reports, 2019, 9, 7803.	3.3	33
291	The trinity of tau, trauma, and time. Lancet Neurology, The, 2019, 18, 715-717.	10.2	0
292	Sleep as a Potential Biomarker of Tau and β-Amyloid Burden in the Human Brain. Journal of Neuroscience, 2019, 39, 6315-6324.	3.6	160
293	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 2316.	7.4	223

#	Article	IF	CITATIONS
294	Putting the New Alzheimer Disease Amyloid, Tau, Neurodegeneration (AT[N]) Diagnostic System to the Test. JAMA - Journal of the American Medical Association, 2019, 321, 2289.		7
295	A mixedâ€methods study of cultural beliefs about dementia and genetic testing among Mexicans and Mexicanâ€Americans atâ€risk for autosomal dominant Alzheimer's disease. Journal of Genetic Counseling, 2019, 28, 921-932.		12
296	Perifovea retinal thickness as an ophthalmic biomarker for mild cognitive impairment and early Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 405-414.		16
297	Development of a mnemonic discrimination task using naturalistic stimuli with applications to aging and preclinical Alzheimer's disease. Learning and Memory, 2019, 26, 219-228.	1.3	17
298	Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease. Hypertension, 2019, 74, 413-420.	2.7	54
299	Predicting longâ€ŧerm clinical stability in amyloidâ€positive subjects by <scp>FDG</scp> â€ <scp>PET</scp> . Annals of Clinical and Translational Neurology, 2019, 6, 1113-1120.	3.7	33
300	Cerebrospinal fluid collection: An informative animation video for patients and caregivers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 435-438.		4
301	EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease. Brain, 2019, 142, 2096-2112.	7.6	131
302	Incidence of Dementia and Alzheimer Disease Over Time: A Metaâ€Analysis. Journal of the American Geriatrics Society, 2019, 67, 1361-1369.	2.6	63
303	Environment-Sensitive Near-Infrared Probe for Fluorescent Discrimination of AÎ <sup>2</sup> and Tau Fibrils in AD Brain. Journal of Medicinal Chemistry, 2019, 62, 6694-6704.		52
304	Measuring gait speed to better identify prodromal dementia. Experimental Gerontology, 2019, 124, 110625.		100
305	A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies. Alzheimer's and Dementia, 2019, 15, 1081-1103.	0.8	16
306	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status. JAMA Neurology, 2019, 76, 1060.	9.0	282
307	Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for Stakeholders. Journal of Alzheimer's Disease, 2019, 70, 323-341.	2.6	146
308	Disruptions of the olfactory and default mode networks in Alzheimer's disease. Brain and Behavior, 2019, 9, e01296.	2.2	23
309	Neuroimaging Biomarkers for Alzheimer's Disease. Molecular Neurodegeneration, 2019, 14, 21.	10.8	161
310	Subthreshold amyloid and its biological and clinical meaning. Neurology, 2019, 93, 72-79.	1.1	39
311	Resting State Abnormalities of the Default Mode Network in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2019, 70, 107-120.	2.6	79

#	Article	IF	CITATIONS
312	Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. Journal of Alzheimer's Disease, 2019, 70, 211-225.		10
313	Neuropsychological subtypes of incident mild cognitive impairment in the Mayo Clinic Study of Aging. Alzheimer's and Dementia, 2019, 15, 878-887.	0.8	41
314	Common Variants in ABI3 Influence Cerebrospinal Fluid Total Tau Levels and Cognitive Decline in Progressive Mild Cognitive Impairment Patients. Journal of Alzheimer's Disease, 2019, 70, 17-23.	2.6	3
316	PLASMA BIOMARKERS OF AD EMERGING AS ESSENTIAL TOOLS FOR DRUG DEVELOPMENT: AN EU/US CTAD TASK FORCE REPORT. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-5.	2.7	43
317	EEG Characterization of the Alzheimer's Disease Continuum by Means of Multiscale Entropies. Entropy, 2019, 21, 544.	2.2	40
318	Potential Value of Plasma Amyloid-β, Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease. ACS Chemical Neuroscience, 2019, 10, 3479-3485.	3.5	44
319	Correlation between CSF biomarkers of Alzheimer's disease and global cognition in a psychogeriatric clinic cohort. Revista Brasileira De Psiquiatria, 2019, 41, 479-484.	1.7	6
320	Optimization of solid-phase extraction (SPE) in the preparation of [18F]D3FSP: A new PET imaging agent for mapping Al <sup>2</sup> plaques. Nuclear Medicine and Biology, 2019, 71, 54-64.	0.6	3
321	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype. Alzheimer's and Dementia, 2019, 15, 888-898.	0.8	290
322	Differential medial temporal lobe and default-mode network functional connectivity and morphometric changes in Alzheimer's disease. NeuroImage: Clinical, 2019, 23, 101860.	2.7	21
323	Diagnosis and treatment of cognitive impairment. Zeitschrift Fur Gerontologie Und Geriatrie, 2019, 52, 309-315.	1.8	14
324	Stimulation over the cerebellum with a regular figure-of-eight coil induces reduced motor cortex inhibition in patients with progressive supranuclear palsy. Brain Stimulation, 2019, 12, 1290-1297.	1.6	23
325	Visual cognition in non-amnestic Alzheimer's disease: Relations to tau, amyloid, and cortical atrophy. NeuroImage: Clinical, 2019, 23, 101889.	2.7	17
326	Genetic Variants of PICALM rs541458 Modulate Brain Spontaneous Activity in Older Adults With Amnestic Mild Cognitive Impairment. Frontiers in Neurology, 2019, 10, 494.	2.4	19
327	Blood Pressure Control and Protection of the Aging Brain. Neurotherapeutics, 2019, 16, 569-579.	4.4	16
328	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. Alzheimer's and Dementia, 2019, 15, 927-939.	0.8	48
329	Neurocognitive disorders in ICDâ€11: a new proposal and its outcome. World Psychiatry, 2019, 18, 232-233.	10.4	7
330	Blood-based diagnostics of Alzheimer's disease. Expert Review of Molecular Diagnostics, 2019, 19, 613-621.	3.1	11

#	Article	IF	CITATIONS
331	A deep learning model for early prediction of Alzheimer's disease dementia based on hippocampal magnetic resonance imaging data. Alzheimer's and Dementia, 2019, 15, 1059-1070.	0.8	151
332	Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 1213-1220.	2.6	12
333	The Italian version of Cognitive Function Instrument (CFI) for tracking changes in healthy elderly: results at 1-year follow-up. Neurological Sciences, 2019, 40, 2147-2153.	1.9	8
334	Disclosure of amyloid PET scan results: A systematic review. Progress in Molecular Biology and Translational Science, 2019, 165, 401-414.	1.7	11
335	Moderate―to highâ€intensity exercise does not modify cortical βâ€amyloid in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 208-215.	3.7	20
336	Alzheimer's pathology targets distinct memory networks in the ageing brain. Brain, 2019, 142, 2492-2509.	7.6	131
337	α-synuclein in the pathophysiology of Alzheimer's disease. Molecular Neurodegeneration, 2019, 14, 23.	10.8	197
338	The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. Expert Review of Proteomics, 2019, 16, 593-600.	3.0	41
339	Developing a Spatial Navigation Screening Tool Sensitive to the Preclinical Alzheimer Disease Continuum. Archives of Clinical Neuropsychology, 2019, 34, 1138-1155.	0.5	17
340	Risk factors for predicting progression from normal cognition to mild cognitive impairment: protocol for a systematic review and meta-analysis of cohort studies. BMJ Open, 2019, 9, e027313.	1.9	4
341	Blood Pressure Lowering With Nilvadipine in Patients With Mildâ€toâ€Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. Journal of the American Heart Association, 2019, 8, e011938.	3.7	10
342	Higher Level of Mismatch in <i>APOE</i> <b>ε</b> 4 Carriers for Amyloid-Beta Peptide Alzheimer's Disease Biomarkers in Cerebrospinal Fluid. ASN Neuro, 2019, 11, 175909141984552.	2.7	10
343	Medial Temporal Lobe Disconnection and Hyperexcitability Across Alzheimer's Disease Stages. Journal of Alzheimer's Disease Reports, 2019, 3, 103-112.	2.2	48
344	Neuropsychological assessment and cortisol levels in biofluids from early Alzheimer's disease patients. Experimental Gerontology, 2019, 123, 10-16.	2.8	19
345	Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. Neurology, 2019, 92, e2699-e2705.	1.1	10
346	Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 764-775.	0.8	122
347	IDEAS becoming reality on the roadmap for biomarker validation in Alzheimer's disease. Lancet Neurology, The, 2019, 18, 519-520.	10.2	0
348	Brain transcriptome analysis of a familial Alzheimer's disease-like mutation in the zebrafish presenilin 1 gene implies effects on energy production. Molecular Brain, 2019, 12, 43.	2.6	33

#	Article	IF	CITATIONS
349	Parkinson's and Lewy body dementia CSF biomarkers. Clinica Chimica Acta, 2019, 495, 318-325.	1.1	38
350	Application of advanced brain positron emission tomography–based molecular imaging for a biological framework in neurodegenerative proteinopathies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 327-332.	2.4	9
351	Social Engagement and Amyloid-β-Related Cognitive Decline in Cognitively Normal Older Adults. American Journal of Geriatric Psychiatry, 2019, 27, 1247-1256.	1.2	56
352	Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau. PLoS ONE, 2019, 14, e0217026.	2.5	18
353	Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer's Disease Biomarker and Mild Cognitive Impairment Diagnoses. Journal of Alzheimer's Disease, 2019, 69, 1171-1182.	2.6	19
354	Prevention and Treatment of Alzheimer's Disease: Biological Mechanisms of Exercise. Journal of Alzheimer's Disease, 2019, 69, 311-338.	2.6	37
355	High amyloid burden is associated with fewer specific words during spontaneous speech in in individuals with subjective cognitive decline. Neuropsychologia, 2019, 131, 184-192.	1.6	22
356	Vascular Dysfunction in Alzheimer's Disease: A Prelude to the Pathological Process or a Consequence of It?. Journal of Clinical Medicine, 2019, 8, 651.	2.4	131
357	Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases. Mayo Clinic Proceedings, 2019, 94, 892-905.	3.0	112
358	Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers. Experimental and Molecular Medicine, 2019, 51, 1-10.	7.7	150
359	Measurement of CSF αâ€ <b>s</b> ynuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease. Journal of Neurochemistry, 2019, 150, 218-230.	3.9	12
360	COMBINATION THERAPY FOR ALZHEIMER'S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-5.	2.7	29
361	Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC). Neurolmage: Clinical, 2019, 23, 101846.	2.7	18
362	Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 383-391.	2.4	53
363	Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort. Alzheimer's Research and Therapy, 2019, 11, 45.	6.2	19
364	Timely Detection of Mild Cognitive Impairment in Italy: An Expert Opinion. Journal of Alzheimer's Disease, 2019, 68, 1401-1414.	2.6	11
365	Gray matter structural covariance networks changes along the Alzheimer's disease continuum. NeuroImage: Clinical, 2019, 23, 101828.	2.7	31
366	Differential effects of neurodegeneration biomarkers on subclinical cognitive decline. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 129-138.	3.7	22

#	Article	IF	CITATIONS
367	Age-Associated Changes in the Immune System and Blood–Brain Barrier Functions. International Journal of Molecular Sciences, 2019, 20, 1632.	4.1	107
368	The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study. NeuroImage: Clinical, 2019, 22, 101795.	2.7	34
369	Differential diagnosis between Alzheimer's disease and other dementias: Role of cerebrospinal fluid biomarkers. Clinical Biochemistry, 2019, 72, 24-29.	1.9	1
370	Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2019, 11, 74.	3.4	59
371	Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurology, 2019, 76, 791.	9.0	436
372	The Limitations of Using Cognitive Cutoff Scores for Enrollment in Alzheimer Trials. American Journal of Geriatric Psychiatry, 2019, 27, 1153-1158.	1.2	4
373	Commentary: Predicting Cognitive Improvement in Normal Pressure Hydrocephalus Patients Using Preoperative Neuropsychological Testing and Cerebrospinal Fluid Biomarkers. Neurosurgery, 2019, 85, E670-E670.	1.1	0
374	A brief history of "Alzheimer disease― Neurology, 2019, 92, 1053-1059.	1.1	52
375	Brain atrophy in primary ageâ€related tauopathy is linked to transactive response DNAâ€binding protein of 43 kDa. Alzheimer's and Dementia, 2019, 15, 799-806.	0.8	14
376	ASAF: altered spontaneous activity fingerprinting in Alzheimer's disease based on multisite fMRI. Science Bulletin, 2019, 64, 998-1010.	9.0	24
377	Self-Agency and Self-Ownership in Cognitive Mapping. Trends in Cognitive Sciences, 2019, 23, 476-487.	7.8	35
378	Frontal variant of Alzheimer's disease masquerading as behavioural-variant frontotemporal dementia: a case study comparison. Neurocase, 2019, 25, 48-58.	0.6	12
379	Physician Practice Patterns Associated with Diagnostic Evaluation of Patients with Suspected Mild Cognitive Impairment and Alzheimer's Disease. International Journal of Alzheimer's Disease, 2019, 2019, 1-8.	2.0	24
380	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain, 2019, 142, 1503-1527.	7.6	873
381	APOE-ε4 risk variant for Alzheimer's disease modifies the association between cognitive performance and cerebral morphology in healthy middle-aged individuals. NeuroImage: Clinical, 2019, 23, 101818.	2.7	18
382	Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). Trials, 2019, 20, 191.	1.6	127
383	Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project. Alzheimer's Research and Therapy, 2019, 11, 33.	6.2	30
384	Determinants of self―and carer―ated quality of life and caregiver burden in Alzheimer disease. International Journal of Geriatric Psychiatry, 2019, 34, 1378-1385.	2.7	32

#	Article	IF	CITATIONS
385	Plasma Levels of Soluble AβPPβ as a Biomarker for Alzheimer's Disease with Dementia. Journal of Alzheimer's Disease, 2019, 69, 83-90.	2.6	0
386	Clinical and Biomarker Characteristics According to Clinical Spectrum of Alzheimer's Disease (AD) in the Validation Cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD. Journal of Clinical Medicine, 2019, 8, 341.	2.4	35
387	The vexing complexity of the amyloidogenic pathway. Protein Science, 2019, 28, 1177-1193.	7.6	25
388	Amyloid beta in nasal secretions may be a potential biomarker of Alzheimer's disease. Scientific Reports, 2019, 9, 4966.	3.3	18
389	Using Varying Diagnostic Criteria to Examine Mild Cognitive Impairment Prevalence and Predict Dementia Incidence in a Community-Based Sample. Journal of Alzheimer's Disease, 2019, 68, 1439-1451.	2.6	16
390	Subjective Cognitive Decline May Be a Stronger Predictor of Incident Dementia in Women than in Men. Journal of Alzheimer's Disease, 2019, 68, 1469-1478.	2.6	28
391	Association between white matter lesions and cerebral glucose metabolism in patients with cognitive impairment. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2019, 38, 160-166.	0.2	7
392	Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimer's Research and Therapy, 2019, 11, 27.	6.2	82
393	Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis. Clinica Chimica Acta, 2019, 494, 74-78.	1.1	20
394	Assessment of 18F-Florbetaben Amyloid PET Imaging in Patients with Suspected Alzheimer's Disease and Isolated Increase in Cerebrospinal Fluid Tau Proteins. Journal of Alzheimer's Disease, 2019, 68, 1061-1069.	2.6	6
395	Is there a difference in regional read [18F]flutemetamol amyloid patterns between end-of-life subjects and those with amnestic mild cognitive impairment?. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1299-1308.	6.4	10
396	The effects of 7â€week cognitive training in patients with vascular cognitive impairment, no dementia (the Cogâ€VACCINE study): A randomized controlled trial. Alzheimer's and Dementia, 2019, 15, 605-614.	0.8	47
397	Effects of CD33 Variants on Neuroimaging Biomarkers in Non-Demented Elders. Journal of Alzheimer's Disease, 2019, 68, 757-766.	2.6	6
398	Diagnostic Behavior for Mild Cognitive Impairment in General and Neuropsychiatric Practices in Germany. Journal of Alzheimer's Disease, 2019, 68, 925-930.	2.6	5
399	Revealing heterogeneity of brain imaging phenotypes in Alzheimer's disease based on unsupervised clustering of blood marker profiles. PLoS ONE, 2019, 14, e0211121.	2.5	10
400	Frontotemporal dementia is the leading cause of "true―Aâ^'/T+ profiles defined with Aβ <sub>42/40</sub> ratio. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 161-169.	2.4	8
401	Longitudinal Brain Atrophy Rates in Transient Ischemic Attack and Minor Ischemic Stroke Patients and Cognitive Profiles. Frontiers in Neurology, 2019, 10, 18.	2.4	15
402	ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology, 2019, 92, e1567-e1579.	1.1	73

#	Article	IF	CITATIONS
403	CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort. Acta Neurologica Belgica, 2019, 119, 445-452.	1.1	18
404	What matters to people with memory problems, healthy volunteers and health and social care professionals in the context of developing treatment to prevent Alzheimer's dementia? A qualitative study. Health Expectations, 2019, 22, 504-517.	2.6	15
405	Translational research on reserve against neurodegenerative disease: consensus report of the International Conference on Cognitive Reserve in the Dementias and the Alzheimer's Association Reserve, Resilience and Protective Factors Professional Interest Area working groups. BMC Medicine, 2019, 17, 47.	5.5	69
406	Brief cognitive screening instruments for early detection of Alzheimer's disease: a systematic review. Alzheimer's Research and Therapy, 2019, 11, 21.	6.2	113
407	Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes. JAMA Neurology, 2019, 76, 598.	9.0	143
408	Concussion Biomarkers. JAMA Neurology, 2019, 76, 515.	9.0	9
409	The time for multiple biomarkers in studies of cognitive aging and dementia is now. Neurology, 2019, 92, 551-552.	1.1	4
411	The Healthy Brain Project: An Online Platform for the Recruitment, Assessment, and Monitoring of Middle-Aged Adults at Risk of Developing Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 68, 1211-1228.	2.6	23
413	Evolution of brain atrophy subtypes during aging predicts long-term cognitive decline and future Alzheimer's clinical syndrome. Neurobiology of Aging, 2019, 79, 22-29.	3.1	13
414	Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease. NeuroImage: Clinical, 2019, 22, 101777.	2.7	29
415	Healthcare and Financial Decision Making and Incident Adverse Cognitive Outcomes among Older Adults. Journal of the American Geriatrics Society, 2019, 67, 1590-1595.	2.6	16
416	Alzheimer's Disease Diagnosis Based on Cortical and Subcortical Features. Journal of Healthcare Engineering, 2019, 2019, 1-13.	1.9	23
417	Cognitive Resilience to Alzheimer's Disease Pathology in the Human Brain. Journal of Alzheimer's Disease, 2019, 68, 1071-1083.	2.6	34
418	The metabolic brain signature of cognitive resilience in the 80+: beyond Alzheimer pathologies. Brain, 2019, 142, 1134-1147.	7.6	72
419	The prognostic value of ATN Alzheimer biomarker profiles in cognitively normal individuals. Neurology, 2019, 92, 643-644.	1.1	12
420	Precision Medicine for Frontotemporal Dementia. Frontiers in Psychiatry, 2019, 10, 75.	2.6	16
421	Association of Glucose Fluctuations with Sarcopenia in Older Adults with Type 2 Diabetes Mellitus. Journal of Clinical Medicine, 2019, 8, 319.	2.4	43
422	Comparative evaluation of two immunoassays for cerebrospinal fluid β-Amyloid1–42 measurement. Clinica Chimica Acta, 2019, 493, 107-111.	1.1	9

#	Article	IF	CITATIONS
423	Preclinical Alzheimer Disease and the Dawn of the Pre-Caregiver. JAMA Neurology, 2019, 76, 631.	9.0	20
424	Machine learning approaches to studying the role of cognitive reserve in conversion from mild cognitive impairment to dementia. International Journal of Geriatric Psychiatry, 2019, 34, 941-949.	2.7	34
425	Selenium and selenium species in the etiology of Alzheimer's dementia: The potential for bias of the case-control study design. Journal of Trace Elements in Medicine and Biology, 2019, 53, 154-162.	3.0	29
426	Preclinical Models of Alzheimer's Disease: Relevance and Translational Validity. Current Protocols in Pharmacology, 2019, 84, e57.	4.0	91
427	A biological classification for Alzheimer's disease - Amyloid, Tau and Neurodegeneration (A/T/N): results from the Argentine-Alzheimer's Disease Neuroimaging Initiative. International Psychogeriatrics, 2019, 31, 1837-1838.	1.0	4
429	Demographically adjusted CERAD wordlist test norms in a Norwegian sample from 40 to 80 years. Clinical Neuropsychologist, 2019, 33, 27-39.	2.3	20
430	Screening for Dementia Caused by Modifiable Lifestyle Choices Using Hybrid PET/MRI. Journal of Alzheimer's Disease Reports, 2019, 3, 31-45.	2.2	6
431	MicroRNAs in Alzheimer's Disease. Frontiers in Genetics, 2019, 10, 153.	2.3	230
432	What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and healthâ€care professionals? A systematic review. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 231-247.	2.4	49
433	The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease. Clinica Chimica Acta, 2019, 494, 71-73.	1.1	26
435	Understanding the Amyloid Hypothesis in Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 68, 493-510.	2.6	77
436	Trajectories of the Hippocampal Subfields Atrophy in the Alzheimer's Disease: A Structural Imaging Study. Frontiers in Neuroinformatics, 2019, 13, 13.	2.5	94
437	Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 291-300.	2.4	56
438	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's and Dementia, 2019, 15, 742-753.	0.8	82
439	Mutation and association analyses of dementia-causal genes in Han Chinese patients with early-onset and familial Alzheimer's disease. Journal of Psychiatric Research, 2019, 113, 141-147.	3.1	20
440	Investigation of brain functional connectivity in patients with mild cognitive impairment: A functional nearâ€infrared spectroscopy (fNIRS) study. Journal of Biophotonics, 2019, 12, e201800298.	2.3	41
441	Association Between Amyloid-β, Small-vessel Disease, and Neurodegeneration Biomarker Positivity, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1753-1760.	3.6	8
442	Clinical Effects of Frontal Behavioral Impairment: Cortical Thickness and Cognitive Decline in Individuals with Subjective Cognitive Decline and Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 69, 213-225.	2.6	0

#	Article	IF	CITATIONS
443	The role of molecular imaging in the frame of the revised dementia with Lewy body criteria. Clinical and Translational Imaging, 2019, 7, 83-98.	2.1	1
444	Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker. Journal of Proteomics, 2019, 200, 144-152.	2.4	50
445	Combined Biomarker Prognosis of Mild Cognitive Impairment: An 11-Year Follow-Up Study in the Alzheimer's Disease Neuroimaging Initiative. Journal of Alzheimer's Disease, 2019, 68, 1549-1559.	2.6	9
446	Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aî²42 concentration in the very high range: a prospective study. Journal of Neurology, 2019, 266, 1685-1692.	3.6	7
447	Treatment of Radiation-Induced Cognitive Decline in Adult Brain Tumor Patients. Current Treatment Options in Oncology, 2019, 20, 42.	3.0	31
448	Neurotrophin Receptor p75 mRNA Level in Peripheral Blood Cells of Patients with Alzheimer's Disease. Neurotoxicity Research, 2019, 36, 101-107.	2.7	3
449	Developing a Brief Neuropsychological Battery for Early Diagnosis of Cognitive Impairment. Journal of the American Medical Directors Association, 2019, 20, 1054.e11-1054.e20.	2.5	12
450	White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 107-117.	3.7	250
451	The role of the protein–RNA recognition code in neurodegeneration. Cellular and Molecular Life Sciences, 2019, 76, 2043-2058.	5.4	17
452	CSF and blood biomarkers for Parkinson's disease. Lancet Neurology, The, 2019, 18, 573-586.	10.2	393
453	Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging. NeuroImage: Clinical, 2019, 22, 101771.	2.7	108
454	Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 591-600.	1.3	18
455	Symptom clusters of subjective cognitive decline amongst cognitively normal older persons and their utilities in predicting objective cognitive performance: structural equationÂmodelling. European Journal of Neurology, 2019, 26, 1153-1160.	3.3	8
456	Design and sample size considerations for Alzheimer's disease prevention trials using multistate models. Clinical Trials, 2019, 16, 111-119.	1.6	15
457	CSF level of β-amyloid peptide predicts mortality in Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 29.	6.2	19
458	How pattern information analyses of semantic brain activity elicited in language comprehension could contribute to the early identification of Alzheimer's Disease. NeuroImage: Clinical, 2019, 22, 101788.	2.7	8
459	Current and Future Treatments in Alzheimer's Disease. Seminars in Neurology, 2019, 39, 227-240.	1.4	161
460	A Multifactor Approach to Mild Cognitive Impairment. Seminars in Neurology, 2019, 39, 179-187.	1.4	12

		CITATION REPORT	
#	Article	IF	Citations
461	Alzheimer's Disease Including Focal Presentations. Seminars in Neurology, 2019, 39, 213-226.	1.4	72
462	Interpretation of Biomarker Data in Diagnosis of Primary Dementias. Seminars in Neurology, 2019, 200-212.	39, 1.4	1
463	An Overview of Primary Dementias as Clinicopathological Entities. Seminars in Neurology, 2019, 39 153-166.	, 1.4	13
464	Fractionating the Rey Auditory Verbal Learning Test: Distinct roles of large-scale cortical networks in prodromal Alzheimer's disease. Neuropsychologia, 2019, 129, 83-92.	1.6	36
465	Amyloid PET and Changes in Clinical Management for Patients With Cognitive Impairment. JAMA - Journal of the American Medical Association, 2019, 321, 1258.	7.4	8
466	Novel methods for integration and visualization of genomics and genetics data in Alzheimer's disea Alzheimer's and Dementia, 2019, 15, 788-798.	se. 0.8	18
467	Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. Neurobiology of Aging, 2019, 79, 131-141.	3.1	23
468	Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1276-1286.	6.4	38
469	Therapeutic Role of Transcranial Direct Current Stimulation in Alzheimer Disease Patients: Double-Blind, Placebo-Controlled Clinical Trial. Neurorehabilitation and Neural Repair, 2019, 33, 384-394.	2.9	44
470	Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project. Neurobiology of Aging, 2019, 79, 50-58.	3.1	41
471	Altered static and dynamic functional network connectivity in Alzheimer's disease and subcortical ischemic vascular disease: shared and specific brain connectivity abnormalities. Human Brain Mappi 2019, 40, 3203-3221.	ng, 3.6	107
472	Mapping the neuroanatomy of functional decline in Alzheimer's disease from basic to advancec activities of daily living. Journal of Neurology, 2019, 266, 1310-1322.	3.6	11
473	Glial activation and inflammation along the Alzheimer's disease continuum. Journal of Neuroinflammation, 2019, 16, 46.	7.2	175
474	Stress and Alzheimer's disease. Journal of Neural Transmission, 2019, 126, 1155-1161.	2.8	28
475	Pathogenesis of age-related HIV neurodegeneration. Journal of NeuroVirology, 2019, 25, 622-633.	2.1	47
476	Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. Scientific Reports, 2019, 9, 2460.	3.3	7
477	Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume. Neurology, 2019, 92, e1331-e1343.	1.1	69
478	The de-Alzheimerization of age-related dementias: implications for drug targets and approaches to effective therapeutics. Current Opinion in Pharmacology, 2019, 44, 62-75.	3.5	8

#	Article	IF	CITATIONS
479	Synaptic vesicle protein 2A as a potential biomarker in synaptopathies. Molecular and Cellular Neurosciences, 2019, 97, 34-42.	2.2	55
480	Sleep oscillation-specific associations with Alzheimer's disease CSF biomarkers: novel roles for sleep spindles and tau. Molecular Neurodegeneration, 2019, 14, 10.	10.8	61
481	Detection of mild cognitive impairment in a communityâ€dwelling population using quantitative, multiparametric MRIâ€based classification. Human Brain Mapping, 2019, 40, 2711-2722.	3.6	6
482	Alzheimer's "Prevention―vs. "Risk Reduction― Transcending Semantics for Clinical Practice. Frontiers in Neurology, 2018, 9, 1179.	2.4	28
483	Quantifying memory deficits in amnestic mild cognitive impairment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 108-114.	2.4	14
484	Dual-phase [18F]florbetapir in frontotemporal dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 304-311.	6.4	18
485	Proteomic Quantification of Human Blood–Brain Barrier SLC and ABC Transporters in Healthy Individuals and Dementia Patients. Molecular Pharmaceutics, 2019, 16, 1220-1233.	4.6	85
486	Comparison between amyloid-PET and CSF amyloid-β biomarkers in a clinical cohort with memory deficits. Clinica Chimica Acta, 2019, 492, 62-68.	1.1	20
487	Is Alzheimer's Disease Risk Modifiable?. Journal of Alzheimer's Disease, 2019, 67, 795-819.	2.6	73
488	Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study. Current Alzheimer Research, 2019, 16, 91-101.	1.4	23
489	The Changing Profile of Patients in a Geriatric Medicine Led Memory Clinic over 12 Years. Journal of Nutrition, Health and Aging, 2019, 23, 310-315.	3.3	4
490	Actual memory as a mediator of the amyloidâ€subjective cognitive decline relationship. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 151-160.	2.4	14
491	Pyroglutamation of amyloid-l²x-42 (Al²x-42) followed by Al²1–40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology. Journal of Biological Chemistry, 2019, 294, 6719-6732.	3.4	49
492	Auditory Brainstem Dysfunction, Non-Invasive Biomarkers for Early Diagnosis and Monitoring of Alzheimer's Disease in Young Urban Residents Exposed to Air Pollution. Journal of Alzheimer's Disease, 2019, 67, 1147-1155.	2.6	9
493	Identification of a Simple and Novel Cut-Point Based Cerebrospinal Fluid and MRI Signature for Predicting Alzheimer's Disease Progression that Reinforces the 2018 NIA-AA Research Framework. Journal of Alzheimer's Disease, 2019, 68, 537-550.	2.6	11
494	Correlations Between Single Nucleotide Polymorphisms, Cognitive Dysfunction, and Postmortem Brain Pathology in Alzheimer's Disease Among Han Chinese. Neuroscience Bulletin, 2019, 35, 193-204.	2.9	10
495	Genome-wide analysis of genetic predisposition to Alzheimer's disease and related sex disparities. Alzheimer's Research and Therapy, 2019, 11, 5.	6.2	61
496	Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases. Journal of Alzheimer's Disease, 2019, 68, 395-404.	2.6	33

#	Article	IF	CITATIONS
497	The Role of Biomarkers in Alzheimer's Disease Drug Development. Advances in Experimental Medicine and Biology, 2019, 1118, 29-61.	1.6	84
498	Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms. Advances in Experimental Medicine and Biology, 2019, 1118, 83-116.	1.6	34
499	Validation of a prototype tau Thr231 phosphorylation CSF ELISA as a potential biomarker for Alzheimer's disease. Journal of Neural Transmission, 2019, 126, 339-348.	2.8	16
500	Optimization of the k2′ Parameter Estimation for the Pharmacokinetic Modeling of Dynamic PIB PET Scans Using SRTM2. Frontiers in Physics, 2019, 7, .	2.1	7
501	Scam Awareness Related to Incident Alzheimer Dementia and Mild Cognitive Impairment. Annals of Internal Medicine, 2019, 170, 702.	3.9	42
502	Asociación entre daños en la sustancia blanca y metabolismo de la glucosa cerebral en pacientes con disfunción cognitiva. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2019, 38, 160-166.	0.0	8
504	Dilated Convolutional Neural Networks for Sequential Manifold-Valued Data. , 2019, 2019, 10620-10630.		11
505	Aiding the discovery of new treatments for dementia by uncovering unknown benefits of existing medications. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 862-870.	3.7	13
506	Framework of treating Alzheimer's dementia. Brain Science Advances, 2019, 5, 82-93.	0.9	8
507	Current Status of the Vietnam Era Twin Study of Aging (VETSA). Twin Research and Human Genetics, 2019, 22, 783-787.	0.6	23
508	Physical Activity as a Moderator of Alzheimer Pathology: A Systematic Review of Observational Studies. Current Alzheimer Research, 2019, 16, 362-378.	1.4	30
509	Demencias degenerativas: ¿un dilema de sÃndromes o de enfermedades?. NeurologÃa, 2019, , .	0.7	Ο
510	Vascular contributions to cognitive impairment and dementia: Research consortia that focus on etiology and treatable targets to lessen the burden of dementia worldwide. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 789-796.	3.7	23
511	Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 871-882.	3.7	79
512	Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2019, 48, 180-195.	1.5	25
513	Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology. Neurology and Therapy, 2019, 8, 95-111.	3.2	16
514	Alzheimer's disease: A clinical perspective and future nonhuman primate research opportunities. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26224-26229.	7.1	61
515	An Integrated View on Vascular Dysfunction in Alzheimer's Disease. Neurodegenerative Diseases, 2019, 19, 109-127.	1.4	62

#	Article	IF	CITATIONS
516	Definition and quantification of six immune- and neuroregulatory serum proteins in healthy and demented elderly. Neurodegenerative Disease Management, 2019, 9, 193-203.	2.2	13
517	Distinct Spontaneous Brain Activity Patterns in Different Biologically-Defined Alzheimer's Disease Cognitive Stage: A Preliminary Study. Frontiers in Aging Neuroscience, 2019, 11, 350.	3.4	24
518	Alcohol drinking exacerbates neural and behavioral pathology in the 3xTg-AD mouse model of Alzheimer's disease. International Review of Neurobiology, 2019, 148, 169-230.	2.0	56
519	Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer's Disease and Inconclusive First Biomarker. Journal of Alzheimer's Disease, 2019, 72, 1193-1207.	2.6	5
520	Gray Matter Changes in Parkinson's and Alzheimer's Disease and Relation to Cognition. Current Neurology and Neuroscience Reports, 2019, 19, 85.	4.2	36
521	Cerebrospinal fluid dynamics disorders. Neurology, 2019, 93, e2237-e2246.	1.1	19
522	Cognitive and neuropsychological examination of the elderly. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 89-104.	1.8	5
523	Alzheimer's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 231-255.	1.8	415
524	Investigating the Association Between Verbal Forgetting and Pathological Markers of Alzheimer's and Lewy Body Diseases. Journal of Alzheimer's Disease, 2019, 70, 877-887.	2.6	0
525	A unified brain system of orientation and its disruption in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2019, 6, 2468-2478.	3.7	9
527	What is new within staging of care for people with dementia? The IDEAL schedule and other recent work. Current Opinion in Psychiatry, 2019, 32, 366-371.	6.3	2
528	<p>Alzheimer's Disease – Why We Need Early Diagnosis</p> . Degenerative Neurological and Neuromuscular Disease, 2019, Volume 9, 123-130.	1.3	181
529	Psychosis in neurodegenerative disorders. Current Opinion in Psychiatry, 2019, 32, 117-122.	6.3	5
530	Undetectable gadolinium brain retention in individuals with an ageâ€dependent bloodâ€brain barrier breakdown in the hippocampus and mild cognitive impairment. Alzheimer's and Dementia, 2019, 15, 1568-1575.	0.8	22
531	Is semantic learning strategy an early clinical marker for amnestic mild cognitive impairment and Alzheimer's disease?. International Psychogeriatrics, 2019, 31, 1695-1697.	1.0	3
532	Update on PET in neurodegenerative and neuroinflammatory disorders manifesting on a behavioural level: imaging for differential diagnosis. Current Opinion in Neurology, 2019, 32, 548-556.	3.6	8
533	EEG analytics: benefits and challenges of data driven EEG biomarkers for neurodegenerative diseases. , 2019, , .		4
534	miR-212 and miR-132 Are Downregulated in Neurally Derived Plasma Exosomes of Alzheimer's Patients. Frontiers in Neuroscience, 2019, 13, 1208.	2.8	129

ARTICLE IF CITATIONS # Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's 535 6.2 78 disease. Alzheimer's Research and Therapy, 2019, 11, 91. Systemic and central nervous system metabolic alterations in Alzheimer's disease. Alzheimer's 6.2 143 Résearch and Therapy, 2019, 11, 93. 537 Evaluation of cognitive impairment., 2019, , 65-113. 1 The evolution of geriatric neurology. Handbook of Clinical Neurology / Edited By P J Vinken and G W 1.8 Bruyn, 2019, 167, 575-584. APPâ€derived peptides reflect neurodegeneration in frontotemporal dementia. Annals of Clinical and 539 3.7 13 Translational Neurology, 2019, 6, 2518-2530. Plasma Al²42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study. Alzheimer's Research and Therapy, 2019, 11, 96. 6.2 Transcranial magnetic stimulation and amyloid markers in mild cognitive impairment: impact on 541 6.2 16 diagnostic confidence and diagnostic accuracy. Alzheimer's Research and Therapy, 2019, 11, 95. Parkinsonism in genetic and sporadic Alzheimer's disease. International Review of Neurobiology, 2019, 2.0 149, 237-247. Bloodâ€based biomarkers for Alzheimer's disease and related dementias: Keys to success and things to 543 2.4 1 consider. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 784-786. Does Empirically Derived Classification of Individuals with Subjective Cognitive Complaints Predict 544 2.3 Dementia?. Brain Sciences, 2019, 9, 314. Which MCI Patients Should be Included in Prodromal Alzheimer Disease Clinical Trials?. Alzheimer 545 12 1.3 Disease and Associated Disorders, 2019, 33, 104-112. Neuropsychological Test Performance and MRI Markers of Dementia Risk. Alzheimer Disease and 1.3 Associated Disorders, 2019, 33, 179-185. The search for improved animal models of Alzheimer's disease and novel strategies for therapeutic 547 2.3 7 intervention. Future Medicinal Chemistry, 2019, 11, 1853-1857. Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641988881. 548 3.5 46 The use of back propagation neural networks and 18F-Florbetapir PET for early detection of Alzheimer's disease using Alzheimer's Disease Neuroimaging Initiative database. PLoS ONE, 2019, 14, 549 2.518 e0226577. Precision Medicine: Role of Biomarkers in Early Prediction and Diagnosis of Alzheimer's Disease. , 2019, In Vivo Assessment of Tau Deposition in Alzheimer Disease and Assessing Its Relationship to Regional 552 1.322 Brain Glucose Metabolism and Cognition. Clinical Nuclear Medicine, 2019, 44, e597-e601. The effects of repetitive transcranial magnetic stimulation in older adults with mild cognitive 1.8 impairment: a protocol for a randomized, controlled three-arm trial. BMC Neurology, 2019, 19, 326.

#	Article	IF	CITATIONS
554	Testing a MultiTEP-based combination vaccine to reduce AÎ <sup>2</sup> and tau pathology in Tau22/5xFAD bigenic mice. Alzheimer's Research and Therapy, 2019, 11, 107.	6.2	19
555	Neuroimaging modality fusion in Alzheimer's classification using convolutional neural networks. PLoS ONE, 2019, 14, e0225759.	2.5	38
556	Increased Inflammation and Unchanged Density of Synaptic Vesicle Glycoprotein 2A (SV2A) in the Postmortem Frontal Cortex of Alzheimer's Disease Patients. Frontiers in Cellular Neuroscience, 2019, 13, 538.	3.7	25
557	Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment. Neurology and Therapy, 2019, 8, 129-145.	3.2	8
558	Diagnostic biomarkers of Alzheimer's disease: A state-of-the-art review. Biomarkers in Neuropsychiatry, 2019, 1, 100005.	1.0	117
559	Therapeutic noninvasive brain stimulation in Alzheimer's disease and related dementias. Current Opinion in Neurology, 2019, 32, 292-304.	3.6	50
560	Automated Alzheimer's Disease Diagnosis using a Low-Density EEG Layout and New Features based on the Power of Modulation Spectral "Patchesâ€e , 2019, , .		1
561	Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research. Biomedicines, 2019, 7, 97.	3.2	161
562	Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment. JAMA Network Open, 2019, 2, e1917363.	5.9	66
563	An Update on Blood-Based Markers of Alzheimer's Disease Using the SiMoA Platform. Neurology and Therapy, 2019, 8, 73-82.	3.2	83
564	A Review on MS-Based Blood Biomarkers for Alzheimer's Disease. Neurology and Therapy, 2019, 8, 113-127.	3.2	35
565	Salivary Biomarkers for Alzheimer's Disease and Related Disorders. Neurology and Therapy, 2019, 8, 83-94.	3.2	54
566	Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria. Medicine (United States), 2019, 98, e16509.	1.0	6
567	Editorial: Facing up to the complexity of neuro degenerative disorders in order to deal with them more effectively. Current Opinion in Neurology, 2019, 32, 253-254.	3.6	Ο
568	A nation-wide initiative for brain imaging and clinical phenotype data federation in Swiss university memory centres. Current Opinion in Neurology, 2019, 32, 557-563.	3.6	12
569	Clinical Use of Integrated Positron Emission Tomography-Magnetic Resonance Imaging for Dementia Patients. Topics in Magnetic Resonance Imaging, 2019, 28, 299-310.	1.2	9
570	Risk of developing cerebral $\hat{l}^2$ -amyloid plaques with posttranslational modification among HIV-infected adults. Aids, 2019, 33, 2157-2166.	2.2	8
571	The Use of Random Forests to Classify Amyloid Brain PET. Clinical Nuclear Medicine, 2019, 44, 784-788.	1.3	15

#	Article	IF	CITATIONS
572	Patient Stakeholder Versus Physician Preferences Regarding Amyloid PET Testing. Alzheimer Disease and Associated Disorders, 2019, 33, 246-253.	1.3	9
573	VGF in Cerebrospinal Fluid Combined With Conventional Biomarkers Enhances Prediction of Conversion From MCI to AD. Alzheimer Disease and Associated Disorders, 2019, 33, 307-314.	1.3	24
574	Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid. Alzheimer's Research and Therapy, 2019, 11, 99.	6.2	23
575	Preserved wake-dependent cortical excitability dynamics predict cognitive fitness beyond age-related brain alterations. Communications Biology, 2019, 2, 449.	4.4	9
576	Dementia is not synonymous with Alzheimerâ $\in$ ${}^{\mathrm{M}}$ s disease. Science Translational Medicine, 2019, 11, .	12.4	11
577	Unambiguous Detection of Elevated Levels of Hypochlorous Acid in Double Transgenic AD Mouse Brain. ACS Chemical Neuroscience, 2019, 10, 4847-4853.	3.5	38
578	Cognitive Aging and Dementia: A Life-Span Perspective. Annual Review of Developmental Psychology, 2019, 1, 177-196.	2.9	94
579	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. JAMA Network Open, 2019, 2, e1917126.	5.9	23
580	PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases. Alzheimer's Research and Therapy, 2019, 11, 100.	6.2	21
582	Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 610-617.	3.7	32
583	Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. Journal of Alzheimer's Disease, 2019, 69, 37-48.	2.6	23
584	Redox proteomics and amyloid βâ€peptide: insights into Alzheimer disease. Journal of Neurochemistry, 2019, 151, 459-487.	3.9	80
585	White matter and its relationship with cognition in subjective cognitive decline. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 28-35.	2.4	30
586	The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale – Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment. European Journal of Neurology, 2019, 26, 733.	3.3	12
587	Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. Molecular and Cellular Neurosciences, 2019, 97, 3-17.	2.2	82
588	Statistics on the burden of dementia: need for stronger data. Lancet Neurology, The, 2019, 18, 25-27.	10.2	31
589	CSF-ApoER2 fragments as a read-out of reelin signaling: Distinct patterns in sporadic and autosomal-dominant Alzheimer disease. Clinica Chimica Acta, 2019, 490, 6-11.	1.1	3
590	Astrocyte Biomarkers in Alzheimer's Disease. Trends in Molecular Medicine, 2019, 25, 77-95.	6.7	203

#	Article	IF	CITATIONS
591	Diet and biomarkers of Alzheimer's disease: a systematic review and meta-analysis. Neurobiology of Aging, 2019, 76, 45-52.	3.1	79
592	MMP13 inhibition rescues cognitive decline in Alzheimer transgenic mice via BACE1 regulation. Brain, 2019, 142, 176-192.	7.6	44
593	Seeding selectivity and ultrasensitive detection of tau aggregate conformers of Alzheimer disease. Acta Neuropathologica, 2019, 137, 585-598.	7.7	95
594	Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 1-9.	2.4	14
595	microRNA diagnostic panel for Alzheimer's disease and epigenetic trade-off between neurodegeneration and cancer. Ageing Research Reviews, 2019, 49, 125-143.	10.9	87
596	Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. Journal of Alzheimer's Disease, 2019, 69, 15-35.	2.6	34
597	Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. JAMA Neurology, 2019, 76, 187.	9.0	66
598	Mild cognitive impairment in long-term brain tumor survivors following brain irradiation. Journal of Neuro-Oncology, 2019, 141, 235-244.	2.9	25
599	Analysis of post-translational modifications in Alzheimer's disease by mass spectrometry. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2040-2047.	3.8	15
600	Disease progression timeline estimation for Alzheimer's disease using discriminative event based modeling. NeuroImage, 2019, 186, 518-532.	4.2	61
601	Impact of Antidepressant Use on the Trajectory of Alzheimer's Disease: Evidence, Mechanisms, and Therapeutic Implications. CNS Drugs, 2019, 33, 17-29.	5.9	7
602	Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis. Alzheimer's Research and Therapy, 2019, 11, 7.	6.2	87
603	The National Institute on Aging and Alzheimer's Association research framework: A commentary from the Cochrane Dementia and Cognitive Improvement Group. Alzheimer's and Dementia, 2019, 15, 179-181.	0.8	6
604	Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. JAMA Neurology, 2019, 76, 264.	9.0	227
605	Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 2.	6.2	19
606	Bad news and good news in AD, and how to reconcile them. Nature Reviews Neurology, 2019, 15, 61-62.	10.1	35
607	18F-FDG-PET Detects Drastic Changes in Brain Metabolism in the Tg4–42 Model of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 425.	3.4	49
608	Vascular dysfunction—The disregarded partner of Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 158-167.	0.8	454

#	ARTICLE	IF	CITATIONS
609	Tau PET imaging in neurodegenerative tauopathies—still a challenge. Molecular Psychiatry, 2019, 24, 1112-1134.	7.9	409
610	Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nature Medicine, 2019, 25, 270-276.	30.7	987
611	Causes and Patterns of Dementia: An Update in the Era of Redefining Alzheimer's Disease. Annual Review of Public Health, 2019, 40, 65-84.	17.4	94
612	Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-l² pathology. Molecular Neurodegeneration, 2019, 14, 1.	10.8	253
613	Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology, 2019, 92, e601-e612.	1.1	196
614	In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion. Journal of Alzheimer's Disease, 2019, 67, 715-723.	2.6	5
615	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.8	37
616	CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum. Neurobiology of Aging, 2019, 74, 182-190.	3.1	45
617	Tetraclinis articulata essential oil mitigates cognitive deficits and brain oxidative stress in an Alzheimer's disease amyloidosis model. Phytomedicine, 2019, 56, 57-63.	5.3	36
618	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease—Data from three memory clinic studies. Alzheimer's and Dementia, 2019, 15, 185-193.	0.8	28
619	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2019, 15, 106-152.	0.8	302
620	Whole brain imaging reveals distinct spatial patterns of amyloid beta deposition in three mouse models of Alzheimer's disease. Journal of Comparative Neurology, 2019, 527, 2122-2145.	1.6	76
621	Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. Alzheimer's and Dementia, 2019, 15, 232-244.	0.8	198
622	When is Alzheimer's not dementia—Cochrane commentary on The National Institute on Ageing and Alzheimer's Association Research Framework for Alzheimer's Disease. Age and Ageing, 2019, 48, 174-177	. 1.6	18
623	Episodic recognition memory and the hippocampus in Parkinson's disease: A review. Cortex, 2019, 113, 191-209.	2.4	72
624	Biomarkers for tau pathology. Molecular and Cellular Neurosciences, 2019, 97, 18-33.	2.2	163
625	Topography of 11C-Pittsburgh compound B uptake in Alzheimer's disease: a voxel-based investigation of cortical and white matter regions. Revista Brasileira De Psiquiatria, 2019, 41, 101-111.	1.7	18
626	A multifunctional compound ebselen reverses memory impairment, apoptosis and oxidative stress in a mouse model of sporadic Alzheimer's disease. Journal of Psychiatric Research, 2019, 107-117.	3.1	66

#	Article	IF	CITATIONS
627	Longitudinal Standards for Mid-life Cognitive Performance: Identifying Abnormal Within-Person Changes in the Wisconsin Registry for Alzheimer's Prevention. Journal of the International Neuropsychological Society, 2019, 25, 1-14.	1.8	19
628	Multistate models and lifetime risk estimation: Application to Alzheimer's disease. Statistics in Medicine, 2019, 38, 1558-1565.	1.6	14
629	Fluidâ€based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. Journal of Neurochemistry, 2019, 151, 417-434.	3.9	15
630	The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease. Acta Neuropathologica, 2019, 137, 89-102.	7.7	64
631	Associations Between Positron Emission Tomography Amyloid Pathology and Diffusion Tensor Imaging Brain Connectivity in Pre-Clinical Alzheimer's Disease. Brain Connectivity, 2019, 9, 162-173.	1.7	11
632	Mild cognitive impairment: A concept analysis. Nursing Forum, 2019, 54, 68-76.	2.3	8
633	Modifying the minimum criteria for diagnosing amnestic MCI to improve prediction of brain atrophy and progression to Alzheimer's disease. Brain Imaging and Behavior, 2020, 14, 787-796.	2.1	14
634	Carotid Intima–Media Thickness and Markers of Brain Health in a Biracial Middle-Aged Cohort: CARDIA Brain MRI Sub-study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 380-386.	3.6	19
635	Longitudinal evaluation of surrogates of regional cerebral blood flow computed from dynamic amyloid PET imaging. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 288-297.	4.3	33
636	Reduction of recruitment costs in preclinical AD trials: validation of automatic pre-screening algorithm for brain amyloidosis. Statistical Methods in Medical Research, 2020, 29, 151-164.	1.5	30
637	A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A â€~C-reactive protein' for psychiatrists and neurologists?. Australian and New Zealand Journal of Psychiatry, 2020, 54, 57-67.	2.3	40
638	The Amyloid Phenomenon and Its Significance in Biology and Medicine. Cold Spring Harbor Perspectives in Biology, 2020, 12, a033878.	5.5	111
639	Predicting Early Mild Cognitive Impairment With Free Recall: The Primacy of Primacy. Archives of Clinical Neuropsychology, 2020, 35, 133-142.	0.5	23
640	What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. Neurobiology of Aging, 2020, 85, 58-73.	3.1	150
641	The role of TREM2 in Alzheimer's disease; evidence from transgenic mouse models. Neurobiology of Aging, 2020, 86, 39-53.	3.1	25
642	Propagation of Tau Pathology: Integrating Insights From Postmortem and InÂVivo Studies. Biological Psychiatry, 2020, 87, 808-818.	1.3	50
643	The Health and Retirement Study Harmonized Cognitive Assessment Protocol Project: Study Design and Methods. Neuroepidemiology, 2020, 54, 64-74.	2.3	84
644	Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation. Journal of Geriatric Psychiatry and Neurology, 2020, 33, 175-184.	2.3	23
#	Article	IF	CITATIONS
-----	---	-----	-----------
645	Cognitive reserve and working memory in cognitive performance of adults with subjective cognitive complaints: longitudinal structural equation modeling. International Psychogeriatrics, 2020, 32, 515-524.	1.0	7
646	Highly biocompatible graphene quantum dots: green synthesis, toxicity comparison and fluorescence imaging. Journal of Materials Science, 2020, 55, 1198-1215.	3.7	50
647	Predictive Value of <sup>18</sup> F-Florbetapir and <sup>18</sup> F-FDG PET for Conversion from Mild Cognitive Impairment to Alzheimer Dementia. Journal of Nuclear Medicine, 2020, 61, 597-603.	5.0	30
648	Quantifying brain metabolism from FDCâ€PET images into a probability of Alzheimer's dementia score. Human Brain Mapping, 2020, 41, 5-16.	3.6	35
649	Late-Life Neuropsychiatric Symptoms: Windows Into Cognitive Decline?. American Journal of Geriatric Psychiatry, 2020, 28, 72-74.	1.2	5
650	Prediction of Alzheimer's disease based on deep neural network by integrating gene expression and DNA methylation dataset. Expert Systems With Applications, 2020, 140, 112873.	7.6	93
651	Prediction of Alzheimer's disease diagnosis within 14Âyears through Aβ misfolding in blood plasma compared to <i>APOE4</i> status, and other risk factors. Alzheimer's and Dementia, 2020, 16, 283-291.	0.8	26
652	Apathy and anxiety are early markers of Alzheimer's disease. Neurobiology of Aging, 2020, 85, 74-82.	3.1	103
653	Marine bacterial extracts as a new rich source of drugs against Alzheimer's disease. Journal of Neurochemistry, 2020, 152, 493-508.	3.9	6
654	Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 270-280.	6.4	23
655	Shared Latent Structures Between Imaging Features and Biomarkers in Early Stages of Alzheimer's Disease: A Predictive Study. IEEE Journal of Biomedical and Health Informatics, 2020, 24, 365-376.	6.3	1
656	Linking two new E-health caregiver interventions to meeting centres for people with dementia and their carers; a process evaluation. Aging and Mental Health, 2020, 24, 1316-1325.	2.8	7
657	Nuclear medical imaging as part of dementia diagnostics in psychiatric day-care clinics and inpatient care settings. Aging Clinical and Experimental Research, 2020, 32, 809-815.	2.9	0
658	Feasibility of a Lifestyle Physical Activity Intervention to Prevent Memory Loss in Older Women With Cardiovascular Disease: A Mixed-Methods Approach. Canadian Journal of Nursing Research, 2020, 52, 278-289.	1.5	5
659	In search of multimodal brain alterations in Alzheimer's and Binswanger's disease. NeuroImage: Clinical, 2020, 26, 101937.	2.7	13
660	In vivo imaging of synaptic loss in Alzheimer's disease with [18F]UCB-H positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 390-402.	6.4	78
661	Neuropsychiatric symptoms as predictors of conversion from MCI to dementia: a machine learning approach. International Psychogeriatrics, 2020, 32, 381-392.	1.0	29
662	Application of an amyloid and tau classification system in subcortical vascular cognitive impairment patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 292-303.	6.4	15

#	Article	IF	CITATIONS
663	Effect of poor sleep quality on subjective cognitive decline (SCD) or SCD-related functional difficulties: Results from 220,000 nationwide general populations without dementia. Journal of Affective Disorders, 2020, 260, 32-37.	4.1	21
665	Specific Signatures of Serum miRNAs as Potential Biomarkers to Discriminate Clinically Similar Neurodegenerative and Vascular-Related Diseases. Cellular and Molecular Neurobiology, 2020, 40, 531-546.	3.3	99
666	Plasma alterations in cholinergic and serotonergic systems in early Alzheimer Disease: Diagnosis utility. Clinica Chimica Acta, 2020, 500, 233-240.	1.1	16
667	Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. Alzheimer's and Dementia, 2020, 16, 262-272.	0.8	47
668	The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis. Alzheimer's and Dementia, 2020, 16, 1553-1560.	0.8	165
669	Usefulness of Plasma Amyloid as a Prescreener for the Earliest Alzheimer Pathological Changes Depends on the Study Population. Annals of Neurology, 2020, 87, 154-155.	5.3	1
670	Berkson's paradox and weighted distributions: An application to Alzheimer's disease. Biometrical Journal, 2020, 62, 238-249.	1.0	5
671	Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 86-98.	6.1	40
672	Prevention of Dementia—Thinking Beyond the Age and Amyloid Boxes. JAMA Neurology, 2020, 77, 160.	9.0	2
673	Exploring Relationships Among Peripheral Amyloid Beta, Tau, Cytokines, Cognitive Function, and Psychosomatic Symptoms in Breast Cancer Survivors. Biological Research for Nursing, 2020, 22, 126-138.	1.9	20
674	Communicating uncertainties when disclosing diagnostic test results for (Alzheimer's) dementia in the memory clinic: The ABIDE project. Health Expectations, 2020, 23, 52-62.	2.6	20
675	New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. Alzheimer's and Dementia, 2020, 16, 131-143.	0.8	45
676	Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study. Alzheimer's and Dementia, 2020, 16, 292-304.	0.8	29
677	Imaging biomarkers in Alzheimer's disease. , 2020, , 343-378.		1
678	Amyloid-β Positivity Predicts Cognitive Decline but Cognition Predicts Progression to Amyloid-β Positivity. Biological Psychiatry, 2020, 87, 819-828.	1.3	24
679	Cognitive and physical markers of prodromal dementia: A 12â€yearâ€long population study. Alzheimer's and Dementia, 2020, 16, 153-161.	0.8	23
680	Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease. BMC Neurology, 2020, 20, 10.	1.8	50
681	Reader response: Type 2 diabetes mellitus, brain atrophy, and cognitive decline. Neurology, 2020, 94, 48.2-49.	1.1	0

38

.,		15	Circumonia
#		lf	CITATIONS
682	A third of community-dwelling elderly with intermediate and high level of Alzheimera€™s neuropathologic changes are not demented: A meta-analysis. Ageing Research Reviews, 2020, 58, 101002.	10.9	15
683	Basal forebrain metabolism in Alzheimer's disease continuum: relationship with education. Neurobiology of Aging, 2020, 87, 70-77.	3.1	15
684	Biosensors on the road to early diagnostic and surveillance of Alzheimer's disease. Talanta, 2020, 211, 120700.	5.5	36
685	Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning. Information Fusion, 2020, 58, 153-167.	19.1	17
686	Concordance of Lumipulse cerebrospinal fluid tâ€ŧau/Aβ42 ratio with amyloid PET status. Alzheimer's and Dementia, 2020, 16, 144-152.	0.8	49
687	CogEvo, a cognitive function balancer, is a sensitive and easy psychiatric test battery for ageâ€related cognitive decline. Geriatrics and Gerontology International, 2020, 20, 248-255.	1.5	21
688	High density lipoprotein and its apolipoprotein-defined subspecies and risk of dementia. Journal of Lipid Research, 2020, 61, 445-454.	4.2	15
689	Real-space navigation testing differentiates between amyloid-positive and -negative aMCI. Neurology, 2020, 94, e861-e873.	1.1	24
690	Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. Brain, 2020, 143, 320-335.	7.6	100
691	Does early cognitive decline require the presence of both tau and amyloid-β?. Brain, 2020, 143, 10-13.	7.6	9
692	Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration. Neurology, 2020, 94, e397-e406.	1.1	93
693	SERSâ€based biosensor for Alzheimer disease evaluation through the fast analysis of human serum. Journal of Biophotonics, 2020, 13, e201960033.	2.3	34
694	Metabolic Network Abnormalities in Drugâ€NaÃ⁻ve Parkinson's Disease. Movement Disorders, 2020, 35, 587-594.	3.9	19
695	Improved quantification of amyloid burden and associated biomarker cut-off points: results from the first amyloid Singaporean cohort with overlapping cerebrovascular disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 319-331.	6.4	16
696	Higher levels of lysosomal associated membrane protein-2 (LAMP-2) in plasma exosomes from Alzheimer's disease: An exploratory study from South India. Asian Journal of Psychiatry, 2020, 48, 101898.	2.0	6
697	Does the neuropsychiatric inventory predict progression from mild cognitive impairment to dementia? A systematic review and meta-analysis. Ageing Research Reviews, 2020, 58, 101004.	10.9	17
698	Changes in brain activation related to visuo-spatial memory after real-time fMRI neurofeedback training in healthy elderly and Alzheimer's disease. Behavioural Brain Research, 2020, 381, 112435.	2.2	8
699	Cerebrospinal fluid biomarkers for dementia: A case of post-lumbar puncture epidural hematoma. Clinical Neurology and Neurosurgery, 2020, 190, 105638.	1.4	0

#	Article	IF	CITATIONS
700	Genetics of Alzheimer's disease: where we are, and where we are going. Current Opinion in Neurobiology, 2020, 61, 40-48.	4.2	144
701	Quinolizidine alkaloids derivatives from Sophora alopecuroides Linn: Bioactivities, structure-activity relationships and preliminary molecular mechanisms. European Journal of Medicinal Chemistry, 2020, 188, 111972.	5.5	63
702	Plasma biomarkers of astrocytic and neuronal dysfunction in early―and lateâ€onset Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 681-695.	0.8	143
703	Cerebrospinal fluid progranulin is associated with increased cortical thickness in early stages of Alzheimer's disease. Neurobiology of Aging, 2020, 88, 61-70.	3.1	23
704	Discrepancy-Based Evidence for Loss of Thinking Abilities (DELTA): Development and Validation of a Novel Approach to Identifying Cognitive Changes. Journal of the International Neuropsychological Society, 2020, 26, 464-479.	1.8	5
705	Validation of the Latin American Spanish version of the face-name associative memory exam in a Colombian Sample. Clinical Neuropsychologist, 2020, 34, 1-12.	2.3	13
706	Antihypertensive agents in Alzheimer's disease: beyond vascular protection. Expert Review of Neurotherapeutics, 2020, 20, 175-187.	2.8	26
707	Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β. JAMA Neurology, 2020, 77, 470.	9.0	154
708	Proteome-wide observation of the phenomenon of life on the edge of solubility. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1015-1020.	7.1	115
709	A multiomics approach to heterogeneity in Alzheimer's disease: focused review and roadmap. Brain, 2020, 143, 1315-1331.	7.6	106
710	Glycan biomarkers for Alzheimer disease correlate with Tâ€ŧau and Pâ€ŧau in cerebrospinal fluid in subjective cognitive impairment. FEBS Journal, 2020, 287, 3221-3234.	4.7	36
711	The Spatial-Temporal Ordering of Amyloid Pathology and Opportunities for PET Imaging. Journal of Nuclear Medicine, 2020, 61, 166-171.	5.0	38
712	Amyloid-β as a Blood Biomarker for Alzheimer's Disease: A Review of Recent Literature. Journal of Alzheimer's Disease, 2020, 73, 819-832.	2.6	25
713	Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice. journal of applied laboratory medicine, The, 2020, 5, 183-193.	1.3	10
714	Neuroimaging of Diseases Causing Dementia. Neurologic Clinics, 2020, 38, 65-94.	1.8	9
715	In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer's disease. Clinical Neurophysiology, 2020, 131, 88-95.	1.5	33
716	Metabolic Network Topology of Alzheimer's Disease and Dementia with Lewy Bodies Generated Using Fluorodeoxyglucose Positron Emission Tomography. Journal of Alzheimer's Disease, 2020, 73, 197-207.	2.6	10
717	Tau PET imaging with <sup>18</sup> F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study. Journal of Nuclear Medicine, 2020, 61, 911-919.	5.0	122

#	Article	IF	CITATIONS
718	Interactions of a multifunctional di-triazole derivative with Alzheimer's Aβ <sub>42</sub> monomer and Aβ <sub>42</sub> protofibril: a systematic molecular dynamics study. Physical Chemistry Chemical Physics, 2020, 22, 1543-1556.	2.8	25
719	Predicting Amyloid-β Levels in Amnestic Mild Cognitive Impairment Using Machine Learning Techniques. Journal of Alzheimer's Disease, 2020, 73, 1211-1219.	2.6	27
720	Metabolomics study to identify plasma biomarkers in alzheimer disease: ApoE genotype effect. Journal of Pharmaceutical and Biomedical Analysis, 2020, 180, 113088.	2.8	10
721	CSF cutoffs for MCI due to AD depend on APOEε4 carrier status. Neurobiology of Aging, 2020, 89, 55-62.	3.1	11
722	Arterial spin labeling versus 18F-FDG-PET to identify mild cognitive impairment. NeuroImage: Clinical, 2020, 25, 102146.	2.7	59
723	Spatially-extended nucleation-aggregation-fragmentation models for the dynamics of prion-like neurodegenerative protein-spreading in the brain and its connectome. Journal of Theoretical Biology, 2020, 486, 110102.	1.7	35
724	Preclinical Alzheimer's disease: a valid concept. Lancet Neurology, The, 2020, 19, 31.	10.2	14
725	"Senior Moments―or More? Diagnostic Evaluation of Cognitive Complaints in Older Adults and the Role of Cerebrospinal Fluid Biomarkers. journal of applied laboratory medicine, The, 2020, 5, 219-224.	1.3	1
726	Brain metabolic signatures across the Alzheimer's disease spectrum. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 256-269.	6.4	27
727	Dengzhan Shengmai capsules and their active component scutellarin prevent cognitive decline in APP/PS1 mice by accelerating AÎ <sup>2</sup> aggregation and reducing oligomers formation. Biomedicine and Pharmacotherapy, 2020, 121, 109682.	5.6	12
728	An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. Current Opinion in Neurobiology, 2020, 61, 29-39.	4.2	67
729	Biological applications of near infrared fluorescence dye probes in monitoring Alzheimer's disease. European Journal of Medicinal Chemistry, 2020, 187, 111982.	5.5	39
730	Anesthesia With and Without Nitrous Oxide and Long-term Cognitive Trajectories in Older Adults. Anesthesia and Analgesia, 2020, 131, 594-604.	2.2	5
731	Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?. Journal of Alzheimer's Disease, 2020, 73, 559-569.	2.6	8
732	Current opinion neurology: visual pathway biomarkers in Alzheimer's disease. Current Opinion in Neurology, 2020, 33, 79-86.	3.6	3
733	Consideration of Sex Differences in the Measurement and Interpretation of Alzheimer Disease-Related Biofluid-Based Biomarkers. journal of applied laboratory medicine, The, 2020, 5, 158-169.	1.3	28
734	Brain imaging measurements of fibrillar amyloidâ€Î² burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the <i>APOE ε4</i> allele. Alzheimer's and Dementia, 2020, 16, 598-609.	0.8	23
735	Alzheimer's/Vascular Spectrum Dementia: Classification in Addition to Diagnosis. Journal of Alzheimer's Disease, 2020, 73, 63-71.	2.6	47

#	Article	IF	CITATIONS
736	Midlife Study of the Louisville Twins: Connecting Cognitive Development to Biological and Cognitive Aging. Behavior Genetics, 2020, 50, 73-83.	2.1	7
737	CSF sTREM2 and Tau Work Together in Predicting Increased Temporal Lobe Atrophy in Older Adults. Cerebral Cortex, 2020, 30, 2295-2306.	2.9	15
738	Neuropsychological predictors of cognitive deterioration in non-demented individuals. Cognitive Neuropsychiatry, 2020, 25, 99-112.	1.3	2
739	The A/T/N model applied through imaging biomarkers in a memory clinic. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 247-255.	6.4	23
740	Evaluation of PiB visual interpretation with CSF Al <sup>2</sup> and longitudinal SUVR in J-ADNI study. Annals of Nuclear Medicine, 2020, 34, 108-118.	2.2	7
741	The Proteome of the Dentate Terminal Zone of the Perforant Path Indicates Presynaptic Impairment in Alzheimer Disease. Molecular and Cellular Proteomics, 2020, 19, 128-141.	3.8	22
742	Contribution of TDP and hippocampal sclerosis to hippocampal volume loss in older-old persons. Neurology, 2020, 94, e142-e152.	1.1	35
743	Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. Alzheimer's and Dementia, 2020, 16, 552-560.	0.8	55
744	Alzheimer's disease and the development of a post-genomic science. New Genetics and Society, 2020, 39, 1-12.	1.2	1
745	Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease. Brain, 2020, 143, 336-358.	7.6	52
746	Positive Association Between Cognitive Function and Cerebrospinal Fluid Orexin A Levels in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 73, 117-123.	2.6	21
747	β-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.1	65
748	Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. Journal of Alzheimer's Disease, 2020, 73, 1143-1156.	2.6	39
749	Developing robust biomarkers for vascular cognitive disorders: adding †V' to the AT(N) research framework. Current Opinion in Psychiatry, 2020, 33, 148-155.	6.3	9
750	Chronic traumatic encephalopathy. Current Opinion in Psychiatry, 2020, 33, 130-135.	6.3	8
751	Plasma isoprostanoids assessment as Alzheimer's disease progression biomarkers. Journal of Neurochemistry, 2021, 157, 2187-2194.	3.9	8
752	The Nâ€glycan profile in cortex and hippocampus is altered in Alzheimer disease. Journal of Neurochemistry, 2021, 159, 292-304.	3.9	32
753	Radionuclide Imaging for Neuroscience: Current Opinion and Future Directions. Molecular Imaging, 2020, 19, 153601212093639.	1.4	3

#	Article	IF	CITATIONS
754	Detection of gray matter microstructural changes in Alzheimer's disease continuum using fiber orientation. BMC Neurology, 2020, 20, 362.	1.8	16
755	The microvascular extracellular matrix in brains with Alzheimer's disease neuropathologic change (ADNC) and cerebral amyloid angiopathy (CAA). Fluids and Barriers of the CNS, 2020, 17, 60.	5.0	16
756	Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?. Alzheimer's Research and Therapy, 2020, 12, 121.	6.2	6
757	RATIONALE FOR EARLY DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT (MCI) SUPPORTED BY EMERGING DIGITAL TECHNOLOGIES. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-7.	2.7	37
758	Non-linear Relationship Between Plasma Amyloid-β 40 Level and Cognitive Decline in a Cognitively Normal Population. Frontiers in Aging Neuroscience, 2020, 12, 557005.	3.4	3
759	Circulating Exosome microRNAs as Diagnostic Biomarkers of Dementia. Frontiers in Aging Neuroscience, 2020, 12, 580199.	3.4	17
760	Vascular contributions to cognitive impairment and dementia (VCID): A report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop. Alzheimer's and Dementia, 2020, 16, 1714-1733.	0.8	108
761	Recent advances in research on Alzheimer's disease in China. Journal of Clinical Neuroscience, 2020, 81, 43-46.	1.5	22
762	The Imaging Features and Clinical Associations of a Novel Tau PET Tracer—18F-APN1607 in Alzheimer Disease. Clinical Nuclear Medicine, 2020, 45, 747-756.	1.3	20
763	Comparison of Amyloid in Cerebrospinal Fluid, Brain Imaging, and Autopsy in a Case of Progressive Supranuclear Palsy. Alzheimer Disease and Associated Disorders, 2020, 34, 275-277.	1.3	2
764	β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.1	62
765	Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease. Neurology, 2021, 96, e193-e202.	1.1	54
766	Neuropathologic burden and the degree of frailty in relation to global cognition and dementia. Neurology, 2020, 95, e3269-e3279.	1.1	33
767	Race- and Sex-Based Disparities in Alzheimer's Disease Clinical Trial Enrollment in the United States and Canada: An Indigenous Perspective. Journal of Alzheimer's Disease Reports, 2020, 4, 325-344.	2.2	8
768	One or more β-amyloid(s)? New insights into the prion-like nature of Alzheimer's disease. Progress in Molecular Biology and Translational Science, 2020, 175, 213-237.	1.7	1
769	Cortisol hypersecretion and the risk of Alzheimer's disease: A systematic review and meta-analysis. Ageing Research Reviews, 2020, 64, 101171.	10.9	34
770	Genome-wide profiling and predicted significance of post-mortem brain microRNA in Alzheimer's disease. Mechanisms of Ageing and Development, 2020, 191, 111352.	4.6	21
771	Multiple markers contribute to risk of progression from normal to mild cognitive impairment. NeuroImage: Clinical, 2020, 28, 102400.	2.7	8

#	Article	IF	CITATIONS
772	Weaker Braking Force, A New Marker of Worse Gait Stability in Alzheimer Disease. Frontiers in Aging Neuroscience, 2020, 12, 554168.	3.4	6
773	Afferent and Efferent Visual Markers of Alzheimer's Disease: A Review and Update in Early Stage Disease. Frontiers in Aging Neuroscience, 2020, 12, 572337.	3.4	15
774	Affective Neuropsychiatric Symptoms as Early Signs of Dementia Risk in Older Adults. Journal of Alzheimer's Disease, 2020, 77, 1195-1207.	2.6	16
775	Gender medicine: Towards a gender-specific treatment of neuropsychiatric disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2020, 175, 437-448.	1.8	6
776	Dickkopf-related protein-1 inhibition attenuates amyloid-beta pathology associated to Alzheimer's disease. Neurochemistry International, 2020, 141, 104881.	3.8	17
777	Cerebrovascular pathology in Alzheimer's disease: Hopes and gaps. Psychiatry Research - Neuroimaging, 2020, 306, 111184.	1.8	16
778	Association of serum Apolipoprotein B with cerebrospinal fluid biomarkers of Alzheimer's pathology. Annals of Clinical and Translational Neurology, 2020, 7, 1766-1778.	3.7	13
779	Amyloidâ€ <i>β</i> PET and CSF in an autopsyâ€confirmed cohort. Annals of Clinical and Translational Neurology, 2020, 7, 2150-2160.	3.7	17
780	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	10.2	254
781	Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. Journal of Alzheimer's Disease, 2020, 78, 989-1010.	2.6	52
782	An approach to classifying subjective cognitive decline in communityâ€dwelling elders. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12103.	2.4	6
783	Spatiotemporal relationship between subthreshold amyloid accumulation and aerobic glycolysis in the human brain. Neurobiology of Aging, 2020, 96, 165-175.	3.1	13
784	Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease. Science Advances, 2020, 6, .	10.3	186
785	Antidiabetic Drugs in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review. Dementia and Geriatric Cognitive Disorders, 2020, 49, 423-434.	1.5	34
786	Awareness of cognitive decline trajectories in asymptomatic individuals at risk for AD. Alzheimer's Research and Therapy, 2020, 12, 129.	6.2	18
787	Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study. Alzheimer's Research and Therapy, 2020, 12, 131.	6.2	17
788	Acute versus Chronic Exposures to Inhaled Particulate Matter and Neurocognitive Dysfunction: Pathways to Alzheimer's Disease or a Related Dementia. Journal of Alzheimer's Disease, 2020, 78, 871-886.	2.6	14
789	Value of Neuropsychological Tests to Identify Patients with Depressive Symptoms on the Alzheimer's Disease Continuum. Journal of Alzheimer's Disease, 2020, 78, 819-826.	2.6	1

			-
#	ARTICLE	IF	CITATIONS
790	Association between cognitive quotient test score and hippocampal volume: a novel, rapid application-based screening tool. Scientific Reports, 2020, 10, 16728.	3.3	3
791	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	7.6	74
792	Cognitive Impairment in the 3xTg-AD Mouse Model of Alzheimer's Disease is Affected by Aβ-ImmunoTherapy and Cognitive Stimulation. Pharmaceutics, 2020, 12, 944.	4.5	17
793	The potential for one drug, administered at the earliest preclinical stage, to prevent the subsequent decline of cognition that eventuates in dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12084.	3.7	4
794	Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions. BMJ, The, 2020, 371, m3684.	6.0	36
795	Proper names from story recall are associated with beta-amyloid in cognitively unimpaired adults at risk for Alzheimer's disease. Cortex, 2020, 131, 137-150.	2.4	17
796	Brief visuospatial memory test-revised normative data and form equivalency for adults ages 80-89. Clinical Neuropsychologist, 2020, , 1-10.	2.3	0
797	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. Brain Communications, 2020, 2, fcaa102.	3.3	11
798	Anisotropic diffusion and traveling waves of toxic proteins in neurodegenerative diseases. Physics Letters, Section A: General, Atomic and Solid State Physics, 2020, 384, 126935.	2.1	5
799	Genetics of neuropsychiatric symptoms in patients with Alzheimer's disease: A <scp>1â€year followâ€up</scp> study. Psychiatry and Clinical Neurosciences, 2020, 74, 645-651.	1.8	7
800	Protein-protein interactions in neurodegenerative diseases: A conspiracy theory. PLoS Computational Biology, 2020, 16, e1008267.	3.2	35
801	The role of synaptic biomarkers in the spectrum of neurodegenerative diseases. Expert Review of Proteomics, 2020, 17, 543-559.	3.0	16
802	Predicting amyloid status using selfâ€report information from an online research and recruitment registry: The Brain Health Registry. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12102.	2.4	2
803	Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12104.	2.4	27
804	Sectoral segmentation of retinal amyloid imaging in subjects with cognitive decline. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12109.	2.4	27
805	Common Brain Structural Alterations Associated with Cardiovascular Disease Risk Factors and Alzheimer's Dementia: Future Directions and Implications. Neuropsychology Review, 2020, 30, 546-557.	4.9	31
806	Retinal biomarkers for Alzheimer's disease and vascular cognitive impairment and dementia (VCID): implication for early diagnosis and prognosis. GeroScience, 2020, 42, 1499-1525.	4.6	64
807	Diagnostic and Prognostic Laboratory Testing for Alzheimer Disease. Clinics in Laboratory Medicine, 2020, 40, 289-303.	1.4	2

#	ARTICLE	IF	CITATIONS
808	nanoparticles (and engineered Ti-rich nanorods). The substantia nigrae is a very early target in young urbanites and the gastrointestinal tract a key brainstem portal. Environmental Research, 2020, 191, 110139.	7.5	50
809	LTP-like plasticity is impaired in amyloid-positive amnestic MCI but independent of PET-amyloid burden. Neurobiology of Aging, 2020, 96, 109-116.	3.1	14
810	Structural imaging in dementia with Lewy bodies: the potential of multivariate data analysis. Psychiatry Research - Neuroimaging, 2020, 306, 111180.	1.8	5
811	Cohort study of electroencephalography markers of amyloid-tau-neurodegeneration pathology. Brain Communications, 2020, 2, fcaa099.	3.3	9
812	Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia. Neurocase, 2020, 26, 259-263.	0.6	6
813	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 88.	6.2	20
814	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. Molecular Psychiatry, 2021, 26, 5967-5976.	7.9	76
815	CD33 and SIGLECL1 Immunoglobulin Superfamily Involved in Dementia. Journal of Neuropathology and Experimental Neurology, 2020, 79, 891-901.	1.7	6
816	Considerations for integrative multiâ€omic approaches to explore Alzheimer's disease mechanisms. Brain Pathology, 2020, 30, 984-991.	4.1	11
817	Longitudinal TSPO expression in tau transgenic P301S mice predicts increased tau accumulation and deteriorated spatial learning. Journal of Neuroinflammation, 2020, 17, 208.	7.2	19
818	Commentary on "The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum― American Journal of Geriatric Psychiatry, 2020, 28, 745-747.	1.2	0
819	ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration. Brain, 2020, 143, 2295-2311.	7.6	24
820	CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer's disease as an indicator of tau phosphorylation. Alzheimer's Research and Therapy, 2020, 12, 83.	6.2	14
821	Relationship between the Presence of the ApoE ε4 Allele and EEG Complexity along the Alzheimer's Disease Continuum. Sensors, 2020, 20, 3849.	3.8	11
822	Meta-Analysis of the Alzheimer's Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. Cell Reports, 2020, 32, 107908.	6.4	199
823	Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology, 2020, 95, e1538-e1553.	1.1	55
824	Weight Loss is a Preclinical Signal of Cerebral Amyloid Deposition and Could Predict Cognitive Impairment in Elderly Adults. Journal of Alzheimer's Disease, 2020, 77, 449-456.	2.6	12
825	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study.	3.1	30

#	Article	IF	CITATIONS
826	Relationship between β-amyloid and structural network topology in decedents without dementia. Neurology, 2020, 95, e532-e544.	1.1	17
827	Nighttime Blood Pressure Interacts with APOE Genotype to Increase the Risk of Incident Dementia of the Alzheimer's Type in Hispanics. Journal of Alzheimer's Disease, 2020, 77, 569-579.	2.6	2
828	The Use of Random Forests to Identify Brain Regions on Amyloid and FDG PET Associated With MoCA Score. Clinical Nuclear Medicine, 2020, 45, 427-433.	1.3	12
829	Glycosylated Hemoglobin Level, Race/Ethnicity, and Cognition in Midlife and Early Old Age. Research in Human Development, 2020, 17, 20-40.	1.3	1
830	Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited. Dementia and Geriatric Cognitive Disorders, 2020, 49, 2-7.	1.5	4
831	Molecular and Imaging Biomarkers in Alzheimer's Disease: A Focus on Recent Insights. Journal of Personalized Medicine, 2020, 10, 61.	2.5	35
832	Associations between NIH Toolbox Cognition Battery and <i>in vivo</i> brain amyloid and tau pathology in nonâ€demented older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12018.	2.4	17
833	An automated clinical mass spectrometric method for identification and quantification of variant and wildâ€type amyloidâ€Î² 1â€40 and 1â€42 peptides in CSF. Alzheimer's and Dementia: Diagnosis, Assessment Disease Monitoring, 2020, 12, e12036.	and	5
835	Development and Validation of a Deep Learning–Based Automatic Brain Segmentation and Classification Algorithm for Alzheimer Disease Using 3D T1-Weighted Volumetric Images. American Journal of Neuroradiology, 2020, 41, 2227-2234.	2.4	37
836	Quo vadis Alois?. Medicina ClÃnica (English Edition), 2020, 155, 491-493.	0.2	0
837	Fluid Candidate Biomarkers for Alzheimer's Disease: A Precision Medicine Approach. Journal of Personalized Medicine, 2020, 10, 221.	2.5	20
838	Evaluation of Naturalistic Driving Behavior Using In-Vehicle Monitoring Technology in Preclinical and Early Alzheimer's Disease. Frontiers in Psychology, 2020, 11, 596257.	2.1	13
839	Extracellular Vesicles in Alzheimer's and Parkinson's Disease: Small Entities with Large Consequences. Cells, 2020, 9, 2485.	4.1	36
840	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	2.7	17
841	Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. Nature Neuroscience, 2020, 23, 1580-1588.	14.8	53
842	Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers. International Journal of Molecular Sciences, 2020, 21, 8651.	4.1	23
843	Theoretical frameworks and approaches used within the Reserve, Resilience and Protective Factors professional interest area of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12115.	2.4	9
844	Amyloid biomarkers as predictors of conversion from mild cognitive impairment to Alzheimer's dementia: a comparison of methods. Alzheimer's Research and Therapy, 2020, 12, 155.	6.2	10

#	Article	IF	CITATIONS
845	Compromised Behavior and Gamma Power During Working Memory in Cognitively Healthy Individuals With Abnormal CSF Amyloid/Tau. Frontiers in Aging Neuroscience, 2020, 12, 574214.	3.4	9
846	Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 8673.	4.1	8
847	Change point analyses in prodromal Alzheimer's disease. Biomarkers in Neuropsychiatry, 2020, 3, 100028.	1.0	4
848	Genome-Wide Scan for Five Brain Oscillatory Phenotypes Identifies a New QTL Associated with Theta EEG Band. Brain Sciences, 2020, 10, 870.	2.3	1
849	A Robust Discriminant Framework Based on Functional Biomarkers of EEG and Its Potential for Diagnosis of Alzheimer's Disease. Healthcare (Switzerland), 2020, 8, 476.	2.0	9
850	Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders. Translational Neurodegeneration, 2020, 9, 41.	8.0	7
851	GERO Cohort Protocol, Chile, 2017–2022: Community-based Cohort of Functional Decline in Subjective Cognitive Complaint elderly. BMC Geriatrics, 2020, 20, 505.	2.7	10
852	Association of Odor Identification Ability With Amyloid-β and Tau Burden: A Systematic Review and Meta-Analysis. Frontiers in Neuroscience, 2020, 14, 586330.	2.8	13
853	Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. Nature Communications, 2020, 11, 6024.	12.8	43
854	Serum neurofilament light chain uncovers neurodegeneration early in the course of Alzheimer's disease. Brain, 2020, 143, 3521-3522.	7.6	1
855	Biomarkers for Alzheimer's Disease: Where Do We Stand and Where Are We Going?. Journal of Personalized Medicine, 2020, 10, 238.	2.5	5
856	Edible dairy formula fortified with coconut oil for neuroprotection against aluminium chloride-induced Alzheimer's disease in rats. Journal of Functional Foods, 2020, 75, 104296.	3.4	20
857	A Novel Computational Proxy for Characterizing Cognitive Reserve in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 78, 1217-1228.	2.6	3
858	Nanobiosensors for Non-Amyloidbeta-Tau Biomarkers as Advanced Reporters of Alzheimer's Disease. Diagnostics, 2020, 10, 913.	2.6	1
859	Physicians and Alzheimer Dementia: Past, Present, and Future. Annals of Internal Medicine, 2020, 172, 695-696.	3.9	4
862	Touchscreen-based location discrimination and paired associate learning tasks detect cognitive impairment at an early stage in an App knock-in mouse model of Alzheimer's disease. Molecular Brain, 2020, 13, 147.	2.6	13
863	Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. Neurology, 2021, 96, e662-e670.	1.1	34
864	Entorhinal Tau Predicts Hippocampal Activation and Memory Deficits in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 78, 1601-1614.	2.6	5

#	Article	IF	CITATIONS
865	Spatial Distribution of Tau and β-Amyloid Pathologies and Their Role in Different Alzheimer Disease Phenotypes. Neurology, 2021, 96, 191-192.	1.1	1
866	Dysregulated Wnt Signalling in the Alzheimer's Brain. Brain Sciences, 2020, 10, 902.	2.3	28
867	A/T/(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy Bodies. Diagnostics, 2020, 10, 1015.	2.6	16
868	Comparison of Transfer Learning and Conventional Machine Learning Applied to Structural Brain MRI for the Early Diagnosis and Prognosis of Alzheimer's Disease. Frontiers in Neurology, 2020, 11, 576194.	2.4	43
869	An α-helix mimetic oligopyridylamide, ADH-31, modulates Aβ <sub>42</sub> monomer aggregation and destabilizes protofibril structures: insights from molecular dynamics simulations. Physical Chemistry Chemical Physics, 2020, 22, 28055-28073.	2.8	12
870	RT-QuIC detection of tauopathies using full-length tau substrates. Prion, 2020, 14, 249-256.	1.8	16
871	Prediction of Alzheimer's disease biomarker status defined by the †ATN framework' among cognitively healthy individuals: results from the EPAD longitudinal cohort study. Alzheimer's Research and Therapy, 2020, 12, 143.	6.2	19
872	A Sensitive and Cost-Effective Chemiluminescence ELISA for Measurement of Amyloid-β 1-42 Peptide in Human Plasma. Journal of Alzheimer's Disease, 2020, 78, 1237-1244.	2.6	6
873	Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia. Annals of Internal Medicine, 2020, 172, 669-677.	3.9	25
874	Combination of snapshot hyperspectral retinal imaging and optical coherence tomography to identify Alzheimer's disease patients. Alzheimer's Research and Therapy, 2020, 12, 144.	6.2	29
875	Alzheimer's disease: from basic science to precision medicine approach. BMJ Neurology Open, 2020, 2, e000079.	1.6	19
876	Graph Theory Analysis Reveals Resting-State Compensatory Mechanisms in Healthy Aging and Prodromal Alzheimer's Disease. Frontiers in Aging Neuroscience, 2020, 12, 576627.	3.4	34
877	Efficacy and Safety of Guilingji Capsules (龟龄集胶囊) for Treating Mild-to-Moderate Cognitive Impairment Protocol for A Randomized, Double-Blind, Positive-Controlled, Multicenter and Noninferiority Trial. Chinese Journal of Integrative Medicine, 2020, 26, 577-582.	:: Study 1.6	3
878	Defining and predicting transdiagnostic categories of neurodegenerative disease. Nature Biomedical Engineering, 2020, 4, 787-800.	22.5	22
879	Association of glial and neuronal degeneration markers with Alzheimer's disease cerebrospinal fluid profile and cognitive functions. Alzheimer's Research and Therapy, 2020, 12, 92.	6.2	18
880	Alzheimer's disease pathology in a community-based sample of older adults without dementia: The MYHAT neuroimaging study. Brain Imaging and Behavior, 2021, 15, 1355-1363.	2.1	7
881	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. Molecular Neurobiology, 2020, 57, 4667-4691.	4.0	33
882	Value of CSF Biomarkers in Predicting Risk of Progression from aMCI to ADD in a 5-Year Follow-Up Cohort. SN Comprehensive Clinical Medicine, 2020, 2, 1543-1550.	0.6	0

#	Article	IF	CITATIONS
883	Sex differences in exercise efficacy: Is midlife a critical window for promoting healthy cognitive aging?. FASEB Journal, 2020, 34, 11329-11336.	0.5	23
884	AD-Related CSF Biomarkers Across Distinct Levels of Cognitive Impairment: Correlations With Global Cognitive State. Journal of Geriatric Psychiatry and Neurology, 2021, 34, 659-667.	2.3	6
885	Association of CSF Al <sup>2</sup> , amyloid PET, and cognition in cognitively unimpaired elderly adults. Neurology, 2020, 95, e2075-e2085.	1.1	31
886	Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers. Journal of Nuclear Medicine, 2020, 61, 1413-1418.	5.0	17
887	Falls Associate with Neurodegenerative Changes in ATN Framework of Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 745-752.	2.6	11
888	Decreased salivary lactoferrin levels are specific to Alzheimer's disease. EBioMedicine, 2020, 57, 102834.	6.1	59
889	Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs. Expert Opinion on Emerging Drugs, 2020, 25, 319-335.	2.4	57
890	Untangling anaesthesia and amyloid. British Journal of Anaesthesia, 2020, 125, 232-235.	3.4	2
891	Does amnesia specifically predict Alzheimer's pathology? AÂneuropathological study. Neurobiology of Aging, 2020, 95, 123-130.	3.1	15
892	The Validation of Multifactor Model of Plasma Aβ42 and Total-Tau in Combination With MoCA for Diagnosing Probable Alzheimer Disease. Frontiers in Aging Neuroscience, 2020, 12, 212.	3.4	18
893	Clinical Utility of Plasma Lipid Peroxidation Biomarkers in Alzheimer's Disease Differential Diagnosis. Antioxidants, 2020, 9, 649.	5.1	11
894	Novel MRI Techniques Identifying Vascular Leak and Paravascular Flow Reduction in Early Alzheimer Disease. Biomedicines, 2020, 8, 228.	3.2	15
895	Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer's Disease. Journal of Personalized Medicine, 2020, 10, 63.	2.5	13
896	Projection to Latent Spaces Disentangles Pathological Effects on Brain Morphology in the Asymptomatic Phase of Alzheimer's Disease. Frontiers in Neurology, 2020, 11, 648.	2.4	6
897	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2020, 324, 772.	7.4	640
898	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8Âyears prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathologica, 2020, 140, 267-278.	7.7	209
899	Role of Executive Functions in the Conversion from Mild Cognitive Impairment to Dementia. Journal of Alzheimer's Disease, 2020, 77, 641-653.	2.6	29
900	18F-Florbetaben Amyloid PET Imaging: A Chinese Study in Cognitive Normal Controls, Mild Cognitive Impairment, and Alzheimer's Disease Patients. Frontiers in Neuroscience, 2020, 14, 745.	2.8	6

#	Article	IF	CITATIONS
901	What we learn about bipolar disorder from largeâ€scale neuroimaging: Findings and future directions from the <scp>ENIGMA</scp> Bipolar Disorder Working Group. Human Brain Mapping, 2022, 43, 56-82.	3.6	67
902	Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease. Neurobiology of Aging, 2020, 95, 143-153.	3.1	34
903	Challenges in Alzheimer's Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences. Journal of Alzheimer's Disease, 2020, 77, 203-217.	2.6	3
904	Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. Alzheimer's and Dementia, 2020, 16, 1182-1195.	0.8	119
905	Brain connectivity during Alzheimer's disease progression and its cognitive impact in a transgenic rat model. Network Neuroscience, 2020, 4, 397-415.	2.6	12
906	Association of vascular brain injury, neurodegeneration, amyloid, and cognitive trajectory. Neurology, 2020, 95, e2622-e2634.	1.1	27
907	Circulating MicroRNA Profile Associated with Obstructive Sleep Apnea in Alzheimer's Disease. Molecular Neurobiology, 2020, 57, 4363-4372.	4.0	10
908	Associations of rest-activity patterns with amyloid burden, medial temporal lobe atrophy, and cognitive impairment. EBioMedicine, 2020, 58, 102881.	6.1	12
909	MA-[D-Leu-4]-OB3, a small molecule synthetic peptide leptin mimetic, improves episodic memory, and reduces serum levels of tumor necrosis factor-alpha and neurodegeneration in mouse models of Type 1 and Type 2 Diabetes Mellitus. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129697.	2.4	6
910	Subchronic administration of auranofin reduced amyloid-Î <sup>2</sup> plaque pathology in a transgenic APPNL-G-F/NL-G-F mouse model. Brain Research, 2020, 1746, 147022.	2.2	2
911	Clinical Presentation of Chronic Traumatic Encephalopathy. Seminars in Neurology, 2020, 40, 370-383.	1.4	12
912	Neuropathological assessment of the Alzheimer spectrum. Journal of Neural Transmission, 2020, 127, 1229-1256.	2.8	34
913	The mitochondrial hypothesis: Dysfunction, bioenergetic defects, and the metabolic link to Alzheimer's disease. International Review of Neurobiology, 2020, 154, 207-233.	2.0	43
914	Tracking the potential involvement of metabolic disease in Alzheimer's disease—Biomarkers and beyond. International Review of Neurobiology, 2020, 154, 51-77.	2.0	6
915	Small vessel disease lesion type and brain atrophy: The role of coâ€occurring amyloid. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12060.	2.4	7
916	Traditional Chinese medicine for anti-Alzheimer's disease: berberine and evodiamine from Evodia rutaecarpa. Chinese Medicine, 2020, 15, 82.	4.0	39
917	Statistical Disease Progression Modeling in Alzheimer Disease. Frontiers in Big Data, 2020, 3, 24.	2.9	33
918	Use of Biomarkers in Ongoing Research Protocols on Alzheimer's Disease. Journal of Personalized Medicine, 2020, 10, 68.	2.5	9

#	Article	IF	CITATIONS
919	Untargeted metabolomics reveal dysregulations in sugar, methionine, and tyrosine pathways in the prodromal state of AD. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12064.	2.4	15
920	Clinical and biomarker trajectories in sporadic Alzheimer's disease: A longitudinal study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12095.	2.4	14
921	Education and Cognitive Functioning Across the Life Span. Psychological Science in the Public Interest: A Journal of the American Psychological Society, 2020, 21, 6-41.	10.7	397
922	Higher CSF sTREM2 and microglia activation are associated with slower rates of betaâ€amyloid accumulation. EMBO Molecular Medicine, 2020, 12, e12308.	6.9	73
923	Elevated matrix metalloproteinaseâ€9 levels in neuronal extracellular vesicles in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2020, 7, 1681-1691.	3.7	32
924	Elevated Tau PET Signal Depends on Abnormal Amyloid Levels and Correlates with Cognitive Impairment in Elderly Persons without Dementia. Journal of Alzheimer's Disease, 2020, 78, 395-404.	2.6	4
925	Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage1. Journal of Alzheimer's Disease, 2020, 78, 265-276.	2.6	43
926	APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer's disease patient iPSC-derived cerebral organoids. Nature Communications, 2020, 11, 5540.	12.8	172
927	The Framing of "Alzheimer's Disease― Differences Between Scientific and Lay Literature and Their Ethical Implications. Gerontologist, The, 2021, 61, 746-755.	3.9	13
928	The impact of a multi-domain intervention on cerebral glucose metabolism: analysis from the randomized ancillary FDG PET MAPT trial. Alzheimer's Research and Therapy, 2020, 12, 134.	6.2	7
929	Perceived Stress is Associated with Alzheimer's Disease Cerebrospinal Fluid Biomarkers in African Americans with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 77, 843-853.	2.6	7
930	Relationship Between PET-Assessed Amyloid Burden and Visual and Verbal Episodic Memory Performance in Elderly Subjects. Journal of Alzheimer's Disease, 2020, 78, 229-244.	2.6	5
931	Inter-band Bispectral Analysis of EEG Background Activity to Characterize Alzheimer's Disease Continuum. Frontiers in Computational Neuroscience, 2020, 14, 70.	2.1	7
932	Tau pathology associates with in vivo cortical thinning in Lewy body disorders. Annals of Clinical and Translational Neurology, 2020, 7, 2342-2355.	3.7	20
933	CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. Trends in Pharmacological Sciences, 2020, 41, 1023-1037.	8.7	48
934	Cerebrospinal fluid sTREM2 in Alzheimer's disease: comparisons between clinical presentation and AT classification. Scientific Reports, 2020, 10, 15886.	3.3	23
935	Unraveling Pathophysiological Mechanisms of Parkinson's Disease: Contribution of CSF Biomarkers. Biomarker Insights, 2020, 15, 117727192096407.	2.5	7
936	Neurogranin: A Potential Biomarker of Neurological and Mental Diseases. Frontiers in Aging Neuroscience, 2020, 12, 584743.	3.4	37

		CITATION REPORT		
#	Article	IF		Citations
937	A Narrative Review of Alzheimer's Disease Stigma. Journal of Alzheimer's Disease, 2020, 7	′8, 515-528. 2. <i>6</i>	5	25
938	Trajectories of subjective cognitive decline, and the risk of mild cognitive impairment and der Alzheimer's Research and Therapy, 2020, 12, 135.	nentia. 6.2	2	22
939	PET Amyloid and Tau Status Are Differently Affected by Patient Features. Journal of Alzheimer Disease, 2020, 78, 1129-1136.	's 2.6	5	4
940	Brain Renin–Angiotensin System at the Intersect of Physical and Cognitive Frailty. Frontiers Neuroscience, 2020, 14, 586314.	; in 2.8	3	80
941	Exploring a Cost-Efficient Model for Predicting Cerebral AÎ <sup>2</sup> Burden Using MRI and Neuropsyc Markers in the ADNI-2 Cohort. Journal of Personalized Medicine, 2020, 10, 197.	hological 2.5	5	0
942	Neuroimaging in dementias. , 2020, , 187-197.			Ο
943	Cerebrospinal fluid and serum d-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease. Biochimica Et Biophysica Acta - Proteins and Proteomics, 20 140537.	)20, 1868, 2.3	3	19
945	Early neurotransmission impairment in non-invasive Alzheimer Disease detection. Scientific R 2020, 10, 16396.	eports, 3.3	3	11
946	The Prevalence of Mild Cognitive Impairment in a Convenience Sample of 202 Gulf War Veter International Journal of Environmental Research and Public Health, 2020, 17, 7158.	ans. 2.6	5	8
947	CCCDTD5 recommendations on early non cognitive markers of dementia: A Canadian conser Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12068	isus. 3.7 β. 3.7	7	29
948	A dynamic microeconomic analysis of the impact of physical activity on cognition among old Economics and Human Biology, 2020, 39, 100933.	2r people. 1.7	,	4
949	Quality of sleep predicts increased frontoparietal network connectivity in patients with mild cognitive impairment. Neurobiology of Aging, 2020, 95, 205-213.	3.1	L	15
950	Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer's d Neurobiology of Aging, 2020, 96, 233-245.	sease. 3.1	L	20
951	Prediction of clinical and biomarker conformed Alzheimer's disease and mild cognitive im from multi-feature brain structural MRI using age-correction from a large independent lifespa sample. NeuroImage: Clinical, 2020, 28, 102387.	pairment n 2.7	7	9
952	Pre―and early postnatal enriched environmental experiences prevent neonatal hypoxiaâ€isc neurodegeneration via metabolic and neuroplastic mechanisms. Journal of Neurochemistry, 2 1911-1929.	hemia late 021, 157, 3.9	)	4
953	Sequence of Alzheimer disease biomarker changes in cognitively normal adults. Neurology, 2 e3104-e3116.	020, 95, 1.1		35
954	Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on ar Emerging Functional Group in Medicinal Chemistry. Journal of Medicinal Chemistry, 2020, 63 14243-14275.	۱ , 6.4	1	184
955	Interaction between Cognitive Reserve and Biomarkers in Alzheimer Disease. International Jo Molecular Sciences, 2020, 21, 6279.	urnal of 4.1	L	10

#	Article	IF	CITATIONS
956	Predicting Thioflavin Fluorescence of Retinal Amyloid Deposits Associated With Alzheimer's Disease from Their Polarimetric Properties. Translational Vision Science and Technology, 2020, 9, 47.	2.2	13
957	CCCDTD5: research diagnostic criteria for Alzheimer's Disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12036.	3.7	3
958	Association of TDP-43 proteinopathy, cerebral amyloid angiopathy, and Lewy bodies with cognitive impairment in individuals with or without Alzheimer's disease neuropathology. Scientific Reports, 2020, 10, 14579.	3.3	29
959	Extending Alzheimer disease biomarker studies into the Hispanic community. Neurology, 2020, 95, 665-666.	1.1	2
960	A rationally designed bicyclic peptide remodels Aβ42 aggregation in vitro and reduces its toxicity in a worm model of Alzheimer's disease. Scientific Reports, 2020, 10, 15280.	3.3	15
961	Antenatal Hypoxia Accelerates the Onset of Alzheimer's Disease Pathology in 5xFAD Mouse Model. Frontiers in Aging Neuroscience, 2020, 12, 251.	3.4	12
962	Cerebral Small Vessel Disease and Alzheimer's Disease: A Review. Frontiers in Neurology, 2020, 11, 927.	2.4	53
963	β-Hydroxybutyrate inhibits inflammasome activation to attenuate Alzheimer's disease pathology. Journal of Neuroinflammation, 2020, 17, 280.	7.2	117
964	Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease. Molecular Neurodegeneration, 2020, 15, 55.	10.8	107
965	Classifications of Neurodegenerative Disorders Using a Multiplex Blood Biomarkers-Based Machine Learning Model. International Journal of Molecular Sciences, 2020, 21, 6914.	4.1	28
966	Amyloid PET imaging in clinical practice. Practical Neurology, 2020, 20, 451-462.	1.1	28
967	Osteopontin/secreted phosphoprotein-1 behaves as a molecular brake regulating the neuroinflammatory response to chronic viral infection. Journal of Neuroinflammation, 2020, 17, 273.	7.2	14
968	Subjective Cognitive Decline, Cognitive Reserve Indicators, and the Incidence of Dementia. Journal of the American Medical Directors Association, 2021, 22, 1449-1455.e4.	2.5	25
969	A Robust Blood-based Signature of Cerebrospinal Fluid Aβ <sub>42</sub> Status. , 2020, 2020, 5523-5526.		3
970	Association of amyloid-Î <sup>2</sup> CSF/PET discordance and tau load 5 years later. Neurology, 2020, 95, e2648-e2657.	1.1	33
971	Neuro-Retina Might Reflect Alzheimer's Disease Stage. Journal of Alzheimer's Disease, 2020, 77, 1455-1468.	2.6	16
972	FDG PET Data is Associated with Cognitive Performance in Patients from a Memory Clinic. Journal of Alzheimer's Disease, 2020, 78, 207-216.	2.6	4
973	Discordant Alzheimer's neurodegenerative biomarkers and their clinical outcomes. Annals of Clinical and Translational Neurology, 2020, 7, 1996-2009.	3.7	3

	CITATION R	CITATION REPORT	
# 974	ARTICLE Alzheimerâ€Related Cerebrovascular Disease in Down Syndrome. Annals of Neurology, 2020, 88, 1165-1177.	IF 5.3	CITATIONS 34
975	Lower practice effects as a marker of cognitive performance and dementia risk: A literature review. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12055.	2.4	39
976	Long-Term Blood Pressure Variability Across the Clinical and Biomarker Spectrum of Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 1655-1669.	2.6	23
977	Alzheimer's Retinopathy: Seeing Disease in the Eyes. Frontiers in Neuroscience, 2020, 14, 921.	2.8	61
978	Longitudinal evaluation of the natural history of amyloid- $\hat{l}^2$ in plasma and brain. Brain Communications, 2020, 2, fcaa041.	3.3	21
979	Classification of Alzheimer's Disease and Mild Cognitive Impairment Based on Cortical and Subcortical Features from MRI T1 Brain Images Utilizing Four Different Types of Datasets. Journal of Healthcare Engineering, 2020, 2020, 1-14.	1.9	26
980	Early role of iron in modulating amyloid's association with neurodegeneration. Neurology, 2020, 95, 809-810.	1.1	0
981	Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use. Medicinal Research Reviews, 2021, 41, 2775-2803.	10.5	39
982	Machine learningâ€based cognitive impairment classification with optimal combination of neuropsychological tests. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12049.	3.7	16
983	APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease. Acta Neuropathologica, 2020, 140, 477-493.	7.7	117
984	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	2.6	7
985	Classification and Graphical Analysis of Alzheimer's Disease and Its Prodromal Stage Using Multimodal Features From Structural, Diffusion, and Functional Neuroimaging Data and the APOE Genotype. Frontiers in Aging Neuroscience, 2020, 12, 238.	3.4	26
986	Sex differences in CSF biomarkers vary by Alzheimer disease stage and <i>APOE</i> ε4 genotype. Neurology, 2020, 95, e2378-e2388.	1.1	48
987	Apolipoprotein E genotype and in vivo amyloid burden in middle-aged Hispanics. Neurology, 2020, 95, e2086-e2094.	1.1	9
988	Impact of COVID-19 on Alzheimer's Disease Risk: Viewpoint for Research Action. Healthcare (Switzerland), 2020, 8, 286.	2.0	35
989	The pathway to secondary prevention of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12069.	3.7	5
990	Decreased Alpha Reactivity from Eyes-Closed to Eyes-Open in Non-Demented Older Adults with Alzheimer's Disease: A Combined EEG and [18F]florbetaben PET Study. Journal of Alzheimer's Disease, 2020, 77, 1681-1692.	2.6	4
991	Regional Cerebral Associations Between Psychometric Tests and Imaging Biomarkers in Alzheimer's Disease. Frontiers in Psychiatry, 2020, 11, 793.	2.6	7

#	Article	IF	CITATIONS
992	Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use. Journal of Personalized Medicine, 2020, 10, 116.	2.5	26
993	CSF glucose tracks regional tau progression based on Alzheimer's disease risk factors. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12080.	3.7	6
994	Fluid Biomarkers for Synaptic Dysfunction and Loss. Biomarker Insights, 2020, 15, 117727192095031.	2.5	74
995	Subjective cognitive decline, anxiety symptoms, and the risk of mild cognitive impairment and dementia. Alzheimer's Research and Therapy, 2020, 12, 107.	6.2	47
996	Sex Differences in in vivo Alzheimer's Disease Neuropathology in Late Middle-Aged Hispanics. Journal of Alzheimer's Disease, 2020, 74, 1243-1252.	2.6	13
997	Corneal Nerve and Brain Imaging in Mild Cognitive Impairment and Dementia. Journal of Alzheimer's Disease, 2020, 77, 1533-1543.	2.6	20
998	Prevention of Alzheimer's disease and dementia: the evidence is out there, but new high-quality studies and implementation are needed. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1140-1141.	1.9	0
999	Kinetic modeling of dynamic processes in the cholinergic synapse. Russian Chemical Bulletin, 2020, 69, 1585-1593.	1.5	4
1000	An analytic framework for conceptualisations of disease: nine structuring questions and how some conceptualisations of Alzheimer's disease can lead to †diseasisation'. Medicine, Health Care and Philosophy, 2020, 23, 677-693.	1.8	2
1001	Optimizing Use of Neuroimaging Tools in Evaluation of Prodromal Alzheimer's Disease and Related Disorders. Journal of Alzheimer's Disease, 2020, 77, 935-947.	2.6	5
1002	Advances in Non-Pharmacological Interventions for Subjective Cognitive Decline: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2020, 77, 903-920.	2.6	10
1003	Different glycaemiaâ€related risk factors for incident Alzheimer's disease in men and women with type 2 diabetes—A sexâ€specific analysis of the Hong Kong diabetes database. Diabetes/Metabolism Research and Reviews, 2021, 37, e3401.	4.0	5
1004	Cerebrovascular disease promotes tau pathology in Alzheimer's disease. Brain Communications, 2020, 2, fcaa132.	3.3	46
1005	Predementia Neurocognitive Disorders in the Elderly. Neuroscience and Behavioral Physiology, 2020, 50, 687-694.	0.4	0
1006	The Other Side of Alzheimer's Disease: Influence of Metabolic Disorder Features for Novel Diagnostic Biomarkers. Journal of Personalized Medicine, 2020, 10, 115.	2.5	8
1007	Proton Magnetic Resonance Spectroscopy in Common Dementias—Current Status and Perspectives. Frontiers in Psychiatry, 2020, 11, 769.	2.6	21
1008	Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment: Results of the MOPEAD Study in Spain. Journal of Clinical Medicine, 2020, 9, 2726.	2.4	4
1009	Relationship between comprehensive geriatric assessment and amyloid PET in older persons with MCI. BMC Geriatrics, 2020, 20, 337.	2.7	12

#	Article	IF	CITATIONS
1010	Increased Cerebrospinal Fluid Concentration of ZnT3 Is Associated with Cognitive Impairment in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 1143-1155.	2.6	13
1011	Development and Preliminary Validation of Standardized Regression-Based Change Scores as Measures of Transitional Cognitive Decline. Archives of Clinical Neuropsychology, 2020, 35, 1168-1181.	0.5	16
1012	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of diseaseâ€modifying therapies. Alzheimer's and Dementia, 2020, 16, 1457-1468.	0.8	43
1013	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study. PLoS Medicine, 2020, 17, e1003289.	8.4	39
1014	Amyloidogenic Nanoplaques in Cerebrospinal Fluid: Relationship to Amyloid Brain Uptake and Clinical Alzheimer's Disease in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2020, 77, 831-842.	2.6	3
1015	AMPK Ameliorates Tau Acetylation and Memory Impairment Through Sirt1. Molecular Neurobiology, 2020, 57, 5011-5025.	4.0	18
1016	Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 97.	6.2	31
1017	Independent and Correlated Role of Apolipoprotein E ɛ4 Genotype and Herpes Simplex Virus Type 1 in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 15-31.	2.6	4
1018	Identification of Earlier Biomarkers for Alzheimer's Disease: A Multimodal Neuroimaging Study of Individuals with Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2020, 77, 1067-1076.	2.6	12
1019	Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. Brain, 2020, 143, 2844-2857.	7.6	44
1020	Serial position effects in the Logical Memory Test: Loss of primacy predicts amyloid positivity. Journal of Neuropsychology, 2021, 15, 448-461.	1.4	16
1021	Glial activation is moderated by sex in response to amyloidosis but not to tau pathology in mouse models of neurodegenerative diseases. Journal of Neuroinflammation, 2020, 17, 374.	7.2	28
1022	Metabotropic Glutamate Receptors in Alzheimer's Disease Synaptic Dysfunction: Therapeutic Opportunities and Hope for the Future. Journal of Alzheimer's Disease, 2020, 78, 1345-1361.	2.6	20
1023	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's <i>continuum</i> when only subtle changes in Aβ pathology are detected. EMBO Molecular Medicine, 2020, 12, e12921.	6.9	202
1025	Reduced monoaminergic nuclei MRI signal detectable in pre-symptomatic older adults with future memory decline. Scientific Reports, 2020, 10, 18707.	3.3	15
1026	Concordance in detecting amyloid positivity between 18F-florbetaben and 18F-flutemetamol amyloid PET using quantitative and qualitative assessments. Scientific Reports, 2020, 10, 19576.	3.3	18
1027	Spatial patterns of correlation between cortical amyloid and cortical thickness in a tertiary clinical population with memory deficit. Scientific Reports, 2020, 10, 20717.	3.3	2
1028	Cellular correlates of cortical thinning throughout the lifespan. Scientific Reports, 2020, 10, 21803.	3.3	80

#	Article	IF	CITATIONS
1029	An Ensemble-Learning Based Application to Predict the Earlier Stages of Alzheimer's Disease (AD). IEEE Access, 2020, 8, 222126-222143.	4.2	16
1030	Distinct Brain Functional Impairment Patterns Between Suspected Non-Alzheimer Disease Pathophysiology and Alzheimer's Disease: A Study Combining Static and Dynamic Functional Magnetic Resonance Imaging. Frontiers in Aging Neuroscience, 2020, 12, 550664.	3.4	14
1031	Nutritional interventions for the prevention of cognitive impairment and dementia in developing economies in East-Asia: a systematic review and meta-analysis. Critical Reviews in Food Science and Nutrition, 2020, , 1-18.	10.3	12
1032	Hyperspectral Imaging for Major Neurocognitive Disorder Detection in Plasma Samples. , 2020, , .		Ο
1033	Saliva Biomarkers in Diagnostics of Early Stages of Alzheimer's Disease. Neurochemical Journal, 2020, 14, 429-438.	0.5	5
1034	Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study. Alzheimer's Research and Therapy, 2020, 12, 167.	6.2	64
1035	Noninvasive Measurement of [11C]PiB Distribution Volume Using Integrated PET/MRI. Diagnostics, 2020, 10, 993.	2.6	3
1036	Distinct effects of betaâ€amyloid and tau on cortical thickness in cognitively healthy older adults. Alzheimer's and Dementia, 2021, 17, 1085-1096.	0.8	34
1037	Radiomics Analysis of Magnetic Resonance Imaging Facilitates the Identification of Preclinical Alzheimer's Disease: An Exploratory Study. Frontiers in Cell and Developmental Biology, 2020, 8, 605734.	3.7	27
1038	Case Report: [18F]Pl2620 as a Tau Imaging Agent in Posterior Cortical Atrophy. Frontiers in Neurology, 2020, 11, 566667.	2.4	1
1039	Alterations in resting-state network dynamics along the Alzheimer's disease continuum. Scientific Reports, 2020, 10, 21990.	3.3	29
1040	A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12128.	2.4	16
1041	Effectiveness of psychosocial interventions among older adults with mild cognitive impairment: a systematic review and meta-analysis. Aging and Mental Health, 2021, 25, 1986-1997.	2.8	15
1042	Vaccination against β-Amyloid as a Strategy for the Prevention of Alzheimer's Disease. Biology, 2020, 9, 425.	2.8	26
1043	A 5-min Cognitive Task With Deep Learning Accurately Detects Early Alzheimer's Disease. Frontiers in Aging Neuroscience, 2020, 12, 603179.	3.4	13
1044	Face Recognition Deficits in a Patient With Alzheimer's Disease: Amnesia or Agnosia? The Importance of Electrophysiological Markers for Differential Diagnosis. Frontiers in Aging Neuroscience, 2020, 12, 580609.	3.4	7
1045	Circadian fragmentation: a harbinger of Alzheimer's disease?. The Lancet Healthy Longevity, 2020, 1, e90-e91.	4.6	0
1046	Locus coeruleus connectivity alterations in late-life major depressive disorder during a visual oddball task. NeuroImage: Clinical, 2020, 28, 102482.	2.7	14

#	Article	IF	CITATIONS
1047	<i>In vivo</i> imaging evidence of poor cognitive resilience to Alzheimer's disease pathology in subjects with very low cognitive reserve from a lowâ€middle income environment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12122.	2.4	4
1048	Quantitative informant―and selfâ€reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE ε4. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12127.	2.4	6
1049	Evaluation of a visual interpretation method for tauâ€PET with <sup>18</sup> Fâ€flortaucipir. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12133.	2.4	17
1050	Chronic Posttraumatic Stress Disorder and Comorbid Cognitive and Physical Impairments in World Trade Center Responders. Journal of Traumatic Stress, 2020, 34, 616-627.	1.8	12
1051	APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12117.	3.7	12
1052	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. Nature Communications, 2020, 11, 6252.	12.8	36
1053	The variability of functional MRI brain signal increases in Alzheimer's disease at cardiorespiratory frequencies. Scientific Reports, 2020, 10, 21559.	3.3	28
1054	Biomarkers: Our Path Towards a Cure for Alzheimer Disease. Biomarker Insights, 2020, 15, 117727192097636.	2.5	21
1055	Exploring the role of RALYL in Alzheimer's disease reserve by network-based approaches. Alzheimer's Research and Therapy, 2020, 12, 165.	6.2	5
1056	Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases. Cells, 2020, 9, 2581.	4.1	20
1057	Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity. Molecular Psychiatry, 2021, 26, 5864-5874.	7.9	22
1058	Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. Journal of Alzheimer's Disease, 2020, 78, 1137-1148.	2.6	5
1059	Uncharacterized RNAs in Plasma of Alzheimer's Patients Are Associated with Cognitive Impairment and Show a Potential Diagnostic Power. International Journal of Molecular Sciences, 2020, 21, 7644.	4.1	7
1060	A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease Using Artificial Intelligence and Machine Learning. Journal of Alzheimer's Disease, 2020, 78, 1381-1392.	2.6	16
1061	Neuromodulation in the Treatment of Alzheimer's Disease: Current and Emerging Approaches. Journal of Alzheimer's Disease, 2020, 78, 1299-1313.	2.6	7
1062	Challenges of BDNF-based therapies: From common to rare diseases. Pharmacological Research, 2020, 162, 105281.	7.1	29
1063	A Brief Version of the LASSI-L Detects Prodromal Alzheimer's Disease States. Journal of Alzheimer's Disease, 2020, 78, 789-799.	2.6	3
1064	Editorial: Language and Mild Cognitive Impairment. Frontiers in Psychology, 2020, 11, 2264.	2.1	2

# 1065	ARTICLE Valor pronÃ <sup>3</sup> stico de los biomarcadores licuorales en el deterioro cognitivo leve debido a enfermedad de Alzheimer. NeurologÃa, 2023, 38, 262-269.	IF 0.7	CITATIONS
1066	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. Alzheimer's Research and Therapy, 2020, 12, 138.	6.2	14
1067	NON-AMYLOID APPROACHES TO DISEASE MODIFICATION FOR ALZHEIMER'S DISEASE: AN EU/US CTAD TASK FORCE REPORT. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-6.	2.7	15
1068	Tauopathy and Movement Disorders—Unveiling the Chameleons and Mimics. Frontiers in Neurology, 2020, 11, 599384.	2.4	16
1069	It's Not Alzheimer Disease; Now What?. , 2020, , 141-143.		0
1070	Cerebral Amyloid Angiopathy. Stroke, 2020, 51, 3487-3488.	2.0	7
1071	α-Secretase nonsense mutation (ADAM10 Tyr167*) in familial Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 139.	6.2	13
1072	Brainstem Volumetric Integrity in Preclinical and Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 1579-1594.	2.6	19
1073	Developmental Exposure to Air Pollution, Cigarettes, and Lead: Implications for Brain Aging. Annual Review of Developmental Psychology, 2020, 2, 585-614.	2.9	4
1074	Potential benefit from extension of IADL scale. International Psychogeriatrics, 2020, 32, 1013-1014.	1.0	1
1075	Serum triglycerides in Alzheimer disease. Neurology, 2020, 94, e2088-e2098.	1.1	63
1076	Amyloid Plaques and Symptoms of Depression Links to Medical Help-Seeking due to Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2020, 75, 879-890.	2.6	7
1077	Cerebral Microhemorrhage at MRI in Mild Cognitive Impairment and Early Alzheimer Disease: Association with Tau and Amyloid β at PET Imaging. Radiology, 2020, 296, 134-142.	7.3	10
1078	Evolution of the Research Literature and the Scientific Community of Alzheimer's Disease from 1983-2017: A 35-Year Survey. Journal of Alzheimer's Disease, 2020, 75, 1105-1134.	2.6	2
1079	The Efficacy of COGnitive tRaining in patiEnts with Amnestic mild coGnitive impairmENT (COG-REAGENT): Protocol for a Multi-Center Randomized Controlled Trial. Journal of Alzheimer's Disease, 2020, 75, 779-787.	2.6	2
1080	Differential blood miRNA expression in brain amyloid imaging-defined Alzheimer's disease and controls. Alzheimer's Research and Therapy, 2020, 12, 59.	6.2	35
1081	Aggregates of RNA Binding Proteins and ER Chaperones Linked to Exosomes in Granulovacuolar Degeneration of the Alzheimer's Disease Brain. Journal of Alzheimer's Disease, 2020, 75, 139-156.	2.6	22
1082	Quantifying and Describing the Natural History and Costs of Alzheimer's Disease and Effects of Hypothetical Interventions. Journal of Alzheimer's Disease, 2020, 75, 891-902.	2.6	22

#	Article	IF	CITATIONS
1083	Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Are Irreversible Inhibitors the Future?. International Journal of Molecular Sciences, 2020, 21, 3438.	4.1	55
1084	Extensive memory testing improves prediction of progression to MCI in late middle age. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12004.	2.4	13
1085	PyrPeg, a Blood–Brain-Barrier-Penetrating Two-Photon Imaging Probe, Selectively Detects Neuritic Plaques, Not Tau Aggregates. ACS Chemical Neuroscience, 2020, 11, 1801-1810.	3.5	9
1086	Nexus between cognitive reserve and modifiable risk factors of dementia. International Psychogeriatrics, 2020, 32, 559-562.	1.0	5
1087	Profiles of Cognitive Change in Preclinical and Prodromal Alzheimer's Disease Using Change-Point Analysis. Journal of Alzheimer's Disease, 2020, 75, 1169-1180.	2.6	21
1088	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurology, 2020, 77, 955.	9.0	136
1089	SWATH-MS analysis of cerebrospinal fluid to generate a robust battery of biomarkers for Alzheimer's disease. Scientific Reports, 2020, 10, 7423.	3.3	13
1090	Subjective cognitive decline and subsequent dementia: a nationwide cohort study of 579,710 people aged 66 years in South Korea. Alzheimer's Research and Therapy, 2020, 12, 52.	6.2	22
1091	Alzheimer's disease progression characterized by alterations in the molecular profiles and biogenesis of brain extracellular vesicles. Alzheimer's Research and Therapy, 2020, 12, 54.	6.2	47
1092	Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia. Alzheimer's Research and Therapy, 2020, 12, 55.	6.2	21
1093	Integrating Convolutional Neural Networks and Multi-Task Dictionary Learning for Cognitive Decline Prediction with Longitudinal Images. Journal of Alzheimer's Disease, 2020, 75, 971-992.	2.6	9
1094	Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer's Disease Spectrum with Amyloid PET Imaging. Journal of Alzheimer's Disease, 2020, 75, 949-958.	2.6	7
1095	Pre-Diabetes, but not Type 2 Diabetes, IsÂRelated to Brain Amyloid in Late Middle-Age. Journal of Alzheimer's Disease, 2020, 75, 1241-1252.	2.6	18
1096	The implications of different approaches to define AT(N) in Alzheimer disease. Neurology, 2020, 94, e2233-e2244.	1.1	80
1097	Pathway Analysis for Plasma β-Amyloid, Tau and Neurofilament Light (ATN) in World Trade Center Responders at Midlife. Neurology and Therapy, 2020, 9, 159-171.	3.2	20
1098	Approach to the Older Adult With New Cognitive Symptoms. Mayo Clinic Proceedings, 2020, 95, 1281-1292.	3.0	3
1099	A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease. Neurobiology of Aging, 2020, 94, 60-70.	3.1	35
1100	Extracellular Sortilin Proteopathy Relative to β-Amyloid and Tau in Aged and Alzheimer's Disease Human Brains. Frontiers in Aging Neuroscience, 2020, 12, 93.	3.4	10

#	Article	IF	CITATIONS
1101	Effect of a multicomponent exercise intervention on brain metabolism: A randomized controlled trial on Alzheimer's pathology (Dementiaâ€MOVE). Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12032.	3.7	12
1102	LTP-like cortical plasticity predicts conversion to dementia in patients with memory impairment. Brain Stimulation, 2020, 13, 1175-1182.	1.6	51
1103	In vivo MRI Structural and PET Metabolic Connectivity Study of Dopamine Pathways in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 75, 1003-1016.	2.6	23
1104	Questioning the Meaning of a Change on the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog): Noncomparable Scores and Item-Specific Effects Over Time. Assessment, 2021, 28, 1708-1722.	3.1	5
1105	Relevance of biomarkers across different neurodegenerative diseases. Alzheimer's Research and Therapy, 2020, 12, 56.	6.2	42
1106	Theta-Burst Stimulation for Auditory-Verbal Hallucination in Very-Late-Onset Schizophrenia-Like Psychosis—A Functional Magnetic Resonance Imaging Case Study. Frontiers in Psychiatry, 2020, 11, 294.	2.6	5
1107	Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review. Journal of the Neurological Sciences, 2020, 415, 116886.	0.6	13
1108	Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals. International Journal of Molecular Sciences, 2020, 21, 3158.	4.1	12
1109	Shared Genomic and Proteomic Contribution of Amyloid and Tau Protein Characteristic of Alzheimer's Disease to Brain Ischemia. International Journal of Molecular Sciences, 2020, 21, 3186.	4.1	15
1110	Positron Emission Tomography Imaging With [ <sup>18</sup> F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurology, 2020, 77, 829.	9.0	244
1111	Cerebral amyloid angiopathy with focal presentation—about 3 cases. Neuroradiology, 2020, 62, 1195-1197.	2.2	0
1112	CSF p-tau/Aβ42 ratio and brain FDG-PET may reliably detect MCI "imminent―converters to AD. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3152-3164.	6.4	26
1113	Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3165-3175.	6.4	28
1114	Neuropsychiatric Aspects of Alzheimer Dementia. Psychiatric Clinics of North America, 2020, 43, 383-397.	1.3	3
1115	Advances in amyloid beta oligomer detection applications in Alzheimer's disease. TrAC - Trends in Analytical Chemistry, 2020, 129, 115919.	11.4	25
1116	Orthostatic Blood Pressure Recovery Is Associated With the Rate of Cognitive Decline and Mortality in Clinical Alzheimer's Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 2169-2176.	3.6	10
1117	Carotid Stiffness is Associated with Brain Amyloid-β Burden in Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 74, 925-935.	2.6	19
1118	Looking for a Treatment for the Early Stage of Alzheimer's Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin. International Journal of Molecular	4.1	24

ARTICLE IF CITATIONS Detection of Mild Cognitive Impairment Using Convolutional Neural Network: Temporal-Feature Maps 1119 3.4 49 of Functional Near-Infrared Spectroscopy. Frontiers in Aging Neuroscience, 2020, 12, 141. Prediction of conversion to Alzheimer's disease using deep survival analysis of MRI images. Brain 3.3 29 Communications, 2020, 2, fcaa057. Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and 1121 3.3 81 comparison to other phenotypes. Brain Communications, 2020, 2, fcaa068. Characterizing Frequency-Selective Network Vulnerability for Alzheimer's Disease by Identifying Critical Harmonic Patterns. , 2020, 2020, 1009-1012. Alzheimer's Disease: What Can We Learn From the Peripheral Olfactory System?. Frontiers in 1123 2.8 30 Neuroscience, 2020, 14, 440. Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer's disease. Clinical Proteomics, 2020, 17, 19. 1124 2.1 Optical coherence tomography angiography as a potential screening tool for cerebral small vessel 1125 6.2 44 diseases. Alzheimer's Research and Therapy, 2020, 12, 73. ATN classification and clinical progression in subjective cognitive decline. Neurology, 2020, 95, 1.1 е46-е58. Generalizable, Reproducible, and Neuroscientifically Interpretable Imaging Biomarkers for Alzheimer's 1127 11.2 53 Disease. Advanced Science, 2020, 7, 2000675. Characterizing the Propagation Pattern of Neurodegeneration in Alzheimer's Disease by Longitudinal Network Analysis. , 2020, 2020, 292-295. Dynamic association between AT(N) profile and cognition mediated by cortical thickness in Alzheimer's 1129 2.7 2 continuum. NeuroImage: Clinical, 2020, 27, 102282. Progressive Memory Circuit Impairments along with Alzheimer's Disease Neuropathology Spread: 2.9 Evidence from in vivo Neuroimaging. Cerebral Cortex, 2020, 30, 5863-5873. The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease. Alzheimer's Research 1131 6.2 53 and Therapy, 2020, 12, 74. Generalization of deep learning models for ultra-low-count amyloid PET/MRI using transfer learning. 6.4 29 European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2998-3007. Training the next generation of radiopharmaceutical scientists. Nuclear Medicine and Biology, 2020, 88-89, 10-13. 1133 0.6 7 Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the 1134 120 Alzheimer's <i>continuum</i>. Alzheimer's and Dementia, 2020, 16, 1358-1371. Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer's Disease Dementia: Findings from the Ontario Neurodegenerative Disease Research Initiative 1135 2.6 9 (ONDRI) Study and Clinical Trials Over the Past 10 Years. Journal of Alzheimer's Disease, 2020, 74, 747-757 Towards a Redefinition of Cognitive Frailty. Journal of Alzheimer's Disease, 2020, 76, 831-843.

#	Article	IF	CITATIONS
1137	Cognition and the Predictive Utility of Three Risk Scores in an Ethnically Diverse Sample. Journal of Alzheimer's Disease, 2020, 75, 1049-1059.	2.6	6
1138	Association of microbiota-derived propionic acid and Alzheimer's disease; bioinformatics analysis. Journal of Diabetes and Metabolic Disorders, 2020, 19, 783-804.	1.9	8
1139	A novel mutation in PSEN1 (p.Arg41Ser) in an Argentinian woman with early onset Parkinsonism. Parkinsonism and Related Disorders, 2020, 77, 21-25.	2.2	13
1140	Prognostic value of ATN Alzheimer biomarkers: 60â€month followâ€up results from the Argentine Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12026.	2.4	20
1141	TDP-43 Is Elevated in Plasma Neuronal-Derived Exosomes of Patients With Alzheimer's Disease. Frontiers in Aging Neuroscience, 2020, 12, 166.	3.4	21
1142	Rational design of a conformation-specific antibody for the quantification of AÎ <sup>2</sup> oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13509-13518.	7.1	61
1143	Predictors of pre-operative cognitive impairment in meningioma patients over 60 years old. BMC Neurology, 2020, 20, 225.	1.8	4
1144	Reproducibility of EEG functional connectivity in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 68.	6.2	73
1145	How Age-Related Changes in the Brain Affect Cognition. , 2020, , 47-61.		2
1146	Repetitive negative thinking is associated with amyloid, tau, and cognitive decline. Alzheimer's and Dementia, 2020, 16, 1054-1064.	0.8	52
1147	Characterizing white matter connectivity in Alzheimer's disease and mild cognitive impairment: An automated fiber quantification analysis with two independent datasets. Cortex, 2020, 129, 390-405.	2.4	30
1148	Protective Role of Cerebrospinal Fluid Inflammatory Cytokines in Patients with Amnestic Mild Cognitive Impairment and Early Alzheimer's Disease Carrying Apolipoprotein E4 Genotype. Journal of Alzheimer's Disease, 2020, 76, 681-689.	2.6	27
1149	Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimer's Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 76, 261-274.	2.6	25
1150	Resting State Functional Connectivity Signature Differentiates Cognitively Normal from Individuals Who Convert to Symptomatic Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 74, 1085-1095.	2.6	18
1151	Depression is Associated with Tau and Not Amyloid Positron Emission Tomography in Cognitively Normal Adults. Journal of Alzheimer's Disease, 2020, 74, 1045-1055.	2.6	52
1152	Behavioral psychological symptoms of dementia and functional connectivity changes: a network-based study. Neurobiology of Aging, 2020, 94, 196-206.	3.1	9
1153	Link between Diabetes and Alzheimer's Disease Due to the Shared Amyloid Aggregation and Deposition Involving Both Neurodegenerative Changes and Neurovascular Damages. Journal of Clinical Medicine, 2020, 9, 1713.	2.4	56
1154	Macular Thickness Decrease in Asymptomatic Subjects at High Genetic Risk of Developing Alzheimer's Disease: An OCT Study. Journal of Clinical Medicine, 2020, 9, 1728.	2.4	22

#	Article	IF	CITATIONS
1155	Translational Scoring of Candidate Treatments for Alzheimer's Disease: A Systematic Approach. Dementia and Geriatric Cognitive Disorders, 2020, 49, 22-37.	1.5	5
1156	Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults. NeuroImage, 2020, 220, 116991.	4.2	31
1157	Optical coherence tomography reveals light-dependent retinal responses in Alzheimer's disease. NeuroImage, 2020, 219, 117022.	4.2	11
1158	Upregulation of AMPK Ameliorates Alzheimer's Disease-Like Tau Pathology and Memory Impairment. Molecular Neurobiology, 2020, 57, 3349-3361.	4.0	27
1159	Neuroanatomical and cognitive correlates of domain-specific anosognosia in early Alzheimer's disease. Cortex, 2020, 129, 236-246.	2.4	18
1160	A typology of clinical conditions. Studies in History and Philosophy of Science Part C:Studies in History and Philosophy of Biological and Biomedical Sciences, 2020, 83, 101291.	1.3	12
1161	Targeting Microglial Population Dynamics in Alzheimer's Disease: Are We Ready for a Potential Impact on Immune Function?. Frontiers in Cellular Neuroscience, 2020, 14, 149.	3.7	19
1162	Indicators of rapid cognitive decline in amnestic mild cognitive impairment: The role of plasma biomarkers using magnetically labeled immunoassays. Journal of Psychiatric Research, 2020, 129, 66-72.	3.1	15
1163	Could Early Identification of Changes in Olfactory Function Be an Indicator of Preclinical Neurodegenerative Disease? A Systematic Review. Neurology and Therapy, 2020, 9, 243-263.	3.2	10
1164	Impact of APOE-ε4 carriage on the onset and rates of neocortical Aβ-amyloid deposition. Neurobiology of Aging, 2020, 95, 46-55.	3.1	32
1165	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. Molecular Neurodegeneration, 2020, 15, 36.	10.8	46
1166	The CNS-specific proteoglycan, brevican, and its ADAMTS4-cleaved fragment show differential serological levels in Alzheimer's disease, other types of dementia and non-demented controls: A cross-sectional study. PLoS ONE, 2020, 15, e0234632.	2.5	8
1167	Clinical Experience in Treatment of Alzheimer's Disease with Jiannao Yizhi Formula (å¥è"'益智æ–1) and Ro Western Medicine. Chinese Journal of Integrative Medicine, 2020, 26, 212-218.	utine 1.6	6
1168	The wrinkling of time: Aging, inflammation, oxidative stress, and the circadian clock in neurodegeneration. Neurobiology of Disease, 2020, 139, 104832.	4.4	72
1169	Innovative IgG Biomarkers Based on Phage Display Microbial Amyloid Mimotope for State and Stage Diagnosis in Alzheimer's Disease. ACS Chemical Neuroscience, 2020, 11, 1013-1026.	3.5	17
1170	Interest of biological biomarkers in the diagnostic approach of neurocognitive disorders in the elderly. Revue Neurologique, 2020, 176, 677-683.	1.5	9
1171	Select Atrophied Regions in Alzheimer disease (SARA): An improved volumetric model for identifying Alzheimer disease dementia. NeuroImage: Clinical, 2020, 26, 102248.	2.7	24
1172	Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy. Journal of Neuropathology and Experimental Neurology, 2020, 79, 465-473.	1.7	17

#	Article	IF	CITATIONS
1173	A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemoryA®) for the early detection of Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 25.	6.2	24
1174	Spectrum-specific encephalography standardized low-resolution brain electromagnetic tomography network and gray matter correlations in vascular dementia patients. International Journal of Distributed Sensor Networks, 2020, 16, 155014771989596.	2.2	1
1175	Functional neuroimaging in subjective cognitive decline: current status and a research path forward. Alzheimer's Research and Therapy, 2020, 12, 23.	6.2	41
1176	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nature Medicine, 2020, 26, 398-407.	30.7	351
1177	Shared neural substrates of cognitive function and postural control in older adults. Alzheimer's and Dementia, 2020, 16, 621-629.	0.8	6
1178	Multiparametric imaging hippocampal neurodegeneration and functional connectivity with simultaneous PET/MRI in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2440-2452.	6.4	34
1179	Neurophysiological signatures in Alzheimer's disease are distinctly associated with TAU, amyloid-β accumulation, and cognitive decline. Science Translational Medicine, 2020, 12, .	12.4	59
1180	Nanoparticles as contrast agents for the diagnosis of Alzheimer's disease: a systematic review. Nanomedicine, 2020, 15, 725-743.	3.3	26
1181	The MemClin project: a prospective multi memory clinics study targeting early stages of cognitive impairment. BMC Geriatrics, 2020, 20, 93.	2.7	6
1182	The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 21.	6.2	183
1183	Association of Late-Onset Unprovoked Seizures of Unknown Etiology With the Risk of Developing Dementia in Older Veterans. JAMA Neurology, 2020, 77, 710.	9.0	52
1184	Proven validity and management impact of amyloid imaging in Alzheimer's disease—repetita juvant. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1787-1790.	6.4	1
1185	Self-reported Sleep Problems Related to Amyloid Deposition in Cortical Regions with High HOMER1 Gene Expression. Cerebral Cortex, 2020, 30, 2144-2156.	2.9	13
1186	Prevalence of mild cognitive impairment in typeÂ2 diabetes mellitus is associated with serum galectinâ€ <del>3</del> level. Journal of Diabetes Investigation, 2020, 11, 1295-1302.	2.4	10
1187	Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase. Alzheimer's Research and Therapy, 2020, 12, 27.	6.2	20
1188	The effect of ApoE ε 4 on clinical and structural MRI markers in prodromal Alzheimer's disease. Quantitative Imaging in Medicine and Surgery, 2020, 10, 464-474.	2.0	13
1189	Exposure to surgery with general anaesthesia during adult life is not associated with increased brain amyloid deposition in older adults. British Journal of Anaesthesia, 2020, 124, 594-602.	3.4	14
1190	Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nature Reviews Neurology, 2020, 16, 213-228.	10.1	73

#	Article	IF	CITATIONS
1191	Virtual reality and real-time neurofeedback functional MRI: a breakthrough in foreseeing Alzheimer's disease?. Brain, 2020, 143, 722-726.	7.6	6
1192	Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study. Brain, 2020, 143, 1220-1232.	7.6	201
1193	Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis. PLoS ONE, 2020, 15, e0229819.	2.5	92
1194	The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. Alzheimer's Research and Therapy, 2020, 12, 30.	6.2	14
1195	Biomarker potential of brainâ€secreted extracellular vesicles in blood in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12001.	2.4	41
1196	Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid. Neurobiology of Aging, 2020, 93, 144.e1-144.e15.	3.1	7
1197	Scalable diagnostic screening of mild cognitive impairment using Al dialogue agent. Scientific Reports, 2020, 10, 5732.	3.3	14
1198	Medial temporal lobe connectivity and its associations with cognition in early Alzheimer's disease. Brain, 2020, 143, 1233-1248.	7.6	164
1199	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathologica, 2020, 139, 1025-1044.	7.7	40
1200	Objective measurement of sleep in mild cognitive impairment: A systematic review and meta-analysis. Sleep Medicine Reviews, 2020, 52, 101308.	8.5	69
1201	Current and Future Treatments in Alzheimer Disease: An Update. Journal of Central Nervous System Disease, 2020, 12, 117957352090739.	1.9	413
1202	Genetic Association of FERMT2, HLA-DRB1, CD2AP, and PTK2B Polymorphisms With Alzheimer's Disease Risk in the Southern Chinese Population. Frontiers in Aging Neuroscience, 2020, 12, 16.	3.4	18
1203	Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 22.	6.2	74
1204	A transistor-based label-free immunosensor for rapid detection of tau protein. Biosensors and Bioelectronics, 2020, 159, 112129.	10.1	25
1205	Topographical distribution of AÎ <sup>2</sup> predicts progression to dementia in AÎ <sup>2</sup> positive mild cognitive impairment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12037.	2.4	7
1206	Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database. Journal of the Neurological Sciences 2020 416 116989	0.6	18
1207	Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. Molecular Psychiatry, 2021, 26, 5989-6001.	7.9	28
1208	CSF biomarkers in Olmsted County. Neurology, 2020, 95, e256-e267.	1.1	14

#	Article	IF	Citations
1209	Immunoadsorption for Treatment of Patients with Suspected Alzheimer Dementia and Agonistic Autoantibodies against Alpha1a-Adrenoceptor—Rationale and Design of the IMAD Pilot Study. Journal of Clinical Medicine, 2020, 9, 1919.	2.4	4
1210	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet, The, 2020, 395, 1988-1997.	13.7	164
1211	The Hypothesis That Refuses to Die. , 2020, , 95-104.		0
1212	Plasma Neurofilament Light: A Marker of Neurodegeneration in Mild Behavioral Impairment. Journal of Alzheimer's Disease, 2020, 76, 1017-1027.	2.6	68
1213	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2020, 76, 1061-1070.	2.6	13
1215	The Shaky Six and the "Second Reality― , 2020, , 1-10.		0
1216	Pieces of a Puzzle?. , 2020, , 11-24.		0
1217	Disease "Redefinition†A Tough Pill to Swallow. , 2020, , 25-32.		0
1218	Disease Subtypes: The Promise and the Fallacy. , 2020, , 33-40.		2
1219	Protein Paradox. , 2020, , 41-56.		0
1220	The Fault in Our Models. , 2020, , 57-70.		0
1221	Biomarkers: The Promise and the Fallacy. , 2020, , 71-80.		0
1222	Lessons from Oncology. , 2020, , 81-86.		0
1223	Symptomatic vs. Disease-Modifying Therapies. , 2020, , 87-94.		3
1224	Our Living Dissonance. , 2020, , 105-110.		0
1225	The Scientific and Lay Narratives. , 2020, , 111-124.		0
1226	Challenges Viewed from Afar. , 2020, , 125-132.		0
1227	The Moonshot: Population-Based Studies of Aging. , 2020, , 133-138.		0

IF

CITATIONS

0

# ARTICLE

1228 Predictions for the 2020s and Beyond., 2020, , 139-147.

Note Added at Press Time – Reviving LOF. , 2020, , 150-150. 1229 Predicting Clinical Dementia Rating Using Blood RNA Levels. Genes, 2020, 11, 706. 2.4 1231 10 Pineal volume reduction in patients with mild cognitive impairment who converted to Alzheimer's 1.8 disease. Psychiatry and Clinical Neurosciences, 2020, 74, 587-593. Expectations and Concerns of Older Adults With Cognitive Impairment About Their Relationship With 1234 2.1 7 Medical Providers: A Call for Therapeutic Alliances. Qualitative Health Research, 2020, 30, 1584-1595. Interactive Effects of Apolipoprotein E  $\hat{I}\mu$ 4 and Triiodothyronine on Memory Performance in Patients 2.6 With Subjective Cognitive Decline. Frontiers in Medicine, 2020, 7, 298. Incremental Value of CSF Biomarkers in Clinically Diagnosed AD and Non-AD Dementia. Frontiers in 1236 2.4 4 Neurology, 2020, 11, 560. Associations of [18F]-APN-1607 Tau PET Binding in the Brain of Alzheimer's Disease Patients With 2.8 Cognition and Glucose Metabolism. Frontiers in Neuroscience, 2020, 14, 604. Deciphering Alzheimer's disease: predicting new therapeutic strategies via improved understanding of 1238 3.4 11 biology and pathogenesis. Expert Opinion on Therapeutic Targets, 2020, 24, 859-868. Association of baseline semantic fluency and progression to mild cognitive impairment in middle-aged 1239 1.1 men. Neurology, 2020, 95, e973-e983. What older adults do with the results of dementia screening programs. PLoS ONE, 2020, 15, e0235534. 1240 2.5 25 Steady-state cerebral autoregulation in older adults with amnestic mild cognitive impairment: linear 1241 2.5 mixed model analysis. Journal of Applied Physiology, 2020, 129, 377-385. The Toxicity and Polymorphism of Î<sup>2</sup>-Amyloid Oligomers. International Journal of Molecular Sciences, 1242 4.1 80 2020, 21, 4477. β-amyloid and tau drive early Alzheimer's disease decline while glucose hypometabolism drives late 1243 4.4 63 decline. Communications Biology, 2020, 3, 352 Dysautonomia in Alzheimer's Disease. Medicina (Lithuania), 2020, 56, 337. 2.0 1244 11 Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology, 2020, 95, 1245 1.1 58 e1134-e1143. Nonlinear biomarker interactions in conversion from mild cognitive impairment to Alzheimer's 1246 3.6 23 disease. Human Brain Mapping, 2020, 41, 4406-4418. Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in 1247 5.2 Alzheimer's disease and other tauopathies. Acta Neuropathologica Communications, 2020, 8, 88.

#	Article	IF	CITATIONS
1248	Design and Rationale of the PACt-MD Randomized Clinical Trial: Prevention of Alzheimer's dementia with Cognitive remediation plus transcranial direct current stimulation in Mild cognitive impairment and Depression. Journal of Alzheimer's Disease, 2020, 76, 733-751.	2.6	27
1249	Profiles of cognitive impairment in the continuum from normal cognition to Alzheimer's clinical syndrome: Contributions of the shortâ€ŧerm memory binding tests. International Journal of Geriatric Psychiatry, 2020, 35, 1331-1340.	2.7	4
1250	Preclinical Alzheimer Disease Drug Development: Early Considerations Based on Phase 3 Clinical Trials. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 888-900.	0.9	6
1251	Protocol of Aerobic Exercise and Cognitive Health (REACH): A Pilot Study. Journal of Alzheimer's Disease Reports, 2020, 4, 107-121.	2.2	7
1252	Relation of plasma <i>β</i> â€amyloid, clusterin, and tau with cerebral microbleeds: Framingham Heart Study. Annals of Clinical and Translational Neurology, 2020, 7, 1083-1091.	3.7	18
1253	Cerebrovascular reactivity in cerebral amyloid angiopathy, Alzheimer disease, and mild cognitive impairment. Neurology, 2020, 95, e1333-e1340.	1.1	18
1254	Initial Physician Experience with [18F]Flutemetamol Amyloid PET Imaging Following Availability for Routine Clinical Use in Japan. Journal of Alzheimer's Disease Reports, 2020, 4, 165-174.	2.2	3
1256	Modelling prognostic trajectories of cognitive decline due to Alzheimer's disease. NeuroImage: Clinical, 2020, 26, 102199.	2.7	48
1257	Using machine learning to quantify structural <scp>MRI</scp> neurodegeneration patterns of Alzheimer's disease into dementia score: Independent validation on 8,834 images from ADNI, AIBL, OASIS, and MIRIAD databases. Human Brain Mapping, 2020, 41, 4127-4147.	3.6	51
1258	Correlation between cognition and plasma noradrenaline level in Alzheimer's disease: a potential new blood marker of disease evolution. Translational Psychiatry, 2020, 10, 213.	4.8	16
1259	A Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders. Frontiers in Neurology, 2020, 11, 614.	2.4	38
1260	Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer's disease. Annals of Clinical and Translational Neurology, 2020, 7, 1225-1239.	3.7	19
1261	A single ultrasensitive assay for detection and discrimination of tau aggregates of Alzheimer and Pick diseases. Acta Neuropathologica Communications, 2020, 8, 22.	5.2	64
1262	Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation. Brain, 2020, 143, 976-992.	7.6	16
1263	Update on Treatments for Cognitive Decline in Alzheimer's Disease. Journal for Nurse Practitioners, 2020, 16, 181-185.	0.8	0
1264	<i>APOE4</i> Accelerates Development of Dementia After Stroke. Stroke, 2020, 51, 699-700.	2.0	16
1265	Associations of Widowhood and β-Amyloid With Cognitive Decline in Cognitively Unimpaired Older Adults. JAMA Network Open, 2020, 3, e200121.	5.9	27
1266	Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease. Journal of Proteome Research, 2020, 19, 1310-1318.	3.7	43

#	Article	IF	CITATIONS
1268	PET Radiopharmaceuticals for Alzheimer's Disease and Parkinson's Disease Diagnosis, the Current and Future Landscape. Molecules, 2020, 25, 977.	3.8	68
1269	Deciphering the factors that influence participation in studies requiring serial lumbar punctures. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12003.	2.4	9
1270	Amyloid duration is associated with preclinical cognitive decline and tau PET. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12007.	2.4	43
1271	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nature Medicine, 2020, 26, 379-386.	30.7	643
1272	Subtle voices, distant futures: a critical look at conditions for patient involvement in Alzheimer's biomarker research and beyond. Journal of Responsible Innovation, 2020, 7, 170-192.	4.9	9
1273	Cortical Microstructural Alterations in Mild Cognitive Impairment and Alzheimer's Disease Dementia. Cerebral Cortex, 2020, 30, 2948-2960.	2.9	61
1274	Novel ELISAs to measure total and phosphorylated tau in cerebrospinal fluid. Neuroscience Letters, 2020, 722, 134826.	2.1	4
1275	Fractional Anisotropy changes in Parahippocampal Cingulum due to Alzheimer's Disease. Scientific Reports, 2020, 10, 2660.	3.3	37
1276	Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau. Brain, 2020, 143, 932-943.	7.6	49
1277	A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer's Disease. Frontiers in Pharmacology, 2019, 10, 1653.	3.5	18
1278	Association of Polygenic Risk Score with Age at Onset and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease in a Chinese Cohort. Neuroscience Bulletin, 2020, 36, 696-704.	2.9	19
1279	Traitement de la maladie d'AlzheimerÂ: une lueur au bout du tunnelÂ?. Pratique Neurologique - FMC, 2020, 11, 46-48.	0.1	0
1280	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. Expert Review of Molecular Diagnostics, 2020, 20, 421-441.	3.1	42
1281	Depression, Anxiety, and Apathy in Mild Cognitive Impairment: Current Perspectives. Frontiers in Aging Neuroscience, 2020, 12, 9.	3.4	153
1282	Functional connectivity between the entorhinal and posterior cingulate cortices underpins navigation discrepancies in at-risk Alzheimer's disease. Neurobiology of Aging, 2020, 90, 110-118.	3.1	19
1283	Alzheimer's Disease and Vascular Aging. Journal of the American College of Cardiology, 2020, 75, 942-951.	2.8	197
1284	Diagnostic and prognostic values of PBMC proteins in amyotrophic lateral sclerosis. Neurobiology of Disease, 2020, 139, 104815.	4.4	19
1285	Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC–MS/MS Reference Method. Clinical Chemistry, 2020, 66, 587-597.	3.2	15

#	Article	IF	CITATIONS
1286	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg. Alzheimer's Research and Therapy, 2020, 12, 20.	6.2	32
1287	Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment. The Cochrane Library, 2020, 3, CD009628.	2.8	67
1288	Potential of PET/CT in assessing dementias with emphasis on cerebrovascular disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2493-2498.	6.4	23
1289	The Uniform Dataset 3.0 Neuropsychological Battery: Factor Structure, Invariance Testing, and Demographically Adjusted Factor Score Calculation. Journal of the International Neuropsychological Society, 2020, 26, 576-586.	1.8	20
1290	Validation of a novel and accurate ApoE4 assay for automated chemistry analyzers. Scientific Reports, 2020, 10, 2138.	3.3	5
1291	Spatial navigation ability predicts progression of dementia symptomatology. Alzheimer's and Dementia, 2020, 16, 491-500.	0.8	31
1292	US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer's Disease: Implications for Global Drug Development. Clinical and Translational Science, 2020, 13, 652-664.	3.1	11
1293	Sex and gender differences in Alzheimer's disease: current challenges and implications for clinical practice. European Journal of Neurology, 2020, 27, 928-943.	3.3	81
1294	Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. Alzheimer's Research and Therapy, 2020, 12, 19.	6.2	29
1295	Word retrieval across the biomarker-confirmed Alzheimer's disease syndromic spectrum. Neuropsychologia, 2020, 140, 107391.	1.6	17
1296	Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention. Antioxidants and Redox Signaling, 2020, 32, 1188-1236.	5.4	61
1297	ls tau in the absence of amyloid on the Alzheimer's continuum?: A study of discordant PET positivity. Brain Communications, 2020, 2, fcz046.	3.3	53
1298	Biological subtypes of Alzheimer disease. Neurology, 2020, 94, 436-448.	1.1	210
1299	Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results. PLoS ONE, 2020, 15, e0229137.	2.5	61
1300	Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2666-2680.	6.4	21
1301	The Role of Free and Cued Selective Reminding Test in Predicting [18F]Florbetaben PET Results in Mild Cognitive Impairment and Mild Dementia. Journal of Alzheimer's Disease, 2020, 73, 1647-1659.	2.6	4
1302	Developing retinal biomarkers for the earliest stages of Alzheimer's disease: What we know, what we don't, and how to move forward. Alzheimer's and Dementia, 2020, 16, 229-243.	0.8	92
1303	Protein-based amide proton transfer-weighted MR imaging of amnestic mild cognitive impairment. NeuroImage: Clinical, 2020, 25, 102153.	2.7	19
#	Article	IF	CITATIONS
------	--	------	-----------
1304	MRI Markers of Mixed Pathology and Cognitive Impairment in Multiethnic Asians. Journal of Alzheimer's Disease, 2020, 73, 1501-1509.	2.6	4
1305	A survey on machine and statistical learning for longitudinal analysis of neuroimaging data in Alzheimer's disease. Computer Methods and Programs in Biomedicine, 2020, 189, 105348.	4.7	44
1306	Diagnostic Accuracy of MRI Visual Rating Scales in the Diagnosis of Early Onset Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 73, 1575-1583.	2.6	12
1307	Soluble TREM2 and Inflammatory Proteins in Alzheimer's Disease Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2020, 73, 1615-1626.	2.6	29
1308	Alzheimer disease starts in childhood in polluted Metropolitan Mexico City. A major health crisis in progress. Environmental Research, 2020, 183, 109137.	7.5	58
1309	Immunotherapy for Parkinson's disease. Neurobiology of Disease, 2020, 137, 104760.	4.4	57
1310	Molecular Tools to Detect Alloforms of Aβ and Tau: Implications for Multiplexing and Multimodal Diagnosis of Alzheimer's Disease. Bulletin of the Chemical Society of Japan, 2020, 93, 507-546.	3.2	39
1311	CSF SerpinA1 in Creutzfeldt–Jakob disease and frontotemporal lobar degeneration. Annals of Clinical and Translational Neurology, 2020, 7, 191-199.	3.7	16
1312	The characterisation of subjective cognitive decline. Lancet Neurology, The, 2020, 19, 271-278.	10.2	627
1313	Clinical trials of new drugs for Alzheimer disease. Journal of Biomedical Science, 2020, 27, 18.	7.0	453
1314	Subjective cognitive decline: what is it good for?. Lancet Neurology, The, 2020, 19, 203-204.	10.2	15
1315	Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiology of Aging, 2020, 89, 99-107.	3.1	34
1316	A kinetics-based approach to amyloid PET semi-quantification. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2175-2185.	6.4	3
1317	Diffusion MRI biomarkers of white matter microstructure vary nonmonotonically with increasing cerebral amyloid deposition. Neurobiology of Aging, 2020, 89, 118-128.	3.1	48
1318	Genome-Wide Association Study Identifies SLAMF1 Affecting the Rate of Memory Decline. Journal of Alzheimer's Disease, 2020, 74, 139-149.	2.6	3
1319	Neuroinflammation and Neurogenesis in Alzheimer's Disease and Potential Therapeutic Approaches. International Journal of Molecular Sciences, 2020, 21, 701.	4.1	108
1320	Hippocampal vascular reserve associated with cognitive performance and hippocampal volume. Brain, 2020, 143, 622-634.	7.6	81
1321	Frontal-executive dysfunction affects dementia conversion in patients with amnestic mild cognitive impairment. Scientific Reports, 2020, 10, 772.	3.3	27

#	Article	IF	CITATIONS
1322	Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease. Nature Communications, 2020, 11, 347.	12.8	185
1323	Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography. JAMA Neurology, 2020, 77, 508.	9.0	79
1324	Clinicians' communication with patients receiving a MCI diagnosis: The ABIDE project. PLoS ONE, 2020, 15, e0227282.	2.5	19
1325	Differential annualized rates of hippocampal subfields atrophy in aging and future Alzheimer's clinical syndrome. Neurobiology of Aging, 2020, 90, 75-83.	3.1	28
1326	Renin-Angiotensin System and Alzheimer's Disease Pathophysiology: From the Potential Interactions to Therapeutic Perspectives. Protein and Peptide Letters, 2020, 27, 484-511.	0.9	25
1327	Alzheimer Disease, Biomarkers, and Clinical Symptoms—Quo Vadis?—Reply. JAMA Neurology, 2020, 77, 394.	9.0	3
1328	Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease by the Plasma and Serum Amyloid-beta 42 Assay through Highly Sensitive Peptoid Nanosheet Sensor. ACS Applied Materials & Interfaces, 2020, 12, 9693-9700.	8.0	24
1329	Management of mild cognitive impairment (MCI): The need for national and international guidelines. World Journal of Biological Psychiatry, 2020, 21, 579-594.	2.6	100
1330	University College London/University of Gothenburg PhD course "Biomarkers in neurodegenerative diseases―2019—course organisation. Alzheimer's Research and Therapy, 2020, 12, 18.	6.2	0
1331	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. PLoS ONE, 2020, 15, e0226784.	2.5	7
1332	Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2020, 4, 21-37.	2.2	30
1333	Proteomic and Genomic Changes in Tau Protein, Which Are Associated with Alzheimer's Disease after Ischemia-Reperfusion Brain Injury. International Journal of Molecular Sciences, 2020, 21, 892.	4.1	36
1334	Informant Reporting in Mild Cognitive Impairment: Sources of Discrepancy on the Functional Activities Questionnaire. Journal of the International Neuropsychological Society, 2020, 26, 503-514.	1.8	27
1335	Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets. Neurotherapeutics, 2020, 17, 935-954.	4.4	40
1336	APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline. Nature, 2020, 581, 71-76.	27.8	705
1337	Imaging biomarkers in neurodegeneration: current and future practices. Alzheimer's Research and Therapy, 2020, 12, 49.	6.2	96
1338	Trends in the public health significance, definitions of disease, and implications for prevention of Alzheimer's disease. Current Epidemiology Reports, 2020, 7, 68-76.	2.4	7
1339	11β-hydroxysteroid dehydrogenase type 1 inhibitor use in human disease-a systematic review and narrative synthesis. Metabolism: Clinical and Experimental, 2020, 108, 154246.	3.4	26

#	Article	IF	CITATIONS
1340	Plasma Amyloid Concentration in Alzheimer's Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer's Disease Cases from Controls. Journal of Alzheimer's Disease, 2020, 74, 1285-1294.	2.6	20
1342	Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment. Translational Psychiatry, 2020, 10, 125.	4.8	48
1343	Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?. Biochemical Pharmacology, 2020, 177, 113945.	4.4	62
1344	Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. JAMA Neurology, 2020, 77, 735.	9.0	182
1345	International drive to illuminate delirium: A developing public health blueprint for action. Alzheimer's and Dementia, 2020, 16, 711-725.	0.8	31
1346	Influence of plasma cytokine levels on the conversion risk from MCI to dementia in the Alzheimer's disease neuroimaging initiative database. Journal of the Neurological Sciences, 2020, 414, 116829.	0.6	3
1347	Amyloid-beta burden predicts prospective decline in body mass index in clinically normal adults. Neurobiology of Aging, 2020, 93, 124-130.	3.1	27
1348	A comparison of resting state EEG and structural MRI for classifying Alzheimer's disease and mild cognitive impairment. NeuroImage, 2020, 215, 116795.	4.2	51
1349	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. Nature Communications, 2020, 11, 1683.	12.8	252
1350	Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nature Medicine, 2020, 26, 769-780.	30.7	547
1351	A combination of total tau and neurofilaments discriminates between neurodegenerative and primary psychiatric disorders. European Journal of Neurology, 2020, 27, 1164-1169.	3.3	16
1352	18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 74, 589-601.	2.6	7
1353	Prevalence of the Preclinical Stages of Alzheimer's Disease in Cognitively Intact Older Adults: The CABLE Study. Journal of Alzheimer's Disease, 2020, 75, 483-492.	2.6	1
1354	Cerebrospinal Fluid and MRI Biomarkers in Neurodegenerative Diseases: A Retrospective Memory Clinic-Based Study. Journal of Alzheimer's Disease, 2020, 75, 751-765.	2.6	10
1355	Late-Onset Epilepsy With Unknown Etiology: A Pilot Study on Neuropsychological Profile, Cerebrospinal Fluid Biomarkers, and Quantitative EEG Characteristics. Frontiers in Neurology, 2020, 11, 199.	2.4	24
1356	Relationship between cortical iron and tau aggregation in Alzheimer's disease. Brain, 2020, 143, 1341-1349.	7.6	101
1357	Visual contrast sensitivity is associated with the presence of cerebral amyloid and tau deposition. Brain Communications, 2020, 2, fcaa019.	3.3	26
1358	Clinical and neuropsychological profile of patients with dementia and chronic traumatic encephalopathy. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 586-592.	1.9	16

#	Article	IF	CITATIONS
1359	Editorial: Biomarkers to Disentangle the Physiological From Pathological Brain Aging. Frontiers in Aging Neuroscience, 2020, 12, 88.	3.4	0
1360	The reduced left hippocampal volume related to the delayed P300 latency in amnestic mild cognitive impairment. Psychological Medicine, 2021, 51, 2054-2062.	4.5	5
1361	Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimer's Disease in Health Screening Population. Diagnostics, 2020, 10, 237.	2.6	9
1362	lf Human Brain Organoids Are the Answer to Understanding Dementia, What Are the Questions?. Neuroscientist, 2020, 26, 438-454.	3.5	23
1363	Contribution of mixed pathology to medial temporal lobe atrophy in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 843-852.	0.8	43
1364	Passive antiamyloid immunotherapy for Alzheimer's disease. Current Opinion in Psychiatry, 2020, 33, 284-291.	6.3	40
1365	Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. Science Advances, 2020, 6, eaaz2387.	10.3	202
1366	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nature Reviews Neurology, 2020, 16, 265-284.	10.1	121
1367	TRanscranial AlterNating current Stimulation FOR patients with Mild Alzheimer's Disease (TRANSFORMâ€AD study): Protocol for a randomized controlled clinical trial. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12005.	3.7	8
1368	Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2911-2922.	6.4	36
1369	Amyloidâ€Î² oligomers in cellular models of Alzheimer's disease. Journal of Neurochemistry, 2020, 155, 348-369.	3.9	50
1370	Alzheimer Drug Trials: Combination of Safe and Efficacious Biologicals to Break the Amyloidosis-Neuroinflammation Vicious Cycle. ASN Neuro, 2020, 12, 175909142091855.	2.7	2
1371	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurology, The, 2020, 19, 422-433.	10.2	668
1372	Amyloid β influences the relationship between cortical thickness and vascular load. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12022.	2.4	7
1373	<scp>Open‣abel</scp> Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2020, 7, 440-447.	1.5	34
1375	Aberrant interactions between amyloid-beta and alpha5 laminins as possible driver of neuronal disfunction in Alzheimer's disease. Biochimie, 2020, 174, 44-48.	2.6	2
1376	Early diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts. Clinical Neurophysiology, 2020, 131, 1287-1310.	1.5	123
1377	CSF amyloid is a consistent predictor of white matter hyperintensities across the disease course from aging to Alzheimer's disease. Neurobiology of Aging, 2020, 91, 5-14.	3.1	30

		REPORT	
# 1378	ARTICLE Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and	IF 3.1	CITATIONS
1379	New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer's disease. Experimental and Molecular Medicine, 2020, 52, 556-568.	7.7	57
1380	The Long-Term Effects of Acupuncture on Hippocampal Functional Connectivity in aMCI with Hippocampal Atrophy: A Randomized Longitudinal fMRI Study. Neural Plasticity, 2020, 2020, 1-9.	2.2	21
1381	Improving the resistance and resilience framework for aging and dementia studies. Alzheimer's Research and Therapy, 2020, 12, 41.	6.2	41
1382	Do subtle cognitive deficits precede amyloid accumulation?. Neurology, 2020, 94, 151-152.	1.1	4
1383	Beneficial association of angiotensin-converting enzyme inhibitors and statins on the occurrence of possible Alzheimer's disease after traumatic brain injury. Alzheimer's Research and Therapy, 2020, 12, 33.	6.2	15
1384	Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. Alzheimer's Research and Therapy, 2020, 12, 36.	6.2	39
1385	Neuropsychiatric symptoms in cognitively normal older persons, and the association with Alzheimer's and non-Alzheimer's dementia. Alzheimer's Research and Therapy, 2020, 12, 35.	6.2	43
1386	Bayesian integrative analysis of epigenomic and transcriptomic data identifies Alzheimer's disease candidate genes and networks. PLoS Computational Biology, 2020, 16, e1007771.	3.2	10
1387	Metabolic Profiles Help Discriminate Mild Cognitive Impairment from Dementia Stage in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 74, 277-286.	2.6	13
1388	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. Frontiers in Immunology, 2020, 11, 456.	4.8	201
1389	Longitudinal Patterns of the Tip-of-the-Tongue Phenomenon in People With Subjective Cognitive Cognitive Cognitive Impairment. Frontiers in Psychology, 2020, 11, 425.	2.1	5
1390	Amyloid Positivity as a Risk Factor for Memory Decline and Lower Memory Performance as an Indicator of Conversion to Amyloid Positivity: Chicken and Egg. Biological Psychiatry, 2020, 87, 782-784.	1.3	2
1391	Early detection of Alzheimer disease using Gadolinium material. Materials Today: Proceedings, 2021, 45, 1094-1101.	1.8	8
1392	Preclinical evaluation of [18F]D3FSP, deuterated AV-45, for imaging of β-amyloid in the brain. Nuclear Medicine and Biology, 2021, 92, 97-106.	0.6	7
1393	Metabolic and amyloid PET network reorganization in Alzheimer's disease: differential patterns and partial volume effects. Brain Imaging and Behavior, 2021, 15, 190-204.	2.1	11
1394	CSF α-synuclein correlates with CSF neurogranin in late-life depression. International Journal of Neuroscience, 2021, 131, 357-361.	1.6	10
1395	The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities. Multiple Sclerosis Journal, 2021, 27, 6-12.	3.0	50

#	Article	IF	CITATIONS
1396	Biomarkers for Alzheimer's disease—preparing for a new era of disease-modifying therapies. Molecular Psychiatry, 2021, 26, 296-308.	7.9	205
1397	Assessment of vascular stiffness in the internal carotid artery proximal to the carotid canal in Alzheimer's disease using pulse wave velocity from low rank reconstructed 4D flow MRI. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 298-311.	4.3	34
1398	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. Neuropharmacology, 2021, 185, 108081.	4.1	27
1400	The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 683-691.	3.6	8
1401	Multiâ€angle development of therapeutic methods for Alzheimer's disease. British Journal of Pharmacology, 2021, 178, 770-783.	5.4	7
1402	Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2233-2244.	6.4	37
1403	Neuropsychological profile of amyloidâ€positive versus amyloidâ€negative amnestic Mild Cognitive Impairment. Journal of Neuropsychology, 2021, 15, 41-52.	1.4	11
1404	Longitudinal Cognitive and Biomarker Measurements Support a Unidirectional Pathway in Alzheimer's Disease Pathophysiology. Biological Psychiatry, 2021, 89, 786-794.	1.3	48
1405	The β-Secretase BACE1 in Alzheimer's Disease. Biological Psychiatry, 2021, 89, 745-756.	1.3	336
1406	Impact of individual and neighborhood dimensions of socioeconomic status on the prevalence of mild cognitive impairment over seven-year follow-up. Aging and Mental Health, 2021, 25, 814-823.	2.8	28
1407	Alzheimer's disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms. Molecular Psychiatry, 2021, 26, 897-906.	7.9	58
1408	Cognitive Phenotypes of Older Adults with Subjective Cognitive Decline and Amnestic Mild Cognitive Impairment: The Czech Brain Aging Study. Journal of the International Neuropsychological Society, 2021, 27, 329-342.	1.8	11
1409	Dynamic brain fluctuations outperform connectivity measures and mirror pathophysiological profiles across dementia subtypes: A multicenter study. NeuroImage, 2021, 225, 117522.	4.2	39
1410	Associations of the Rate of Change in Geriatric Depression Scale with Amyloid and Cerebral Glucose Metabolism in Cognitively Normal Older Adults: A Longitudinal Study. Journal of Affective Disorders, 2021, 280, 77-84.	4.1	10
1411	Worth the Wait: Delayed Recall after 1 Week Predicts Cognitive and Medial Temporal Lobe Trajectories in Older Adults. Journal of the International Neuropsychological Society, 2021, 27, 382-388.	1.8	3
1412	βâ€Amyloid may accumulate in the human brain after focal bacterial infection: An <sup>18</sup> Fâ€flutemetamol positron emission tomography study. European Journal of Neurology, 2021, 28, 877-883.	3.3	6
1413	Principal-Component Analysis–Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes. Journal of Nuclear Medicine, 2021, 62, 855-860.	5.0	6
1414	Rapid Progress Toward Reliable Blood Tests for Alzheimer Disease. JAMA Neurology, 2021, 78, 143.	9.0	16

#	Article	IF	CITATIONS
1415	Determining Amyloid-β Positivity Using <sup>18</sup> F-AZD4694 PET Imaging. Journal of Nuclear Medicine, 2021, 62, 247-252.	5.0	65
1416	Decrease in sleep depth is associated with higher cerebrospinal fluid neurofilament light levels in patients with Alzheimer's disease. Sleep, 2021, 44, .	1.1	22
1417	Aggregation of Abnormal Memory Scores and Risk of Incident Alzheimer's Disease Dementia: A Measure of Objective Memory Impairment in Amnestic Mild Cognitive Impairment. Journal of the International Neuropsychological Society, 2021, 27, 146-157.	1.8	3
1418	Association Between Visual Memory and <i>In Vivo</i> Amyloid and Tau Pathology in Preclinical Autosomal Dominant Alzheimer's Disease. Journal of the International Neuropsychological Society, 2021, 27, 47-55.	1.8	6
1419	Obstructive sleep apnea and Alzheimer's disease-related cerebrospinal fluid biomarkers in mild cognitive impairment. Sleep, 2021, 44, .	1.1	24
1420	The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases. American Journal of Geriatric Psychiatry, 2021, 29, 375-383.	1.2	36
1421	Temporal contiguity and ageing: The role of memory organization in cognitive decline. Journal of Neuropsychology, 2021, 15, 53-65.	1.4	5
1422	Alzheimer's disease genetic risk and sleep phenotypes in healthy young men: association with more slow waves and daytime sleepiness. Sleep, 2021, 44, .	1.1	6
1423	Multi-scale graph-based grading for Alzheimer's disease prediction. Medical Image Analysis, 2021, 67, 101850.	11.6	28
1424	Prediction of 7â€year's conversion from subjective cognitive decline to mild cognitive impairment. Human Brain Mapping, 2021, 42, 192-203.	3.6	29
1425	Retinal imaging in Alzheimer's and neurodegenerative diseases. Alzheimer's and Dementia, 2021, 17, 103-111.	0.8	89
1426	Statistical Agnostic Mapping: A framework in neuroimaging based on concentration inequalities. Information Fusion, 2021, 66, 198-212.	19.1	19
1427	Retinal changes in Alzheimer's disease— integrated prospects of imaging, functional and molecular advances. Progress in Retinal and Eye Research, 2021, 82, 100899.	15.5	71
1428	An SPRi-based biosensor pilot study: Analysis of multiple circulating extracellular vesicles and hippocampal volume in Alzheimer's disease. Journal of Pharmaceutical and Biomedical Analysis, 2021, 192, 113649.	2.8	23
1429	Hippocampal subregional volume changes in elders classified using positron emission tomographyâ€based Alzheimer's biomarkers of βâ€amyloid deposition and neurodegeneration. Journal of Neuroscience Research, 2021, 99, 481-501.	2.9	6
1430	Developing univariate neurodegeneration biomarkers with low-rank and sparse subspace decomposition. Medical Image Analysis, 2021, 67, 101877.	11.6	10
1431	The age-dependent associations of white matter hyperintensities and neurofilament light in early- and late-stage Alzheimer's disease. Neurobiology of Aging, 2021, 97, 10-17.	3.1	18
1432	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. Journal of the International Neuropsychological Society, 2021, 27, 426-438.	1.8	30

#	Article	IF	CITATIONS
1433	Selfâ€reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease timeâ€dependent progression. Alzheimer's and Dementia, 2021, 17, 226-245.	0.8	23
1434	Metabolic syndrome and its components in relation to inÂvivo brain amyloid and neurodegeneration in late middle age. Neurobiology of Aging, 2021, 97, 89-96.	3.1	12
1435	Biphasic cortical macro―and microstructural changes in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 618-628.	0.8	27
1436	Effect of mindfulness intervention versus health education program on salivary AÎ <sup>2</sup> -42 levels in community-dwelling older adults with mild cognitive impairment: A randomized controlled trial. Journal of Psychiatric Research, 2021, 136, 619-625.	3.1	7
1437	Iron Accumulation, Not β-Amyloid or Brain Volumes, Is Linked to Cognition in Older Patients Who Are Nondemented. Radiology, 2021, 298, 363-364.	7.3	0
1438	A Brief Digital Cognitive Assessment for Detection of Cognitive Impairment in Cuban Older Adults. Journal of Alzheimer's Disease, 2021, 79, 85-94.	2.6	18
1439	Headâ€ŧoâ€head comparison of clinical performance of CSF phosphoâ€ŧau T181 and T217 biomarkers for Alzheimer's disease diagnosis. Alzheimer's and Dementia, 2021, 17, 755-767.	0.8	81
1440	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nature Aging, 2021, 1, 114-123.	11.6	94
1441	Distinct Atrophy Pattern of Hippocampal Subfields in Patients with Progressive and Stable Mild Cognitive Impairment: A Longitudinal MRI Study. Journal of Alzheimer's Disease, 2021, 79, 237-247.	2.6	18
1442	Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2021, 8, 259-265.	3.7	25
1443	Biomarkerâ€based stability in limbicâ€predominant amnestic mild cognitive impairment. European Journal of Neurology, 2021, 28, 1123-1133.	3.3	13
1444	Implications of Oligomeric Amyloid-Beta (oAβ <sub>42</sub> ) Signaling through α7β2-Nicotinic Acetylcholine Receptors (nAChRs) on Basal Forebrain Cholinergic Neuronal Intrinsic Excitability and Cognitive Decline. Journal of Neuroscience, 2021, 41, 555-575.	3.6	26
1445	Diagnostic Impact of Cerebrospinal Fluid Biomarkers in Atypical Dementias in Canada. Canadian Journal of Neurological Sciences, 2021, 48, 312-320.	0.5	0
1446	Brain MRI after critical care admission: A longitudinal imaging study. Journal of Critical Care, 2021, 62, 117-123.	2.2	7
1447	Contributions of PET and MRI imaging in the evaluation of CNS drugs in human neurodegenerative diseases. Therapie, 2021, 76, 121-126.	1.0	0
1448	Blood-Based ATN Biomarkers of Alzheimer's Disease: A Meta-Analysis. Journal of Alzheimer's Disease, 2021, 79, 177-195.	2.6	25
1449	Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease. Brain, 2021, 144, 310-324.	7.6	123
1450	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurology, 2021, 78, 149.	9.0	176

#	Article	IF	CITATIONS
1451	Metalloneurochemistry. , 2021, , 994-1015.		0
1452	Immunity and amyloid beta, total tau and neurofilament light chain: Findings from a communityâ€based cohort study. Alzheimer's and Dementia, 2021, 17, 446-456.	0.8	14
1453	<scp>FDGâ€PET</scp> Patterns Predict Amyloid Deposition and Clinical Profile in Corticobasal Syndrome. Movement Disorders, 2021, 36, 651-661.	3.9	22
1454	Frontiers in Neuroscience Imaging. PET Clinics, 2021, 16, 137-146.	3.0	1
1455	Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. Neurology, 2021, 96, e619-e631.	1.1	45
1456	Egocentric and Allocentric Spatial Memory in Mild Cognitive Impairment with Real-World and Virtual Navigation Tasks: A Systematic Review. Journal of Alzheimer's Disease, 2021, 79, 95-116.	2.6	25
1457	Cerebrospinal fluid biomarker profiling in corticobasal degeneration: Application of the AT(N) and other classification systems. Parkinsonism and Related Disorders, 2021, 82, 44-49.	2.2	13
1458	ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration. Alzheimer's and Dementia, 2021, 17, 822-830.	0.8	27
1459	Oxidative Damage and Antioxidant Response in Frontal Cortex of Demented and Nondemented Individuals with Alzheimer's Neuropathology. Journal of Neuroscience, 2021, 41, 538-554.	3.6	41
1460	Biomarkers and phenotypic expression in Alzheimer's disease: exploring the contribution of frailty in the Alzheimer's Disease Neuroimaging Initiative. GeroScience, 2021, 43, 1039-1051.	4.6	25
1461	Coordination chemistry of ligands: Insights into the design of amyloid beta/tau-PET imaging probes and nanoparticles-based therapies for Alzheimer's disease. Coordination Chemistry Reviews, 2021, 430, 213659.	18.8	8
1462	Utility of Plasma Neurofilament Light in the 1Florida Alzheimer's Disease Research Center (ADRC). Journal of Alzheimer's Disease, 2021, 79, 59-70.	2.6	16
1463	Toward a theoryâ€based specification of nonâ€pharmacological treatments in aging and dementia: Focused reviews and methodological recommendations. Alzheimer's and Dementia, 2021, 17, 255-270.	0.8	55
1464	Dementia in Latin America: Paving the way toward a regional action plan. Alzheimer's and Dementia, 2021, 17, 295-313.	0.8	68
1465	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	6.4	27
1466	Detection of Alzheimer's Disease using cortical diffusion tensor imaging. Human Brain Mapping, 2021, 42, 967-977.	3.6	22
1467	Latent Factor Structure and Measurement Invariance of the NIH Toolbox Cognition Battery in an Alzheimer's Disease Research Sample. Journal of the International Neuropsychological Society, 2021, 27, 412-425.	1.8	13
1468	Quantitative Susceptibility Mapping of the Hippocampal Fimbria in Alzheimer's Disease. Journal of Magnetic Resonance Imaging, 2021, 53, 1823-1832.	3.4	13

#	Article	IF	CITATIONS
1469	Clinical relevance of brain atrophy subtypes categorization in memory clinics. Alzheimer's and Dementia, 2021, 17, 641-652.	0.8	14
1470	APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid1. Journal of Alzheimer's Disease, 2021, 79, 511-530.	2.6	11
1471	Education Exerts Different Effects on Cognition in Individuals with Subjective Cognitive Decline and Cognitive Impairment: A Population-Based Study. Journal of Alzheimer's Disease, 2021, 79, 653-661.	2.6	10
1472	Abnormal Regional and Global Connectivity Measures in Subjective Cognitive Decline Depending on Cerebral Amyloid Status. Journal of Alzheimer's Disease, 2021, 79, 493-509.	2.6	14
1473	Quantitative Measurement of Cerebrospinal Fluid Amyloid-β Species by Mass Spectrometry. Journal of Alzheimer's Disease, 2021, 79, 573-584.	2.6	13
1474	Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 79, 729-741.	2.6	10
1475	An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum. Alzheimer's and Dementia, 2021, 17, 431-445.	0.8	80
1476	18F-labeled 2-phenylbenzoheterocycles with chiral dihydroxyl side chains as β-amyloid imaging probes. Bioorganic and Medicinal Chemistry, 2021, 29, 115884.	3.0	3
1477	Cross-sectional and longitudinal medial temporal lobe subregional atrophy patterns in semantic variant primary progressive aphasia. Neurobiology of Aging, 2021, 98, 231-241.	3.1	5
1478	Imaging of Tau Pathology in Neurodegenerative Diseases: An Update. Seminars in Nuclear Medicine, 2021, 51, 253-263.	4.6	29
1479	Predementia constructs: Mild cognitive impairment or mild neurocognitive disorder? A narrative review. International Journal of Geriatric Psychiatry, 2021, 36, 743-755.	2.7	5
1480	Regional Strength of Large-Scale Functional Brain Networks is Associated with Regional Volumes in Older Adults and in Alzheimer's Disease. Brain Connectivity, 2021, 11, 201-212.	1.7	8
1481	Learning Common Harmonic Waves on Stiefel Manifold – A New Mathematical Approach for Brain Network Analyses. IEEE Transactions on Medical Imaging, 2021, 40, 419-430.	8.9	14
1482	Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2021, 33, 3-13.	1.8	17
1483	Stacked autoencoders as new models for an accurate Alzheimer's disease classification support using resting-state EEG and MRI measurements. Clinical Neurophysiology, 2021, 132, 232-245.	1.5	30
1484	Topographic Distribution of Amyloid-β, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease. Neurology, 2021, 96, e81-e92.	1.1	31
1485	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. Molecular Psychiatry, 2021, 26, 429-442.	7.9	186
1486	Association of PETâ€based stages of amyloid deposition with neuropathological markers of Aβ pathology. Annals of Clinical and Translational Neurology, 2021, 8, 29-42.	3.7	7

#	Article	IF	CITATIONS
1487	Sleep and its regulation: An emerging pathogenic and treatment frontier in Alzheimer's disease. Progress in Neurobiology, 2021, 197, 101902.	5.7	33
1488	Towards early disease modification of Parkinson's disease: a review of lessons learned in the Alzheimer field. Journal of Neurology, 2021, 268, 724-733.	3.6	12
1489	Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer's Disease Continuum. Cerebral Cortex, 2021, 31, 1-14.	2.9	34
1490	Narrative Review of Sensory Changes as a Biomarker for Alzheimer's Disease. Biological Research for Nursing, 2021, 23, 223-230.	1.9	7
1491	Selective linkage of mitochondrial enzymes to intracellular calcium stores differs between humanâ€induced pluripotent stem cells, neural stem cells, and neurons. Journal of Neurochemistry, 2021, 156, 867-879.	3.9	2
1492	APOE interacts with tau PET to influence memory independently of amyloid PET in older adults without dementia. Alzheimer's and Dementia, 2021, 17, 61-69.	0.8	39
1493	Classification of negative and positive 18F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 721-728.	6.4	16
1494	The Association Between Functional Assessment and Structural Brain Biomarkers in an Ethnically Diverse Sample With Normal Cognition, Mild Cognitive Impairment, or Dementia. Archives of Clinical Neuropsychology, 2021, 36, 51-61.	0.5	3
1495	Systems-based proteomics to resolve the biology of Alzheimer's disease beyond amyloid and tau. Neuropsychopharmacology, 2021, 46, 98-115.	5.4	70
1496	A Systematic Review of Delirium Biomarkers and Their Alignment with the <scp>NIAâ€AA</scp> Research Framework. Journal of the American Geriatrics Society, 2021, 69, 255-263.	2.6	17
1497	Grey zone amyloid burden affects memory function: the SCIENCe project. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 747-756.	6.4	5
1498	Procedural Learning in Individuals with Amnestic Mild Cognitive Impairment and Alzheimer's Dementia: a Systematic Review and Meta-analysis. Neuropsychology Review, 2021, 31, 103-114.	4.9	26
1499	B-Tensor: Brain Connectome Tensor Factorization for Alzheimer's Disease. IEEE Journal of Biomedical and Health Informatics, 2021, 25, 1591-1600.	6.3	1
1500	Hippocampal blood–brain barrier permeability is related to the APOE4 mutation status of elderly individuals without dementia. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1351-1361.	4.3	29
1501	Bridging the divide between biomedical and psychosocial approaches in dementia research: the 2019 INTERDEM manifesto. Aging and Mental Health, 2021, 25, 206-212.	2.8	42
1502	RELATIONSHIP BETWEEN ALZHEIMER'S DISEASE, CEREBROVASCULAR AND CARDIOVASCULAR DISEASES (literature review). Bulletin of Problems Biology and Medicine, 2021, 1, 302.	0.1	1
1503	A comparative study on the application of machine learning algorithms for neurodegenerative disease prediction. , 2021, , 283-302.		0
1504	Hippocampal atrophy and cognitive function in transient ischemic attack and minor stroke patients over three years. Cerebral Circulation - Cognition and Behavior, 2021, 2, 100019.	0.9	2

#	Article	IF	CITATIONS
1505	The NGF Metabolic Pathway: New Opportunities for Biomarker Research and Drug Target Discovery. Advances in Experimental Medicine and Biology, 2021, 1331, 31-48.	1.6	2
1506	Case of early-onset Alzheimer's disease with atypical manifestation. Annals of General Psychiatry, 2021, 34, e100283.	3.1	4
1507	Biomarcadores en la enfermedad de Alzheimer. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2021, 2, 39-50.	0.2	2
1508	Association of CSF Alzheimer's disease biomarkers with postoperative delirium in older adults. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12125.	3.7	12
1509	Neuroimaging Advances in Diagnosis and Differentiation of HIV, Comorbidities, and Aging in the cART Era. Current Topics in Behavioral Neurosciences, 2021, 50, 105-143.	1.7	2
1510	Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias. Journal of Alzheimer's Disease, 2021, 79, 819-832.	2.6	6
1512	Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis. Health Economics Review, 2021, 11, 4.	2.0	12
1513	Plasma β-Amyloid Levels Associated With Structural Integrity Based on Diffusion Tensor Imaging in Subjective Cognitive Decline: The SILCODE Study. Frontiers in Aging Neuroscience, 2020, 12, 592024.	3.4	4
1514	Preventative medicine and Alzheimer's disease: is Alzheimer's disease risk reduction achievable?. Neural Regeneration Research, 2021, 16, 1772.	3.0	0
1515	Genetic Insights into Alzheimer's Disease. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 351-376.	22.4	11
1517	Too narrow and too broad: Differentiating late-onset dementia from its historical entanglement with Alzheimer's disease. Aging Brain, 2021, 1, 100010.	1.3	0
1518	Pâ€ŧau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12190.	2.4	34
1519	Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease. Neurology, 2021, 96, e1470-e1481.	1.1	19
1520	Flortaucipir (tau) PET in LGI1 antibody encephalitis. Annals of Clinical and Translational Neurology, 2021, 8, 491-497.	3.7	7
1521	Alzheimer's disease drug development pipeline: 2021. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12179.	3.7	259
1522	The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer's Disease. Journal of Central Nervous System Disease, 2021, 13, 117957352110291.	1.9	64
1523	A Novel Computerized Cognitive Stress Test to Detect Mild Cognitive Impairment. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-7.	2.7	3
1524	Contrasting Metabolic Insufficiency in Aging and Dementia. , 2021, 12, 1081.		14

#	Article	IF	CITATIONS
1525	Gray matter volumes discriminate cognitively impaired and unimpaired people with HIV. NeuroImage: Clinical, 2021, 31, 102775.	2.7	5
1526	Machine learning approaches to predicting amyloid status using data from an online research and recruitment registry: The Brain Health Registry. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12207.	2.4	3
1527	A profile of brain reserve in adults at genetic risk of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12208.	2.4	4
1528	Prediction of the progression from mild cognitive impairment to Alzheimer's disease using a radiomics-integrated model. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110295.	3.5	16
1529	Measuring 129 Xe transfer across the bloodâ€brain barrier using MR spectroscopy. Magnetic Resonance in Medicine, 2021, 85, 2939-2949.	3.0	11
1530	Analysis of Risk Factors in Dementia Through Machine Learning. Journal of Alzheimer's Disease, 2021, 79, 845-861.	2.6	5
1531	Use of the Montreal Cognitive Assessment Thai Version to Discriminate Amnestic Mild Cognitive Impairment from Alzheimer's Disease and Healthy Controls: Machine Learning Results. Dementia and Geriatric Cognitive Disorders, 2021, 50, 183-194.	1.5	33
1532	The impact of lockdown during SARS-CoV-2 outbreak on behavioral and psychological symptoms of dementia. Neurological Sciences, 2021, 42, 825-833.	1.9	25
1533	Rapid Universal Early Screening for Alzheimer's Disease and Related Dementia via Pattern Discovery in Diagnostic History. SSRN Electronic Journal, 0, , .	0.4	0
1534	Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. Current Opinion in Neurology, 2021, 34, 266-274.	3.6	54
1535	Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers. Neural Regeneration Research, 2021, 16, 36.	3.0	23
1536	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease. Translational Psychiatry, 2021, 11, 76.	4.8	78
1537	Retinal imaging demonstrates reduced capillary density in clinically unimpaired <i>APOE</i> ε4 gene carriers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12181.	2.4	14
1538	Cardiorespiratory fitness mitigates brain atrophy and cognitive decline in adults at risk for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12212.	2.4	16
1539	Unsupervised mobile cognitive testing for use in preclinical Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12243.	2.4	19
1540	Risk of dementia in <i>APOE</i> Îμ4 carriers is mitigated by a polygenic risk score. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12229.	2.4	16
1541	Communicating 5-Year Risk of Alzheimer's Disease Dementia: Development and Evaluation of Materials that Incorporate Multiple Genetic and Biomarker Research Results. Journal of Alzheimer's Disease, 2021, 79, 559-572.	2.6	12
1542	Comparison of Cerebrospinal Fluid Amyloidogenic Nanoplaques With Core Biomarkers of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2020, 12, 608628	3.4	3

	CITATION RE	PORT	
#	Article	IF	Citations
1543	Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 860.	4.1	32
1545	Aβ misfolding in blood plasma measured by immunoâ€infraredâ€sensor as an ageâ€independent risk marker of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12151.	2.4	2
1546	The contribution of beta-amyloid to dementia in Lewy body diseases: a 1-year follow-up study. Brain Communications, 2021, 3, fcab180.	3.3	17
1547	NGF and the Amyloid Precursor Protein in Alzheimer's Disease: From Molecular Players to Neuronal Circuits. Advances in Experimental Medicine and Biology, 2021, 1331, 145-165.	1.6	7
1548	New PET radiopharmaceuticals for imaging CNS diseases. , 2021, , .		0
1549	Major Surgery Affects Memory in Individuals with Cerebral Amyloid-β Pathology. Journal of Alzheimer's Disease, 2021, 79, 863-874.	2.6	9
1550	Aptamarker prediction of brain amyloid-β status in cognitively normal individuals at risk for Alzheimer's disease. PLoS ONE, 2021, 16, e0243902.	2.5	5
1551	A double-dichotomy clustering of dual pathology dementia patients. Cerebral Circulation - Cognition and Behavior, 2021, 2, 100011.	0.9	6
1552	Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12154.	3.7	19
1553	ITEM-LEVEL INVESTIGATION OF PARTICIPANT AND STUDY PARTNER REPORT ON THE COGNITIVE FUNCTION INDEX FROM THE A4 STUDY SCREENING DATA. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-6.	2.7	12
1554	Estimation of Causal Effects in the Presence of Unobserved Confounding inÂthe Alzheimer's Continuum. Lecture Notes in Computer Science, 2021, , 45-57.	1.3	4
1555	Open peer review commentary on building clinically relevant outcomes across the Alzheimer's disease spectrum. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12192.	3.7	Ο
1556	Concatenating plasma p-tau to Alzheimer's disease. Brain, 2021, 144, 14-17.	7.6	6
1557	Elucidating the Risk Factors for Progression from Amyloid-Negative Amnestic Mild Cognitive Impairment to Dementia. Current Alzheimer Research, 2021, 17, 893-903.	1.4	4
1558	Memory-relevant nap sleep physiology in healthy and pathological aging. Sleep, 2021, 44, .	1.1	14
1559	A systemsâ€biology clinical trial of a personalized multimodal lifestyle intervention for early Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12191.	3.7	10
1560	A sensitivity analysis of a mathematical model for the synergistic interplay of amyloid beta and tau on the dynamics of Alzheimer's disease. Brain Multiphysics, 2021, 2, 100020.	2.3	11
1561	microRNAs as Early Biomarkers of Alzheimer's Disease: A Synaptic Perspective. Cells, 2021, 10, 113	4.1	37

#	Article	IF	Citations
1562	Aducanumab: Appropriate Use Recommendations. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-13.	2.7	115
1563	Tau Pathologies Mediate the Associations of Vascular Risk Burden with Cognitive Impairments in Non-demented Elders: The CABLE Study. journal of prevention of Alzheimer's disease, The, 2022, 9, 1-8.	2.7	3
1564	Feasibility of pharmacokinetic parametric PET images in scaled subprofile modelling using principal component analysis. NeuroImage: Clinical, 2021, 30, 102625.	2.7	4
1565	Latent patterns of task-related functional connectivity in relation to regions of hyperactivation in in in individuals at risk of Alzheimer's disease. NeuroImage: Clinical, 2021, 30, 102643.	2.7	6
1566	Intermittent Hypoxic Conditioning Rescues Cognition and Mitochondrial Bioenergetic Profile in the Triple Transgenic Mouse Model of Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 461.	4.1	14
1567	Klinik der Demenzen. , 2021, , 59-92.		0
1568	Mitochondrial Dysfunction in Alzheimer's Disease: A Biomarker of the Future?. Biomedicines, 2021, 9, 63.	3.2	62
1569	Smarticle Particles: Leveraging Emotional Intelligence for Organizational Performance within the Military. Open Journal of Business and Management, 2021, 09, 2605-2634.	0.7	0
1570	Evaluation of the early-phase [18F]AV45 PET as an optimal surrogate of [18F]FDG PET in ageing and Alzheimer's clinical syndrome. NeuroImage: Clinical, 2021, 31, 102750.	2.7	6
1571	Dual-phase 18F-florbetaben PET provides cerebral perfusion proxy along with beta-amyloid burden in Alzheimer's disease. NeuroImage: Clinical, 2021, 31, 102773.	2.7	8
1572	Stability of Subjective Executive Functioning in Older Adults with aMCI and Subjective Cognitive Decline. Archives of Clinical Neuropsychology, 2021, 36, 1012-1018.	0.5	4
1573	Longitudinal evaluation of a novel BChE PET tracer as an early <i>in vivo</i> biomarker in the brain of a mouse model for Alzheimer disease. Theranostics, 2021, 11, 6542-6559.	10.0	12
1574	Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration. Neurology, 2021, 96, e1358-e1368.	1.1	11
1576	How Comorbidity Reflects on Cerebrospinal Fluid Biomarkers of Neurodegeneration in Aging. Journal of Alzheimer's Disease Reports, 2021, 5, 87-92.	2.2	1
1577	Personalized Healthcare for Dementia. Healthcare (Switzerland), 2021, 9, 128.	2.0	1
1578	Biomarker testing in MCI patients—deciding who to test. Alzheimer's Research and Therapy, 2021, 13, 14.	6.2	6
1580	Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development. , 2021, , 367-412.		0
1581	Progress regarding the context-of-use of tau as biomarker of Alzheimerâ $\in$ <sup>M</sup> s disease and other neurodegenerative diseases. Expert Review of Proteomics, 2021, 18, 27-48.	3.0	8

#	Article	IF	Citations
1582	Parametric estimation of reference signal intensity in the quantification of amyloid-beta deposition: an 18F-AV-45 study. Quantitative Imaging in Medicine and Surgery, 2021, 11, 249-263.	2.0	6
1583	Adding cognition to AT(N) models improves prediction of cognitive and functional decline. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12174.	2.4	8
1584	Amyloidâ€ <i>β</i> , cortical thickness, and subsequent cognitive decline in cognitively normal oldestâ€old. Annals of Clinical and Translational Neurology, 2021, 8, 348-358.	3.7	9
1585	Development of Random Forest Algorithm Based Prediction Model of Alzheimer's Disease Using Neurodegeneration Pattern. Psychiatry Investigation, 2021, 18, 69-79.	1.6	17
1586	Early Î'-Amyloid Accumulation in the Brain Is Associated With Blood T and B Cell Alterations. SSRN Electronic Journal, 0, , .	0.4	0
1587	Amyloid in the ageing brain: New frameworks and perspectives. Aging Brain, 2021, 1, 100008.	1.3	1
1588	Sex and gender considerations in clinical trials for Alzheimer's disease: Current state and recommendations. , 2021, , 309-327.		0
1589	A Connection Between Pattern Classification by Machine Learning and Statistical Inference With the General Linear Model. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 5332-5343.	6.3	9
1590	Measurement batch differences and betweenâ€batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12194.	2.4	2
1591	White matter microstructure disruption in early stage amyloid pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12124.	2.4	16
1592	Selective hippocampal subfield volume reductions in World Trade Center responders with cognitive impairment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12165.	2.4	10
1593	Private payer coverage policies for ApoE-e4 genetic testing. Genetics in Medicine, 2021, 23, 614-620.	2.4	6
1594	Automated quantitative MRI volumetry reports support diagnostic interpretation in dementia: a multi-rater, clinical accuracy study. European Radiology, 2021, 31, 5312-5323.	4.5	19
1595	PET and SPECT Imaging of Neurodegenerative Diseases. , 2021, , 1309-1334.		0
1596	Colorimetric metasurfaces shed light on fibrous biological tissue. Journal of Materials Chemistry C, 2021, 9, 11619-11639.	5.5	4
1597	Associations of Alzheimer's disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration. Alzheimer's Research and Therapy, 2021, 13, 15.	6.2	38
1598	Deciphering the Disaggregation Mechanism of Amyloid Beta Aggregate by 4-(2-Hydroxyethyl)-1-Piperazinepropanesulfonic Acid Using Electrochemical Impedance Spectroscopy. Sensors, 2021, 21, 788.	3.8	8
1599	Routine magnetoencephalography in memory clinic patients: A machine learning approach. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12227.	2.4	9

	Сітатіс	n Report	
#	Article	IF	CITATIONS
1600	The application of optical coherence tomography angiography in Alzheimer's disease: A systematic review. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12149.	2.4	23
1601	Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau. NeuroImage: Clinical, 2021, 31, 102717.	2.7	6
1602	Biomarkers. , 2022, , 693-724.		5
1603	Neurological diseases: Sex and gender evidence in stroke, migraine, and Alzheimer's dementia. , 2021, , 229-258.		0
1604	Views on Early Diagnosis of Alzheimer's Disease Among Dutch Physicians: A Qualitative Interview Study. Journal of Alzheimer's Disease, 2021, 79, 917-927.	2.6	14
1605	Digital Screening for Cognitive Impairment – A Proof of Concept Study. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-8.	2.7	5
1606	Artificial intelligence and machine learning for Alzheimer's disease: let's not forget about the retina. British Journal of Ophthalmology, 2021, 105, 593-594.	3.9	9
1607	Early brainstem [18F]THK5351 uptake is linked to cortical hyperexcitability in healthy aging. JCI Insight, 2021, 6, .	5.0	6
1608	The neuroimaging of neurodegenerative and vascular disease in the secondary prevention of cognitive decline. Neural Regeneration Research, 2021, 16, 1490.	3.0	2
1609	Management of Patients with Dementia: An Introduction. , 2021, , 1-18.		1
1610	Anti-dementia Medication. , 2021, , 73-104.		0
1611	Sex and gender differences in neuropsychological symptoms for clinical diagnosis of Alzheimer's disease. , 2021, , 163-185.		0
1612	Everyday Function in Alzheimer's and Parkinson's Patients with Mild Cognitive Impairment. Journal o Alzheimer's Disease, 2021, 79, 197-209.	of 2.6	4
1613	Aducanumab: Appropriate Use Recommendations. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-2.	2.7	4
1614	Pathology Dynamics in Healthy-Toxic Protein Interaction and the Multiscale Analysis of Neurodegenerative Diseases. Lecture Notes in Computer Science, 2021, , 528-540.	1.3	4
1615	Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-16.	2.7	90
1616	A kinetic ensemble of the Alzheimer's Aβ peptide. Nature Computational Science, 2021, 1, 71-78.	8.0	42
1617	Safety and efficacy of sargramostim (GM SF) in the treatment of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12158.	3.7	44

		CITATION REPORT		
# 1618	ARTICLE Polyphenols attenuate mitochondrial dysfunction induced by amyloid peptides. , 2021, , 317-33	7.	IF	CITATIONS
1619	Resting-state electroencephalographic biomarkers of Alzheimer's disease. NeuroImage: Clini 31, 102711.	cal, 2021,	2.7	20
1620	Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation. Theranostics, 2021, 11, 8964-8976.		10.0	12
1621	Headâ€toâ€head comparison of amplified plasmonic exosome Aβ42 platform and singleâ€mole immunoassay in a memory clinic cohort. European Journal of Neurology, 2021, 28, 1479-1489.	cule array	3.3	11
1622	Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated individuals from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's Research and 7 2021, 13, 17.	tau in Therapy,	6.2	35
1623	Pathobiolgy and Management of Alzheimer's Disease. Chonnam Medical Journal, 2021, 57, 108.		0.9	4
1624	Chinese nutraceuticals and physical activity; their role in neurodegenerative tauopathies. Chines Medicine, 2021, 16, 1.	e	4.0	24
1625	Clinically Available Software for Automatic Brain Volumetry: Comparisons of Volume Measureme and Validation of Intermethod Reliability. Korean Journal of Radiology, 2021, 22, 405.	ents	3.4	16
1626	Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: V how, and what we still need to know. Alzheimer's and Dementia: Diagnosis, Assessment and Dis Monitoring, 2021, 13, e12150.	vhy, ease	2.4	22
1627	Cortical thickness across the lifespan in a Colombian cohort with autosomalâ€dominant Alzhein disease: A crossâ€sectional study. Alzheimer's and Dementia: Diagnosis, Assessment and Diseas Monitoring, 2021, 13, e12233.	ner's e	2.4	2
1628	A long story for a short peptide: therapeutic efficacy of a cleavage-specific tau antibody. Neural Regeneration Research, 2021, 16, 2417.		3.0	4
1629	Development of molecular tools for diagnosis of Alzheimer's disease that are based on deter amyloidogenic proteins. Prion, 2021, 15, 56-69.	ction of	1.8	12
1630	Amyloid beta associations with connected speech in cognitively unimpaired adults. Alzheimer's Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12203.	and	2.4	17
1631	Improved amyloid burden quantification with nonspecific estimates using deep learning. Europe Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1842-1853.	an	6.4	12
1632	Impact of the ambulatory blood pressure monitoring profile on cognitive and imaging findings o cerebral small-vessel disease in older adults with cognitive complaints. Journal of Human Hypertension, 2022, 36, 14-23.	f	2.2	7
1633	Rationally Designed Bicyclic Peptides Prevent the Conversion of AÎ <sup>2</sup> 42 Assemblies Into Fibrillar Structures. Frontiers in Neuroscience, 2021, 15, 623097.		2.8	6
1634	Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkir diseases. Nature Reviews Chemistry, 2021, 5, 277-294.	ison	30.2	56
1635	Frailty and neuropathology in relation to dementia status: the Cambridge City over-75s Cohort s International Psychogeriatrics, 2021, 33, 1035-1043.	tudy.	1.0	13

#	Article	IF	CITATIONS
1636	Clinical Relevance of [18F]Florbetaben and [18F]FDG PET/CT Imaging on the Management of Patients with Dementia. Molecules, 2021, 26, 1282.	3.8	5
1639	The combination of MMSE with VSRAD and eZIS has greater accuracy for discriminating mild cognitive impairment from early Alzheimer's disease than MMSE alone. PLoS ONE, 2021, 16, e0247427.	2.5	9
1641	Identifying Preclinical Alzheimer's Disease Using Everyday Driving Behavior: Proof of Concept. Journal of Alzheimer's Disease, 2021, 79, 1009-1014.	2.6	13
1642	Subclinical Atherosclerosis and Brain Metabolism in Middle-Aged Individuals. Journal of the American College of Cardiology, 2021, 77, 888-898.	2.8	24
1643	Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2200-2211.	6.4	19
1645	Machine Learning for Diagnosis of AD and Prediction of MCI Progression From Brain MRI Using Brain Anatomical Analysis Using Diffeomorphic Deformation. Frontiers in Neurology, 2020, 11, 576029.	2.4	35
1646	The search for a convenient procedure to detect one of the earliest signs of Alzheimer's disease: A systematic review of the prediction of brain amyloid status. Alzheimer's and Dementia, 2021, 17, 866-887.	0.8	14
1647	Comprehensive Evaluation of the Functional Activities Questionnaire (FAQ) and Its Reliability and Validity. Assessment, 2022, 29, 748-763.	3.1	27
1648	Alzheimer's disease in primary care: new tools for improved and simplified diagnostics. Journal of Internal Medicine, 2021, 290, 477-479.	6.0	0
1649	The synaptic marker neurogranin as a disease state biomarker in Alzheimer's disease: a systematic review and meta-analysis. International Journal of Neuroscience, 2021, , 1-9.	1.6	2
1650	Novel Variants in the CLCN1, RYR2, and DCTN1 Found in Elderly Japanese Dementia Patients: A Case Series. Geriatrics (Switzerland), 2021, 6, 14.	1.7	1
1651	Discordance Between Cerebrospinal Fluid Biomarkers and Amyloid Positron Emission Tomography in Alzheimer's Sheds Light on Clinical Trial Exclusion Criteria. Cureus, 2021, 13, e13481.	0.5	0
1652	Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. Acta Neuropathologica Communications, 2021, 9, 19.	5.2	17
1653	Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics. Molecular Neurodegeneration, 2021, 16, 10.	10.8	101
1654	Plasma pâ€ŧau181, pâ€ŧau217, and other bloodâ€based Alzheimer's disease biomarkers in a multiâ€ethnic, community study. Alzheimer's and Dementia, 2021, 17, 1353-1364.	0.8	160
1655	Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults. Neurology, 2021, 96, e1844-e1854.	1.1	38
1656	What have we learned from cognition in the oldest-old. Current Opinion in Neurology, 2021, 34, 258-265.	3.6	17
1657	FNDC5/Irisin System in Neuroinflammation and Neurodegenerative Diseases: Update and Novel Perspective. International Journal of Molecular Sciences, 2021, 22, 1605.	4.1	61

#	Article	IF	CITATIONS
1658	AD Resemblance Atrophy Index as a Diagnostic Biomarker for Alzheimer's Disease: A Retrospective Clinical and Biological Validation. Journal of Alzheimer's Disease, 2021, 79, 1023-1032.	2.6	14
1659	Machine Learning Algorithms and Statistical Approaches for Alzheimer's Disease Analysis Based on Resting-State EEG Recordings: A Systematic Review. International Journal of Neural Systems, 2021, 31, 2130002.	5.2	47
1660	Brain Ischemia as a Prelude to Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 636653.	3.4	37
1661	Detection of β-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers. Brain Communications, 2021, 3, fcab008.	3.3	51
1662	In vivo tau pathology is associated with synaptic loss and altered synaptic function. Alzheimer's Research and Therapy, 2021, 13, 35.	6.2	47
1663	Texture-Based Analysis of 18F-Labeled Amyloid PET Brain Images. Applied Sciences (Switzerland), 2021, 11, 1991.	2.5	0
1664	Systematic Assessment of the Impact of DTI Methodology on Fractional Anisotropy Measures in Alzheimer's Disease. Tomography, 2021, 7, 20-38.	1.8	7
1665	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2110-2120.	6.4	33
1666	Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2097-2109.	6.4	34
1667	Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives. Brain Sciences, 2021, 11, 215.	2.3	58
1668	Prognostic Role of CSF β-amyloid 1–42/1–40 Ratio in Patients Affected by Amyotrophic Lateral Sclerosis. Brain Sciences, 2021, 11, 302.	2.3	8
1669	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta Neuropathologica, 2021, 141, 709-724.	7.7	285
1670	Early diagnosis of prodromal dementia with Lewy bodies using clinical history of probable <scp>REM</scp> sleep behaviour disorder and cardiac <scp><sup>123</sup>lâ€MIBG</scp> scintigraphy in memory clinics. Psychogeriatrics, 2021, 21, 288-295.	1.2	7
1671	What is â€~Alzheimer's disease'? The neuropathological heterogeneity of clinically defined Alzheimer's dementia. Current Opinion in Neurology, 2021, 34, 237-245.	3.6	39
1672	Detection Gap of Right-Asymmetric Neuronal Degeneration by CERAD Test Battery in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 611595.	3.4	2
1673	Evidence of the Cellular Senescence Stress Response in Mitotically Active Brain Cells—Implications for Cancer and Neurodegeneration. Life, 2021, 11, 153.	2.4	16
1674	Lower Locus Coeruleus MRI intensity in patients with late-life major depression. PeerJ, 2021, 9, e10828.	2.0	14
1675	High performance liquid chromatography determination of l-glutamate, l-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease. Amino Acids, 2021, 53, 435-449.	2.7	14

#	Article	IF	CITATIONS
1676	Data-driven FDG-PET subtypes of Alzheimer's disease-related neurodegeneration. Alzheimer's Research and Therapy, 2021, 13, 49.	6.2	44
1677	Imaging Techniques in Alzheimer's Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring. International Journal of Molecular Sciences, 2021, 22, 2110.	4.1	79
1678	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?. Alzheimer's Research and Therapy, 2021, 13, 47.	6.2	32
1679	Sleep-Dependent Memory in Older People With and Without MCI: The Relevance of Sleep Microarchitecture, OSA, Hippocampal Subfields, and Episodic Memory. Cerebral Cortex, 2021, 31, 2993-3005.	2.9	21
1680	Association between methylation of BIN1 promoter in peripheral blood and preclinical Alzheimer's disease. Translational Psychiatry, 2021, 11, 89.	4.8	12
1681	Spatially constrained kinetic modeling with dual reference tissues improves 18F-flortaucipir PET in studies of Alzheimer disease. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3172-3186.	6.4	6
1682	Resilience to Plasma and Cerebrospinal Fluid Amyloid-β in Cognitively Normal Individuals: Findings From Two Cohort Studies. Frontiers in Aging Neuroscience, 2021, 13, 610755.	3.4	3
1683	Informant report of practical judgment ability in a clinical sample of older adults with subjective cognitive decline, mild cognitive impairment, and dementia. Aging, Neuropsychology, and Cognition, 2021, , 1-19.	1.3	4
1684	Cerebral Amyloid Angiopathy in Amyloid-Positive Patients from a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2021, 79, 1661-1672.	2.6	8
1686	Metabolites Associated with Early Cognitive Changes Implicated in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 79, 1041-1054.	2.6	4
1687	Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2212-2224.	6.4	29
1688	Cerebrovascular and Neurodegenerative Pathologies in Long-Term Stable Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 79, 1269-1283.	2.6	3
1689	Detecting Alzheimer's disease biomarkers with a brief tablet-based cognitive battery: sensitivity to Aβ and tau PET. Alzheimer's Research and Therapy, 2021, 13, 36.	6.2	10
1690	Profiling of Serum Exosome MiRNA Reveals the Potential of a MiRNA Panel as Diagnostic Biomarker for Alzheimer's Disease. Molecular Neurobiology, 2021, 58, 3084-3094.	4.0	42
1691	Application of Cerebrospinal Fluid AT(N) Framework on the Diagnosis of AD and Related Cognitive Disorders in Chinese Han Population. Clinical Interventions in Aging, 2021, Volume 16, 311-323.	2.9	9
1692	Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 46.	6.2	9
1693	MicroRNAs as Candidate Biomarkers for Alzheimer's Disease. Non-coding RNA, 2021, 7, 8.	2.6	10
1694	Cerebrospinal Fluid Biomarkers in Patients With Alcohol Use Disorder and Persistent Cognitive Impairment. Alcoholism: Clinical and Experimental Research, 2021, 45, 561-565.	2.4	8

#	Article	IF	CITATIONS
1695	Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. The Lancet Healthy Longevity, 2021, 2, e87-e95.	4.6	85
1696	Cognitive aging is associated with redistribution of synaptic weights in the hippocampus. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	22
1697	Carotenoids and Cognitive Outcomes: A Meta-Analysis of Randomized Intervention Trials. Antioxidants, 2021, 10, 223.	5.1	37
1698	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2157-2168.	6.4	18
1699	Nanomaterial-based Optical and Electrochemical Biosensors for Amyloid beta and Tau: Potential for early diagnosis of Alzheimer's Disease. Expert Review of Molecular Diagnostics, 2021, 21, 175-193.	3.1	18
1700	Multi-scale optoacoustic molecular imaging of brain diseases. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4152-4170.	6.4	50
1701	Resting state EEG biomarkers of cognitive decline associated with Alzheimer's disease and mild cognitive impairment. PLoS ONE, 2021, 16, e0244180.	2.5	98
1702	Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders. Frontiers in Neuroscience, 2021, 15, 647783.	2.8	17
1703	Molecular Factors Mediating Neural Cell Plasticity Changes in Dementia Brain Diseases. Neural Plasticity, 2021, 2021, 1-20.	2.2	13
1704	Early Detection of Incipient Alzheimer Pathology. Neurology, 2021, 96, 647-648.	1.1	1
1705	Toward a Universal Readout for <sup>18</sup> F-Labeled Amyloid Tracers: The CAPTAINs Study. Journal of Nuclear Medicine, 2021, 62, 999-1005.	5.0	9
1706	Amyloid burden quantification depends on PET and MR image processing methodology. PLoS ONE, 2021, 16, e0248122.	2.5	5
1708	Medical Cloud Computing Data Processing to Optimize the Effect of Drugs. Journal of Healthcare Engineering, 2021, 2021, 1-15.	1.9	1
1709	New Trajectory of Clinical and Biomarker Changes in Sporadic Alzheimer's Disease. Cerebral Cortex, 2021, 31, 3363-3373.	2.9	4
1710	Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer's disease and cognitively unimpaired individuals. Translational Neurodegeneration, 2021, 10, 11.	8.0	17
1711	Associations of Vascular Risk with Cognition, Brain Glucose Metabolism, and Clinical Progression in Cognitively Intact Elders. Journal of Alzheimer's Disease, 2021, 80, 321-330.	2.6	5
1712	Addressing neuropsychological diagnostics in adults with epilepsy: Introducing the International Classification of Cognitive Disorders in Epilepsy: The IC CODE Initiative. Epilepsia Open, 2021, 6, 266-275.	2.4	31
1713	Evaluating cognitive profiles of patients undergoing clinical amyloid-PET imaging. Brain Communications, 2021, 3, fcab035.	3.3	5

#	Article	IF	CITATIONS
1714	Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 2929.	4.1	31
1715	Synthesis and Initial Characterization of a Reversible, Selective 18F-Labeled Radiotracer for Human Butyrylcholinesterase. Molecular Imaging and Biology, 2021, 23, 505-515.	2.6	4
1716	Comparison of [ <sup>11</sup> C]UCB-J and [ <sup>18</sup> F]FDG PET in Alzheimer's disease: A tracer kinetic modeling study. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2395-2409.	4.3	43
1717	Plasma Pâ€ŧau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. Alzheimer's and Dementia, 2021, 17, 1649-1662.	0.8	37
1718	FDC-PET assessment of the locus coeruleus in Alzheimer's disease. NeuroImage Reports, 2021, 1, 100002.	1.0	9
1719	Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer's disease: a systematic review and meta-analysis. Translational Neurodegeneration, 2021, 10, 10.	8.0	21
1720	Deep Learning Based Multimodal Progression Modeling for Alzheimer's Disease. Statistics in Biopharmaceutical Research, 2021, 13, 337-343.	0.8	8
1721	The Diagnostic Value of Exosome-Derived Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment: A Meta-Analysis. Frontiers in Aging Neuroscience, 2021, 13, 637218.	3.4	12
1722	Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review. European Journal of Medicinal Chemistry, 2021, 214, 113209.	5.5	33
1723	Comparison of the clinical impact of 2-[18F]FDC-PET and cerebrospinal fluid biomarkers in patients suspected of Alzheimer's disease. PLoS ONE, 2021, 16, e0248413.	2.5	5
1724	Risk Variants in Three Alzheimer's Disease Genes Show Association with EEG Endophenotypes. Journal of Alzheimer's Disease, 2021, 80, 209-223.	2.6	4
1725	Microglia Biomarkers in Alzheimer's Disease. Molecular Neurobiology, 2021, 58, 3388-3404.	4.0	8
1726	Integrated 18F-T807 Tau PET, Structural MRI, and Plasma Tau in Tauopathy Neurodegenerative Disorders. Frontiers in Aging Neuroscience, 2021, 13, 646440.	3.4	13
1727	A Comparison of Two Statistical Mapping Tools for Automated Brain FDC-PET Analysis in Predicting Conversion to Alzheimer's Disease in Subjects with Mild Cognitive Impairment. Current Alzheimer Research, 2021, 17, 1186-1194.	1.4	4
1728	The Relationship Between Anxiety and Alzheimer's Disease1. Journal of Alzheimer's Disease Reports, 2021, 5, 171-177.	2.2	53
1730	National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome. Neurology, 2021, 96, 848-863.	1.1	149
1731	Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers. Alzheimer's and Dementia, 2021, 17, 801-812.	0.8	18
1732	Quantitative assessment of retinal thickness and vessel density using optical coherence tomography angiography in patients with Alzheimer's disease and glaucoma. PLoS ONE, 2021, 16, e0248284.	2.5	13

#	Article	IF	CITATIONS
1733	2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2121-2139.	6.4	43
1734	Molecular Imaging Approaches in Dementia. Radiology, 2021, 298, 517-530.	7.3	27
1735	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. Alzheimer's and Dementia, 2021, 17, 1575-1582.	0.8	51
1736	Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 2021, 17, 1452-1464.	0.8	13
1737	An Open Question: Is the A2A Adenosine Receptor a Novel Target for Alzheimer's Disease Treatment?. Frontiers in Pharmacology, 2021, 12, 652455.	3.5	15
1738	Expanding Representation of Low and Middle Income Countries in Global Dementia Research: Commentary From the Alzheimer's Association. Frontiers in Neurology, 2021, 12, 633777.	2.4	11
1739	27-Hydroxycholesterol, cognition, and brain imaging markers in the FINGER randomized controlled trial. Alzheimer's Research and Therapy, 2021, 13, 56.	6.2	18
1740	The Forgetful Golfer. , 2021, , 26-29.		0
1742	Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest. Frontiers in Aging Neuroscience, 2021, 13, 604119.	3.4	17
1743	Quality of life in early-onset Alzheimer's disease due to a PSEN1-E280A mutation. Neurological Sciences, 2021, 42, 4637-4645.	1.9	3
1744	First symptom guides diagnosis and prognosis in neurodegenerative diseases—a retrospective study of autopsy proven cases. European Journal of Neurology, 2021, 28, 1801-1811.	3.3	11
1745	The Latest Research on RT-QuIC Assays—A Literature Review. Pathogens, 2021, 10, 305.	2.8	16
1746	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2140-2156.	6.4	83
1747	Brain changes associated with sleep disruption in cognitively unimpaired older adults: A short review of neuroimaging studies. Ageing Research Reviews, 2021, 66, 101252.	10.9	13
1748	The contributions of metabolomics in the discovery of new therapeutic targets in Alzheimer's disease. Fundamental and Clinical Pharmacology, 2021, 35, 582-594.	1.9	10
1749	Uses of Human MR and PET Imaging in Research of Neurodegenerative Brain Diseases. Neurotherapeutics, 2021, 18, 661-672.	4.4	9
1750	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2086-2096.	6.4	11
1751	A 4-Year Follow-Up of Subjects with Visually Equivocal Amyloid Positron Emission Tomography Findings from the Alzheimer's Disease Neuroimaging Initiative Cohort. Nuclear Medicine and Molecular Imaging, 2021, 55, 71-78.	1.0	2

#	Article	IF	CITATIONS
1752	The Associations of Cerebrospinal Fluid ApoE and Biomarkers of Alzheimer's Disease: Exploring Interactions With Sex. Frontiers in Neuroscience, 2021, 15, 633576.	2.8	7
1753	Affective symptoms and regional cerebral tau burden in earlyâ€stage Alzheimer's disease. International Journal of Geriatric Psychiatry, 2021, 36, 1050-1058.	2.7	10
1754	Changes in Resting-State Functional Connectivity of Cerebellum in Amnestic Mild Cognitive Impairment and Alzheimer's Disease: A Case-Control Study. Frontiers in Systems Neuroscience, 2021, 15, 596221.	2.5	5
1755	Advances in computerized MRIâ€based biomarkers in Alzheimer's disease. Brain Science Advances, 2021, 7, 26-43.	0.9	6
1757	Prionopathies and Prionlike Protein Aberrations in Neurodegenerative Diseases. Neurographics, 2021, 11, 127-148.	0.1	0
1758	Early prevention of cognitive impairment in the community population: The Beijing Aging Brain Rejuvenation Initiative. Alzheimer's and Dementia, 2021, 17, 1610-1618.	0.8	28
1759	Serum transthyretin and risk of cognitive decline and dementia: 22-year longitudinal study. Neurological Sciences, 2021, 42, 5093-5100.	1.9	5
1760	Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI) Tj ETQq1	1.0,7843 6.0	14-rgBT /O
1761	Psycho-Electrophysiological Benefits of Forest Therapies Focused on Qigong and Walking with Elderly Individuals. International Journal of Environmental Research and Public Health, 2021, 18, 3004.	2.6	17
1762	A Young Man with Memory and Walking Difficulties. , 2021, , 10-13.		0
1763	The Anaesthetic Biobank of Cerebrospinal fluid: a unique repository for neuroscientific biomarker research. Annals of Translational Medicine, 2021, 9, 455-455.	1.7	7
1764	Inflammation, Nitro-Oxidative Stress, Impaired Autophagy, and Insulin Resistance as a Mechanistic Convergence Between Arterial Stiffness and Alzheimer's Disease. Frontiers in Molecular Biosciences, 2021, 8, 651215.	3.5	16
1765	Diagnostic accuracy of the Cogstate Brief Battery for prevalent MCI and prodromal AD (MCI) Tj ETQq0 0 0 rgBT /C	)verlock 1 0.8	0 Tf 50 262
1766	One-Year Aerobic Exercise Reduced Carotid Arterial Stiffness and Increased Cerebral Blood Flow in Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 80, 841-853.	2.6	48
1767	Alzheimer's Dementia: The Emerging Role of Positron Emission Tomography. Neuroscientist, 2022, 28, 507-519.	3.5	8
1768	Ferulic Acid Ameliorates Alzheimer's Disease-like Pathology and Repairs Cognitive Decline by Preventing Capillary Hypofunction in APP/PS1 Mice. Neurotherapeutics, 2021, 18, 1064-1080.	4.4	29
1769	New insights into atypical Alzheimer's disease in the era of biomarkers. Lancet Neurology, The, 2021, 20, 222-234.	10.2	214
1770	Drift Diffusion Model of Animacy Categorization Task Can Detect Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease. Frontiers in Biomedical Technologies, 0, , .	0.0	0

#	Article	IF	CITATIONS
1771	Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial. Alzheimer's Research and Therapy, 2021, 13, 64.	6.2	6
1772	Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. Alzheimer's Research and Therapy, 2021, 13, 66.	6.2	16
1773	Brain Molecular Connectivity in Neurodegenerative Conditions. Brain Sciences, 2021, 11, 433.	2.3	7
1775	Neural cell-surface and intracellular autoantibodies in patients with cognitive impairment from a memory clinic cohort. Journal of Neural Transmission, 2021, 128, 357-369.	2.8	13
1776	Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient. Journal of Neuroimmunology, 2021, 352, 577474.	2.3	2
1777	Effect of a purine derivative containing selenium to improve memory decline and anxiety through modulation of the cholinergic system and Na+/K+-ATPase in an Alzheimer's disease model. Metabolic Brain Disease, 2021, 36, 871-888.	2.9	12
1778	Biomarker-Based Risk Prediction of Alzheimer's Disease Dementia in Mild Cognitive Impairment: Psychosocial, Ethical, and Legal Aspects. Journal of Alzheimer's Disease, 2021, 80, 601-617.	2.6	11
1779	Stages of Objective Memory Impairment Predict Alzheimer's Disease Neuropathology: Comparison with the Clinical Dementia Rating Scale–Sum of Boxes. Journal of Alzheimer's Disease, 2021, 80, 185-195.	2.6	10
1780	Probing the Role of a Regional Quantitative Assessment of Amyloid PET. Journal of Alzheimer's Disease, 2021, 80, 383-396.	2.6	3
1781	Cognitive Effects of Aerobic Exercise in Alzheimer's Disease: A Pilot Randomized Controlled Trial. Journal of Alzheimer's Disease, 2021, 80, 233-244.	2.6	55
1782	Quantitative Methods for the Detection of Tau Seeding Activity in Human Biofluids. Frontiers in Neuroscience, 2021, 15, 654176.	2.8	4
1783	Value-Generating Exploratory Trials in Neurodegenerative Dementias. Neurology, 2021, 96, 944-954.	1.1	14
1784	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2070-2085.	6.4	22
1785	Preclinical validation of a potent γ-secretase modulator for Alzheimer's disease prevention. Journal of Experimental Medicine, 2021, 218, .	8.5	39
1786	Mild Behavioral Impairment and Subjective Cognitive Decline Predict Cognitive and Functional Decline. Journal of Alzheimer's Disease, 2021, 80, 459-469.	2.6	77
1787	Cholesterol, Atherosclerosis, and APOE in Vascular Contributions to Cognitive Impairment and Dementia (VCID): Potential Mechanisms and Therapy. Frontiers in Aging Neuroscience, 2021, 13, 647990.	3.4	31
1788	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 69.	6.2	34
1789	International Psychogeriatric Association (IPA) consensus for defining psychosis in major and mild neurocognitive disorders. International Psychogeriatrics, 2022, 34, 203-207.	1.0	2

#	Article	IF	CITATIONS
1790	The predictive value of normal EEGs in dementia due to Alzheimer's disease. Annals of Clinical and Translational Neurology, 2021, 8, 1038-1048.	3.7	3
1791	Predicting Dementia With Prefrontal Electroencephalography and Event-Related Potential. Frontiers in Aging Neuroscience, 2021, 13, 659817.	3.4	20
1792	Pharmacotherapy for Frontotemporal Dementia. CNS Drugs, 2021, 35, 425-438.	5.9	9
1793	Prognostic Impact of 18-F-Florbetaben Amyloid PET Imaging in Patients with Isolated Increases in Cerebrospinal Fluid Phospho-Tau Biomarkers: A Longitudinal Study. Journal of Alzheimer's Disease, 2021, 80, 1389-1394.	2.6	0
1794	Neuropsychological profile in the preclinical stages of dementia: principal component analysis approach. Dementia E Neuropsychologia, 2021, 15, 192-199.	0.8	3
1795	Finding our way through the labyrinth of dementia biomarkers. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2320-2324.	6.4	5
1796	<scp>NIAâ€AA</scp> Alzheimer's Disease Framework: Clinical Characterization of Stages. Annals of Neurology, 2021, 89, 1145-1156.	5.3	31
1797	Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research. Alzheimer's and Dementia, 2021, 17, 1554-1574.	0.8	114
1798	Ambient fine particulate matter exposure and incident mild cognitive impairment and dementia. Journal of the American Geriatrics Society, 2021, 69, 2185-2194.	2.6	14
1799	Diagnose it yourself: will there be a home test kit for Alzheimer's disease?. Neurodegenerative Disease Management, 2021, 11, 167-176.	2.2	2
1800	Hippocampal and Hippocampal-Subfield Volumes From Early-Onset Major Depression and Bipolar Disorder to Cognitive Decline. Frontiers in Aging Neuroscience, 2021, 13, 626974.	3.4	15
1801	White matter hyperintensities and patterns of atrophy in early onset Alzheimer's disease with causative gene mutations. Clinical Neurology and Neurosurgery, 2021, 203, 106552.	1.4	5
1802	Associations between subregional thalamic volume and brain pathology in autosomal dominant Alzheimer's disease. Brain Communications, 2021, 3, fcab101.	3.3	11
1803	Dementia is an ageâ€independent risk factor for severity and death in COVIDâ€19 inpatients. Alzheimer's and Dementia, 2021, 17, 1818-1831.	0.8	71
1804	Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology. Neurotherapeutics, 2021, 18, 728-752.	4.4	30
1805	Key Disease Mechanisms Linked to Alzheimer's Disease in the Entorhinal Cortex. International Journal of Molecular Sciences, 2021, 22, 3915.	4.1	17
1806	Can discourse processing performance serve as an early marker of Alzheimer's disease and mild cognitive impairment? A systematic review of text comprehension. European Journal of Ageing, 2022, 19, 3-18.	2.8	1
1807	Recent advances in pre-clinical diagnosis of Alzheimer's disease. Metabolic Brain Disease, 2021, , 1.	2.9	3

#	Article	IF	CITATIONS
1808	Theoretical impact of the AT(N) framework on dementia using a community autopsy sample. Alzheimer's and Dementia, 2021, 17, 1879-1891.	0.8	5
1809	Multimodal Capture of Patient Behaviour for Improved Detection of Early Dementia: Clinical Feasibility and Preliminary Results. Frontiers in Computer Science, 2021, 3, .	2.8	11
1810	Gut microbiome-mediated epigenetic regulation of brain disorder and application of machine learning for multi-omics data analysis. Genome, 2021, 64, 355-371.	2.0	25
1811	Brain cells derived from Alzheimer's disease patients have multiple specific innate abnormalities in energy metabolism. Molecular Psychiatry, 2021, 26, 5702-5714.	7.9	54
1812	Optimizing Subjective Cognitive Decline to Detect Early Cognitive Dysfunction. Journal of Alzheimer's Disease, 2021, 80, 1185-1196.	2.6	10
1813	F-18 ML-104 tau PET imaging in mild cognitive impairment. Nuclear Medicine Communications, 2021, Publish Ahead of Print, 914-921.	1.1	0
1814	Agingâ€related Alzheimer's diseaseâ€like neuropathology and functional decline in captive vervet monkeys ( <i>Chlorocebus aethiops sabaeus</i> ). American Journal of Primatology, 2021, 83, e23260.	1.7	16
1815	Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2021, 80, 1629-1642.	2.6	10
1816	Mild traumatic brain injury induces microvascular injury and accelerates Alzheimer-like pathogenesis in mice. Acta Neuropathologica Communications, 2021, 9, 74.	5.2	31
1817	Plasma Amyloid- $\hat{I}^2$ Oligomerization Tendency Predicts Amyloid PET Positivity. Clinical Interventions in Aging, 2021, Volume 16, 749-755.	2.9	10
1820	Distinct fiber-specific white matter reductions pattern in early- and late-onset Alzheimer's disease. Aging, 2021, 13, 12410-12430.	3.1	7
1821	Preclinical Evaluation of TSPO and MAO-B PET Radiotracers in an LPS Model of Neuroinflammation. PET Clinics, 2021, 16, 233-247.	3.0	15
1822	The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders. Neurotherapeutics, 2021, 18, 686-708.	4.4	19
1823	Diagnostic Precision in the Detection of Mild Cognitive Impairment: A Comparison of Two Approaches. American Journal of Geriatric Psychiatry, 2022, 30, 54-64.	1.2	12
1824	New insights into the pathophysiology of Alzeimer's disease. European Journal of Neurology, 2021, 28, 2143-2144.	3.3	1
1825	Empirically defining the preclinical stages of the Alzheimer's continuum in the Alzheimer's Disease Neuroimaging Initiative. Psychogeriatrics, 2021, 21, 491-502.	1.2	6
1826	Meningeal lymphatics affect microglia responses and anti-AÎ <sup>2</sup> immunotherapy. Nature, 2021, 593, 255-260.	27.8	179
1827	Neuronal and Astrocytic Extracellular Vesicle Biomarkers in Blood Reflect Brain Pathology in Mouse Models of Alzheimer's Disease. Cells, 2021, 10, 993.	4.1	37

#	Article	IF	CITATIONS
1828	Quantitative Radiomic Features as New Biomarkers for Alzheimer's Disease: An Amyloid PET Study. Cerebral Cortex, 2021, 31, 3950-3961.	2.9	18
1829	Glucose metabolism in the right middle temporal gyrus could be a potential biomarker for subjective cognitive decline: a study of a Han population. Alzheimer's Research and Therapy, 2021, 13, 74.	6.2	33
1831	Neuroimaging Biomarkers of Chronic Traumatic Encephalopathy: Targets for the Academic Memory Disorders Clinic. Neurotherapeutics, 2021, 18, 772-791.	4.4	13
1832	The application of a neuropsychological measure of executive working memory in older adults with memory impairment. Applied Neuropsychology Adult, 2021, , 1-10.	1.2	1
1835	Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study. Alzheimer's Research and Therapy, 2021, 13, 89.	6.2	28
1836	Distinguishing Alzheimer's Disease Patients and Biochemical Phenotype Analysis Using a Novel Serum Profiling Platform: Potential Involvement of the VWF/ADAMTS13 Axis. Brain Sciences, 2021, 11, 583.	2.3	4
1837	Effects of APOE Îμ2 on the Fractional Amplitude of Low-Frequency Fluctuation in Mild Cognitive Impairment: A Study Based on the Resting-State Functional MRI. Frontiers in Aging Neuroscience, 2021, 13, 591347.	3.4	5
1838	Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis. International Journal of Molecular Sciences, 2021, 22, 4440.	4.1	17
1840	Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges. Journal of Nanobiotechnology, 2021, 19, 122.	9.1	60
1841	Reduced synchrony in alpha oscillations during life predicts <i>post mortem</i> neurofibrillary tangle density in earlyâ€onset and atypical Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 2009-2019.	0.8	17
1842	Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease. Neurology, 2021, 97, e76-e87.	1.1	17
1843	Candidate Alzheimer's Disease Biomarker miR-483-5p Lowers TAU Phosphorylation by Direct ERK1/2 Repression. International Journal of Molecular Sciences, 2021, 22, 3653.	4.1	22
1844	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimer's and Dementia, 2021, 17, 1189-1204.	0.8	44
1845	Analyzing The Spatiotemporal Interaction And Propagation Of Atn Biomarkers In Alzheimer's Disease Using Longitudinal Neuroimaging Data. , 2021, , .		3
1846	Alternative Targets to Fight Alzheimer's Disease: Focus on Astrocytes. Biomolecules, 2021, 11, 600.	4.0	16
1847	Exploring the Alterations in the Distribution of Neural Network Weights in Dementia Due to Alzheimer's Disease. Entropy, 2021, 23, 500.	2.2	3
1848	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. Brain Communications, 2021, 3, fcab073.	3.3	15
1849	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, 2021, 78, 396.	9.0	146

#	Article	IF	CITATIONS
1850	Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 84.	6.2	26
1851	Core Alzheimer's disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods. Alzheimer's Research and Therapy, 2021, 13, 79.	6.2	0
1852	Repetition Priming in Individuals with Amnestic Mild Cognitive Impairment and Alzheimer's Dementia: a Systematic Review and Meta-Analysis. Neuropsychology Review, 2022, 32, 228-246.	4.9	3
1853	In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer's Brain Tissue. Journal of Alzheimer's Disease, 2021, 80, 1723-1737.	2.6	33
1854	Associations of healthy lifestyles with cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact older adults: the CABLE study. Alzheimer's Research and Therapy, 2021, 13, 81.	6.2	7
1855	Multimodal Imaging in a Patient With Alzheimer Disease and Parkinsonism Because of a Presenilin-1 Mutation. Clinical Nuclear Medicine, 2021, Publish Ahead of Print, e483-e484.	1.3	2
1856	Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer's disease. Molecular Neurodegeneration, 2021, 16, 28.	10.8	32
1857	Oral Microbiota Changes in Elderly Patients, an Indicator of Alzheimer's Disease. International Journal of Environmental Research and Public Health, 2021, 18, 4211.	2.6	33
1858	Bridging Scales in Alzheimer's Disease: Biological Framework for Brain Simulation With The Virtual Brain. Frontiers in Neuroinformatics, 2021, 15, 630172.	2.5	20
1859	Accelerated longâ€ŧerm forgetting in individuals with subjective cognitive decline and amyloidâ€Î² positivity. International Journal of Geriatric Psychiatry, 2021, 36, 1037-1049.	2.7	6
1861	<i>IN VIVO</i> ASSESSMENT OF AMYLOID AND GLUCOSE SIGNATURES IN SUBJECTIVE COGNITIVE DECLINE SUBJECTS. Journal of Mechanics in Medicine and Biology, 2021, 21, 2140018.	0.7	2
1862	The Clinician's Interviewâ€Based Impression of Change (Plus caregiver input) and goal attainment in two dementia drug trials: Clinical meaningfulness and the initial treatment response. Alzheimer's and Dementia, 2021, 17, 856-865.	0.8	6
1863	The Effects of CSF Neurogranin and APOE ε4 on Cognition and Neuropathology in Mild Cognitive Impairment and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 667899.	3.4	6
1864	Alzheimer's Disease: New Concepts on the Role of Autoimmunity and NLRP3 Inflammasome in the Pathogenesis of the Disease. Current Neuropharmacology, 2021, 19, 498-512.	2.9	16
1865	Associations Between Physical Activity, Blood-Based Biomarkers of Neurodegeneration, and Cognition in Healthy Older Adults: The MAPT Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 1382-1390.	3.6	20
1867	Accuracy of Cardiac Innervation Scintigraphy for Mild Cognitive Impairment With Lewy Bodies. Neurology, 2021, 96, e2801-e2811.	1.1	25
1868	Cerebrovascular Disease and Cognitive Outcome in Patients with Cardiac Disease. Seminars in Neurology, 2021, 41, 463-472.	1.4	5
1869	Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain, 2021, 144, 1263-1276.	7.6	245

#	Article	IF	CITATIONS
1870	Serum Levels of Clusterin, PKR, and RAGE Correlate with Amyloid Burden in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 80, 1067-1077.	2.6	7
1871	Alzheimer's disease. Lancet, The, 2021, 397, 1577-1590.	13.7	1,530
1872	Elevated Inflammatory Markers and Arterial Stiffening Exacerbate Tau but Not Amyloid Pathology in Older Adults with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 80, 1451-1463.	2.6	7
1873	Etiology of Dementia in Thai Patients. Dementia and Geriatric Cognitive Disorders Extra, 2021, 11, 64-70.	1.3	4
1874	Novel noninvasive biomarkers of prodromal Alzheimer disease: The role of optical coherence tomography and optical coherence tomography–angiography. European Journal of Neurology, 2021, 28, 2185-2191.	3.3	11
1875	Haemodynamic impairment along the Alzheimer's disease continuum. European Journal of Neurology, 2021, 28, 2168-2173.	3.3	7
1876	White matter hyperintensities and cognition across different Alzheimer's biomarker profiles. Journal of the American Geriatrics Society, 2021, 69, 1906-1915.	2.6	14
1877	Simulating the outcome of amyloid treatments in Alzheimer's disease from imaging and clinical data. Brain Communications, 2021, 3, fcab091.	3.3	10
1878	Effects of Morning Blue-Green 500 nm Light Therapy on Cognition and Biomarkers in Middle-Aged and Older Adults with Subjective Cognitive Decline and Mild Cognitive Impairment: Study Protocol for a Randomized Controlled Trial. Journal of Alzheimer's Disease, 2021, 83, 1521-1536.	2.6	6
1879	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 872-880.	1.9	17
1880	Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. Alzheimer's and Dementia, 2021, 17, 1528-1553.	0.8	64
1881	Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study. Journal of Clinical Medicine, 2021, 10, 1907.	2.4	15
1882	Largeâ€scale plasma proteomic profiling identifies a highâ€performance biomarker panel for Alzheimer's disease screening and staging. Alzheimer's and Dementia, 2022, 18, 88-102.	0.8	65
1883	Impact de l'imagerie TEP métabolique et moléculaire dans les maladies neurodégénératives cognit Pratique Neurologique - FMC, 2021, 12, 180-189.	ives. 0.1	0
1884	Biomarqueurs du liquide cérébrospinal. Pratique Neurologique - FMC, 2021, 12, 165-179.	0.1	1
1885	Screening for Early-Stage Alzheimer's Disease Using Optimized Feature Sets and Machine Learning. Journal of Alzheimer's Disease, 2021, 81, 355-366.	2.6	21
1886	Fluid Biomarkers in Clinical Trials for Alzheimer's Disease: Current and Future Application. Journal of Alzheimer's Disease, 2021, 81, 19-32.	2.6	3
1887	TMA-93 Validation by Alzheimer's Disease Biomarkers: A Comparison with the Free and Cued Selective Reminding Test on a Biobank Sample. Journal of Alzheimer's Disease, 2021, 82, 401-410.	2.6	4

#	Article	IF	CITATIONS
1888	Operationalizing the clinical staging scheme in the 2018 NIA–AA research framework. Nature Reviews Neurology, 2021, 17, 395-396.	10.1	1
1889	A Precision Medicine Approach to Treating Alzheimer's Disease Using Rosiglitazone Therapy: A Biomarker Analysis of the REFLECT Trials. Journal of Alzheimer's Disease, 2021, 81, 557-568.	2.6	13
1890	Relationship Between General Cognition, Visual Assessed Cortical Atrophy, and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: A Cross-Sectional Study from a Chinese PUMCH Cohort. Journal of Alzheimer's Disease, 2021, 82, 1-10.	2.6	4
1891	Association of Midlife Depressive Symptoms with Regional Amyloid-Î <sup>2</sup> and Tau in the Framingham Heart Study. Journal of Alzheimer's Disease, 2021, 82, 249-260.	2.6	9
1892	Neuronal loss and microgliosis are restricted to the core of AÎ <sup>2</sup> deposits in mouse models of Alzheimer's disease. Aging Cell, 2021, 20, e13380.	6.7	16
1893	Comprehensive Management of Daily Living Activities, behavioral and Psychological Symptoms, and Cognitive Function in Patients with Alzheimer's Disease: A Chinese Consensus on the Comprehensive Management of Alzheimer's Disease. Neuroscience Bulletin, 2021, 37, 1025-1038.	2.9	16
1894	Alzheimer disease. Nature Reviews Disease Primers, 2021, 7, 33.	30.5	784
1895	Patterns of tau pathology identified with 18 Fâ€MKâ€6240 PET imaging. Alzheimer's and Dementia, 2021, , .	0.8	12
1896	Aging-associated deficit in CCR7 is linked to worsened glymphatic function, cognition, neuroinflammation, and $\hat{I}^2$ -amyloid pathology. Science Advances, 2021, 7, .	10.3	73
1897	Plasma β-Amyloid in Mild Behavioural Impairment – Neuropsychiatric Symptoms on the Alzheimer's Continuum. Journal of Geriatric Psychiatry and Neurology, 2022, 35, 434-441.	2.3	44
1898	Brain [F-18]FDG PET for Clinical Dementia Workup: Differential Diagnosis of Alzheimer's Disease and Other Types of Dementing Disorders. Seminars in Nuclear Medicine, 2021, 51, 230-240.	4.6	44
1899	Cerebrospinal Fluid C18 Ceramide Associates with Markers of Alzheimer's Disease and Inflammation at the Pre- and Early Stages of Dementia. Journal of Alzheimer's Disease, 2021, 81, 231-244.	2.6	19
1900	KLâ^—VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOEâ^—4 carriers. Neurobiology of Aging, 2021, 101, 123-129.	3.1	10
1901	Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults. Alzheimer's and Dementia, 2022, 18, 65-76.	0.8	18
1902	Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2021, 81, 629-640.	2.6	18
1903	An Insight into the Role of Artificial Intelligence in the Early Diagnosis of Alzheimer's Disease. CNS and Neurological Disorders - Drug Targets, 2022, 21, 901-912.	1.4	3
1904	A Link Between Cardiovascular Risk Management and Alzheimer Disease Is Still Elusive. JAMA Neurology, 2021, 78, 524.	9.0	3
1905	Subjective cognitive complaints at age 70: associations with amyloid and mental health. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1215-1221.	1.9	16

#	Article	IF	CITATIONS
1906	Outdoor green space exposure and brain health measures related to Alzheimer's disease: a rapid review. BMJ Open, 2021, 11, e043456.	1.9	31
1907	The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimer's Disease, Parkinson's Disease and Multiple Sclerosis. International Journal of Molecular Sciences, 2021, 22, 4958.	4.1	28
1908	Clinical Impact of PET With 18F-FDG and 11C-PIB in Patients With Dementia in a Developing Country. Frontiers in Neurology, 2021, 12, 630958.	2.4	1
1909	Astrocyte subtype-specific approach to Alzheimer's disease treatment. Neurochemistry International, 2021, 145, 104956.	3.8	10
1910	MRI-based Alzheimer's disease-resemblance atrophy index in the detection of preclinical and prodromal Alzheimer's disease. Aging, 2021, 13, 13496-13514.	3.1	10
1911	History in perspective: How Alzheimer's Disease came to be where it is?. Brain Research, 2021, 1758, 147342.	2.2	8
1912	Functional connectivity differences in Alzheimer's disease and amnestic mild cognitive impairment associated with AT(N) classification and anosognosia. Neurobiology of Aging, 2021, 101, 22-39.	3.1	15
1913	Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney. Alzheimer's and Dementia, 2022, 18, 178-190.	0.8	5
1914	Living with Dementia in Aotearoa (LiDiA): a cross-sectional feasibility study protocol for a multiethnic dementia prevalence study in Aotearoa/New Zealand. BMJ Open, 2021, 11, e046143.	1.9	2
1915	Pathological drivers of neurodegeneration in suspected non-Alzheimer's disease pathophysiology. Alzheimer's Research and Therapy, 2021, 13, 100.	6.2	13
1916	Effect of antiamyloid-β drugs on Alzheimer's disease: study protocol for a systematic review and meta-analysis. BMJ Open, 2021, 11, e048453.	1.9	0
1917	Is Late-Onset Alzheimer Disease Spelled "ATV(N)�. Neurology, 2021, 97, 155-156.	1.1	0
1918	Marked Mild Cognitive Deficits in Humanized Mouse Model of Alzheimer's-Type Tau Pathology. Frontiers in Behavioral Neuroscience, 2021, 15, 634157.	2.0	6
1919	The role of <i>NOTCH3</i> variants in Alzheimer's disease and subcortical vascular dementia in the Chinese population. CNS Neuroscience and Therapeutics, 2021, 27, 930-940.	3.9	7
1920	Deep learning based neuronal soma detection and counting for Alzheimer's disease analysis. Computer Methods and Programs in Biomedicine, 2021, 203, 106023.	4.7	10
1921	Hearing Impairment and Cognition in an Aging World. JARO - Journal of the Association for Research in Otolaryngology, 2021, 22, 387-403.	1.8	26
1922	Cortical [ <scp><sup>18</sup>F</scp> ] <scp>PI</scp> â€2620 Binding Differentiates Corticobasal Syndrome Subtypes. Movement Disorders, 2021, 36, 2104-2115.	3.9	46
1923	Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new diseaseâ€modifying treatments—EQâ€5D data from the Swedish BioFINDER study. Alzheimer's and Dementia, 2021, 17, 1832-1842.	0.8	5

#	Article	IF	CITATIONS
1924	Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1998-2008.	0.8	25
1925	Binding characteristics of [ <sup>18</sup> F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2957-2972.	4.3	30
1926	Genetic predisposition, Aβ misfolding in blood plasma, and Alzheimer's disease. Translational Psychiatry, 2021, 11, 261.	4.8	4
1927	Characterization of Alzheimer's tau biomarker discordance using plasma, CSF, and PET. Alzheimer's Research and Therapy, 2021, 13, 93.	6.2	16
1928	Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer's Disease. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 1311-1339.	2.2	13
1929	Functional Connectivity Between the Posterior Default Mode Network and Parahippocampal Gyrus Is Disrupted in Older Adults with Subjective Cognitive Decline and Correlates with Subjective Memory Ability. Journal of Alzheimer's Disease, 2021, 82, 435-445.	2.6	9
1930	Dual-Phase β-Amyloid PET Captures Neuronal Injury and Amyloidosis in Corticobasal Syndrome. Frontiers in Aging Neuroscience, 2021, 13, 661284.	3.4	13
1931	A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2295-2305.	6.4	41
1932	Astrocyte Biomarkers in Alzheimer Disease. Neurology, 2021, 96, .	1.1	70
1933	Better Identification of Cognitive Decline With Interleukin-2 Than With Amyloid and Tau Protein Biomarkers in Amnestic Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2021, 13, 670115.	3.4	8
1934	Design of an Innovative Methodology for Cerebrospinal Fluid Analysis: Preliminary Results. Sensors, 2021, 21, 3767.	3.8	4
1935	Relationship between F-18 florbetapir uptake in occipital lobe and neurocognitive performance in Alzheimer's disease. Japanese Journal of Radiology, 2021, 39, 984-993.	2.4	4
1936	Glitter in the Darkness? Nonfibrillar β-Amyloid Plaque Components Significantly Impact the β-Amyloid PET Signal in Mouse Models of Alzheimer Disease. Journal of Nuclear Medicine, 2022, 63, 117-124.	5.0	14
1937	Correlation between brain glucose metabolism (18F-FDG) and cerebral blood flow with amyloid tracers (18F-Florbetapir) in clinical routine: Preliminary evidences. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 41, 146-152.	0.2	2
1938	Multi-template Neuroimaging Feature Selection Using Weight-constrained Low-rank Learning for Alzheimer's Disease Classification. , 2021, , .		1
1939	Saccadic Eye Movement in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis. Neuropsychology Review, 2022, 32, 193-227.	4.9	36
1941	Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. Life, 2021, 11, 484.	2.4	11
1942	The Association Between Homocysteine and Memory in Older Adults. Journal of Alzheimer's Disease, 2021, 81, 413-426.	2.6	6

#	Article	IF	CITATIONS
1943	PET Agents in Dementia: An Overview. Seminars in Nuclear Medicine, 2021, 51, 196-229.	4.6	23
1944	Dynamic Amyloid PET: Relationships to Flortaucipir Tau PET Measures. Journal of Nuclear Medicine, 2021, , jnumed.120.254490.	5.0	6
1945	Stateâ€ofâ€theâ€art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 159-177.	0.8	33
1946	Tripartite Relationship Among Synaptic, Amyloid, and Tau Proteins: An In Vivo and Postmortem Study. Neurology, 2021, , 10.1212/WNL.000000000012145.	1.1	8
1947	Virtual disclosure of preclinical Alzheimer's biomarkers: Preliminary experiences. Journal of the American Geriatrics Society, 2021, 69, 2044-2047.	2.6	3
1948	Lipocalin 2 regulates iron homeostasis, neuroinflammation, and insulin resistance in the brains of patients with dementia: Evidence from the current literature. CNS Neuroscience and Therapeutics, 2021, 27, 883-894.	3.9	30
1949	Associations of Anxiety with Amyloid, Tau, and Neurodegeneration in Older Adults without Dementia: A Longitudinal Study. Journal of Alzheimer's Disease, 2021, 82, 273-283.	2.6	5
1951	Degenerative dementias: a question of syndrome or disease?. NeurologÃa (English Edition), 2021, , .	0.4	Ο
1952	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. Nature Medicine, 2021, 27, 1034-1042.	30.7	236
1953	Sex is a defining feature of neuroimaging phenotypes in major brain disorders. Human Brain Mapping, 2022, 43, 500-542.	3.6	25
1954	Causal structural covariance network revealing atrophy progression in Alzheimer's disease continuum. Human Brain Mapping, 2021, 42, 3950-3962.	3.6	16
1955	Advances in Brain Amyloid Imaging. Seminars in Nuclear Medicine, 2021, 51, 241-252.	4.6	30
1956	High-Sensitivity and Trace-Amount Specimen Electrochemical Sensors for Exploring the Levels of β-Amyloid in Human Blood and Tears. Analytical Chemistry, 2021, 93, 8099-8106.	6.5	19
1957	Alzheimer and Purinergic Signaling: Just a Matter of Inflammation?. Cells, 2021, 10, 1267.	4.1	15
1959	Knowledge gaps in Alzheimer's disease immune biomarker research. Alzheimer's and Dementia, 2021, 17, 2030-2042.	0.8	11
1960	Protein and Imaging Biomarkers in the Eye for Early Detection of Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2021, 5, 375-387.	2.2	10
1961	IRM encéphaliqueÂ: quelle place dans le bilan des maladies neurologiques à expression cognitiveÂ?. Pratique Neurologique - FMC, 2021, 12, 158-164.	0.1	0
1962	Autopsy-diagnosed neurodegenerative dementia cases support the use of cerebrospinal fluid protein biomarkers in the diagnostic work-up. Scientific Reports, 2021, 11, 10837.	3.3	9

#	Article	IF	CITATIONS
1963	Deciphering the links between psychological stress, depression, and neurocognitive decline in patients with Down syndrome. Neurobiology of Stress, 2021, 14, 100305.	4.0	4
1964	Left Ventricular Ejection Fraction and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Normal Older Adults: The CABLE Study. Journal of Alzheimer's Disease, 2021, 81, 743-750.	2.6	3
1965	Semantic Memory as an Early Cognitive Marker of Alzheimer's Disease: Role of Category and Phonological Verbal Fluency Tasks. Journal of Alzheimer's Disease, 2021, 81, 619-627.	2.6	15
1966	In Vivo Amyloid, Neurodegeneration, and Verbal Learning in Late Middle-Aged Hispanics. Journal of Alzheimer's Disease, 2021, 82, 1-9.	2.6	0
1968	Biomarkers and Tools for Predicting Alzheimer's Disease in the Preclinical Stage. Current Neuropharmacology, 2022, 20, 713-737.	2.9	8
1969	A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among communityâ€dwelling Mexican Americans and nonâ€Hispanic Whites: A method for increasing representation of diverse populations in clinical research. Alzheimer's and Dementia, 2022, 18, 77-87.	0.8	21
1971	PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research. Frontiers in Aging Neuroscience, 2021, 13, 624330.	3.4	39
1972	Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer's disease. Scientific Reports, 2021, 11, 9736.	3.3	49
1973	Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1976-1987.	0.8	35
1974	Soluble Pâ€ŧau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Molecular Medicine, 2021, 13, e14022.	6.9	90
1975	Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimer's Research and Therapy, 2021, 13, 98.	6.2	152
1976	Brain SPECT as a Biomarker of Neurodegeneration in Dementia in the Era of Molecular Imaging: Still a Valid Option?. Frontiers in Neurology, 2021, 12, 629442.	2.4	22
1977	Heterogeneity of Cerebrospinal Fluid Biomarkers Profiles in Individuals with Distinct Levels of Cognitive Decline: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2021, 81, 949-962.	2.6	4
1979	Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer's disease: the Altoida large cohort study. Npj Digital Medicine, 2021, 4, 101.	10.9	23
1980	DEF8 and Autophagy-Associated Genes Are Altered in Mild Cognitive Impairment, Probable Alzheimer's Disease Patients, and a Transgenic Model of the Disease. Journal of Alzheimer's Disease, 2021, 82, S163-S178.	2.6	6
1981	Retinal imaging in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 983-994.	1.9	46
1982	Memory for public events in amnestic mild cognitive impairment: The role of hippocampus and ventroâ€medial prefrontal cortex. Journal of Neuropsychology, 2022, 16, 131-148.	1.4	4
1983	Entorhinal Perfusion Predicts Future Memory Decline, Neurodegeneration, and White Matter Hyperintensity Progression in Older Adults. Journal of Alzheimer's Disease, 2021, 81, 1711-1725.	2.6	15
#	Article	IF	CITATIONS
------	--	------	-----------
1984	A longitudinal observation of brain structure between AD and FTLD. Clinical Neurology and Neurosurgery, 2021, 205, 106604.	1.4	5
1985	ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. Nature Aging, 2021, 1, 521-534.	11.6	64
1986	APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer's mice via cyclophilin A independently of amyloid-β. Nature Aging, 2021, 1, 506-520.	11.6	77
1987	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain, 2021, 144, 2826-2836.	7.6	65
1988	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurology, The, 2021, 20, 484-496.	10.2	396
1989	The Experts' Advice: Prevention and Responsibility in German Media and Scientific Discourses on Dementia. Qualitative Health Research, 2021, 31, 2005-2018.	2.1	10
1990	Aî² receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nature Communications, 2021, 12, 3451.	12.8	26
1991	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1206-1214.	1.9	30
1992	Neuropsychological Equivalence of the Clinical Diagnosis of Mild Cognitive Impairment in the National Alzheimer's Coordinating Center Uniform Data Set and Alzheimer's Disease Neuroimaging Initiative. Dementia and Geriatric Cognitive Disorders, 2021, 50, 231-236.	1.5	2
1993	Emerging insights into the role of albumin with plasma exchange in Alzheimer's disease management. Transfusion and Apheresis Science, 2021, 60, 103164.	1.0	12
1994	Identifying novel genetic variants for brain amyloid deposition: a genome-wide association study in the Korean population. Alzheimer's Research and Therapy, 2021, 13, 117.	6.2	7
1995	Novel Pyridineâ€Containing Sultones: Structureâ€Activity Relationship and Biological Evaluation as Selective AChE Inhibitors for the Treatment of Alzheimer's disease. ChemMedChem, 2021, 16, 3189-3200.	3.2	6
1997	Alix: A Candidate Serum Biomarker of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 669612.	3.4	1
1998	"Don't Phos Over Tau†recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies. Molecular Neurodegeneration, 2021, 16, 37.	10.8	89
1999	Cerebrospinal Fluid Inflammatory Markers in Alzheimer's Disease: Influence of Comorbidities. Current Alzheimer Research, 2021, 18, 157-170.	1.4	3
2000	Alzheimer's Disease Genetics: A Dampened Microglial Response?. Neuroscientist, 2023, 29, 245-263.	3.5	11
2001	Hippocampal vascularization patterns exert local and distant effects on brain structure but not vascular pathology in old age. Brain Communications, 2021, 3, fcab127.	3.3	9
2002	Deep learning of resting-state electroencephalogram signals for three-class classification of Alzheimer's disease, mild cognitive impairment and healthy ageing. Journal of Neural Engineering, 2021, 18, 046087.	3.5	37

#	Article	IF	CITATIONS
2003	Associations of cerebrospinal fluid amyloidogenic nanoplaques with cytokines in Alzheimer's disease. Translational Neurodegeneration, 2021, 10, 18.	8.0	6
2004	Temporal Ordering of Inflammatory Analytes sTNFR2 and sTREM2 in Relation to Alzheimer's Disease Biomarkers and Clinical Outcomes. Frontiers in Aging Neuroscience, 2021, 13, 676744.	3.4	11
2005	Reassessment of Pioglitazone for Alzheimer's Disease. Frontiers in Neuroscience, 2021, 15, 666958.	2.8	30
2006	In vivo multi-parametric manganese-enhanced MRI for detecting amyloid plaques in rodent models of Alzheimer's disease. Scientific Reports, 2021, 11, 12419.	3.3	7
2007	Increased Glucose Activity in Subgenual Anterior Cingulate and Hippocampus of High Performing Older Adults, Despite Amyloid Burden. Journal of Alzheimer's Disease, 2021, 81, 1419-1428.	2.6	3
2008	Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer's disease. GeroScience, 2021, 43, 1627-1634.	4.6	11
2009	Association between thyroid function and Alzheimer's disease: A systematic review. Metabolic Brain Disease, 2021, 36, 1523-1543.	2.9	13
2010	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and pâ€ŧau. Alzheimer's and Dementia, 2022, 18, 283-293.	0.8	72
2011	Baseline Neurodegeneration Influences the Longitudinal Effects of Tau on Cognition. Journal of Alzheimer's Disease, 2021, 82, 159-167.	2.6	1
2012	The Cognitive Scale of Basic and Instrumental Activities of Daily Living for Multidomain Mild Cognitive Impairment and Dementia Patients: Validation of its Extended Version. Journal of the International Neuropsychological Society, 2022, 28, 628-641.	1.8	4
2013	A Machine Learning Method to Identify Genetic Variants Potentially Associated With Alzheimer's Disease. Frontiers in Genetics, 2021, 12, 647436.	2.3	8
2014	Deep learning-based amyloid PET positivity classification model in the Alzheimer's disease continuum by using 2-[18F]FDG PET. EJNMMI Research, 2021, 11, 56.	2.5	20
2015	CSF1R inhibition rescues tau pathology and neurodegeneration in an A/T/N model with combined AD pathologies, while preserving plaque associated microglia. Acta Neuropathologica Communications, 2021, 9, 108.	5.2	22
2016	A New Highly Deuterated [ <sup>18</sup> F]AV-45, [ <sup>18</sup> F]D15FSP, for Imaging β-Amyloid Plaques in the Brain. ACS Medicinal Chemistry Letters, 2021, 12, 1086-1092.	2.8	10
2017	Resting-State Network Alterations Differ between Alzheimer's Disease Atrophy Subtypes. Cerebral Cortex, 2021, 31, 4901-4915.	2.9	12
2018	Traumatic brain injury fast-forwards Alzheimer's pathology: evidence from amyloid positron emission tomorgraphy imaging. Journal of Neurology, 2022, 269, 873-884.	3.6	19
2019	The Role of High Triglycerides Level in Predicting Cognitive Impairment: A Review of Current Evidence. Nutrients, 2021, 13, 2118.	4.1	36
2020	Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. International Journal of Molecular Sciences, 2021, 22, 6355	4.1	74

#	Article	IF	CITATIONS
2022	New frontiers in Alzheimer's disease diagnostic: Monoamines and their derivatives in biological fluids. Experimental Gerontology, 2021, 152, 111452.	2.8	10
2023	Pathological correlates of impaired self-awareness of memory function in Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 118.	6.2	7
2024	The neural economics of brain aging. Scientific Reports, 2021, 11, 12167.	3.3	0
2025	A Systematic Review and Meta-Analysis of Retinal Microvascular Features in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 683824.	3.4	7
2026	Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nature Communications, 2021, 12, 3555.	12.8	115
2027	Local Functional MR Change Pattern and Its Association With Cognitive Function in Objectively-Defined Subtle Cognitive Decline. Frontiers in Aging Neuroscience, 2021, 13, 684918.	3.4	19
2028	Protocol of the Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness cOhort (PRO) SubStudy. BMJ Open, 2021, 11, e043114.	1.9	4
2029	Nutraceutical and Probiotic Approaches to Examine Molecular Interactions of the Amyloid Precursor Protein APP in Drosophila Models of Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 7022.	4.1	5
2030	Shared Genetic Etiology between Alzheimer's Disease and Blood Levels of Specific Cytokines and Growth Factors. Genes, 2021, 12, 865.	2.4	2
2031	Amyloid PET in the diagnostic workup of neurodegenerative disease. Clinical and Translational Imaging, 2021, 9, 383-397.	2.1	1
2032	Is neuroticism differentially associated with risk of Alzheimer's disease, vascular dementia, and frontotemporal dementia?. Journal of Psychiatric Research, 2021, 138, 34-40.	3.1	25
2033	APP, PSEN1, and PSEN2 Variants in Alzheimer's Disease: Systematic Re-evaluation According to ACMG Guidelines. Frontiers in Aging Neuroscience, 2021, 13, 695808.	3.4	33
2034	Insomnia Moderates the Relationship Between Amyloid-β and Cognitive Decline in Late-Life Adults without Dementia. Journal of Alzheimer's Disease, 2021, 81, 1701-1710.	2.6	4
2035	Microglia show differential transcriptomic response to AÎ <sup>2</sup> peptide aggregates ex vivo and in vivo. Life Science Alliance, 2021, 4, e202101108.	2.8	17
2036	Clinical and Dynamic Features and Prognostic Value of Non-Cognitive Psychopathological Symptoms in Mild Cognitive Impairment (MCI). Psychiatry, 2021, 19, 17-28.	0.7	2
2037	The Latin America and the Caribbean Consortium on Dementia (LAC-CD): From Networking to Research to Implementation Science. Journal of Alzheimer's Disease, 2021, 82, S379-S394.	2.6	39
2038	Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer's disease pathology in aged squirrel monkeys. Brain, 2021, 144, 2146-2165.	7.6	19
2039	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. Journal of Internal Medicine, 2021, 290, 583-601.	6.0	54

#	Article	IF	CITATIONS
2040	False Memory and Alzheimer's Disease Pathology in Patients with Amnestic Mild Cognitive Impairment: A Study with Amyloid PET. Dementia and Geriatric Cognitive Disorders Extra, 2021, 11, 172-180.	1.3	2
2041	Unraveling the heterogeneity in Alzheimer's disease progression across multiple cohorts and the implications for dataâ€driven disease modeling. Alzheimer's and Dementia, 2022, 18, 251-261.	0.8	18
2042	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	12.8	219
2043	Interplay between stress-related genes may influence Alzheimer's disease development: The results of genetic interaction analyses of human data. Mechanisms of Ageing and Development, 2021, 196, 111477.	4.6	3
2045	A Comparative Study on the Predictive Value of Different Resting-State Functional Magnetic Resonance Imaging Parameters in Preclinical Alzheimer's Disease. Frontiers in Psychiatry, 2021, 12, 626332.	2.6	3
2046	Association of plasma P-tau181 with memory decline in non-demented adults. Brain Communications, 2021, 3, fcab136.	3.3	33
2047	Extracellular vesicles (exosomes and ectosomes) play key roles in the pathology of brain diseases. Molecular Biomedicine, 2021, 2, 18.	4.4	17
2049	A review of the mechanisms underlying selected comorbidities in Alzheimer's disease. Pharmacological Reports, 2021, 73, 1565-1581.	3.3	23
2050	Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age. Neurobiology of Aging, 2021, 102, 151-160.	3.1	6
2051	Neuroprotective effects of ononin against the aluminium chloride-induced Alzheimer's disease in rats. Saudi Journal of Biological Sciences, 2021, 28, 4232-4239.	3.8	45
2052	The Neuroinflammasome in Alzheimer's Disease and Cerebral Stroke. Dementia and Geriatric Cognitive Disorders Extra, 2021, 11, 159-167.	1.3	10
2053	Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease. Translational Psychiatry, 2021, 11, 356.	4.8	34
2054	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nature Medicine, 2021, 27, 1187-1196.	30.7	182
2055	Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1289-1295.	1.9	29
2056	The changing definition of Alzheimer's disease. Lancet Neurology, The, 2021, 20, 414-415.	10.2	7
2057	Longitudinal Cerebral Blood Flow Changes in Normal Aging and the Alzheimer's Disease Continuum Identified by Arterial Spin Labeling MRI. Journal of Alzheimer's Disease, 2021, 81, 1727-1735.	2.6	27
2058	Low-degree trisomy 21 mosaicism promotes early-onset Alzheimer disease. Neurobiology of Aging, 2021, 103, 147.e1-147.e5.	3.1	4
2059	Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status. Alzheimer's Research and Therapy, 2021, 13, 133.	6.2	19

#	Article	IF	CITATIONS
2060	Refining the amyloid l̂² peptide and oligomer fingerprint ambiguities in Alzheimer's disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. Journal of Neurochemistry, 2021, 159, 234-257.	3.9	8
2061	Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile. Alzheimer's Research and Therapy, 2021, 13, 134.	6.2	8
2062	The informed road map to prevention of Alzheimer Disease: A call to arms. Molecular Neurodegeneration, 2021, 16, 49.	10.8	43
2063	The Neurovascular Unit in Dementia: An Opinion on Current Research and Future Directions. Frontiers in Aging Neuroscience, 2021, 13, 721937.	3.4	8
2064	Meta-analysis of ICU Delirium Biomarkers and Their Alignment With the NIA-AA Research Framework. American Journal of Critical Care, 2021, 30, 312-319.	1.6	5
2065	Genomic Mosaicism Formed by Somatic Variation in the Aging and Diseased Brain. Genes, 2021, 12, 1071.	2.4	17
2066	A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation. Alzheimer's Research and Therapy, 2021, 13, 132.	6.2	4
2067	Family members' perspectives on learning cognitively unimpaired older adults' amyloidâ€Î² <scp>PET</scp> scan results. Journal of the American Geriatrics Society, 2021, 69, 3203-3211.	2.6	12
2068	Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 321-330.	6.4	1
2070	The Progress of Label-Free Optical Imaging in Alzheimer's Disease Screening and Diagnosis. Frontiers in Aging Neuroscience, 2021, 13, 699024.	3.4	4
2071	Metabolic Syndrome Is Associated With Poor Cognition: A Population-Based Study of 70-Year-Old Adults Without Dementia. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 2275-2283.	3.6	20
2072	Longitudinal changes in the control mechanisms for blood pressure and cerebral blood flow in Alzheimer's disease: Secondary results of a randomized controlled trial. Cerebral Circulation - Cognition and Behavior, 2021, 2, 100024.	0.9	2
2073	The human connectome in Alzheimer disease — relationship to biomarkers and genetics. Nature Reviews Neurology, 2021, 17, 545-563.	10.1	106
2074	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. Frontiers in Aging Neuroscience, 2021, 13, 712545.	3.4	16
2075	Effect of Point Spread Function Deconvolution in Reconstruction of Brain 18F-FDG PET Images on the Diagnostic Thinking Efficacy in Alzheimer's Disease. Frontiers in Medicine, 2021, 8, 721551.	2.6	2
2076	Differences in Alzheimer's Disease and Related Dementias Pathology Among African American and Hispanic Women: A Qualitative Literature Review of Biomarker Studies. Frontiers in Systems Neuroscience, 2021, 15, 685957.	2.5	9
2077	Life Course Adiposity and Alzheimer's Disease: A Mendelian Randomization Study. Journal of Alzheimer's Disease, 2021, 82, 503-512.	2.6	10
2078	Application of Near-Infrared Spectroscopy for Evidence-Based Psychotherapy. Frontiers in Psychology, 2021, 12, 527335.	2.1	3

#	Article	IF	CITATIONS
2079	Validity Evidence for the Research Category, "Cognitively Unimpaired – Declining,―as a Risk Marker for Mild Cognitive Impairment and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 688478.	3.4	21
2080	Multiple Cognitive and Behavioral Factors Link Association Between Brain Structure and Functional Impairment of Daily Instrumental Activities in Older Adults. Journal of the International Neuropsychological Society, 2022, 28, 673-686.	1.8	5
2081	Progression of Early Subclinical Atherosclerosis (PESA) Study. Journal of the American College of Cardiology, 2021, 78, 156-179.	2.8	56
2082	Event-related brain potential indexes provide evidence for some decline in healthy people with subjective memory complaints during target evaluation and response inhibition processing. Neurobiology of Learning and Memory, 2021, 182, 107450.	1.9	4
2083	A deep learning approach for monitoring parietal-dominant Alzheimer's disease in World Trade Center responders at midlife. Brain Communications, 2021, 3, fcab145.	3.3	4
2084	Peripheral inflammatory biomarkers predict the deposition and progression of amyloid-β in cognitively unimpaired older adults. Brain, Behavior, and Immunity, 2021, 95, 178-189.	4.1	22
2085	The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3033-3036.	6.4	6
2086	Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 703876.	3.4	13
2088	Cerebral Small Vessel Disease in Sporadic and Familial Alzheimer Disease. American Journal of Pathology, 2021, 191, 1888-1905.	3.8	28
2089	Parkinson disease-associated cognitive impairment. Nature Reviews Disease Primers, 2021, 7, 47.	30.5	391
2090	The Effects of Multi-Domain Interventions on Cognition: A Systematic Review. Western Journal of Nursing Research, 2022, 44, 1134-1154.	1.4	4
2091	Physical Activity and Neurodegeneration in Older Adults: Comment on: "Associations Between Physical Activity, Blood-Based Biomarkers of Neurodegeneration and Cognition in Healthy Older Adults: The MAPT Studyâ€: Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, e34-e35	3.6	0
2092	Emerging topics in dementia care and services. Journal of the American Geriatrics Society, 2021, 69, 1763-1773.	2.6	14
2093	Comparing dataâ€driven and hypothesisâ€driven MRIâ€based predictors of cognitive impairment in individuals from the Atherosclerosis Risk in Communities (ARIC) study. Alzheimer's and Dementia, 2022, 18, 561-571.	0.8	4
2094	Accumulation of saposin in dystrophic neurites is linked to impaired lysosomal functions in Alzheimer's disease brains. Molecular Neurodegeneration, 2021, 16, 45.	10.8	26
2095	Diabetes Mellitus and Cognition. Neurology, 2021, 97, e836-e848.	1.1	23
2096	Amyloid and tau positive mild cognitive impairment: clinical and biomarker characteristics of dementia progression. Chinese Medical Journal, 2021, 134, 1709-1719.	2.3	7
2097	Tau PET correlates with different Alzheimer's diseaseâ€related features compared to CSF and plasma pâ€tau biomarkers. EMBO Molecular Medicine, 2021, 13, e14398	6.9	58

#	Article	IF	CITATIONS
2098	Reproductive period and preclinical cerebrospinal fluid markers for Alzheimer disease: a 25-year study. Menopause, 2021, 28, 1099-1107.	2.0	6
2099	The complexity of Alzheimer's disease: an evolving puzzle. Physiological Reviews, 2021, 101, 1047-1081.	28.8	110
2100	Past, present and future role of retinal imaging in neurodegenerative disease. Progress in Retinal and Eye Research, 2021, 83, 100938.	15.5	60
2101	Moral motivation regarding dementia risk testing among affected persons in Germany and Israel. Journal of Medical Ethics, 2022, 48, 861-867.	1.8	3
2102	Cohort Analysis of the Association of Delirium Severity With Cerebrospinal Fluid Amyloid-Tau-Neurodegeneration Pathologies. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 494-501.	3.6	20
2103	Participation of persons with dementia and their caregivers in research. Journal of the American Geriatrics Society, 2021, 69, 1784-1792.	2.6	10
2105	Characterizing plasma NfL in a communityâ€dwelling multiâ€ethnic cohort: Results from the HABLE study. Alzheimer's and Dementia, 2022, 18, 240-250.	0.8	39
2106	The Gaze Fixation Assessed by Microperimetry: A Useful Tool for the Monitoring of the Cognitive Function in Patients with Type 2 Diabetes. Journal of Personalized Medicine, 2021, 11, 698.	2.5	4
2108	Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics. Cells, 2021, 10, 1930.	4.1	34
2109	EEG measures for clinical research in major vascular cognitive impairment: recommendations by an expert panel. Neurobiology of Aging, 2021, 103, 78-97.	3.1	9
2110	Case Report: Coexistence of Anti-AMPA Receptor Encephalitis and Positive Biomarkers of Alzheimer's Disease. Frontiers in Neurology, 2021, 12, 673347.	2.4	2
2111	The In Vivo Diagnosis of Concomitant Alzheimer and Lewy Body Pathology: A Case Report. Journal of Neuropathology and Experimental Neurology, 2021, 80, 1085-1087.	1.7	1
2112	High Correlation of Static First-Minute-Frame (FMF) PET Imaging after 18F-Labeled Amyloid Tracer Injection with [18F]FDG PET Imaging. Sensors, 2021, 21, 5182.	3.8	6
2113	Updates and new challenges in the prevention of dementia. Minerva Medica, 2021, 112, 427-429.	0.9	3
2114	Volumetry of Olfactory Structures in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and a Meta-Analysis. Brain Sciences, 2021, 11, 1010.	2.3	16
2115	Three-dimensional mapping of neurofibrillary tangle burden in the human medial temporal lobe. Brain, 2021, 144, 2784-2797.	7.6	38
2116	Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy. Neurology, 2021, 97, .	1.1	50
2117	Plasma neurofilament light chain levels and cognitive testing as predictors of fast progression in Alzheimer's disease. European Journal of Neurology, 2021, 28, 2980-2988.	3.3	6

ARTICLE IF CITATIONS # White matter hyperintensity topography in Alzheimer's disease and links to cognition. Alzheimer's and 2118 0.8 59 Dementia, 2022, 18, 422-433. Is cognitive screening useful for long-term prediction of incident dementia?. The Lancet Healthy 4.6 Longevity, 2021, 2, e387-e388. Genetic overlap between Alzheimer's disease and blood lipid levels. Neurobiology of Aging, 2021, 108, 2120 3.15 189-195. Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Alzheimer's and Dementia, 2022, 18, 602-611. Community-based Model for Dementia Risk Screening: The Beijing Aging Brain Rejuvenation Initiative 2122 (BABRI) Brain Health System. Journal of the American Medical Directors Association, 2021, 22, 2.5 7 1500-1506.e3. Sex differences in in vivo tau neuropathology in a multiethnic sample of late middle-aged adults. Neurobiology of Aging, 2021, 103, 109-116. 3.1 When Does Alzheimer's Disease Really Start? The Role of Biomarkers. Focus (American Psychiatric) Tj ETQq0 0 Q rgBT /Overlock 10 1 2124 Altered Gut Microbiota in Adults with Subjective Cognitive Decline: The SILCODE Study. Journal of 29 2.6 Alzheimer's Disease, 2021, 82, 513-526. Detection of Alzheimer's disease amyloid beta 1â€42, pâ€tau, and tâ€tau assays. Alzheimer's and Dementia, 2126 0.8 28 2022, 18, 635-644. Differences in structural and functional default mode network connectivity in amyloid positive mild 2.2 cognitive impairment: a longitudinal study. Neuroradiology, 2022, 64, 141-150. Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum 2128 6.2 39 of Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 123. Familiarity in Mild Cognitive Impairment as a Function of Patients' Clinical Outcome 4 Years Later. 1.3 Alzheimer Disease and Associated Disorders, 2021, 35, 321-326. Multiplex Mass Spectrometry Analysis of Amyloid Proteins in Human Plasma for Alzheimer's Disease 2130 3.7 6 Diagnosis. Journal of Proteome Research, 2021, 20, 4106-4112. Robust EEG Based Biomarkers to Detect Alzheimer's Disease. Brain Sciences, 2021, 11, 1026. 2131 2.3

CITATION REPORT

2132	Reappraisal of metabolic dysfunction in neurodegeneration: Focus on mitochondrial function and calcium signaling. Acta Neuropathologica Communications, 2021, 9, 124.	5.2	33
2133	A Graph Theory Approach to Clarifying Aging and Disease Related Changes in Cognitive Networks. Frontiers in Aging Neuroscience, 2021, 13, 676618.	3.4	13
2134	Current Nosology of Neural Autoantibody-Associated Dementia. Frontiers in Aging Neuroscience, 2021, 13, 711195.	3.4	10
	Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive		

Supranuclear Palsy Tau Pathology With [18F]PI-2620. Frontiers in Neurology, 2021, 12, 684523.

#	Article	IF	CITATIONS
2136	Repetitive Transcranial Magnetic Stimulation of the Dorsolateral Prefrontal Cortex Modulates Electroencephalographic Functional Connectivity in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 679585.	3.4	7
2137	Prediction of differentially expressed microRNAs in blood as potential biomarkers for Alzheimer's disease by meta-analysis and adaptive boosting ensemble learning. Alzheimer's Research and Therapy, 2021, 13, 126.	6.2	26
2139	How Does Dementia Begin to Manifest in Bipolar Disorder? A Description of Prodromal Clinical and Cognitive Changes. Journal of Alzheimer's Disease, 2021, 82, 737-748.	2.6	2
2140	Cognitive reserve and Alzheimer's biological continuum: clues for prediction and prevention of dementia. Minerva Medica, 2021, 112, 441-447.	0.9	10
2141	Association of Tau Pathology With Clinical Symptoms in the Subfields of Hippocampal Formation. Frontiers in Aging Neuroscience, 2021, 13, 672077.	3.4	4
2142	Neuroinflammation modulates the association of PGRN with cerebral amyloid-Î <sup>2</sup> burden. Neurobiology of Aging, 2021, 103, 52-59.	3.1	3
2143	Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nature Reviews Neurology, 2021, 17, 580-589.	10.1	144
2144	Prevalence and Predictors of Prolonged Cognitive and Psychological Symptoms Following COVID-19 in the United States. Frontiers in Aging Neuroscience, 2021, 13, 690383.	3.4	34
2145	Amyloid-β positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume. Neurobiology of Aging, 2021, 104, 24-31.	3.1	13
2146	Estimating Progression Rates Across the Spectrum of Alzheimer's Disease for Amyloid-Positive Individuals Using National Alzheimer's Coordinating Center Data. Neurology and Therapy, 2021, 10, 941-953.	3.2	12
2148	Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIAD. Alzheimer's Research and Therapy, 2021, 13, 142.	6.2	14
2150	Challenges in LC–MS-based metabolomics for Alzheimer's disease early detection: targeted approaches versus untargeted approaches. Metabolomics, 2021, 17, 78.	3.0	19
2151	Predictors of cognitive impairment in primary age-related tauopathy: an autopsy study. Acta Neuropathologica Communications, 2021, 9, 134.	5.2	32
2152	Tau-related grey matter network breakdown across the Alzheimer's disease continuum. Alzheimer's Research and Therapy, 2021, 13, 138.	6.2	10
2153	Default mode network connectivity and cognition in the aging brain: the effects of age, sex, and APOE genotype Neurobiology of Aging, 2021, 104, 10-23.	3.1	12
2154	Validation of the Cognitive Telephone Screening Instruments COGTEL and COGTEL+ in Identifying Clinically Diagnosed Neurocognitive Disorder Due to Alzheimer's Disease in a Naturalistic Clinical Setting, Journal of Alzheimer's Disease, 2021, 83, 259-268.	2.6	8
2155	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. Proteomes, 2021, 9, 36.	3.5	9
2156	Association of Short and Long Sleep Duration With Amyloid-β Burden and Cognition in Aging. JAMA Neurology, 2021, 78, 1187.	9.0	103

#	Article	IF	CITATIONS
2157	Longitudinal Changes in Hippocampal Network Connectivity in Alzheimer's Disease. Annals of Neurology, 2021, 90, 391-406.	5.3	25
2158	GABAergic dysfunction, neural network hyperactivity and memory impairments in human aging and Alzheimer's disease. Seminars in Cell and Developmental Biology, 2021, 116, 146-159.	5.0	77
2159	Longitudinal predictive modeling of tau progression along the structural connectome. NeuroImage, 2021, 237, 118126.	4.2	8
2160	Relevance of Complaint Severity in Predicting the Progression of Subjective Cognitive Decline and Mild Cognitive Impairment: A Machine Learning Approach. Journal of Alzheimer's Disease, 2021, 82, 1229-1242.	2.6	9
2161	Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer's and other neurodegenerative diseases. Expert Review of Neurotherapeutics, 2021, 21, 949-967.	2.8	4
2162	Bias-generating factors in biofluid amyloid-β measurements for Alzheimer's disease diagnosis. Biomedical Engineering Letters, 2021, 11, 287-295.	4.1	6
2163	High cerebrospinal amyloid-β 42 is associated with normal cognition in individuals with brain amyloidosis. EClinicalMedicine, 2021, 38, 100988.	7.1	69
2164	Are there consistent abnormalities in eventâ€related EEG oscillations in patients with Alzheimer's disease compared to other diseases belonging to dementia?. Psychophysiology, 2022, 59, e13934.	2.4	19
2165	Reduced Levels of miR-342-5p in Plasma Are Associated With Worse Cognitive Evolution in Patients With Mild Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 705989.	3.4	9
2166	Association of Social Support With Brain Volume and Cognition. JAMA Network Open, 2021, 4, e2121122.	5.9	31
2167	Association between handgrip strength and cognition in a Chinese population with Alzheimer's disease and mild cognitive impairment. BMC Geriatrics, 2021, 21, 459.	2.7	15
2168	Optimal Combinations of AT(N) Biomarkers to Determine Longitudinal Cognition in the Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 718959.	3.4	10
2169	Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease. Frontiers in Neurology, 2021, 12, 694329.	2.4	8
2171	Sensitive Measures of Cognition in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 82, 1123-1136.	2.6	2
2172	<i>MAPT</i> R406W increases tau T217 phosphorylation in absence of amyloid pathology. Annals of Clinical and Translational Neurology, 2021, 8, 1817-1830.	3.7	11
2173	Association of Midlife Plasma Amyloid-β Levels With Cognitive Impairment in Late Life. Neurology, 2021, 97, e1123-e1131.	1.1	13
2174	Tackling Stereochemistry in Drug Molecules with Vibrational Optical Activity. Pharmaceuticals, 2021, 14, 877.	3.8	17

#	Article	IF	CITATIONS
2178	Combining Low-Dose Radiation Therapy and Magnetic Resonance Guided Focused Ultrasound to Reduce Amyloid-β Deposition in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 84, 1-4.	2.6	0
2180	Amyloid Deposition Is Greater in Cerebral Gyri than in Cerebral Sulci with Worsening Clinical Diagnosis Across the Alzheimer's Disease Spectrum. Journal of Alzheimer's Disease, 2021, 83, 423-433.	2.6	0
2181	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's continuum. Alzheimer's Research and Therapy, 2021, 13, 135.	6.2	30
2182	Deficits in short-term memory binding are detectable in individuals with brain amyloid deposition in the absence of overt neurodegeneration in the Alzheimer's disease continuum. Brain and Cognition, 2021, 152, 105749.	1.8	9
2183	Serum Apo J as a potential marker of conversion from mild cognitive impairment to dementia. Journal of the Neurological Sciences, 2021, 427, 117537.	0.6	4
2184	Artificial Intelligence for Alzheimer's Disease: Promise or Challenge?. Diagnostics, 2021, 11, 1473.	2.6	38
2185	Cognitive Decline Assessment: A Review From Medical Imaging Perspective. Frontiers in Aging Neuroscience, 2021, 13, 704661.	3.4	6
2186	The PrecivityADâ,,¢ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis. Clinica Chimica Acta, 2021, 519, 267-275.	1.1	57
2187	Impaired Hippocampal Neurovascular Coupling in a Mouse Model of Alzheimer's Disease. Frontiers in Physiology, 2021, 12, 715446.	2.8	13
2188	Divergent Connectivity Changes in Gray Matter Structural Covariance Networks in Subjective Cognitive Decline, Amnestic Mild Cognitive Impairment, and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 686598.	3.4	15
2189	The Relationship of Anxiety with Alzheimer's Disease: A Narrative Review. Current Alzheimer Research, 2021, 18, 359-371.	1.4	8
2190	Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum. Neurology, 2021, 97, e1276-e1287.	1.1	44
2191	Biobanking for Neurodegenerative Diseases: Challenge for Translational Research and Data Privacy. Neuroscientist, 2021, , 107385842110366.	3.5	2
2193	Blood-Based Biomarkers of Neuroinflammation in Alzheimer's Disease: A Central Role for Periphery?. Diagnostics, 2021, 11, 1525.	2.6	20
2194	Aging biomarkers and the brain. Seminars in Cell and Developmental Biology, 2021, 116, 180-193.	5.0	33
2195	Mass spectrometryâ€based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids. Journal of Neurochemistry, 2021, 159, 211-233.	3.9	29
2196	Quantum dots as a theranostic approach in Alzheimer's disease: a systematic review. Nanomedicine, 2021, 16, 1595-1611.	3.3	23
2197	Decreased Alpha Peak Frequency Is Linked to Episodic Memory Impairment in Pathological Aging. Frontiers in Aging Neuroscience, 2021, 13, 711375.	3.4	4

#	Article	IF	CITATIONS
2198	Retinal Dysfunction in Alzheimer's Disease and Implications for Biomarkers. Biomolecules, 2021, 11, 1215.	4.0	15
2199	Upregulation of Local Hepcidin Contributes to Iron Accumulation in Alzheimer's Disease Brains. Journal of Alzheimer's Disease, 2021, 82, 1487-1497.	2.6	11
2200	Association of Stress with Risk of Dementia and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2021, 82, 1573-1590.	2.6	35
2201	Re: Shang etÂal.: The association between vision impairment and incidence of dementia and cognitive impairment: a systematic review and meta-analysis (Ophthalmology. 2021;128:1135–1149). Ophthalmology, 2021, 128, e39.	5.2	1
2202	Relationships between preoperative cortical thickness, postoperative electroencephalogram slowing, and postoperative delirium. British Journal of Anaesthesia, 2021, 127, 236-244.	3.4	11
2204	Effects of Mild Excitotoxic Stimulus on Mitochondria Ca2+ Handling in Hippocampal Cultures of a Mouse Model of Alzheimer's Disease. Cells, 2021, 10, 2046.	4.1	8
2205	Are Parkinson's Disease Patients the Ideal Preclinical Population for Alzheimer's Disease Therapeutics?. Journal of Personalized Medicine, 2021, 11, 834.	2.5	3
2206	Associations Between Cognitive Complaints, Memory Performance, Mood, and Amyloid-β Accumulation in Healthy Amyloid Negative Late-Midlife Individuals. Journal of Alzheimer's Disease, 2021, 83, 127-141.	2.6	4
2207	Altered Spontaneous Brain Activity in Subjects With Different Cognitive States of Biologically Defined Alzheimer's Disease: A Surface-Based Functional Brain Imaging Study. Frontiers in Aging Neuroscience, 2021, 13, 683783.	3.4	3
2208	Blood Biomarkers for Alzheimer's Disease in Down Syndrome. Journal of Clinical Medicine, 2021, 10, 3639.	2.4	17
2209	Connectome-based model predicts episodic memory performance in individuals with subjective cognitive decline and amnestic mild cognitive impairment. Behavioural Brain Research, 2021, 411, 113387.	2.2	9
2210	Resting State Alpha Electroencephalographic Rhythms Are Differently Related to Aging in Cognitively Unimpaired Seniors and Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 82, 1085-1114.	2.6	8
2211	Oculomotor Behaviors and Integrative Memory Functions in the Alzheimer's Clinical Syndrome. Journal of Alzheimer's Disease, 2021, 82, 1033-1044.	2.6	5
2212	Astrocyte-neuron metabolic cooperation shapes brain activity. Cell Metabolism, 2021, 33, 1546-1564.	16.2	143
2213	Diabetes mellitus contributes to higher cerebrospinal fluid tau levels selectively in Alzheimer's disease patients with the APOE4 genotype. European Journal of Neurology, 2021, 28, 3965-3971.	3.3	7
2214	Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimer's Research and Therapy, 2021, 13, 137.	6.2	59
2215	A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 83, 1537-1552.	2.6	38
2216	Longitudinal Observation of Early-Onset Alzheimer's Disease Dementia with Positive CSF Biomarkers/Negative Amyloid-β Positron-Emission Tomography. Journal of the Korean Neurological Association, 2021, 39, 214-218.	0.1	0

		CITATION RE	PORT	
#	Article		IF	CITATIONS
2217	Relevance of cortical excitability in Alzheimer's disease. Clinical Neurophysiology, 2	021, 132, 1961-1963.	1.5	2
2218	Motor Dysfunction Questionnaire and Dopamine Transporter Imaging Composite Scale Differentiating Dementia With Lewy Bodies From Alzheimer's Disease With Motor Dysf Frontiers in Aging Neuroscience, 2021, 13, 709215.	Improve unction.	3.4	3
2220	Retinal biomarkers in Alzheimer's disease and mild cognitive impairment: A systema meta-analysis. Ageing Research Reviews, 2021, 69, 101361.	atic review and	10.9	47
2221	The Role of Age on Beta-Amyloid1–42 Plasma Levels in Healthy Subjects. Frontiers in Neuroscience, 2021, 13, 698571.	Aging	3.4	8
2222	Millipore xMap® Luminex (HATMAC-68K): An Accurate and Cost-Effective Method for Alzheimer's Biomarkers in Cerebrospinal Fluid. Frontiers in Psychiatry, 2021, 12, 71668	Evaluating 6.	2.6	9
2223	Inflammatory Biomarkers Aid in Diagnosis of Dementia. Frontiers in Aging Neuroscience 717344.	e, 2021, 13,	3.4	17
2224	Meta-analysis of Controlled Oral Word Association Test (COWAT) FAS performance in cognitive impairment and cognitively unimpaired older adults. Applied Neuropsycholog 30, 424-430.	amnestic mild y Adult, 2023,	1.2	4
2225	Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimera Journal of Nanobiotechnology, 2021, 19, 249.	's disease.	9.1	4
2226	RNA Dynamics in Alzheimer's Disease. Molecules, 2021, 26, 5113.		3.8	29
2227	Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimerâ Neurology and Therapy, 2021, 10, 919-940.	€™s Disease.	3.2	25
2228	Al̂² misfolding in blood plasma is inversely associated with body mass index even in mic Alzheimer's Research and Therapy, 2021, 13, 145.	dle adulthood.	6.2	3
2229	Intranasal Paclitaxel Alters Alzheimer's Disease Phenotypic Features in 3xTg-AD Mic Alzheimer's Disease, 2021, 83, 379-394.	e. Journal of	2.6	9
2230	Cerebrospinal Fluid Amyloid-β Oligomer Levels in Patients with Idiopathic Normal Press Hydrocephalus. Journal of Alzheimer's Disease, 2021, 83, 179-190.	ure	2.6	6
2231	Data-Driven vs Consensus Diagnosis of MCI. Neurology, 2021, 97, e1288-e1299.		1.1	12
2232	Role of Oxidative Damage in Alzheimer's Disease and Neurodegeneration: From Pat to Biomarker Discovery. Antioxidants, 2021, 10, 1353.	thogenic Mechanisms	5.1	57
2233	Asymmetric Amyloid- $\hat{l}^2$ Burden and Neurodegeneration in Late-Onset Alzheimerâ $\in$ <sup>Ms</sup> D Journal of the Korean Neurological Association, 2021, 39, 197-201.	Pisease Dementia.	0.1	1
2234	Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzh Brain, 2022, 145, 713-728.	eimer's disease.	7.6	43
2235	The Amyloid-β Pathway in Alzheimer's Disease. Molecular Psychiatry, 2021, 26, 548	81-5503.	7.9	478

#	Article	IF	CITATIONS
2236	Predicting Brain Amyloid Using Multivariate Morphometry Statistics, Sparse Coding, and Correntropy: Validation in 1,101 Individuals From the ADNI and OASIS Databases. Frontiers in Neuroscience, 2021, 15, 669595.	2.8	15
2237	Sleep Time Estimated by an Actigraphy Watch Correlates With CSF Tau in Cognitively Unimpaired Elders: The Modulatory Role of APOE. Frontiers in Aging Neuroscience, 2021, 13, 663446.	3.4	11
2238	Alzheimer's Disease Biomarkers in Idiopathic Normal Pressure Hydrocephalus: Linking Functional Connectivity and Clinical Outcome. Journal of Alzheimer's Disease, 2021, 83, 1-12.	2.6	8
2239	The <i>APOE</i> ε4 variant and hippocampal atrophy in Alzheimer's disease and Lewy body dementia: a systematic review of magnetic resonance imaging studies and therapeutic relevance. Expert Review of Neurotherapeutics, 2021, 21, 851-870.	2.8	7
2240	Awareness of Cognitive Decline in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. Frontiers in Aging Neuroscience, 2021, 13, 697234.	3.4	17
2241	Cerebrospinal Fluid Neurotransmitters, Cytokines, and Chemokines in Alzheimer's and Lewy Body Diseases. Journal of Alzheimer's Disease, 2021, 82, 1067-1074.	2.6	13
2242	Clinical Phenotype and Mutation Spectrum of Alzheimer's Disease with Causative Genetic Mutation in a Chinese Cohort. Current Alzheimer Research, 2021, 18, 265-272.	1.4	5
2243	Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project. Alzheimer's Research and Therapy, 2021, 13, 136.	6.2	30
2244	Diagnosi clinicolaboratoristica della malattia di Alzheimer. EMC - Neurologia, 2021, 21, 1-15.	0.0	0
2245	Aducanumab: What about the Patient?. Annals of Neurology, 2021, 90, 334-335.	5.3	10
2246	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	9.0	148
2248	The association of epigenetic clocks in brain tissue with brain pathologies and common aging phenotypes. Neurobiology of Disease, 2021, 157, 105428.	4.4	36
2249	Clinical Applications of PET/MR Imaging. Radiologic Clinics of North America, 2021, 59, 853-874.	1.8	5
2250	Multimodal neuroimaging of sex differences in cognitively impaired patients on the Alzheimer's continuum: greater tau-PET retention in females. Neurobiology of Aging, 2021, 105, 86-98.	3.1	29
2251	Positive Effects of Education on Cognitive Functioning Depend on Clinical Status and Neuropathological Severity. Frontiers in Human Neuroscience, 2021, 15, 723728.	2.0	13
2252	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. Neurology, 2021, 97, e1681-e1694.	1.1	60
2253	The association between hippocampal volume and memory in pathological aging is mediated by functional redundancy. Neurobiology of Aging, 2021, 108, 179-188.	3.1	11
2254	Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer's disease. Brain Pathology, 2022, 32, e13016.	4.1	13

#	Article	IF	CITATIONS
2255	Examining racial disparities in the diagnosis of mild cognitive impairment. Applied Neuropsychology Adult, 2023, 30, 749-756.	1.2	8
2256	Definitive roles of TOMM40-APOE-APOC1 variants in the Alzheimer's risk. Neurobiology of Aging, 2022, 110, 122-131.	3.1	15
2257	Acknowledging and addressing the many ethical aspects of disease. Patient Education and Counseling, 2022, 105, 1201-1208.	2.2	7
2258	Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimer's and Dementia, 2022, 18, 1128-1140.	0.8	88
2259	BIOFACE: A Prospective Study of Risk Factors, Cognition, and Biomarkers in a Cohort of Individuals with Early-Onset Mild Cognitive Impairment. Study Rationale and Research Protocols. Journal of Alzheimer's Disease, 2021, 83, 1233-1249.	2.6	7
2260	Blood pressure variability and medial temporal atrophy in apolipoprotein Ϊμ4 carriers. Brain Imaging and Behavior, 2022, 16, 792-801.	2.1	13
2261	Aî² initiates brain hypometabolism, network dysfunction and behavioral abnormalities via NOX2-induced oxidative stress in mice. Communications Biology, 2021, 4, 1054.	4.4	23
2262	Association of cortical microstructure with amyloid-β and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. Molecular Psychiatry, 2021, 26, 7813-7822.	7.9	17
2263	Extracellular vesicles in the treatment of neurological disorders. Neurobiology of Disease, 2021, 157, 105445.	4.4	28
2264	Using Optical Coherence Tomography to Screen for Cognitive Impairment and Dementia. Journal of Alzheimer's Disease, 2021, 84, 723-736.	2.6	9
2265	The circadian rest-activity pattern predicts cognitive decline among mild-moderate Alzheimer's disease patients. Alzheimer's Research and Therapy, 2021, 13, 161.	6.2	15
2266	Clinical Implications of Amyloid-Beta Accumulation in Occipital Lobes in Alzheimer's Continuum. Brain Sciences, 2021, 11, 1232.	2.3	6
2267	Berberine loaded nanostructured lipid carrier for Alzheimer's disease: Design, statistical optimization and enhanced in vivo performance. Life Sciences, 2021, 285, 119990.	4.3	21
2269	The relationship of glucose-stimulated insulin secretion to cerebral glucose metabolism and cognition in healthy middle-aged and older adults. Neurobiology of Aging, 2021, 105, 174-185.	3.1	1
2270	Relationships between frontal metabolites and Alzheimer's disease biomarkers in cognitively normal older adults. Neurobiology of Aging, 2022, 109, 22-30.	3.1	8
2271	Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurology, 2021, 78, 1108.	9.0	114
2272	Assessment of Tau Pathology as Measured by 18F-THK5317 and 18F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 84, 103-117.	2.6	4
2273	Menopause and cognitive impairment: A narrative review of current knowledge. World Journal of Psychiatry, 2021, 11, 412-428.	2.7	28

#	Article	IF	CITATIONS
2274	Associations among vascular risk factors, neuroimaging biomarkers, and cognition: Preliminary analyses from the Multiâ€Ethnic Study of Atherosclerosis (MESA). Alzheimer's and Dementia, 2022, 18, 551-560.	0.8	19
2276	Retinal Vasculopathy in Alzheimer's Disease. Frontiers in Neuroscience, 2021, 15, 731614.	2.8	40
2277	Beyond the AJR: Tau PET, Amyloid PET, and MRI, as Prognostic Markers in Early Alzheimer Disease. American Journal of Roentgenology, 2022, , 1.	2.2	0
2278	Brain energy metabolism and neurodegeneration: hints from CSF lactate levels in dementias. Neurobiology of Aging, 2021, 105, 333-339.	3.1	14
2279	Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. Journal of Alzheimer's Disease, 2021, 84, 119-128.	2.6	3
2280	Editorial: Immunological Mechanisms, Biomarkers and Immunotherapies of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 733282.	3.4	0
2281	Diagnostic performance of the medial temporal lobe atrophy scale in patients with Alzheimer's disease: a systematic review and meta-analysis. European Radiology, 2021, 31, 9060-9072.	4.5	8
2282	Lipid Profiling of Alzheimer's Disease Brain Highlights Enrichment in Glycerol(phospho)lipid, and Sphingolipid Metabolism. Cells, 2021, 10, 2591.	4.1	38
2283	Relationship between cortisol, Interleukin-6 and homocysteine in Alzheimer's disease. Qatar Medical Journal, 2021, 2021, 1-10.	0.5	11
2284	Taking the A Train? Limited Consistency of Aβ42 and the Aβ42/40 Ratio in the AT(N) Classification. Journal of Alzheimer's Disease, 2021, 83, 1033-1038.	2.6	6
2285	Cerebrospinal fluid orexin in Alzheimer's disease: a systematic review and meta-analysis. Sleep Medicine, 2021, 85, 230-238.	1.6	6
2286	The relationship of functional hippocampal activity, amyloid deposition, and longitudinal memory decline to memory complaints in cognitively healthy older adults. Neurobiology of Aging, 2021, 105, 318-326.	3.1	11
2287	Analysis the Link between Periodontal Diseases and Alzheimer's Disease: A Systematic Review. International Journal of Environmental Research and Public Health, 2021, 18, 9312.	2.6	37
2288	A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimer's Disease Based on Cogstate One Card Learning Accuracy Performance. Journal of Alzheimer's Disease, 2021, 83, 861-877.	2.6	7
2289	Personalized prediction of progression in preâ€dementia patients based on individual biomarker profile: A development and validation study. Alzheimer's and Dementia, 2021, 17, 1938-1949.	0.8	9
2290	Dementia in Africa: Current evidence, knowledge gaps, and future directions. Alzheimer's and Dementia, 2022, 18, 790-809.	0.8	34
2291	Spatial organization of protein aggregates on red blood cells as physical biomarkers of Alzheimer's disease pathology. Science Advances, 2021, 7, eabj2137.	10.3	10
2292	Systematic Search for Novel Circulating Biomarkers Associated with Extracellular Vesicles in Alzheimer's Disease: Combining Literature Screening and Database Mining Approaches. Journal of Personalized Medicine, 2021, 11, 946.	2.5	6

#	Article	IF	CITATIONS
2293	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in the Era of Disease-Modifying Treatments. Brain Sciences, 2021, 11, 1258.	2.3	3
2294	Alzheimer's AÎ <sup>2</sup> assembly binds sodium pump and blocks endothelial NOS activity via ROS-PKC pathway in brain vascular endothelial cells. IScience, 2021, 24, 102936.	4.1	7
2295	Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus. Nature Reviews Neurology, 2021, 17, 689-701.	10.1	169
2296	Relation between Alpha-Synuclein and Core CSF Biomarkers of Alzheimer's Disease. Medicina (Lithuania), 2021, 57, 954.	2.0	5
2297	Distinct amyloid and tau PET signatures are associated with diverging clinical and imaging trajectories in patients with amnestic syndrome of the hippocampal type. Translational Psychiatry, 2021, 11, 498.	4.8	8
2298	A machine learning approach to screen for preclinical Alzheimer's disease. Neurobiology of Aging, 2021, 105, 205-216.	3.1	18
2299	Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2021, 128, 479-486.	6.1	35
2300	Clinical study of central cholinergic pathway damage in two mild cognitive impairment patients. Neurological Sciences, 2021, 42, 4707-4717.	1.9	2
2301	Concordance of Intrinsic Brain Connectivity Measures Is Disrupted in Alzheimer's Disease. Brain Connectivity, 2021, , .	1.7	2
2302	Metabolic determinants of Alzheimer's disease: A focus on thermoregulation. Ageing Research Reviews, 2021, 72, 101462.	10.9	18
2302 2303	Metabolic determinants of Alzheimer's disease: A focus on thermoregulation. Ageing Research Reviews, 2021, 72, 101462. Mild Cognitive Impairment or Attention-Deficit/Hyperactivity Disorder in Older Adults? A Cross Sectional Study. Frontiers in Psychiatry, 2021, 12, 737357.	10.9 2.6	18 9
2302 2303 2304	Metabolic determinants of Alzheimer's disease: A focus on thermoregulation. Ageing Research Reviews, 2021, 72, 101462.         Mild Cognitive Impairment or Attention-Deficit/Hyperactivity Disorder in Older Adults? A Cross Sectional Study. Frontiers in Psychiatry, 2021, 12, 737357.         Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 151.	10.9 2.6 6.2	18 9 9
2302 2303 2304 2305	Metabolic determinants of Alzheimer's disease: A focus on thermoregulation. Ageing Research Reviews, 2021, 72, 101462.         Mild Cognitive Impairment or Attention-Deficit/Hyperactivity Disorder in Older Adults? A Cross Sectional Study. Frontiers in Psychiatry, 2021, 12, 737357.         Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 151.         Amyloid-Beta Influences Memory via Functional Connectivity During Memory Retrieval in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 721171.	10.9 2.6 6.2 3.4	18 9 9 4
2302 2303 2304 2305 2306	Metabolic determinants of Alzheimer's disease: A focus on thermoregulation. Ageing Research         Reviews, 2021, 72, 101462.         Mild Cognitive Impairment or Attention-Deficit/Hyperactivity Disorder in Older Adults? A Cross         Sectional Study. Frontiers in Psychiatry, 2021, 12, 737357.         Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease.         Alzheimer's Research and Therapy, 2021, 13, 151.         Amyloid-Beta Influences Memory via Functional Connectivity During Memory Retrieval in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 721171.         Predictive Accuracy of Blood-Derived Biomarkers for Amyloid-β Brain Deposition Along with the Alzheimer's Disease, 2021, 84, 1-15.	10.9 2.6 6.2 3.4 2.6	18 9 9 4
2302 2303 2304 2305 2306 2307	Metabolic determinants of Alzheimer's disease: A focus on thermoregulation. Ageing Research Reviews, 2021, 72, 101462.         Mild Cognitive Impairment or Attention-Deficit/Hyperactivity Disorder in Older Adults? A Cross Sectional Study. Frontiers in Psychiatry, 2021, 12, 737357.         Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 151.         Amyloid-Beta Influences Memory via Functional Connectivity During Memory Retrieval in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 721171.         Predictive Accuracy of Blood-Derived Biomarkers for Amyloid-β Brain Deposition Along with the Alzheimer's Disease Continuum: A Systematic Review. Journal of Alzheimer's Disease, 2021, 84, 1-15.         Investigating Auditory Electrophysiological Measures of Participants with Mild Cognitive Impairment and Alzheimer's Disease; A Systematic Review and Meta-Analysis of Event-Related Potential Studies. Journal of Alzheimer's Disease, 2021, 84, 419-448.	<ol> <li>10.9</li> <li>2.6</li> <li>6.2</li> <li>3.4</li> <li>2.6</li> <li>2.6</li> </ol>	<ul> <li>18</li> <li>9</li> <li>9</li> <li>4</li> <li>6</li> <li>13</li> </ul>
2302 2303 2304 2305 2306 2307	Metabolic determinants of Alzheimer's disease: A focus on thermoregulation. Ageing Research Reviews, 2021, 72, 101462.         Mild Cognitive Impairment or Attention-Deficit/Hyperactivity Disorder in Older Adults? A Cross Sectional Study. Frontiers in Psychiatry, 2021, 12, 737357.         Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 151.         Amyloid-Beta Influences Memory via Functional Connectivity During Memory Retrieval in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 721171.         Predictive Accuracy of Blood-Derived Biomarkers for Amyloid-β Brain Deposition Along with the Alzheimer〙s Disease Continuum: A Systematic Review. Journal of Alzheimer's Disease, 2021, 84, 1-15.         Investigating Auditory Electrophysiological Measures of Participants with Mild Cognitive Impairment and Alzheimer's Disease; A Systematic Review and Meta-Analysis of Event-Related Potential Studies. Journal of Alzheimer's Disease; A Systematic Review and Meta-Analysis of Event-Related Potential Studies. Journal of Alzheimer's Disease; A Systematic Review and Meta-Analysis of Event-Related Potential Studies. Journal of Alzheimer's Disease, 2021, 84, 419-448.         Development and validation of the dialysis dementia risk score: A retrospective, populationâ€based, nested caseâ€control study. European Journal of Neurology, 2022, 29, 59-68.	<ol> <li>10.9</li> <li>2.6</li> <li>6.2</li> <li>3.4</li> <li>2.6</li> <li>2.6</li> <li>3.3</li> </ol>	<ul> <li>18</li> <li>9</li> <li>9</li> <li>4</li> <li>6</li> <li>13</li> <li>3</li> </ul>
<ul> <li>2302</li> <li>2303</li> <li>2304</li> <li>2305</li> <li>2306</li> <li>2307</li> <li>2308</li> <li>2309</li> </ul>	Metabolic determinants of Alzheimer's disease: A focus on thermoregulation. Ageing Research Reviews, 2021, 72, 101462.         Mild Cognitive Impairment or Attention-Deficit/Hyperactivity Disorder in Older Adults? A Cross Sectional Study. Frontiers in Psychiatry, 2021, 12, 737357.         Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 151.         Amyloid-Beta Influences Memory via Functional Connectivity During Memory Retrieval in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 721171.         Predictive Accuracy of Blood-Derived Biomarkers for Amyloid-β Brain Deposition Along with the Alzheimer's Disease Continuum: A Systematic Review. Journal of Alzheimer's Disease, 2021, 84, 1-15.         Investigating Auditory Electrophysiological Measures of Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis of Event-Related Potential Studies. Journal of Alzheimer's Disease. 2021, 84, 419-448.         Development and validation of the dialysis dementia risk score: A retrospective, populationâ€based, nested caseâ€control study. European Journal of Neurology, 2022, 29, 59-68.         Potential Roles of Sestrin2 in Alzheimer's Disease: Antioxidation, Autophagy Promotion, and Beyond. Biomedicines, 2021, 9, 1308.	<ol> <li>10.9</li> <li>2.6</li> <li>6.2</li> <li>3.4</li> <li>2.6</li> <li>2.6</li> <li>3.3</li> <li>3.2</li> </ol>	<ol> <li>18</li> <li>9</li> <li>9</li> <li>4</li> <li>6</li> <li>13</li> <li>3</li> <li>3</li> </ol>

#	Article	IF	CITATIONS
2311	Ultrasensitive capacitance sensor to detect amyloid-beta 1-40 in human serum using supramolecular recognition of β-CD/RGO/ITO micro-disk electrode. Talanta, 2022, 237, 122907.	5.5	16
2312	Case Report: Usefulness of Biomarkers for Alzheimer's Disease in Two Cases With Very-Late-Onset Schizophrenia-Like Psychosis. Frontiers in Psychiatry, 2021, 12, 742659.	2.6	4
2313	Porphyromonas Gingivalis as a Risk Factor to Alzheimer's Disease: A Systematic Review. Journal of Alzheimer's Disease Reports, 2021, 5, 721-732.	2.2	28
2314	The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nature Reviews Neurology, 2021, 17, 703-714.	10.1	65
2315	Oxygen Sensing and Signaling in Alzheimer's Disease: A Breathtaking Story!. Cellular and Molecular Neurobiology, 2022, 42, 3-21.	3.3	6
2316	Using Fractional Anisotropy Imaging to Detect Mild Cognitive Impairment and Alzheimer's Disease among Mexican Americans and Non-Hispanic Whites: A HABLE Study. Dementia and Geriatric Cognitive Disorders, 2021, 50, 266-273.	1.5	7
2317	ls comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease. Alzheimer's Research and Therapy, 2021, 13, 153.	6.2	3
2319	Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1231-1241.	1.9	51
2320	Long-term television viewing patterns and gray matter brain volume in midlife. Brain Imaging and Behavior, 2022, 16, 637-644.	2.1	4
2321	Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study. Translational Psychiatry, 2021, 11, 483.	4.8	23
2322	Involvement of cerebrovascular abnormalities in the pathogenesis and progression of Alzheimer's disease: an adrenergic approach. Aging, 2021, 13, 21791-21806.	3.1	9
2323	Clinical Characteristic in Primary Progressive Aphasia in Relation to Alzheimer's Disease Biomarkers. Journal of Alzheimer's Disease, 2021, 84, 633-645.	2.6	1
2324	A2A Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer's Disease. Cells, 2021, 10, 2344.	4.1	15
2325	In-vitro and in-vivo characterization of CRANAD-2 for multi-spectral optoacoustic tomography and fluorescence imaging of amyloid-beta deposits in Alzheimer mice. Photoacoustics, 2021, 23, 100285.	7.8	32
2326	Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy. Alzheimer's Research and Therapy, 2021, 13, 160.	6.2	5
2327	Mitochondrial links between brain aging and Alzheimer's disease. Translational Neurodegeneration, 2021, 10, 33.	8.0	26
2328	Abnormal tau in amyloid PET negative individuals. Neurobiology of Aging, 2022, 109, 125-134.	3.1	22
2329	Effects of baseline serum uric acid and apolipoprotein E4 on longitudinal cognition and cerebral metabolism. Neurobiology of Aging, 2021, 106, 223-231.	3.1	8

CITATION REPORT ARTICLE IF CITATIONS Diagnostic contribution and therapeutic perspectives of transcranial magnetic stimulation in 1.5 85 dementia. Clinical Neurophysiology, 2021, 132, 2568-2607. Random walks on B distributed resting-state functional connectivity to identify Alzheimer's disease 1.5 and Mild Cognitive Impairment. Clinical Neurophysiology, 2021, 132, 2540-2550. Fully automated chemiluminescence enzyme immunoassays showing high correlation with immunoprecipitation mass spectrometry assays for l2-amyloid (1–40) and (1–42) in plasma samples. 2.1 11 Biochemical and Biophysical Research Communications, 2021, 576, 22-26. Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. 7.9 Molecular Psychiatry, 2021, 26, 5888-5898. Improvement of cognitive performance by a nutraceutical formulation: Underlying mechanisms 2.9 3 revealed by laboratory studies. Free Radical Biology and Medicine, 2021, 174, 281-304. Biomimetic silibinin-loaded macrophage-derived exosomes induce dual inhibition of Al2 aggregation and astrocyte activation to alleviate cognitive impairment in a model of Alzheimer's disease. Materials 7.3 24 Science and Engineering C, 2021, 129, 112365. Regulation of cerebral blood flow in humans: physiology and clinical implications of autoregulation. 28.8 303 Physiological Reviews, 2021, 101, 1487-1559. Intact circadian rhythm despite cortisol hypersecretion in Alzheimer's disease: A meta-analysis. 2.7 10 Psychoneuroendocrinology, 2021, 132, 105367. Evolution of genetic testing supports precision medicine for caring Alzheimer's disease patients. 3.5 5 Current Opinion in Pharmacology, 2021, 60, 275-280. Mini-review: The suspected non-Alzheimer's disease pathophysiology. Neuroscience Letters, 2021, 764, 2.1 136208. Association of plasma Al<sup>2</sup>40/Al<sup>2</sup>42 ratio and brain Al<sup>2</sup> accumulation: testing a whole-brain PLS-VIP approach 3.15 in individuals at risk of Alzheimer's disease. Neurobiology of Aging, 2021, 107, 57-69. CSF neurofilament light may predict progression from amnestic mild cognitive impairment to 3.1 Alzheimer's disease dementia. Neurobiology of Aging, 2021, 107, 78-85 Proteomic correlates of cortical thickness in cognitively normal individuals with normal and 3.1 2 abnormal cerebrospinal fluid beta-amyloid1-42. Neurobiology of Aging, 2021, 107, 42-52. Cerebral blood flow in mild cognitive impairment and Alzheimer's disease: A systematic review and 39 meta-analysis. Ageing Research Reviews, 2021, 71, 101450. Diagnostic accuracy of blood biomarkers for Alzheimer's disease and amnestic mild cognitive 10.9 15 impairment: A meta-analysis. Ageing Research Reviews, 2021, 71, 101446.

2346	Changes in LASSI-L performance over time among older adults with amnestic MCI and amyloid positivity: A preliminary study. Journal of Psychiatric Research, 2021, 143, 98-105.	3.1	5
2347	Female specific risk factors for the development of Alzheimer's disease neuropathology and cognitive impairment: Call for a precision medicine approach. Ageing Research Reviews, 2021, 71, 101459.	10.9	26

4.2

Relationships between Î<sup>2</sup>-amyloid and tau in an elderly population: An accelerated failure time model.

2330

2332

2334

2336

2338

2339

2340

2341

2342

2343

2344

2345

Neurolmage, 2021, 242, 118440.

#	Article	IF	CITATIONS
2348	The role of depression and anxiety in the relationship between poor sleep quality and subjective cognitive decline in Chinese elderly: Exploring parallel, serial, and moderated mediation. Journal of Affective Disorders, 2021, 294, 464-471.	4.1	21
2349	BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCe project. Neurobiology of Aging, 2021, 108, 146-154.	3.1	6
2350	Diagnostic biomarkers in Alzheimer's disease. Biomarkers in Neuropsychiatry, 2021, 5, 100041.	1.0	12
2352	Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia. Neurobiology of Aging, 2021, 108, 99-109.	3.1	13
2353	Advances in electrochemical detection for probing protein aggregation. Current Opinion in Electrochemistry, 2021, 30, 100820.	4.8	8
2354	Higher motor cortical excitability linked to greater cognitive dysfunction in Alzheimer's disease: results from two independent cohorts. Neurobiology of Aging, 2021, 108, 24-33.	3.1	15
2355	Memory Binding. , 2022, , 455-461.		0
2356	Neuroepidemiology. , 2022, , 215-225.		0
2357	Hydrogen-rich water ameliorates neuropathological impairments in a mouse model of Alzheimer's disease through reducing neuroinflammation and modulating intestinal microbiota. Neural Regeneration Research, 2022, 17, 409.	3.0	12
2358	Vascular Dementia and Cognitive Impairment. , 2022, , 221-236.e8.		1
2359	Younger-Onset Dementias: Behavioral Neurology/Brain Diseases/Healthy & Pathological Aging. , 2022, , 88-96.		0
2360	Memory, Executive Function and Social Cognition in Neurological Disorders. , 2022, , 140-147.		0
2361	Multimodal retinal imaging to detect and understand Alzheimer's and Parkinson's disease. Current Opinion in Neurobiology, 2022, 72, 1-7.	4.2	14
2362	PET imaging in Down syndrome and Alzheimer's disease. , 2022, , 173-192.		1
2363	Circulating extracellular vesicles: friends and foes in neurodegeneration. Neural Regeneration Research, 2022, 17, 534.	3.0	20
2364	Neuroepidemiology: New Methods, Results, and Challenges in the Definition of the Early Phases of Alzheimer's Disease: Insights From Subjective Memory Complaints and Subjective Cognitive Decline. , 2022, , 26-42.		0
2365	Cognitive profile of aging and dementia. , 2022, , 289-305.		0
2366	Fluid Biomarkers of Frontotemporal Lobar Degeneration. Advances in Experimental Medicine and Biology, 2021, 1281, 123-139.	1.6	7

#	Article	IF	CITATIONS
2368	Biomarkers of Diseases: Their Role in Emergency Medicine. , 0, , .		0
2369	Identification of Cathepsin D as a Plasma Biomarker for Alzheimer's Disease. Cells, 2021, 10, 138.	4.1	16
2370	Comparing CSF amyloidâ€beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12182.	2.4	26
2371	Preliminary Validation of the Triana Test: A New Story Recall Test Based on Emotional Material. American Journal of Alzheimer's Disease and Other Dementias, 2021, 36, 153331752110259.	1.9	1
2372	Temporal Dynamics of β-Amyloid Accumulation in Aging and Alzheimer Disease. Neurology, 2021, 96, e1347-e1357.	1.1	54
2373	Re-claiming the Power of Definition—The Value of Reflexivity in Research on Mental Health at Risk. , 2021, , 135-165.		2
2374	Sex differences in CSF biomarkers of Alzheimer's disease. , 2021, , 107-123.		0
2375	Evaluation of semi-quantitative measures of 18F-flutemetamol PET for the clinical diagnosis of Alzheimer's disease. Quantitative Imaging in Medicine and Surgery, 2022, 12, 493-509.	2.0	6
2376	Cognitive Reserve, Alzheimer's Neuropathology, and Risk of Dementia: A Systematic Review and Meta-Analysis. Neuropsychology Review, 2021, 31, 233-250.	4.9	77
2377	Naphthalene Monoimide Derivative Ameliorates Amyloid Burden and Cognitive Decline in a Transgenic Mouse Model of Alzheimer's Disease. Advanced Therapeutics, 2021, 4, 2000225.	3.2	18
2378	Topographic patterns of white matter hyperintensities are associated with multimodal neuroimaging biomarkers of Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 29.	6.2	24
2379	Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12031.	2.4	9
2380	Development of a Plasma Biomarker Diagnostic Model Incorporating Ultrasensitive Digital Immunoassay as a Screening Strategy for Alzheimer Disease in a Chinese Population. Clinical Chemistry, 2021, 67, 1628-1639.	3.2	20
2381	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1145-1156.	0.8	174
2383	Blood biomarkers for dementia in Hispanic and nonâ€Hispanic White adults. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12164.	3.7	14
2384	PET Chemistry: Radiopharmaceuticals. , 2021, , 177-199.		0
2386	Neural correlates of daily function: A pilot study of the white matter retrogenesis hypothesis and three separate performance-based functional assessments Neuropsychology, 2021, 35, 103-110.	1.3	4
2387	Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia. Journal of Personalized Medicine, 2021, 11, 47.	2.5	9

~			-		
CIT	ΓΑΤΙ	ON	- K F	FPO	RT

#	Article	IF	CITATIONS
2389	Alzheimer's disease: neuropathology, neuropsychological differential diagnosis, and treatment. , 2021, , 57-128.		0
2390	Diagnosis of Alzheimer's Disease in Developed and Developing Countries: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy. Journal of Alzheimer's Disease Reports, 2021, 5, 15-30.	2.2	16
2391	Building clinically relevant outcomes across the Alzheimer's disease spectrum. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12181.	3.7	16
2393	Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12198.	2.4	4
2394	Transfer learningâ€ŧrained convolutional neural networks identify novel MRI biomarkers of Alzheimer's disease progression. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12140.	2.4	17
2395	Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management. Frontiers in Neurology, 2020, 11, 592302.	2.4	23
2396	Early-Onset Alzheimer's Disease: What Is Missing in Research?. Current Neurology and Neuroscience Reports, 2021, 21, 4.	4.2	88
2397	Quantification of the Trans-Synaptic Partners Neuroligin-Neurexin in CSF of Neurodegenerative Diseases by Parallel Reaction Monitoring Mass Spectrometry. SSRN Electronic Journal, 0, , .	0.4	0
2398	The Health & Aging Brain among Latino Elders (HABLE) study methods and participant characteristics. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12202.	2.4	36
2400	Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimer's disease. NeuroImage: Clinical, 2021, 32, 102804.	2.7	28
2401	The AppNL-G-F mouse retina is a site for preclinical Alzheimer's disease diagnosis and research. Acta Neuropathologica Communications, 2021, 9, 6.	5.2	22
2402	Lower functional hippocampal redundancy in mild cognitive impairment. Translational Psychiatry, 2021, 11, 61.	4.8	17
2403	Changes in the use of psychotropic drugs during the course of Alzheimer's disease: A largeâ€scale longitudinal study of French medical records. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12210.	3.7	0
2404	The association of circulating amylin with βâ€amyloid in familial Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12130.	3.7	21
2405	A Workshop on Cognitive Aging and Impairment in the 9/11-Exposed Population. International Journal of Environmental Research and Public Health, 2021, 18, 681.	2.6	10
2406	Plasma Neurofilament Light Combined with Risk Genes for the Diagnosis of Alzheimer?s Disease. , 0, 83,		1
2407	Identification of plasma proteins relating to brain neurodegeneration and vascular pathology in cognitively normal individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12240.	2.4	4
2408	Association of walking energetics with amyloid beta status: Findings from the Baltimore Longitudinal Study of Aging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12228.	2.4	7

#	Article	IF	CITATIONS
2409	Current advances in digital cognitive assessment for preclinical Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12217.	2.4	63
2410	Assessment of Plasma Amyloid-β <sub>42/40</sub> and Cognitive Decline Among Community-Dwelling Older Adults. JAMA Network Open, 2020, 3, e2028634.	5.9	54
2411	Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment. The Cochrane Library, 2019, 2019, CD011905.	2.8	78
2412	Accelerated longâ€ŧerm forgetting over three months in asymptomatic APOE É›4 carriers. Annals of Clinical and Translational Neurology, 2021, 8, 477-484.	3.7	7
2413	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's diseaseâ€informed machineâ€learning. Alzheimer's and Dementia, 2020, 16, 501-511.	0.8	47
2414	The AT(N) framework for Alzheimer's disease in adults with Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12062.	2.4	12
2415	A quadratic function of activation in individuals at risk of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12139.	2.4	15
2416	Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12114.	3.7	49
2417	Advances in Retinal Imaging: Retinal Amyloid Imaging. , 2020, , 83-122.		3
2420	Die Rolle personalisierter mHealth-Anwendungen zur Risikoreduktion der Alzheimererkrankung. , 2020, , 157-175.		1
2421	Unraveling Alzheimer's Disease Using Drosophila. , 2019, , 251-277.		10
2422	Cerebrospinal Fluid and Plasma Tau as aÂBiomarker for Brain Tauopathy. Advances in Experimental Medicine and Biology, 2019, 1184, 393-405.	1.6	11
2424	Proteomic applications in pathology and laboratory medicine: Present state and future prospects. Clinical Biochemistry, 2020, 82, 12-20.	1.9	5
2425	Gait and balance disturbances are common in young urbanites and associated with cognitive impairment. Air pollution and the historical development of Alzheimer's disease in the young. Environmental Research, 2020, 191, 110087.	7.5	23
2426	The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials. Alzheimer's and Dementia, 2019, 15, 172-178.	0.8	94
2427	Artificial intelligence and neuropsychological measures: The case of Alzheimer's disease. Neuroscience and Biobehavioral Reviews, 2020, 114, 211-228.	6.1	51
2428	Free-water metrics in medial temporal lobe white matter tract projections relate to longitudinal cognitive decline. Neurobiology of Aging, 2020, 94, 15-23.	3.1	23
2429	A probabilistic atlas of locus coeruleus pathways to transentorhinal cortex for connectome imaging in Alzheimer's disease. NeuroImage, 2020, 223, 117301.	4.2	24

#	Article	IF	CITATIONS
2430	Intracranial vascular flow oscillations in Alzheimer's disease from 4D flow MRI. NeuroImage: Clinical, 2020, 28, 102379.	2.7	14
2431	Cholinergic dysfunction, neurodegeneration, and amyloid-beta pathology in neurodegenerative diseases. Psychiatry Research - Neuroimaging, 2020, 302, 111099.	1.8	9
2433	A Perspective on Multi-target Drugs for Alzheimer's Disease. Trends in Pharmacological Sciences, 2020, 41, 434-445.	8.7	148
2434	Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. Lancet Neurology, The, 2020, 19, 699-710.	10.2	96
2437	Brain-behavior relations and effects of aging and common comorbidities in alcohol use disorder: A review Neuropsychology, 2019, 33, 760-780.	1.3	42
2438	Using multivariate base rates of low scores to understand early cognitive declines on the uniform data set 3.0 Neuropsychological Battery Neuropsychology, 2020, 34, 629-640.	1.3	21
2439	Sex-related differences in the relationship between β-amyloid and cognitive trajectories in older adults Neuropsychology, 2020, 34, 835-850.	1.3	9
2440	Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. Nature Communications, 2020, 11, 619.	12.8	67
2441	Language Performance of Individuals at Risk for Mild Cognitive Impairment. Journal of Speech, Language, and Hearing Research, 2019, 62, 706-722.	1.6	30
2442	Syntactic Complexity as a Linguistic Marker to Differentiate Mild Cognitive Impairment From Normal Aging. Journal of Speech, Language, and Hearing Research, 2020, 63, 1416-1429.	1.6	24
2444	Idea selection for propositional language production. Aging, Neuropsychology, and Cognition, 2022, 29, 260-283.	1.3	4
2445	Relationship Between Thyroid Hormone Levels and the Pathology of Alzheimer's Disease in Euthyroid Subjects. Thyroid, 2020, 30, 1547-1555.	4.5	16
2446	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	7.6	89
2447	OUP accepted manuscript. Brain, 2021, 144, 434-449.	7.6	54
2448	Cognitive profiles in persons with depressive disorder and Alzheimer's disease. Brain Communications, 2020, 2, fcaa206.	3.3	8
2449	Mechanical property alterations across the cerebral cortex due to Alzheimer's disease. Brain Communications, 2020, 2, fcz049.	3.3	57
2450	Beyond cardiovascular medicine: potential future uses of icosapent ethyl. European Heart Journal Supplements, 2020, 22, J54-J64.	0.1	9
2451	Value of a Panel of 6 Serum Biomarkers to Differentiate Between Healthy Controls and Mild Cognitive Impairment Due to Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2020, 34, 318-324.	1.3	7

#	Article	IF	CITATIONS
2452	An Initial Empirical Operationalization of the Earliest Stages of the Alzheimer's Continuum. Alzheimer Disease and Associated Disorders, 2021, 35, 62-67.	1.3	8
2453	Biomarker Use for Dementia With Lewy Body Diagnosis. Alzheimer Disease and Associated Disorders, 2021, 35, 55-61.	1.3	8
2454	Retinal Microvascular Alterations as the Biomarkers for Alzheimer Disease: Are We There Yet?. Journal of Neuro-Ophthalmology, 2021, 41, 251-260.	0.8	7
2487	European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment. European Journal of Neurology, 2021, 28, 2147-2155.	3.3	20
2488	Translating genetic risk of Alzheimer's disease into mechanistic insight and drug targets. Science, 2020, 370, 61-66.	12.6	84
2489	Alzheimer's Disease: Many Failed Trials, So Where Do We Go from Here?. Journal of Investigative Medicine, 2020, 68, 1135-1140.	1.6	17
2490	Cognitive and Psychological Impacts of Different Treatment Options for Prostate Cancer: A Critical Analysis. Current Urology, 2020, 14, 169-177.	0.6	7
2491	Bilingualism Delays Expression of Alzheimer's Clinical Syndrome. Dementia and Geriatric Cognitive Disorders, 2019, 48, 281-289.	1.5	10
2492	Pathobiological Subtypes of Alzheimer Disease. Dementia and Geriatric Cognitive Disorders, 2020, 49, 321-333.	1.5	33
2493	Biomarker Testing: Piercing the Fog of Alzheimer's and Related Dementia. Biomedicine Hub, 2020, 5, 1-22.	1.2	7
2494	Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimer's Research and Therapy, 2020, 12, 118.	6.2	129
2495	Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. Alzheimer's Research and Therapy, 2020, 12, 169.	6.2	31
2496	Clinical impact of digital and conventional PET control databases for semi-quantitative analysis of brain 18F-FDG digital PET scans. EJNMMI Research, 2020, 10, 144.	2.5	5
2497	Spill-in counts in the quantification of 18F-florbetapir on $A^{\hat{l}2}$ -negative subjects: the effect of including white matter in the reference region. EJNMMI Physics, 2019, 6, 27.	2.7	9
2498	Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies. British Journal of Psychiatry, 2021, 218, 276-282.	2.8	18
2499	Late-onset Alzheimer Disease. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 14-33.	0.8	70
2500	Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology, 2020, 95, e3026-e3035.	1.1	31
2501	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology, 2021, 96, e671-e683.	1.1	84

#	Article	IF	CITATIONS
2502	Alzheimer Disease Spectrum. Neurology, 2021, 96, 299-300.	1.1	5
2503	Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, <i>APOE</i> ε4, and Cognitive Impairment. Neurology, 2021, 96, e975-e985.	1.1	42
2504	Cognitive Profile and Markers of Alzheimer Disease–Type Pathology in Patients With Lewy Body Dementias. Neurology, 2021, 96, e1855-e1864.	1.1	28
2505	Alzheimer's Disease Diagnosis Using Misfolding Proteins in Blood. Dementia and Neurocognitive Disorders, 2020, 19, 1.	1.4	9
2506	The Prevalence of Rapid Eye Movement Sleep Behavior Disorder in Amyloid Positron Emission Tomography Positive Alzheimer's Disease. Journal of Sleep Medicine, 2019, 16, 102-108.	0.3	1
2507	Olfactory response as a marker for Alzheimer's disease: Evidence from perceptual and frontal lobe oscillation coherence deficit. PLoS ONE, 2020, 15, e0243535.	2.5	13
2508	HEALTH LITERACY IN INDIVIDUALS AT RISK FOR ALZHEIMER'S DEMENTIA: A SYSTEMATIC REVIEW. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-9.	2.7	13
2509	EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN PRIMARY CARE. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-6.	2.7	58
2510	EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN AN AT-HOME SETTING. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-8.	2.7	38
2511	Comparative Analysis of Different Definitions of Amyloid-Î <sup>2</sup> Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-10.	2.7	9
2512	Physical Activity and Alzheimerâ $\in$ Ms Disease: A Narrative Review. , 2019, 10, 1282.		30
2513	miR-22 exerts anti-alzheimic effects via the regulation of apoptosis of hippocampal neurons. Cellular and Molecular Biology, 2019, 64, 84-89.	0.9	11
2514	Biomarkers in Alzheimer's disease. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2021, 2, 27-37.	0.2	13
2515	Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. Molecular Systems Biology, 2020, 16, e9356.	7.2	157
2516	Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges. Revista Brasileira De Psiquiatria, 2020, 42, 431-441.	1.7	42
2517	Behavioral variant of frontotemporal dementia or frontal variant of Alzheimer's disease? A case study. Dementia E Neuropsychologia, 2019, 13, 356-360.	0.8	10
2518	Challenges in the diagnosis of dementia: insights from the United Kingdom-Brazil Dementia Workshop. Dementia E Neuropsychologia, 2020, 14, 201-208.	0.8	12
2519	Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing "where―by "whatâ€â€¦. Dementia E Neuropsychologia, 2020, 14, 237-242.	0.8	13

#	Article	IF	CITATIONS
2521	Aβ Plaques. Free Neuropathology, 2020, 1, .	3.0	21
2522	Risk estimation before progression to mild cognitive impairment and Alzheimer's disease: an AD resemblance atrophy index. Aging, 2019, 11, 6217-6236.	3.1	20
2523	Neurofilament light chain plasma concentration predicts neurodegeneration and clinical progression in nondemented elderly adults. Aging, 2019, 11, 6904-6914.	3.1	34
2524	Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein. Aging, 2020, 12, 1011-1033.	3.1	48
2525	Telomere shortening reflecting physical aging is associated with cognitive decline and dementia conversion in mild cognitive impairment due to Alzheimer's disease. Aging, 2020, 12, 4407-4423.	3.1	30
2526	Prediction of chronological and biological age from laboratory data. Aging, 2020, 12, 7626-7638.	3.1	16
2527	Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer's disease. Aging, 2020, 12, 9365-9379.	3.1	12
2528	High pulse pressure is a risk factor for prodromal Alzheimer's disease: a longitudinal study. Aging, 2020, 12, 18221-18237.	3.1	5
2529	Perceived Impediments to Completed Brain Autopsies Among Diverse Older Adults Who Have Signed a Uniform Anatomical Gift Act for Brain Donation for Clinical Research. Ethnicity and Disease, 2020, 30, 709-718.	2.3	8
2530	The structural MRI markers and cognitive decline in prodromal Alzheimer's disease: a 2-year longitudinal study. Quantitative Imaging in Medicine and Surgery, 2018, 8, 1004-1019.	2.0	25
2531	Lipid Nanoparticles as Carriers for the Treatment of Neurodegeneration Associated with Alzheimer's Disease and Glaucoma: Present and Future Challenges. Current Pharmaceutical Design, 2020, 26, 1235-1250.	1.9	14
2532	The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy "In Vivo―in the Differential Diagnosis of Alzheimer's Dementia. Current Alzheimer Research, 2019, 16, 587-595.	1.4	17
2533	A Conceptual Framework for Research on Cognitive Impairment with no Dementia in Memory Clinic. Current Alzheimer Research, 2020, 17, 517-525.	1.4	10
2534	The Association between Polygenic Hazard and Markers of Alzheimer's Disease Following Stratification for APOE Genotype. Current Alzheimer Research, 2020, 17, 667-679.	1.4	2
2535	The Links between Cardiovascular Diseases and Alzheimer's Disease. Current Neuropharmacology, 2020, 19, 152-169.	2.9	23
2536	Amyloid-Negative Dementia in the Elderly is Associated with High Accumulation of Tau in the Temporal Lobes. Open Biomedical Engineering Journal, 2019, 13, 55-66.	0.5	1
2537	Cognitive-Communicative Predictors of Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. Audiology and Speech Research, 2020, 16, 276-294.	0.3	1
2538	Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease. JMIR Formative Research, 2019, 3, e13417.	1.4	38

$\sim$		<u> </u>	
			ЪΤ
	ITAL	<b>KLPU</b>	IN I

#	Article	IF	CITATIONS
2539	Dietary intake of pantothenic acid is associated with cerebral amyloid burden in patients with cognitive impairment. Food and Nutrition Research, 2018, 62, .	2.6	19
2540	What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. Journal of Nuclear Medicine, 2021, 62, 614-619.	5.0	21
2541	The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. Journal of Nuclear Medicine, 2020, 61, 263S-272S.	5.0	67
2542	Cut-Off Scores of an Olfactory Function Test for Mild Cognitive Impairment and Dementia. Psychiatry Investigation, 2020, 17, 1021-1030.	1.6	8
2543	Antidiabetic therapies and Alzheimer disease. Dialogues in Clinical Neuroscience, 2019, 21, 83-91.	3.7	19
2544	What are we trying to prevent in Alzheimer disease?. Dialogues in Clinical Neuroscience, 2019, 21, 27-34.	3.7	6
2545	Physical activity for cognitive health: what advice can we give to older adults with subjective cognitive decline and mild cognitive impairment?. Dialogues in Clinical Neuroscience, 2019, 21, 61-68.	3.7	44
2546	Ethical issues in early diagnosis and prevention of Alzheimer disease. Dialogues in Clinical Neuroscience, 2019, 21, 101-108.	3.7	20
2547	Dementia prevention and reserve against neurodegenerative disease. Dialogues in Clinical Neuroscience, 2019, 21, 53-60.	3.7	17
2548	Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease. Dialogues in Clinical Neuroscience, 2019, 21, 177-191.	3.7	17
2549	Aberrant Hippocampal Functional Connectivity Is Associated with Fornix White Matter Integrity in Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 75, 1153-1168.	2.6	14
2550	Cognitive Reserve, Brain Reserve, APOE ɛ4, and Cognition in Individuals with Subjective Cognitive Decline in the SILCODE Study. Journal of Alzheimer's Disease, 2020, 76, 249-260.	2.6	9
2551	Quality Reporting of Radiomics Analysis in Mild Cognitive Impairment and Alzheimer's Disease: A Roadmap for Moving Forward. Korean Journal of Radiology, 2020, 21, 1345.	3.4	29
2552	Medical Informatics Platform (MIP): A Pilot Study Across Clinical Italian Cohorts. Frontiers in Neurology, 2020, 11, 1021.	2.4	10
2553	How Your Blood Knows Your Brain Is Sick. Frontiers for Young Minds, 0, 8, .	0.8	2
2554	Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF. Cells, 2021, 10, 38.	4.1	16
2555	Role of Body-Fluid Biomarkers in Alzheimer's Disease Diagnosis. Diagnostics, 2020, 10, 326.	2.6	12
2556	A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages. Journal of Personalized Medicine. 2021. 11. 14.	2.5	19

#	Article	IF	CITATIONS
2557	Elevated plasma levels of exosomal BACE1‑AS combined with the volume and thickness of the right entorhinal cortex may serve as a biomarker for the detection of Alzheimer's disease. Molecular Medicine Reports, 2020, 22, 227-238.	2.4	43
2558	Consequences of redefining Alzheimer's disease in terms of amyloid burden without regard to cognitive decline. Neural Regeneration Research, 2018, 13, 2098.	3.0	1
2559	Glutamate receptor delocalization in postsynaptic membrane and reduced hippocampal synaptic plasticity in the early stage of Alzheimer's disease. Neural Regeneration Research, 2019, 14, 1037.	3.0	17
2560	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. ELife, 2019, 8, .	6.0	57
2561	Hippocampal and cortical mechanisms at retrieval explain variability in episodic remembering in older adults. ELife, 2020, 9, .	6.0	38
2562	Longitudinal stability of medial temporal lobe connectivity is associated with tau-related memory decline. ELife, 2020, 9, .	6.0	3
2563	Cross-Sectional and Longitudinal Comparisons of Biomarkers and Cognition Among Asymptomatic Middle-Aged Individuals with a Parental History of Either Autosomal Dominant or Late Onset Alzheimer Disease. SSRN Electronic Journal, 0, , .	0.4	0
2564	Machine learning of brain structural biomarkers for Alzheimer's disease (AD) diagnosis, prediction of disease progression, and amyloid beta deposition in the Japanese population. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12246.	2.4	4
2565	Hippocampus- and thalamus-related fiber-specific white matter reductions in mild cognitive impairment. Cerebral Cortex, 2022, 32, 3159-3174.	2.9	9
2566	Amyloid pathology but not <i>APOE</i> ε4 status is permissive for tau-related hippocampal dysfunction. Brain, 2022, 145, 1473-1485.	7.6	17
2568	The persistent impact of adolescent binge alcohol on adult brain structural, cellular, and behavioral pathology: A role for the neuroimmune system and epigenetics. International Review of Neurobiology, 2021, 160, 1-44.	2.0	11
2569	Demencia prevenció: A korai diagnózistól a személyre szabott intervencióig. Scientia Et Securitas, 2021, 2, 207-219.	0.2	0
2570	Increased plasma brain-derived neurotrophic factor (BDNF) as a potential biomarker for and compensatory mechanism in mild cognitive impairment: a case-control study. Aging, 2021, 13, 22666-22689.	3.1	11
2571	Association of Amyotrophic Lateral Sclerosis and Alzheimer's Disease: New Entity or Coincidence? A Case Series. Journal of Alzheimer's Disease, 2021, 84, 1439-1446.	2.6	2
2572	Tauâ€Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. Annals of Neurology, 2021, 90, 751-762.	5.3	19
2574	DCTclock: Clinically-Interpretable and Automated Artificial Intelligence Analysis of Drawing Behavior for Capturing Cognition. Frontiers in Digital Health, 2021, 3, 750661.	2.8	19
2575	Reducing Your Risk of Alzheimer's Dementia: Building a Better Brain as We Age. Archives of Clinical Neuropsychology, 2021, 36, 1257-1265.	0.5	2
2576	Performance of Plasma Amyloid β, Total Tau, and Neurofilament Light Chain in the Identification of Probable Alzheimer's Disease in South China. Frontiers in Aging Neuroscience, 2021, 13, 749649.	3.4	9

#	Article	IF	CITATIONS
2577	Baseline MRI atrophy predicts 2-year cognitive outcomes in early-onset Alzheimer's disease. Journal of Neurology, 2022, 269, 2573-2583.	3.6	6
2578	Decreased Global EEG Synchronization in Amyloid Positive Mild Cognitive Impairment and Alzheimer's Disease Patients—Relationship to APOE ε4. Brain Sciences, 2021, 11, 1359.	2.3	8
2579	Association Between Plasma Amyloid-β and Neuropsychological Performance in Patients With Cognitive Decline. Frontiers in Aging Neuroscience, 2021, 13, 736937.	3.4	10
2580	Changes in retinal multilayer thickness and vascular network of patients with Alzheimer's disease. BioMedical Engineering OnLine, 2021, 20, 97.	2.7	9
2581	Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers. Frontiers in Neurology, 2021, 12, 619388.	2.4	1
2582	Serum Adiponectin in Alzheimer's Disease (AD): Association with AD Biomarkers and Cognitive Outcome. Journal of Alzheimer's Disease, 2021, 84, 1163-1172.	2.6	5
2583	Age, vascular disease, and Alzheimer's disease pathologies in amyloid negative elderly adults. Alzheimer's Research and Therapy, 2021, 13, 174.	6.2	15
2584	Sequential pathway inference for multimodal neuroimaging analysis. Stat, 2022, 11, e433.	0.4	1
2585	Medial Temporal Lobe Subregional Atrophy in Aging and Alzheimer's Disease: A Longitudinal Study. Frontiers in Aging Neuroscience, 2021, 13, 750154.	3.4	19
2586	Ex vivo MRI atlas of the human medial temporal lobe: characterizing neurodegeneration due to tau pathology. Acta Neuropathologica Communications, 2021, 9, 173.	5.2	14
2587	Dementia risk communication. A user manual for Brain Health Services—part 3 of 6. Alzheimer's Research and Therapy, 2021, 13, 170.	6.2	21
2588	Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside. Journal of Clinical Investigation, 2021, 131, .	8.2	21
2589	The Diagnostic Value of a Short Memory Test: The TNI-93. Journal of Alzheimer's Disease, 2021, , 1-11.	2.6	1
2590	The prognostic utility of CSF neurogranin in predicting future cognitive decline in the Alzheimer's disease continuum: A systematic review and meta-analysis with narrative synthesis. Ageing Research Reviews, 2021, 72, 101491.	10.9	11
2591	Iron Responsive Element-Mediated Responses to Iron Dyshomeostasis in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 84, 1597-1630.	2.6	18
2592	A Review of miRNAs as Biomarkers and Effect of Dietary Modulation in Obesity Associated Cognitive Decline and Neurodegenerative Disorders. Frontiers in Molecular Neuroscience, 2021, 14, 756499.	2.9	11
2593	Alzheimer's disease clinical trial update 2019–2021. Journal of Neurology, 2022, 269, 1038-1051.	3.6	39
2594	The MTA score—simple and reliable, the best for now?. European Radiology, 2021, 31, 9057-9059	4.5	4

#	Article	IF	CITATIONS
2595	Altered Volume and Structural Connectivity of the Hippocampus in Alzheimer's Disease and Amnestic Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2021, 13, 705030.	3.4	9
2596	Education, APOE ε4, and Cognition in Individuals with Subjective Cognitive Decline with Worry in the SILCODE Study. Current Alzheimer Research, 2021, 18, 492-498.	1.4	1
2597	AuNPs- Aβ-Ni-HRP sandwich assay: A new sensitive colorimetric method for the detection of Aβ 1-40. Talanta, 2022, 237, 122946.	5.5	9
2599	Microglial activation states drive glucose uptake and FDC-PET alterations in neurodegenerative diseases. Science Translational Medicine, 2021, 13, eabe5640.	12.4	108
2600	Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain, 2022, 145, 27-44.	7.6	38
2601	Metabolic Syndrome and Cognitive Function. Current Cardiology Reports, 2021, 23, 180.	2.9	22
2602	Current research status of blood biomarkers in Alzheimer's disease: Diagnosis and prognosis. Ageing Research Reviews, 2021, 72, 101492.	10.9	16
2603	An Optimized Decision Tree with Genetic Algorithm Rule-Based Approach to Reveal the Brain's Changes During Alzheimer's Disease Dementia. Journal of Alzheimer's Disease, 2021, 84, 1577-1584.	2.6	2
2604	Dementia subtype prediction models constructed by penalized regression methods for multiclass classification using serum microRNA expression data. Scientific Reports, 2021, 11, 20947.	3.3	5
2605	Proposed diagnostic criteria for mild cognitive impairment in Down syndrome population. Journal of Applied Research in Intellectual Disabilities, 2022, 35, 495-505.	2.0	5
2606	Age-Related Cognitive Decline and Prevalence of Mild Cognitive Impairment in the Iwaki Health Promotion Project. Journal of Alzheimer's Disease, 2021, 84, 1233-1245.	2.6	7
2607	Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer's Disease and Amnestic Mild Cognitive Impairment. Current Alzheimer Research, 2021, 18, 523-532.	1.4	6
2608	Functional Abnormality Associated With Tau Deposition in Alzheimer's Disease – A Hybrid Positron Emission Tomography/MRI Study. Frontiers in Aging Neuroscience, 2021, 13, 758053.	3.4	4
2609	Multiomics Profiling of Alzheimer's Disease Serum for the Identification of Autoantibody Biomarkers. Journal of Proteome Research, 2021, 20, 5115-5130.	3.7	15
2610	The potential antiâ€ <b>a</b> myloidogenic candidate, SPA1413, for Alzheimer's disease. British Journal of Pharmacology, 2021, , .	5.4	4
2612	From Cerebrospinal Fluid Neurochemistry to Clinical Diagnosis of Alzheimer's Disease in the Era of Anti-Amyloid Treatments. Report of Four Patients. Biomedicines, 2021, 9, 1376.	3.2	3
2613	Influence of PICALM and CLU risk variants on beta EEG activity in Alzheimer's disease patients. Scientific Reports, 2021, 11, 20465.	3.3	4
2614	Aplysia Neurons as a Model of Alzheimer's Disease: Shared Genes and Differential Expression. Journal of Molecular Neuroscience, 2022, 72, 287-302.	2.3	3

#	Article	IF	CITATIONS
2615	proNGF Measurement in Cerebrospinal Fluid Samples of a Large Cohort of Living Patients With Alzheimer's Disease by a New Automated Immunoassay. Frontiers in Aging Neuroscience, 2021, 13, 741414.	3.4	2
2616	Comorbidity Trajectories Associated With Alzheimer's Disease: A Matched Case-Control Study in a United States Claims Database. Frontiers in Neuroscience, 2021, 15, 749305.	2.8	10
2617	A microRNA signature that correlates with cognition and is a target against cognitive decline. EMBO Molecular Medicine, 2021, 13, e13659.	6.9	29
2618	Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression. Scientific Reports, 2021, 11, 20375.	3.3	9
2619	Immunomodulation induced by central nervous systemâ€related peptides as a therapeutic strategy for neurodegenerative disorders. Pharmacology Research and Perspectives, 2021, 9, e00795.	2.4	6
2620	Inhibition of Rho Kinase by Fasudil Ameliorates Cognition Impairment in APP/PS1 Transgenic Mice via Modulation of Gut Microbiota and Metabolites. Frontiers in Aging Neuroscience, 2021, 13, 755164.	3.4	19
2621	Automatic Prediction of Cognitive and Functional Decline Can Significantly Decrease the Number of Subjects Required for Clinical Trials in Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 84, 1-8.	2.6	2
2622	Cerebrospinal Fluid Biomarker Levels as Markers for Nursing Home Placement and Survival Time in Alzheimer's Disease. Current Alzheimer Research, 2021, 18, 573-584.	1.4	3
2623	Development of the First WHO Guidelines for Risk Reduction of Cognitive Decline and Dementia: Lessons Learned and Future Directions. Frontiers in Neurology, 2021, 12, 763573.	2.4	19
2624	PET Imaging of Tau Pathology and Amyloid-β, and MRI for Alzheimer's Disease Feature Fusion and Multimodal Classification. Journal of Alzheimer's Disease, 2021, 84, 1497-1514.	2.6	5
2625	Presumed small vessel disease, imaging and cognition markers in the Alzheimer's Disease Neuroimaging Initiative. Brain Communications, 2021, 3, fcab226.	3.3	2
2626	Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials. Frontiers in Neurology, 2021, 12, 712565.	2.4	5
2627	Characterizing the Resilience Effect of Neurodegeneration for the Mechanistic Pathway of Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 84, 1351-1362.	2.6	1
2628	Association Between Polygenic Risk Score and the Progression from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 84, 1323-1335.	2.6	7
2629	Cognitive reserve proxies, Alzheimer pathologies, and cognition. Neurobiology of Aging, 2022, 110, 88-95.	3.1	10
2630	Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer's disease. Scientific Reports, 2021, 11, 19853.	3.3	6
2631	Complex Profiles of Cerebrovascular Disease Pathologies in the Aging Brain and Their Relationship With Cognitive Decline. Stroke, 2022, 53, 218-227.	2.0	14
2632	Association of cerebral small vessel disease burden with brain structure and cognitive and vascular risk trajectories in mid-to-late life. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 600-612.	4.3	9

#	Article	IF	CITATIONS
2633	Amyloid-Î <sup>2</sup> PET Classification on Cognitive Aging Stages Using the Centiloid Scale. Molecular Imaging and Biology, 2022, 24, 394-403.	2.6	8
2634	Resting-state functional reorganisation in Alzheimer's disease and amnestic mild cognitive impairment: protocol for a systematic review and meta-analysis. BMJ Open, 2021, 11, e049798.	1.9	4
2635	Visuospatial memory impairment as a potential neurocognitive marker to predict tau pathology in Alzheimer's continuum. Alzheimer's Research and Therapy, 2021, 13, 167.	6.2	8
2636	A conceptual model for achieving well-being in adults with mild cognitive impairment. Geriatric Nursing, 2021, 42, 1467-1473.	1.9	1
2637	Task switching reveals abnormal brain-heart electrophysiological signatures in cognitively healthy individuals with abnormal CSF amyloid/tau, a pilot study. International Journal of Psychophysiology, 2021, 170, 102-111.	1.0	6
2638	A geroscience motivated approach to treat Alzheimer's disease: Senolytics move to clinical trials. Mechanisms of Ageing and Development, 2021, 200, 111589.	4.6	15
2642	Imagerie moléculaire de demain : quels biomarqueurs et pour quelle maladie ?. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 1523-1527.	0.0	0
2646	Memory disorders and neuropsychological memory tests in clinical practice. Neurologie Pro Praxi, 2018, 19, 405-410.	0.1	1
2647	Suizid und Demenz. , 2019, , 225-237.		0
2650	A TURNING POINT IN ALZHEIMER'S RESEARCH: HARMONIZED RESEARCH STRATEGIES AND NOVEL INVESTMENTS IN PUBLIC HEALTH INFRASTRUCTURE ARE REENERGIZING THE FIELD, AND REKINDLING HOPE FOR THOSE AFFECTED BY ALZHEIMER'S AND RELATED DEMENTIAS. journal of prevention of Alzheimer's disease. The. 2019. 6, 1-3.	2.7	1
2652	Research Ethics in Geriatric Psychiatry. , 2019, , 109-119.		0
2653	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. , 2019, , 1-119.		0
2654	The Whole Picture: From Isolated to Global MRI Measures of Neurovascular and Neurodegenerative Disease. Advances in Experimental Medicine and Biology, 2019, 1205, 25-53.	1.6	1
2655	A New Biological Definition of Alzheimer's Disease: Introduction of 2018 National Institute on Aging-Alzheimer's Association Research Framework. Journal of the Korean Neurological Association, 2019, 37, 1-7.	0.1	2
2660	Neurocognitive Disorders. , 2019, , .		0
2662	Neurocognitive Disorders. , 2019, , .		0
2671	Neuroimaging techniques for diagnosing Alzheimer's disease and cerebrovascular diseases with cognitive impairment. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2019, 11, 18-25.	1.2	7
2675	Genome-wide association study identifies <i>CBFA2T3</i> affecting the rate of CSF AÎ <sup>2</sup> 42 decline in non-demented elders. Aging, 2019, 11, 5433-5444.	3.1	5

#	Article	IF	CITATIONS
2676	The Diagnostic Value Of Mattis Dementia Rating Scale- Initiation Perseveration Subscale In Vascular Cognitive Disorders. Neuro Research, 2019, 1, .	1.8	1
2679	Ruolo dei biomarcatori nella diagnostica liquorale della malattia di Alzheimer. Rivista Italiana Della Medicina Di Laboratorio, 2019, 15, .	0.4	0
2681	Common Proteomic and Genomic Contribution to Ischemic Brain Damage and Alzheimer's Disease. , 0, , 53-68.		0
2688	The Positivity Effect in Memory in Older Adults with Subjective Cognitive Decline: A Comparison with Normal Elderly and Patients with Mild Cognitive Impairment. The Korean Journal of Developmental Psychology, 2019, 32, 21-42.	0.2	2
2689	Multiple aetiologies of the progressive dysexecutive syndrome and the importance of biomarkers. Brain Communications, 2020, 2, fcaa127.	3.3	3
2690	EFFECTIVENESS OF THE OPEN SCREENING PROGRAMS IN RECRUITING SUBJECTS TO PRODROMAL AND MILD ALZHEIMER'S DISEASE CLINICAL TRIALS. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-5.	2.7	2
2691	Mild Cognitive Impairment and Early Dementia. , 2020, , 215-236.		0
2692	A Comprehensive Visual Rating Scale for Predicting Progression from Mild Cognitive Impairment to Dementia in Patients with Alzheimer's Pathology or Suspected Non-Alzheimer's Pathology. Dementia and Neurocognitive Disorders, 2020, 19, 129.	1.4	2
2696	On the misalignment between research and clinical practice in psychology: An example from the Alzheimer's and dementia field Canadian Psychology, 2020, 61, 127-139.	2.1	0
2702	Biomarcadores en la demencia tipo alzheimer: sistema sanitario y edadismo. International Journal of Developmental and Educational Psychology Revista INFAD De PsicologÃa, 2020, 1, 247-254.	0.1	0
2708	Psychopathology of Dementia: Psychology's Pivotal Role. European Journal of Medical and Health Sciences, 2021, 3, 61-69.	0.2	0
2709	Blood Pressure and T-Tau in Spinal Fluid Are Associated With Delayed Recall in Participants With Memory Complaints and Dementia of the Alzheimer's Type. Frontiers in Aging Neuroscience, 2021, 13, 652510.	3.4	2
2710	Retinal Venular Tortuosity Jointly with Retinal Amyloid Burden Correlates with Verbal Memory Loss: A Pilot Study. Cells, 2021, 10, 2926.	4.1	14
2711	Relationships between social withdrawal and facial emotion recognition in neuropsychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 113, 110463.	4.8	10
2712	Evaluation of N, O-Benzamide difluoroboron derivatives as near-infrared fluorescent probes to detect β-amyloid and tau tangles. European Journal of Medicinal Chemistry, 2022, 227, 113968.	5.5	15
2714	Alzheimer's disease related biomarkers in bipolar disorder – A longitudinal one-year case-control study. Journal of Affective Disorders, 2022, 297, 623-633.	4.1	13
2715	Personal Utility and Early Intervention in Alzheimer's Disease. AJOB Neuroscience, 2021, 12, 226-228.	1.1	0
2716	Cerebrospinal Fluid Dynamics and Discordant Amyloid Biomarkers. Neurobiology of Aging, 2021, 110, 27-36.	3.1	7

# 2717	ARTICLE Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment. Metabolic Brain Disease, 2022, 37, 67-104.	IF 2.9	CITATIONS
2718	Diffusion MRI: Applications in the Brain. Advances in Magnetic Resonance Technology and Applications, 2020, 1, 605-636.	0.1	0
2719	Psychopharmacologic treatment. , 2020, , 315-399.		1
2720	Alzheimer's disease and Down syndrome. , 2020, , 283-297.		0
2723	Diagnostic précoce et biomarqueurs biologiques de la maladie d'Alzheimer. NPG Neurologie - Psychiatrie - Geriatrie, 2020, 20, 120S7-120S10.	0.2	0
2724	PET-Amyloid After Inconclusive Cerebrospinal Fluid Biomarkers in Clinical Practice. Is it Necessary to Duplicate Procedures?. Current Alzheimer Research, 2020, 17, 698-708.	1.4	1
2725	The ethics of innovation for Alzheimer's disease: the risk of overstating evidence for metabolic enhancement protocols. Theoretical Medicine and Bioethics, 2020, 41, 223-237.	0.8	15
2726	Psychiatric Disorders in Dementia. , 2021, , 317-385.		0
2727	Reader Response: Simple MRI Score Aids Prediction of Dementia in Cerebral Small Vessel Disease. Neurology, 2021, 96, 39.2-40.	1.1	0
2728	Hypertriglyceridemia and Alzheimer Disease: Opening the Mind to New Therapeutic Opportunities. Clinical Chemistry, 2021, 67, 6-8.	3.2	0
2729	APOE Genotypes and Brain Imaging Classes in Normal Cognition, Mild Cognitive Impairment, and Alzheimer's Disease: A Longitudinal Study. Current Alzheimer Research, 2020, 17, 766-780.	1.4	3
2730	¿Quo vadis Alois?. Medicina ClÃnica, 2020, 155, 491-493.	0.6	0
2732	APOE Variants in an Iberian Alzheimer Cohort Detected through an Optimized Sanger Sequencing Protocol. Genes, 2021, 12, 4.	2.4	4
2733	Neuronal Loss of NCLX-Dependent Mitochondrial Calcium Efflux Contributes to Age-Associated Cognitive Decline. SSRN Electronic Journal, 0, , .	0.4	0
2734	PM2.5 exposure in association with AD-related neuropathology and cognitive outcomes. Environmental Pollution, 2022, 292, 118320.	7.5	52
2735	Sex-specificities in anxiety and depressive symptoms across the lifespan and their links with multimodal neuroimaging. Journal of Affective Disorders, 2022, 296, 593-602.	4.1	5
2736	Non-transcription analysis of connected speech in mild cognitive impairment using an information unit scoring system. Journal of Neurolinguistics, 2022, 61, 101035.	1.1	2
2737	Vibrio harveyi infections induce production of proinflammatory cytokines in murine peritoneal macrophages via activation of p38 MAPK and NF-κB pathways, but reversed by PI3K/AKT pathways. Developmental and Comparative Immunology, 2022, 127, 104292.	2.3	13

#	Article	IF	CITATIONS
2738	SEARCHING FOR THE HOLY GRAIL WILL NEED BIOMARKERS. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-3.	2.7	3
2739	Multiplex connectome changes across the alzheimer's disease spectrum using gray matter and amyloid data. Cerebral Cortex, 2022, 32, 3501-3515.	2.9	10
2740	LncRNA BDNF-AS as ceRNA Regulates the miR-9-5p/BACE1 Pathway Affecting Neurotoxicity in Alzheimer's disease. SSRN Electronic Journal, 0, , .	0.4	0
2742	Centenarians as Models of Resistance and Resilience to Alzheimer's Disease and Related Dementias. Advances in Geriatric Medicine and Research, 2020, 2, .	0.6	8
2743	Butyrylcholinesterase as a biomarker in Alzheimer's disease. , 2020, , 263-280.		1
2744	THE ROLE OF CLINICAL TRIALS IN PRECLINICAL ALZHEIMER'S DISEASE DRUG DEVELOPMENT PROGRAMS. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-3.	2.7	1
2745	Linking gradient echo plural contrast imaging metrics of tissue microstructure with Alzheimer disease. , 2020, , 507-519.		0
2746	https://link.springer.com/article/10.14283/jfa.2020.9. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-2.	2.7	0
2747	Pathophysiology of Vascular Cognitive Impairment (II): Amyloid Contribution in Vascular Cognitive Impairment. Stroke Revisited, 2020, , 87-97.	0.2	1
2748	Executive Summary of the 2019 International Conference of Korean Dementia Association: Exploring the Novel Concept of Alzheimer's Disease and Other Dementia: a Report from the Academic Committee of the Korean Dementia Association. Dementia and Neurocognitive Disorders, 2020, 19, 39.	1.4	1
2749	Commentary: Viewing Alzheimer's disease from an ophthalmologist's eyes. Indian Journal of Ophthalmology, 2020, 68, 562.	1.1	0
2750	Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum. Journal of Korean Medical Science, 2020, 35, e361.	2.5	13
2751	CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12098.	3.7	5
2752	Ethics of Informed Consent, Coercive and Preventive Medication. , 2020, , 1-16.		0
2753	Applying the Alzheimer Disease ATN Diagnostic Framework in Atypical Dementia. Alzheimer Disease and Associated Disorders, 2020, 34, 357-359.	1.3	3
2754	The Limbic System. , 2020, , 745-830.		3
2755	Salivary Biomarkers and Neurodegenerative Conditions. , 2020, , 263-286.		2
2756	Implication of microRNAs in Alzheimer's disease pathogenesis. , 2020, , 131-145.		3
#	Article	IF	CITATIONS
------	---	------	-----------
2757	Use of cerebrospinal fluid in diagnosis of dementia. , 2020, , 225-237.		0
2762	Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid-β Positron Emission Tomography. Journal of Alzheimer's Disease, 2020, 74, 101-112.	2.6	2
2763	Differential Deficits of Nouns and Verbs in a Generative Naming Task for Individuals with Mild Cognitive Impairment. Communication Sciences and Disorders, 2020, 25, 50-62.	0.4	3
2765	A Meta-Analysis Study on Alzheimer's Disease. Journal of Bioscience & Biomedical Engineering, 0, , .	0.0	0
2766	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. JAMA Neurology, 2021, 78, 1471.	9.0	204
2767	Plasma Total Tau and Neurobehavioral Symptoms of Cognitive Decline in Cognitively Normal Older Adults. Frontiers in Psychology, 2021, 12, 774049.	2.1	4
2768	First Immunoassay for Measuring Isoaspartate in Human Serum Albumin. Molecules, 2021, 26, 6709.	3.8	9
2769	Locus Coeruleus magnetic resonance imaging in cognitively intact elderly subjects. Brain Imaging and Behavior, 2021, , 1.	2.1	8
2770	Subjective Cognitive Decline: Level of Risk for Future Dementia and Mild Cognitive Impairment, a Meta-Analysis of Longitudinal Studies. Neuropsychology Review, 2022, 32, 703-735.	4.9	54
2771	Alzheimer's disease associated with Down syndrome: a genetic form of dementia. Lancet Neurology, The, 2021, 20, 930-942.	10.2	93
2772	Subjective cognitive decline in idiopathic Parkinson´s disease: A systematic review. Ageing Research Reviews, 2022, 74, 101508.	10.9	8
2773	Neuropathology of Alzheimer's Disease. Neurotherapeutics, 2022, 19, 173-185.	4.4	83
2774	Brain Function and Falls. , 2021, , 130-143.		0
2775	Cerebral amyloid load determination in a clinical setting: interpretation of amyloid biomarker discordances aided by tau and neurodegeneration measurements. Neurological Sciences, 2021, , 1.	1.9	0
2776	MEG activity of the dorsolateral prefrontal cortex during optic flow stimulations detects mild cognitive impairment due to Alzheimer's disease. PLoS ONE, 2021, 16, e0259677.	2.5	3
2777	Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA. Molecular Neurodegeneration, 2021, 16, 74.	10.8	10
2778	Association between Sleep, Alzheimer's, and Parkinson's Disease. Biology, 2021, 10, 1127.	2.8	13
2779	Lipids as Early and Minimally Invasive Biomarkers for Alzheimer's Disease. Current Neuropharmacology, 2022, 20, 1613-1631.	2.9	4

#	Article	IF	CITATIONS
2780	Subjective cognitive decline-related worries modulate the relationship between global amyloid load and gray matter volume in preclinical Alzheimer's disease. Brain Imaging and Behavior, 2021, , 1.	2.1	2
2781	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	3.2	7
2783	Peptoid Nanosheet-Based Sensing System for the Diagnosis and Surveillance of Amnestic Mild Cognitive Impairment and Alzheimer's Disease. ACS Chemical Neuroscience, 2021, 12, 4257-4264.	3.5	5
2784	Cognitive Impairment in Old Age. European Psychologist, 2020, 25, 174-185.	3.1	3
2787	Old Age Dementia: Clinical Patterns of Progression. Part 1. Psychiatry, 2020, 18, 108-120.	0.7	1
2790	Chinese patients with Lewy body dementia had shorter survival and developed complications earlier than those with Alzheimer's disease. Singapore Medical Journal, 2020, 61, 551-558.	0.6	2
2793	Small Vessel Disease and Associations with Cerebrospinal Fluid Amyloid, Tau, and Neurodegeneration (ATN) Biomarkers and Cognition in Young Onset Dementia. Journal of Alzheimer's Disease, 2020, 77, 1305-1314.	2.6	9
2794	Factors Associated with Lumbar Puncture Participation in Alzheimer's Disease Research. Journal of Alzheimer's Disease, 2020, 77, 1559-1567.	2.6	19
2795	Aβ Imaging in Aging, Alzheimer's Disease, and Other Neurodegenerative Conditions. , 2021, , 283-343.		0
2796	Neuroimaging Findings in Mild Cognitive Impairment. , 2021, , 367-425.		1
2797	Impact of the New Conceptual Framework of Alzheimer's Disease in Imaging Studies. , 2021, , 427-451.		0
2803	Alzheimer disease biomarker profiles in dementia with Lewy bodies. Neurology, 2020, 95, 1076-1077.	1.1	0
2804	Antidementiva. , 2021, , 581-626.		1
2808	Association between Matrix Metalloproteinases, Their Tissue Inhibitor and White Matter Lesions in Mild Cognitive Impairment. Current Alzheimer Research, 2020, 17, 547-555.	1.4	6
2809	Hypoxic Preconditioning Ameliorates Amyloid-β Pathology and Longterm Cognitive Decline in AβPP/PS1 Transgenic Mice. Current Alzheimer Research, 2020, 17, 626-634.	1.4	4
2810	F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 268-281.	1.0	19
2811	Detection of Alzheimer's Disease. Yale Journal of Biology and Medicine, 2018, 91, 291-300.	0.2	21
2812	Reframing Alzheimer's Disease: Guided by a New Research Framework, the Field is Poised For Greater Precision and Promising Horizons. P and T, 2019, 44, 282-289.	0.9	0

#	Article	IF	CITATIONS
2813	Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting. Innovations in Clinical Neuroscience, 2020, 17, 14-19.	0.1	0
2814	Up-regulation of miR-137 can inhibit PTN in target manner to regulate PTN/PTPRZ pathway to prevent cognitive dysfunction caused by propofol. American Journal of Translational Research (discontinued), 2020, 12, 7490-7500.	0.0	1
2815	Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein. Medical Science Monitor, 2021, 27, e934077.	1.1	1
2816	Studying Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis with 7-T magnetic resonance. European Radiology Experimental, 2021, 5, 36.	3.4	2
2817	Molecular Imaging Biomarkers in Dementia: Amyloid and tau PET imaging aids evaluation of patients suspected of having Alzheimer disease or other dementias. Practical Neurology, 2020, 19, 34-45.	0.5	0
2818	Acrolein, an endogenous aldehyde induces Alzheimer's disease-like pathologies in mice: A new sporadic AD animal model. Pharmacological Research, 2022, 175, 106003.	7.1	14
2819	Exploring brain glucose metabolic patterns in cognitively normal adults at risk of Alzheimer's disease: A cross-validation study with Chinese and ADNI cohorts. NeuroImage: Clinical, 2022, 33, 102900.	2.7	8
2820	Generating diagnostic profiles of cognitive decline and dementia using magnetoencephalography. Neurobiology of Aging, 2022, 111, 82-94.	3.1	5
2821	Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration. Scientific Reports, 2021, 11, 22675.	3.3	27
2822	Selective Impairment of Long-Range Default Mode Network Functional Connectivity as a Biomarker for Preclinical Alzheimer's Disease in People with Down Syndrome. Journal of Alzheimer's Disease, 2022, 85, 153-165.	2.6	3
2823	Effects of Meditation on Structural Changes of the Brain in Patients With Mild Cognitive Impairment or Alzheimer's Disease Dementia. Frontiers in Human Neuroscience, 2021, 15, 728993.	2.0	6
2824	Biomarkers of Cerebral Glucose Metabolism and Neurodegeneration in Parkinson's Disease: A Cerebrospinal Fluid-Based Study. Journal of Parkinson's Disease, 2022, 12, 537-544.	2.8	3
2825	Association of a Total Cholesterol Polygenic Score with Cholesterol Levels and Pathological Biomarkers across the Alzheimer's Disease Spectrum. Genes, 2021, 12, 1805.	2.4	3
2826	Subjective memory concerns, poor vascular health, and male sex predict exacerbated memory decline trajectories: An integrative data-driven class and prediction analysis Neuropsychology, 2022, 36, 128-139.	1.3	6
2827	The molecular mechanisms of signal pathway activating effect of E2F-1/NF-κB/GSK-3β on cognitive dysfunction of Alzheimer rats. Bioengineered, 2021, 12, 10000-10008.	3.2	6
2828	Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer's disease dementia. Alzheimer's and Dementia, 2021, 17, 1855-1867.	0.8	11
2829	A metabolite panel that differentiates Alzheimer's disease from other dementia types. Alzheimer's and Dementia, 2022, 18, 1345-1356.	0.8	20
2830	Amyloid Imaging in Dementia and Neurodegenerative Disease. , 2022, , 99-110.		1

#	Article	IF	Citations
2831	Characteristics of Bipolar Patients with Cognitive Impairment of Suspected Neurodegenerative Origin: A Multicenter Cohort. Journal of Personalized Medicine, 2021, 11, 1183.	2.5	5
2832	Anaemia and cerebrospinal fluid biomarkers of Alzheimer's pathology in cognitively normal elders: the CABLE study. BMC Neurology, 2021, 21, 454.	1.8	2
2833	Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer's disease. BMC Medicine, 2021, 19, 264.	5.5	12
2834	Neuroimaging Biomarkers Predicting the Efficacy of Multimodal Rehabilitative Intervention in the Alzheimer's Dementia Continuum Pathology. Frontiers in Aging Neuroscience, 2021, 13, 735508.	3.4	2
2835	The Use of Dual Modality PET/MRI in Population Studies: Considerations on Exposures, Economics, Strengths, and Limitations. , 2022, , 35-44.		0
2836	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	10.8	9
2837	Comparison of Serum Triiodothyronine with Biomarkers for Alzheimer's Disease Continuum in Euthyroid Subjects. Journal of Alzheimer's Disease, 2021, , 1-10.	2.6	0
2838	Positron Emission Tomography in Animal Models of Alzheimer's Disease Amyloidosis: Translational Implications. Pharmaceuticals, 2021, 14, 1179.	3.8	13
2839	Boosting the diagnostic power of amyloid-β PET using a data-driven spatially informed classifier for decision support. Alzheimer's Research and Therapy, 2021, 13, 185.	6.2	1
2840	Case 1: Mild Cognitive Impairment (MCI)—[18F]FDG and Amyloid PET. , 2022, , 3-7.		0
2841	Ultrasensitive Detection of Alzheimer's Amyloids on a Plasmonic-Gold Platform. ACS Applied Materials & Interfaces, 2021, 13, 57036-57042.	8.0	7
2842	Spatial Pattern Separation Testing Differentiates Alzheimer's Disease Biomarker-Positive and Biomarker-Negative Older Adults With Amnestic Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2021, 13, 774600.	3.4	5
2844	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. JAMA Neurology, 2022, 79, 32.	9.0	38
2845	Proteoforms and their expanding role in laboratory medicine. Practical Laboratory Medicine, 2022, 28, e00260.	1.3	15
2846	D-Amino Acids and D-Amino Acid-Containing Peptides: Potential Disease Biomarkers and Therapeutic Targets?. Biomolecules, 2021, 11, 1716.	4.0	37
2847	It Is Time to Study Overlapping Molecular and Circuit Pathophysiologies in Alzheimer's and Lewy Body Disease Spectra. Frontiers in Systems Neuroscience, 2021, 15, 777706.	2.5	8
2848	Common pathways in dementia and diabetic retinopathy: understanding the mechanisms of diabetes-related cognitive decline. Trends in Endocrinology and Metabolism, 2022, 33, 50-71.	7.1	34
2849	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurology, The, 2022, 21, 66-77.	10.2	360

#	Article	IF	CITATIONS
2850	Association of Superficial White Matter Alterations with Cerebrospinal Fluid Biomarkers and Cognitive Decline in Neurodegenerative Dementia. Journal of Alzheimer's Disease, 2022, 85, 431-442.	2.6	2
2851	Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer's Disease?. Journal of Alzheimer's Disease, 2021, , 1-9.	2.6	2
2852	Magnetic Resonance Imaging in Animal Models of Alzheimer's Disease Amyloidosis. International Journal of Molecular Sciences, 2021, 22, 12768.	4.1	18
2853	Secondary Prevention of Dementia: Combining Risk Factors and Scalable Screening Technology. Frontiers in Neurology, 2021, 12, 772836.	2.4	9
2857	Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer's amyloid, tau and FDG PET status. Translational Psychiatry, 2021, 11, 585.	4.8	31
2858	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nature Reviews Neuroscience, 2022, 23, 53-66.	10.2	203
2859	Mitochondrial Membrane Potential Influences Amyloid-β Protein Precursor Localization and Amyloid-β Secretion. Journal of Alzheimer's Disease, 2022, 85, 381-394.	2.6	16
2860	Disrupted White Matter Integrity and Cognitive Functions in Amyloid-β Positive Alzheimer's Disease with Concomitant Lobar Cerebral Microbleeds. Journal of Alzheimer's Disease, 2021, , 1-12.	2.6	3
2861	Cognitive impairment and World Trade Centre-related exposures. Nature Reviews Neurology, 2022, 18, 103-116.	10.1	18
2862	Teaching an old dog new tricks: serum troponin T as a biomarker in amyotrophic lateral sclerosis. Brain Communications, 2021, 3, fcab274.	3.3	10
2863	Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 85, 457-472.	2.6	6
2864	Characterization of preâ€analytical sample handling effects on a panel of Alzheimer's disease–related bloodâ€based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. Alzheimer's and Dementia, 2022, 18, 1484-1497.	0.8	84
2865	Plasma amyloid beta, neurofilament light chain, and total tau in the Systolic Blood Pressure Intervention Trial (SPRINT). Alzheimer's and Dementia, 2022, 18, 1472-1483.	0.8	8
2867	A Revisit to Etiopathogenesis and Therapeutic Strategies in Alzheimer's Disease. Current Drug Targets, 2022, 23, 486-512.	2.1	6
2868	Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer's Disease Continuum. Journal of Alzheimer's Disease, 2022, 85, 223-234.	2.6	4
2869	In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer's disease phases. Alzheimer's Research and Therapy, 2021, 13, 187.	6.2	29
2870	Anatomically Standardized Detection of MRI Atrophy Patterns in Early-Stage Alzheimer's Disease. Brain Sciences, 2021, 11, 1491.	2.3	5
2871	Digging Deeper: Advancements in Visualization of Inhibitory Synapses in Neurodegenerative Disorders. International Journal of Molecular Sciences, 2021, 22, 12470.	4.1	1

#	Article	IF	CITATIONS
2872	Large-Scale Functional Networks, Cognition and Brain Structures Supporting Social Cognition and Theory of Mind Performance in Prodromal to Mild Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 766703.	3.4	7
2873	Brain transcriptomes of zebrafish and mouse Alzheimer's disease knock-in models imply early disrupted energy metabolism. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	8
2874	Microglia-Based Sex-Biased Neuropathology in Early-Stage Alzheimer's Disease Model Mice and the Potential Pharmacologic Efficacy of Dioscin. Cells, 2021, 10, 3261.	4.1	5
2875	Modified Low-Temperature Extraction Method for Isolation of Bletilla striata Polysaccharide as Antioxidant for the Prevention of Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 12760.	4.1	11
2876	Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective. International Journal of Molecular Sciences, 2021, 22, 13002.	4.1	14
2877	Qu'apporte l'imagerie hybride TEP-IRM dans l'étude des pathologies neuro-dégénératives�. L'Academie Nationale De Medecine, 2021, 206, 28-28.	Bulletin D 0.0	0e <sub>0</sub>
2878	CSF-Derived CD4+ T-Cell Diversity Is Reduced in Patients With Alzheimer Clinical Syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, e1106.	6.0	11
2879	Evidence against altered excitatory/inhibitory balance in the posteromedial cortex of young adult APOE E4 carriers: A resting state 1H-MRS study. NeuroImage Reports, 2021, 1, 100059.	1.0	0
2880	Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 196.	6.2	13
2881	MicroRNA-Target Interaction Regulatory Network in Alzheimer's Disease. Journal of Personalized Medicine, 2021, 11, 1275.	2.5	11
2882	What can 7T sodium MRI tell us about cellular energy depletion and neurotransmission in Alzheimer's disease?. Alzheimer's and Dementia, 2021, 17, 1843-1854.	0.8	6
2883	Determining Appropriate Screening Tools and Cutoffs for Cognitive Impairment in the Chinese Elderly. Frontiers in Psychiatry, 2021, 12, 773281.	2.6	16
2884	Neurofilament Levels Are Reflecting the Loss of Presynaptic Dopamine Receptors in Movement Disorders. Frontiers in Neuroscience, 2021, 15, 690013.	2.8	8
2885	Resting-state functional MRI signal fluctuation amplitudes are correlated with brain amyloid- <b>β</b> deposition in patients with mild cognitive impairment. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 876-890.	4.3	3
2886	The relative contributions of biomarkers, disease modifying treatment, and dementia severity to Alzheimer's stigma: A vignette-based experiment. Social Science and Medicine, 2022, 292, 114620.	3.8	13
2887	Plasma pâ€ŧau <sub>181</sub> shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau. Alzheimer's and Dementia, 2022, 18, 1523-1536.	0.8	18
2888	Spatial variation of perfusion MRI reflects cognitive decline in mild cognitive impairment and early dementia. Scientific Reports, 2021, 11, 23325.	3.3	10
2889	A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure. Nature Communications, 2021, 12, 7065.	12.8	38

#	Article	IF	CITATIONS
2891	Variability in Cognitive Performance on Mobile Devices Is Sensitive to Mild Cognitive Impairment: Results From the Einstein Aging Study. Frontiers in Digital Health, 2021, 3, 758031.	2.8	25
2892	Cognitive screening with functional assessment improves diagnostic accuracy and attenuates bias. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12250.	2.4	6
2893	Neuroimaging correlates of Stages of Objective Memory Impairment (SOMI) system. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12224.	2.4	5
2894	Investigating cognition in midlife. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12234.	3.7	0
2896	Cerebrovascular stiffness and flow dynamics in the presence of amyloid and tau biomarkers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12253.	2.4	4
2897	Quantitative MRI Differences Between Early versus Late Onset Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2021, 36, 153331752110553.	1.9	3
2898	The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNIâ€3 updates and global perspectives. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12226.	3.7	23
2899	Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention. journal of prevention of Alzheimer's disease, The, 2022, 9, 1-10.	2.7	9
2900	Prediction and Modeling of Neuropsychological Scores in Alzheimer's Disease Using Multimodal Neuroimaging Data and Artificial Neural Networks. Frontiers in Computational Neuroscience, 2021, 15, 769982.	2.1	9
2901	A review of dementia, focusing on the distinct roles of viral protein corona and MMP9 in dementia: Potential pharmacotherapeutic priorities. Ageing Research Reviews, 2022, 75, 101560.	10.9	13
2902	Cerebrospinal fluid neurofilament light predicts the rate of executive function decline in younger-onset dementia. Journal of the Neurological Sciences, 2022, 432, 120088.	0.6	1
2903	Speech pause distribution as an early marker for Alzheimer's disease. Speech Communication, 2022, 136, 107-117.	2.8	16
2904	Serum neurofilament light chain level as a predictor of cognitive stage transition. Alzheimer's Research and Therapy, 2022, 14, 6.	6.2	19
2905	Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry. EBioMedicine, 2022, 75, 103793.	6.1	4
2907	S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5. Neurobiology of Disease, 2022, 163, 105603.	4.4	4
2908	Biomarkers used in Alzheimer's disease diagnosis, treatment, and prevention. Ageing Research Reviews, 2022, 74, 101544.	10.9	60
2909	LncRNA BDNF-AS as ceRNA regulates the miR-9-5p/BACE1 pathway affecting neurotoxicity in Alzheimer's disease. Archives of Gerontology and Geriatrics, 2022, 99, 104614.	3.0	27
2910	A review of the application of deep learning in the detection of Alzheimer's disease. International Journal of Cognitive Computing in Engineering, 2022, 3, 1-8.	8.2	26

ARTICLE IF CITATIONS Research on Malicious TLS Traffic Identification Based on Hybrid Neural Network., 2020,,. 0 2911 A Network-Guided Reaction-Diffusion Model of AT[N] Biomarkers in Alzheimer's Disease. , 2020, , . 2912 Novel Methodology for Alzheimer's Disease Biomarker Identification in Plasma using Hyperspectral 2913 2 Microscopy., 2020, , . A Preliminary Study of Robotic Media Effects on Older Adults with Mild Cognitive Impairment in 2914 Solitude. Lecture Notes in Computer Science, 2021, , 453-463. N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. Brain, 2022, 145, 2915 7.6 20 2834-2848. El Sistema de Salud Colombiano y el reconocimiento de la enfermedad de Alzheimer. Revista De Salud 0.1 Publica, 2021, 23, 1-9. Connectivity and Patterns of Regional Cerebral Blood Flow, Cerebral Glucose Uptake, and AÎ<sup>2</sup>-Amyloid 2917 Deposition in Alzheimer's Disease (Early and Late-Onset) Compared to Normal Ageing. Current 1.4 5 Alzheimer Research, 2021, 18, 646-655. Studying Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis with 7-T magnetic 2918 3.4 10 resonance. European Radiology Experimental, 2021, 5, 36. The Relationship Between Funcation Connectivity and Amyloid Accumulation in AD Continuum., 2021, 2919 0 An overview of Alzheimer's disease and its diagnosis using conventional and novel methods., 2021, , . Advances in Genetics and Epigenetic Alterations in Alzheimer's Disease: A Notion for Therapeutic 2921 2.4 9 Treatment. Genes, 2021, 12, 1959. The Assessment of Visuospatial Skills and Verbal Fluency in the Diagnosis of Alzheimer's Disease. 3.4 Frontiers in Aging Neuroscience, 2021, 13, 737104. The Impact of Uremic Toxins on Alzheimer's Disease. Current Alzheimer Research, 2022, 19, 104-118. 2923 1.4 0 Heterogeneity in Alzheimer's Disease Diagnosis and Progression Rates: Implications for Therapeutic 2924 4.4 Trials. Neurotherapeutics, 2022, 19, 8-25 Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive 2925 3.3 22 impairment and Alzheimer's disease: a randomized trial. Scientific Reports, 2022, 12, 1346. Neuronal-Derived EV Biomarkers Track Cognitive Decline in Alzheimer's Disease. Cells, 2022, 11, 436. 2926 4.1 Postoperative delirium and its relationship with biomarkers for dementia: a meta-analysis. 2927 1.0 9 International Psychogeriatrics, 2022, 34, 377-390. Clinical usefulness of the CSF β-amyloid Al̂21-42/Al̂21-40 ratio for Alzheimer's disease diagnosis: a 2928 1.1 retrospective study in a Belgian academic hospital. Acta Neurologica Belgica, 2022, 122, 245-247.

#	Article	IF	CITATIONS
2930	Synaptic dysfunction in early phases of Alzheimer's Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, 184, 417-438.	1.8	27
2931	Multivariate Assessment of Lipoxidative Metabolites, Trace Biometals, and Antioxidant and Detoxifying Activities in the Cerebrospinal Fluid Define a Fingerprint of Preclinical Stages of Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 86, 387-402.	2.6	3
2933	Plasma Phosphorylated Tau181 is a Biomarker of Alzheimer's Disease Pathology and Associated with Cognitive and Functional Decline. SSRN Electronic Journal, 0, , .	0.4	6
2934	Memory Binding Test and Its Associations With Hippocampal Volume Across the Cognitive Continuum Preceding Dementia. Assessment, 2023, 30, 856-872.	3.1	4
2935	Model-based stratification of progression along the Alzheimer disease continuum highlights the centrality of biomarker synergies. Alzheimer's Research and Therapy, 2022, 14, 16.	6.2	5
2936	What Matters to Patients with Alzheimer's Disease and Their Care Partners? Implications for Understanding the Value of Future Interventions. journal of prevention of Alzheimer's disease, The, 0, , 1.	2.7	5
2937	Deep Sea Water Alleviates Tau Phosphorylation and Cognitive Impairment via PI3K/Akt/GSK-3β Pathway. Marine Biotechnology, 2022, 24, 68-81.	2.4	2
2938	Getting Fit to Counteract Cognitive Aging: Evidence and Future Directions. Physiology, 2022, 37, 197-206.	3.1	4
2939	2-(4-Hydroxyphenyl)benzothiazole dicarboxylate ester TACN chelators for <sup>64</sup> Cu PET imaging in Alzheimer's disease. Dalton Transactions, 2022, 51, 1216-1224.	3.3	8
2941	Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1951-1963.	6.4	8
2942	An Argument for Simple Tests of Treatment of Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, , 1-4.	2.6	9
2943	Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers. Brain, 2022, 145, 4056-4064.	7.6	19
2944	Associations of risk genes with onset age and plasma biomarkers of Alzheimer's disease: a large case–control study in mainland China. Neuropsychopharmacology, 2022, 47, 1121-1127.	5.4	5
2945	The impact of physical activity on blood inflammatory cytokines and neuroprotective factors in individuals with mild cognitive impairment: a systematic review and meta-analysis of randomized-controlled trials. Aging Clinical and Experimental Research, 2022, 34, 1471-1484.	2.9	10
2946	Serum progranulin is not associated with rs5848 polymorphism in Korean patients with neurodegenerative diseases. PLoS ONE, 2022, 17, e0261007.	2.5	0
2947	Patterns of Symptom Tracking by Caregivers and Patients With Dementia and Mild Cognitive Impairment: Cross-sectional Study. Journal of Medical Internet Research, 2022, 24, e29219.	4.3	2
2948	Research Criteria for the Behavioral Variant of Alzheimer Disease. JAMA Neurology, 2022, 79, 48.	9.0	44
2949	The Outcome of Patients with Amyloid-Negative Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2022, 86, 629-640.	2.6	2

<u> </u>		<u> </u>	
( 15	ГАТІ	NEDC	DT
	IAL	NLPC	ואר

#	Article	IF	CITATIONS
2950	Specificity of Adaptive Immune Responses in Central Nervous System Health, Aging and Diseases. Frontiers in Neuroscience, 2021, 15, 806260.	2.8	11
2951	Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise. FEBS Journal, 2023, 290, 1420-1453.	4.7	61
2952	Total and Phosphorylated Cerebrospinal Fluid Tau in the Differential Diagnosis of Sporadic Creutzfeldt-Jakob Disease and Rapidly Progressive Alzheimer's Disease. Viruses, 2022, 14, 276.	3.3	10
2953	International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 895-904.	6.4	23
2954	Psychotherapeutic interventions in individuals at risk for Alzheimer's dementia: a systematic review. Alzheimer's Research and Therapy, 2022, 14, 18.	6.2	6
2955	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
2956	Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies. Neurology, 2022, 98, .	1.1	10
2957	Imaging Clinical Subtypes and Associated Brain Networks in Alzheimer's Disease. Brain Sciences, 2022, 12, 146.	2.3	4
2958	Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer's disease. Journal of Neurochemistry, 2023, 164, 309-324.	3.9	43
2959	Prediction of Cognitive Progression in Individuals with Mild Cognitive Impairment Using Radiomics as an Improvement of the ATN System: A Five-Year Follow-Up Study. Korean Journal of Radiology, 2022, 23, 89.	3.4	3
2960	Human microRNA (miR-20b-5p) modulates Alzheimer's disease pathways and neuronal function, and a specific polymorphism close to the MIR20B gene influences Alzheimer's biomarkers. Molecular Psychiatry, 2022, 27, 1256-1273.	7.9	26
2961	Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy. journal of prevention of Alzheimer's disease, The, 2022, 9, 211-220.	2.7	25
2962	Kynurenine Pathway Metabolites as Biomarkers in Alzheimer's Disease. Disease Markers, 2022, 2022, 1-15.	1.3	21
2963	2021 marks a new era for Alzheimer's therapeutics. Lancet Neurology, The, 2022, 21, 3-4.	10.2	10
2964	News about Therapies of Alzheimer's Disease: Extracellular Vesicles from Stem Cells Exhibit Advantages Compared to Other Treatments. Biomedicines, 2022, 10, 105.	3.2	9
2965	N6-methyladenine-modified DNA was decreased in Alzheimer's disease patients. World Journal of Clinical Cases, 2022, 10, 448-457.	0.8	3
2966	Correlation between Phase-Difference-Enhanced MR Imaging and Amyloid Positron Emission Tomography: A Study on Alzheimer's Disease Patients and Normal Controls. Magnetic Resonance in Medical Sciences, 2022, , .	2.0	0
2967	Diagnosing vascular cognitive impairment: Current challenges and future perspectives. International Journal of Stroke, 2023, 18, 36-43.	5.9	12

#	Article	IF	CITATIONS
2968	Co-expression network analysis of frontal cortex during the progression of Alzheimer's disease. Cerebral Cortex, 2022, 32, 5108-5120.	2.9	4
2969	Corticobasal Syndrome as Alzheimer's Disease Subtype: A Case Report. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2023, 29, 220-223.	0.3	0
2970	Regional brain atrophy and cognitive decline depend on definition of subjective cognitive decline. NeuroImage: Clinical, 2022, 33, 102923.	2.7	16
2971	Episodic Memory Impairment Mediates the Loss of Awareness in Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2021, 13, 802501.	3.4	7
2976	Suppression of Fli-1 protects against pericyte loss and cognitive deficits in Alzheimer's disease. Molecular Therapy, 2022, 30, 1451-1464.	8.2	14
2977	Evidence-Based Tools for Dietary Assessments in Nutrition Epidemiology Studies for Dementia Prevention. journal of prevention of Alzheimer's disease, The, 2022, 9, 1-5.	2.7	4
2978	The Beneficial Effects of Combining Anti-Aβ Antibody NP106 and Curcumin Analog TML-6 on the Treatment of Alzheimer's Disease in APP/PS1 Mice. International Journal of Molecular Sciences, 2022, 23, 556.	4.1	4
2979	Random Forest Model in the Diagnosis of Dementia Patients with Normal Mini-Mental State Examination Scores. Journal of Personalized Medicine, 2022, 12, 37.	2.5	9
2980	Regional uptakes from early-frame amyloid PET and 18F-FDG PET scans are comparable independent of disease state. European Journal of Hybrid Imaging, 2022, 6, 2.	1.5	8
2981	Dynamic changes of CSF sPDGFRÎ <sup>2</sup> during ageing and AD progression and associations with CSF ATN biomarkers. Molecular Neurodegeneration, 2022, 17, 9.	10.8	24
2982	Using radiomics-based modelling to predict individual progression from mild cognitive impairment to Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2163-2173.	6.4	20
2983	The Road to Personalized Medicine in Alzheimer's Disease: The Use of Artificial Intelligence. Biomedicines, 2022, 10, 315.	3.2	15
2984	An unbiased algorithm for objective separation of Alzheimer's, Alzheimer's mixed with cerebrovascular symptomology, and healthy controls from one another using electrovestibulography (EVestG). Medical and Biological Engineering and Computing, 2022, 60, 797-810.	2.8	3
2985	Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases. Frontiers in Neurology, 2021, 12, 792227.	2.4	17
2986	Plasma Lipocalin 2 in Alzheimer's disease: potential utility in the differential diagnosis and relationship with other biomarkers. Alzheimer's Research and Therapy, 2022, 14, 9.	6.2	2
2987	Mitochondrial complex I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer's disease. European Journal of Neurology, 2022, 29, 1324-1334.	3.3	8
2988	Human neural cell typeâ€specificÂextracellular vesicle proteome defines diseaseâ€related molecules associated with activated astrocytes in Alzheimer's disease brain. Journal of Extracellular Vesicles, 2022, 11, e12183.	12.2	54
2989	Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil. Journal of Psychiatric Research, 2022, 148, 159-164.	3.1	5

#	Article	IF	CITATIONS
2990	Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type. Brain, 2022, 145, 2507-2517.	7.6	16
2991	Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition. Neurology, 2022, 98, .	1.1	22
2992	Neurogenetic disorders across the lifespan: from aberrant development to degeneration. Nature Reviews Neurology, 2022, 18, 117-124.	10.1	19
2993	Dietâ€induced Alzheimer'sâ€like syndrome in the rabbit. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12241.	3.7	4
2994	A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer's Disease: Towards a More Continuous Approach. Journal of Alzheimer's Disease, 2022, 86, 511-524.	2.6	5
2996	Cognitive practice effects delay diagnosis of MCI: Implications for clinical trials. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12228.	3.7	7
2997	Exosomal MicroRNA-Based Predictive Model for Preclinical Alzheimer's Disease: A Multicenter Study. Biological Psychiatry, 2022, 92, 44-53.	1.3	11
2998	Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia. Frontiers in Aging Neuroscience, 2021, 13, 751897.	3.4	12
2999	Prescription Medications and Co-Morbidities in Late Middle-Age are Associated with Greater Cognitive Declines: Results from WRAP. Frontiers in Aging, 2022, 2, .	2.6	4
3000	Optimal transport- and kernel-based early detection of mild cognitive impairment patients based on magnetic resonance and positron emission tomography images. Alzheimer's Research and Therapy, 2022, 14, 4.	6.2	1
3001	Simple Quantification of Surface Uptake in F-18 Florapronol PET/CT Imaging for the Validation of Alzheimer's Disease. Diagnostics, 2022, 12, 132.	2.6	2
3002	Associations between Cortical Thickness and Metamemory in Alzheimer's Disease. Brain Imaging and Behavior, 2022, , 1.	2.1	2
3003	Blood-based biomarkers of agitation in Alzheimer's disease: Advances and future prospects. Neurochemistry International, 2022, 152, 105250.	3.8	8
3004	Multimodal Preventive Trial for Alzheimer's Disease: MIND-ADmini Pilot Trial Study Design and Progress. journal of prevention of Alzheimer's disease, The, 2022, 9, 1-10.	2.7	5
3005	Brave New World: Harnessing the promise of biomarkers to help solve the epigenetic puzzle. Schizophrenia Research, 2022, 242, 35-41.	2.0	9
3006	Neuroimaging of Mouse Models of Alzheimer's Disease. Biomedicines, 2022, 10, 305.	3.2	13
3007	White matter microstructure associations to amyloid burden in adults with Down syndrome. NeuroImage: Clinical, 2022, 33, 102908.	2.7	1
3008	Longitudinal amyloid cognitive composite in preclinical Alzheimer's disease. European Journal of Neurology, 2022, 29, 980-989.	3.3	2

#	Article	IF	CITATIONS
3009	Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data. Alzheimer's Research and Therapy, 2022, 14, 14.	6.2	10
3010	Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer's Disease Pathology and Cognitive Decline. Biological Psychiatry, 2022, 92, 34-43.	1.3	21
3011	Lessons from Detecting Cognitive Impairment Including Dementia (DetectCID) in Primary Care. Journal of Alzheimer's Disease, 2022, 86, 655-665.	2.6	5
3012	Predicted Cognitive Conversion in Guiding Early Decision-Tailoring on Patients With Cognitive Impairment. Frontiers in Aging Neuroscience, 2021, 13, 813923.	3.4	1
3013	Unravelling the Association Between Amyloid-PET and Cerebrospinal Fluid Biomarkers in the Alzheimer's Disease Spectrum: Who Really Deserves an A+?. Journal of Alzheimer's Disease, 2022, 85, 1009-1020.	2.6	5
3014	BPGAN: Brain PET synthesis from MRI using generative adversarial network for multi-modal Alzheimer's disease diagnosis. Computer Methods and Programs in Biomedicine, 2022, 217, 106676.	4.7	32
3015	Alzheimer's disease susceptibility locus in CD2AP is associated with increased cerebrospinal fluid tau levels in mild cognitive impairment. Neuroscience Letters, 2022, 771, 136419.	2.1	3
3016	Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study. Journal of Alzheimer's Disease, 2022, 85, 1143-1151.	2.6	7
3017	The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone. Alzheimer's Research and Therapy, 2022, 14, 20.	6.2	18
3018	Mild behavioral impairment is associated with progression to Alzheimer's disease: A clinicopathological study. Alzheimer's and Dementia, 2022, 18, 2199-2208.	0.8	28
3019	Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurology, The, 2022, 21, 140-152.	10.2	34
3020	Forecasting the prevalence of dementia. Lancet Public Health, The, 2022, 7, e94-e95.	10.0	19
3021	Studying APOE É>4 Allele Dose Effects withÂa Univariate Morphometry Biomarker. Journal of Alzheimer's Disease, 2022, 85, 1233-1250.	2.6	1
3022	Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. Neurology, 2022, 98, .	1.1	41
3023	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. Alzheimer's and Dementia, 2022, 18, 2218-2233.	0.8	24
3024	Challenges and hopes for Alzheimer's disease. Drug Discovery Today, 2022, 27, 1027-1043.	6.4	87
3025	New therapeutic opportunities for Alzheimer disease. , 2022, 1, 15-21.		0
3026	Systematic Review of the Psychometric Properties of the Saint Louis University Mental Status (SLUMS) Examination. Clinical Gerontologist, 2022, , 1-13.	2.2	7

#	Article	IF	CITATIONS
3027	Components of gait in people with and without mild cognitive impairment. Gait and Posture, 2022, 93, 83-89.	1.4	7
3028	miR-129 Regulates Cell Viability in Alzheimer's Disease Through Targeting Amyloid Precursor Protein (APP). Journal of Biomaterials and Tissue Engineering, 2022, 12, 867-872.	0.1	0
3029	Alpha desynchronization during Stroop test unmasks cognitively healthy individuals with abnormal CSF Amyloid/Tau. Neurobiology of Aging, 2022, 112, 87-101.	3.1	8
3030	Soluble TREM2: Innocent bystander or active player in neurological diseases?. Neurobiology of Disease, 2022, 165, 105630.	4.4	41
3031	Cognitive impairment networks in Alzheimer's disease: Analysis of three double-blind randomized, placebo-controlled, clinical trials of donepezil. European Neuropsychopharmacology, 2022, 57, 50-58.	0.7	2
3032	Subtle postoperative cognitive disorder in preclinical Alzheimer's disease. Experimental Gerontology, 2022, 161, 111715.	2.8	0
3033	Identification of subjective cognitive decline due to Alzheimer's disease using multimodal MRI combining with machine learning. Cerebral Cortex, 2023, 33, 557-566.	2.9	11
3034	Impact of sex and <i>APOE</i> ε4 on the association of cognition and hippocampal volume in clinically normal, amyloid positive adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12271.	2.4	4
3035	Neurodegeneration from the AT(N) framework is different among Mexican Americans compared to nonâ€Hispanic Whites: A Health & Aging Brain among Latino Elders (HABLE) Study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12267.	2.4	18
3036	Neuropathological substrates of cognition in Parkinson's disease. Progress in Brain Research, 2022, 269, 177-193.	1.4	4
3037	Alzheimer's Disease: From Pathogenesis to Mesenchymal Stem Cell Therapy – Bridging the Missing Link. Frontiers in Cellular Neuroscience, 2021, 15, 811852.	3.7	11
3038	Altered central and blood glutathione in Alzheimer's disease and mild cognitive impairment: a meta-analysis. Alzheimer's Research and Therapy, 2022, 14, 23.	6.2	22
3039	Deep residual inception encoderâ€decoder network for amyloid PET harmonization. Alzheimer's and Dementia, 2022, 18, 2448-2457.	0.8	10
3040	Distinctive Temporal Trajectories of Alzheimer's Disease Biomarkers According to Sex and APOE Genotype: Importance of Striatal Amyloid. Frontiers in Aging Neuroscience, 2022, 14, 829202.	3.4	9
3041	Des traitements symptomatiques qui ne sont plus remboursés mais qui sont toujours utilisés dans la maladie d'Alzheimer: Pourquoi?. La Presse Médicale Formation, 2022, , .	0.1	0
3042	Markers of Cerebrovascular Injury, Inflammation, and Plasma Lipids Are Associated with Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Cognitively Normal Persons. Journal of Alzheimer's Disease, 2022, 86, 813-826.	2.6	5
3043	Effects of Cognitive Reserve in Alzheimer's Disease and Cognitively Unimpaired Individuals. Frontiers in Aging Neuroscience, 2021, 13, 784054.	3.4	13
3044	Effects of transcranial magnetic stimulation on neurobiological changes in Alzheimer's disease (Review). Molecular Medicine Reports, 2022, 25, .	2.4	8

#	Article	IF	CITATIONS
3045	Barriers to Effective Memory Assessments for Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 90, 981-988.	2.6	4
3046	Biomarqueurs de la maladie d'Alzheimer: des avancées très rapides. La Presse Médicale Formation, 2022, , .	0.1	0
3047	Large-scale deep multi-layer analysis of Alzheimer's disease brain reveals strong proteomic disease-related changes not observed at the RNA level. Nature Neuroscience, 2022, 25, 213-225.	14.8	202
3048	Reduced Peripheral Nerve Conduction Velocity is Associated with Alzheimer's Disease: A Cross-Sectional Study from China. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 231-242.	2.2	3
3050	Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review. Alzheimer's Research and Therapy, 2022, 14, 31.	6.2	25
3051	18F-APN-1607 Tau Positron Emission Tomography Imaging for Evaluating Disease Progression in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 789054.	3.4	7
3052	Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline. Brain Communications, 2022, 4, fcac026.	3.3	4
3053	The reduction of hippocampal volume in Parkinson's disease. Journal of Neural Transmission, 2022, , 1.	2.8	1
3054	Blood–brain barrier link to human cognitive impairment and Alzheimer's disease. , 2022, 1, 108-115.		45
3055	CRIDECO Anticholinergic Load Scale: An Updated Anticholinergic Burden Scale. Comparison with the ACB Scale in Spanish Individuals with Subjective Memory Complaints. Journal of Personalized Medicine, 2022, 12, 207.	2.5	11
3056	ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease – Study Protocol and Baseline Characteristics. Frontiers in Neurology, 2022, 13, 826423.	2.4	7
3057	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. EBioMedicine, 2022, 76, 103836.	6.1	65
3058	Correlation Between Urine Formaldehyde and Cognitive Abilities in the Clinical Spectrum of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2022, 14, 820385.	3.4	8
3059	Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention. Journal of Nuclear Medicine, 2022, 63, 981-985.	5.0	9
3060	The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimer's Research and Therapy, 2022, 14, 26.	6.2	49
3061	Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers. Movement Disorders, 2022, 37, 669-683.	3.9	30
3062	Impact of Current Alcohol Consumption on Cognitive Function in Patients with Self-Perceived Memory Decline: A Comparative Study of Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer-Type Dementia Groups. Journal of the Korean Neurological Association, 2022, 40, 29-38.	0.1	0
3063	A systematic review and meta-analysis of studies on screening for mild cognitive impairment in primary healthcare. BMC Psychiatry, 2022, 22, 97.	2.6	9

#	Article	IF	CITATIONS
3064	Phosphorylated neurofilament heavy chain: a potential diagnostic biomarker in amyotrophic lateral sclerosis. Journal of Neurophysiology, 2022, 127, 737-745.	1.8	5
3065	Isolated Amyloid-β Pathology Is Associated with Preserved Cortical Plasticity in APOE4 Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2022, 86, 773-778.	2.6	2
3066	Exploring dynamic functional connectivity alterations in the preclinical stage of Alzheimer's disease: an exploratory study from SILCODE. Journal of Neural Engineering, 2022, , .	3.5	2
3067	Machine learning prediction and tau-based screening identifies potential Alzheimer's disease genes relevant to immunity. Communications Biology, 2022, 5, 125.	4.4	18
3068	Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. EBioMedicine, 2022, 76, 103837.	6.1	34
3069	Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis. Frontiers in Aging Neuroscience, 2021, 13, 748198.	3.4	3
3070	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurology, 2022, 79, 149.	9.0	66
3071	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.8	24
3072	Recent update on the heterogeneity of the Alzheimer's disease spectrum. Journal of Neural Transmission, 2022, 129, 1-24.	2.8	37
3073	Subtyping of mild cognitive impairment using a deep learning model based on brain atrophy patterns. Cell Reports Medicine, 2021, 2, 100467.	6.5	15
3074	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. Alzheimer's Research and Therapy, 2021, 13, 198.	6.2	87
3075	Impaired SorLA maturation and trafficking as a new mechanism for SORL1 missense variants in Alzheimer disease. Acta Neuropathologica Communications, 2021, 9, 196.	5.2	17
3076	Lifestyle Variables Such as Daily Internet Use, as Promising Protective Factors against Cognitive Impairment in Patients with Subjective Memory Complaints. Preliminary Results. Journal of Personalized Medicine, 2021, 11, 1366.	2.5	4
3077	Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. journal of prevention of Alzheimer's disease, The, 2022, 9, 197-210.	2.7	201
3078	Site Readiness Framework to Improve Health System Preparedness for a Potential New Alzheimer's Disease Treatment Paradigm. journal of prevention of Alzheimer's disease, The, 0, , 1.	2.7	0
3079	Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration. journal of prevention of Alzheimer's disease, The, 0, , 1.	2.7	1
3080	Anodal transcranial direct current stimulation alleviates cognitive impairment in an APP/PS1 model of Alzheimer's disease in the preclinical stage. Neural Regeneration Research, 2022, 17, 2278.	3.0	5
3081	Towards a WPA Position Document on the Human Rights of Older Adults with Mental Health Conditions. Consortium Psychiatricum, 2022, 3, 16-21.	0.7	0

#	Article	IF	CITATIONS
3082	Subjective Cognitive Decline in a Registry Sample: Relation to Psychiatric History, Loneliness, and Personality. journal of prevention of Alzheimer's disease, The, 0, , 1.	2.7	2
3083	Loss of corneal nerves and brain volume in mild cognitive impairment and dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12269.	3.7	5
3084	Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report. journal of prevention of Alzheimer's disease, The, 2022, 9, 231-235.	2.7	2
3085	Grip Strength, Gait Speed and Plasma Markers of Neurodegeneration in Asymptomatic Middle-aged and Older Adults. Journal of Frailty & Aging,the, 0, , 1.	1.3	4
3086	Basic Knowledge of Dementia Treatment required for Neurosurgeons. Japanese Journal of Neurosurgery, 2022, 31, 165-171.	0.0	0
3087	A threeâ€range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12270.	3.7	3
3088	ET and DEMENTIA. International Review of Neurobiology, 2022, , .	2.0	3
3089	A study of the longitudinal changes in multiple cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers on converter and nonâ€converter Alzheimer's disease subjects with consideration for their amyloid beta status. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12258.	2.4	2
3090	OUP accepted manuscript. Archives of Clinical Neuropsychology, 2022, , .	0.5	1
3091	Sleep and dementia. , 2022, , .		0
3092	Does essential tremor increase risk of cognitive impairment and dementia? Yes. International Review of Neurobiology, 2022, , 195-231.	2.0	9
3093	Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12298.	2.4	6
3094	New Perspectives for Treatment in Alzheimer's Disease. , 2022, , 199-225.		0
3095	Development of early biomarkers of Alzheimer's disease: A precision medicine perspective. , 2024, , 511-525.		0
3096	Metals, Nanoparticles, Particulate Matter, and Cognitive Decline. Frontiers in Neurology, 2021, 12, 794071.	2.4	6
3097	Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12288.	2.4	2
3098	How useful are biomarkers for the diagnosis of Alzheimer's disease and especially for its therapy?. Neural Regeneration Research, 2022, 17, 2205.	3.0	6
3099	CSF proteomic signature predicts progression to Alzheimer's disease dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12240.	3.7	3

#	Article	IF	CITATIONS
3100	Improving mouse models for the study of Alzheimer's disease. Current Topics in Developmental Biology, 2022, 148, 79-113.	2.2	1
3101	The Evolution of Diagnostic Boundaries of Alzheimer's Disease and Novel Therapeutic Options. Consortium Psychiatricum, 2022, 3, 8-15.	0.7	0
3102	Cerebrovascular Reactivity Across the Entire Brain in Cerebral Amyloid Angiopathy. Neurology, 2022, 98, .	1.1	14
3103	Biofluidâ€based biomarkers for Alzheimer's disease–related pathologies: An update and synthesis of the literature. Alzheimer's and Dementia, 2022, 18, 1687-1693.	0.8	24
3104	Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study. Alzheimer's and Dementia, 2022, 18, 2537-2550.	0.8	21
3105	Difference in Amyloid Load Between Single Memory Domain and Multidomain Subjective Cognitive Decline: A Study from the SILCODE. Journal of Alzheimer's Disease, 2022, 85, 1573-1582.	2.6	0
3106	Tau Pathologies Mediate the Association of Cigarette Smoking with Cognitive Impairment in Older Adults Without Dementia: The CABLE Study. Journal of Alzheimer's Disease, 2022, 86, 1849-1859.	2.6	4
3108	Differential protein expression in the hippocampi of resilient individuals identified by digital spatial profiling. Acta Neuropathologica Communications, 2022, 10, 23.	5.2	21
3109	Are plasma markers for Alzheimer's disease ready for clinical use?. Nature Aging, 2022, 2, 94-96.	11.6	1
3110	Single-Cell RNA-Seq Analysis of Olfactory Mucosal Cells of Alzheimer's Disease Patients. Cells, 2022, 11, 676.	4.1	20
3111	Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. Neurology, 2022, 98, .	1.1	49
3112	A Systematic Review of Neuroimaging Studies Comparing Individuals with Subjective Cognitive Decline to Healthy Controls. Journal of Alzheimer's Disease, 2022, 86, 1545-1567.	2.6	9
3114	Tracerâ€specific reference tissues selection improves detection of <scp><sup>18</sup>Fâ€FDG</scp> , <scp><sup>18</sup>F</scp> â€florbetapir, and <scp><sup>18</sup>F</scp> â€flortaucipir <scp>PET SUVR</scp> changes in Alzheimer's disease. Human Brain Mapping, 2022, 43, 2121-2133.	3.6	8
3115	The China Alzheimer Report 2022. Annals of General Psychiatry, 2022, 35, e100751.	3.1	79
3116	Amyloid Beta Pathology Exacerbates Weight Loss and Brain Cytokine Responses following Low-Dose Lipopolysaccharide in Aged Female Tg2576 Mice. International Journal of Molecular Sciences, 2022, 23, 2377.	4.1	6
3117	Predicting Brain Amyloid-β PET Grades with Graph Convolutional Networks Based on Functional MRI and Multi-Level Functional Connectivity. Journal of Alzheimer's Disease, 2022, 86, 1679-1693.	2.6	4
3118	Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer's disease: a cross-sectional analysis from the SILCODE study. Alzheimer's Research and Therapy, 2022, 14, 35.	6.2	22
3119	Recent Advancements in Strategies for Abnormal Protein Clearance in Alzheimer's Disease. Mini-Reviews in Medicinal Chemistry, 2022, 22, 2260-2270.	2.4	4

#	Article	IF	CITATIONS
3120	Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer's disease. Alzheimer's Research and Therapy, 2022, 14, 38.	6.2	14
3121	Image-level trajectory inference of tau pathology using variational autoencoder for Flortaucipir PET. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3061-3072.	6.4	5
3122	Metabolic Factors Are Related to Brain Amyloid Among Mexican Americans: A HABS-HD Study. Journal of Alzheimer's Disease, 2022, 86, 1745-1750.	2.6	5
3123	Characterizing Network Selectiveness to the Dynamic Spreading of Neuropathological Events in Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 86, 1805-1816.	2.6	1
3125	Air Pollution, Ultrafine Particles, and Your Brain: Are Combustion Nanoparticle Emissions and Engineered Nanoparticles Causing Preventable Fatal Neurodegenerative Diseases and Common Neuropsychiatric Outcomes?. Environmental Science & Technology, 2022, 56, 6847-6856.	10.0	55
3126	Overview of tau PET molecular imaging. Current Opinion in Neurology, 2022, 35, 230-239.	3.6	18
3127	Tau proteins in blood as biomarkers of Alzheimer's disease and other proteinopathies. Journal of Neural Transmission, 2022, 129, 239-259.	2.8	8
3128	The Role of Hub and Spoke Regions in Theory of Mind in Early Alzheimer's Disease and Frontotemporal Dementia. Biomedicines, 2022, 10, 544.	3.2	8
3129	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. Journal of Neural Transmission, 2022, 129, 231-237.	2.8	7
3130	Alzheimer's disease amyloid-β pathology in the lens of the eye. Experimental Eye Research, 2022, 221, 108974.	2.6	5
3131	Recent Advances in Understanding of Alzheimer's Disease Progression Through Mass Spectrometry-Based Metabolomics. Phenomics, 2022, 2, 1-17.	2.9	10
3132	Caspase-1 variant influencing CSF tau and FDG PET levels in non-demented elders from the ADNI cohort. BMC Neurology, 2022, 22, 59.	1.8	1
3133	Genetic and Molecular Evaluation of SQSTM1/p62 on the Neuropathologies of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2022, 14, 829232.	3.4	7
3134	Diagnosing Alzheimer's Disease from Circulating Blood Leukocytes Using a Fluorescent Amyloid Probe. Journal of Alzheimer's Disease, 2022, 85, 1721-1734.	2.6	3
3135	Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI. Neurology, 2022, 98, .	1.1	10
3136	Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults. Alzheimer's and Dementia, 2022, 18, 2570-2581.	0.8	8
3137	The Humanistic and Economic Burden of Alzheimer's Disease. Neurology and Therapy, 2022, 11, 525-551.	3.2	41
3138	The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study. Journal of Alzheimer's Disease, 2022, 85, 1441-1452.	2.6	7

<b>C</b>	 	. n		~	
			ъD	( ) I	2
$\sim$					

#	Article	IF	CITATIONS
3139	Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing. Alzheimer's and Dementia, 2022, 18, 1969-1979.	0.8	8
3140	Association Between Common Variants of APOE, ABCA7, A2M, BACE1, and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: Data from the PUMCH Dementia Cohort. Journal of Alzheimer's Disease, 2022, 85, 1511-1518.	2.6	3
3141	Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimer's Disease. Life, 2022, 12, 275.	2.4	9
3143	Brain Atrophy and Clinical Characterization of Adults With Mild Cognitive Impairment and Different Cerebrospinal Fluid Biomarker Profiles According to the AT(N) Research Framework of Alzheimer's Disease. Frontiers in Human Neuroscience, 2022, 16, 799347.	2.0	4
3144	Subjective memory complaints as a predictor of mild cognitive impairment and Alzheimer's disease. Discover Psychology, 2022, 2, 1.	0.9	8
3145	A Machine Learning-Based Holistic Approach to Predict the Clinical Course of Patients within the Alzheimer's Disease Spectrum1. Journal of Alzheimer's Disease, 2022, 85, 1639-1655.	2.6	7
3146	Amyloidosis in Alzheimer's Disease: Pathogeny, Etiology, and Related Therapeutic Directions. Molecules, 2022, 27, 1210.	3.8	45
3147	Inhibiting microRNA-142–5p improves learning and memory in Alzheimer's disease rats via targeted regulation of the PTPN1-mediated Akt pathway. Brain Research Bulletin, 2023, 192, 107-114.	3.0	7
3148	Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change. Acta Neuropathologica, 2022, 143, 487-503.	7.7	89
3149	The canonical pattern of Alzheimer's disease atrophy is linked to white matter hyperintensities in normal controls, differently in normal controls compared to in AD. Neurobiology of Aging, 2022, 114, 105-112.	3.1	5
3150	Many Changes in Speech through Aging Are Actually a Consequence of Cognitive Changes. International Journal of Environmental Research and Public Health, 2022, 19, 2137.	2.6	6
3151	Progression from Subjective Cognitive Decline to Mild Cognitive Impairment or Dementia: The Role of Baseline Cognitive Performance. Journal of Alzheimer's Disease, 2022, 86, 1763-1774.	2.6	2
3152	The <scp>NLRP3</scp> inflammasome modulates tau pathology and neurodegeneration in a tauopathy model. Glia, 2022, 70, 1117-1132.	4.9	22
3153	Identifying health conditions associated with Alzheimer's disease up to 15 years before diagnosis: an agnostic study of French and British health records. The Lancet Digital Health, 2022, 4, e169-e178.	12.3	28
3154	Alzheimer's Disease: Epidemiology and Clinical Progression. Neurology and Therapy, 2022, 11, 553-569.	3.2	113
3155	Cognitive differences across ethnoracial category, socioeconomic status across the Alzheimer's disease spectrum: Can an ability discrepancy score level the playing field?. Memory and Cognition, 2023, 51, 543-560.	1.6	5
3157	Genome-wide association study identifies APOE locus influencing plasma p-tau181 levels. Journal of Human Genetics, 2022, 67, 459-463.	2.3	4
3158	Effect of 3-Month Aerobic Dance on Hippocampal Volume and Cognition in Elderly People With Amnestic Mild Cognitive Impairment: A Randomized Controlled Trial. Frontiers in Aging Neuroscience, 2022, 14, 771413	3.4	9

#	Article	IF	CITATIONS
3159	Periodontal microorganisms and Alzheimer disease – A causative relationship?. Periodontology 2000, 2022, 89, 59-82.	13.4	34
3160	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease. Nature Communications, 2022, 13, 1495.	12.8	11
3161	Hemispheric Cortical, Cerebellar and Caudate Atrophy Associated to Cognitive Impairment in Metropolitan Mexico City Young Adults Exposed to Fine Particulate Matter Air Pollution. Toxics, 2022, 10, 156.	3.7	11
3162	From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?. , 2022, , 343-353.		1
3163	Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer's disease: review, recommendation, implementation and application. Molecular Neurodegeneration, 2022, 17, 17.	10.8	40
3167	A Multi-Dimensional Comparison of Alzheimer's Disease Neurodegenerative Biomarkers. Journal of Alzheimer's Disease, 2022, 87, 197-209.	2.6	1
3168	Quantified Brain Magnetic Resonance Imaging Volumes Differentiate Behavioral Variant Frontotemporal Dementia from Early-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, , 1-9.	2.6	1
3169	Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years. Neurology, 2022, 98, .	1.1	10
3170	Verbal and Nonverbal Memory in Neurodegenerative and Stroke Aphasia: Evidence From the Turkish Version of the Three Words Three Shapes Test. Cognitive and Behavioral Neurology, 2022, 35, 49-65.	0.9	1
3171	Transcript levels in plasma contribute substantial predictive value as potential Alzheimer's disease biomarkers in African Americans. EBioMedicine, 2022, , 103929.	6.1	2
3172	Plasma Aβ as a biomarker for predicting Aβ-PET status in Alzheimer's disease:a systematic review with meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 513-520.	1.9	10
3173	Complex Processes Underlying the Dynamic Changes of D-serine Levels in AD Brains. Current Alzheimer Research, 2022, 19, 485-493.	1.4	3
3174	Should Doctors Offer Biomarker Testing to Those Afraid to Develop Alzheimer's Dementia?. Journal of Bioethical Inquiry, 2022, , 1.	1.5	3
3175	Exploring common genetic contributors to neuroprotection from amyloid pathology. Brain Communications, 2022, 4, fcac066.	3.3	10
3176	Association Between Plasma Apolipoprotein M With Alzheimer's Disease: A Cross-Sectional Pilot Study From China. Frontiers in Aging Neuroscience, 2022, 14, 838223.	3.4	3
3177	2022 Alzheimer's disease facts and figures. Alzheimer's and Dementia, 2022, 18, 700-789.	0.8	1,135
3178	Fluid Biomarkers in Alzheimer's Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments. Diagnostics, 2022, 12, 796.	2.6	4
3179	Tai Chi enhances cognitive training effects on delaying cognitive decline in mild cognitive impairment. Alzheimer's and Dementia, 2023, 19, 136-149.	0.8	10

#	Article	IF	CITATIONS
3180	Alzheimer's Disease Drug Development: A Research and Development Ecosystem. , 2022, , 1-24.		2
3181	Alzheimer's Association Funding and Policy for Alzheimer's Disease Drug Development. , 2022, , 486-495.		Ο
3182	Globalization of Alzheimer's Disease Clinical Trials. , 2022, , 275-280.		0
3183	Rational design and synthesis of a novel BODIPY-based probe for selective imaging of tau tangles in human iPSC-derived cortical neurons. Scientific Reports, 2022, 12, 5257.	3.3	11
3184	Greater Diffusion Restriction in White Matter in Preclinical Alzheimer Disease. Annals of Neurology, 2022, , .	5.3	6
3186	Relevance of Subjective Cognitive Decline in Older Adults with a First-Degree Family History of Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 87, 545-555.	2.6	5
3187	Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2022, 9, 756-761.	3.7	12
3188	Automatized FACEmemory® scoring is related to Alzheimer's disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort. Alzheimer's Research and Therapy, 2022, 14, 43.	6.2	8
3190	The Importance of Phase 2 in Drug Development for Alzheimer's Disease. , 2022, , 150-161.		0
3191	Differential effects of white matter hyperintensities and regional amyloid deposition on regional cortical thickness. Neurobiology of Aging, 2022, 115, 12-19.	3.1	5
3192	Circulating Naturally Occurring Antibodies to P2RY2 Are Decreased in Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 87, 711-719.	2.6	3
3193	Association of Hippocampal Subfield Volumes with Amyloid-Beta Deposition in Alzheimer's Disease. Journal of Clinical Medicine, 2022, 11, 1526.	2.4	4
3194	Neuronal synchrony abnormalities associated with subclinical epileptiform activity in early-onset Alzheimer's disease. Brain, 2022, 145, 744-753.	7.6	25
3195	Identification of cognitively impaired patients at risk for development of Alzheimer's disease dementia: an analysis of US Medicare claims data. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, , 1-14.	1.4	1
3196	Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease. Journal of Personalized Medicine, 2022, 12, 444.	2.5	21
3197	Cerebrospinal Fluid Total Tau Protein Correlates With Longitudinal, Progressing Cognitive Dysfunction in Anti-Neural Autoantibody-Associated Dementia and Alzheimer's Dementia: A Case–Control Study. Frontiers in Immunology, 2022, 13, 837376.	4.8	7
3198	Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review. European Journal of Neuroscience, 2022, 56, 5650-5713.	2.6	4
3199	Lipid Homeostasis and Its Links With Protein Misfolding Diseases. Frontiers in Molecular Neuroscience, 2022, 15, 829291.	2.9	11

#	Article	IF	CITATIONS
3200	Peripheral Immune Cells and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study. Journal of Alzheimer's Disease, 2022, 87, 721-730.	2.6	2
3201	Enhanced Association of Tau Pathology and Cognitive Impairment in Mild Cognitive Impairment Subjects with Behavior Symptoms. Journal of Alzheimer's Disease, 2022, 87, 557-568.	2.6	3
3202	Gene Expression Analysis of the Endocannabinoid System in Presymptomatic APP/PS1 Mice. Frontiers in Pharmacology, 2022, 13, 864591.	3.5	5
3203	Subjective cognitive decline, APOE e4 allele, and the risk of neurocognitive disorders: Age- and sex-stratified cohort study. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1664-1675.	2.3	5
3204	A computational model of neurodegeneration in Alzheimer's disease. Nature Communications, 2022, 13, 1643.	12.8	32
3205	A Novel Method for Establishing Functional Change in Older Adults With Cognitive Impairment. Alzheimer Disease and Associated Disorders, 2022, Publish Ahead of Print, .	1.3	0
3206	Rates of β-amyloid deposition indicate widespread simultaneous accumulation throughout the brain. Neurobiology of Aging, 2022, 115, 1-11.	3.1	4
3207	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. Molecular Neurodegeneration, 2022, 17, 27.	10.8	30
3208	Waning locus coeruleus integrity precedes cortical tau accrual in preclinical autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 169-180.	0.8	11
3209	Microglia in Alzheimer's Disease: a Key Player in the Transition Between Homeostasis and Pathogenesis. Neurotherapeutics, 2022, 19, 186-208.	4.4	19
3211	Drug Development for Alzheimer's Disease: An Historical Perspective. , 2022, , 25-33.		0
3212	Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review. Frontiers in Aging Neuroscience, 2022, 14, 683689.	3.4	13
3214	Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes. Nature Reviews Neurology, 2022, 18, 323-332.	10.1	29
3215	Examining the association between bloodâ€based biomarkers and human <i>post mortem</i> neuropathology in the University of Kentucky Alzheimer's Disease Research Center autopsy cohort. Alzheimer's and Dementia, 2023, 19, 67-78.	0.8	18
3216	Association between Visceral Adipose Tissue Metabolism and Alzheimer's Disease Pathology. Metabolites, 2022, 12, 258.	2.9	9
3217	Voxel-based morphometry and a deep learning model for the diagnosis of early Alzheimer's disease based on cerebral gray matter changes. Cerebral Cortex, 2023, 33, 754-763.	2.9	18
3218	The Role of Regulatory Agencies in Alzheimer's Disease Drug Development. , 2022, , 319-332.		0
3219	Culture, Ethnicity, and Level of Education in Alzheimer's Disease. Neurotherapeutics, 2022, 19, 26-54.	4.4	37

#	Article	IF	CITATIONS
3220	Accelerated decline in white matter microstructure in subsequently impaired older adults and its relationship with cognitive decline. Brain Communications, 2022, 4, fcac051.	3.3	16
3221	Exposing the Brain Proteomic Signatures of Alzheimer's Disease in Diverse Racial Groups: Leveraging Multiple Data Sets and Machine Learning. Journal of Proteome Research, 2022, 21, 1095-1104.	3.7	6
3223	Decreased CSF clearance and increased brain amyloid in Alzheimer's disease. Fluids and Barriers of the CNS, 2022, 19, 21.	5.0	41
3224	Reduced cerebellar cortical thickness in World Trade Center responders with cognitive impairment. Translational Psychiatry, 2022, 12, 107.	4.8	8
3225	Impairments of glutamatergic synaptic transmission in Alzheimer's disease. Seminars in Cell and Developmental Biology, 2023, 139, 24-34.	5.0	15
3226	Association of Emerging β-Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults. Neurology, 2022, 98, .	1.1	20
3227	β-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns. Brain Communications, 2022, 4, fcac084.	3.3	6
3228	The European Prevention of Alzheimer's Disease Program: A Public–Private Partnership to Facilitate the Secondary Prevention of Alzheimer's Disease Dementia. , 2022, , 190-206.		1
3229	Biofluid Biomarkers of Alzheimer's Disease: Progress, Problems, and Perspectives. Neuroscience Bulletin, 2022, 38, 677-691.	2.9	24
3230	The Role of Vascular Risk Factors in Biomarker-Based AT(N) Groups: A German-Dutch Memory Clinic Study. Journal of Alzheimer's Disease, 2022, 87, 185-195.	2.6	6
3231	Connecting acute and chronic neurocognitive impairment. International Psychogeriatrics, 2022, 34, 323-325.	1.0	1
3232	Type 2 Diabetes Mellitus as a Risk Factor for Alzheimer's Disease: Review and Meta-Analysis. Biomedicines, 2022, 10, 778.	3.2	21
3233	Evaluation of the Accuracy of Cognitive Screening Tests in Detecting Dementia Associated with Alzheimer's Disease: A Hierarchical Bayesian Latent Class Meta-Analysis. Journal of Alzheimer's Disease, 2022, 87, 285-304.	2.6	5
3234	Association of plasma biomarkers, pâ€ŧau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and longâ€ŧerm clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years. Alzheimer's and Dementia, 2023, 19, 25-35.	0.8	26
3235	Preclinical Longitudinal In Vivo Biomarker Platform for Alzheimer's Disease Drug Discovery. , 2022, , 106-122.		0
3236	Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment. Journal of Neurology, 2022, 269, 4270-4280.	3.6	30
3237	Wolframin is a novel regulator of tau pathology and neurodegeneration. Acta Neuropathologica, 2022, 143, 547-569.	7.7	22
3238	Development of Alzheimer's Disease Biomarkers: From CSF- to Blood-Based Biomarkers. Biomedicines, 2022, 10, 850.	3.2	19

#	Article	IF	CITATIONS
3239	Degradation and inhibition of epigenetic regulatory protein BRD4 exacerbate Alzheimer's disease-related neuropathology in cell models. Journal of Biological Chemistry, 2022, 298, 101794.	3.4	8
3240	Characterizing the propagation pathway of neuropathological events of Alzheimer's disease using harmonic wavelet analysis. Medical Image Analysis, 2022, 79, 102446.	11.6	2
3241	Modifiable psychosocial risk factors and delayed onset of dementia in older populations: analysis of two prospective US cohorts. BMJ Open, 2022, 12, e059317.	1.9	3
3243	Cerebrospinal fluid catecholamines in Alzheimer's disease patients with and without biological disease. Translational Psychiatry, 2022, 12, 151.	4.8	16
3244	Diagnostic Accuracy of the Five-Word Test for Mild Cognitive Impairment Due to Alzheimer's Disease. Neurology International, 2022, 14, 357-367.	2.8	2
3245	Rhythm Control Better Prevents Dementia than Rate Control Strategies in Patients with Atrial Fibrillation—A Nationwide Cohort Study. Journal of Personalized Medicine, 2022, 12, 572.	2.5	6
3246	Primary care costs due to prodromal Alzheimer disease: a real-world study in patients with a 10-year or longer medical history. Current Medical Research and Opinion, 2022, 38, 743-747.	1.9	1
3247	Sleep in Alzheimer's disease: a systematic review and meta-analysis of polysomnographic findings. Translational Psychiatry, 2022, 12, 136.	4.8	41
3248	Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer's Disease. Cellular and Molecular Neurobiology, 2023, 43, 797-811.	3.3	19
3249	Vitamin D in Alzheimer's Disease: Low Levels in Cerebrospinal Fluid Despite Normal Amounts in Serum. Journal of Alzheimer's Disease, 2022, 86, 1301-1314.	2.6	5
3250	Proteomic Profiles of Neurodegeneration Among Mexican Americans and Non-Hispanic Whites in the HABS-HD Study. Journal of Alzheimer's Disease, 2022, 86, 1243-1254.	2.6	6
3251	Lights and Shadows of Cerebrospinal Fluid Biomarkers in the Current Alzheimer's Disease Framework. Journal of Alzheimer's Disease, 2022, 86, 1061-1072.	2.6	1
3252	Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 87, 991-997.	2.6	10
3253	Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer's disease. Science Advances, 2022, 8, eabm5667.	10.3	6
3254	Quantification of amyloid PET for future clinical use: a state-of-the-art review. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3508-3528.	6.4	34
3255	Relationship Between Plasma Neurofilament Light Chain, Gut Microbiota, and Dementia: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2022, 86, 1323-1335.	2.6	5
3256	Are subjective cognitive complaints associated with executive functions and mental health of older adults?. Cognitive Processing, 2022, 23, 503-512.	1.4	2
3257	What's the cut-point?: a systematic investigation of tau PET thresholding methods. Alzheimer's Research and Therapy, 2022, 14, 49.	6.2	13

#	Article	IF	CITATIONS
3258	Association between sleep parameters and longitudinal shortening of telomere length. Aging, 2022, 14, 2930-2944.	3.1	7
3259	Aduhelm, the Newly Approved Medication for Alzheimer Disease: What Epidemiologists Can Learn and What Epidemiology Can Offer. American Journal of Epidemiology, 2022, 191, 1347-1351.	3.4	5
3260	A robust and interpretable machine learning approach using multimodal biological data to predict future pathological tau accumulation. Nature Communications, 2022, 13, 1887.	12.8	16
3262	Alteration of Neural Pathways and Its Implications in Alzheimer's Disease. Biomedicines, 2022, 10, 845.	3.2	8
3263	Effects of a staged integral art-based cognitive intervention (SIACI) program in older adults with cognitive impairments: protocol for a randomized controlled trial. BMC Geriatrics, 2022, 22, 296.	2.7	2
3264	Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid-β and Tau Pathology in Middle-Aged Adults: The Framingham Study. Journal of Alzheimer's Disease, 2022, 86, 1371-1383.	2.6	18
3265	Novel Ultrasensitive Detection Technologies for the Identification of Early and Minimally Invasive Alzheimer's Disease Blood Biomarkers. Journal of Alzheimer's Disease, 2022, 86, 1337-1369.	2.6	4
3266	Current Status of Alzheimer's Disease and Pathological Mechanisms Investigating the Therapeutic Molecular Targets. Current Molecular Medicine, 2023, 23, 492-508.	1.3	5
3267	Spillover: The Approval of New Medications for Alzheimer's Disease Dementia Will Impact Biomarker Disclosure Among Asymptomatic Research Participants. Journal of Alzheimer's Disease, 2022, , 1-9.	2.6	3
3268	Radiomics Analysis of Brain [18F]FDG PET/CT to Predict Alzheimer's Disease in Patients with Amyloid PET Positivity: A Preliminary Report on the Application of SPM Cortical Segmentation, Pyradiomics and Machine-Learning Analysis. Diagnostics, 2022, 12, 933.	2.6	15
3269	Alzheimer's disease prediction based on continuous feature representation using multi-omics data integration. Chemometrics and Intelligent Laboratory Systems, 2022, 223, 104536.	3.5	6
3270	Vestibular Function Predicts Balance and Fall Risk in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 86, 1159-1168.	2.6	13
3271	Patterns of Cerebrospinal Fluid Alzheimer's Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition. Viruses, 2022, 14, 753.	3.3	6
3272	LC-MS biomarker diagnostics for neuroinflammatory disorders. EBioMedicine, 2022, 78, 103984.	6.1	1
3273	Clinical Utility of Cerebrospinal Fluid Aβ42 and Tau Measures in Diagnosing Mild Cognitive Impairment in Early Onset Dementia. Journal of Alzheimer's Disease, 2022, , 1-10.	2.6	1
3274	Categorical predictive and disease progression modeling in the early stage of Alzheimer's disease. Journal of Neuroscience Methods, 2022, 374, 109581.	2.5	2
3275	Artificial intelligence in brain MRI analysis of Alzheimer's disease over the past 12 years: A systematic review. Ageing Research Reviews, 2022, 77, 101614.	10.9	33
3276	Long-term stability and age-dependence of six regulatory serum proteins. Biomarkers in Medicine, 2022, 16, 511-521.	1.4	3

#	άρτις ε	IF	CITATIONS
" 3277	The identification of PSEN1 p.Tyr159Ser mutation in a non-canonic early-onset Alzheimer's disease family. Molecular and Cellular Neurosciences, 2022, 120, 103715	2.2	4
3278	SimulAD: a dynamical model for personalized simulation and disease staging in Alzheimer's disease. Neurobiology of Aging, 2022, 113, 73-83.	3.1	2
3279	P-tau217 in Alzheimer's disease. Clinica Chimica Acta, 2022, 531, 100-111.	1.1	14
3280	The prion protein and its ligands: Insights into structure-function relationships. Biochimica Et Biophysica Acta - Molecular Cell Research, 2022, 1869, 119240.	4.1	10
3281	Higher-order multi-shell diffusion measures complement tensor metrics and volume in gray matter when predicting age and cognition. NeuroImage, 2022, 253, 119063.	4.2	9
3282	Neighborhood characteristics as confounders and effect modifiers for the association between air pollution exposure and subjective cognitive functioning. Environmental Research, 2022, 212, 113221.	7.5	10
3283	Assessment of Social Behavior Using a Passive Monitoring App in Cognitively Normal and Cognitively Impaired Older Adults: Observational Study. JMIR Aging, 2022, 5, e33856.	3.0	2
3284	Using the ATN system as a guide for the neuropsychological assessment of Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 2021, 43, 926-943.	1.3	6
3285	Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction. Current Alzheimer Research, 2021, 18, 1010-1022.	1.4	12
3286	Recent advances in blood and gut microbiota biomarkers for Alzheimer's disease. Scientia Sinica Vitae, 2021, , .	0.3	0
3288	Effects of Specific Inhibitors for CaMK1D on a Primary Neuron Model for Alzheimer's Disease. Molecules, 2021, 26, 7669.	3.8	4
3289	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.8	26
3290	Graph-guided Bayesian SVM with Adaptive Structured Shrinkage Prior for High-dimensional Data. , 2021, 2021, 4472-4479.		0
3292	Normal cerebrospinal fluid concentrations of PDGFRÎ <sup>2</sup> in patients with cerebral amyloid angiopathy and Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 1788-1796.	0.8	6
3293	Yi-Zhi-Fang-Dai Formula Exerts Neuroprotective Effects Against Pyroptosis and Blood–Brain Barrier–Glymphatic Dysfunctions to Prevent Amyloid-Beta Acute Accumulation After Cerebral Ischemia and Reperfusion in Rats. Frontiers in Pharmacology, 2021, 12, 791059.	3.5	8
3294	Current Understanding of the Physiopathology, Diagnosis and Therapeutic Approach to Alzheimer's Disease. Biomedicines, 2021, 9, 1910.	3.2	35
3295	Identifying Combinatorial Significance for Classification of Alzheimer's Disease Proteomics Expression with Logical Analysis of Data. , 2021, , .		0
3297	Investigation of Possible Correlation Between Retinal Neurovascular Biomarkers and Early Cognitive Impairment in Patients With Chronic Kidney Disease. Translational Vision Science and Technology, 2021, 10, 9.	2.2	6

#	Article	IF	CITATIONS
3298	Saturation Transfer MRI for Detection of Metabolic and Microstructural Impairments Underlying Neurodegeneration in Alzheimer's Disease. Brain Sciences, 2022, 12, 53.	2.3	3
3299	Applications and Challenges of Machine Learning Methods in Alzheimer's Disease Multi-Source Data Analysis. Current Genomics, 2021, 22, 564-582.	1.6	3
3300	Is kallikrein-8 a blood biomarker for detecting amnestic mild cognitive impairment? Results of the population-based Heinz Nixdorf Recall study. Alzheimer's Research and Therapy, 2021, 13, 202.	6.2	1
3301	A longitudinal investigation of $A\hat{l}^2$ , anxiety, depression, and mild cognitive impairment. Alzheimer's and Dementia, 2022, 18, 1824-1831.	0.8	14
3302	Diffusion MRI metrics and their relation to dementia severity: effects of harmonization approaches. , 2021, , .		6
3303	Structural Covariance Network as an Endophenotype in Alzheimer's Disease-Susceptible Single-Nucleotide Polymorphisms and the Correlations With Cognitive Outcomes. Frontiers in Aging Neuroscience, 2021, 13, 721217.	3.4	5
3305	Alzheimer's disease classification accuracy is Improved by MRI harmonization based on attention-guided generative adversarial networks. , 2021, 12088, .		5
3306	Adverse Childhood Experiences and Subjective Cognitive Decline in the US. Journal of Applied Gerontology, 2022, 41, 1090-1100.	2.0	8
3307	NRM 2021 Abstract Booklet. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 11-309.	4.3	0
3309	China Registry Study on Cognitive Impairment in the Elderly: Protocol of a Prospective Cohort Study. Frontiers in Aging Neuroscience, 2021, 13, 797704.	3.4	2
3310	Deep Learning With 18F-Fluorodeoxyglucose-PET Gives Valid Diagnoses for the Uncertain Cases in Memory Impairment of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 764272.	3.4	2
3311	Rheum tanguticum Alleviates Cognitive Impairment in APP/PS1 Mice by Regulating Drug-Responsive Bacteria and Their Corresponding Microbial Metabolites. Frontiers in Pharmacology, 2021, 12, 766120.	3.5	1
3312	Hyperconnectivity Associated with Anosognosia Accelerating Clinical Progression in Amnestic Mild Cognitive Impairment. ACS Chemical Neuroscience, 2022, 13, 120-133.	3.5	3
3313	Gram-negative bacteria and their lipopolysaccharides in Alzheimer's disease: pathologic roles and therapeutic implications. Translational Neurodegeneration, 2021, 10, 49.	8.0	36
3314	Applied machine learning in Alzheimer's disease research: omics, imaging, and clinical data. Emerging Topics in Life Sciences, 2021, 5, 765-777.	2.6	22
3315	Alzheimer disease effects of different stages on intestinal flora. Medicine (United States), 2021, 100, e28462.	1.0	1
3316	Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques. Neurology, 2022, 98, .	1.1	89
3317	EANM procedure guidelines for brain PET imaging using [18F]FDC, version 3. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 632-651.	6.4	82

#	Article	IF	CITATIONS
3318	Vascular Cognitive Impairment (VCI). Neurotherapeutics, 2022, 19, 68-88.	4.4	67
3319	Alzheimer's disease biomarkers in Black and nonâ€Hispanic White cohorts: A contextualized review of the evidence. Alzheimer's and Dementia, 2022, 18, 1545-1564.	0.8	29
3320	Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer's Disease. Diagnostics, 2021, 11, 2339.	2.6	7
3321	Tau and Alzheimer's Disease: Molecular Mechanisms and Treatment Approaches. SN Comprehensive Clinical Medicine, 2021, 4, 1.	0.6	0
3322	Bloodâ€based biomarkers for Alzheimer's disease. EMBO Molecular Medicine, 2022, 14, e14408.	6.9	122
3323	Limited Longitudinal Change in Self-reported Spatial Navigation Ability in Preclinical Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2022, 36, 15-21.	1.3	3
3324	Genomics and Functional Genomics of Alzheimer's Disease. Neurotherapeutics, 2022, 19, 152-172.	4.4	26
3325	Regulatory role of cathepsin L in induction of nuclear laminopathy in Alzheimer's disease. Aging Cell, 2022, 21, e13531.	6.7	17
3326	Establishing pre-analytical requirements and maximizing peptide recovery in the analytical phase for mass spectrometric quantification of amyloid-β peptides 1–42 and 1–40 in CSF. Clinical Chemistry and Laboratory Medicine, 2022, 60, 198-206.	2.3	2
3327	Cross-Modality Generation of Amyloid PET from FDG PET for Alzheimer's Disease Diagnosis. , 2021, , .		2
3329	Arterial stiffness, pulsatile hemodynamics, and the vascular contributions to dementia. , 2022, , 649-663.		0
3330	Emerging blood exosome-based biomarkers for preclinical and clinical Alzheimer's disease: a meta-analysis and systematic review. Neural Regeneration Research, 2022, 17, 2381.	3.0	22
3331	Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels in Down Syndrome and Sporadic Alzheimer´S Disease: A Cross-Sectional Study. SSRN Electronic Journal, 0, , .	0.4	0
3332	Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2022, 14, 858429.	3.4	9
3334	Quantitative analysis of regional distribution of tau pathology with 11C-PBB3-PET in a clinical setting. PLoS ONE, 2022, 17, e0266906.	2.5	7
3335	What Influences the Willingness of Blacks and African Americans to Enroll in Preclinical Alzheimer's Disease Biomarker Research? A Qualitative Vignette Analysis. Journal of Alzheimer's Disease, 2022, 87, 1167-1179.	2.6	7
3336	Importance of cerebrospinal fluid storage conditions for the Alzheimer's disease diagnostics on an automated platform. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1058-1063.	2.3	4
3337	Reactions to Amyloid PET Scan Results and Levels of Anxious and Depressive Symptoms: CARE IDEAS Study. Gerontologist, The, 2023, 63, 71-81.	3.9	6

#	Article	IF	CITATIONS
3338	Cross-Sectional Association Between Blood Cell Phenotypes, Cognitive Function, and Brain Imaging Measures in the Community-Based Framingham Heart Study. Journal of Alzheimer's Disease, 2022, 87, 1291-1305.	2.6	1
3339	Clinical and Molecular Findings in a Turkish Family Who Had a (c.869- 1G>A) Splicing Variant in PSEN1 Gene with A Rare Condition: The Variant Alzheimer's Disease with Spastic Paraparesis. Current Alzheimer Research, 2022, 19, 223-235.	1.4	3
3340	How long does it take to diagnose young-onset dementia? A comparison with late-onset dementia. Neurological Sciences, 2022, 43, 4729-4734.	1.9	6
3341	Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease. Alzheimer's Research and Therapy, 2022, 14, 54.	6.2	24
3342	Comparison and aggregation of event sequences across ten cohorts to describe the consensus biomarker evolution in Alzheimer's disease. Alzheimer's Research and Therapy, 2022, 14, 55.	6.2	2
3343	Functional Connectome Analysis in Mild Cognitive Impairment: Comparing Alzheimer's Disease Continuum and Suspected Non-Alzheimer Pathology. Brain Connectivity, 2022, 12, 774-783.	1.7	1
3344	Associations of β-Amyloid and Vascular Burden With Rates of Neurodegeneration in Cognitively Normal Members of the 1946 British Birth Cohort. Neurology, 2022, 99, .	1.1	12
3345	Inhibitory Control of Saccadic Eye Movements and Cognitive Impairment in Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2022, 14, 871432.	3.4	8
3346	Diabetic patients treated with metformin during early stages of Alzheimer's disease show a better integral performance: data from ADNI study. GeroScience, 2022, 44, 1791-1805.	4.6	7
3347	Heterozygous and Homozygous Variants in SORL1 Gene in Alzheimer's Disease Patients: Clinical, Neuroimaging and Neuropathological Findings. International Journal of Molecular Sciences, 2022, 23, 4230.	4.1	3
3348	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease. Acta Neuropathologica, 2022, 143, 571-583.	7.7	3
3349	Possibility of Enlargement in Left Medial Temporal Areas Against Cerebral Amyloid Deposition Observed During Preclinical Stage. Frontiers in Aging Neuroscience, 2022, 14, 847094.	3.4	Ο
3350	Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics. Journal of Alzheimer's Disease, 2022, , 1-10.	2.6	0
3351	Cross-Cultural Longitudinal Study on Cognitive Decline (CLoCODE) for Subjective Cognitive Decline in China and Germany: A Protocol for Study Design. Journal of Alzheimer's Disease, 2022, , 1-15.	2.6	6
3352	Optical Nanosensor for Intracellular and Intracranial Detection of Amyloid-Beta. ACS Nano, 2022, 16, 7269-7283.	14.6	14
3353	Nucleic acid liquid biopsies in Alzheimer's disease: current state, challenges, and opportunities. Heliyon, 2022, 8, e09239.	3.2	5
3354	Neuroproteomics Chip-Based Mass Spectrometry and Other Techniques for Alzheimer's Disease Biomarkers – Update. Current Pharmaceutical Design, 2022, 28, 1124-1151.	1.9	4
3355	Uncommon Noninvasive Biomarkers for the Evaluation and Monitoring of the Etiopathogenesis of Alzheimer's Disease. Current Pharmaceutical Design, 2022, 28, .	1.9	3

		CITATION REP	ORT	
#	Article		IF	Citations
3356	Association of Subjective Memory Complaints With White Matter Hyperintensities and Cognitive Decline Among Older Adults in Chicago, Illinois. JAMA Network Open, 2022, 5, e227512.		5.9	9
3357	Use of Cognitive Testing, Questionnaires, and Plasma Biomarkers to Quantify Cognitive Impairme an Aging Pet Dog Population. Journal of Alzheimer's Disease, 2022, 87, 1367-1378.	nt in	2.6	13
3358	Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer's Disease Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 1155-1167.	to	2.8	9
3359	Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimer's Brain, 2022, 145, 2149-2160.	disease.	7.6	20
3360	Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incider clinically meaningful cognitive decline in older adults. GeroScience, 2022, 44, 1489-1503.	ce of	4.6	3
3361	The Patient Voice: Exploring Treatment Preferences in Participants with Mild Cognitive Concerns Inform Regulatory Decision Making. Patient, 2022, , .	.0	2.7	2
3362	α-synuclein as an emerging pathophysiological biomarker of Alzheimer's disease. Expert Revi Molecular Diagnostics, 2022, 22, 411-425.	ew of	3.1	4
3363	Unravelling neural correlates of empathy deficits in Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease. Behavioural Brain Research, 2022, 428, 113893.		2.2	6
3431	Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. Alzheimer's and Dementia, 2023, 19, 487-497.		0.8	25
3432	Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer's Disease Using S Modeling. Neurology and Therapy, 2022, 11, 863-880.	imulation	3.2	24
3434	Validation of Picture Free and Cued Selective Reminding Test for Illiteracy in Lima, Peru. American Journal of Alzheimer's Disease and Other Dementias, 2022, 37, 153331752210943.		1.9	2
3435	Advances in the development of new biomarkers for Alzheimer's disease. Translational Neurodegeneration, 2022, 11, 25.		8.0	65
3436	Predicting Amyloid Positivity in Cognitively Unimpaired Older Adults. Neurology, 2022, 98, .		1.1	7
3437	Huntington's Disease Regulatory Science Consortium: Accelerating Medical Product Develop Journal of Huntington's Disease, 2022, 11, 97-104.	nent.	1.9	2
3438	Impact of Donepezil on Brain Glucose Metabolism Assessed Using [18F]2-Fluoro-2-deoxy-D-Gluco Positron Emission Tomography Imaging in a Mouse Model of Alzheimer's Disease Induced by Intracerebroventricular Injection of Amyloid-Beta Peptide. Frontiers in Neuroscience, 2022, 16, 83	se 55577.	2.8	3
3439	Alzheimer's disease: Newer biomarkers. Industrial Psychiatry, 2021, 30, 315.		0.8	1
3440	The management of dementia worldwide: A review on policy practices, clinical guidelines, end-of- care, and challenge along with aging population. BioScience Trends, 2022, 16, 119-129.	ife	3.4	7
3441	Case Study: A Precision Medicine Approach to Multifactorial Dementia and Alzheimer's Disease.	2021,		0

11,.

#	Article	IF	CITATIONS
3442	Glucose Metabolism is a Better Marker for Predicting Clinical Alzheimer's Disease than Amyloid or Tau Journal of Cellular Immunology, 2022, 4, 15-18.	0.8	0
3443	Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease. journal of prevention of Alzheimer's disease, The, 0, , .	2.7	6
3444	The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report. journal of prevention of Alzheimer's disease, The, 0, , .	2.7	7
3445	Prediction of Cognitive Decline for Enrichment of Alzheimer's Disease Clinical Trials. journal of prevention of Alzheimer's disease, The, 0, , 1.	2.7	2
3446	Deviation From Model of Normal Aging in Alzheimer's Disease: Application of Deep Learning to Structural MRI Data and Cognitive Tests. IEEE Access, 2022, 10, 53234-53249.	4.2	6
3447	Neuroimaging studies of mental disorders. , 2023, , 608-615.		Ο
3448	Subjective short-term memory difficulties at ages 50–75 predict dementia risk in a community-based cohort followed over 17Âyears. Age and Ageing, 2022, 51, .	1.6	4
3449	Networkâ€wise concordance of multimodal neuroimaging features across the Alzheimer's disease continuum. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12304.	2.4	4
3450	Clinical Research Investigating Alzheimer's Disease in China: Current Status and Future Perspectives Toward Prevention. journal of prevention of Alzheimer's disease, The, 0, , 1.	2.7	2
3451	Glycosylation alterations in serum of Alzheimer's disease patients show widespread changes in <i>N</i> â€glycosylation of proteins related to immune function, inflammation, and lipoprotein metabolism. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12309.	2.4	6
3452	A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease. journal of prevention of Alzheimer's disease, The, 0, , .	2.7	2
3453	Sex-Driven Differences in the Effectiveness of Individualized Clinical Management of Alzheimer's Disease Risk. journal of prevention of Alzheimer's disease, The, 0, , .	2.7	1
3454	Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12314.	2.4	15
3455	Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12315.	2.4	16
3456	Verbal fluency response times predict incident cognitive impairment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12277.	2.4	4
3457	Disentangled Representation of Longitudinal Î'-Amyloid for AD Via Sequential Graph Variational Autoencoder with Supervision. , 2022, , .		0
3458	Retinal Biomarkers for Alzheimer Disease: The Facts and the Future. Asia-Pacific Journal of Ophthalmology, 2022, 11, 140-148.	2.5	10
3459	A Neuropathological Hub Identification for Alzheimer's Disease Via joint Analysis of Topological Structure and Neuropathological Burden. , 2022, ,		2

#	Article	IF	CITATIONS
3460	The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort. Alzheimer's Research and Therapy, 2022, 14, 60.	6.2	16
3461	Structural progression of Alzheimer's disease over decades: the MRI staging scheme. Brain Communications, 2022, 4, fcac109.	3.3	35
3462	Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study. Biomedicines, 2022, 10, 1045.	3.2	1
3463	Beyond amyloid: Immune, cerebrovascular, and metabolic contributions to Alzheimer disease in people with Down syndrome. Neuron, 2022, 110, 2063-2079.	8.1	8
3464	Role of inflammatory markers in the diagnosis of vascular contributions to cognitive impairment and dementia: a systematic review and meta-analysis. GeroScience, 2022, 44, 1373-1392.	4.6	36
3465	Electrochemical Tau Protein Immunosensor Based on MnS/GO/PANI and Magnetiteâ€incorporated Gold Nanoparticles. Electroanalysis, 2022, 34, 1519-1528.	2.9	26
3466	Alzheimer's Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint. Frontiers in Neuroscience, 2022, 16, 837390.	2.8	12
3467	Blood Tests for Alzheimer's Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance. Journal of Alzheimer's Disease, 2022, , 1-8.	2.6	8
3468	Decreased Vessel Density in Retinal Capillary Plexus and Thinner Ganglion Cell Complex Associated With Cognitive Impairment. Frontiers in Aging Neuroscience, 2022, 14, 872466.	3.4	7
3469	Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice. Alzheimer's Research and Therapy, 2022, 14, 59.	6.2	57
3470	How to use neuroimaging biomarkers in the diagnosis framework of neurodegenerative diseases?. Revue Neurologique, 2022, 178, 490-497.	1.5	2
3471	Plasma Phosphorylated-tau181 Is a Predictor of Post-stroke Cognitive Impairment: A Longitudinal Study. Frontiers in Aging Neuroscience, 2022, 14, 889101.	3.4	2
3472	Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade. International Journal of Molecular Sciences, 2022, 23, 5023.	4.1	64
3473	Functional Imaging for Neurodegenerative Diseases. Presse Medicale, 2022, 51, 104121.	1.9	3
3475	Adolescent Binge Alcohol Enhances Early Alzheimer's Disease Pathology in Adulthood Through Proinflammatory Neuroimmune Activation. Frontiers in Pharmacology, 2022, 13, 884170.	3.5	24
3476	Using Deep Learning Radiomics to Distinguish Cognitively Normal Adults at Risk of Alzheimer's Disease From Normal Control: An Exploratory Study Based on Structural MRI. Frontiers in Medicine, 2022, 9, 894726.	2.6	6
3478	Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies. Medicina (Lithuania), 2022, 58, 612.	2.0	1
3479	Neuroinflammation as a Potential Therapeutic Target in Alzheimer's Disease. Clinical Interventions in Aging, 2022, Volume 17, 665-674.	2.9	27

#	Article	IF	CITATIONS
3480	Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer's Disease and Other Tauopathies. Frontiers in Aging Neuroscience, 2022, 14, 838034.	3.4	19
3481	Everyday function profiles in prodromal stages of MCI: Prospective cohort study. Alzheimer's and Dementia, 2023, 19, 498-506.	0.8	8
3482	Practice Effects in Mild Cognitive Impairment Increase Reversion Rates and Delay Detection of New Impairments. Frontiers in Aging Neuroscience, 2022, 14, 847315.	3.4	3
3483	Cerebrospinal fluid lactate levels along the Alzheimer's disease continuum and associations with blood-brain barrier integrity, age, cognition, and biomarkers. Alzheimer's Research and Therapy, 2022, 14, 61.	6.2	9
3484	Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults. Neurobiology of Aging, 2022, 116, 80-91.	3.1	5
3485	Cerebrospinal Fluid sTREM2 Has Paradoxical Association with Brain Structural Damage Rate in Early- and Late-Stage Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 88, 117-126.	2.6	1
3486	Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population. ACS Chemical Neuroscience, 2022, 13, 1558-1565.	3.5	7
3487	Biomarkers for Alzheimer's Disease in the Current State: A Narrative Review. International Journal of Molecular Sciences, 2022, 23, 4962.	4.1	21
3488	Mild Traumatic Brain Injury Is Related to Elevated Cerebrospinal Fluid Tau in Alzheimer's Disease Dementia. Journal of Alzheimer's Disease, 2022, 87, 1491-1496.	2.6	1
3489	Biomarker modeling of Alzheimer's disease using PET-based Braak staging. Nature Aging, 2022, 2, 526-535.	11.6	73
3490	The Relationship Between Muscle Strength and Cognitive Performance Across Alzheimer's Disease Clinical Continuum. Frontiers in Neurology, 2022, 13, .	2.4	12
3491	Associations Between Dietary Patterns and Neuroimaging Markers: A Systematic Review. Frontiers in Nutrition, 2022, 9, 806006.	3.7	8
3492	How can we define the presymptomatic C9orf72 disease in 2022? An overview on the current definitions of preclinical and prodromal phases. Revue Neurologique, 2022, 178, 426-436.	1.5	2
3493	Translation of Research on Sarcopenia Into Clinical Practice. Journal of the American Medical Directors Association, 2022, 23, 705-706.	2.5	0
3494	Nonlocal models in the analysis of brain neurodegenerative protein dynamics with application to Alzheimer's disease. Scientific Reports, 2022, 12, 7328.	3.3	9
3495	Disentangling Alzheimer's disease neurodegeneration from typical brain ageing using machine learning. Brain Communications, 2022, 4, .	3.3	12
3496	Pathogenic tau recruits wild-type tau into brain inclusions and induces gut degeneration in transgenic SPAM mice. Communications Biology, 2022, 5, 446.	4.4	4
3497	Effect of Time to Detection on the Measured Concentrations of Blood Proteins Associated with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2022, 12, 82-89.	1.3	1

~		_	
	ON		DT
CHAH		ILEPU	ואי

#	Article	IF	CITATIONS
3498	β-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer's disease and predicts cerebral amyloidosis. Alzheimer's Research and Therapy, 2022, 14, 66.	6.2	15
3499	The Role of Cerebrospinal Fluid Biomarkers in Dementia and Other Related Neurodegenerative Disorders. Brain Sciences, 2022, 12, 627.	2.3	2
3500	Common Fatal Neurodegenerative Diseases Revisited: Beyond Age, Comorbidities, and Devastating Terminal Neuropathology There Is Hope With Prevention. Frontiers in Neurology, 2022, 13, .	2.4	5
3501	Abnormal Dynamic Functional Networks in Subjective Cognitive Decline and Alzheimer's Disease. Frontiers in Computational Neuroscience, 2022, 16, 885126.	2.1	5
3502	Rapidly progressive dementias — aetiologies, diagnosis and management. Nature Reviews Neurology, 2022, 18, 363-376.	10.1	30
3503	Tau-PET-based biological staging of Alzheimer's disease in vivo. Nature Aging, 0, , .	11.6	0
3504	Data-Driven Analyses of Longitudinal Hippocampal Imaging Trajectories: Discrimination and Biomarker Prediction of Change Classes. Journal of Alzheimer's Disease, 2022, , 1-19.	2.6	1
3505	Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy. Brain, 2022, 145, 3546-3557.	7.6	15
3506	Dementia-Specific Nursing Care Competencies for Nursing Education and Long-Term Care Practice. Nursing Clinics of North America, 2022, , .	1.5	0
3507	Effects of different kinds of anti-Alzheimer's disease drugs on cognitive improvement: protocol for a systematic review and network meta-analysis of phase III clinical trials. Systematic Reviews, 2022, 11, 84.	5.3	2
3508	Combining Multiple Factors to Predict Alzheimer's Disease. Neuroscience Bulletin, 2022, 38, 969-972.	2.9	1
3509	The aging immune system in Alzheimer's and Parkinson's diseases. Seminars in Immunopathology, 2022, 44, 649-657.	6.1	13
3510	Multimer Detection System-Oligomerized Amyloid Beta (MDS-OAβ): A Plasma-Based Biomarker Differentiates Alzheimer's Disease from Other Etiologies of Dementia. International Journal of Alzheimer's Disease, 2022, 2022, 1-6.	2.0	3
3511	Divergent magnetic resonance imaging atrophy patterns in Alzheimer's disease and primary age-related tauopathy. Neurobiology of Aging, 2022, 117, 1-11.	3.1	6
3512	PET Imaging of Dementia. Clinical Nuclear Medicine, 2022, 47, 763-773.	1.3	7
3513	Amyloid, cerebrovascular disease, and neurodegeneration biomarkers are associated with cognitive trajectories in a racially and ethnically diverse, community-based sample. Neurobiology of Aging, 2022, 117, 83-96.	3.1	3
3514	Neuronal ER-Signalosome Proteins as Early Biomarkers in Prodromal Alzheimer's Disease Independent of Amyloid-β Production and Tau Phosphorylation. Frontiers in Molecular Neuroscience, 2022, 15, .	2.9	6
3515	Biomarker A+Tâ^': is this Alzheimer's disease or not? A combined CSF and pathology study. Brain, 2023, 146, 1166-1174.	7.6	12

#	Article	IF	CITATIONS
3516	Diagnostic performance of hippocampal volumetry in Alzheimer's disease or mild cognitive impairment: a meta-analysis. European Radiology, 2022, 32, 6979-6991.	4.5	6
3517	Investigation of Whole and Glandular Saliva as a Biomarker for Alzheimer's Disease Diagnosis. Brain Sciences, 2022, 12, 595.	2.3	9
3518	Phosphoâ€specific plasma pâ€ŧau181 assay detects clinical as well as asymptomatic Alzheimer's disease. Annals of Clinical and Translational Neurology, 2022, 9, 734-746.	3.7	11
3519	The cross-sectional and longitudinal relationship of diabetic retinopathy to cognitive impairment: a systematic review and meta-analysis. Eye, 2023, 37, 220-227.	2.1	3
3520	Investigating the Association Between Polygenic Risk Scores for Alzheimer's Disease With Cognitive Performance and Intrinsic Functional Connectivity in Healthy Adults. Frontiers in Aging Neuroscience, 2022, 14, .	3.4	0
3521	Chronic Ethanol Causes Persistent Increases in Alzheimer's Tau Pathology in Female 3xTg-AD Mice: A Potential Role for Lysosomal Impairment. Frontiers in Behavioral Neuroscience, 2022, 16, .	2.0	7
3522	Circulating micro-RNAs Differentially Expressed in Korean Alzheimer's Patients With Brain Aβ Accumulation Activate Amyloidogenesis. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 292-303.	3.6	2
3523	Assisting dementia diagnosis through the electrochemical immunosensing of glial fibrillary acidic protein. Talanta, 2022, 246, 123526.	5.5	4
3524	Brain simulation augments machineâ€learning–based classification of dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	10
3525	Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	28
3526	Naturally-Occurring Antibodies Against Bim are Decreased in Alzheimer's Disease and Attenuate AD-type Pathology in a Mouse Model. Neuroscience Bulletin, 2022, , .	2.9	3
3527	Accelerated atrophy in dopaminergic targets and medial temporo-parietal regions precedes the onset of delusions in patients with Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 2023, 273, 229-241.	3.2	5
3528	Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217. Alzheimer's Research and Therapy, 2022, 14, 67.	6.2	18
3529	Loss of speech and functional impairment in Alzheimer's disease-related primary progressive aphasia: predictive factors of decline. Neurobiology of Aging, 2022, 117, 59-70.	3.1	6
3530	The association of enlarged perivascular space with microglia-related inflammation and Alzheimer's pathology in cognitively normal elderly. Neurobiology of Disease, 2022, 170, 105755.	4.4	15
3531	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nature Reviews Neurology, 2022, 18, 400-418.	10.1	99
3532	Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data. Neurobiology of Aging, 2022, 117, 212-221.	3.1	4
3533	Treatment effects on event-related EEG potentials and oscillations in Alzheimer's disease. International Journal of Psychophysiology, 2022, 177, 179-201.	1.0	7
#	Article	IF	CITATIONS
------	---	-----	-----------
3534	Alzheimer disease neuropathology in a patient previously treated with aducanumab. Acta Neuropathologica, 2022, 144, 143-153.	7.7	18
3535	Autosomal dominant and sporadic late onset Alzheimer's disease share a common <i>in vivo</i> pathophysiology. Brain, 2022, 145, 3594-3607.	7.6	20
3536	Aberrant topological organization and age-related differences in the human connectome in subjective cognitive decline byÂusing regional morphology from magnetic resonance imaging. Brain Structure and Function, 2022, 227, 2015-2033.	2.3	6
3537	The Association Between Acquired Color Deficiency and PET Imaging of Neurodegeneration in Mild Cognitive Impairment and Alzheimer Disease. , 2022, 63, 20.		1
3538	Pratique de l'annonce du diagnostic de la maladie d'Alzheimer. La Presse Médicale Formation, 2022, 3, 234-234.	0.1	0
3539	A novel approach to type 3 diabetes mechanism: The interplay between noncoding RNAs and insulin signaling pathway in Alzheimer's disease. Journal of Cellular Physiology, 2022, 237, 2838-2861.	4.1	4
3540	Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment. GeroScience, 2022, 44, 2319-2336.	4.6	8
3541	The Current Landscape of Prevention Trials in Dementia. Neurotherapeutics, 2022, 19, 228-247.	4.4	10
3542	<i>APOE ɛ4</i> dose associates with increased brain iron and β-amyloid via blood–brain barrier dysfunction. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 772-778.	1.9	19
3543	Brain Metabolism and Amyloid Load in Individuals With Subjective Cognitive Decline or Pre–Mild Cognitive Impairment. Neurology, 2022, 99, .	1.1	5
3544	Determining Vascular Risk Factors for Dementia and Dementia Risk Prediction Across Mid- to Later Life. Neurology, 2022, 99, .	1.1	23
3545	Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia. Neurology, 2022, , 10.1212/WNL.000000000000200582.	1.1	0
3546	Single-Cell Radiotracer Allocation via Immunomagnetic Sorting to Disentangle PET Signals at Cellular Resolution. Journal of Nuclear Medicine, 2022, 63, 1459-1462.	5.0	8
3547	Phenotypic Displays of Cholinergic Enzymes Associate With Markers of Inflammation, Neurofibrillary Tangles, and Neurodegeneration in Pre- and Early Symptomatic Dementia Subjects. Frontiers in Aging Neuroscience, 2022, 14, .	3.4	1
3548	Cross-sectional associations of CSF tau levels with Rey's AVLT: A recency ratio study Neuropsychology, 2023, 37, 628-635.	1.3	4
3550	Comparison of Three Automated Approaches for Classification of Amyloid-PET Images. Neuroinformatics, 2022, 20, 1065-1075.	2.8	1
3551	Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3797-3808.	6.4	6
3552	Association of Long-term Exposure to Ambient Air Pollution With Cognitive Decline and Alzheimer's Disease–Related Amyloidosis. Biological Psychiatry, 2023, 93, 780-789.	1.3	15

#	Article	IF	CITATIONS
3553	Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study. Alzheimer's Research and Therapy, 2022, 14, .	6.2	12
3555	What plasma biomarkers tell us about hippocampal microstructural changes in Alzheimer's disease. Brain, 0, , .	7.6	0
3556	CSF phosphorylated tau as an indicator of subsequent tau accumulation. Neurobiology of Aging, 2022, 117, 189-200.	3.1	4
3557	A tough trek in the development of an anti-amyloid therapy for Alzheimer's disease: Do we see hope in the distance?. Journal of the Neurological Sciences, 2022, 438, 120294.	0.6	9
3558	Association between Cerebral Small Vessel and Alzheimer's Disease. Journal of the Korean Society of Radiology, 2022, 83, 486.	0.2	0
3559	Brain MRI-Based Artificial Intelligence Software in Patients with Neurodegenerative Diseases: Current Status. Journal of the Korean Society of Radiology, 2022, 83, 473.	0.2	2
3560	Effect of masupirdine (SUVNâ€502) on cognition in patients with moderate Alzheimer's disease: A randomized, doubleâ€blind, phase 2, proofâ€ofâ€concept study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	6
3561	Identifying candidate genes and drug targets for Alzheimer's disease by an integrative network approach using genetic and brain region-specific proteomic data. Human Molecular Genetics, 2022, 31, 3341-3354.	2.9	3
3562	β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease. Neurology, 2022, 99, .	1.1	3
3563	Brain alterations in the early Alzheimer's continuum with amyloid-β, tau, glial and neurodegeneration CSF markers. Brain Communications, 2022, 4, .	3.3	12
3564	A Prospective Viewpoint on Neurological Diseases and Their Biomarkers. Molecules, 2022, 27, 3516.	3.8	9
3566	Al-Based Predictive Modelling of the Onset and Progression of Dementia. Smart Cities, 2022, 5, 700-714.	9.4	2
3567	Neuropsychological Performance Is Correlated With Tau Protein Deposition and Glucose Metabolism in Patients With Alzheimer's Disease. Frontiers in Aging Neuroscience, 0, 14, .	3.4	5
3568	Survey Results of Speech-Language Pathologists Working With Cognitive-Communication Disorders: Improving Practices for Mild Cognitive Impairment and Early-Stage Dementia From Alzheimer's Disease. American Journal of Speech-Language Pathology, 2022, 31, 1653-1671.	1.8	3
3569	Impact of APOE ε4 Carrier Status on Associations Between Subthreshold, Positive Amyloid-β Deposition, Brain Function, and Cognitive Performance in Cognitively Normal Older Adults: A Prospective Study. Frontiers in Aging Neuroscience, 0, 14, .	3.4	2
3570	Drug Distribution in Brain and Cerebrospinal Fluids in Relation to IC50 Values in Aging and Alzheimer's Disease, Using the Physiologically Based LeiCNS-PK3.0 Model. Pharmaceutical Research, 2022, 39, 1303-1319.	3.5	3
3571	Increasing Brain Gamma Activity Improves Episodic Memory and Restores Cholinergic Dysfunction in Alzheimer's Disease. Annals of Neurology, 2022, 92, 322-334.	5.3	38
3572	Non-invasive visualization of amyloid-beta deposits in Alzheimer amyloidosis mice using magnetic resonance imaging and fluorescence molecular tomography. Biomedical Optics Express, 2022, 13, 3809.	2.9	8

#	Article	IF	CITATIONS
3574	Decreased Cerebral Amyloid-β Depositions in Patients With a Lifetime History of Major Depression With Suspected Non-Alzheimer Pathophysiology. Frontiers in Aging Neuroscience, 0, 14, .	3.4	4
3575	FMNL2 regulates gliovascular interactions and is associated with vascular risk factors and cerebrovascular pathology in Alzheimer's disease. Acta Neuropathologica, 2022, 144, 59-79.	7.7	19
3576	Lower Posterior Cingulate N-acetylaspartate to Creatine Level in Early Detection of Biologically Defined Alzheimer's Disease. Brain Sciences, 2022, 12, 722.	2.3	5
3577	Role of Vaginal Mucosa, Host Immunity and Microbiota in Vulvovaginal Candidiasis. Pathogens, 2022, 11, 618.	2.8	15
3578	Altered excitatory and inhibitory neuronal subpopulation parameters are distinctly associated with tau and amyloid in Alzheimer's disease. ELife, 0, 11, .	6.0	45
3579	Structural covariance changes in major cortico-basal ganglia and thalamic networks in amyloid-positive patients with white matter hyperintensities. Neurobiology of Aging, 2022, 117, 117-127.	3.1	2
3580	Diagnosis of Idiopathic Premature Ovarian Failure by Color Doppler Ultrasound under the Intelligent Segmentation Algorithm. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-10.	1.3	5
3581	Analysis of Genetic Association Between ABCA7 Polymorphism and Alzheimer's Disease Risk in the Southern Chinese Population. Frontiers in Aging Neuroscience, 0, 14, .	3.4	3
3584	A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. Neurology, 2022, 99, .	1.1	8
3585	Increasing the Cognitive Screening Efficiency of Global Phase III Trials in Early Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2022, 36, 185-191.	1.3	1
3586	α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies. Neurology, 2022, 99, 195-205.	1.1	45
3587	The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review. Journal of Nuclear Medicine, 2022, 63, 13S-19S.	5.0	34
3588	Integrated analysis of direct and proxy genome wide association studies highlights polygenicity of Alzheimer's disease outside of the APOE region. PLoS Genetics, 2022, 18, e1010208.	3.5	10
3589	Effects of Interventions on Cerebral Perfusion in the Alzheimer's Disease Spectrum: A Systematic Review. Ageing Research Reviews, 2022, , 101661.	10.9	5
3590	Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q. Science Translational Medicine, 2022, 14, .	12.4	38
3591	Cognitive Decline in Older People with Multiple Sclerosis—A Narrative Review of the Literature. Geriatrics (Switzerland), 2022, 7, 61.	1.7	2
3593	Imaging of Synaptic Density in Neurodegenerative Disorders. Journal of Nuclear Medicine, 2022, 63, 60S-67S.	5.0	29
3594	A comparison of advanced semi-quantitative amyloid PET analysis methods. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4097-4108.	6.4	4

#	Article	IF	CITATIONS
3595	Global estimates on the number of persons across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2023, 19, 658-670.	0.8	146
3596	Tau PET Imaging in Neurodegenerative Disorders. Journal of Nuclear Medicine, 2022, 63, 20S-26S.	5.0	26
3597	Cross-Sectional and Longitudinal Hippocampal Atrophy, Not Cortical Thinning, Occurs in Amyloid-Negative, p-Tau-Positive, Older Adults With Non-Amyloid Pathology and Mild Cognitive Impairment. , 2022, 1, .		0
3598	Platelet-Derived Amyloid-β Protein Precursor as a Biomarker of Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 88, 589-599.	2.6	4
3599	Different Profiles of Spatial Navigation Deficits In Alzheimer's Disease Biomarker-Positive Versus Biomarker-Negative Older Adults With Amnestic Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 0, 14, .	3.4	11
3600	Face recognition from research brain PET: An unexpected PET problem. NeuroImage, 2022, 258, 119357.	4.2	6
3601	Future Directions in Molecular Imaging of Neurodegenerative Disorders. Journal of Nuclear Medicine, 2022, 63, 68S-74S.	5.0	7
3602	<sup>18</sup> F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies. Journal of Nuclear Medicine, 2022, 63, 2S-12S.	5.0	27
3603	A new generation of AD biomarkers: 2019 to 2021. Ageing Research Reviews, 2022, 79, 101654.	10.9	14
3605	Description of the Method for Evaluating Digital Endpoints in Alzheimer Disease Study: Protocol for an Exploratory, Cross-sectional Study. JMIR Research Protocols, 2022, 11, e35442.	1.0	3
3606	Recent Updates on PET Imaging in Neurodegenerative Diseases. Journal of the Korean Society of Radiology, 2022, 83, 453.	0.2	1
3607	Metabolic brain pattern in dementia with Lewy bodies: Relationship to Alzheimer's disease topography. NeuroImage: Clinical, 2022, 35, 103080.	2.7	13
3608	Everyday Functioning and Entorhinal and Inferior Temporal Tau Burden in Cognitively Normal Older Adults. journal of prevention of Alzheimer's disease, The, 0, , .	2.7	3
3609	Histoire naturelle et diagnostic deÂla maladie d'Alzheimer. , 2022, , 143-161.		0
3610	Cerebral Aβ deposition in an Aβ-precursor protein-transgenic rhesus monkey. Aging Brain, 2022, 2, 100044.	1.3	2
3611	Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer's disease. European Radiology, 2022, 32, 7789-7799.	4.5	3
3612	Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 6922.	4.1	2
3613	Genetic Variants Associated With Subjective Cognitive Decline in Patients With Migraine. Frontiers in Aging Neuroscience, 0, 14, .	3.4	3

#	Article	IF	CITATIONS
3614	Assessment of Instrumental Activities of Daily Living in Preclinical Alzheimer Disease. OTJR Occupation, Participation and Health, 0, , 153944922211007.	0.8	0
3615	The Association of CSF sTREM2 With Cognitive Decline and Its Dynamic Change in Parkinson's Disease: Analysis of the PPMI Cohort. Frontiers in Aging Neuroscience, 0, 14, .	3.4	8
3617	Plasma Levels of Tissue-Type Plasminogen Activator (tPA) in Normal Aging and Alzheimer's Disease: Links With Cognition, Brain Structure, Brain Function and Amyloid Burden. Frontiers in Aging Neuroscience, 0, 14, .	3.4	1
3618	Acute OSA Impacts Diurnal Alzheimer's Biomarkers through Nocturnal Hypoxemia and State Transitions. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1039-1042.	5.6	4
3619	Disclosing Alzheimer Disease Biomarker Results to Research Participants. JAMA Neurology, 2022, 79, 645.	9.0	11
3620	The Value of Neuroimaging in Dementia Diagnosis. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 800-821.	0.8	2
3621	Brain Structural and Functional Changes in Cognitive Impairment Due to Alzheimer's Disease. Frontiers in Psychology, 0, 13, .	2.1	14
3623	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected nonâ€Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2023, 19, 807-820.	0.8	4
3624	Application of the Amyloid/Tau/Neurodegeneration Framework in Cognitively Intact Adults: The <scp>CABLE</scp> Study. Annals of Neurology, 2022, 92, 439-450.	5.3	10
3625	Longitudinal evaluation of neuroinflammation and oxidative stress in a mouse model of Alzheimer disease using positron emission tomography. Alzheimer's Research and Therapy, 2022, 14, .	6.2	6
3626	Alzheimer Disease. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 648-675.	0.8	6
3627	Associations of Vascular Risk and Amyloid Burden with Subsequent Dementia. Annals of Neurology, 2022, 92, 607-619.	5.3	10
3629	Natural Pattern of Cognitive Aging. Journal of Alzheimer's Disease, 2022, 88, 1147-1155.	2.6	3
3630	Differential Patterns of Domain-Specific Cognitive Complaints and Awareness Across the Alzheimer's Disease Spectrum. Frontiers in Aging Neuroscience, 0, 14, .	3.4	4
3633	Cortical excitability and plasticity in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis of transcranial magnetic stimulation studies. Ageing Research Reviews, 2022, 79, 101660.	10.9	15
3634	<scp>TDP</scp> â€43 Pathology Exacerbates Cognitive Decline in Primary <scp>Ageâ€Related</scp> Tauopathy. Annals of Neurology, 2022, 92, 425-438.	5.3	12
3635	A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer's dementia: China Aging and Neurodegenerative Initiative (CANDI) study. Alzheimer's and Dementia, 2023, 19, 749-760.	0.8	20
3636	Case Report: Alzheimer's Dementia Associated With Cerebrospinal Fluid Neurochondrin Autoantibodies. Frontiers in Neurology, 0, 13, .	2.4	5

#	Article	IF	CITATIONS
3637	Amyloid-β impairs mitochondrial dynamics and autophagy in Alzheimer's disease experimental models. Scientific Reports, 2022, 12, .	3.3	22
3638	Pure word deafness: a case report of an atypical manifestation of Alzheimer's disease. Neurological Sciences, 2022, 43, 5275-5279.	1.9	2
3639	Descriptive Epidemiology of Neurodegenerative Diseases: What Are the Critical Questions?. Neuroepidemiology, 2022, 56, 309-318.	2.3	13
3640	Neuropathology of Dementia Disorders. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 834-851.	0.8	11
3641	Predictive Scale for Amyloid PET Positivity Based on Clinical and MRI Variables in Patients with Amnestic Mild Cognitive Impairment. Journal of Clinical Medicine, 2022, 11, 3433.	2.4	3
3642	APOEÎμ4 Genotype Is Related to Brain Amyloid Among Mexican Americans in the HABS-HD Study. Frontiers in Neurology, 0, 13, .	2.4	4
3643	CT-Detected MTA Score Related to Disability and Behavior in Older People with Cognitive Impairment. Biomedicines, 2022, 10, 1381.	3.2	0
3645	Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. International Journal of Molecular Sciences, 2022, 23, 6891.	4.1	13
3646	The clinical and mechanistic roles of bile acids in depression, Alzheimer's disease, and stroke. Proteomics, 2022, 22, .	2.2	14
3647	Mouse Models of Alzheimerâ $\in$ Ms Disease. Frontiers in Molecular Neuroscience, 0, 15, .	2.9	50
3648	B Lymphocytes in Alzheimer's Disease—A Comprehensive Review. Journal of Alzheimer's Disease, 2022, 88, 1241-1262.	2.6	5
3650	The Dark Side of Alzheimer's Disease: Neglected Physiological Biomarkers of Brain Hyperexcitability and Abnormal Consciousness Level. Journal of Alzheimer's Disease, 2022, 88, 801-807.	2.6	8
3651	Molecular PET Imaging in Alzheimer's Disease. Journal of Medical and Biological Engineering, 2022, 42, 301-317.	1.8	6
3652	Staging of Alzheimer's disease: past, present, and future perspectives. Trends in Molecular Medicine, 2022, 28, 726-741.	6.7	36
3653	Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis. European Archives of Psychiatry and Clinical Neuroscience, 2023, 273, 243-252.	3.2	8
3654	Spatial Distribution and Hierarchical Clustering of β-Amyloid and Glucose Metabolism in Alzheimer's Disease. Frontiers in Aging Neuroscience, 0, 14, .	3.4	1
3655	The Associations of Cerebrospinal Fluid Ferritin with Neurodegeneration and Neuroinflammation Along the Alzheimer's Disease Continuum. Journal of Alzheimer's Disease, 2022, 88, 1115-1125.	2.6	6
3657	Alzheimer's Disease CSF Biomarker Profiles in Idiopathic Normal Pressure Hydrocephalus. Journal of Personalized Medicine, 2022, 12, 935.	2.5	4

#	Article	IF	CITATIONS
3658	Alzheimer's disease pattern derived from relative cerebral flow as an alternative for the metabolic pattern using SSM/PCA. EJNMMI Research, 2022, 12, .	2.5	4
3659	A Novel Explainability Approach for Technology-Driven Translational Research on Brain Aging. Journal of Alzheimer's Disease, 2022, , 1-11.	2.6	2
3660	Effect of cerebellum stimulation on cognitive recovery in patients with Alzheimer disease: A randomized clinical trial. Brain Stimulation, 2022, 15, 910-920.	1.6	19
3661	The Perspective of Exosomal MicroRNAs as Biomarkers for Preclinical Alzheimer's Disease. Biological Psychiatry, 2022, 92, 5-7.	1.3	1
3663	Early phase amyloid PET or "two birds with one Stone― Revista Espanola De Medicina Nuclear E Imagen Molecular, 2022, 41, 213-214.	0.2	0
3664	Abnormal Functional Connectivity of Thalamic Subdivisions in Alzheimer's Disease: A Functional Magnetic Resonance Imaging Study. Neuroscience, 2022, 496, 73-82.	2.3	6
3665	Promising Blood Biomarkers for Clinical Use in Alzheimer's Disease: A Focused Update. Journal of		

#	Article	IF	CITATIONS
3677	Neurodegenerative and Cerebrovascular Brain Pathologies Are Differentially Associated With Declining Grip Strength and Gait In Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 504-513.	3.6	6
3678	Item-Level Story Recall Predictors of Amyloid-Beta in Late Middle-Aged Adults at Increased Risk for Alzheimer's Disease. Frontiers in Psychology, 0, 13, .	2.1	4
3679	Traumatic brain injury and postâ€ŧraumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers. Alzheimer's and Dementia, 2023, 19, 884-895.	0.8	13
3681	Tau as a Biomarker of Neurodegeneration. International Journal of Molecular Sciences, 2022, 23, 7307.	4.1	28
3682	Metacognition, cortical thickness, and tauopathy in aging. Neurobiology of Aging, 2022, 118, 44-54.	3.1	3
3683	Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline. Brain, 2022, 145, 2823-2833.	7.6	22
3684	Escalation of Tau Accumulation after a Traumatic Brain Injury: Findings from Positron Emission Tomography. Brain Sciences, 2022, 12, 876.	2.3	2
3685	Identification and validation of Alzheimer's disease-related metabolic brain pattern in biomarker confirmed Alzheimer's dementia patients. Scientific Reports, 2022, 12, .	3.3	13
3686	Novel PSEN1 (P284S) Mutation Causes Alzheimer's Disease with Cerebellar Amyloid β-Protein Deposition. Current Alzheimer Research, 2022, 19, 523-529.	1.4	1
3687	Clinical Spectrum of Tauopathies. Frontiers in Neurology, 0, 13, .	2.4	9
3688	Perceptions of Research Burden and Retention Among Participants in ADRC Cohorts. Alzheimer Disease and Associated Disorders, 0, Publish Ahead of Print, .	1.3	5
3689	An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer's disease. Nature Aging, 2022, 2, 616-634.	11.6	11
3690	Amylin and Secretases in the Pathology and Treatment of Alzheimer's Disease. Biomolecules, 2022, 12, 996.	4.0	5
3691	Screening of Human Circular RNAs as Biomarkers for Early Onset Detection of Alzheimer's Disease. Frontiers in Neuroscience, 0, 16, .	2.8	2
3692	Introducing a gatekeeping system for amyloid status assessment in mild cognitive impairment. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	6.4	0
3693	Non-tremor motor dysfunction in Lewy body dementias is associated with AD biomarkers. Parkinsonism and Related Disorders, 2022, 100, 33-36.	2.2	5
3694	RNA-binding protein ELAVL4/HuD ameliorates Alzheimer's disease-related molecular changes in human iPSC-derived neurons. Progress in Neurobiology, 2022, 217, 102316.	5.7	6
3695	The complex relationship of air pollution and neighborhood socioeconomic status and their association with cognitive decline. Environment International, 2022, , 107416.	10.0	10

#	Article	IF	CITATIONS
3696	Subjective Cognitive Decline: Is a Resilient Personality Protective Against Progression to Objective Cognitive Impairment? Findings from Two Community-Based Cohort Studies. Journal of Alzheimer's Disease, 2022, 89, 87-105.	2.6	4
3697	A Validation Study of the Hong Kong Brief Cognitive Test for Screening Patients with Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 88, 1523-1532.	2.6	3
3698	Upregulated Blood miR-150-5p in Alzheimer's Disease Dementia Is Associated with Cognition, Cerebrospinal Fluid Amyloid-β, and Cerebral Atrophy. Journal of Alzheimer's Disease, 2022, 88, 1567-1584.	2.6	2
3699	Transcranial magnetic stimulation treatment in Alzheimer's disease: a meta-analysis of its efficacy as a function of protocol characteristics and degree of personalization. Journal of Neurology, 2022, 269, 5283-5301.	3.6	9
3701	Pharmacological Properties of 4′, 5, 7-Trihydroxyflavone (Apigenin) and Its Impact on Cell Signaling Pathways. Molecules, 2022, 27, 4304.	3.8	20
3702	Extracellular vesicle biomarkers for cognitive impairment in Parkinson's disease. Brain, 2023, 146, 195-208.	7.6	35
3703	Cerebrospinal Fluid Synaptosomal-Associated Protein 25 Levels in Patients with Alzheimer's Disease: A Meta-Analysis. Journal of Alzheimer's Disease, 2022, , 1-12.	2.6	0
3704	Effects of combined cognitive and physical intervention on enhancing cognition in older adults with and without mild cognitive impairment: A systematic review and meta-analysis. Frontiers in Aging Neuroscience, 0, 14, .	3.4	8
3705	Frontal Atrophy and Executive Dysfunction Relate to Complex Numbers Impairment in Progressive Supranuclear Palsy. Journal of Alzheimer's Disease, 2022, 88, 1553-1566.	2.6	2
3706	The Role of Monoaminergic Tones and Brain Metabolism in Cognition in De Novo Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 1945-1955.	2.8	1
3707	Multiscale optical and optoacoustic imaging of amyloid-β deposits in mice. Nature Biomedical Engineering, 2022, 6, 1031-1044.	22.5	39
3708	Neuropsychological Decline Stratifies Dementia Risk in Cognitively Unimpaired and Impaired Older Adults. Frontiers in Aging Neuroscience, 0, 14, .	3.4	0
3709	The TAS Test project: a prospective longitudinal validation of new online motor-cognitive tests to detect preclinical Alzheimer's disease and estimate 5-year risks of cognitive decline and dementia. BMC Neurology, 2022, 22, .	1.8	8
3710	A Comparison of Operational Definitions for Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2022, 88, 1663-1678.	2.6	4
3711	Altered Balance of Reelin Proteolytic Fragments in the Cerebrospinal Fluid of Alzheimer's Disease Patients. International Journal of Molecular Sciences, 2022, 23, 7522.	4.1	3
3712	Blood-based AÎ <sup>2</sup> 42 increases in the earliest pre-pathological stage before decreasing with progressive amyloid pathology in preclinical models and human subjects: opening new avenues for prevention. Acta Neuropathologica, 2022, 144, 489-508.	7.7	6
3713	P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles. Alzheimer's Research and Therapy, 2022, 14, .	6.2	5
3714	Identification and validation of a gray matter volume network in Alzheimer's disease. Journal of the Neurological Sciences, 2022, 440, 120344.	0.6	0

ARTICLE IF CITATIONS From Subjective Cognitive Decline to Mild Cognitive Impairment to Dementia: Clinical and Capacity 3715 0 1.6 Assessment Considerations. Psychological Injury and Law, 0, , . Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up 3716 pattern. Molecular Psychiatry, 2022, 27, 4244-4251. Blood extracellular vesicles carrying synaptic function―and brainâ€related proteins as potential 3717 0.8 21 biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 909-923. Does Loss of Integrity of the Cingulum Bundle Link Amyloid-Î<sup>2</sup> Accumulation and Neurodegeneration in 3718 Alzheimer's Disease?. Journal of Alzheimer's Diseasé, 2022, 89, 39-49. Sleep Quality and Aging: A Systematic Review on Healthy Older People, Mild Cognitive Impairment and 3719 2.6 35 Alzheimer's Disease. Intérnational Journal of Environmental Research and Public Health, 2022, 19, 8457. Findings of <scp> <sup>18</sup> Fâ€Pl </scp> â€2620 tau <scp>PET</scp> imaging in patients with Alzheimer's disease and healthy controls in relation to the plasma Pâ€tau181 levels in a Japanese sample. 2.3 Neuropsychopharmacology Reports, 0, , . Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer's 3721 6.4 16 continuum. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4567-4579. A Multimodal Neuroimaging and Neuropsychological Study of Visual Hallucinations in Alzheimerâ∈™s 2.6 Disease. Journal of Alzheimer's Disease, 2022, 89, 133-149. Cognitive Performance at Time of AD Diagnosis: A Clinically Augmented Register-Based Study. 3723 2.1 0 Frontiers in Psychology, 0, 13, . <scp>TREM2</scp>â€induced activation of microglia contributes to synaptic integrity in cognitively 3724 4.1 intact aged individuals with Alzheimer's neuropathology. Brain Pathology, 2023, 33, Pharmacotherapy for Alzheimer's disease: what's new on the horizon?. Expert Opinion on 3725 1 1.8 Pharmacotherapy, 0, , 1-19. Cerebral amyloid angiopathy criteria: the next generation. Lancet Neurology, The, 2022, 21, 674-676. 10.2 The road to precision medicine: Eliminating the "One Size Fits All―approach in Alzheimer's disease. 3727 5.6 17 Biomedicine and Pharmacotherapy, 2022, 153, 113337. Hemodynamic response function (HRF) as a novel brain marker: Applications in subjective cognitive 3728 4.5 decline (SCD). Neuroscience Informatics, 2022, 2, 100093. 3729 Alzheimer diseases., 2023, , 313-336. 3 Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. Frontiers in Aging Neuroscience, 0, 14, . Geriatricians' Perspectives on the Multiple Dimensions of Utility of Genetic Testing for Alzheimer's 3731 2.6 3 Disease: A Qualitative Study. Journal of Alzheimer's Disease, 2022, 90, 1011-1019. Targeted BACE-1 inhibition in microglia enhances amyloid clearance and improved cognitive performance. Science Advances, 2022, 8, .

#	Article	IF	CITATIONS
3733	Potential Diagnostic Applications of Multi-Delay Arterial Spin Labeling in Early Alzheimer's Disease: The Chinese Imaging, Biomarkers, and Lifestyle Study. Frontiers in Neuroscience, 0, 16, .	2.8	3
3734	MRI-Visible Perivascular Spaces Associated With Cognitive Impairment in Military Veterans With Traumatic Brain Injury Mediated by CSF P-Tau. Frontiers in Psychiatry, 0, 13, .	2.6	5
3735	Sex-specific effects of microglial activation on Alzheimer's disease proteinopathy in older adults. Brain, 2022, 145, 3536-3545.	7.6	20
3736	Biomarkers for Alzheimer's Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation. Medicina (Lithuania), 2022, 58, 952.	2.0	14
3737	YKL-40 changes are not detected in post-mortem brain of patients with Alzheimer's disease and frontotemporal lobar degeneration. Alzheimer's Research and Therapy, 2022, 14, .	6.2	6
3738	Prospective biomarkers of Alzheimer's disease: A systematic review and meta-analysis. Ageing Research Reviews, 2022, 81, 101699.	10.9	17
3739	Inflammation Disrupts Cognitive Integrity via Plasma Neurofilament Light Chain Coupling Brain Networks in Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 89, 505-518.	2.6	4
3740	Predictive value of phospho-tau/total-tau ratio in amyloid-negative Mild Cognitive Impairment. Neuroscience Letters, 2022, 787, 136811.	2.1	3
3741	Disentangling the effects of Alzheimer's and small vessel disease on white matter fibre tracts. Brain, 2023, 146, 678-689.	7.6	14
3742	Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer's Disease. Pharmaceutics, 2022, 14, 1532.	4.5	3
3743	Amyloidâ€beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years. Alzheimer's and Dementia, 2023, 19, 1020-1028.	0.8	23
3744	Alzheimer's disease: a scoping review of biomarker research and development for effective disease diagnosis. Expert Review of Molecular Diagnostics, 2022, 22, 681-703.	3.1	5
3745	Molecular signatures underlying neurofibrillary tangle susceptibility in Alzheimer's disease. Neuron, 2022, 110, 2929-2948.e8.	8.1	48
3746	Epigenetic Peripheral Biomarkers for Early Diagnosis of Alzheimer's Disease. Genes, 2022, 13, 1308.	2.4	12
3748	A Hierarchical Bayesian Latent Class Model for the Diagnostic Performance of Mini-Mental State Examination and Montreal Cognitive Assessment in Screening Mild Cognitive Impairment Due to Alzheimer's Disease. journal of prevention of Alzheimer's disease, The, 0, , .	2.7	1
3749	From clinical phenotype to proteinopathy: molecular neuroimaging in neurodegenerative dementias. Arquivos De Neuro-Psiquiatria, 2022, 80, 24-35.	0.8	0
3750	Are we ready to use anti-amyloid therapy in Alzheimer's disease?. Arquivos De Neuro-Psiquiatria, 2022, 80, 15-23.	0.8	2
3751	Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment. JAMA Neurology, 2022, 79, 975.	9.0	36

#	Article	IF	CITATIONS
3752	Deletion of Abi3/Gngt2 influences age-progressive amyloid $\hat{I}^2$ and tau pathologies in distinctive ways. Alzheimer's Research and Therapy, 2022, 14, .	6.2	6
3753	Combining Structural with Metabolic Networkbased on PET/MR Imaging to Classify AD Continuum. , 2022, , .		0
3754	Episodic Memory, Hippocampal Volume, and Function for Classification of Mild Cognitive Impairment Patients Regarding Amyloid Pathology. Journal of Alzheimer's Disease, 2022, , 1-12.	2.6	1
3755	Shared mechanisms across the major psychiatric and neurodegenerative diseases. Nature Communications, 2022, 13, .	12.8	48
3756	The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey. Journal of Alzheimer's Disease, 2022, 89, 535-551.	2.6	7
3757	Identifying the regional substrates predictive of Alzheimer's disease progression through a convolutional neural network model and occlusion. Human Brain Mapping, 0, , .	3.6	3
3758	Synaptic Disruption by Soluble Oligomers in Patients with Alzheimer's and Parkinson's Disease. Biomedicines, 2022, 10, 1743.	3.2	6
3759	Long-term test-retest of cerebral [18F]MK-6240 binding and longitudinal evaluation of extracerebral tracer uptake in healthy controls and amnestic MCI patients. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4580-4588.	6.4	2
3760	Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer's disease. Acta Neuropathologica, 2022, 144, 843-859.	7.7	17
3761	Bridging Integrator 1 (BIN1, rs6733839) and Sex Are Moderators of Vascular Health Predictions of Memory Aging Trajectories. Journal of Alzheimer's Disease, 2022, 89, 265-281.	2.6	1
3762	The past, present, and future of research on neuroinflammation-induced mild cognitive impairment: A bibliometric analysis. Frontiers in Aging Neuroscience, 0, 14, .	3.4	3
3763	Associations of multiple visual rating scales based on structural magnetic resonance imaging with disease severity and cerebrospinal fluid biomarkers in patients with Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	3.4	2
3764	Association of Carotid Intima Media Thickening with Future Brain Region Specific Amyloid-β Burden. Journal of Alzheimer's Disease, 2022, , 1-10.	2.6	1
3765	A robust framework to investigate the reliability and stability of explainable artificial intelligence markers of Mild Cognitive Impairment and Alzheimer's Disease. Brain Informatics, 2022, 9, .	3.0	15
3766	[18F]ROStrace detects oxidative stress in vivo and predicts progression of Alzheimer's disease pathology in APP/PS1 mice. EJNMMI Research, 2022, 12, .	2.5	3
3767	Altered visual entrainment in patients with Alzheimer's disease: magnetoencephalography evidence. Brain Communications, 2022, 4, .	3.3	6
3768	Diet, Gut Microbiome, and Cognitive Decline. Current Nutrition Reports, 2022, 11, 643-652.	4.3	15
3769	The Link between Obstructive Sleep Apnea and Neurocognitive Impairment: An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2022, 19, 1245-1256.	3.2	33

#	Article	IF	CITATIONS
3770	Biomarkers for the Diagnosis of Alzheimer's Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria. International Journal of Molecular Sciences, 2022, 23, 8598.	4.1	9
3771	Proteomic Discovery and Validation of Novel Fluid Biomarkers for Improved Patient Selection and Prediction of Clinical Outcomes in Alzheimer's Disease Patient Cohorts. Proteomes, 2022, 10, 26.	3.5	9
3772	Cutaneous amyloid is a biomarker in early <scp>ATTRv</scp> neuropathy and progresses across disease stages. Annals of Clinical and Translational Neurology, 2022, 9, 1370-1383.	3.7	10
3773	An accurate fully automated panel of plasma biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 1204-1215.	0.8	45
3774	Development and validation of immune-based biomarkers and deep learning models for Alzheimer's disease. Frontiers in Genetics, 0, 13, .	2.3	5
3775	Cerebrospinal fluid growth-associated protein 43 levels in patients with progressive and stable mild cognitive impairment. Aging Clinical and Experimental Research, 2022, 34, 2399-2406.	2.9	2
3776	A + T ± status across MCI and dementia due to AD: a clinic-based, retrospective study. Neurolo Sciences, 0, , .	ogical 1.9	1
3777	Report of two pedigrees with heterozygous <i>HTRA1</i> variantsâ€related cerebral small vessel disease and literature review. Molecular Genetics & Genomic Medicine, 0, , .	1.2	2
3778	Statins and cognition: Modifying factors and possible underlying mechanisms. Frontiers in Aging Neuroscience, 0, 14, .	3.4	11
3779	Amyloid-Î <sup>2</sup> levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy. Brain, 2022, 145, 4032-4041.	7.6	12
3780	Discriminating Aging Cognitive Decline Spectrum Using PET and Magnetic Resonance Image Features. Journal of Alzheimer's Disease, 2022, 89, 977-991.	2.6	1
3781	Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	3.4	7
3782	Recent updates in the development of small molecules as potential clinical candidates for Alzheimer's disease: AÂreview. Chemical Biology and Drug Design, 2022, 100, 674-681.	3.2	4
3783	Association of AK4 Protein From Stem Cell–Derived Neurons With Cognitive Reserve. Neurology, 2022, 99, .	1.1	5
3785	Induction of A Disintegrin and Metalloproteinase with Thrombospondin motifs 1 by a rare variant or cognitive activities reduces hippocampal amyloid-β and consequent Alzheimer's disease risk. Frontiers in Aging Neuroscience, 0, 14, .	3.4	3
3786	The characteristics of arterial spin labeling cerebral blood flow in patients with subjective cognitive decline: The Chinese imaging, biomarkers, and lifestyle study. Frontiers in Neuroscience, 0, 16, .	2.8	3
3787	Is liquid biopsy mature enough for the diagnosis of Alzheimer's disease?. Frontiers in Aging Neuroscience, 0, 14, .	3.4	9
3788	Dysfunctional Glucose Metabolism in Alzheimer's Disease Onset and Potential Pharmacological Interventions. International Journal of Molecular Sciences, 2022, 23, 9540.	4.1	25

#	Article	IF	CITATIONS
3790	Evaluating the performance of Bayesian and frequentist approaches for longitudinal modeling: application to Alzheimer's disease. Scientific Reports, 2022, 12, .	3.3	0
3791	Sex differences in earlyâ€onset Alzheimer's disease. European Journal of Neurology, 2022, 29, 3623-3632.	3.3	7
3792	Perspectives and challenges in patient stratification in Alzheimer's disease. Alzheimer's Research and Therapy, 2022, 14, .	6.2	19
3793	A Novel Deep Learning Radiomics Model to Discriminate AD, MCI and NC: An Exploratory Study Based on Tau PET Scans from ADNI. Brain Sciences, 2022, 12, 1067.	2.3	2
3794	Exploring cognitive and brain oxygenation changes over a 1-year period in physically active individuals with mild cognitive impairment: a longitudinal fNIRS pilot study. BMC Geriatrics, 2022, 22, .	2.7	4
3795	Atypical Alzheimer's disease phenotypes with normal or borderline PET biomarker profiles. Journal of Neurology, 2022, 269, 6613-6626.	3.6	3
3796	Associations of sensory and motor function with blood-based biomarkers of neurodegeneration and Alzheimer's disease in midlife. Neurobiology of Aging, 2022, 120, 177-188.	3.1	7
3797	The age-specific pathological changes of $\hat{l}^2$ -amyloid plaques in the cortex and hippocampus of APP/PS1 transgenic AD mice. Neurological Research, 0, , 1-13.	1.3	0
3798	Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach. International Journal of Molecular Sciences, 2022, 23, 9305.	4.1	13
3799	Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 83-86.	1.9	7
3800	Associations Between Sub-Threshold Amyloid-β Deposition, Cortical Volume, and Cognitive Function Modulated by APOE É>4 Carrier Status in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2022, , 1-14.	2.6	0
3801	Interactive Effects of Pulse Pressure and Tau Imaging on Longitudinal Cognition. Journal of Alzheimer's Disease, 2022, 89, 633-640.	2.6	6
3802	Artificial Intelligence Models in the Diagnosis of Adult-Onset Dementia Disorders: A Review. Bioengineering, 2022, 9, 370.	3.5	15
3803	Categorical Perception of Lexical Tones in Mandarin-Speaking Seniors. Journal of Speech, Language, and Hearing Research, 2022, 65, 2789-2800.	1.6	0
3804	A circular RNA blood panel that differentiates Alzheimer's disease from other dementia types. Biomarker Research, 2022, 10, .	6.8	4
3806	Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice. American Journal of Neuroradiology, 2022, 43, E19-E35.	2.4	31
3807	Temporal Cortical Thickness and Cognitive Associations among Typical and Atypical Phenotypes of Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2022, 6, 479-491.	2.2	4
3808	Proteomic Markers and Early Prediction of Alzheimer's Disease. Biochemistry (Moscow), 2022, 87, 762-776.	1.5	2

#	Article	IF	CITATIONS
3809	Phosphorylated tau sites that are elevated in Alzheimer's disease fluid biomarkers are visualized in early neurofibrillary tangle maturity levels in the <i>post mortem</i> brain. Alzheimer's and Dementia, 2023, 19, 1029-1040.	0.8	15
3811	Intraneuronal sortilin aggregation relative to granulovacuolar degeneration, tau pathogenesis and sorfra plaque formation in human hippocampal formation. Frontiers in Aging Neuroscience, 0, 14, .	3.4	3
3812	From Biomarkers to Precision Medicine in Neurodegenerative Diseases: Where Are We?. Journal of Clinical Medicine, 2022, 11, 4515.	2.4	9
3813	Residual reserve index modifies the effect of amyloid pathology on fluorodeoxyglucose metabolism: Implications for efficiency and capacity in cognitive reserve. Frontiers in Aging Neuroscience, 0, 14, .	3.4	1
3814	Label-free hyperspectral imaging and deep-learning prediction of retinal amyloid $\hat{l}^2$ -protein and phosphorylated tau. , 2022, 1, .		8
3815	Association Plasma Aβ42 Levels with Alzheimer's Disease and Its Influencing Factors in Chinese Elderly Population. Neuropsychiatric Disease and Treatment, 0, Volume 18, 1831-1841.	2.2	1
3816	Biological determinants of bloodâ€based cytokines in the Alzheimer's disease clinical continuum. Journal of Neurochemistry, 0, , .	3.9	2
3817	Fineâ€mapping and replication of EWAS loci harboring putative epigenetic alterations associated with AD neuropathology in a large collection of human brain tissue samples. Alzheimer's and Dementia, 2023, 19, 1216-1226.	0.8	2
3818	Remote self-administration of digital cognitive tests using the Brief Assessment of Cognition: Feasibility, reliability, and sensitivity to subjective cognitive decline. Frontiers in Psychiatry, 0, 13, .	2.6	3
3819	The inter-relationship between delirium and dementia: the importance of delirium prevention. Nature Reviews Neurology, 2022, 18, 579-596.	10.1	73
3820	Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease. Neurology, 2022, 99, .	1.1	13
3821	Spatial Navigation and Its Association With Biomarkers and Future Dementia in Memory Clinic Patients Without Dementia. Neurology, 2022, 99, .	1.1	10
3822	Improving Our Understanding of Driving Changes in Preclinical and Early Symptomatic Alzheimer's Disease: The Role of Naturalistic Driving Studies. Journal of Alzheimer's Disease Reports, 2022, 6, 521-528.	2.2	1
3823	Quantitative susceptibility mapping as an imaging biomarker for Alzheimer's disease: The expectations and limitations. Frontiers in Neuroscience, 0, 16, .	2.8	12
3824	Sex differences in risk factors that predict progression from mild cognitive impairment to Alzheimer's dementia. Journal of the International Neuropsychological Society, 2023, 29, 360-368.	1.8	7
3825	The AHEAD 3â€45 Study: Design of a prevention trial for Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 1227-1233.	0.8	34
3826	Different AT(N) profiles and clinical progression classified by two different N markers using total tau and neurofilament light chain in cerebrospinal fluid. BMJ Neurology Open, 2022, 4, e000321.	1.6	10
3827	β-Amyloid promotes platelet activation and activated platelets act as bridge between risk factors and Alzheimer's Disease. Mechanisms of Ageing and Development, 2022, , 111725.	4.6	4

#	Article	IF	CITATIONS
3828	Frequency, Severity, and Duration of Autonomic Symptoms in Patients of Prodromal Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2022, , 1-7.	2.6	4
3829	Associations of digital neuro-signatures with molecular and neuroimaging measures of brain resilience: The altoida large cohort study. Frontiers in Psychiatry, 0, 13, .	2.6	3
3830	Historical efforts to develop 99mTc-based amyloid plaque targeting radiotracers. Frontiers in Nuclear Medicine, 0, 2, .	1.2	1
3831	Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan. Brain, 2022, 145, 4459-4473.	7.6	15
3832	Plasma P-Tau181 for the Discrimination of Alzheimer's Disease from Other Primary Dementing and/or Movement Disorders. Biomolecules, 2022, 12, 1099.	4.0	3
3833	Energy crisis links to autophagy and ferroptosis in Alzheimer's disease: current evidence and future avenues. Current Neuropharmacology, 2022, 20, .	2.9	2
3834	Association of Microglial Activation With Spontaneous ARIA-E and CSF Levels of Anti-Al $^2$ Autoantibodies. Neurology, 2022, 99, .	1.1	17
3835	Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease. Nature Medicine, 0, , .	30.7	58
3836	Designing the next-generation clinical care pathway for Alzheimer's disease. Nature Aging, 2022, 2, 692-703.	11.6	44
3837	The CORCOBIA study: Cut-off points of Alzheimer's disease CSF biomarkers in a clinical cohort. NeurologÃa (English Edition), 2022, , .	0.4	4
3838	Brief cognitive tests as a decision-making tool in primary care. A population and validation study. NeurologÃa (English Edition), 2022, , .	0.4	1
3839	The cognitive performance in the Phototest is predictor ofÂbiological markers of Alzheimer's disease. International Journal of Geriatric Psychiatry, 2022, 37, .	2.7	0
3840	Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer's disease. Science Translational Medicine, 2022, 14, .	12.4	13
3841	International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer's Disease. Phenomics, 2023, 3, 375-389.	2.9	12
3842	Multi-feature computational framework for combined signatures of dementia in underrepresented settings. Journal of Neural Engineering, 2022, 19, 046048.	3.5	15
3843	Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer's disease. Molecular Psychiatry, 2022, 27, 4781-4789.	7.9	43
3844	Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer's Disease. Biomedicines, 2022, 10, 1879.	3.2	1
3845	Biomarker and therapeutic potential of peripheral extracellular vesicles in Alzheimer's disease. Advanced Drug Delivery Reviews, 2022, 190, 114486.	13.7	14

#	Article	IF	CITATIONS
3847	Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint. Alzheimer's Research and Therapy, 2022, 14, .	6.2	3
3848	DTI Connectometry Analysis Reveals White Matter Changes in Cognitively Impaired World Trade Center Responders at Midlife. Journal of Alzheimer's Disease, 2022, 89, 1075-1089.	2.6	4
3849	Multimodal magnetic resonance imaging reveals distinct sensitivity of hippocampal subfields in asymptomatic stage of Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	3.4	1
3850	Exploring Early Physical Examination Diagnostic Biomarkers for Alzheimer's Disease Based on Least Absolute Shrinkage and Selection Operator. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-10.	1.3	2
3851	Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer's disease dementia in Chinese individuals. Frontiers in Aging Neuroscience, 0, 14, .	3.4	5
3852	Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease. Human Brain Mapping, 2023, 44, 327-340.	3.6	2
3853	Dementia Prevention Research Clinic: a longitudinal study investigating factors influencing the development of Alzheimer's disease in Aotearoa, New Zealand. Journal of the Royal Society of New Zealand, 0, , 1-22.	1.9	2
3854	Validation of the Alzheimer's disease-resemblance atrophy index in classifying and predicting progression in Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	3.4	3
3855	Plasma Biomarkers of Alzheimer's Disease Are Associated with Physical Functioning Outcomes Among Cognitively Normal Adults in the Multiethnic HABS-HD Cohort. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 9-15.	3.6	6
3856	Inhibition of PLK2 activity affects APP and tau pathology and improves synaptic content in a sex-dependent manner in a 3xTg mouse model of Alzheimer's disease. Neurobiology of Disease, 2022, 172, 105833.	4.4	3
3857	FDG-PET combined with learning vector quantization allows classification of neurodegenerative diseases and reveals the trajectory of idiopathic REM sleep behavior disorder. Computer Methods and Programs in Biomedicine, 2022, 225, 107042.	4.7	11
3858	Individualized diagnosis of preclinical Alzheimer's Disease using deep neural networks. Expert Systems With Applications, 2022, 210, 118511.	7.6	4
3859	Targeting Microtubule-Associated Protein Tau in Chemotherapy-Resistant Models of High-Grade Serous Ovarian Carcinoma. Cancers, 2022, 14, 4535.	3.7	2
3860	The use of optical coherence tomography in neurology: a review. Brain, 2022, 145, 4160-4177.	7.6	12
3861	Objectifying Subjective Cognitive Decline. Neurology, 2022, 99, 735-736.	1.1	2
3862	Longitudinal change in ATN biomarkers in cognitively normal individuals. Alzheimer's Research and Therapy, 2022, 14, .	6.2	2
3863	Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients. CNS Neuroscience and Therapeutics, 2022, 28, 2195-2205.	3.9	10
3864	Iron in Alzheimer's Disease: From Physiology to Disease Disabilities. Biomolecules, 2022, 12, 1248.	4.0	18

#	Article	IF	CITATIONS
3865	Shengmai san-derived compound prescriptions: A review on chemical constituents, pharmacokinetic studies, quality control, and pharmacological properties. Phytomedicine, 2022, 107, 154433.	5.3	9
3866	Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 423-434.	6.4	10
3867	KL-FGF23-VD Axis in Improving Late-Onset Alzheimer's Disease by Modulating IKK/NF-κB Signal Pathway. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-13.	1.2	1
3869	Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report. Medicine (United States), 2022, 101, e30666.	1.0	1
3870	Donepezil-Induced Complex Multimodal Hallucinations: Two Cases and a Review of the Literature. Case Reports in Neurology, 2022, 14, 359-365.	0.7	2
3871	A hypothesis-driven method based on machine learning for neuroimaging data analysis. Neurocomputing, 2022, 510, 159-171.	5.9	0
3872	Angiotensin Receptor Blockers Are Associated With a Lower Risk of Progression From Mild Cognitive Impairment to Dementia. Hypertension, 2022, 79, 2159-2169.	2.7	17
3873	Advances in Alzheimer's disease research over the past two decades. Lancet Neurology, The, 2022, 21, 866-869.	10.2	20
3874	The Zinc-sensing Receptor (GPR39) Modulates Declarative Memory and Age-related Hippocampal Gene Expression in Male Mice. Neuroscience, 2022, 503, 1-16.	2.3	3
3875	Investigating the temporal pattern of neuroimaging-based brain age estimation as a biomarker for Alzheimer's Disease related neurodegeneration. NeuroImage, 2022, 263, 119621.	4.2	7
3876	Theory of Mind and social functioning among neuropsychiatric disorders: A transdiagnostic study. European Neuropsychopharmacology, 2022, 64, 19-29.	0.7	5
3877	Unifying framework for cognitive training interventions in brain aging. Ageing Research Reviews, 2022, 81, 101724.	10.9	2
3878	Reducing variations in multi-center Alzheimer's disease classification with convolutional adversarial autoencoder. Medical Image Analysis, 2022, 82, 102585.	11.6	8
3879	Progress of advanced nanomaterials in diagnosis of neurodegenerative diseases. Biosensors and Bioelectronics, 2022, 217, 114717.	10.1	5
3880	Effective connectivity in individuals with Alzheimer's disease and mild cognitive impairment: A systematic review. Neuroscience Informatics, 2022, 2, 100104.	4.5	1
3881	How molecular imaging studies can disentangle disease mechanisms in age-related neurodegenerative disorders. , 2023, , 455-492.		Ο
3882	Biomarkers in cerebrospinal fluid and blood aid diagnosis of dementia. , 2023, , 47-68.		0
3883	Cationic molecular probes based on aggregation-induced emission for fluorescent sensing and super-resolution imaging of insulin fibrosis. Chemical Engineering Journal, 2023, 451, 139027.	12.7	8

~		_	
Γιτλτι	ON	12 FD(	DT
CITAT		NLFV	

#	Article	IF	CITATIONS
3884	Hypothalamic-pituitary-adrenal (HPA) axis activity and anxiety-like behavior during aging: A test of the glucocorticoid cascade hypothesis in amyloidogenic APPswe/PS1dE9 mice. General and Comparative Endocrinology, 2023, 330, 114126.	1.8	6
3885	The role of dyadic cognitive report and subjective cognitive decline in early ADRD clinical research and trials: Current knowledge, gaps, and recommendations. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	7
3886	Alzheimer $ imes$ <sup>3</sup> s Disease: One of the Pandemics of the 21st Century. , 2022, , .		0
3887	Innovations in Neurophysiology and Its Role in Neuropsychiatry. Noropsikiyatri Arsivi, 2022, , .	0.3	0
3888	Age, Sex, Hypertension and HDL-C Alter Serum BACE1 Activity in Cognitively Normal Subjects: Implications for Alzheimer's Disease. journal of prevention of Alzheimer's disease, The, 0, , .	2.7	0
3889	Associations of the Lifestyle for Brain Health index with longitudinal cognition and brain amyloid beta in clinically unimpaired older adults: Findings from the Wisconsin Registry for Alzheimer's Prevention. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	0
3890	A surrogate marker for very early-stage tau pathology is detectable by molecular magnetic resonance imaging. Theranostics, 2022, 12, 5504-5521.	10.0	3
3891	Amyloid PET ordering practices in a memory disorders clinic. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	3
3892	Impact of amyloid PET in the clinical care of veterans in a tertiary memory disorders clinic. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	1
3893	Elevation of plasma phosphorylated tau181 during neurological illnesses affecting consciousness and kidney dysfunction. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	1
3894	OMICS in Schizophrenia and Alzheimer's Disease. , 2022, , 109-119.		0
3895	The temporal lobe in typical and atypical Alzheimer disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2022, , 449-466.	1.8	5
3896	Brain-age is associated with progression to dementia in memory clinic patients. NeuroImage: Clinical, 2022, 36, 103175.	2.7	15
3897	Exploring discordant low amyloid beta and high neocortical tau positron emission tomography cases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	6
3898	Sex and gender differences in dementia. International Review of Neurobiology, 2022, , 179-233.	2.0	3
3899	Uncertainties in the PET defined Aâ€ <del>/</del> T <sub>Neocortical</sub> + subtype. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	0
3900	Sleep duration and biomarkers of inflammation in African American and white participants with a parental history of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	4
3901	Exploring the role of protein quality control in aging and age-associated neurodegenerative diseases. , 2022, , 139-171.		0

#	Article	IF	CITATIONS
3902	Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	9
3903	Amyloid Conversion is Related to Risk Factors ForÂDementia. SSRN Electronic Journal, 0, , .	0.4	0
3904	The Coaching for Cognition in Alzheimer's (COCOA) trial: Study design. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	5
3905	Roadmap for ecosystem-based approach for patients with Alzheimer disease in Russia: current needs, barriers, and possible solutions (resolution of the scientific and practical experts meeting). Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 121.	0.7	1
3906	Ketogenic dietary lifestyle intervention effects on sleep, cognition, and behavior in mild cognitive impairment: Study design. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	1
3907	A Survey on Computational Intelligence Techniques in Learning and Memory. Communications in Computer and Information Science, 2022, , 129-153.	0.5	0
3908	No difference in retinal fluorescence after oral curcumin intake in amyloidâ€proven AD cases compared to controls. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	1
3909	Contributions of twin research to the study of Alzheimer's disease and related dementias. , 2022, , 529-544.		1
3910	Biomarkers of neurodegeneration in neural autoantibody-associated psychiatric syndromes: A retrospective cohort study. Journal of Translational Autoimmunity, 2022, 5, 100169.	4.0	1
3911	Predicting conversion from mild cognitive impairment to Alzheimer's disease with multimodal latent factors. Journal of Clinical and Experimental Neuropsychology, 2022, 44, 316-335.	1.3	0
3912	DNA Methylation Clocks in Age-related Disease. , 2023, , 479-495.		0
3913	Neuroimaging methods. , 2023, , 27-45.		0
3915	Clinical aspects of diagnosis in dementia. , 2023, , 1-26.		0
3916	An unsupervised region of interest extraction model for tau PET images and its application in the diagnosis of Alzheimer's disease. , 2022, , .		0
3917	Development of a Machine Learning Model to Discriminate Mild Cognitive Impairment Subjects from Normal Controls in Community Screening. Brain Sciences, 2022, 12, 1149.	2.3	3
3918	A Retrospective Study on Clinical Assessment of Cognitive Impairment in a Swedish Cohort: Is There Inequality Between Natives and Foreign-Born?. Journal of Alzheimer's Disease, 2022, , 1-10.	2.6	0
3919	Mapping the association between tau-PET and Aβ-amyloid-PET using deep learning. Scientific Reports, 2022, 12, .	3.3	2
3920	Screening for preclinical Alzheimer's disease: Deriving optimal policies using a partially observable Markov model. Health Care Management Science, 2023, 26, 1-20.	2.6	0

#	Article	IF	CITATIONS
3921	Neural network process simulations support a distributed memory system and aid design of a novel computer adaptive digital memory test for preclinical and prodromal Alzheimer's disease Neuropsychology, 2023, 37, 698-715.	1.3	3
3923	CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology. Neurology, 2022, 99, .	1.1	6
3924	Machine learning-based automatic estimation of cortical atrophy using brain computed tomography images. Scientific Reports, 2022, 12, .	3.3	0
3925	Cognitive reserve and mental health in cognitive frailty phenotypes: Insights from a study with a Portuguese sample. Frontiers in Psychology, 0, 13, .	2.1	2
3928	Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An instrumental variable metaâ€analysis. Alzheimer's and Dementia, 2023, 19, 1292-1299.	0.8	5
3929	Multi-scale discriminative regions analysis in FDG-PET imaging for early diagnosis of Alzheimer's disease. Journal of Neural Engineering, 2022, 19, 046030.	3.5	1
3930	Combined Effects of Synaptic and Axonal Integrity on Longitudinal Gray Matter Atrophy in Cognitively Unimpaired Adults. Neurology, 2022, 99, .	1.1	3
3931	Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study. Medicina (Lithuania), 2022, 58, 1179.	2.0	4
3932	High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. Revue Neurologique, 2022, 178, 1011-1030.	1.5	40
3933	Understanding the Relationship Between Age-Related Hearing Loss and Alzheimer's Disease: A Narrative Review. Journal of Alzheimer's Disease Reports, 2022, 6, 539-556.	2.2	5
3934	Identification of the molecular subgroups in Alzheimer's disease by transcriptomic data. Frontiers in Neurology, 0, 13, .	2.4	2
3935	Alzheimer's Disease and Inflammaging. Brain Sciences, 2022, 12, 1237.	2.3	26
3936	Level of Amyloid-β (Aβ) Binding Leading to Differential Effects on Resting State Functional Connectivity in Major Brain Networks. Biomedicines, 2022, 10, 2321.	3.2	2
3937	Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 410-422.	6.4	6
3938	Circulating Amyloid-β and Methionine-Related Metabolites to Predict the Risk of Mild Cognitive Impairment: A Nested Case-Control Study. Journal of Alzheimer's Disease, 2022, 90, 389-404.	2.6	1
3939	Data-driven causal model discovery and personalized prediction in Alzheimer's disease. Npj Digital Medicine, 2022, 5, .	10.9	2
3940	Alzheimer's Disease Diagnosis Based on the Amyloid, Tau, and Neurodegeneration Scheme (ATN) in a Real-Life Multicenter Cohort of General Neurological Centers. Journal of Alzheimer's Disease, 2022, 90, 419-432.	2.6	3
3941	Population pharmacokineticâ€pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1578-1591.	2.5	9

#	Article	IF	CITATIONS
3943	Sensory Loss and Risk of Dementia. Neuroscientist, 0, , 107385842211260.	3.5	5
3944	Current Naturopathy to Combat Alzheimer's Disease. Current Neuropharmacology, 2023, 21, 808-841.	2.9	2
3945	Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits. International Journal of Molecular Sciences, 2022, 23, 11418.	4.1	5
3946	Distribution of cortical atrophy associated with cognitive decline in Alzheimer's disease: a cross-sectional quantitative structure MRI study from PUMCH dementia cohort. Current Alzheimer Research, 2022, 19, .	1.4	0
3947	International Consensus Statement on Obstructive Sleep Apnea. International Forum of Allergy and Rhinology, 2023, 13, 1061-1482.	2.8	39
3948	Sensitivity of memory subtests and learning slopes from the ADAS-Cog to distinguish along the continuum of the NIA-AA Research Framework for Alzheimer's Disease. Aging, Neuropsychology, and Cognition, 2023, 30, 866-884.	1.3	7
3949	Unified framework for brain connectivity-based biomarkers in neurodegenerative disorders. Frontiers in Neuroscience, 0, 16, .	2.8	0
3950	Vascular burden and cognition: Mediating roles of neurodegeneration and amyloid PET. Alzheimer's and Dementia, 2023, 19, 1503-1517.	0.8	12
3951	One-year outcome of a lumboperitoneal shunt in older adults with idiopathic normal pressure hydrocephalus. Frontiers in Surgery, 0, 9, .	1.4	0
3952	Association between Gut Microbiota with Mild Cognitive Impairment and Alzheimer's Disease in a Thai Population. Neurodegenerative Diseases, 2022, 22, 43-54.	1.4	13
3953	The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification. Journal of Nuclear Medicine, 0, , jnumed.122.264031.	5.0	4
3954	A Combination of Neurofilament Light, Clial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias. Journal of Alzheimer's Disease, 2022, 90, 363-380.	2.6	8
3955	Association of cardiovascular health with the risk of dementia in older adults. Scientific Reports, 2022, 12, .	3.3	4
3956	Biomarkers for dementia in Latin American countries: Gaps and opportunities. Alzheimer's and Dementia, 2023, 19, 721-735.	0.8	15
3957	Longitudinal change in serial position scores in older adults with entorhinal and hippocampal neuropathologies. Journal of the International Neuropsychological Society, 2023, 29, 561-571.	1.8	3
3958	Association of Presynaptic Loss with Alzheimer's Disease and Cognitive Decline. Annals of Neurology, 2022, 92, 1001-1015.	5.3	16
3959	CSF AÎ <sup>2</sup> 40 and P-Tau181 Might Differentiate Atypical from Typical AD Phenotypes: Preliminary Evidence. Neurodegenerative Diseases, 2022, 22, 83-86.	1.4	1
3960	Characteristics Scanning of Brain Structure and Function Changes in Patients with Different Degrees of Alzheimer's Disease. Contrast Media and Molecular Imaging, 2022, 2022, 1-8.	0.8	1

#	Article	IF	CITATIONS
3961	Gamma Frequency Inhibits the Secretion and Aggregation of Amyloid-Î <sup>2</sup> and Decreases the Phosphorylation of mTOR and Tau Proteins in vitro. Journal of Alzheimer's Disease, 2022, 90, 917-928.	2.6	2
3963	<i>In vivo</i> tau staging in Alzheimer's disease. Aging, 2022, 14, 6842-6843.	3.1	2
3964	Hypnosis for pain and anxiety management in cognitively impaired older adults undergoing scheduled lumbar punctures: a randomized controlled pilot study. Alzheimer's Research and Therapy, 2022, 14, .	6.2	1
3965	White matter integrity and key structures affected in Alzheimer's disease characterized by diffusion tensor imaging. European Journal of Neuroscience, 2022, 56, 5319-5331.	2.6	8
3966	Stage-dependent differential influence of metabolic and structural networks on memory across Alzheimer's disease continuum. ELife, 0, 11, .	6.0	0
3967	Inflammation-Related microRNAs-146a and -155 Are Upregulated in Mild Cognitive Impairment Subjects Among Older Age Population in Montenegro. Journal of Alzheimer's Disease, 2022, 90, 625-638.	2.6	3
3968	Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer's disease patients. Brain Communications, 2022, 4, .	3.3	1
3969	Transcranial alternating current stimulation combined with sound stimulation improves the cognitive function of patients with Alzheimer's disease: A case report and literature review. Frontiers in Neurology, 0, 13, .	2.4	7
3970	Retrospective real-world pilot data on transcranial pulse stimulation in mild to severe Alzheimer's patients. Frontiers in Neurology, 0, 13, .	2.4	6
3971	Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals. Brain, 2023, 146, 1580-1591.	7.6	15
3972	Quality of Life and the Experience of Living with Early-Stage Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, , 1-8.	2.6	2
3974	A single-center, randomized, parallel design study to evaluate the efficacy of donepezil in improving visuospatial abilities in patients with mild cognitive impairment using eye-tracker: the COG-EYE study protocol for a phase II trial. Trials, 2022, 23, .	1.6	0
3976	How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful?. Alzheimer's and Dementia, 2023, 19, 1073-1085.	0.8	1
3977	β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population. Neurology, 2022, 99, .	1.1	11
3979	A review of brain imaging biomarker genomics in Alzheimer's disease: implementation and perspectives. Translational Neurodegeneration, 2022, 11, .	8.0	9
3980	Modulation of Amyloid-β and Tau in Alzheimer's Disease Plasma Neuronal-Derived Extracellular Vesicles by Cerebrolysin® and Donepezil. Journal of Alzheimer's Disease, 2022, 90, 705-717.	2.6	4
3981	Memory markers in the continuum of the Alzheimer's clinical syndrome. Alzheimer's Research and Therapy, 2022, 14, .	6.2	6
3983	A <scp>populationâ€based metaâ€analysis</scp> of circulating <scp>GFAP</scp> for cognition and dementia risk. Annals of Clinical and Translational Neurology, 2022, 9, 1574-1585.	3.7	9

#	Article	IF	CITATIONS
3984	Effects of Hypertension on Alzheimer's Disease and Related Disorders. Current Hypertension Reports, 2022, 24, 615-625.	3.5	6
3985	Progressive attenuation of visual global precedence across healthy aging and Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	3.4	0
3986	A Review of Application of Aβ42/40 Ratio in Diagnosis and Prognosis of Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 90, 495-512.	2.6	12
3987	Assessment of Alzheimer's Disease Imaging Biomarkers in World Trade Center Responders with Cognitive Impairment at Midlife. World Journal of Nuclear Medicine, 2022, 21, 267-275.	0.5	3
3988	Combining visual rating scales to identify prodromal Alzheimer's disease and Alzheimer's disease dementia in a population from a low and middle-income country. Frontiers in Neurology, 0, 13, .	2.4	2
3990	Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 113-120.	1.9	10
3991	Whole-exome sequencing reveals PSEN1 and ATP7B combined variants as a possible cause of early-onset Lewy body dementia: a case study of genotype–phenotype correlation. Neurogenetics, 0, , .	1.4	1
3992	The conundrum of the AD continuum. Alzheimer's and Dementia, 2023, 19, 371-372.	0.8	1
3993	Capturing Cognitive Aging in Vivo: Application of a Neuropsychological Framework for Emerging Digital Tools. JMIR Aging, 2022, 5, e38130.	3.0	6
3994	Current Insights on Neurodegeneration by the Italian Proteomics Community. Biomedicines, 2022, 10, 2297.	3.2	3
3996	Association of Data-Driven White Matter Hyperintensity Spatial Signatures With Distinct Cerebral Small Vessel Disease Etiologies. Neurology, 2022, 99, .	1.1	29
3997	Design, Docking, Synthesis and Biological Evaluation of Novel Nicotinohydrazone Derivatives as Potential Butyrylcholinesterase Enzyme Inhibitor. ChemistrySelect, 2022, 7, .	1.5	5
3998	Amyloid-Tau-Neurodegeneration Profiles and Longitudinal Cognition in Sporadic Young-Onset Dementia. Journal of Alzheimer's Disease, 2022, , 1-9.	2.6	3
3999	Aberrant energy metabolism in Alzheimer's disease. Journal of Translational Internal Medicine, 2022, 10, 197-206.	2.5	12
4000	Epigenetic aging as a biomarker of dementia and related outcomes: a systematic review. Epigenomics, 2022, 14, 1125-1138.	2.1	21
4001	Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance. Alzheimer's and Dementia, 2023, 19, 1403-1414.	0.8	45
4002	Tear Biomarkers in Alzheimer's and Parkinson's Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review). International Journal of Molecular Sciences, 2022, 23, 10123.	4.1	14
4003	The Transcranial Light Therapy Improves Synaptic Plasticity in the Alzheimer's Disease Mouse Model. Brain Sciences, 2022, 12, 1272.	2.3	8

#	Article	IF	CITATIONS
4004	Interaction between Alzheimer's Disease and Cerebral Small Vessel Disease: A Review Focused on Neuroimaging Markers. International Journal of Molecular Sciences, 2022, 23, 10490.	4.1	8
4005	Immune-mediated diseases are associated with a higher incidence of dementia: a prospective cohort study of 375,894 individuals. Alzheimer's Research and Therapy, 2022, 14, .	6.2	9
4008	The Immune System as a Therapeutic Target for Alzheimer's Disease. Life, 2022, 12, 1440.	2.4	6
4009	Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease. Brain, 2023, 146, 1602-1614.	7.6	10
4010	High Cerebrospinal Fluid CX3CL1 Levels in Alzheimer's Disease Patients but Not in Non-Alzheimer's Disease Dementia. Journal of Clinical Medicine, 2022, 11, 5498.	2.4	8
4011	Imaging markers of cerebral amyloid angiopathy and hypertensive arteriopathy differentiate Alzheimer disease subtypes synergistically. Alzheimer's Research and Therapy, 2022, 14, .	6.2	1
4012	Preclinical Alzheimer Disease and the Electronic Health Record. Neurology, 2022, 99, 987-994.	1.1	4
4013	Characterization of Mild Cognitive Impairment and Dementia among Community-Dwelling Mexican Americans and Non-Hispanic Whites. Journal of Alzheimer's Disease, 2022, 90, 905-915.	2.6	1
4014	The Parietal Lobe in Alzheimer's Disease and Blindness. Journal of Alzheimer's Disease, 2022, , 1-10.	2.6	1
4015	Association between inflammatory biomarkers and cognitive aging. PLoS ONE, 2022, 17, e0274350.	2.5	11
4016	Development of a deep learning network for Alzheimer's disease classification with evaluation of imaging modality and longitudinal data. Physics in Medicine and Biology, 2022, 67, 195014.	3.0	0
4018	Willis Lecture: Biomarkers for Inflammatory White Matter Injury in Binswanger Disease Provide Pathways to Precision Medicine. Stroke, 2022, 53, 3514-3523.	2.0	2
4019	Brain state transition analysis using ultra-fast fMRI differentiates MCI from cognitively normal controls. Frontiers in Neuroscience, 0, 16, .	2.8	2
4020	Cerebrospinal Fluid Sphingomyelins in Alzheimer's Disease, Neurodegeneration, and Neuroinflammation1. Journal of Alzheimer's Disease, 2022, 90, 667-680.	2.6	3
4021	Mental health care for older adults: recent advances and new directions in clinical practice and research. World Psychiatry, 2022, 21, 336-363.	10.4	49
4022	Aquaporin-4 cerebrospinal fluid levels are higher in neurodegenerative dementia: looking at glymphatic system dysregulation. Alzheimer's Research and Therapy, 2022, 14, .	6.2	18
4023	Communicating and Using Dementia Risk Evidence. Journal of Alzheimer's Disease, 2022, 90, 933-944.	2.6	2
4024	CSF peptides from VGF and other markers enhance prediction of MCI to AD progression using the ATN framework. Neurobiology of Aging, 2023, 121, 15-27.	3.1	6

#	Article	IF	CITATIONS
4025	Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy. Alzheimer's Research and Therapy, 2022, 14, .	6.2	1
4026	Limbic-Predominant Age-Related TDP-43 Encephalopathy: LATE-Breaking Updates in Clinicopathologic Features and Biomarkers. Current Neurology and Neuroscience Reports, 2022, 22, 689-698.	4.2	5
4027	Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors. JAMA Network Open, 2022, 5, e2235068.	5.9	13
4028	Estimating Likelihood of Dementia in the Absence of Diagnostic Data: A Latent Dementia Index in 10 Genetically Informed Studies. Journal of Alzheimer's Disease, 2022, 90, 1187-1201.	2.6	1
4029	Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	3.4	2
4030	Cognitive tasks propagate the neural entrainment in response to a visual 40 Hz stimulation in humans. Frontiers in Aging Neuroscience, 0, 14, .	3.4	10
4031	Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals. Neurology, 2023, 100, .	1.1	8
4032	Altered glucose metabolism in Alzheimer's disease: Role of mitochondrial dysfunction and oxidative stress. Free Radical Biology and Medicine, 2022, 193, 134-157.	2.9	46
4033	COVID-19 and Alzheimer's Disease: Neuroinflammation, Oxidative Stress, Ferroptosis, and Mechanisms Involved. Current Medicinal Chemistry, 2023, 30, 3993-4031.	2.4	6
4034	Cerebrospinal Fluid sTREM2 in Alzheimer's Disease Is Associated with Both Amyloid and Tau Pathologies but not with Cognitive Status. Journal of Alzheimer's Disease, 2022, 90, 1123-1138.	2.6	3
4035	Identification of hsa-miR-365b-5p's role in Alzheimer's disease: A combined analysis of miRNA and mRNA microarrays. Neuroscience Letters, 2022, 790, 136892.	2.1	0
4036	System Form Modifications and Data Corrections for a Radiofrequency Penetrable PET Insert for Simultaneous PET/MRI. , 2021, , .		1
4037	Multipronged diagnostic and therapeutic strategies for Alzheimer's disease. Chemical Science, 2022, 13, 13657-13689.	7.4	25
4038	Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force. journal of prevention of Alzheimer's disease, The, 0, , .	2.7	14
4039	Research Progress on the Impact of Sleep Disorders on Alzheimer's Disease. Advances in Clinical Medicine, 2022, 12, 8999-9005.	0.0	0
4040	Free water derived by multiâ€shell diffusion MRI reflects tau/neuroinflammatory pathology in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, .	3.7	5
4041	Associations of Naturally Occurring Antibodies to Presenilin-1 with Brain Amyloid-β Load and Cognitive Impairment in Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, , 1-8.	2.6	3
4042	Adulthood cognitive trajectories over 26 years and brain health at 70 years of age: findings from the 1946 British Birth Cohort. Neurobiology of Aging, 2023, 122, 22-32.	3.1	1

#	Article	IF	Citations
4043	Research progress of psychoradiology in geriatric neurodegenerative diseases. Scientia Sinica Vitae, 2022, , .	0.3	0
4044	Cholinergic white matter pathways along the Alzheimer's disease continuum. Brain, 2023, 146, 2075-2088.	7.6	12
4045	Relevance of plasma biomarkers to pathologies in Alzheimer's disease, Parkinson's disease and frontotemporal dementia. Scientific Reports, 2022, 12, .	3.3	3
4046	Educational and Clinical Associations With Longitudinal Cognitive Function and Brain Imaging in American Indians. Neurology, 2022, 99, .	1.1	6
4047	Blood and Cerebrospinal Fluid Biomarkers in Vascular Dementia and Alzheimer's Disease. Clinics in Geriatric Medicine, 2023, 39, 67-76.	2.6	7
4048	E2F4DN Transgenic Mice: A Tool for the Evaluation of E2F4 as a Therapeutic Target in Neuropathology and Brain Aging. International Journal of Molecular Sciences, 2022, 23, 12093.	4.1	1
4049	<scp>Magnetic Resonance</scp> Images Implicate That Glymphatic Alterations Mediate Cognitive Dysfunction in <scp>Alzheimer Disease</scp> . Annals of Neurology, 2023, 93, 164-174.	5.3	42
4050	Perivascular Space Predicts Brain Hypometabolism of Individuals with Underlying Amyloid Pathology. Journal of Alzheimer's Disease, 2022, 90, 1329-1337.	2.6	1
4051	Age-linked suppression of lipoxin A4 associates with cognitive deficits in mice and humans. Translational Psychiatry, 2022, 12, .	4.8	4
4052	Spatio-temporal metabolic rewiring in the brain of TgF344-AD rat model of Alzheimer's disease. Scientific Reports, 2022, 12, .	3.3	0
4053	Albumin: A Multi-talented Clinical and Pharmaceutical Player. Biotechnology and Bioprocess Engineering, 2022, 27, 765-787.	2.6	1
4054	Retinal Examinations Provides Early Warning of Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, , 1-17.	2.6	3
4055	Deep-Learning-Based System for Assisting People with Alzheimer's Disease. Electronics (Switzerland), 2022, 11, 3229.	3.1	3
4056	Altered metamemory precedes cognitive impairment in subjective cognitive decline with positive amyloid-beta. Frontiers in Aging Neuroscience, 0, 14, .	3.4	3
4057	World Trade Center Site Exposure Duration Is Associated with Hippocampal and Cerebral White Matter Neuroinflammation. Molecular Neurobiology, 2023, 60, 160-170.	4.0	3
4058	Ethical Frameworks for Disclosure of Alzheimer Disease Biomarkers to Research Participants: Conflicting Norms and a Nuanced Policy. Ethics & Human Research, 2022, 44, 2-13.	0.9	0
4060	Neuropsychological profiles and neural correlates in typical and atypical variants of Alzheimer disease: A systematic qualitative review. Neurology Perspectives, 2022, , .	0.5	0
4062	Hypothesis review: Alzheimer's overture guidelines. Brain Pathology, 2023, 33, .	4.1	18

#	Article	IF	CITATIONS
4063	Assessment of Alzheimer's disease-related biomarkers in patients with obstructive sleep apnea: A systematic review and meta-analysis. Frontiers in Aging Neuroscience, 0, 14, .	3.4	4
4064	Perivascular spaces as a potential biomarker of Alzheimer's disease. Frontiers in Neuroscience, 0, 16, .	2.8	18
4065	Depressive Pseudodementia with Reversible AD-like Brain Hypometabolism: A Case Report and a Review of the Literature. Journal of Personalized Medicine, 2022, 12, 1665.	2.5	2
4066	Synaptic Proteins as Fluid Biomarkers in Alzheimer's Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2022, 90, 1381-1393.	2.6	2
4067	Potential biomarkers of Alzheimer's disease and cerebral small vessel disease. Frontiers in Molecular Neuroscience, 0, 15, .	2.9	3
4068	Dementia with Lewy bodies: Impact of coâ€pathologies and implications for clinical trial design. Alzheimer's and Dementia, 2023, 19, 318-332.	0.8	15
4069	Observational studies in Alzheimer disease: bridging preclinical studies and clinical trials. Nature Reviews Neurology, 0, , .	10.1	0
4070	Research on Alzheimer's syndromes is critical to improve diagnosis, patient management and non-pharmacological treatments, but is under-pursued. Frontiers in Aging Neuroscience, 0, 14, .	3.4	1
4071	Moringa Oleifera Alleviates Al <sup>2</sup> Burden and Improves Synaptic Plasticity and Cognitive Impairments in APP/PS1 Mice. Nutrients, 2022, 14, 4284.	4.1	7
4073	Touchscreen Cognitive Tools for Mild Cognitive Impairment and Dementia Used in Primary Care Across Diverse Cultural and Literacy Populations: A Systematic Review. Journal of Alzheimer's Disease, 2022, , 1-22.	2.6	2
4074	Sleep slow waves' negative-to-positive-phase transition: a marker of cognitive and apneic status in aging. Sleep, 2023, 46, .	1.1	4
4075	Blood pressure variability and plasma Alzheimer's disease biomarkers in older adults. Scientific Reports, 2022, 12, .	3.3	4
4076	Semiquantitative Approach to Amyloid Positron Emission Tomography Interpretation in Clinical Practice. World Journal of Nuclear Medicine, 2023, 22, 015-021.	0.5	0
4077	A Plasma Circular RNA Profile Differentiates Subjects with Alzheimer's Disease and Mild Cognitive Impairment from Healthy Controls. International Journal of Molecular Sciences, 2022, 23, 13232.	4.1	7
4078	Differential Diagnosis of Alzheimer Disease vs. Mild Cognitive Impairment Based on Left Temporal Lateral Lobe Hypomethabolism on 18F-FDG PET/CT and Automated Classifiers. Diagnostics, 2022, 12, 2425.	2.6	2
4079	Investigating p62 Concentrations in Cerebrospinal Fluid of Patients with Dementia: A Potential Autophagy Biomarker In Vivo?. Brain Sciences, 2022, 12, 1414.	2.3	3
4080	Cerebrospinal Fluid Biomarker Profile in TDP-43-Related Genetic Frontotemporal Dementia. Journal of Personalized Medicine, 2022, 12, 1747.	2.5	4
4082	Social cognition deficits and biometric signatures in the behavioural variant of Alzheimer's disease. Brain, 2023, 146, 2163-2174.	7.6	4

#	Article	IF	CITATIONS
4083	Preclinical Alzheimer's dementia: a useful concept or another dead end?. European Journal of Ageing, 2022, 19, 997-1004.	2.8	5
4084	Discordance and Concordance Between Cerebrospinal and [ <sup>18</sup> F]FDG-PET Biomarkers in Assessing Atypical and Early-Onset AD Dementia Cases. Neurology, 2022, 99, .	1.1	4
4085	Plasma Aβ42/Aβ40 and p-tau181 Predict Long-Term Clinical Progression in a Cohort with Amnestic Mild Cognitive Impairment. Clinical Chemistry, 2022, 68, 1552-1563.	3.2	6
4086	Multi-Omic analyses characterize the ceramide/sphingomyelin pathway as a therapeutic target in Alzheimer's disease. Communications Biology, 2022, 5, .	4.4	21
4089	Comprehensive characterization of elevated tau PET signal in the absence of amyloid-beta. Brain Communications, 2022, 4, .	3.3	5
4090	Improving community healthâ€care systems' early detection of cognitive decline and dementia. Alzheimer's and Dementia, 2022, 18, 2375-2381.	0.8	1
4091	Homocysteine, Cognitive Functions, and Degenerative Dementias: State of the Art. Biomedicines, 2022, 10, 2741.	3.2	12
4092	Amide proton transfer imaging of Alzheimer's disease and Parkinson's disease. Magnetic Resonance Letters, 2022, , .	1.3	1
4093	European consensus for the diagnosis of MCI and mild dementia: Preparatory phase. Alzheimer's and Dementia, 2023, 19, 1729-1741.	0.8	10
4094	Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a communityâ€engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4. Alzheimer's and Dementia, 2023, 19, 307-317.	0.8	27
4095	Potential Protective Mechanisms of S-equol, a Metabolite of Soy Isoflavone by the Gut Microbiome, on Cognitive Decline and Dementia. International Journal of Molecular Sciences, 2022, 23, 11921.	4.1	12
4096	Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates. Npj Vaccines, 2022, 7, .	6.0	5
4097	Fluctuation of depressive symptoms in cognitively unimpaired participants and the risk of mild cognitive impairment 5 years later: Results of the Heinz Nixdorf Recall study. Frontiers in Behavioral Neuroscience, 0, 16, .	2.0	1
4098	Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders. Journal of Nuclear Medicine, 2023, 64, 12-19.	5.0	5
4099	Influence of Gender on Tau Precipitation in Alzheimer's Disease According to ATN Research Framework. Phenomics, 2023, 3, 565-575.	2.9	7
4100	Investigating Tissue-Specific Abnormalities in Alzheimer's Disease with Multi-Shell Diffusion MRI. Journal of Alzheimer's Disease, 2022, 90, 1771-1791.	2.6	2
4101	Multiomics and artificial intelligence enabled peripheral blood-based prediction of amnestic mild cognitive impairment. Current Research in Translational Medicine, 2023, 71, 103367.	1.8	2
4102	Do informant-reported subjective cognitive complaints predict progression to mild cognitive impairment and dementia better than self-reported complaints in old adults? A meta-analytical study. Ageing Research Reviews, 2022, 82, 101772.	10.9	9

#	Article	IF	CITATIONS
4103	Cerebrospinal fluid neurofilament light and cerebral atrophy in youngerâ€onset dementia and primary psychiatric disorders. Internal Medicine Journal, 2023, 53, 1564-1569.	0.8	3
4104	D-Ï€-A-Based Trisubstituted Alkenes as Environmentally Sensitive Fluorescent Probes to Detect Lewy Pathologies. Analytical Chemistry, 2022, 94, 15261-15269.	6.5	6
4105	Brain PET and Cerebrovascular Disease. PET Clinics, 2023, 18, 115-122.	3.0	1
4106	Cortisol, cognition and Alzheimer's disease biomarkers among memory clinic patients. BMJ Neurology Open, 2022, 4, e000344.	1.6	6
4107	Cognitive Impairment in Older Adults. Psychiatric Clinics of North America, 2022, 45, 639-661.	1.3	12
4108	Language performance as a prognostic factor for developing Alzheimer's clinical syndrome and mild cognitive impairment: Results from the population-based HELIAD cohort. Journal of the International Neuropsychological Society, 2023, 29, 450-458.	1.8	5
4109	Machine-Based Learning Shifting to Prediction Model of Deteriorative MCI Due to Alzheimer's Disease - A Two-Year Follow-Up Investigation. Current Alzheimer Research, 2022, 19, 708-715.	1.4	1
4110	The ATN Framework—Moving Preclinical Alzheimer Disease to Clinical Relevance. JAMA Neurology, 2022, 79, 968.	9.0	7
4111	Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers. JAMA Neurology, 2022, 79, 1155.	9.0	12
4112	CSF GAP-43 as a biomarker of synaptic dysfunction is associated with tau pathology in Alzheimer's disease. Scientific Reports, 2022, 12, .	3.3	13
4113	Can hippocampal subfield measures supply information that could be used to improve the diagnosis of Alzheimer's disease?. PLoS ONE, 2022, 17, e0275233.	2.5	3
4114	The association between cerebrospinal ferritin and soluble triggering receptor expressed on myeloid cells 2 along Alzheimer's continuum. Frontiers in Neurology, 0, 13, .	2.4	4
4115	Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer's disease patients. Alzheimer's Research and Therapy, 2022, 14, .	6.2	7
4116	Clinical utility of cerebrospinal fluid biomarkers measured by <scp> LUMIPULSE <sup>®</sup> </scp> system. Annals of Clinical and Translational Neurology, 0, , .	3.7	1
4117	Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases. Fundamental Research, 2023, 3, 505-519.	3.3	4
4119	Plasma Phosphorylated Tau at Threonine 181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease. Neurology, 2023, 100, .	1.1	24
4120	A Group of Long Non-coding RNAs in Blood Acts as a Specific Biomarker of Alzheimer's Disease. Molecular Neurobiology, 2023, 60, 566-575.	4.0	3
4122	Case analysis of early-onset Alzheimer's disease associated with TBK1 p.Tyr235Phe gene mutation. Frontiers in Neurology, 0, 13, .	2.4	0

#	Article	IF	CITATIONS
4124	Automated differential diagnosis of dementia syndromes using FDG PET and machine learning. Frontiers in Aging Neuroscience, 0, 14, .	3.4	4
4126	Increased functional connectivity between nucleus basalis of Meynert and amygdala in cognitively intact elderly along the Alzheimer's continuum. NeuroImage: Clinical, 2022, 36, 103256.	2.7	4
4127	SPARE-Tau: A flortaucipir machine-learning derived early predictor of cognitive decline. PLoS ONE, 2022, 17, e0276392.	2.5	1
4128	Cholesterol dysregulation in peripheral blood mononuclear cells of Alzheimer's disease. Journal of Neuroimmunology, 2022, 373, 577996.	2.3	0
4129	Sözel Akıcılık Testleri, Alzheimer Hastalığı klinik ölçütlerine göre evrelenmiş demans ve HKB a yarar saÄŸlayabilir. Cukurova Medical Journal, 0, , 1403-1411.	ayrımı	nda
4130	What a single electroencephalographic (EEG) channel can tell us about patients with dementia due to Alzheimer's disease. International Journal of Psychophysiology, 2022, 182, 169-181.	1.0	4
4131	Relationship between consistent subjective cognitive decline and occurrence of falls six months later. Archives of Gerontology and Geriatrics, 2023, 104, 104841.	3.0	4
4132	Need for an Update for the Guideline for the Management of Mild Cognitive Impairment. Dementia and Neurocognitive Disorders, 2022, 21, 107.	1.4	0
4133	Fluid biomarkers in Alzheimer's disease. Advances in Clinical Chemistry, 2023, , 249-281.	3.7	7
4134	Alterations in metamemory capacity and neural correlates in a subtype of subjective cognitive decline. NeuroImage: Clinical, 2022, 36, 103255.	2.7	3
4135	Subjective cognitive decline in Brazil: Prevalence and association with dementia modifiable risk factors in a populationâ€based study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	3
4136	Ethics of Informed Consent: Coercive and Preventive Medication. , 2022, , 739-753.		0
4137	Parkinson's disease and related disorders. , 2023, , 3-19.		0
4138	A new EEG determinism analysis method based on multiscale dispersion recurrence plot. Biomedical Signal Processing and Control, 2023, 80, 104301.	5.7	1
4139	Bloodâ€based biomarkers for Alzheimer's disease. Progress in Neurology and Psychiatry, 2022, 26, 10-14.	0.9	1
4140	Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer's Disease and Identifying Promising Drug Targets, Biomolecules, 2022, 12, 1676.	4.0	24

4142	Longitudinal neighbourhood determinants with cognitive health and dementia disparities: protocol of the Multi-Ethnic Study of Atherosclerosis Neighborhoods and Aging prospective cohort study. BMJ Open, 2022, 12, e066971.	1.9	4
4143	Bioinformatics tools and data resources for assay development of fluid protein biomarkers. Biomarker Research 2022–10	6.8	8

#	Article	IF	CITATIONS
4144	<scp><i>APOE</i></scp> É>4 allele and <scp><i>TOMM40</i>â€<i>APOC1</i></scp> variants jointly contribute to survival to older ages. Aging Cell, 2022, 21, .	6.7	6
4145	Clinical Correlates of Cerebrospinal Fluid 14-3-3 Protein in Non-Prion Rapid Progressive Dementia. Journal of Alzheimer's Disease, 2022, , 1-10.	2.6	0
4146	Disease specific and nonspecific metabolic brain networks in behavioral variant of frontotemporal dementia. Human Brain Mapping, 2023, 44, 1079-1093.	3.6	7
4147	Alzheimer's Disease: Treatment Strategies and Their Limitations. International Journal of Molecular Sciences, 2022, 23, 13954.	4.1	66
4148	Comparison of performance between an F18-FDG PET normal brain template and a commercial template using the MIMneuro software. Journal of Medical Imaging, 2022, 9, .	1.5	0
4149	Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nature Medicine, 2022, 28, 2381-2387.	30.7	99
4150	Cognitive Performance following Single- or Multi-Session Exercise Intervention in Middle Age: A Systematic Review. Experimental Aging Research, 0, , 1-37.	1.2	0
4151	Blood-based biomarkers in Alzheimer's disease: a mini-review. Metabolic Brain Disease, 2023, 38, 185-193.	2.9	5
4152	Brain metabolic correlates of Locus Coeruleus degeneration in Alzheimer's disease: a multimodal neuroimaging study. Neurobiology of Aging, 2023, 122, 12-21.	3.1	3
4153	Alzheimer disease's cerebrospinal fluid biomarkers differences between immigrants and natives in a Belgian memory clinic. Acta Neurologica Belgica, 0, , .	1.1	0
4155	CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels. Nature Aging, 2022, 2, 1040-1053.	11.6	21
4156	Protein and Gene Delivery Systems for Neurodegenerative Disorders: Where Do We Stand Today?. Pharmaceutics, 2022, 14, 2425.	4.5	8
4157	Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer's Disease in Clinical Practice. International Journal of Molecular Sciences, 2022, 23, 13488.	4.1	0
4158	Altered functional connectivity pattern of hippocampal subfields in individuals with objectivelyâ€defined subtle cognitive decline and its association with cognition and cerebrospinal fluid biomarkers. European Journal of Neuroscience, 2022, 56, 6227-6238.	2.6	2
4159	An Explainable Convolutional Neural Network for the Early Diagnosis of Alzheimer's Disease from 18F-FDG PET. Journal of Digital Imaging, 2023, 36, 189-203.	2.9	4
4162	Science disconnected: the translational gap between basic science, clinical trials, and patient care in Alzheimer's disease. The Lancet Healthy Longevity, 2022, 3, e797-e803.	4.6	6
4164	Omics-based biomarkers discovery for Alzheimer's disease. Cellular and Molecular Life Sciences, 2022, 79, .	5.4	10
4165	Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease. Nature Communications, 2022, 13, .	12.8	40

#	Article	IF	CITATIONS
4166	Current and Future Trends in Biomarkers for the Early Detection of Alzheimer's Disease in Asia: Expert Opinion. Journal of Alzheimer's Disease Reports, 2022, 6, 699-710.	2.2	3
4167	Vascular endothelial adherin as a marker of endothelial injury in preclinical Alzheimer disease. Annals of Clinical and Translational Neurology, 2022, 9, 1926-1940.	3.7	9
4168	Preclinical and clinical imaging techniques as pathophysiological biomarkers — A preface to the special issue "Brain Imaging― Journal of Neurochemistry, 0, , .	3.9	0
4169	Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease. Alzheimer's Research and Therapy, 2022, 14, .	6.2	10
4170	Hippocampal Neuronal Integrity and Functional Connectivity Within the Default Mode Network in Mild Cognitive Impairment: A Multimodal Investigation. Brain Connectivity, 2023, 13, 143-153.	1.7	1
4171	Hyperconnectivity matters in early-onset Alzheimer's disease: a resting-state EEG connectivity study. Neurophysiologie Clinique, 2022, 52, 459-471.	2.2	3
4172	Overview of the blood biomarkers in Alzheimer's disease: Promises and challenges. Revue Neurologique, 2023, 179, 161-172.	1.5	12
4173	Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology. EBioMedicine, 2022, 86, 104336.	6.1	20
4174	Design, synthesis, and preliminary evaluation of [18F]-aryl flurosulfates PET radiotracers via SuFEx methods for β-amyloid plaques in Alzheimer's disease. Bioorganic and Medicinal Chemistry, 2022, 75, 117087.	3.0	3
4175	Associations of the APOE ε2 and ε4 alleles and polygenic profiles comprising APOE-TOMM40-APOC1 variants with Alzheimer's disease biomarkers. Aging, 2022, 14, 9782-9804.	3.1	4
4176	Herpes simplex virus alters Alzheimer's disease biomarkers ―A hypothesis paper. Alzheimer's and Dementia, 2023, 19, 2117-2134.	0.8	6
4177	Endocannabinoid System Biomarkers in Alzheimer's Disease. Cannabis and Cannabinoid Research, 0, , .	2.9	0
4178	Identification of hub proteins in cerebrospinal fluid as potential biomarkers of Alzheimer's disease by integrated bioinformatics. Journal of Neurology, 2023, 270, 1487-1500.	3.6	7
4179	The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [ <sup>18</sup> F]MK6240 Tau PET in Target Regions. Journal of Nuclear Medicine, 2023, 64, 452-459.	5.0	2
4180	Clinical usefulness of cerebrospinal fluid biomarkers in Alzheimer's disease. European Journal of Clinical Investigation, 2023, 53, .	3.4	5
4181	What Are the Key Diagnostic Cognitive Impairment and Dementia Subtypes and How to Integrate all of the Diagnostic Data to Establish a Diagnosis?. Clinics in Geriatric Medicine, 2023, 39, 77-90.	2.6	1
4182	Brain Reserve, Resilience, and Cognitive Stimulation Across the Lifespan. Clinics in Geriatric Medicine, 2023, 39, 151-160.	2.6	2
4183	Plasma pâ€ŧau181/Aβ <sub>1â€42</sub> ratio predicts Aβâ€PET status and correlates with CSFâ€pâ€ŧau181/Aβ <sub>1â€42</sub> and future cognitive decline. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	6

#	Article	IF	Citations
4184	Toward the Identification of Neurophysiological Biomarkers for Alzheimer's Disease in Down Syndrome: A Potential Role for Cross-Frequency Phase-Amplitude Coupling Analysis. , 2022, .		2
4185	Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases. European Journal of Pharmacology, 2023, 938, 175439.	3.5	12
4186	Altered structural and functional homotopic connectivity associated with the progression from mild cognitive impairment to Alzheimer's disease. Psychiatry Research, 2023, 319, 115000.	3.3	3
4187	State-of-the-art imaging of neuromodulatory subcortical systems in aging and Alzheimer's disease: Challenges and opportunities. Neuroscience and Biobehavioral Reviews, 2023, 144, 104998.	6.1	5
4188	Interleukin-17 (IL-17) triggers systemic inflammation, peripheral vascular dysfunction, and related prothrombotic state in a mouse model of Alzheimer's disease. Pharmacological Research, 2023, 187, 106595.	7.1	8
4189	Brain PET Imaging. PET Clinics, 2023, 18, 103-113.	3.0	0
4190	Alzheimer's disease-like cortical atrophy mediates the effect of air pollution on global cognitive function. Environment International, 2023, 171, 107703.	10.0	6
4191	New unexpected role for Wolfram Syndrome protein WFS1: a novel therapeutic target for Alzheimer's disease?. Neural Regeneration Research, 2023, 18, 1501.	3.0	3
4192	Advanced theragnostics for the central nervous system (CNS) and neurological disorders using functional inorganic nanomaterials. Advanced Drug Delivery Reviews, 2023, 192, 114636.	13.7	7
4193	Plasma neurofilament light chain in memory clinic practice: Evidence from a real-life study. Neurobiology of Disease, 2023, 176, 105937.	4.4	8
4194	Mediterranean diet and structural neuroimaging biomarkers of Alzheimer's and cerebrovascular disease: A systematic review. Experimental Gerontology, 2023, 172, 112065.	2.8	8
4195	The metal ion hypothesis of Alzheimer's disease and the anti-neuroinflammatory effect of metal chelators. Bioorganic Chemistry, 2023, 131, 106301.	4.1	35
4196	Direct coupling of fiber-in-tube solid-phase microextraction with tandem mass spectrometry to determine amyloid beta peptides as biomarkers for Alzheimer's disease in cerebrospinal fluid samples. Talanta, 2023, 254, 124186.	5.5	5
4197	Sleep disturbance predicts worse cognitive performance in subsequent years: A longitudinal population-based cohort study. Archives of Gerontology and Geriatrics, 2023, 106, 104899.	3.0	8
4198	Evolution of the diagnostic frontiers of Alzheimer's disease and new therapeutic possibilities. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 38.	0.7	0
4199	Memoryâ€driven eye movements prospectively predict dementia in people at risk of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	1
4200	Cerebrospinal fluid levels of fatty acid–binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	2.4	3
4201	Alzheimer Disease Biomarkers in Clinical Practice: A Blood-Based Diagnostic Revolution. Journal of Primary Care and Community Health, 2022, 13, 215013192211411.	2.1	2

#	Article	IF	CITATIONS
4202	3T sodium MR imaging in Alzheimer's disease shows stage-dependent sodium increase influenced by age and local brain volume. NeuroImage: Clinical, 2022, 36, 103274.	2.7	1
4203	The CircRNAs for Diagnostic, Prognostic, and Therapy in Alzheimer's Disease. Advances in Bioscience and Biotechnology (Print), 2022, 13, 507-526.	0.7	0
4204	Diagnóstico do comprometimento cognitivo vascular: recomendações do Departamento CientÃfico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. Dementia E Neuropsychologia, 2022, 16, 53-72.	0.8	2
4205	Diagnosis of vascular cognitive impairment: recommendations of the scientific department of cognitive neurology and aging of the Brazilian Academy of Neurology. Dementia E Neuropsychologia, 2022, 16, 53-72.	0.8	1
4206	Toward the optimized assessment of clinical outcomes in studies of novel treatments for Alzheimer's disease. Expert Review of Neurotherapeutics, 2022, 22, 863-873.	2.8	1
4207	Systematic evaluation of urinary formic acid as a new potential biomarker for Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	3.4	9
4208	Who's driving? The default mode network in healthy elderly individuals at risk of cognitive decline. Frontiers in Neurology, 0, 13, .	2.4	1
4209	Cerebrospinal Fluid Biomarkers in iNPH: A Narrative Review. Diagnostics, 2022, 12, 2976.	2.6	1
4210	Cerebrospinal fluid/serum albumin quotient (Q-Alb) is not increased in Alzheimer's disease compared to neurological disease controls: a retrospective study on 276 patients. Neurological Sciences, 2023, 44, 709-713.	1.9	2
4211	Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer's disease pathology. Nature Aging, 2022, 2, 1138-1144.	11.6	19
4212	Mapping the current trends and hotspots of vascular cognitive impairment from 2000–2021: A bibliometric analysis. CNS Neuroscience and Therapeutics, 2023, 29, 771-782.	3.9	6
4213	Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort. Neurology, 2023, 100, e860-e873.	1.1	16
4214	Brain Microstructural Changes in Patients with Amnestic mild Cognitive Impairment. Clinical Neuroradiology, 0, , .	1.9	1
4215	Kinetic evaluation and assessment of longitudinal changes in reference region and extracerebral [ <sup>18</sup> F]MK-6240 PET uptake. Journal of Cerebral Blood Flow and Metabolism, 2023, 43, 581-594.	4.3	5
4216	Autoimmune Encephalitis Misdiagnosis in Adults. JAMA Neurology, 2023, 80, 30.	9.0	77
4217	Identification of causal effects of neuroanatomy on cognitive decline requires modeling unobserved confounders. Alzheimer's and Dementia, 0, , .	0.8	0
4218	The Frontal Assessment Battery (FAB) effectively discriminates between MCI and dementia within the clinical spectrum of neurochemically confirmed Alzheimer's disease. Frontiers in Psychology, 0, 13, .	2.1	1
4219	Connectivity between default mode and frontoparietal networks mediates the association between global amyloidâ€î² and episodic memory. Human Brain Mapping, 2023, 44, 1147-1157.	3.6	4

#	Article	IF	CITATIONS
4220	Evidence of Filamin A loss of solubility at the prodromal stage of neuropathologically-defined Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	3.4	4
4221	Cell type-specific changes identified by single-cell transcriptomics in Alzheimer's disease. Genome Medicine, 2022, 14, .	8.2	14
4222	Blood Pressure Variability and Cognitive Decline: A Post Hoc Analysis of the SPRINT MIND Trial. American Journal of Hypertension, 2023, 36, 168-175.	2.0	7
4224	Plasma Leptin Is Associated With Amyloid CSF Biomarkers and Alzheimer's Disease Diagnosis in Cognitively Impaired Patients. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 645-652.	3.6	9
4225	What a Single Electroencephalographic (EEG) Channel Can Tell us About Alzheimer's Disease Patients With Mild Cognitive Impairment. Clinical EEG and Neuroscience, 2023, 54, 21-35.	1.7	3
4226	A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson's disease. Npj Parkinson's Disease, 2022, 8, .	5.3	4
4227	Research Evidence of the Role of the Glymphatic System and Its Potential Pharmacological Modulation in Neurodegenerative Diseases. Journal of Clinical Medicine, 2022, 11, 6964.	2.4	11
4228	Data and sample sharing as an enabler for large-scale biomarker research and development: The EPND perspective. Frontiers in Neurology, 0, 13, .	2.4	4
4230	Precision medicine for Parkinson's disease: The subtyping challenge. Frontiers in Aging Neuroscience, 0, 14, .	3.4	2
4232	Plasma phosphorylated tau181 predicts cognitive and functional decline. Annals of Clinical and Translational Neurology, 2023, 10, 18-31.	3.7	7
4233	The Strategies for Treating "Alzheimer's Disease― Insulin Signaling May Be a Feasible Target. Current Issues in Molecular Biology, 2022, 44, 6172-6188.	2.4	5
4235	Hierarchical Two-Stage Cost-Sensitive Clinical Decision Support System for Screening Prodromal Alzheimer's Disease and Related Dementias. Journal of Alzheimer's Disease, 2023, 91, 895-909.	2.6	3
4236	Neuroinflammation is independently associated with brain network dysfunction in Alzheimer's disease. Molecular Psychiatry, 2023, 28, 1303-1311.	7.9	22
4237	Features of Cerebral Small Vessel Disease Contributes to the Differential Diagnosis of Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 91, 795-804.	2.6	1
4239	The effects of herbal medicine (Jujadokseo-hwan) on quality of life in patients with mild cognitive impairment: Cost-effectiveness analysis alongside randomized controlled trial. Integrative Medicine Research, 2022, , 100914.	1.8	0
4240	Persisting neuropsychiatric symptoms, Alzheimer's disease, and cerebrospinal fluid cortisol and dehydroepiandrosterone sulfate. Alzheimer's Research and Therapy, 2022, 14, .	6.2	4
4241	Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration. Brain, 2023, 146, 1152-1165.	7.6	58
4242	Hippocampal subfield volumetry in corticobasal syndrome of diverse underlying pathologies. Journal of Neurology, 2023, 270, 2059-2068.	3.6	1
#	Article	IF	CITATIONS
------	--	------	-----------
4243	Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia. Nature Communications, 2022, 13, .	12.8	21
4245	Clinical and Economic Assessment in Early-Stage Dementia by Severity and Amyloid-β Status: A 5-Year Retrospective Claims Study of GERAS-US Patients. Journal of Alzheimer's Disease, 2022, , 1-13.	2.6	1
4246	Volume atrophy in medial temporal cortex and verbal memory scores in American Indians: Data from the Strong Heart Study. Alzheimer's and Dementia, 2023, 19, 2298-2306.	0.8	3
4247	Quantification of [ <sup>18</sup> F]florbetaben amyloidâ€PET imaging in a mixed memory clinic population: The ABIDE project. Alzheimer's and Dementia, 2023, 19, 2397-2407.	0.8	3
4248	Aβ42 as a Biomarker of Alzheimer's Disease: Is Saliva a Viable Alternative to Cerebrospinal Fluid?. Brain Sciences, 2022, 12, 1729.	2.3	2
4249	Associations of phosphorylated tau pathology with wholeâ€hemisphere ex vivo morphometry in 7 tesla MRI. Alzheimer's and Dementia, 0, , .	0.8	2
4250	Blood-brain barrier disruption measured by albumin index correlates with inflammatory fluid biomarkers. Journal of Cerebral Blood Flow and Metabolism, 2023, 43, 712-721.	4.3	7
4251	The Early Diagnosis of Alzheimer's Disease: A Patient-Centred Conversation with the Care Team. Neurology and Therapy, 0, , .	3.2	1
4252	GRK5 Deficiency in the Hippocampus Leads to Cognitive Impairment via Abnormal Microglial Alterations. Molecular Neurobiology, 0, , .	4.0	0
4255	Tau PET Visual Reads: Research and Clinical Applications and Future Directions. Journal of Nuclear Medicine, 0, , jnumed.122.265017.	5.0	0
4256	The Role of Construct Specification Equations and Entropy in the Measurement of Memory. Springer Series in Measurement Science and Technology, 2023, , 269-309.	0.8	1
4257	Gray to white matter signal ratio as a novel biomarker of neurodegeneration in Alzheimer's disease. NeuroImage: Clinical, 2023, 37, 103303.	2.7	2
4258	Effects of multi-mode physical stimulation on APP/PS1 Alzheimer's disease model mice. Heliyon, 2022, 8, e12366.	3.2	1
4259	Vitamin D in Neurological Diseases. International Journal of Molecular Sciences, 2023, 24, 87.	4.1	13
4260	The <scp> <i>APOE4</i> </scp> effect: structural brain differences in Alzheimer's disease according to the age at symptom onset. European Journal of Neurology, 0, , .	3.3	1
4261	Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurology, 2023, 80, 188.	9.0	55
4262	Differences in resting state functional connectivity underlie visuomotor performance declines in older adults with a genetic risk (APOE ε4) for Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	3.4	0
4263	Development of a quantitative semiâ€mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Qâ€ATN model). Alzheimer's and Dementia, 2023, 19, 2287-2297.	0.8	1

#	Article	IF	CITATIONS
4265	Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline. ACS Chemical Neuroscience, 2023, 14, 170-179.	3.5	4
4266	Diffusion Changes in Hippocampal Cingulum in Early Biologically Defined Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, , 1-11.	2.6	0
4267	PICALM rs3851179 Variants Modulate Left Postcentral Cortex Thickness, CSF Amyloid β42, and Phosphorylated Tau in the Elderly. Brain Sciences, 2022, 12, 1681.	2.3	2
4268	A framework for addressing Alzheimer's disease: Without a frame, the work has no aim. Alzheimer's and Dementia, 2023, 19, 1568-1578.	0.8	1
4269	Preserved visuoconstruction in patients with Alzheimer's pathology and anti-neural autoantibodies: A case control study. , 0, 1, .		0
4271	Sexually Dimorphic Association of Circulating Plasminogen Activator Inhibitor-1 Levels and Body Mass Index with Cerebrospinal Fluid Biomarkers of Alzheimer's Pathology in Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, , 1-11.	2.6	1
4272	Salivary Aβ1–42 may be a quick-tested biomarker for clinical use in Alzheimer's disease: a meta-analysis. Journal of Neurology, 2023, 270, 1945-1954.	3.6	5
4273	Functional brain networks in the evaluation of patients with neurodegenerative disorders. Nature Reviews Neurology, 2023, 19, 73-90.	10.1	17
4274	The effect of the cyclic GMP-AMP synthase-stimulator of interferon genes signaling pathway on organ inflammatory injury and fibrosis. Frontiers in Pharmacology, 0, 13, .	3.5	0
4276	Transferability of Alzheimer Disease Polygenic Risk Score Across Populations and Its Association With Alzheimer Disease-Related Phenotypes. JAMA Network Open, 2022, 5, e2247162.	5.9	15
4277	Proteomic profiling of circulating plasma exosomes reveals novel biomarkers of Alzheimer's disease. Alzheimer's Research and Therapy, 2022, 14, .	6.2	11
4279	Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer's disease continuum. Molecular Neurodegeneration, 2022, 17, .	10.8	21
4280	Projective diffeomorphic mapping of molecular digital pathology with tissue MRI. , 2022, 1, .		3
4281	Handgrip Strength Is Related to Hippocampal and Lobar Brain Volumes in a Cohort of Cognitively Impaired Older Adults with Confirmed Amyloid Burden. Journal of Alzheimer's Disease, 2023, 91, 999-1006.	2.6	4
4282	White matter hyperintensity, neurofilament light chain, and cognitive decline. Annals of Clinical and Translational Neurology, 2023, 10, 321-327.	3.7	3
4283	Health Conditions Associated with Alzheimer's Disease and Vascular Dementia. Annals of Neurology, 2023, 93, 805-818.	5.3	2
4284	Mayoâ€PACC: A parsimonious preclinical Alzheimer's disease cognitive composite comprised of publicâ€domain measures to facilitate clinical translation. Alzheimer's and Dementia, 2023, 19, 2575-2584.	0.8	6
4285	Medial temporal tau predicts memory decline in cognitively unimpaired elderly. Brain Communications, 2022, 5, .	3.3	5

#	Article	IF	CITATIONS
4286	Design and application of a customizable relational <scp>DataBase</scp> to assess clinicopathological correlations and concomitant pathology in neurodegenerative diseases. Brain Pathology, 2023, 33, .	4.1	3
4287	Coherence in event-related EEG oscillations in patients with Alzheimer's disease dementia and amnestic mild cognitive impairment. Cognitive Neurodynamics, 2023, 17, 1621-1635.	4.0	2
4288	How far is the goal of applying β-amyloid in cerebrospinal fluid for clinical diagnosis of Alzheimer's disease with standardization of measurements?. Clinical Biochemistry, 2023, 112, 33-42.	1.9	3
4289	The potential diagnostic accuracy of urine formaldehyde levels in Alzheimer's disease: A systematic review and meta-analysis. Frontiers in Aging Neuroscience, 0, 14, .	3.4	4
4290	Proteomic clusters underlie heterogeneity in preclinical Alzheimer's disease progression. Brain, 2023, 146, 2944-2956.	7.6	4
4291	Association of CSF GAP-43 and APOE ε4 with Cognition in Mild Cognitive Impairment and Alzheimer's Disease. Cells, 2023, 12, 13.	4.1	3
4292	Vascular contributions to Alzheimer's disease. Translational Research, 2023, 254, 41-53.	5.0	26
4293	Assessment of perfusion deficit with early phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol-amyloid-PET recordings. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1384-1394.	6.4	3
4294	CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease. Neurology, 2023, 100, .	1.1	5
4295	A Qualitative Examination of Knowledge, Experiences, and Considerations of PET Brain Scan Participation Among Older Black and Latino Adults. Journal of Alzheimer's Disease, 2022, , 1-16.	2.6	0
4296	Microglial Activation and Priming in Alzheimer's Disease: State of the Art and Future Perspectives. International Journal of Molecular Sciences, 2023, 24, 884.	4.1	12
4297	Priorities for research on neuromodulatory subcortical systems in Alzheimer's disease: Position paper from the NSS PIA of ISTAART. Alzheimer's and Dementia, 2023, 19, 2182-2196.	0.8	11
4298	Nicotinamide as potential biomarker for Alzheimer's disease: A translational study based on metabolomics. Frontiers in Molecular Biosciences, 0, 9, .	3.5	2
4299	The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort. journal of prevention of Alzheimer's disease, The, 0, , .	2.7	0
4300	Translational potential of synaptic alterations in Alzheimer`s disease patients and <i>App</i> knock-in mice. Brain Communications, 0, , .	3.3	0
4301	Current Updates and Unmet Needs of Brain MRI-Based Artificial Intelligence Software for Patients With Neurodegenerative Diseases in the Republic of Korea. Investigative Magnetic Resonance Imaging, 2022, 26, 237.	0.4	0
4302	CSF biomarkers for early-onset Alzheimer's disease in Chinese population from PUMCH dementia cohort. Frontiers in Neurology, 0, 13, .	2.4	1
4303	Structural But Not Functional Connectivity Differences within Default Mode Network Indicate Conversion to Dementia. Journal of Alzheimer's Disease, 2023, , 1-12.	2.6	2

#	Article	IF	CITATIONS
4304	Alzheimer's disease and synapse Loss: What can we learn from induced pluripotent stem Cells?. Journal of Advanced Research, 2023, 54, 105-118.	9.5	5
4305	The role of anxiety and depressive symptoms in mediating the relationship between subjective sleep quality and cognitive function among older adults in China. Journal of Affective Disorders, 2023, 325, 640-646.	4.1	4
4306	A gene variant protects against Alzheimer's disease. Aging Brain, 2023, 3, 100063.	1.3	0
4307	Functional Network Alterations Associated with Cognition in Pre-Clinical Alzheimer's Disease. Brain Connectivity, 2023, 13, 275-286.	1.7	2
4308	A Case of Minimally Progressive Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 0, , 1-4.	2.2	0
4309	Potential Anti-Cholinesterase Activity of Bioactive Compounds Extracted from Cassia grandis L.f. and Cassia timoriensis DC Plants, 2023, 12, 344.	3.5	1
4310	Rapid Eye Movement Sleep, Neurodegeneration, and Amyloid Deposition in Aging. Annals of Neurology, 2023, 93, 979-990.	5.3	8
4311	Crossâ€sectional and longitudinal comparisons of biomarkers and cognition among asymptomatic middleâ€aged individuals with a parental history of either autosomal dominant or lateâ€onset Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 2923-2932.	0.8	1
4312	Longitudinal changes in 18F-Flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: Methodological considerations. NeuroImage: Clinical, 2023, 37, 103321.	2.7	1
4314	Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multiâ€cohort study. Alzheimer's and Dementia, 2023, 19, 2943-2955.	0.8	12
4315	Plasma biomarkers for neurodegenerative disorders: ready for prime time?. Current Opinion in Psychiatry, 2023, 36, 112-118.	6.3	12
4316	Plasma biomarker profiles in autosomal dominant Alzheimer's disease. Brain, 2023, 146, 1132-1140.	7.6	19
4317	Sporadic Creutzfeldt–Jakob disease is associated with reorganization of metabolic connectivity in a pathological brain network. European Journal of Neurology, 0, , .	3.3	3
4318	The Role of the JAK/STAT Signaling Pathway in the Pathogenesis of Alzheimer's Disease: New Potential Treatment Target. International Journal of Molecular Sciences, 2023, 24, 864.	4.1	25
4319	<i>GSN</i> gene frameshift mutations in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 436-447.	1.9	3
4320	Prion Protein Complex with mGluR5 Mediates Amyloid-ß Synaptic Loss in Alzheimer's Disease. , 2023, , 467-481.		0
4321	<scp>sTREM2</scp> is associated with amyloidâ€related pâ€tau increases and glucose hypermetabolism in Alzheimer's disease. EMBO Molecular Medicine, 2023, 15, .	6.9	13
4322	Transcranial alternating current stimulation combined with sound stimulation improves cognitive function in patients with Alzheimer's disease: Study protocol for a randomized controlled trial. Frontiers in Aging Neuroscience, 0, 14, .	3.4	3

#	Article	IF	CITATIONS
4323	Systematic Review of EEG Coherence in Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 91, 1261-1272.	2.6	2
4324	A blood mRNA panel that differentiates Alzheimer's disease from other dementia types. Journal of Neurology, 0, , .	3.6	1
4325	The foundation and architecture of precision medicine in neurology and psychiatry. Trends in Neurosciences, 2023, 46, 176-198.	8.6	29
4326	Pre-targeting amyloid-β with antibodies for potential molecular imaging of Alzheimer's disease. Chemical Communications, 2023, 59, 2243-2246.	4.1	3
4327	Exploring the combined effects of sleep apnea and APOE-e4 on biomarkers of Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	3.4	2
4328	Parsing an Early Stage of Alzheimer's Disease: Obj-SCD Versus SCD. Neuroscience, 2023, , .	2.3	0
4329	Fornix degeneration in risk factors of Alzheimer's disease, possible trigger of cognitive decline Cerebral Circulation - Cognition and Behavior, 2023, , 100158.	0.9	3
4330	Neuropsychological Assessment in the Distinction Between Biomarker Defined Frontal-Variant of Alzheimer's Disease and Behavioral-Variant of Frontotemporal Dementia. Journal of Alzheimer's Disease, 2023, 91, 1303-1312.	2.6	1
4331	Functional Correlates of Striatal Dopamine Transporter Cerebrospinal Fluid Levels in Alzheimer's Disease: A Preliminary 18F-FDG PET/CT Study. International Journal of Molecular Sciences, 2023, 24, 751.	4.1	3
4332	Optimizing the Aging Brain: The BEAD Study on the Ethics of Dementia Prevention. Journal of Frailty & Aging,the, 0, , .	1.3	1
4333	Novel heterozygous mutation in alpha-2-macroglobulin (A2M) suppressing the binding of amyloid-β (Aβ). Frontiers in Neurology, 0, 13, .	2.4	1
4334	Visuoconstructional Abilities of Patients With Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease. Journal of Geriatric Psychiatry and Neurology, 0, , 089198872211355.	2.3	0
4335	Cerebrospinal Fluid Homer-3 Autoantibodies in a Patient with Amnestic Mild Cognitive Impairment. Brain Sciences, 2023, 13, 125.	2.3	1
4336	The Synergic Effect of AT(N) Profiles and Depression on the Risk of Conversion to Dementia in Patients with Mild Cognitive Impairment. International Journal of Molecular Sciences, 2023, 24, 1371.	4.1	3
4337	ls Citicoline Effective in Preventing and Slowing Down Dementia?—A Systematic Review and a Meta-Analysis. Nutrients, 2023, 15, 386.	4.1	4
4338	Application of the AT(N) and Other CSF Classification Systems in Behavioral Variant Frontotemporal Dementia. Diagnostics, 2023, 13, 332.	2.6	1
4339	A Review on Phyto-Therapeutic Approaches in Alzheimer's Disease. Journal of Functional Biomaterials, 2023, 14, 50.	4.4	5
4340	Altered Mitochondrial Morphology and Bioenergetics in a New Yeast Model Expressing Al <sup>2</sup> 42. International Journal of Molecular Sciences, 2023, 24, 900.	4.1	5

#	Article	IF	CITATIONS
43	Insomnia Symptoms and Biomarkers of Alzheimer's Disease in the Community. Journal of Alzheimer's Disease, 2023, 91, 1423-1434.	2.6	1
43	Efficient Training on Alzheimer's Disease Diagnosis with Learnable Weighted Pooling for 3D PET Brain Image Classification. Electronics (Switzerland), 2023, 12, 467.	3.1	7
43	APOE Îμ4 status and plasma p-tau181 interact to influence cognitive performance among non-demented older adults. Neuroscience Letters, 2023, 796, 137052.	2.1	2
43	Assess the documentation of cognitive tests and biomarkers in electronic health records via natural language processing for Alzheimer's disease and related dementias. International Journal of Medical Informatics, 2023, 170, 104973.	3.3	3
43	MDS-UDPRS-III in the diagnosis of idiopathic Normal Pressure Hydrocephalus and identification of candidates for Ventriculo-Peritoneal Shunting surgery. Results from a retrospective large cohort of patients. Journal of the Neurological Sciences, 2023, 445, 120536.	0.6	1
43	The TgF344-AD rat: behavioral and proteomic changes associated with aging and protein expression in a transgenic rat model of Alzheimer's disease. Neurobiology of Aging, 2023, 123, 98-110.	3.1	4
43	Machine Learning Reveals a Multipredictor Nomogram for Diagnosing the Alzheimer's Disease Based on Chemiluminescence Immunoassay for Total Tau in Plasma. Frontiers in Aging Neuroscience, 0, 14, .	3.4	0
43	Use of the Laboratory in the Diagnostic Workup of Older Adults. , 2022, , .		0
43	Neuropsychological Assessment of Late-Life Cognitive Disorders. , 2022, , .		0
43	Epidemiology of Psychiatric Disorders in Later Life. , 2022, , .		Ο
43 43	<ul> <li>Epidemiology of Psychiatric Disorders in Later Life. , 2022, , .</li> <li>AÎ<sup>2</sup>42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts. Alzheimer's Research and Therapy, 2022, 14, .</li> </ul>	6.2	0
43 43 43	<ul> <li>Epidemiology of Psychiatric Disorders in Later Life. , 2022, , .</li> <li>AÎ<sup>2</sup>42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts. Alzheimer's Research and Therapy, 2022, 14, .</li> <li>Exploring cognitive and biological correlates of sleep quality and their potential links with Alzheimer's disease (ALFASleep project): protocol for an observational study. BMJ Open, 2022, 12, e067159.</li> </ul>	6.2 1.9	0 3 1
43 43 43 43	<ul> <li>Epidemiology of Psychiatric Disorders in Later Life. , 2022, , .</li> <li>AÎ<sup>2</sup>42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts. Alzheimer's Research and Therapy, 2022, 14, .</li> <li>Exploring cognitive and biological correlates of sleep quality and their potential links with Alzheimer's disease (ALFASleep project): protocol for an observational study. BMJ Open, 2022, 12, e067159.</li> <li>Dynamic changes of CSF clusterin levels across the Alzheimer's disease continuum. BMC Neurology, 2022, 22, .</li> </ul>	6.2 1.9 1.8	0 3 1 5
43 43 43 43 43	<ul> <li>Epidemiology of Psychiatric Disorders in Later Life. , 2022, , .</li> <li>AÎ<sup>2</sup>42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts. Alzheimer's Research and Therapy, 2022, 14, .</li> <li>Exploring cognitive and biological correlates of sleep quality and their potential links with Alzheimer's disease (ALFASleep project): protocol for an observational study. BMJ Open, 2022, 12, e067159.</li> <li>Dynamic changes of CSF clusterin levels across the Alzheimer's disease continuum. BMC Neurology, 2022, 22, .</li> <li>Multifaceted Pharmacological Potentials of Curcumin, Genistein, and Tanshinone IIA through Proteomic Approaches: An In-Depth Review. Cancers, 2023, 15, 249.</li> </ul>	6.2 1.9 1.8 3.7	0 3 1 5 7
43 43 43 43 43 43	<ul> <li>Epidemiology of Psychiatric Disorders in Later Life. , 2022, , .</li> <li>AÎ<sup>2</sup>42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts. Alzheimer's Research and Therapy, 2022, 14, .</li> <li>Exploring cognitive and biological correlates of sleep quality and their potential links with Alzheimer's disease (ALFASleep project): protocol for an observational study. BMJ Open, 2022, 12, e067159.</li> <li>Dynamic changes of CSF clusterin levels across the Alzheimer's disease continuum. BMC Neurology, 2022, 22, .</li> <li>Multifaceted Pharmacological Potentials of Curcumin, Genistein, and Tanshinone IIA through Proteomic Approaches: An In-Depth Review. Cancers, 2023, 15, 249.</li> <li>Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases. Diagnostics, 2023, 13, 73.</li> </ul>	6.2 1.9 1.8 3.7 2.6	0 3 1 5 7 2
<ul> <li>43</li> <li>43</li> <li>43</li> <li>43</li> <li>43</li> <li>43</li> <li>43</li> </ul>	<ul> <li>Epidemiology of Psychiatric Disorders in Later Life. , 2022, , .</li> <li>AÎ<sup>2</sup>42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts. Alzheimer's Research and Therapy, 2022, 14, .</li> <li>Exploring cognitive and biological correlates of sleep quality and their potential links with Alzheimer's disease (ALFASIeep project): protocol for an observational study. BMJ Open, 2022, 12, e067159.</li> <li>Dynamic changes of CSF clusterin levels across the Alzheimer's disease continuum. BMC Neurology, 2022, 22, .</li> <li>Multifaceted Pharmacological Potentials of Curcumin, Genistein, and Tanshinone IIA through Proteomic Approaches: An In-Depth Review. Cancers, 2023, 15, 249.</li> <li>Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases. Diagnostics, 2023, 13, 73.</li> <li>Lower semantic fluency scores and a phonemic-over-semantic advantage predict abnormal CSF P-tau181 levels in Al²â€‰+ patients within the Alzheimer〙s disease clinical spectrum. Neurological Sciences, C</li> </ul>	6.2 1.9 1.8 3.7 2.6 ), , . 1.9	0 3 1 5 7 2 1
<ul> <li>43</li> <li>43</li> <li>43</li> <li>43</li> <li>43</li> <li>43</li> <li>43</li> <li>43</li> </ul>	<ul> <li>Epidemiology of Psychiatric Disorders in Later Life. , 2022, , .</li> <li>Aî<sup>2</sup>42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts. Alzheimer's Research and Therapy, 2022, 14, .</li> <li>Exploring cognitive and biological correlates of sleep quality and their potential links with Alzheimer's disease (ALFASIeep project): protocol for an observational study. BMJ Open, 2022, 12, e067159.</li> <li>Dynamic changes of CSF clusterin levels across the Alzheimer's disease continuum. BMC Neurology, 2022, 22, .</li> <li>Multifaceted Pharmacological Potentials of Curcumin, Cenistein, and Tanshinone IIA through Proteomic Approaches: An In-Depth Review. Cancers, 2023, 15, 249.</li> <li>Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases. Diagnostics, 2023, 13, 73.</li> <li>Lower semantic fluency scores and a phonemic-over-semantic advantage predict abnormal CSF P-tau181 levels in Al²ã€‰+〉patients within the Alzheimer〙s disease clinical spectrum. Neurological Sciences, of Alzheimer〙s Disease. Journal of Personalized Medicine, 2023, 13, 208.</li> </ul>	6.2 1.9 1.8 3.7 2.6 0, , . 1.9 2.5	0 3 1 5 7 2 1 3
<ul> <li>43</li> <li>43</li> <li>43</li> <li>43</li> <li>43</li> <li>43</li> <li>43</li> <li>43</li> <li>43</li> </ul>	<ul> <li>Epidemiology of Psychiatric Disorders in Later Life. , 2022, , .</li> <li>Al<sup>2</sup>42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts. Alzheimer's Research and Therapy, 2022, 14, .</li> <li>Exploring cognitive and biological correlates of sleep quality and their potential links with Alzheimer's disease (ALFASIeep project): protocol for an observational study. BMJ Open, 2022, 12, e067159.</li> <li>Dynamic changes of CSF clusterin levels across the Alzheimer's disease continuum. BMC Neurology, 2022, 22, .</li> <li>Multifaceted Pharmacological Potentials of Curcumin, Genistein, and Tanshinone IIA through Proteomic Approaches: An In-Depth Review. Cancers, 2023, 15, 249.</li> <li>Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases. Diagnostics, 2023, 13, 73.</li> <li>Lower semantic fluency scores and a phonemic-over-semantic advantage predict abnormal CSF P-tau181 levels in Al<sup>2</sup>Ae‰+A€‰patients within the Alzheimer's disease clinical spectrum. Neurological Sciences, Q Alzheimer's Disease. Journal of Personalized Medicine, 2023, 13, 208.</li> <li>Selective In Vitro and Ex Vivo Staining of Brain Neurofibrillary Tangles and Amyloid Plaques by Novel Ethylene Ethynylene-Based Optical Sensors. Biosensors, 2023, 13, 151.</li> </ul>	6.2 1.9 1.8 3.7 2.6 0,,. 1.9 2.5 4.7	0 3 1 2 2 1 3 3

#	Article	IF	CITATIONS
4363	Separation of Isomeric Tau Phosphopeptides from Alzheimer's Disease Brain by Cyclic Ion Mobility Mass Spectrometry. Journal of the American Society for Mass Spectrometry, 2023, 34, 394-400.	2.8	5
4364	WissensbestÄ <b>¤</b> de und Wissensquellen im Entscheidungsprozess zur RisikoprÄ <b>d</b> iktion der Alzheimer-Demenz. Medizinische Expert*innen und andere epistemische AutoritĤen. , 2023, , 111-124.		1
4366	Classifying Alzheimer's disease and frontotemporal dementia using machine learning with crossâ€sectional and longitudinal magnetic resonance imaging data. Human Brain Mapping, 2023, 44, 2234-2244.	3.6	4
4368	Predictive Utility of Plasma Amyloid and Tau for Cognitive Decline in Cognitively Normal Adults. journal of prevention of Alzheimer's disease, The, 0, , .	2.7	0
4369	Robustness of CSF Aβ42/40 and Aβ42/Pâ€ŧau181 measured using fully automated immunoassays to detect ADâ€related outcomes. Alzheimer's and Dementia, 2023, 19, 2994-3004.	0.8	4
4370	Development of digital voice biomarkers and associations with cognition, cerebrospinal biomarkers, and neural representation in early Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	9
4371	The Vascular-Immune Hypothesis of Alzheimer's Disease. Biomedicines, 2023, 11, 408.	3.2	5
4372	Alzheimer's Disease: Not Just for the Aged?. Journal of Alzheimer's Disease, 2023, 91, 923-924.	2.6	1
4373	Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum. Neurology, 2023, 100, 1010-1019.	1.1	13
4374	Interactions Between Neuropsychiatric Symptoms and Alzheimer's Disease Neuroimaging Biomarkers in Predicting Longitudinal Cognitive Decline. Psychiatric Research and Clinical Practice, 2023, 5, 4-15.	2.4	2
4375	Glial cell transcriptome analyses in 3xTg-AD mice: Effects of aging, disease progression, and anti-Aβ immunotherapy. Aging Brain, 2023, 3, 100066.	1.3	3
4377	Intrasession Repeatability of Optical Coherence Tomography Angiography Parameters in Neurodegenerative Disease. Ophthalmology Science, 2023, , 100275.	2.5	0
4378	Molecular Mechanisms of Neuroinflammation in Aging and Alzheimer's Disease Progression. International Journal of Molecular Sciences, 2023, 24, 1869.	4.1	25
4379	Interplay between the catecholaminergic enzymatic axis and neurodegeneration/neuroinflammation processes in the Alzheimer's disease continuum. European Journal of Neurology, 2023, 30, 839-848.	3.3	4
4380	Validity of Normative Volumetric Estimates from Open Access Software in Amnestic Mild Cognitive Impairment. journal of prevention of Alzheimer's disease, The, 0, , .	2.7	0
4381	Ethical Aspects of Prodromal Synucleinopathy Prognostic Counseling. Seminars in Neurology, 2023, 43, 166-177.	1.4	6
4382	Brain Gray Matter Volume Mediated the Correlation Between Plasma P-Tau and Cognitive Function of Early Alzheimer's Disease in China: A Cross-Sectional Observational Study. Journal of Alzheimer's Disease, 2023, 92, 81-93.	2.6	2
4383	Decreased Cerebrospinal Fluid Amyloid Î <sup>2</sup> 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy. Annals of Neurology, 2023, 93, 1173-1186.	5.3	11

#	Article	IF	CITATIONS
4384	Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	4
4385	Thwarting Alzheimer's Disease through Healthy Lifestyle Habits: Hope for the Future. Neurology International, 2023, 15, 162-187.	2.8	3
4386	Plasma biomarkers predict amyloid pathology in cognitively normal monozygotic twins after 10 years. Brain Communications, 2022, 5, .	3.3	3
4387	The association between white matter hyperintensities and amyloid and tau deposition. NeuroImage: Clinical, 2023, 38, 103383.	2.7	5
4388	Role of novel endpoints and evaluations of response in Parkinson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 325-345.	1.8	0
4389	Cognitive and behavioral abnormalities in individuals with Alzheimer's disease, mild cognitive impairment, and subjective memory complaints. Current Psychology, 2024, 43, 800-810.	2.8	4
4390	Multiomics profiling of human plasma and cerebrospinal fluid reveals ATNâ€derived networks and highlights causal links in Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 3350-3364.	0.8	2
4393	Predicting amyloid PET and tau PET stages with plasma biomarkers. Brain, 2023, 146, 2029-2044.	7.6	22
4394	Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment. Journal of Nanobiotechnology, 2023, 21, .	9.1	2
4395	Corneal nerve loss predicts dementia in patients with mild cognitive impairment. Annals of Clinical and Translational Neurology, 0, , .	3.7	1
4396	Individualized network analysis: A novel approach to investigate tau PET using graph theory in the Alzheimer's disease continuum. Frontiers in Neuroscience, 0, 17, .	2.8	2
4397	Bloodâ€brain barrier integrity impacts the use of plasma amyloidâ€Î² as a proxy of brain amyloidâ€Î² pathology. Alzheimer's and Dementia, 2023, 19, 3815-3825.	0.8	6
4398	Natural IgG antibodies to β amyloid are decreased in patients with Parkinson's disease. Immunity and Ageing, 2023, 20, .	4.2	0
4400	Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease. Chinese Medical Journal, 2023, 136, 505-521.	2.3	4
4401	Neuropsychiatric Symptoms and Commonly Used Biomarkers of Alzheimer's Disease: A Literature Review from a Machine Learning Perspective. Journal of Alzheimer's Disease, 2023, 92, 1131-1146.	2.6	3
4402	Normative Cerebral Hemodynamics in Middle-aged and Older Adults Using 4D Flow MRI: Initial Analysis of Vascular Aging. Radiology, 2023, 307, .	7.3	10
4403	Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer's disease: an expert opinion and practical guideline. Journal of Neurology, 2023, 270, 3159-3170.	3.6	3
4404	The Eye as a Diagnostic Tool for Alzheimer's Disease. Life, 2023, 13, 726.	2.4	2

#	Article	IF	CITATIONS
4405	Differentiation of Alzheimer's Disease from Frontotemporal Dementia and Mild Cognitive Impairment Based on Arterial Spin Labeling Magnetic Resonance Imaging: A Pilot Cross-Sectional Study from PUMCH Dementia Cohort. Journal of Alzheimer's Disease, 2023, 93, 509-519.	2.6	1
4406	<scp>TDP</scp> â€43 and tau concurrence in the entorhinal subfields in primary <scp>ageâ€related</scp> tauopathy and preclinical Alzheimer's disease. Brain Pathology, 2023, 33, .	4.1	5
4408	Blood biomarkers: ready for clinical practice?. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 409-410.	1.9	1
4409	Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 411-419.	1.9	8
4410	Auditory Event-Related Potentials in Older Adults with Subjective Memory Complaints. Journal of Alzheimer's Disease, 2023, 92, 1093-1109.	2.6	1
4411	A Residual Marker of Cognitive Reserve Is Associated with Resting-State Intrinsic Functional Connectivity Along the Alzheimer's Disease Continuum. Journal of Alzheimer's Disease, 2023, 92, 925-940.	2.6	0
4412	Structural polymorphism and cytotoxicity of brainâ€derived βâ€amyloid extracts. Protein Science, 2023, 32,	7.6	4
4413	Retinal photoreceptor layer thickness has disease specificity and distinguishes predicted FTLD-Tau from biomarker-determined Alzheimer's disease. Neurobiology of Aging, 2023, 125, 74-82.	3.1	0
4414	Hyperoside alleviates toxicity of β-amyloid via endoplasmic reticulum-mitochondrial calcium signal transduction cascade in APP/PS1 double transgenic Alzheimer's disease mice. Redox Biology, 2023, 61, 102637.	9.0	5
4415	Prospective analysis of plasma amyloid beta and postoperative delirium in the Interventions for Postoperative Delirium: Biomarker-3 study. British Journal of Anaesthesia, 2023, 130, 546-556.	3.4	2
4416	Sex Differences in Alzheimer's Disease. Neurologic Clinics, 2023, 41, 343-358.	1.8	9
4417	The effect of aquaporin-4 mis-localization on Aβ deposition in mice. Neurobiology of Disease, 2023, 181, 106100.	4.4	9
4418	Plasma-based diagnostic and screening platform using a combination of biosensing signals in Alzheimer's disease. Biosensors and Bioelectronics, 2023, 230, 115246.	10.1	5
4419	Elevated plasma sulfides are associated with cognitive dysfunction and brain atrophy in human Alzheimer's disease and related dementias. Redox Biology, 2023, 62, 102633.	9.0	8
4420	Abnormal white matter changes in Alzheimer's disease based on diffusion tensor imaging: A systematic review. Ageing Research Reviews, 2023, 87, 101911.	10.9	15
4421	The association of dietary and nutrient patterns on neurocognitive decline: A systematic review of MRI and PET studies. Ageing Research Reviews, 2023, 87, 101892.	10.9	3
4422	Diagnosis of Alzheimer's disease: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. Dementia E Neuropsychologia, 2022, 16, 25-39.	0.8	2
4423	Neuronal loss of NCLX-dependent mitochondrial calcium efflux mediates age-associated cognitive decline. IScience, 2023, 26, 106296.	4.1	8

#	Article	IF	CITATIONS
4424	Respective influence of beta-amyloid and APOE ε4 genotype on medial temporal lobe subregions in cognitively unimpaired older adults. Neurobiology of Disease, 2023, 181, 106127.	4.4	0
4425	Multimodal comparisons of QSM and PET in neurodegeneration and aging. NeuroImage, 2023, 273, 120068.	4.2	9
4426	Annualized changes in rate of amyloid deposition and neurodegeneration are greater in participants who become amyloid positive than those who remain amyloid negative. Neurobiology of Aging, 2023, 127, 33-42.	3.1	0
4429	Cortical hyperexcitability and plasticity in Alzheimer's disease: developments in understanding and management. Expert Review of Neurotherapeutics, 2022, 22, 981-993.	2.8	1
4431	PSEN2 and ABCA7 variants causing early-onset preclinical pathological changes in Alzheimer's disease: a case report and literature review. Neurological Sciences, 0, , .	1.9	0
4432	Emotion recognition and baseline cortisol levels relationship in early Alzheimer disease. Biological Psychology, 2023, 177, 108511.	2.2	3
4433	Common Genetic Factors and Pathways in Alzheimer's Disease and Ischemic Stroke: Evidences from GWAS. Genes, 2023, 14, 353.	2.4	0
4434	Re: Aducanumab-Related ARIA. Clinical Nuclear Medicine, 2023, 48, 505-506.	1.3	1
4436	Distinct spatiotemporal subtypes of amyloid deposition are associated with diverging disease profiles in cognitively normal and mild cognitive impairment individuals. Translational Psychiatry, 2023, 13, .	4.8	3
4437	Neuroanatomical and neurocognitive changes associated with subjective cognitive decline. Frontiers in Medicine, 0, 10, .	2.6	5
4438	A review of the application of three-dimensional convolutional neural networks for the diagnosis of Alzheimer's disease using neuroimaging. Reviews in the Neurosciences, 2023, .	2.9	5
4439	Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA Neurology, 2023, 80, 360.	9.0	58
4440	An attention-based deep learning approach for the classification of subjective cognitive decline and mild cognitive impairment using resting-state EEG. Journal of Neural Engineering, 2023, 20, 016048.	3.5	13
4441	An empirical measure of resilience explains individual differences in the effect of tau pathology on memory change in aging. Nature Aging, 2023, 3, 229-237.	11.6	3
4442	Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 92, 467-475.	2.6	2
4443	Comparison of Retinal Structural and Neurovascular Changes between Patients with and without Amyloid Pathology. Journal of Clinical Medicine, 2023, 12, 1310.	2.4	2
4444	Outcome measures for Alzheimer's disease: A global interâ€societal Delphi consensus. Alzheimer's and Dementia, 2023, 19, 2707-2729.	0.8	2
4445	Longitudinal Spatial Relationships Between Atrophy and Hypometabolism Across the Alzheimer's Disease Continuum. Journal of Alzheimer's Disease, 2023, 92, 513-527.	2.6	0

#	Article	IF	CITATIONS
4446	Design of a Coumarin-Based Fluorescent Probe for Efficient <i>In Vivo</i> Imaging of Amyloid-β Plaques. ACS Chemical Neuroscience, 2023, 14, 829-838.	3.5	8
4447	Expectations and clinical meaningfulness of randomized controlled trials. Alzheimer's and Dementia, 2023, 19, 2730-2736.	0.8	25
4448	Characteristics of Subjective Cognitive Decline Associated with Alzheimer's Disease Amyloid Pathology: Findings from The CABLE Study. Journal of Alzheimer's Disease, 2023, 92, 581-590.	2.6	1
4449	The dynamics of plasma biomarkers across the Alzheimer's continuum. Alzheimer's Research and Therapy, 2023, 15, .	6.2	21
4450	Revisiting the intersection of microglial activation and neuroinflammation in Alzheimer's disease from the perspective of ferroptosis. Chemico-Biological Interactions, 2023, 375, 110387.	4.0	12
4451	Contributions of blood–brain barrier imaging to neurovascular unit pathophysiology of Alzheimer's disease and related dementias. Frontiers in Aging Neuroscience, 0, 15, .	3.4	4
4452	Alzheimer's disease and COVID-19: Interactions, intrinsic linkages, and the role of immunoinflammatory responses in this process. Frontiers in Immunology, 0, 14, .	4.8	7
4454	Visual-spatial processing impairment in the occipital-frontal connectivity network at early stages of Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 15, .	3.4	7
4455	Neural biomarker diagnosis and prediction to mild cognitive impairment and Alzheimer's disease using EEG technology. Alzheimer's Research and Therapy, 2023, 15, .	6.2	14
4456	Forecasting individual progression trajectories in Alzheimer's disease. Nature Communications, 2023, 14, .	12.8	7
4457	The Quest for Neurodegenerative Disease Treatment—Focusing on Alzheimer's Disease Personalised Diets. Current Issues in Molecular Biology, 2023, 45, 1519-1535.	2.4	2
4458	Associations Between Plasma Klotho with Renal Function and Cerebrospinal Fluid Amyloid-β Levels in Alzheimer's Disease: The Chongqing Ageing & Dementia Study. Journal of Alzheimer's Disease, 2023, 92, 477-485.	2.6	1
4459	Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study. Journal of Alzheimer's Disease, 2023, 92, 653-665.	2.6	5
4460	Retinal pathological features and proteome signatures of Alzheimer's disease. Acta Neuropathologica, 2023, 145, 409-438.	7.7	20
4462	Neurodegeneration cell per cell. Neuron, 2023, 111, 767-786.	8.1	8
4463	Comparison Between <sup>18</sup> F-Florapronol and <sup>18</sup> F-Florbetaben Imaging in Patients		

#	Article	IF	CITATIONS
4466	Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer's disease and synucleinopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 187-218.	1.8	1
4467	The Alzheimer's Disease Mitochondrial Cascade Hypothesis: A Current Overview. Journal of Alzheimer's Disease, 2023, 92, 751-768.	2.6	19
4468	Diagnostic Tools for Alzheimer's Disease: A Narrative Review Based on Our Own Research Experience. Dementia and Neurocognitive Disorders, 2023, 22, 16.	1.4	1
4470	Alzheimer's Disease: A Brief History of Immunotherapies Targeting Amyloid β. International Journal of Molecular Sciences, 2023, 24, 3895.	4.1	18
4471	Immune cell counts in cerebrospinal fluid predict cognitive function in aging and neurodegenerative disease. Alzheimer's and Dementia, 2023, 19, 3339-3349.	0.8	5
4473	In vivo characterization of cerebrovascular impairment induced by amyloid β peptide overload in glymphatic clearance system using swept-source optical coherence tomography. Neurophotonics, 2023, 10, .	3.3	2
4474	Forecasting the Prevalence of Alzheimer's Disease at Mild Cognitive Impairment and Mild Dementia Stages in France in 2022. journal of prevention of Alzheimer's disease, The, 0, , .	2.7	0
4475	Literature review on the interdisciplinary biomarkers of multi-target and multi-time herbal medicine therapy to modulate peripheral systems in cognitive impairment. Frontiers in Neuroscience, 0, 17, .	2.8	1
4476	The Fault in Our Astrocytes - cause or casualties of proteinopathies of ALS/FTD and other neurodegenerative diseases?. Frontiers in Molecular Medicine, 0, 3, .	1.9	0
4477	Neuroimaging in Dementia. CONTINUUM Lifelong Learning in Neurology, 2023, 29, 219-254.	0.8	1
4478	CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab. Alzheimer's and Dementia, 2023, 19, 3379-3388.	0.8	1
4480	Protein Interactome of Amyloid-β as a Therapeutic Target. Pharmaceuticals, 2023, 16, 312.	3.8	4
4481	Associations Between Levels of Peripheral NCAPH2 Promoter Methylation and Different Stages of Alzheimer's Disease: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2023, 92, 899-909.	2.6	1
4482	Let's Not Repeat History's Mistakes: Two Cautions to Scientists on the Use of Race in Alzheimer's Disease and Alzheimer's Disease Related Dementias Research. Journal of Alzheimer's Disease, 2023, 92, 729-740.	2.6	Ο
4483	Cognitive Trajectories and Associated Biomarkers in Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2023, 92, 803-814.	2.6	1
4484	sTREM2 and GFAP Mediated the Association of IGF-1 Signaling Biomarkers with Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2023, 92, 791-797.	2.6	Ο
4485	Impact of Nut Consumption on Cognition across the Lifespan. Nutrients, 2023, 15, 1000.	4.1	3
4486	Associations of Neurodegeneration Biomarkers in Cerebrospinal Fluid with Markers of Alzheimer's Disease and Vascular Pathology. Journal of Alzheimer's Disease, 2023, 92, 887-898.	2.6	1

#	Article	IF	CITATIONS
4487	Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer's disease diagnosis in a memory clinic cohort. Alzheimer's Research and Therapy, 2023, 15, .	6.2	5
4488	Management of patients with cognitive impairment. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2023, 15, 97-102.	1.2	2
4489	Ethical issues when using digital biomarkers and artificial intelligence for the early detection of dementia. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery, 2023, 13, .	6.8	7
4490	Role of Interaction between Zinc and Amyloid Beta in Pathogenesis of Alzheimer's Disease. Biochemistry (Moscow), 2023, 88, S75-S87.	1.5	1
4491	CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer's Disease and Frontotemporal Dementias. Diagnostics, 2023, 3 783.	<sup>13</sup> 2.6	4
4492	Thymol in <i>Trachyspermum ammi</i> seed extract exhibits neuroprotection, learning, and memory enhancement in scopolamineâ€induced Alzheimer's disease mouse model. Phytotherapy Research, 2023, 37, 2811-2826.	5.8	3
4493	Based on Tau PET Radiomics Analysis for the Classification of Alzheimer's Disease and Mild Cognitive Impairment. Brain Sciences, 2023, 13, 367.	2.3	2
4495	Royal jelly improves learning and memory deficits in an amyloid β-induced model of Alzheimer's disease in male rats: Involvement of oxidative stress. Metabolic Brain Disease, 2023, 38, 1239-1248.	2.9	0
4496	Bilateral Hippocampal Volume Mediated the Relationship Between Plasma BACE1 Concentration and Memory Function in the Early Stage of Alzheimer's Disease: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2023, 92, 1001-1013.	2.6	0
4497	Exploring Neurocognitive Deterioration in Alzheimer's Disease. Biology, 2023, 12, 343.	2.8	0
4498	Associations between different tau-PET patterns and longitudinal atrophy in the Alzheimer's disease continuum: biological and methodological perspectives from disease heterogeneity. Alzheimer's Research and Therapy, 2023, 15, .	6.2	6
4500	PASSED: Brain atrophy in non-demented individuals in a long-term longitudinal study from two independent cohorts. Frontiers in Aging Neuroscience, 0, 15, .	3.4	1
4501	A multidimensional ODE-based model of Alzheimer's disease progression. Scientific Reports, 2023, 13, .	3.3	2
4502	Macular vessel density in the superficial plexus is not associated to cerebrospinal fluid core biomarkers for Alzheimer's disease in individuals with mild cognitive impairment: The NORFACE cohort. Frontiers in Neuroscience, 0, 17, .	2.8	2
4503	Development of a candidate reference measurement procedure by ID-LC-MS/MS for total tau protein measurement in cerebrospinal fluid (CSF). Clinical Chemistry and Laboratory Medicine, 2023, 61, 1235-1244.	2.3	1
4504	Source space connectomics of neurodegeneration: One-metric approach does not fit all. Neurobiology of Disease, 2023, 179, 106047.	4.4	9
4505	The Association Between Neurocognitive Disorders and Gustatory Dysfunction: A Systematic Review and Meta-Analysis. Neuropsychology Review, 2024, 34, 192-213.	4.9	1
4507	Extraction of clinical phenotypes for Alzheimer's disease dementia from clinical notes using natural language processing. JAMIA Open, 2023, 6, .	2.0	2

#	Article	IF	CITATIONS
4508	Protein disulfide isomerases as CSF biomarkers for the neuronal response to tau pathology. Alzheimer's and Dementia, 0, , .	0.8	2
4509	Pathogenesis of Alzheimer's disease: Involvement of the choroid plexus. Alzheimer's and Dementia, 2023, 19, 3537-3554.	0.8	8
4510	Contribution of Alzheimer's disease pathology to biological and clinical progression: A longitudinal study across two cohorts. Alzheimer's and Dementia, 0, , .	0.8	0
4511	Differences between <i>ante mortem</i> Alzheimer's disease biomarkers in predicting neuropathology at autopsy. Alzheimer's and Dementia, 2023, 19, 3613-3624.	0.8	2
4512	Diagnóstico da doença de Alzheimer: recomendações do Departamento CientÃfico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. Dementia E Neuropsychologia, 2022, 16, 25-39.	0.8	5
4513	Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer's Disease. Cellular and Molecular Neurobiology, 2023, 43, 2491-2523.	3.3	8
4514	Cerebral Small Vessel Disease–Related Dementia: More Questions Than Answers. Stroke, 2023, 54, 648-660.	2.0	8
4515	Association of plasma phosphor-tau181 with Al² levels may vary by APOE lµ4 status and sex among non-demented old adults. Neuroscience Letters, 2023, 802, 137161.	2.1	0
4516	The necessary of ternary amyloid classification for clinical practice: An alternative to the binary amyloid definition. View, 2023, 4, .	5.3	4
4517	Functional Correlates of Microglial and Astrocytic Activity in Symptomatic Sporadic Alzheimer's Disease: A CSF/18F-FDG-PET Study. Biomedicines, 2023, 11, 725.	3.2	1
4518	Differences in Risk of Alzheimer's Disease Following Later-Life Traumatic Brain Injury in Veteran and Civilian Populations. Journal of Head Trauma Rehabilitation, 2023, 38, E384-E393.	1.7	1
4519	The Amyloid Cascade Hypothesis in Alzheimer's Disease: Should We Change Our Thinking?. Biomolecules, 2023, 13, 453.	4.0	13
4520	Tau, β-Amyloid, and Glucose Metabolism Following Service-Related Traumatic Brain Injury in Vietnam War Veterans: The Australian Imaging Biomarkers and Lifestyle Study of Aging-Veterans Study (AIBL-VETS). Journal of Neurotrauma, 2023, 40, 1086-1097.	3.4	2
4522	Fluorescent Probes as a Tool in Diagnostic and Drug Delivery Systems. Pharmaceuticals, 2023, 16, 381.	3.8	13
4523	Plasma Glial Fibrillary Acidic Protein in the Alzheimer Disease Continuum: Relationship to Other Biomarkers, Differential Diagnosis, and Prediction of Clinical Progression. Clinical Chemistry, 2023, 69, 411-421.	3.2	16
4524	Clinical outcomes of increased focal amyloid uptake in individuals with subthreshold global amyloid levels. Frontiers in Aging Neuroscience, 0, 15, .	3.4	1
4525	Brain reserve contributes to distinguishing preclinical Alzheimer's stages 1 and 2. Alzheimer's Research and Therapy, 2023, 15, .	6.2	2
4526	Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment. Frontiers in Neurology, 0, 14, .	2.4	10

#	Article	IF	CITATIONS
4527	Genome-wide Survival Study Identifies PARL as a Novel Locus for Clinical Progression and Neurodegeneration in Alzheimer's Disease. Biological Psychiatry, 2023, 94, 732-742.	1.3	1
4528	Modifying Dietary Protein Impacts mTOR Signaling and Brain Deposition of Amyloid β in a Knock-In Mouse Model of Alzheimer Disease. Journal of Nutrition, 2023, 153, 1407-1419.	2.9	1
4529	Correlations between cerebrospinal fluid homovanillic acid and dopamine transporter SPECT in degenerative parkinsonian syndromes. Journal of Neural Transmission, 2023, 130, 513-520.	2.8	0
4530	Cognitive and Neuropathophysiological Outcomes of Gamma-tACS in Dementia: A Systematic Review. Neuropsychology Review, 2024, 34, 338-361.	4.9	6
4531	Advances in sample preparation and HPLC–MS/MS methods for determining amyloid-β peptide in biological samples: a review. Analytical and Bioanalytical Chemistry, 2023, 415, 4003-4021.	3.7	3
4532	Evaluation of transfer learning methods for detecting Alzheimer's disease with brain MRI. , 2023, , .		3
4533	Study of the possible effect of sacubitril/valsartan combination versus valsartan on the cognitive function in Alzheimer's disease model in rats. International Journal of Immunopathology and Pharmacology, 2023, 37, 039463202311614.	2.1	3
4534	Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials. Neurology, 2023, 101, 38-45.	1.1	5
4535	Early Diagnosis of Alzheimer's Disease: Moving Toward a Blood-Based Biomarkers Era. Clinical Interventions in Aging, 0, Volume 18, 353-358.	2.9	0
4536	Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia. Neurology, 2023, 100, .	1.1	8
4537	Blood biomarkers in mild cognitive impairment patients: Relationship between analytes and progression to Alzheimer disease dementia. European Journal of Neurology, 2023, 30, 1565-1573.	3.3	8
4538	Cerebrospinal Fluid sTREM-2, GFAP, and β-S100 in Symptomatic Sporadic Alzheimer's Disease: Microglial, Astrocytic, and APOE Contributions Along the Alzheimer's Disease Continuum. Journal of Alzheimer's Disease, 2023, 92, 1385-1397.	2.6	3
4540	Association of cardiovascular risk factors and blood biomarkers with cognition: The HABSâ€HD study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	3
4541	Default mode network failure and neurodegeneration across aging and amnestic and dysexecutive Alzheimer's disease. Brain Communications, 2023, 5, .	3.3	5
4542	Plasma amyloid beta 40/42, phosphorylated tau 181, and neurofilament light are associated with cognitive impairment and neuropathological changes among World Trade Center responders: A prospective cohort study of exposures and cognitive aging at midlife. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	1
4544	Vision Transformer Approach for Classification of Alzheimer's Disease Using 18F-Florbetaben Brain Images. Applied Sciences (Switzerland), 2023, 13, 3453.	2.5	4
4545	Retinal Alterations as Potential Biomarkers of Structural Brain Changes in Alzheimer's Disease Spectrum Patients. Brain Sciences, 2023, 13, 460.	2.3	4
4546	Utility of Amyloid Positron Emission Tomography Imaging in Older Adults With Epilepsy and Cognitive Decline. American Journal of Alzheimer's Disease and Other Dementias, 2023, 38, 153331752311600.	1.9	1

#	Article	IF	CITATIONS
4547	Beyond the amyloid cascade: An update of Alzheimer's disease pathophysiology. Revue Neurologique, 2023, 179, 812-830.	1.5	6
4548	Reconfiguration of brain network dynamics underlying spatial deficits in subjective cognitive decline. Neurobiology of Aging, 2023, 127, 82-93.	3.1	Ο
4551	Atrophy, hypometabolism and implication regarding pathology in late-life major depression with suspected non-alzheimer pathophysiology (SNAP). Biomedical Journal, 2023, 46, 100589.	3.1	3
4552	Classification and prediction of cognitive trajectories of cognitively unimpaired individuals. Frontiers in Aging Neuroscience, 0, 15, .	3.4	1
4553	CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease. Nature Aging, 2023, 3, 391-401.	11.6	26
4555	Alzheimer's Disease from the Amyloidogenic Theory to the Puzzling Crossroads between Vascular, Metabolic and Energetic Maladaptive Plasticity. Biomedicines, 2023, 11, 861.	3.2	1
4556	Detecting amyloidâ€Î² positivity using regions of interest from structural magnetic resonance imaging. European Journal of Neurology, 2023, 30, 1574-1584.	3.3	2
4557	The Global Deterioration Scale for Down Syndrome Population (GDS-DS): A Rating Scale to Assess the Progression of Alzheimer's Disease. International Journal of Environmental Research and Public Health, 2023, 20, 5096.	2.6	1
4558	Sphingolipids in Cerebrospinal Fluid and Plasma Lipoproteins of APOE4 Homozygotes and Non-APOE4 Carriers with Mild Cognitive Impairment versus Subjective Cognitive Decline. Journal of Alzheimer's Disease Reports, 0, , 1-16.	2.2	0
4559	Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity. Frontiers in Aging Neuroscience, 0, 15, .	3.4	1
4560	Posterior cortical atrophy: clinical, neuroimaging, and neuropathological features. Expert Review of Neurotherapeutics, 2023, 23, 227-236.	2.8	1
4561	Early amygdala and ERC atrophy linked to 3D reconstruction of rostral neurofibrillary tau tangle pathology in Alzheimer's disease. NeuroImage: Clinical, 2023, 38, 103374.	2.7	4
4562	Effect of renal function on the diagnostic performance of plasma biomarkers for Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 15, .	3.4	8
4563	Machine learning for automatic Alzheimer's disease detection: addressing domain shift issues for building robust models. , 2023, 2, .		0
4564	Magnetic resonance evidence of increased iron content in subcortical brain regions in asymptomatic Alzheimer's disease. Human Brain Mapping, 2023, 44, 3072-3083.	3.6	6
4565	Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications. Molecular Neurodegeneration, 2023, 18, .	10.8	22
4566	Ontology-Driven Knowledge Sharing in Alzheimer's Disease Research. Information (Switzerland), 2023, 14, 188.	2.9	1
4567	The future is precision medicine-guided diagnoses, preventions and treatments for neurodegenerative diseases. Frontiers in Aging Neuroscience, 0, 15, .	3.4	1

#	Article	IF	CITATIONS
4568	The clinical application of optimized AT(N) classification in Alzheimer's clinical syndrome (ACS) and non-ACS conditions. Neurobiology of Aging, 2023, 127, 23-32.	3.1	3
4569	The Role of Dietary Antioxidants and Their Potential Mechanisms in Alzheimer's Disease Treatment. Metabolites, 2023, 13, 438.	2.9	4
4570	Preclinical Alzheimer's disease: how to predict who will decline next year?. Brain Communications, 2023, 5, .	3.3	0
4571	Brain Changes in Diabetes and Cognitive Dysfunction. Contemporary Diabetes, 2023, , 381-395.	0.0	Ο
4572	The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease. Human Brain Mapping, 2023, 44, 3147-3157.	3.6	5
4574	Neuromodulation in the treatment of chronic neuropathic pain and neurodegenerative diseases. , 0, 36, 83-89.		Ο
4576	Circulating long non-coding RNAs as novel diagnostic biomarkers for Alzheimer's disease (AD): A systematic review and meta-analysis. PLoS ONE, 2023, 18, e0281784.	2.5	8
4579	Probing neural circuit mechanisms in Alzheimer's disease using novel technologies. Molecular Psychiatry, 2023, 28, 4407-4420.	7.9	3
4580	Prefrontal EEG slowing, synchronization, and ERP peak latency in association with predementia stages of Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 15, .	3.4	3
4582	Design of a Non-Interventional Study to Assess Neurologists' Perspectives and Pharmacological Treatment Decisions in Early Alzheimer's Disease. Neurology and Therapy, 2023, 12, 995-1006.	3.2	1
4583	The Potential Role of Gustatory Function as an Early Diagnostic Marker for the Risk of Alzheimer's Disease in Subjective Cognitive Decline. Journal of Alzheimer's Disease Reports, 2023, 7, 249-262.	2.2	0
4584	Attitudes of Neurologists Toward the Use of Biomarkers in the Diagnosis of Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 93, 275-282.	2.6	1
4585	Thalamic nuclei changes in early and late onset Alzheimer's disease. Current Research in Neurobiology, 2023, 4, 100084.	2.3	4
4587	The Future of Cognitive Screening in Neurodegenerative Diseases. Journal of Alzheimer's Disease, 2023, , 1-13.	2.6	Ο
4589	Plasma ApoE4 Levels Are Lower than ApoE2 and ApoE3 Levels, and Not Associated with Plasma Aβ 40/42 Ratio as a Biomarker of Amyloid-β Amyloidosis in Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, , 1-16.	2.6	0
4590	ADAM10 Gene Variants in AD Patients and Their Relationship to CSF Protein Levels. International Journal of Molecular Sciences, 2023, 24, 6113.	4.1	Ο
4591	Cerebral Small Vessel Disease Burden Predicts Neurodegeneration and Clinical Progression in Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, , 1-12.	2.6	0
4593	Protein fibril length in cerebrospinal fluid is increased in Alzheimer's disease. Communications Biology, 2023, 6,	4.4	2

#	Article	IF	CITATIONS
4594	Exploring the ATN classification system using brain morphology. Alzheimer's Research and Therapy, 2023, 15, .	6.2	3
4595	Uncovering heterogeneous cognitive trajectories in mild cognitive impairment: a data-driven approach. Alzheimer's Research and Therapy, 2023, 15, .	6.2	2
4596	[18F]F-DED PET imaging of reactive astrogliosis in neurodegenerative diseases: preclinical proof of concept and first-in-human data. Journal of Neuroinflammation, 2023, 20, .	7.2	8
4597	Decrease in naturally occurring antibodies against epitopes of Alzheimer's disease (AD) risk gene products is associated with cognitive decline in AD. Journal of Neuroinflammation, 2023, 20, .	7.2	1
4598	Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts. Alzheimer's Research and Therapy, 2023, 15, .	6.2	4
4599	A Hybrid-Layered Framework for Detection and Diagnosis of Alzheimer's Disease (AD) from Fundus Images. , 2023, , .		0
4600	State, trait, and accumulated features of the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADASâ€Cog) in mild Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2023, 9, .	3.7	1
4602	<i>APOE</i> and immunity: Research highlights. Alzheimer's and Dementia, 2023, 19, 2677-2696.	0.8	5
4603	Salivary Exosomes in Health and Disease: Future Prospects in the Eye. International Journal of Molecular Sciences, 2023, 24, 6363.	4.1	1
4604	Eigenvector centrality dynamics are related to Alzheimer's disease pathological changes in non-demented individuals. Brain Communications, 2023, 5, .	3.3	3
4606	Correlation between cognitive impairment and serum phosphorylated tau181 protein in patients with preeclampsia. Frontiers in Aging Neuroscience, 0, 15, .	3.4	0
4607	Tau pathology as determinant of changes in atrophy and cerebral blood flow: a multi-modal longitudinal imaging study. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 2409-2419.	6.4	1
4608	Oligomeric, phosphorylated, and truncated tau and spliceosome pathology within the entorhinal–hippocampal connectome across stages of Alzheimer's disease. Journal of Comparative Neurology, 2023, 531, 2080-2108.	1.6	0
4611	Neuronal accumulation of hyperphosphorylated tau protein predicts stable memory impairment in people living with HIV. Aids, 2023, 37, 1247-1256.	2.2	4
4612	Predicting cognitive stage transition using pâ€ŧau181, Centiloid, and other measures. Alzheimer's and Dementia, 2023, 19, 4641-4650.	0.8	4
4613	Visual-somatosensory integration (VSI) as a novel marker of Alzheimer's disease: A comprehensive overview of the VSI study. Frontiers in Aging Neuroscience, 0, 15, .	3.4	3
4614	Tau accumulates differently in four subtypes of Alzheimer's disease. Neurology and Clinical Neuroscience, 2023, 11, 231-238.	0.4	0
4615	Measurement of Cerebral Perfusion Indices from the Early Phase of [ <sup>18</sup> F]MK6240 Dynamic Tau PET Imaging. Journal of Nuclear Medicine, 0, , jnumed.122.265072.	5.0	1

#	Article	IF	CITATIONS
4616	Brain <scp>p3â€Alcβ</scp> peptide restores neuronal viability impaired by Alzheimer's amyloid βâ€peptide. EMBO Molecular Medicine, 0, , .	6.9	3
4618	Tau positron emission tomography in tauopathies: A narrative review. Precision and Future Medicine, 2023, 7, 7-24.	1.6	Ο
4619	The Use of Diffusion Kurtosis Imaging for the Differential Diagnosis of Alzheimer's Disease Spectrum. Brain Sciences, 2023, 13, 595.	2.3	2
4620	Association of APOE Îμ4/Îμ4 with fluid biomarkers in patients from the PUMCH dementia cohort. Frontiers in Aging Neuroscience, 0, 15, .	3.4	2
4621	Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer's Disease: An Overview of Tests for Clinical Practice in the United States and Europe. journal of prevention of Alzheimer's disease, The, 0, ,	2.7	2
4622	Moving beyond amyloid and tau to capture the biological heterogeneity of Alzheimer's disease. Trends in Neurosciences, 2023, 46, 426-444.	8.6	11
4623	A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress. Scientific Reports, 2023, 13, .	3.3	8
4624	APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly. Alzheimer's Research and Therapy, 2023, 15, .	6.2	5
4625	Annual stability of the plasma Aß40/42 ratio and associated factors. Annals of Clinical and Translational Neurology, 2023, 10, 879-891.	3.7	1
4626	Molecules of senescent glial cells differentiate Alzheimer's disease from ageing. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 550-559.	1.9	4
4627	Repurposing drugs against Alzheimer's disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?. Journal of Neural Transmission, 2023, 130, 1003-1012.	2.8	4
4628	Blood Kallikrein-8 and Non-Amnestic Mild Cognitive Impairment: An Exploratory Study. Journal of Alzheimer's Disease Reports, 0, , 1-11.	2.2	0
4629	NEURONORMA Cognitive Battery Associations with Cerebrospinal Fluid Amyloid-β and Tau Levels in the Continuum of Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 92, 1303-1321.	2.6	0
4630	Low blood carotenoid status in dementia and mild cognitive impairment: A systematic review and meta-analysis. BMC Geriatrics, 2023, 23, .	2.7	2
4631	Integrated Proteomics to Understand the Role of Neuritin (NRN1) as a Mediator of Cognitive Resilience to Alzheimer's Disease. Molecular and Cellular Proteomics, 2023, 22, 100542.	3.8	10
4632	Differential involvement of hippocampal subfields in the relationship between Alzheimer's pathology and memory interference in older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	1
4633	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidenceâ€Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. Journal of Clinical Apheresis, 2023, 38, 77-278.	1.3	81
4634	A global view of the genetic basis of Alzheimer disease. Nature Reviews Neurology, 2023, 19, 261-277.	10.1	19

#	Article	IF	CITATIONS
4635	Targeting the function of the transentorhinal cortex to identify early cognitive markers of Alzheimer's disease. Cognitive, Affective and Behavioral Neuroscience, 2023, 23, 986-996.	2.0	1
4636	Lowering levels of reelin in entorhinal cortex layer II-neurons results in lowered levels of intracellular amyloid-Î <sup>2</sup> . Brain Communications, 2023, 5, .	3.3	3
4637	Eigenvector centrality and its variability over time are promising indicators of alterations in brain function due to early amyloid deposition. Brain Communications, 2023, 5, .	3.3	1
4638	Rapid, scalable assay of amylin-β amyloid co-aggregation in brain tissue and blood. Journal of Biological Chemistry, 2023, 299, 104682.	3.4	3
4640	Prognostic value of cerebrospinal fluid biomarkers in mild cognitive impairment due to Alzheimer disease. NeurologÃa (English Edition), 2023, , .	0.4	0
4641	White matter hyperintensities in Alzheimer's disease: Beyond vascular contribution. Alzheimer's and Dementia, 2023, 19, 3738-3748.	0.8	12
4642	Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults. Acta Neuropathologica, 2023, 146, 1-11.	7.7	4
4643	Distinct CSF biomarker-associated DNA methylation in Alzheimer's disease and cognitively normal subjects. Alzheimer's Research and Therapy, 2023, 15, .	6.2	4
4644	The identification and cognitive correlation of perfusion patterns measured with arterial spin labeling MRI in Alzheimer's disease. Alzheimer's Research and Therapy, 2023, 15, .	6.2	1
4645	Plasma NfL is associated with the APOE ε4 allele, brain imaging measurements of neurodegeneration, and lower recall memory scores in cognitively unimpaired late-middle-aged and older adults. Alzheimer's Research and Therapy, 2023, 15, .	6.2	7
4646	Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders. Alzheimer's Research and Therapy, 2023, 15, .	6.2	1
4647	Proposal for a Biologic Staging System of Parkinson's Disease. Journal of Parkinson's Disease, 2023, 13, 297-309.	2.8	23
4648	A cross-sectional study of retinal vessel changes based on optical coherence tomography angiography in Alzheimer's disease and mild cognitive impairment. Frontiers in Aging Neuroscience, 0, 15, .	3.4	3
4649	18F-AV45 PET and MRI Reveal the Influencing Factors of Alzheimer's Disease Biomarkers in Subjective Cognitive Decline Population. Journal of Alzheimer's Disease, 2023, 93, 585-594.	2.6	2
4651	α-synuclein seed amplification and its uses in Parkinson's disease. Lancet Neurology, The, 2023, 22, 369-371.	10.2	6
4652	Arterial spin labelling reveals multi-regional cerebral hypoperfusion in patients with transient ischemic attack that are unrelated to ischemia location: A proof-of-concept study. Cerebral Circulation - Cognition and Behavior, 2023, 4, 100164.	0.9	0
4653	Blood βâ€ <b>s</b> ynuclein is related to amyloid PET positivity in memory clinic patients. Alzheimer's and Dementia, 2023, 19, 4896-4907.	0.8	1
4654	Accelerated hypometabolism with disease progression associated with faster cognitive decline among amyloid positive patients. Frontiers in Neuroscience, 0, 17, .	2.8	1

#	Article	IF	CITATIONS
4655	Stimulus material selection for the Dutch famous faces test for older adults. Frontiers in Medicine, 0, 10, .	2.6	1
4656	Enlarged perivascular spaces and plasma Aβ42/Aβ40 ratio in older adults without dementia. Neurobiology of Aging, 2023, 128, 43-48.	3.1	2
4657	Wellbeing and Aging-related Decline in Financial and Health Literacy in Advanced Age. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 0, , .	3.9	1
4658	CSF-based liquid biopsy pointing to a diagnosis of diffuse glioma in a patient with supposed neurodegenerative disorder. Neurological Sciences, 0, , .	1.9	0
4659	Biological brain age prediction using machine learning on structural neuroimaging data: Multi-cohort validation against biomarkers of Alzheimer's disease and neurodegeneration stratified by sex. ELife, 0, 12, .	6.0	6
4661	Altered limbic functional connectivity in individuals with subjective cognitive decline: Converging and diverging findings across Chinese and German cohorts. Alzheimer's and Dementia, 0, , .	0.8	4
4662	Usefulness of the Visual Cognitive Assessment Test in Detecting Mild Cognitive Impairment in the Community. Journal of Alzheimer's Disease, 2023, , 1-9.	2.6	1
4665	Biomarkers of Alzheimer's disease: Past, present and future clinical use. Biomarkers in Neuropsychiatry, 2023, 8, 100063.	1.0	3
4666	Navigation in individuals at risk for Alzheimer's disease. , 2024, , .		0
4667	The Relationship between Whole-Grain Intake and Measures of Cognitive Decline, Mood, and Anxiety—A Systematic Review. Advances in Nutrition, 2023, 14, 652-670.	6.4	2
4668	Characterizing Early-Onset Alzheimer Disease Using Multiprobe PET/MRI. Clinical Nuclear Medicine, 0, Publish Ahead of Print, .	1.3	0
4669	A 12-month randomised pilot trial of the Alzheimer's and music therapy study: a feasibility assessment of music therapy and physical activity in patients with mild-to-moderate Alzheimer's disease. Pilot and Feasibility Studies, 2023, 9, .	1.2	1
4670	Cerebral Small Vessel Disease Progression and the Risk of Dementia: A 14-Year Follow-Up Study. American Journal of Psychiatry, 2023, 180, 508-518.	7.2	4
4671	Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer's Disease: Systematic Review and Meta-Analysis. Cells, 2023, 12, 1184.	4.1	2
4672	Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	1
4673	Degradation of EEG microstates patterns in subjective cognitive decline and mild cognitive impairment: Early biomarkers along the Alzheimer's Disease continuum?. NeuroImage: Clinical, 2023, 38, 103407.	2.7	8
4675	Discoveries and future significance of research into amyloid-beta/α7-containing nicotinic acetylcholine receptor (nAChR) interactions. Pharmacological Research, 2023, 191, 106743.	7.1	3
4676	Equivalence of plasma pâ€ŧau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 4967-4977.	0.8	17

#	Article	IF	CITATIONS
4678	New perspectives on the basal forebrain cholinergic system in Alzheimer's disease. Neuroscience and Biobehavioral Reviews, 2023, 150, 105192.	6.1	8
4679	Ferulic Acid Improves Synaptic Plasticity and Cognitive Impairments by Alleviating the PP2B/DARPP-32/PP1 Axis-Mediated STEP Increase and AÎ <sup>2</sup> Burden in Alzheimer's Disease. Neurotherapeutics, 2023, 20, 1081-1108.	4.4	5
4680	Plasma ATN(I) classification and precision pharmacology in Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 4729-4734.	0.8	3
4681	Age-related and amyloid-beta-independent tau deposition and its downstream effects. Brain, 2023, 146, 3192-3205.	7.6	6
4682	Category Switching Test: A Brief Amyloid-Î <sup>2</sup> -Sensitive Assessment Tool for Mild Cognitive Impairment. Assessment, 2024, 31, 543-556.	3.1	0
4683	Effects of storage conditions on the stability of blood-based markers for the diagnosis of Alzheimer's disease. Clinical Chemistry and Laboratory Medicine, 2023, 61, 1580-1589.	2.3	4
4684	Prospective classification of Alzheimer's disease conversion from mild cognitive impairment. Neural Networks, 2023, 164, 335-344.	5.9	6
4685	Small-molecule theranostics in Alzheimer's disease. European Journal of Medicinal Chemistry, 2023, 255, 115382.	5.5	9
4686	Associations of category fluency clustering performance with <i>in vivo</i> brain pathology in autosomal dominant Alzheimer's disease. Journal of the International Neuropsychological Society, 2024, 30, 77-83.	1.8	0
4687	Sex and gender differences in Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis: A narrative review. Mechanisms of Ageing and Development, 2023, 212, 111821.	4.6	8
4690	Comprehensive review of task-based neuroimaging studies of cognitive deficits in Alzheimer's disease using electrophysiological methods. Ageing Research Reviews, 2023, 88, 101950.	10.9	0
4691	MiR-431 attenuates synaptic plasticity and memory deficits in APPswe/PS1dE9 mice. JCI Insight, 2023, 8, .	5.0	4
4692	Plasma and CSF concentrations of Nâ€ŧerminal tau fragments associate with in vivo neurofibrillary tangle burden. Alzheimer's and Dementia, 2023, 19, 5343-5354.	0.8	6
4693	A blood-based composite panel that screens Alzheimerâ $\in$ $^{\mathrm{Ms}}$ s disease. Biomarker Research, 2023, 11, .	6.8	1
4694	Multifactorial Modeling of Cognitive Trajectories Using an Advanced Regression Technique: Improving Our Understanding of Biomarkers and Modifiable Variables that Support Cognition. Journal of Alzheimer's Disease, 2023, 93, 815-819.	2.6	0
4695	Comparing machine learningâ€derived MRIâ€based and bloodâ€based neurodegeneration biomarkers in predicting syndromal conversion in early AD. Alzheimer's and Dementia, 2023, 19, 4987-4998.	0.8	3
4697	Revolutionizing the Early Detection of Alzheimer's Disease through Non-Invasive Biomarkers: The Role of Artificial Intelligence and Deep Learning. Sensors, 2023, 23, 4184.	3.8	16
4698	Tau activation of microglial cGAS–IFN reduces MEF2C-mediated cognitive resilience. Nature Neuroscience, 2023, 26, 737-750.	14.8	40

#	Article	IF	CITATIONS
4699	Determinants of informal care time, distress, depression, and quality of life in care partners along the trajectory of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	1
4700	Sexual dimorphism in the peripheral metabolic homeostasis and behavior in the <scp>TgF344â€AD</scp> rat model of Alzheimer's disease. Aging Cell, 2023, 22, .	6.7	6
4701	Spatial navigation is associated with subcortical alterations and progression risk in subjective cognitive decline. Alzheimer's Research and Therapy, 2023, 15, .	6.2	2
4702	Peripheral ApoE4 Leads to Cerebrovascular Dysfunction and AÎ <sup>2</sup> Deposition in Alzheimer's Disease. Neuroscience Bulletin, 2023, 39, 1330-1332.	2.9	3
4703	An Insight into Cellular and Molecular Mechanisms Underlying the Pathogenesis of Neurodegeneration in Alzheimer's Disease. Biomedicines, 2023, 11, 1398.	3.2	12
4704	Preserved autophagy in cognitively intact nonâ€demented individuals with Alzheimer's neuropathology. Alzheimer's and Dementia, 2023, 19, 5355-5370.	0.8	4
4705	APOEε4 and risk of Alzheimer's disease – time to move forward. Frontiers in Neuroscience, 0, 17, .	2.8	2
4706	Deep learning application for the classification of Alzheimer's disease using 18F-flortaucipir (AV-1451) tau positron emission tomography. Scientific Reports, 2023, 13, .	3.3	2
4707	Elecsys Cerebrospinal Fluid Immunoassays Accurately Detect Alzheimer's Disease Regardless of Concomitant Small Vessel Disease. Journal of Alzheimer's Disease, 2023, , 1-13.	2.6	0
4708	Midlife Neuropsychological Profiles and Associated Vascular Risk: The Bogalusa Heart Study. Journal of Alzheimer's Disease, 2023, 94, 101-113.	2.6	0
4709	Exercise program to reduce the risk of cognitive decline and physical frailty in older adults: study protocol for an open label double-arm clinical trial. Frontiers in Aging Neuroscience, 0, 15, .	3.4	1
4710	Longitudinal changes in metabolic network activity in early Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 4061-4072.	0.8	3
4711	Current Diagnostic Pathways for Alzheimer's Disease: A Cross-Sectional Real-World Study Across Six Countries. Journal of Alzheimer's Disease Reports, 2023, 7, 659-674.	2.2	1
4712	Preclinical Disease or Risk Factor? Alzheimer's Disease as a Case Study of Changing Conceptualizations of Disease. Journal of Medicine and Philosophy, 2023, 48, 322-334.	0.8	2
4713	Plasmon-activated water as a therapeutic strategy in Alzheimer's disease by altering gut microbiota. Aging, 2023, 15, 3715-3737.	3.1	1
4714	Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. Nature Medicine, 2023, 29, 1437-1447.	30.7	56
4715	Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study. EBioMedicine, 2023, 90, 104547.	6.1	9
4716	Tau in cerebrospinal fluid induces neuronal hyperexcitability and alters hippocampal theta oscillations. Acta Neuropathologica Communications, 2023, 11, .	5.2	4

	CITATION	i Report	
#	Article	IF	CITATIONS
4717	Correlation between ankleâ€brachial index and subtle cognitive decline. Brain and Behavior, 2023, 13, .	2.2	0
4718	Frontier on Alzheimer's Disease. International Journal of Molecular Sciences, 2023, 24, 7748.	4.1	5
4720	CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment. Npj Parkinson's Disease, 2023, 9, .	5.3	2
4721	Gray matter reserve determines glymphatic system function in youngâ€onset Alzheimer's disease: Evidenced by <scp>DTlâ€ALPS</scp> and compared with ageâ€matched controls. Psychiatry and Clinical Neurosciences, 2023, 77, 401-409.	1.8	7
4722	Measurement of Dimensions of Self-awareness of Memory Function and Their Association With Clinical Progression in Cognitively Normal Older Adults. JAMA Network Open, 2023, 6, e239964.	5.9	1
4723	Comparing three neuropsychological subgrouping approaches in subjective and mild cognitive impairment from a naturalistic multicenter study. Neurobiology of Aging, 2023, 129, 41-49.	3.1	0
4725	Rapidly progressive dementia with early onset associated with the I143T mutation in the PSEN1 gene: a clinical case in a family from Russia. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2023, 15, 63-67.	1.2	0
4726	Machine learning application for classification of Alzheimer's disease stages using 18F-flortaucipir positron emission tomography. BioMedical Engineering OnLine, 2023, 22, .	2.7	0
4727	A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer's disease. Alzheimer's Research and Therapy, 2023, 15, .	6.2	0
4729	Predementia Counseling. GeroPsych: the Journal of Gerontopsychology and Geriatric Psychiatry, 0, , .	0.5	0
4730	Speech changes in old age: Methodological considerations for speechâ€based discrimination of healthy ageing and Alzheimer's disease. International Journal of Language and Communication Disorders, 2024, 59, 13-37.	1.5	1
4731	Role of piRNA biogenesis and its neuronal function in the development of neurodegenerative diseases. Frontiers in Aging Neuroscience, 0, 15, .	3.4	4
4732	Neuroimaging in Alzheimer's Disease for Early Diagnosis: A Comprehensive Review. Cureus, 2023, , .	0.5	2
4733	BACE1 regulates expression of Clusterin in astrocytes for enhancing clearance of β-amyloid peptides. Molecular Neurodegeneration, 2023, 18, .	10.8	2
4734	Plasma tau and neurofilament light chain as biomarkers of Alzheimer's disease and their relation to cognitive functions. Journal of Medicine and Life, 2023, 16, 284-289.	1.3	0
4735	A new perspective on Alzheimerâ $\in$ <sup>M</sup> s disease: m6A modification. Frontiers in Genetics, 0, 14, .	2.3	0
4736	Patterns of amyloid accumulation in amyloid-negative cases. Neurobiology of Aging, 2023, 129, 99-108.	3.1	0
4737	Higher cortical thickness/volume in Alzheimer's-related regions: protective factor or risk factor?. Neurobiology of Aging, 2023, 129, 185-194.	3.1	1

#	Article	IF	Citations
4738	Long-Term Course of Neural Autoantibody-Associated Psychiatric Disorders: Retrospective Data from a Specifically Immunopsychiatric Outpatient Clinic. Antibodies, 2023, 12, 34.	2.5	0
4739	Machine Learning on Visibility Graph Features Discriminates the Cognitive Event-Related Potentials of Patients with Early Alzheimer's Disease from Healthy Aging. Brain Sciences, 2023, 13, 770.	2.3	1
4740	Overcoming Pandemic-Related Challenges in Recruitment and Screening. Journal of Cardiovascular Nursing, 0, Publish Ahead of Print, .	1.1	0
4741	Acute stressors do not impair short-term memory or attention in an aged mouse model of amyloidosis. Frontiers in Behavioral Neuroscience, 0, 17, .	2.0	1
4742	Visual reading for [18F]Florzolotau ([18F]APN-1607) tau PET imaging in clinical assessment of Alzheimer's disease. Frontiers in Neuroscience, 0, 17, .	2.8	4
4743	Ultra-Early Screening of Cognitive Decline Due to Alzheimer's Pathology. Biomedicines, 2023, 11, 1423.	3.2	0
4744	An Exploratory Study of Sleep-Wake Differences of Autonomic Activity in Patients with Mild Cognitive Impairment: The Role of Melatonin as a Modulating Factor. Clinical Interventions in Aging, 0, Volume 18, 771-781.	2.9	0
4745	Targeting Neuroinflammation as Disease Modifying Approach to Alzheimer's Disease: Potential and Challenges. Mini-Reviews in Medicinal Chemistry, 2023, 23, 2097-2116.	2.4	1
4746	Language dysfunction correlates with cognitive impairments in older adults without dementia mediated by amyloid pathology. Frontiers in Neurology, 0, 14, .	2.4	0
4747	Alzheimer's disease pathogenetic progression is associated with changes in regulated retained introns and editing of circular RNAs. Frontiers in Molecular Neuroscience, 0, 16, .	2.9	4
4748	Recent advances in electrochemical biosensors for the detection of Aβ42, a biomarker for Alzheimer disease diagnosis. TrAC - Trends in Analytical Chemistry, 2023, 164, 117087.	11.4	8
4750	Towards a future where Alzheimer's disease pathology is stopped before the onset of dementia. Nature Aging, 2023, 3, 494-505.	11.6	13
4751	Largeâ€scale proteome and metabolome analysis of CSF implicates altered glucose and carbon metabolism and succinylcarnitine in Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 5447-5470.	0.8	6
4752	Associations Between Circulating Levels of Myostatin and Plasma β-Amyloid 42/40 in a Biracial Cohort of Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2023, 78, 2077-2082.	3.6	0
4753	Sex-specific associations of matrix metalloproteinases in Alzheimer's disease. Biology of Sex Differences, 2023, 14, .	4.1	1
4754	Near-lifespan longitudinal tracking of brain microvascular morphology, topology, and flow in male mice. Nature Communications, 2023, 14, .	12.8	3
4755	Dual-stage cognitive assessment: a two-stage screening for cognitive impairment in primary care. BMC Psychiatry, 2023, 23, .	2.6	0
4756	Fine particle air pollution and lung cancer risk: Extending the long list of health risks. Cell, 2023, 186, 2285-2287.	28.9	1

#	Article	IF	CITATIONS
4757	Retinal imaging biomarkers of Alzheimer's disease: A systematic review and metaâ€analysis of studies using brain amyloid beta status for case definition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	3
4758	Low circulating adropin concentrations predict increased risk of cognitive decline in community-dwelling older adults. GeroScience, 2024, 46, 897-911.	4.6	2
4759	Astrocyte Signature in Alzheimer's Disease Continuum through a Multi-PET Tracer Imaging Perspective. Cells, 2023, 12, 1469.	4.1	1
4760	Toward standardization of tau PET imaging corresponding to various tau PET tracers: a multicenter phantom study. Annals of Nuclear Medicine, 2023, 37, 494-503.	2.2	0
4762	Cyclic β-hairpin peptide loaded PLGA nanoparticles: A potential anti-amyloid therapeutic. Materials Today Communications, 2023, 35, 106322.	1.9	1
4763	Levels of Alzheimer's disease blood biomarkers are altered after food intake—A pilot intervention study in healthy adults. Alzheimer's and Dementia, 2023, 19, 5531-5540.	0.8	11
4764	Research Applications of Positron Emission Tomography/Magnetic Resonance (PET/MR) Imaging in Alzheimer's Disease (AD). , 2023, , 161-186.		0
4765	Parkinsonism of uncertain clinical significance (PUCS): A proposed new diagnostic entity. Journal of the Neurological Sciences, 2023, 451, 120696.	0.6	1
4766	Evidence against a temporal association between cerebrovascular disease and Alzheimer's disease imaging biomarkers. Nature Communications, 2023, 14, .	12.8	1
4767	Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease. Nature Medicine, 2023, 29, 1775-1781.	30.7	49
4769	Plasma TDPâ€43 levels are associated with neuroimaging measures of brain structure in limbic regions. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	0
4770	Structural and molecular imaging in dementia: the heterogeneity of Alzheimer's disease. European Radiology, 0, , .	4.5	0
4771	Association of Sleep-Disordered Breathing and Medial Temporal Lobe Atrophy in Cognitively Unimpaired Amyloid-Positive Older Adults. Neurology, 2023, 101, .	1.1	5
4772	Frontal variant Alzheimer's disease: A systematic narrative synthesis. Cortex, 2023, 166, 121-153.	2.4	1
4773	Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer's disease? From preclinical studies to the clinical trials. Molecular Psychiatry, 2023, 28, 2197-2214.	7.9	6
4776	Unsupervised [18F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 3265-3275.	6.4	1
4777	Alzheimer's Disease Treatment: The Search for a Breakthrough. Medicina (Lithuania), 2023, 59, 1084.	2.0	6
4779	Blood-brain barrier breakdown is linked to tau pathology and neuronal injury in a differential manner according to amyloid deposition. Journal of Cerebral Blood Flow and Metabolism, 0, , 0271678X2311800.	4.3	2

#	Article	IF	CITATIONS
4780	Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape. Neuron, 2023, 111, 2781-2799.	8.1	16
4781	Biomarkers of chronic traumatic encephalopathy: A state-of-the art review. Biomarkers in Neuropsychiatry, 2023, 8, 100066.	1.0	1
4782	Correlating continuously captured home-based digital biomarkers of daily function with postmortem neurodegenerative neuropathology. PLoS ONE, 2023, 18, e0286812.	2.5	0
4783	Representativeness of samples enrolled in Alzheimer's disease research centers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	3
4784	Clinical Utilization of Brain Magnetic Resonance Imaging-Based Artificial Intelligence Software in the Spectrum of Alzheimer's Disease: Case Series. Journal of Korean Neuropsychiatric Association, 2023, 62, 86.	0.5	1
4785	Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 5620-5631.	0.8	3
4786	Impact of white matter hyperintensities on subjective cognitive decline phenotype in a diverse cohort of cognitively normal older adults. International Journal of Geriatric Psychiatry, 2023, 38, .	2.7	0
4787	Clinical considerations in early-onset cerebral amyloid angiopathy. Brain, 2023, 146, 3991-4014.	7.6	6
4788	Tau positron emission tomography in patients with cognitive impairment and suspected Alzheimer's disease. Fukushima Journal of Medical Sciences, 2023, , .	0.4	0
4789	Cerebrospinal fluid biomarkers in psychiatric autoimmune encephalitis: a retrospective cohort study. Frontiers in Psychiatry, 0, 14, .	2.6	1
4790	Phosphorylated tau in Alzheimer's disease. Advances in Clinical Chemistry, 2023, , 31-111.	3.7	0
4791	Genetic risk scores enhance the diagnostic value of plasma biomarkers of brain amyloidosis. Brain, 2023, 146, 4508-4519.	7.6	1
4792	EEG, ERPs, and EROs in patients with cognitive deficits due to progressive neurodegenerative diseases: The dark side of the precision medicine. International Journal of Psychophysiology, 2023, 190, 56-59.	1.0	0
4793	ArhGAP11A mediates amyloid-β generation and neuropathology in an Alzheimer's disease-like mouse model. Cell Reports, 2023, 42, 112624.	6.4	2
4798	Impact of asthma on the brain: evidence from diffusion MRI, CSF biomarkers and cognitive decline. Brain Communications, 2023, 5, .	3.3	6
4799	The Diagnostic Potential of Circulating Autoantibodies to Amyloid-β in Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, , 1-10.	2.6	0
4800	Detection of Tau-PET Positivity in Clinically Diagnosed Mild Cognitive Impairment with Multidimensional Features. Journal of Alzheimer's Disease, 2023, , 1-14.	2.6	0
4801	A Graph Convolutional Network Based on Univariate Neurodegeneration Biomarker for Alzheimer's Disease Diagnosis. IEEE Journal of Translational Engineering in Health and Medicine, 2023, 11, 405-416.	3.7	0

#	Article	IF	CITATIONS
4802	Gut microbiome composition may be an indicator of preclinical Alzheimer's disease. Science Translational Medicine, 2023, 15, .	12.4	38
4803	Early βâ€amyloid accumulation in the brain is associated with peripheral T cell alterations. Alzheimer's and Dementia, 2023, 19, 5642-5662.	0.8	9
4804	The contribution of initial concussive forces and resulting acrolein surge to β-amyloid accumulation and functional alterations in neuronal networks using a TBI-on-a-chip model. Lab on A Chip, 0, , .	6.0	0
4805	Eye movement changes as an indicator of mild cognitive impairment. Frontiers in Neuroscience, 0, 17, .	2.8	1
4806	Comprehensive transcript-level analysis reveals transcriptional reprogramming during the progression of Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 15, .	3.4	1
4807	Reading and lexical–semantic retrieval tasks outperforms single task speech analysis in the screening of mild cognitive impairment and Alzheimer's disease. Scientific Reports, 2023, 13, .	3.3	0
4808	The Importance of Subjective Cognitive Decline Recognition and the Potential of Molecular and Neurophysiological Biomarkers—A Systematic Review. International Journal of Molecular Sciences, 2023, 24, 10158.	4.1	2
4810	A Systematic Review of the Effects of Capsaicin on Alzheimer's Disease. International Journal of Molecular Sciences, 2023, 24, 10176.	4.1	3
4811	Copper, oxidative stress, Alzheimer's disease, and dementia. , 2023, , 65-85.		0
4812	Mitochondria-Related Candidate Genes and Diagnostic Model to Predict Late-Onset Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2023, , 1-17.	2.6	1
4813	Heterogenous Genetic, Clinical, and Imaging Features in Patients with Neuronal Intranuclear Inclusion Disease Carrying NOTCH2NLC Repeat Expansion. Brain Sciences, 2023, 13, 955.	2.3	1
4815	Nonlinear changes in delayed functional network topology in Alzheimer's disease: relationship with amyloid and tau pathology. Alzheimer's Research and Therapy, 2023, 15, .	6.2	1
4816	Urinary Cytokines as Potential Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease: A Pilot Study. Journal of Alzheimer's Disease Reports, 2023, 7, 649-657.	2.2	2
4817	The Impact of Loneliness and Social Isolation on Cognitive Aging: A Narrative Review. Journal of Alzheimer's Disease Reports, 2023, 7, 699-714.	2.2	2
4818	Comprehensive genetic screening of early-onset dementia patients in an Austrian cohort-suggesting new disease-contributing genes. Human Genomics, 2023, 17, .	2.9	1
4820	Neuropsychological Performance in Alzheimer's Disease versus Late-Life Depression: A Systematic Review and Meta-Analysis. Archives of Clinical Neuropsychology, 2023, 38, 991-1016.	0.5	1
4821	Development of a Revised Version of Subjective Memory Complaints Questionnaire in Taiwan: A Preliminary Study. Archives of Clinical Neuropsychology, 2024, 39, 78-91.	0.5	0
4822	Humanized APOE genotypes influence lifespan independently of tau aggregation in the P301S mouse model of tauopathy. Acta Neuropathologica Communications, 2023, 11, .	5.2	1

#	Article	IF	CITATIONS
4824	The A-to-Z factors associated with cognitive impairment. Results of the DeCo study. Frontiers in Psychology, 0, 14, .	2.1	0
4826	Relationships between quantitative retinal microvascular characteristics and cognitive function based on automated artificial intelligence measurements. Frontiers in Cell and Developmental Biology, 0, 11, .	3.7	2
4827	Specific post-translational modifications of soluble tau protein distinguishes Alzheimer's disease and primary tauopathies. Nature Communications, 2023, 14, .	12.8	8
4828	Alzheimer's Disease Prediction with K-means Clustering and Reinforcement Learning Approach. , 2023, ,		0
4829	Retinal and Choriocapillaris Vascular Changes in Early Alzheimer Disease Patients Using Optical Coherence Tomography Angiography. Journal of Neuro-Ophthalmology, 2023, Publish Ahead of Print, .	0.8	2
4830	CEST 2022-three-dimensional amide proton transfer (APT) imaging can identify the changes of cerebral cortex in Parkinson's disease. Magnetic Resonance Imaging, 2023, 102, 235-241.	1.8	0
4831	Neuroimaging modalities in the detection of Alzheimer's disease-associated biomarkers. Psychoradiology, 0, , .	2.3	2
4832	Distinct cerebral small vessel disease impairment in earlyâ€Âand lateâ€onset Alzheimer's disease. Annals of Clinical and Translational Neurology, 2023, 10, 1326-1337.	3.7	0
4833	Cohort profile: rationale and methods of UK Biobank repeat imaging study eye measures to study dementia. BMJ Open, 2023, 13, e069258.	1.9	0
4834	Occipital Amyloid Deposition Is Associated with Rapid Cognitive Decline in the Alzheimer's Disease Continuum. Journal of Alzheimer's Disease, 2023, , 1-12.	2.6	Ο
4837	Preliminary validation of a structural magnetic resonance imaging metric for tracking dementia-related neurodegeneration and future decline. NeuroImage: Clinical, 2023, 39, 103458.	2.7	0
4838	Reflections from the OARSI 2022 clinical trials symposium: The pain of OA—Deconstruction of pain and patient-reported outcome measures for the benefit of patients and clinical trial design. Osteoarthritis and Cartilage, 2023, 31, 1293-1302.	1.3	2
4839	Predicting cognitive decline in older people by structural and molecular imaging. Current Opinion in Neurology, 2023, 36, 253-263.	3.6	0
4840	Amyloid beta-correlated plasma metabolite dysregulation in Alzheimer's disease: an untargeted metabolism exploration using high-resolution mass spectrometry toward future clinical diagnosis. Frontiers in Aging Neuroscience, 0, 15, .	3.4	1
4841	Regional contributions of D-serine to Alzheimer's disease pathology in male AppNL–G–F/NL–G–F mice Frontiers in Aging Neuroscience, 0, 15, .	<sup>2</sup> .3.4	1
4842	MRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease. Current Opinion in Neurology, 2023, 36, 239-244.	3.6	Ο
4843	Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints. Translational Neurodegeneration, 2023, 12, .	8.0	0
4844	Performance on complex memory tests is associated with βâ€amyloid in individuals at risk of developing Alzheimer's disease. Journal of Neuropsychology, 2024, 18, 120-135.	1.4	1

#	Article	IF	CITATIONS
4845	Stricker Learning Span criterion validity: a remote self-administered multi-device compatible digital word list memory measure shows similar ability to differentiate amyloid and tau PET-defined biomarker groups as in-person Auditory Verbal Learning Test. Journal of the International Neuropsychological Society, 2024, 30, 138-151.	1.8	1
4846	Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR‧B. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 1029-1042.	2.5	1
4847	Higher plasma βâ€synuclein indicates early synaptic degeneration in Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 5095-5102.	0.8	2
4848	Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Nature Aging, 2023, 3, 661-669.	11.6	19
4849	The potential of the gut microbiome for identifying Alzheimer's disease diagnostic biomarkers and future therapies. Frontiers in Neuroscience, 0, 17, .	2.8	10
4850	Sleep movements and respiratory coupling as a biobehavioral metric for early Alzheimer's disease in independently dwelling adults. BMC Geriatrics, 2023, 23, .	2.7	2
4851	Early-onset Alzheimer's disease with depression as the first symptom: a case report with literature review. Frontiers in Psychiatry, 0, 14, .	2.6	8
4852	Longitudinal association between ß-amyloid accumulation and cognitive decline in cognitively healthy older adults: A systematic review. Aging Brain, 2023, 3, 100074.	1.3	1
4853	The heterogeneity of asymmetric tau distribution is associated with an early age at onset and poor prognosis in Alzheimer's disease. NeuroImage: Clinical, 2023, 38, 103416.	2.7	4
4854	Cerebrospinal fluid neurofilament light predicts longitudinal diagnostic change in patients with psychiatric and neurodegenerative disorders. Acta Neuropsychiatrica, 2024, 36, 17-28.	2.1	2
4855	Rumo a uma nova era no diagnóstico e tratamento da doença de Alzheimer. PAJAR - Pan-American Journal of Aging Research, 2023, 11, e44542.	0.1	1
4856	Insulin resistance and body mass index are associated with TSPO PET in cognitively unimpaired elderly. Journal of Cerebral Blood Flow and Metabolism, 2023, 43, 1588-1600.	4.3	3
4857	Blood-Based Proteomic Profiling Identifies Potential Biomarker Candidates and Pathogenic Pathways in Dementia. International Journal of Molecular Sciences, 2023, 24, 8117.	4.1	3
4858	Toward a Patient-Specific Readout of Neurodegeneration. Neurology, 2023, 100, 1125-1126.	1.1	1
4859	DEAD-Box Helicase 17 Promotes Amyloidogenesis by Regulating BACE1 Translation. Brain Sciences, 2023, 13, 745.	2.3	2
4860	Sensory impairment and betaâ€amyloid deposition in the Baltimore longitudinal study of aging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	1
4861	Fluid and Biopsy Based Biomarkers in Parkinson's Disease. Neurotherapeutics, 2023, 20, 932-954.	4.4	6
4862	Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer's disease. Journal of Neuroinflammation, 2023, 20, .	7.2	1

#	Article	IF	CITATIONS
4863	Learning pyramidal multi-scale harmonic wavelets for identifying the neuropathology propagation patterns of Alzheimer's disease. Medical Image Analysis, 2023, 87, 102812.	11.6	1
4865	Vitreous Humor Biomarkers Reflect Pathological Changes in the Brain for Alzheimer's Disease and Chronic Traumatic Encephalopathy. Journal of Alzheimer's Disease, 2023, 93, 1181-1193.	2.6	1
4866	Banks of the Superior Temporal Sulcus in Alzheimer's Disease: A Pilot Quantitative Susceptibility Mapping Study. Journal of Alzheimer's Disease, 2023, 93, 1125-1134.	2.6	3
4867	Meta-Analysis of Variations in Association between APOE ɛ4 and Alzheimer's Disease and Related Dementias Across Hispanic Regions of Origin. Journal of Alzheimer's Disease, 2023, 93, 1095-1109.	2.6	1
4868	Quantification of the robustness of functional neural networks: application to the characterization of Alzheimer's disease continuum. Journal of Neural Engineering, 2023, 20, 036023.	3.5	1
4869	Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in Alzheimer's Disease. Scientific Data, 2023, 10, .	5.3	11
4870	Routine Hearing Assessments in Midlife to Detect Future Dementia. JAMA Otolaryngology - Head and Neck Surgery, 2023, 149, 578.	2.2	0
4871	Serum cortisol is negatively related to hippocampal volume, brain structure, and memory performance in healthy aging and Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 15, .	3.4	5
4872	Development and Implementation of an Internal Quality Control Sample to Standardize Oligomer-Based Diagnostics of Alzheimer's Disease. Diagnostics, 2023, 13, 1702.	2.6	0
4873	Brain proteomic analysis implicates actin filament processes and injury response in resilience to Alzheimer's disease. Nature Communications, 2023, 14, .	12.8	6
4874	The fusiform gyrus exhibits differential gene-gene co-expression in Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 15, .	3.4	0
4875	Transcriptomic and glycomic analyses highlight pathway-specific glycosylation alterations unique to Alzheimer's disease. Scientific Reports, 2023, 13, .	3.3	6
4876	Association of <i>APOE</i> -ε4, Osteoarthritis, β-Amyloid, and Tau Accumulation in Primary Motor and Somatosensory Regions in Alzheimer Disease. Neurology, 2023, 101, .	1.1	2
4878	Microvascular Contributions to Alzheimer Disease Pathogenesis: Is Alzheimer Disease Primarily an Endotheliopathy?. Biomolecules, 2023, 13, 830.	4.0	1
4879	CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease. Neurology, 2023, 101, .	1.1	7
4880	The Use of F-18 FDG PET-Based Cognitive Reserve to Evaluate Cognitive Decline in Alzheimer's Disease, Independent of Educational Influence. Medicina (Lithuania), 2023, 59, 945.	2.0	0
4881	Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer's disease. Journal of Neuroinflammation, 2023, 20, .	7.2	1
4882	White matter microstructural metrics are sensitively associated with clinical staging in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	4

	CITATION I	EPORT	
#	Article	IF	CITATIONS
4883	Blood biomarkers for Alzheimera€™s disease in clinical practice and trials. Nature Aging, 2023, 3, 506-519.	11.6	36
4884	Plasma levels of phosphorylated tau and neurofilament light chain as potential biomarkers for Alzheimer's disease: A biochemical analysis in Pakistani population. Saudi Pharmaceutical Journal, 2023, 31, 1202-1209.	2.7	1
4885	Verbal memory formation across PET-based Braak stages of tau accumulation in Alzheimer's disease. Brain Communications, 2023, 5, .	3.3	0
4887	Prediction of Amyloid $\hat{I}^2$ -Positivity with both MRI Parameters and Cognitive Function Using Machine Learning. Journal of the Korean Society of Radiology, 2023, 84, 638.	0.2	0
4888	Grid cell disruption in a mouse model of early Alzheimer's disease reflects reduced integration of self-motion cues. Current Biology, 2023, 33, 2425-2437.e5.	3.9	4
4889	EEG Reveals Alterations in Motor Imagery in People With Amnestic Mild Cognitive Impairment. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 0, , .	3.9	Ο
4890	Association between Cerebrospinal Fluid Soluble TREM2, Alzheimer's Disease and Other Neurodegenerative Diseases. Journal of Clinical Medicine, 2023, 12, 3589.	2.4	0
4891	Stress granules sequester Alzheimer's disease-associated gene transcripts and regulate disease-related neuronal proteostasis. Aging, 2023, 15, 3984-4011.	3.1	1
4892	Longitudinal changes in Alzheimer'sâ€related plasma biomarkers and brain amyloid. Alzheimer's and Dementia, 2023, 19, 4335-4345.	0.8	12
4893	Translating blood biomarkers into clinical practice for Alzheimer's disease: Challenges and perspectives. Alzheimer's and Dementia, 2023, 19, 4226-4236.	0.8	0
4895	Heart rate variability during slow wave sleep is linked to functional connectivity in the central autonomic network. Brain Communications, 2023, 5, .	3.3	5
4896	A review of current evidence for mild behavioral impairment as an early potential novel marker of Alzheimer's disease. Frontiers in Psychiatry, 0, 14, .	2.6	3
4897	Emerging concepts towards a translational framework in Alzheimer's disease. Neuroscience and Biobehavioral Reviews, 2023, 152, 105246.	6.1	1
4898	Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease. Frontiers in Neurology, 0, 14, .	2.4	0
4899	An automated, geometry-based method for hippocampal shape and thickness analysis. NeuroImage, 2023, 276, 120182.	4.2	0
4900	Subjective cognitive decline in patients with Parkinson's disease: an updated review. Frontiers in Aging Neuroscience, 0, 15,	3.4	3
4901	Co-twin design in brain imaging—review on biomarkers of Alzheimer's disease. Cerebral Cortex, 2023, 33, 9054-9066.	2.9	1
4902	Reference intervals for plasma amyloid-β, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment. Alzheimer's Research and Therapy, 2023, 15, .	6.2	3

#	Article	IF	CITATIONS
4904	APOE Peripheral and Brain Impact: APOE4 Carriers Accelerate Their Alzheimer Continuum and Have a High Risk of Suicide in PM2.5 Polluted Cities. Biomolecules, 2023, 13, 927.	4.0	2
4905	New horizons in emotional wellâ€being and brain aging: Potential lessons from crossâ€species research. International Journal of Geriatric Psychiatry, 2023, 38, .	2.7	0
4906	A Systematic Review of Clinical Practice Guidelines for Alzheimer's Disease and Strategies for Future Advancements. Neurology and Therapy, 2023, 12, 1257-1284.	3.2	3
4907	Predicting amyloidâ€beta pathology in the general population. Alzheimer's and Dementia, 2023, 19, 5506-5517.	0.8	1
4908	Prognostic value of imaging-based ATN profiles in a memory clinic cohort. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 3313-3323.	6.4	2
4909	Reduction of class I histone deacetylases ameliorates <scp>ER</scp> â€mitochondria crossâ€ŧalk in Alzheimer's disease. Aging Cell, 2023, 22, .	6.7	4
4910	Hippocampal sclerosis of aging at postâ€nortem is evident on MRI more than a decade prior. Alzheimer's and Dementia, 0, , .	0.8	1
4912	Cognitive assessment in primary care. Nurse Practitioner, 2023, 48, 26-35.	0.3	0
4913	Tipping points in neurodegeneration. Neuron, 2023, 111, 2954-2968.	8.1	7
4914	Astrogliosis, neuritic microstructure, and sex effects: CFAP is an indicator of neuritic orientation in women. Brain, Behavior, and Immunity, 2023, 113, 124-135.	4.1	3
4915	TNAP and P2X7R: New Plasma Biomarkers for Alzheimer's Disease. International Journal of Molecular Sciences, 2023, 24, 10897.	4.1	2
4916	Clinical trials in dementia with Lewy bodies: the evolving concept of co-pathologies, patient selection and biomarkers. Current Opinion in Neurology, 2023, 36, 264-275.	3.6	3
4917	Serum NfL and GFAP are associated with incident dementia and dementia mortality in older adults: The cardiovascular health study. Alzheimer's and Dementia, 0, , .	0.8	4
4918	Recent developments in the role of DNA damage response and understanding its implications for new therapeutic approaches in Alzheimer's disease. Translational Medicine of Aging, 2023, 7, 52-65.	1.3	1
4919	Single-molecule immunoassay technology: Recent advances. Talanta, 2023, 265, 124903.	5.5	3
4920	Features of event-related potentials during retrieval of episodic memory in patients with mild cognitive impairment due to Alzheimer's disease. Frontiers in Neuroscience, 0, 17, .	2.8	0
4921	FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer's Disease: Benefits and Pitfalls. Diagnostics, 2023, 13, 2254.	2.6	1
4922	Post-COVID cognitive dysfunction: current status and research recommendations for high risk population. The Lancet Regional Health - Western Pacific, 2023, 38, 100836.	2.9	18

#	Article	IF	CITATIONS
4923	Bibliometric analysis of global research on the role of apolipoprotein E in Alzheimer's disease. Heliyon, 2023, 9, e17987.	3.2	1
4924	The QPLEX™ Plus Assay Kit for the Early Clinical Diagnosis of Alzheimer's Disease. International Journal of Molecular Sciences, 2023, 24, 11119.	4.1	1
4925	Probabilistic estimation for acrossâ€batch compatibility enhancement for amyloid PET. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	0
4927	Ethical Issues of Primary and Secondary Dementia Prevention. GeroPsych: the Journal of Gerontopsychology and Geriatric Psychiatry, 2023, 36, 177-187.	0.5	0
4928	Ethical challenges of using remote monitoring technologies for clinical research: A case study of the role of local research ethics committees in the RADAR-AD study. PLoS ONE, 2023, 18, e0285807.	2.5	3
4929	The Aging Patterns of Brain Structure, Function, and Energy Metabolism. Advances in Experimental Medicine and Biology, 2023, , 85-97.	1.6	0
4930	Molecular Design of Magnetic Resonance Imaging Agents Binding to Amyloid Deposits. International Journal of Molecular Sciences, 2023, 24, 11152.	4.1	2
4931	A review of neuroimaging-based data-driven approach for Alzheimer's disease heterogeneity analysis. Reviews in the Neurosciences, 2024, 35, 121-139.	2.9	2
4932	Modifiable risk factors for dementia, cognition, and plasma phosphorylated tau 181 in a large-scale cohort of Australian older adults. Neurobiology of Aging, 2023, 131, 106-114.	3.1	3
4934	Human hippocampal astrocytes: Computational dissection of their transcriptome, sexual differences and exosomes across ageing and mildâ€cognitive impairment. European Journal of Neuroscience, 2023, 58, 2677-2707.	2.6	1
4935	Rare forms of cerebral amyloid angiopathy: pathogenesis, biological and clinical features of CAA-ri and iCAA. Frontiers in Neuroscience, 0, 17, .	2.8	2
4936	Virtual Reality and Serious Games Digital Solutions for Remote Cognitive Screening of Older Adults. Advances in Game-based Learning Book Series, 2023, , 311-342.	0.2	0
4937	Advances in diagnosing mild cognitive impairment and Alzheimer's disease using 11C-PIB- PET/CT and common neuropsychological tests. Frontiers in Neuroscience, 0, 17, .	2.8	0
4938	A task force for diagnosis and treatment of people with Alzheimer's disease in Latin America. Frontiers in Neurology, 0, 14, .	2.4	2
4939	Precipitating Mechanisms of Falls in Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2023, 7, 739-750.	2.2	1
4940	Can neurocognitive assessment be a lower-cost substitute for biomarkers in predicting progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD)? A narrative review. Biomarkers in Neuropsychiatry, 2023, 9, 100069.	1.0	1
4941	Optical Coherence Tomography Assessment of Macular Thickness in Alzheimer's Dementia with Different Neuropsychological Severities. Journal of Personalized Medicine, 2023, 13, 1118.	2.5	1
4942	A Real-Time Neurophysiologic Stress Test for the Aging Brain: Novel Perioperative and ICU Applications of EEG in Older Surgical Patients. Neurotherapeutics, 2023, 20, 975-1000.	4.4	3

#	Article	IF	CITATIONS
4943	Illustrated Neuropathologic Diagnosis of Alzheimer's Disease. Neurology International, 2023, 15, 857-867.	2.8	0
4944	Alzheimer's disease diagnostic accuracy by fluid and neuroimaging <scp>ATN</scp> framework. CNS Neuroscience and Therapeutics, 2024, 30, .	3.9	Ο
4945	Primacy and recency effects in verbal memory are differentially associated with post-mortem frontal cortex p-tau 217 and 202 levels in a mixed sample of community-dwelling older adults. Journal of Clinical and Experimental Neuropsychology, 2023, 45, 770-785.	1.3	1
4946	The complex pathway between amyloid $\hat{I}^2$ and cognition: implications for therapy. Lancet Neurology, The, 2023, 22, 847-857.	10.2	5
4948	Thirty Years After the Launch of the Amyloid Cascade Hypothesis: Is there a Shift of Gears atÂLast?. , 2023, , 527-573.		0
4949	Driving Forces of Alzheimer's Research Directions. , 2023, , 471-526.		0
4950	Repositioning of Anti-Diabetic Drugs against Dementia: Insight from Molecular Perspectives to Clinical Trials. International Journal of Molecular Sciences, 2023, 24, 11450.	4.1	4
4951	Estimation of brain amyloid accumulation using deep learning in clinical [11C]PiB PET imaging. EJNMMI Physics, 2023, 10, .	2.7	Ο
4952	Cognitive reserve, neuropathology, and progression towards Alzheimer's disease. Aging, 2023, 15, 5963-5965.	3.1	0
4953	Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum. Alzheimer's Research and Therapy, 2023, 15, .	6.2	2
4954	More than just risk for Alzheimer's disease: APOE ε4's impactÂon the aging brain. Trends in Neurosciences, 2023, 46, 750-763.	8.6	2
4956	Emerging Treatments for Alzheimer's Disease. , 0, 54, 280-286.		0
4957	Disease progression modelling of Alzheimer's disease using probabilistic principal components analysis. NeuroImage, 2023, 278, 120279.	4.2	2
4958	Progressive human-like tauopathy with downstream neurodegeneration and neurovascular compromise in a transgenic rat model. Neurobiology of Disease, 2023, 184, 106227.	4.4	1
4959	Trial of Solanezumab in Preclinical Alzheimer's Disease. New England Journal of Medicine, 2023, 389, 1096-1107.	27.0	31
4960	Recent Advancements in the Early Diagnosis and Treatment of Alzheimer's Disease. Advanced Therapeutics, 2023, 6, .	3.2	0
4961	The Role of Clearance in Neurodegenerative Diseases. SIAM Journal on Applied Mathematics, 0, , S172-S198.	1.8	1
4962	Donanemab in Early Symptomatic Alzheimer Disease. JAMA - Journal of the American Medical Association, 2023, 330, 512.	7.4	254

#	Article	IF	CITATIONS
4963	Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease. JAMA - Journal of the American Medical Association, 2023, 330, 507.	7.4	12
4965	Insights into the pathological basis of dementia from populationâ€based neuropathology studies. Neuropathology and Applied Neurobiology, 2023, 49, .	3.2	1
4967	Cognitive effects of Lewy body pathology in clinically unimpaired individuals. Nature Medicine, 2023, 29, 1971-1978.	30.7	11
4969	A proteomics analysis of 5xFAD mouse brain regions reveals the lysosome-associated protein Arl8b as a candidate biomarker for Alzheimer's disease. Genome Medicine, 2023, 15, .	8.2	2
4970	Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life. Science Translational Medicine, 2023, 15, .	12.4	16
4971	Identifying healthy individuals with Alzheimer's disease neuroimaging phenotypes in the UK Biobank. Communications Medicine, 2023, 3, .	4.2	1
4972	Reference Data for Attentional, Executive, Linguistic, and Visual Processing Tests Obtained from Cognitively Healthy Individuals with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. Journal of Alzheimer's Disease, 2023, , 1-13.	2.6	0
4973	Decoupling of Regional Cerebral Blood Flow and Brain Function Along the Alzheimer's Continuum. Journal of Alzheimer's Disease, 2023, , 1-12.	2.6	0
4974	Distinguishing Alzheimer's disease from other dementias using pattern profile analysis in the Meyers Neuropsychological Battery: An exploratory study. Applied Neuropsychology Adult, 0, , 1-16.	1.2	0
4975	Alzheimer's disease-associated complement gene variants influence plasma complement protein levels. Journal of Neuroinflammation, 2023, 20, .	7.2	4
4976	Eye-tracking paradigms for the assessment of mild cognitive impairment: a systematic review. Frontiers in Psychology, 0, 14, .	2.1	5
4977	Using Cognitive Reserve to Create Norms for the TMA-93 (Relational Binding of Images). Journal of Alzheimer's Disease, 2023, , 1-11.	2.6	0
4978	Plasma long non-coding RNAs ASMTL-AS1, AP001363.1, AC005730.3 and AL133415.1 as a potential biomarker for Alzheimer's disease. Neurological Research, 2023, 45, 804-817.	1.3	1
4979	Computer-Aided Diagnosis and Prediction in Brain Disorders. Neuromethods, 2023, , 459-490.	0.3	0
4980	A Comprehensive Review onÂtheÂldentification ofÂBlood-Based Biomarkers forÂAlzheimer's Disease Detection Through Computational Approaches. Lecture Notes in Networks and Systems, 2023, , 435-449.	0.7	0
4981	The novel function of bexarotene for neurological diseases. Ageing Research Reviews, 2023, , 102021.	10.9	1
4982	Frontotemporal Dementia, Where Do We Stand? A Narrative Review. International Journal of Molecular Sciences, 2023, 24, 11732.	4.1	14
4983	Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update. Neurotherapeutics, 2023, 20, 914-931.	4.4	22
#	Article	IF	CITATIONS
------	--	------	-----------
4984	Association of Novelty-Related Locus Coeruleus Function With Entorhinal Tau Deposition and Memory Decline in Preclinical Alzheimer Disease. Neurology, 0, , 10.1212/WNL.0000000000207646.	1.1	1
4985	ATN profile classification across two independent prospective cohorts. Frontiers in Medicine, 0, 10, .	2.6	0
4986	Quantification of race/ethnicity representation in Alzheimer's disease neuroimaging research in the USA: a systematic review. Communications Medicine, 2023, 3, .	4.2	3
4987	Compilation of reported protein changes in the brain in Alzheimer's disease. Nature Communications, 2023, 14, .	12.8	14
4988	Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic. Translational Psychiatry, 2023, 13, .	4.8	4
4989	Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease. Neurology, 2023, 101, 842-852.	1.1	6
4990	Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A crossâ€platform validation study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	0
4992	Individual regional associations between AÎ <sup>2</sup> -, tau- and neurodegeneration (ATN) with microglial activation in patients with primary and secondary tauopathies. Molecular Psychiatry, 2023, 28, 4438-4450.	7.9	7
4993	Assessment of synaptic loss in mouse models of β-amyloid and tau pathology using [18F]UCB-H PET imaging. Neurolmage: Clinical, 2023, 39, 103484.	2.7	0
4994	Persistent 18F-FDG Brain PET Fronto-Temporal Hypometabolism and Cognitive Symptoms Two Years after SARS-CoV-2 Infection: A Case Report. Neurology International, 2023, 15, 908-916.	2.8	1
4995	Speech and language markers of neurodegeneration: a call for global equity. Brain, 2023, 146, 4870-4879.	7.6	7
4996	Greater cognitive reserve is related to lower cortical excitability in healthy cognitive aging, but not in early clinical Alzheimer's disease. Frontiers in Human Neuroscience, 0, 17, .	2.0	1
4997	Diterminan Sosial - Ekonomi dan Kesehatan Mental pada Kaum Ibu di Kawasan Provinsi Bengkulu. , 2023, 2, 22-29.		0
4998	Pericyte Loss in Diseases. Cells, 2023, 12, 1931.	4.1	5
4999	Impact of sharing Alzheimer's disease biomarkers with individuals without dementia: A systematic review and metaâ€analysis of empirical data. Alzheimer's and Dementia, 2023, 19, 5773-5794.	0.8	1
5000	Effect of Transcranial Pulse Stimulation for the Treatment of Alzheimer´s Disease and its Related Symptoms. Current Alzheimer Research, 2023, 20, .	1.4	0
5001	The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline. Alzheimer's and Dementia, 2024, 20, 221-233.	0.8	6
5002	Shanghai Cognitive Screening: A Mobile Cognitive Assessment Tool Using Voice Recognition to Detect Mild Cognitive Impairment and Dementia in the Community. Journal of Alzheimer's Disease, 2023, 95, 227-236.	2.6	2

#	Article	IF	CITATIONS
5003	Clinical effects of Lewy body pathology in cognitively impaired individuals. Nature Medicine, 2023, 29, 1964-1970.	30.7	14
5005	The Sigma Receptors in Alzheimer's Disease: New Potential Targets for Diagnosis and Therapy. International Journal of Molecular Sciences, 2023, 24, 12025.	4.1	2
5007	Associations of the A/T/N profiles in PET, CSF, and plasma biomarkers with Alzheimer's disease neuropathology at autopsy. Alzheimer's and Dementia, 2023, 19, 4421-4435.	0.8	4
5008	FDCâ€PET markers of heterogeneity and different risk of progression in amnestic MCI. Alzheimer's and Dementia, 2024, 20, 159-172.	0.8	2
5009	Inhibition of Pro-Inflammatory Microglia with Minocycline Improves Cognitive and Sleep-Wake Dysfunction Under Respiratory Stress in a Sporadic Model for Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 95, 317-337.	2.6	1
5010	The performance of plasma phosphorylated tau231 in detecting Alzheimer's disease: A systematic review with metaâ€analysis. European Journal of Neuroscience, 2023, 58, 3132-3149.	2.6	1
5011	A dataâ€driven approach to complement the A/T/(N) classification system using CSF biomarkers. CNS Neuroscience and Therapeutics, 2024, 30, .	3.9	1
5012	Optimizing detection of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO. Molecular Neurodegeneration, 2023, 18, .	10.8	7
5013	Pathology steered stratification network for subtype identification in Alzheimer's disease. Medical Physics, 2024, 51, 1190-1202.	3.0	0
5014	Voltage-Gated Na+ Channels in Alzheimer's Disease: Physiological Roles and Therapeutic Potential. Life, 2023, 13, 1655.	2.4	0
5015	Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease. JAMA Neurology, 2023, 80, 969.	9.0	4
5016	Case report: Anti-ARHGAP26 autoantibodies in atypical dementia with Lewy bodies. , 0, 2, .		0
5017	Clinical characteristics of patients with suspected Alzheimer's disease within a CSF Aß-ratio grey zone. Neurological Research and Practice, 2023, 5, .	2.0	1
5018	Plasma neurofilament light chain in relation to 10-year change in cognition and neuroimaging markers: a population-based study. GeroScience, 0, , .	4.6	1
5019	Plasma pâ€ŧau231 and pâ€ŧau217 inform on tau tangles aggregation in cognitively impaired individuals. Alzheimer's and Dementia, 2023, 19, 4463-4474.	0.8	2
5020	Changes in Plasma Neutral and Ether-Linked Lipids Are Associated with The Pathology and Progression of Alzheimer's Disease. , 2023, 14, 1728.		1
5021	Serum Neurofilament Light Chain in the Diagnostic Evaluation of Patients with Cognitive Symptoms in the Neurological Consultation of a Tertiary Center. Journal of Alzheimer's Disease, 2023, , 1-7.	2.6	0
5022	Semantic intrusion errors are associated with plasma Ptau-181 among persons with amnestic mild cognitive impairment who are amyloid positive. Frontiers in Neurology, 0, 14, .	2.4	0

#	Article	IF	CITATIONS
5023	Multiple cross-frequency coupling analysis of resting-state EEG in patients with mild cognitive impairment and Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 15, .	3.4	1
5024	Tear biomarkers for Alzheimer's disease screening and diagnosis (the TearAD study): design and rationale of an observational longitudinal multicenter study. BMC Neurology, 2023, 23, .	1.8	1
5025	Intervention of next-generation sequencing in diagnosis of Alzheimer's disease: challenges and future prospects. Dementia E Neuropsychologia, 0, 17, .	0.8	0
5026	Stability and bifurcation analysis of Alzheimer's disease model with diffusion and three delays. Chaos, 2023, 33, .	2.5	0
5027	Influence of N6-methyladenosine (m6A) modification on cell phenotype in Alzheimer's disease. PLoS ONE, 2023, 18, e0289068.	2.5	0
5028	Cerebrospinal fluid lipidomic fingerprint of obstructive sleep apnoea in Alzheimer's disease. Alzheimer's Research and Therapy, 2023, 15, .	6.2	4
5029	Exploring the role of COX-2 in Alzheimer's disease: Potential therapeutic implications of COX-2 inhibitors. Saudi Pharmaceutical Journal, 2023, 31, 101729.	2.7	3
5030	Rhombomere 1 r1. , 2023, , 391-436.		0
5031	Dissociation of Arousal Index Between REM and NREM Sleep in Elderly Adults with Cognitive Impairment, No Dementia: A Pilot Study. Journal of Alzheimer's Disease, 2023, , 1-15.	2.6	0
5032	Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease. Nature Medicine, 2023, 29, 1979-1988.	30.7	24
5033	Events in the brain during the evolution of Alzheimer's disease. Nature Medicine, 2023, 29, 1916-1917.	30.7	0
5034	Investigating the relationship between allocentric spatial working memory and biomarker status in preclinical and prodromal Alzheimer's disease. Applied Neuropsychology Adult, 0, , 1-13.	1.2	0
5035	Uncovering Diverse Mechanistic Spreading Pathways in Disease Progression of Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2023, 7, 855-872.	2.2	0
5036	Editorial: Highlights in Alzheimer's and Parkinson's disease. Frontiers in Human Neuroscience, 0, 17, .	2.0	0
5037	Emerging role of vascular burden in AT(N) classification in individuals with Alzheimer's and concomitant cerebrovascular burdens. Journal of Neurology, Neurosurgery and Psychiatry, 2024, 95, 44-51.	1.9	1
5038	Association of sleep disorders with clinical symptoms and age in Chinese older adult patients with and without cognitive decline. Frontiers in Aging Neuroscience, 0, 15, .	3.4	0
5039	Driving Automation for Older Adults with Preclinical Alzheimer's Disease. Gerontology, 2023, 69, 1307-1314.	2.8	0
5040	A new diagnostic tool for brain disorders: extracellular vesicles derived from neuron, astrocyte, and oligodendrocyte. Frontiers in Molecular Neuroscience, 0, 16, .	2.9	0

#	Article	IF	CITATIONS
5041	Prodromes in demyelinating disorders, amyotrophic lateral sclerosis, Parkinson disease, and Alzheimer's dementia. Revue Neurologique, 2023, , .	1.5	1
5042	Multimodal imaging of microstructural cerebral alterations and loss of synaptic density in Alzheimer's disease. Neurobiology of Aging, 2023, 132, 24-35.	3.1	2
5043	Meta-Analysis of Animal Fluency Performance in Amnestic Mild Cognitive Impairment and Cognitively Unimpaired Older Adults. Alzheimer Disease and Associated Disorders, 2023, 37, 259-264.	1.3	0
5044	Diminished activation of excitatory neurons in the prelimbic cortex leads to impaired working memory capacity in mice. BMC Biology, 2023, 21, .	3.8	0
5045	"And Does That Necessarily Mean Absolutely Alzheimer's?―An Analysis of Questions Raised Following Amyloid PET Results Disclosure. American Journal of Geriatric Psychiatry, 2023, , .	1.2	1
5046	A dementia ellÃįtÃįsa a hÃįziorvosi gyakorlatban. Orvosi Hetilap, 2023, 164, 1263-1270.	0.4	0
5047	Associations between Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers in People with Mild Cognitive Impairment. Brain Sciences, 2023, 13, 1195.	2.3	0
5048	Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity. JAMA Neurology, 2023, 80, 1051.	9.0	7
5049	Longitudinal hippocampal atrophy in hippocampal sclerosis of aging. Aging Brain, 2023, 4, 100092.	1.3	2
5050	The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2023, 9, .	3.7	0
5051	The relationship between <i>APOE</i> genotype, <scp>CSF</scp> Tau and cognition across the Alzheimer's disease spectrum, moderation and mediation role of insula network connectivity. CNS Neuroscience and Therapeutics, 2024, 30, .	3.9	0
5053	Defying syntactic preservation in Alzheimer's disease: what type of impairment predicts syntactic change in dementia (if it does) and why?. , 0, 2, .		1
5054	European Projects for Patients with Dementia and Their Caregivers. Advances in Experimental Medicine and Biology, 2023, , 609-618.	1.6	2
5055	Association of the fibronectin type III domain–containing protein 5 rs1746661 single nucleotide polymorphism with reduced brain glucose metabolism in elderly humans. Brain Communications, 2023, 5, .	3.3	0
5057	Neurotheranostics: The Next Frontier for Health Span. Journal of Nuclear Medicine Technology, 2023, 51, 266-270.	0.8	0
5058	Whole genome deconvolution unveils Alzheimer's resilient epigenetic signature. Nature Communications, 2023, 14, .	12.8	2
5059	State of the Science on Brain Insulin Resistance and Cognitive Decline Due to Alzheimer's Disease. , 2023, .		5
5061	The importance of phospholipases A2 in Alzheimer's disease mechanisms, pathology, and potential therapies. , 2023, , 135-151.		0

#	Article	IF	CITATIONS
5063	Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2023, 9, .	3.7	1
5065	Artificial intelligence for dementia drug discovery and trials optimization. Alzheimer's and Dementia, 2023, 19, 5922-5933.	0.8	3
5066	Harmonization and standardization of biofluidâ€based biomarker measurements for AT(N) classification in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	0
5067	Alzheimer's disease biomarker profiling in a memory clinic cohort without common comorbidities. Brain Communications, 2023, 5, .	3.3	2
5068	International Variations in Dementia and Alzheimer Disease Diagnosis and Certification Habits and Their Associations With Dementia and Alzheimer Disease Mortality. Alzheimer Disease and Associated Disorders, 2023, 37, 215-221.	1.3	0
5069	Alterations in Peripheral Metabolites as Key Actors in Alzheimer's Disease. Current Alzheimer Research, 2023, 20, .	1.4	0
5070	Cortical Amyloid Burden Relates to Basal Forebrain Volume in Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2023, , 1-16.	2.6	0
5071	The heritability of bloodâ€based biomarkers related to risk of Alzheimer's disease in a populationâ€based sample of early oldâ€age men. Alzheimer's and Dementia, 2024, 20, 356-365.	0.8	0
5072	Spatiotemporal Characteristics of Regional Brain Perfusion Associated with Neuropsychiatric Symptoms in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 95, 981-993.	2.6	2
5073	Predictive factors for Alzheimer's disease progression: a comprehensive retrospective analysis of 3,553 cases with 211 months follow-up. Frontiers in Neurology, 0, 14, .	2.4	2
5074	Detecting Dementia by Saliva Analysis: A Fingerprinting Unobtrusive Method Based on a Fast and Cheap Sensor System. Journal of Alzheimer's Disease, 2023, , 1-9.	2.6	0
5075	The interaction of global small vessel disease burden and Alzheimer's disease pathologies do not change the independent association of amyloidâ€beta with hippocampal volume: A longitudinal study on mild cognitive impairment subjects. Hippocampus, 0, , .	1.9	0
5076	Nuclear Imaging Dataâ€Driven Classification of Parkinson's Disease. Movement Disorders, 2023, 38, 2053-2063.	3.9	2
5077	Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	0
5078	Developing Explainable Deep Model for Discovering Novel Control Mechanism of Neuro-Dynamics. IEEE Transactions on Medical Imaging, 2023, , 1-1.	8.9	0
5079	Toward Reagent-Free Discrimination of Alzheimer's Disease Using Blood Plasma Spectral Digital Biomarkers and Machine Learning. Journal of Alzheimer's Disease, 2023, , 1-14.	2.6	Ο
5080	Clinical utility of self- and informant-reported memory, attention, and spatial navigation in detecting biomarkers associated with Alzheimer disease in clinically normal adults. Journal of the International Neuropsychological Society, 2024, 30, 232-243.	1.8	1
5081	Pathway-Specific Polygenic Risk Scores Correlate with Clinical Status and Alzheimer's Disease-Related Biomarkers. Journal of Alzheimer's Disease, 2023, 95, 915-929.	2.6	1

#	Article	IF	CITATIONS
5082	AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome. Alzheimer's and Dementia, 2024, 20, 366-375.	0.8	1
5083	The role of A\$\$eta \$\$ and Tau proteins in Alzheimer's disease: a mathematical model on graphs. Journal of Mathematical Biology, 2023, 87, .	1.9	0
5084	Novel fluid biomarkers for mild cognitive impairment: A systematic review and meta-analysis. Ageing Research Reviews, 2023, 91, 102046.	10.9	3
5085	Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer〙s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study. Alzheimer's Research and Therapy, 2023, 15, .	6.2	0
5086	Preclinical Brain Network Abnormalities in Patients with Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2023, , 1-13.	2.6	0
5087	Longitudinal interplay between subclinical atherosclerosis, cardiovascular risk factors, and cerebral glucose metabolism in midlife: results from the PESA prospective cohort study. The Lancet Healthy Longevity, 2023, 4, e487-e498.	4.6	2
5088	The impact of technology-based compensatory behaviors on subjective cognitive decline in older adults with a family history of dementia. Applied Neuropsychology Adult, 0, , 1-9.	1.2	0
5089	The emerging role of blood biomarkers in diagnosis and treatment of Alzheimer's disease. European Geriatric Medicine, 2023, 14, 913-917.	2.8	1
5090	APOE ε4 Gene Carriers Demonstrate Reduced Retinal Capillary Densities in Asymptomatic Older Adults. Journal of Clinical Medicine, 2023, 12, 5649.	2.4	2
5091	Cerebrospinal fluid neurofilament light chain and total-tau as biomarkers of neurodegeneration in Alzheimer's disease and frontotemporal dementia. Neurobiology of Disease, 2023, 186, 106267.	4.4	0
5092	Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti–Amyloid-β Therapy. Radiographics, 2023, 43, .	3.3	4
5093	A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases. Nature Aging, 2023, 3, 1079-1090.	11.6	10
5094	Invited Commentary: Radiologist's Role in Anti-Amyloid Therapy for Alzheimer Disease. Radiographics, 2023, 43, .	3.3	0
5095	Influence of preanalytical and analytical factors on the quantification of six regulatory serum proteins. Bioanalysis, 2023, 15, 1157-1167.	1.5	1
5096	Olfactory Dysfunction Is Associated with Cerebral Amyloid Deposition and Cognitive Function in the Trajectory of Alzheimer's Disease. Biomolecules, 2023, 13, 1336.	4.0	2
5097	Clinical and biochemical markers of neurodegenerative process in Alzheimer's disease. Vestnik Nevrologii, Psihiatrii I Nejrohirurgii, 2023, , 675-686.	0.1	0
5098	Vitamin D, a Secosteroid Hormone and Its Multifunctional Receptor, Vitamin D Receptor, in Alzheimer's Type Neurodegeneration. Journal of Alzheimer's Disease, 2023, 95, 1273-1299.	2.6	4
5099	The efficacy and practicality of the Neurotrack Cognitive Battery assessment for utilization in clinical settings for the identification of cognitive decline in an older Japanese population. Frontiers in Aging Neuroscience, 0, 15, .	3.4	0

#	Article	IF	CITATIONS
5100	The diamagnetic component map from quantitative susceptibility mapping (QSM) source separation reveals pathological alteration in Alzheimer's disease-driven neurodegeneration. NeuroImage, 2023, 280, 120357.	4.2	2
5101	Aerobic Exercise, Training Dose, and Cardiorespiratory Fitness: Effects and Relationships with Resting Plasma Neurotrophic Factors in Alzheimer's Dementia. , 2023, 2, 351-366.		0
5102	Eye movement patterns during viewing face images with neutral expressions in patients with earlyâ€stage Alzheimer's disease and amnestic mild cognitive impairment. Brain and Behavior, 2023, 13, .	2.2	1
5103	DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease. Nature Aging, 2023, 3, 1201-1209.	11.6	7
5104	Genetic risks of Alzheimer's by <i>APOE</i> and <i>MAPT</i> on cortical morphology in young healthy adults. Brain Communications, 2023, 5, .	3.3	2
5105	Head-to-Head Comparison of Two Plasma Phospho-tau Assays in Predicting Conversion of Mild Cognitive Impairment to Dementia. Clinical Chemistry, 2023, 69, 1072-1083.	3.2	1
5106	New Community and Sociohealth Challenges Arising from the Early Diagnosis of Mild Cognitive Impairment (MCI). Journal of Personalized Medicine, 2023, 13, 1410.	2.5	0
5107	The Deficits of Insulin Signal in Alzheimer's Disease and the Mechanisms of Vanadium Compounds in Curing AD. Current Issues in Molecular Biology, 2023, 45, 6365-6382.	2.4	1
5108	Antiâ€amyloid antibody treatments for Alzheimer's disease. European Journal of Neurology, 2024, 31, .	3.3	0
5109	Radiomics and Artificial Intelligence for the Diagnosis and Monitoring of Alzheimer's Disease: A Systematic Review of Studies in the Field. Journal of Clinical Medicine, 2023, 12, 5432.	2.4	3
5110	Morphofunctional Changes in Brain and Peripheral Blood in Adult and Aged Wistar Rats with AlCl3-Induced Neurodegeneration. Biomedicines, 2023, 11, 2336.	3.2	0
5111	Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies. International Journal of Molecular Sciences, 2023, 24, 13900.	4.1	3
5112	A how-to guide for a precision medicine approach to the diagnosis and treatment of Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 15, .	3.4	6
5113	Communication about diagnosis, prognosis, and prevention in the memory clinic: perspectives of European memory clinic professionals. Alzheimer's Research and Therapy, 2023, 15, .	6.2	1
5114	Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias. Alzheimer's Research and Therapy, 2023, 15, .	6.2	0
5115	Impact of hs-CRP concentration on brain structure alterations and cognitive trajectory in Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 15, .	3.4	2
5116	Exploring the significance of lipids in Alzheimer's disease and the potential of extracellular vesicles. Proteomics, 0, , .	2.2	1
5117	Improving comparability across cognitive training trials for brain aging: A focus on interoperability. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2023, 9, .	3.7	0

#	Article	IF	CITATIONS
5118	Gait dysfunction in Alzheimer disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 267-274.	1.8	0
5119	Structural degeneration of the nucleus basalis of Meynert in mild cognitive impairment and Alzheimer's disease – Evidence from an MRI-based meta-analysis. Neuroscience and Biobehavioral Reviews, 2023, 154, 105393.	6.1	2
5120	Dimensional clinical phenotyping using <i>postâ€mortem</i> brain donor medical records: <i>postâ€mortem</i> RDoC profiling is associated with Alzheimer's disease neuropathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	0
5121	White matter hyperintensity longitudinal morphometric analysis in association with Alzheimer disease. Alzheimer's and Dementia, 2023, 19, 4488-4497.	0.8	0
5122	Dementia death rates prediction. BMC Psychiatry, 2023, 23, .	2.6	4
5123	Digit Ratio (2D:4D) Is Not Associated with Alzheimer's Disease in the Elderly. Brain Sciences, 2023, 13, 1229.	2.3	0
5124	The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022. Alzheimer's and Dementia, 2024, 20, 652-694.	0.8	3
5125	Disease progression model anchored around clinical diagnosis in longitudinal cohorts: example of Alzheimer's disease and related dementia. BMC Medical Research Methodology, 2023, 23, .	3.1	0
5126	Plasma Aβ42/40 and cognitive variability are associated with cognitive function in Black Americans: Findings from the AAâ€FAIM cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2023, 9, .	3.7	0
5127	Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status. Alzheimer's Research and Therapy, 2023, 15, .	6.2	1
5128	Navigating Early Alzheimer's Diagnosis: A Comprehensive Review of Diagnostic Innovations. Cureus, 2023, , .	0.5	0
5129	The Role of Clinical Assessment in the Era of Biomarkers. Neurotherapeutics, 2023, 20, 1001-1018.	4.4	1
5130	A holo-spectral EEG analysis provides an early detection of cognitive decline and predicts the progression to Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 15, .	3.4	1
5131	SIMOA-based analysis of plasma NFL levels in MCI and AD patients: a systematic review and meta-analysis. BMC Neurology, 2023, 23, .	1.8	2
5132	A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer's disease. Science Translational Medicine, 2023, 15, .	12.4	8
5133	Visualization of the elevated levels of hypochlorous acid in Alzheimer's disease with a ruthenium(II) complex-based luminescence probe. Analytica Chimica Acta, 2023, 1279, 341779.	5.4	3
5134	An integrated neuroimaging-omics approach for the gut-brain communication pathways in Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 15, .	3.4	1
5135	Resting-state electroencephalographic characteristics related to mild cognitive impairments. Frontiers in Psychiatry, 0, 14, .	2.6	0

#	Article	IF	CITATIONS
5136	CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa <sup>®</sup> assays targeting distinct amyloid regions. Clinical Chemistry and Laboratory Medicine, 2024, 62, 332-340.	2.3	3
5137	Bridging the rodent to human translational gap: Marmosets as model systems for the study of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2023, 9, .	3.7	3
5138	NcRNAs: A synergistically antiapoptosis therapeutic tool in Alzheimer's disease. CNS Neuroscience and Therapeutics, 0, , .	3.9	0
5140	Glucose metabolism in posterior cingulate cortex has supplementary value to predict the progression of cognitively unimpaired to dementia due to Alzheimer's disease: an exploratory study of 18F-FDC-PET. GeroScience, 0, , .	4.6	1
5141	A Federated Learning Model Based on Hardware Acceleration for the Early Detection of Alzheimer's Disease. Sensors, 2023, 23, 8272.	3.8	1
5142	Amyloid PET Radiopharmaceuticals and Imaging for Clinical and Research Applications in Thailand. Siriraj Medical Journal, 2023, 75, 688-698.	0.3	0
5143	Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease. Molecular Neurodegeneration, 2023, 18, .	10.8	10
5144	Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology. Clinical Chemistry, 0, , .	3.2	0
5145	Association of Plasma Aβ <sub>42</sub> /Aβ <sub>40</sub> Ratio and Late-Onset Epilepsy. Neurology, 2023, 101, .	1.1	4
5146	Examining the role of participant and study partner report in widely-used classification approaches of mild cognitive impairment in demographically-diverse community dwelling individuals: results from the Einstein aging study. Frontiers in Aging Neuroscience, 0, 15, .	3.4	0
5147	Cortical microstructural changes predict tau accumulation and episodic memory decline in older adults harboring amyloid. Communications Medicine, 2023, 3, .	4.2	2
5148	Application of biomarker-derived fluorescent probes for the detection of Alzheimer's disease. TrAC - Trends in Analytical Chemistry, 2023, 169, 117369.	11.4	2
5149	Objective Physical Function in the Alzheimer's Disease Continuum: Association with Cerebrospinal Fluid Biomarkers in the ALBION Study. International Journal of Molecular Sciences, 2023, 24, 14079.	4.1	0
5150	Blood–Brain Barrier Dysfunction and Aβ42/40 Ratio Dose-Dependent Modulation with the ApoE Genotype within the ATN Framework. International Journal of Molecular Sciences, 2023, 24, 12151.	4.1	1
5151	The therapeutic landscape of tauopathies: challenges and prospects. Alzheimer's Research and Therapy, 2023, 15, .	6.2	1
5152	Creatine Kinase MB Isoenzyme Is a Complementary Biomarker in Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2023, 24, 11682.	4.1	2
5153	Improved connectivity and cognition due to cognitive stimulation in Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 15, .	3.4	0
5154	Synaptic PET Imaging in Neurodegeneration. , 2023, , 157-167.		0

#	Article	IF	CITATIONS
5155	The autophagy protein Def8 is altered in Alzheimer's disease and AÎ <sup>2</sup> 42-expressing Drosophila brains. Scientific Reports, 2023, 13, .	3.3	0
5156	Amyloid PET across the cognitive spectrum in former professional and college American football players: findings from the DIAGNOSE CTE Research Project. Alzheimer's Research and Therapy, 2023, 15, .	6.2	3
5157	PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimer's Disease With machine learning: the PREVIEW study protocol. BMC Neurology, 2023, 23, .	1.8	2
5158	Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A crossâ€sectional and longitudinal study. European Journal of Neurology, 2024, 31, .	3.3	0
5159	Secondary neurodegeneration following Stroke: what can blood biomarkers tell us?. Frontiers in Neurology, 0, 14, .	2.4	1
5160	Physical activity monitoring in Alzheimer's disease during sport interventions: a multi-methodological perspective. Frontiers in Neurology, 0, 14, .	2.4	0
5161	Psychosocial and Behavioral Outcomes for Persons With Cognitive Impairment and Caregivers Following Amyloid-β PET Scan Disclosure. Alzheimer Disease and Associated Disorders, 2023, 37, 246-258.	1.3	0
5162	Local and long-range GABAergic circuits in hippocampal area CA1 and their link to Alzheimer's disease. Frontiers in Neural Circuits, 0, 17, .	2.8	2
5163	The association between retina thinning and hippocampal atrophy in Alzheimer's disease and mild cognitive impairment: a meta-analysis and systematic review. Frontiers in Aging Neuroscience, 0, 15, .	3.4	4
5164	Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer's disease: a phase I/II clinical trial. Annals of General Psychiatry, 2023, 36, e101143.	3.1	5
5165	Differential diagnosis of neurodegenerative dementias with the explainable MRI based machine learning algorithm MUQUBIA. Scientific Reports, 2023, 13, .	3.3	0
5166	Identification of Candidate Biomarkers of Alzheimer's Disease via Multiplex Cerebrospinal Fluid and Serum Proteomics. International Journal of Molecular Sciences, 2023, 24, 14225.	4.1	1
5167	A Knowledge Graph Framework for Dementia Research Data. Applied Sciences (Switzerland), 2023, 13, 10497.	2.5	0
5168	Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update. Journal of Biomedical Science, 2023, 30, .	7.0	17
5169	The effect of plasma cortisol on hippocampal atrophy and clinical progression in mild cognitive impairment. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	0
5170	Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification. Drugs, 2023, 83, 1387-1408.	10.9	8
5171	Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers. International Journal of Molecular Sciences, 2023, 24, 14151.	4.1	0
5173	Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer's Disease. CNS Drugs, 2023, 37, 671-677.	5.9	6

#	Article	IF	CITATIONS
5174	Genetic architectures of cerebral ventricles and their overlap with neuropsychiatric traits. Nature Human Behaviour, 0, , .	12.0	0
5175	Comparison of Brain Amyloid Deposition and Cortical Glucose Metabolism Between Clinic- and Community-Based Cohort. Journal of Alzheimer's Disease, 2023, 95, 299-306.	2.6	0
5176	The Effect of Genetic Predisposition to Alzheimer's Disease and Related Traits on Recruitment Bias in a Study of Cognitive Aging. Twin Research and Human Genetics, 2023, 26, 209-214.	0.6	0
5177	Simple Synthesis of [18F] AV-45 and its Clinical Application in the Diagnosis of Alzheimer's Disease. Current Medicinal Chemistry, 2023, 31, .	2.4	0
5178	Associations of plasma NfL, GFAP, and t-tau with cerebral small vessel disease and incident dementia: longitudinal data of the AGES-Reykjavik Study. GeroScience, 2024, 46, 505-516.	4.6	1
5180	Relationship between default mode network and resting-state electroencephalographic alpha rhythms in cognitively unimpaired seniors and patients with dementia due to Alzheimer's disease. Cerebral Cortex, 2023, 33, 10514-10527.	2.9	1
5181	Nurse-led pre-test counseling for Alzheimer's disease biomarker testing: Knowledge and skills required to meet the needs of patients and families. Geriatric Nursing, 2023, 53, 130-134.	1.9	0
5182	The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease. Brain, 2024, 147, 12-25.	7.6	4
5183	Genomeâ€Wide Metaâ€Analysis of Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Parkinson's Disease Cohorts. Movement Disorders, 2023, 38, 1697-1705.	3.9	2
5186	Tau Pathology Without Aβ—A Limited PART of Clinical Progression. JAMA Neurology, 2023, 80, 1025.	9.0	1
5187	Neuroimaging of tissue microstructure as a marker of neurodegeneration in the AT(N) framework: defining abnormal neurodegeneration and improving prediction of clinical status. Alzheimer's Research and Therapy, 2023, 15, .	6.2	2
5189	Healthy aging and Alzheimer's disease. Advances in Magnetic Resonance Technology and Applications, 2023, , 537-547.	0.1	0
5191	The tauopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 251-265.	1.8	2
5192	The value of <scp>FDG</scp> combined with <scp>PiB PET</scp> in the diagnosis of patients with cognitive impairment in a memory clinic. CNS Neuroscience and Therapeutics, 2024, 30, .	3.9	0
5193	A trichotomy method for defining homogeneous subgroups in a dementia population. Annals of Clinical and Translational Neurology, 2023, 10, 1802-1815.	3.7	1
5194	Thinner inner retinal layers are associated with lower cognitive performance, lower brain volume, and altered white matter network structure—The Maastricht Study. Alzheimer's and Dementia, 2024, 20, 316-329.	0.8	1
5195	Research on digital tool in cognitive assessment: a bibliometric analysis. Frontiers in Psychiatry, 0, 14,	2.6	0
5197	Individualized Assessment of Brain AÎ <sup>2</sup> Deposition With fMRI Using Deep Learning. IEEE Journal of Biomedical and Health Informatics, 2023, 27, 5430-5438.	6.3	2

#	Article	IF	CITATIONS
5198	Microstructural Neurodegeneration of the Entorhinal-Hippocampus Pathway along the Alzheimer's Disease Continuum. Journal of Alzheimer's Disease, 2023, 95, 1107-1117.	2.6	0
5199	Appropriate Use of Biomarkers in Suspected Neurodegenerative Diseases. , 2023, , 15-34.		0
5200	Implication of the cooking oil-peroxidation product "hydroxynonenal―for Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 15, .	3.4	3
5202	Introductory editorial to the special issue: Alzheimer's disease biomarkers and cognitive functioning along the Alzheimer's continuum. Aging, Neuropsychology, and Cognition, 2023, 30, 861-865.	1.3	1
5203	Uncovering the System Vulnerability and Criticality of Human Brain Under Dynamical Neuropathological Events in Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 95, 1201-1219.	2.6	1
5204	Hydralazine inhibits neuroinflammation and oxidative stress in APP/PS1 mice via TLR4/NF-κB and Nrf2 pathways. Neuropharmacology, 2023, 240, 109706.	4.1	2
5205	Identification of diagnostic and prognostic biomarkers of PD using a multiplex proteomics approach. Neurobiology of Disease, 2023, 186, 106281.	4.4	1
5206	Biomarkers and Risk Assessment of Alzheimer's Disease in Low- and Middle-Income Countries. Journal of Alzheimer's Disease, 2023, 95, 1339-1349.	2.6	1
5207	Posttraumatic Stress and Traumatic Brain Injury: Cognition, Behavior, and Neuroimaging Markers in Vietnam Veterans. Journal of Alzheimer's Disease, 2023, 95, 1427-1448.	2.6	0
5208	Injection of exogenous amyloid-β oligomers aggravated cognitive deficits, and activated necroptosis, in APP23 transgenic mice. Brain Research, 2023, 1821, 148565.	2.2	0
5209	The intracerebral injection of Aβ1-42 oligomers does not invariably alter seizure susceptibility in mice. Frontiers in Aging Neuroscience, 0, 15, .	3.4	0
5210	The relationship between learning slopes and Alzheimer's Disease biomarkers in cognitively unimpaired participants with and without subjective memory concerns. Journal of Clinical and Experimental Neuropsychology, 2023, 45, 727-743.	1.3	3
5212	Coexistence of Amyotrophic Lateral Sclerosis and Alzheimer's Disease: Case Report and Review of the Literature. Journal of Alzheimer's Disease, 2023, 95, 1383-1399.	2.6	1
5214	Effects of de-facing software mri_reface on utility of imaging biomarkers used in Alzheimer's disease research. NeuroImage: Clinical, 2023, 40, 103507.	2.7	0
5215	Habitual glucosamine use, APOE genotypes, and risk of incident cause-specific dementia in the older population. Alzheimer's Research and Therapy, 2023, 15, .	6.2	0
5217	Using a dual-stream attention neural network to characterize mild cognitive impairment based on retinal images. Computers in Biology and Medicine, 2023, 166, 107411.	7.0	1
5218	Amyloid and tauâ€PET in earlyâ€onset AD: Baseline data from the Longitudinal Earlyâ€onset Alzheimer's Disease Study (LEADS). Alzheimer's and Dementia, 2023, 19, .	0.8	6
5219	Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community. Multiple Sclerosis Journal, 2023, 29, 1363-1372.	3.0	0

#	Article	IF	CITATIONS
5220	Dynamic functional connectivity MEG features of Alzheimer's disease. NeuroImage, 2023, 281, 120358.	4.2	1
5221	Dissecting Mitochondrial Mechanisms of Alzheimer's Disease Using Gene Dependency Network and Its Implications for Discovering Nutrients Combatting the Disease. Journal of Alzheimer's Disease, 2023, 95, 1709-1722.	2.6	0
5222	Exploring the Potential Association Between Self-Reported Psychological Stress and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease in Midlife: A Cross-Sectional Study. Journal of Alzheimer's Disease Reports, 2023, 7, 1025-1031.	2.2	0
5223	Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer's Disease pathology in Subjective Cognitive Decline and Mild Cognitive Impairment. Journal of the Neurological Sciences, 2023, 453, 120805.	0.6	1
5224	APOE ɛ4 Status and Plasma p-tau181 Levels May Influence Memory and Executive Function Decline in Older Adults Without Dementia. Journal of Alzheimer's Disease, 2023, 95, 1509-1518.	2.6	0
5225	Supported decision making: Facilitating the selfâ€determination of persons living with Alzheimer's and related diseases. Journal of the American Geriatrics Society, 0, , .	2.6	0
5226	Cerebrospinal fluid amyloid beta with amyloid positron emission tomography concordance rates in a heterogeneous group of patients including lateâ€onset psychotic disorders: a retrospective crossâ€sectional study. Psychogeriatrics, 2023, 23, 1091-1093.	1.2	0
5231	Bioluminescence Imaging with Functional Amyloid Reservoirs in Alzheimer's Disease Models. Analytical Chemistry, 2023, 95, 14261-14270.	6.5	3
5232	Dissociable Effects of Alzheimer's Disease-Related Cognitive Dysfunction and Aging on Functional Brain Network Segregation. Journal of Neuroscience, 2023, 43, 7879-7892.	3.6	3
5233	Early Detection of Dementia using Risk Classification in MCI: Outcomes of Shanghai Mild Cognitive Impairment Cohort Study. Current Alzheimer Research, 2023, 20, 431-439.	1.4	1
5234	Serum brain-derived neurotrophic factor levels as a predictor for Alzheimer disease progression. Journal of the Chinese Medical Association, 0, , .	1.4	0
5237	Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation. Brain, 2024, 147, 949-960.	7.6	1
5238	Is headache a risk factor for dementia? A systematic review and meta-analysis. Neurological Sciences, 2024, 45, 1017-1030.	1.9	0
5239	The role of plasma neurofilament light chain and glial fibrillary acidic protein in subjective cognitive decline and mild cognitive impairment. Neurological Sciences, 2024, 45, 1031-1039.	1.9	2
5240	Preliminary PET Imaging of Microtubule-Based PET Radioligand [ <sup>11</sup> C]MPC-6827 in a Nonhuman Primate Model of Alzheimer's Disease. ACS Chemical Neuroscience, 2023, 14, 3745-3751.	3.5	0
5241	Alzheimer's disease: From immunotherapy to immunoprevention. Cell, 2023, 186, 4260-4270.	28.9	17
5242	Neuroimaging in Dementia: More than Typical Alzheimer Disease. Radiology, 2023, 308, .	7.3	6
5243	Multimodal magnetic resonance imaging on brain structure and function changes in subjective cognitive decline: a mini-review. Frontiers in Aging Neuroscience, 0, 15, .	3.4	0

		CITATION REPORT		
#	Article		IF	Citations
5244	Risk of cognitive decline progression is associated to increased bloodâ€brainâ€barrier pe longitudinal study in a memory unit clinical cohort. Alzheimer's and Dementia, 2024, 20	ermeability: A , 538-548.	0.8	0
5245	Editorial for "Associations of Alzheimer's Disease Pathology and Small Vessel Disease White Matter Degeneration: A Tractâ€Based <scp>MR</scp> Diffusion Imaging Studyâ€ Magnetic Resonance Imaging, 0, , .	With Cerebral Journal of	3.4	0
5246	Preserving cognitive function in patients with Alzheimer's disease: The Alzheimer's disea neuroprotection research initiative (ADNRI). , 2023, 1, 84-98.	se		2
5247	Effects of Brain Pathologies on Spatiotemporal Gait Parameters in Patients with Mild Co Impairment. Journal of Alzheimer's Disease, 2023, 96, 161-171.	gnitive	2.6	0
5248	Deep learning analysis of UPLC-MS/MS-based metabolomics data to predict Alzheimer's of the Neurological Sciences, 2023, 453, 120812.	disease. Journal	0.6	1
5249	Genuine Memory Deficits as Assessed by the Free and Cued Selective Reminding Test (F Behavioural Variant of Frontotemporal Dementia. A Systematic Review and Meta-analysi Neuropsychology Review, 0, , .	CSRT) in the s Study.	4.9	0
5250	Reconceptualization of the Erlangen Score for the Assessment of Dementia Risk: The ER Journal of Alzheimer's Disease, 2023, 96, 265-275.	langen Score.	2.6	0
5251	Impact of Eating a Carbohydrate-Restricted Diet on Cortical Atrophy in a Cross-Section of Positive Patients with Alzheimer's Disease: A Small Sample Study. Journal of Alzheim 96, 329-342.	∮f Amyloid er's Disease, 2023,	2.6	0
5252	Criterion Validation of Tau PET Staging Schemes in Relation to Cognitive Outcomes. Jou Alzheimer's Disease, 2023, 96, 197-214.	rnal of	2.6	0
5253	ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the States Dementia with Lewy Bodies Consortium. Alzheimer's and Dementia, 2024, 20, 54	United 9-562.	0.8	1
5255	Cognitive load associates prolonged P300 latency during target stimulus processing in i with mild cognitive impairment. Scientific Reports, 2023, 13, .	ndividuals	3.3	0
5257	Physical activity interventions in cognitive aging. , 2023, , .			Ο
5258	Associations Between Plasma, Imaging, and Cerebrospinal Fluid Biomarkers with Driving Cognitive Tests: Implications for Biomarker Usefulness. Journal of Alzheimer's Disease Re 1095-1102.	Behavior and ports, 2023, 7,	2.2	0
5261	Comparative assessment of Alzheimer's disease-related biomarkers in plasma and ne extracellular vesicles: a nested case-control study. Frontiers in Molecular Biosciences, 0,	euron-derived 10, .	3.5	1
5262	CTâ€based volumetric measures obtained through deep learning: Association with biom neurodegeneration. Alzheimer's and Dementia, 2024, 20, 629-640.	arkers of	0.8	0
5264	The Genomics of Cognitive Aging in Social Isolation. , 2023, , 105-116.			Ο
5265	Shared metabolic shifts in endothelial cells in stroke and Alzheimer's disease reveale analysis. Scientific Data, 2023, 10, .	d by integrated	5.3	1
5266	Improving Clinical Trials of Antioxidants in Alzheimer's Disease. Journal of Alzheimer' 1-11.	s Disease, 2023, ,	2.6	1

#	Article	IF	CITATIONS
5267	Hearing loss is associated with decreased default-mode network connectivity in individuals with mild cognitive impairment. NeuroImage Reports, 2023, 3, 100188.	1.0	0
5268	TauFlowNet: Uncovering Propagation Mechanism of Tau Aggregates by Neural Transport Equation. Lecture Notes in Computer Science, 2023, , 77-86.	1.3	0
5269	Personalized Patch-Based Normality Assessment ofÂBrain Atrophy inÂAlzheimer's Disease. Lecture Notes in Computer Science, 2023, , 55-62.	1.3	0
5270	Association of Adipokines with Alzheimer's Disease in a Chinese Cohort. Journal of Alzheimer's Disease, 2023, , 1-11.	2.6	0
5271	Informing Disclosure: Efficacy of a Brief Educational Intervention on Research Participants' Knowledge about Alzheimer's Disease Biomarkers. Journal of Alzheimer's Disease, 2023, , 1-8.	2.6	0
5272	The Underestimated Relevance of Alzheimer's Disease Copathology in Amyotrophic Lateral Sclerosis. Journal of Alzheimer's Disease, 2023, 95, 1401-1404.	2.6	0
5273	Olfactory function, neurofilament light chain, and cognitive trajectory: A 12â€year followâ€up of the Shanghai Aging Study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	1
5274	Patients with type 1 diabetes and albuminuria have a reduced brain glycolytic capability that is correlated with brain atrophy. Frontiers in Neuroscience, 0, 17, .	2.8	0
5275	Associations between recall of proper names in story recall and CSF amyloid and tau in adults without cognitive impairment. Neurobiology of Aging, 2024, 133, 87-98.	3.1	0
5276	A meta-analysis of neurogenic exosomes in the diagnosis of Alzheimer's disease. Heliyon, 2023, 9, e20604.	3.2	0
5279	Demographic and Clinical Characteristics Associated With Serum GFAP Levels in an Ethnically Diverse Cohort. Neurology, 2023, 101, e1531-e1541.	1.1	0
5280	Diagnostic performance of MRI radiomics for classification of Alzheimer's disease, mild cognitive impairment, and normal subjects: a systematic review and meta-analysis. Aging Clinical and Experimental Research, 2023, 35, 2333-2348.	2.9	1
5281	Development of a Cognitive Composite for Preclinical Alzheimer's Disease in Korean Older Adults. Journal of Alzheimer's Disease, 2023, , 1-9.	2.6	0
5283	CSF Aβ40 Levels Do Not Correlate with the Clinical Manifestations of Alzheimer's Disease. Neurodegenerative Diseases, 2022, 22, 151-158.	1.4	0
5284	Trelagliptin relieved cognitive impairment of diabetes mellitus rats: Involvement of PI3K/Akt/GSK-3β and inflammation pathway. Experimental Gerontology, 2023, 182, 112307.	2.8	0
5285	Artificial Intelligence Techniques for the effective diagnosis of Alzheimer's Disease: A Review. Multimedia Tools and Applications, 0, , .	3.9	0
5286	Image-to-Image Translation Between Tau Pathology and Neuronal Metabolism PET in Alzheimer Disease with Multi-domain Contrastive Learning. Lecture Notes in Computer Science, 2023, , 3-13.	1.3	0
5287	Association between Sleep and Alzheimer's Disease: A Bibliometric Analysis from 2003 to 2022. Neuroepidemiology, 2023, 57, 377-390.	2.3	0

#	Article	IF	CITATIONS
5290	Basal forebrain activity predicts functional degeneration in the entorhinal cortex in Alzheimer's disease. Brain Communications, 0, , .	3.3	1
5291	Transforming Neurology and Psychiatry. PET Clinics, 2023, , .	3.0	0
5293	Chain Mediation Analysis of the Effects of Nutrition and Cognition on the Association of Apolipoprotein E ɛ4 with Neuropsychiatric Symptoms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 96, 669-681.	2.6	1
5294	Current Challenges in the Diagnosis of Progressive Neurocognitive Disorders: A Critical Review of the Literature and Recommendations for Primary and Secondary Care. Brain Sciences, 2023, 13, 1443.	2.3	1
5295	A Remotely Coached Multimodal Lifestyle Intervention for Alzheimer's Disease Ameliorates Functional and Cognitive Outcomes. Journal of Alzheimer's Disease, 2023, , 1-17.	2.6	0
5296	Resolving heterogeneity in Alzheimer's disease based on individualized structural covariance network. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2024, 129, 110873.	4.8	0
5297	Body Mass Index Decrease Has a Distinct Association with Alzheimer's Disease Pathophysiology in APOE ɛ4 Carriers and Non-Carriers. Journal of Alzheimer's Disease, 2023, , 1-13.	2.6	0
5299	Neurobiological correlation between phosphorylated tau and mood symptoms in memory clinic patients. Psychogeriatrics, 2023, 23, 954-962.	1.2	0
5300	Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline. Neurology, 2023, 101, .	1.1	1
5301	Mitochondrial SOS: how mtDNA may act as a stress signal in Alzheimer's disease. Alzheimer's Research and Therapy, 2023, 15, .	6.2	0
5302	Association of cancer history with structural brain aging markers of Alzheimer's disease and related dementias risk. Alzheimer's and Dementia, 2024, 20, 880-889.	0.8	0
5303	Sex-Related Disparities in the Resting State Functional Connectivity of the Locus Coeruelus and Salience Network in Preclinical Alzheimer's Disease. International Journal of Molecular Sciences, 2023, 24, 15092.	4.1	0
5304	Association of Blood-Based DNA Methylation Markers With Late-Onset Alzheimer Disease. Neurology, 2023, 101, .	1.1	2
5305	Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop. Neurotherapeutics, 2023, 20, 1682-1691.	4.4	1
5306	Medicare Coverage of Amyloid PET: Implications for Clinical Practice. American Journal of Neuroradiology, 0, , .	2.4	0
5307	Study on the effect of 40 Hz non-invasive light therapy system. A protocol for a randomized, double-blinded, placebo-controlled clinical trial. Frontiers in Aging Neuroscience, 0, 15, .	3.4	0
5308	A randomized, doubleâ€blind, placeboâ€controlled, parallelâ€group 12â€week pilot phase II trial of SaiLuoTong (SLT) for cognitive function in older adults with mild cognitive impairment. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2023, 9, .	3.7	0
5310	Neurodegenerative Disease Tauopathies. Annual Review of Pathology: Mechanisms of Disease, 2024, 19, .	22.4	1

# 5311	ARTICLE Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants. Alzheimer's Research and Therapy, 2023, 15, .	IF 6.2	Citations 3
5313	Diagnostic Efficacy and Clinical Relevance of Artificial Intelligence in Detecting Cognitive Decline. Cureus, 2023, , .	0.5	0
5314	Liquordiagnostik in der Intensivmedizin. , 2023, , 179-199.		0
5315	Advances in targeted tracking and detection of soluble amyloid-β aggregates as a biomarker of Alzheimer's disease. Talanta, 2024, 268, 125311.	5.5	0
5316	Case Study 6: The Diagnostic Challenge of a 75-Year-Old Man Who Had, Then Didn't Have, Then Did Have Alzheimer's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2023, 35, 325-332.	1.8	0
5317	Unveiling the Molecular Footprint: Proteome-Based Biomarkers for Alzheimer's Disease. Proteomes, 2023, 11, 33.	3.5	0
5318	Accelerating Alzheimer's therapeutic development: The past and future of clinical trials. Cell, 2023, 186, 4757-4772.	28.9	8
5319	A New Framework for Dementia Nomenclature. JAMA Neurology, 2023, 80, 1364.	9.0	2
5320	Alzheimer Disease. Neurology: Clinical Practice, 2023, 13, .	1.6	1
5321	The Effects of Antimicrobial Mouthwashes on Systemic Disease: What Is the Evidence?. International Dental Journal, 2023, 73, S82-S88.	2.6	0
5325	Hybrid PET/MRI with Flutemetamol and FDG in Alzheimer's Disease Clinical Continuum. Current Alzheimer Research, 2023, 20, .	1.4	0
5326	Longitudinal resting-state EEG in amyloid-positive patients along the Alzheimer's disease continuum: considerations for clinical trials. Alzheimer's Research and Therapy, 2023, 15, .	6.2	2
5327	Recent contributions to the field of subjective cognitive decline in aging: A literature review. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	0
5328	Identification of preclinical dementia according to ATN classification for stratified trial recruitment: A machine learning approach. PLoS ONE, 2023, 18, e0288039.	2.5	0
5329	Decision making in clinical trials: Interim analyses, innovative design, and biomarkers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2023, 9, .	3.7	0
5330	Sex modifies effects of imaging and CSF biomarkers on cognitive and functional outcomes: A study of Alzheimer's disease. Neurobiology of Aging, 2023, , .	3.1	0
5331	Explainable Vision Transformer with Self-Supervised Learning to Predict Alzheimer's Disease Progression Using 18F-FDG PET. Bioengineering, 2023, 10, 1225.	3.5	0
5332	Age-related hearing loss is not linked to cerebrospinal fluid levels of β-amyloid or p-tau181. Neurological Sciences, 0, , .	1.9	1

#	Article	IF	CITATIONS
5333	The role of visual rating and automated brain volumetry in early detection and differential diagnosis of Alzheimer's disease. CNS Neuroscience and Therapeutics, 0, , .	3.9	1
5334	Dopamine transporter positron emission tomography in patients with Alzheimer's disease with Lewy body disease features. Neurobiology of Aging, 2024, 134, 57-65.	3.1	0
5335	<scp>T1</scp> and <scp>FLAIR</scp> signal intensities are related to tau pathology in dominantly inherited Alzheimer disease. Human Brain Mapping, 0, , .	3.6	0
5336	Plasma biomarkers predict Alzheimer's disease before clinical onset in Chinese cohorts. Nature Communications, 2023, 14, .	12.8	3
5338	Crossâ€sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	1
5339	Antidementiva. , 2023, , 637-689.		0
5340	Estimating the prevalence of diagnosed Alzheimer disease in England across deprivation groups using electronic health records: a clinical practice research datalink study. BMJ Open, 2023, 13, e075800.	1.9	0
5341	The efficacy and safety of anti-Aβ agents for delaying cognitive decline in Alzheimer's disease: a meta-analysis. Frontiers in Aging Neuroscience, 0, 15, .	3.4	1
5342	Lawton's Instrumental Activities of Daily Living for Greek-Speaking Adults with Cognitive Impairment: A Psychometric Evaluation Study with Additional Receiver Operating Characteristic Curve Analysis. Brain Sciences, 2023, 13, 1093.	2.3	0
5343	Genome-Wide Association Analysis across Endophenotypes in Alzheimer's Disease: Main Effects and Disease Stage-Specific Interactions. Genes, 2023, 14, 2010.	2.4	0
5344	The Healthy Brain Initiative (HBI): A prospective cohort study protocol. PLoS ONE, 2023, 18, e0293634.	2.5	1
5345	Targeting Progranulin as an Immuno-Neurology Therapeutic Approach. International Journal of Molecular Sciences, 2023, 24, 15946.	4.1	0
5346	Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer's disease continuum. Alzheimer's Research and Therapy, 2023, 15, .	6.2	0
5347	Sustained CREB phosphorylation by lipid-peptide liquid crystalline nanoassemblies. Communications Chemistry, 2023, 6, .	4.5	2
5348	Therapeutic potentials of ononin with mechanistic insights: A comprehensive review. Food Bioscience, 2023, 56, 103302.	4.4	3
5349	Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer's disease. Expert Review of Molecular Diagnostics, 2023, 23, 1195-1207.	3.1	1
5350	Prediction of Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Amyloid PET and Brain MR Imaging Data: A 48-Month Follow-Up Analysis of the Alzheimer's Disease Neuroimaging Initiative Cohort. Diagnostics, 2023, 13, 3375.	2.6	0
5351	Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer's disease: findings based on urine proteomics and machine learning. Alzheimer's Research and Therapy, 2023, 15, .	6.2	1

#	Article	IF	CITATIONS
5352	Neuropsychiatric symptoms as a prodromal factor in Alzheimer's type neurodegenerative disease: a scoping review. Clinical Neuropsychologist, 0, , 1-22.	2.3	0
5353	Subjective cognitive complaints and blood biomarkers of neurodegenerative diseases: a longitudinal cohort study. Alzheimer's Research and Therapy, 2023, 15, .	6.2	1
5354	Molecular biomarkers for vascular cognitive impairment and dementia. Nature Reviews Neurology, 2023, 19, 737-753.	10.1	4
5355	Roles of peripheral lipoproteins and cholesteryl ester transfer protein in the vascular contributions to cognitive impairment and dementia. Molecular Neurodegeneration, 2023, 18, .	10.8	1
5356	Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia. Annals of Neurology, 0, , .	5.3	0
5357	Piecing it together: atrophy profiles of hippocampal subfields relate to cognitive impairment along the Alzheimer's disease spectrum. Frontiers in Aging Neuroscience, 0, 15, .	3.4	0
5358	Comparison of CSF and plasma NfL and pNfH for Alzheimer's disease diagnosis: a memory clinic study. Journal of Neurology, 2024, 271, 1297-1310.	3.6	1
5359	The olfactory working memory capacity paradigm: A more sensitive and robust method of assessing cognitive function in male <scp>5XFAD</scp> mice. Journal of Neuroscience Research, 2024, 102, .	2.9	0
5360	Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study. Alzheimer's Research and Therapy, 2023, 15, .	6.2	0
5361	Effects of DHA on cognitive dysfunction in aging and Alzheimer's disease: The mediating roles of ApoE. Progress in Lipid Research, 2024, 93, 101256.	11.6	1
5362	Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study. European Archives of Psychiatry and Clinical Neuroscience, 0, , .	3.2	0
5363	Cerebrospinal fluid neutral lipids predict progression from mild cognitive impairment to Alzheimer's disease. GeroScience, 0, , .	4.6	1
5364	Relationship between baseline plasma pâ€ŧau181 and longitudinal changes in cognition and structural brain measures in a cohort of cognitively unimpaired older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	0
5365	Association of Cerebrovascular Imaging Biomarkers, Depression, and Anxiety, with Mild Cognitive Impairment. Journal of Alzheimer's Disease Reports, 2023, 7, 1237-1246.	2.2	0
5366	In pursuit of degenerative brain disease diagnosis: Dementia biomarkers detected by DNA aptamer-attached portable graphene biosensor. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	7.1	0
5367	Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals. Alzheimer's and Dementia, 2024, 20, 1284-1297.	0.8	1
5368	Proteomics revealed an association between ribosome-associated proteins and amyloid beta deposition in Alzheimer's disease. Metabolic Brain Disease, 0, , .	2.9	0
5369	Relationship Between FERMT2, CELF1, COPI, CHRNA2, and ABCA7 Genetic Polymorphisms and Alzheimer's Disease Risk in the Southern Chinese Population. Journal of Alzheimer's Disease Reports, 2023, 7, 1247-1257.	2.2	0

#	Article	IF	CITATIONS
5370	CSF 14-3-3β is associated with progressive cognitive decline in Alzheimer's disease. Brain Communications, 2023, 5, .	3.3	0
5371	Cell-type-specific Alzheimer's disease polygenic risk scores are associated with distinct disease processes in Alzheimer's disease. Nature Communications, 2023, 14, .	12.8	1
5372	Smaller grey matter volume in the central olfactory system in mild cognitive impairment. Experimental Gerontology, 2023, 183, 112325.	2.8	1
5373	Functional connectivity changes in mild cognitive impairment: A meta-analysis of M/EEG studies. Clinical Neurophysiology, 2023, 156, 183-195.	1.5	0
5374	Changes in Multiparametric Magnetic Resonance Imaging and Plasma Amyloid-Beta Protein in Subjective Cognitive Decline. Brain Sciences, 2023, 13, 1624.	2.3	0
5375	Evaluating Explanations ofÂanÂAlzheimer's Disease 18F-FDG Brain PET Black-Box Classifier. Communications in Computer and Information Science, 2023, , 558-581.	0.5	0
5376	Optimized RT-qPCR and a novel normalization method for validating circulating miRNA biomarkers in ageing-related diseases. Scientific Reports, 2023, 13, .	3.3	0
5377	Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis. Alzheimer's Research and Therapy, 2023, 15, .	6.2	1
5378	Cerebrospinal and Blood Biomarkers in Alzheimer's Disease: Did Mild Cognitive Impairment Definition Affect Their Clinical Usefulness?. International Journal of Molecular Sciences, 2023, 24, 16908.	4.1	0
5379	qEEG Methods to Probe Abnormal Brain Rhythms Related to Quiet Vigilance in Patients with Dementia Due to Alzheimer's, Parkinson's, and Lewy Body Diseases. Neuromethods, 2024, , 67-89.	0.3	0
5380	Topical Cellular/Tissue and Molecular Aspects Regarding Nonpharmacological Interventions in Alzheimer's Disease—A Systematic Review. International Journal of Molecular Sciences, 2023, 24, 16533.	4.1	0
5381	Liquid Biopsy in Alzheimer's Disease Patients Reveals Epigenetic Changes in the PRLHR Gene. Cells, 2023, 12, 2679.	4.1	0
5382	Diverse signaling mechanisms and heterogeneity of astrocyte reactivity in Alzheimer's disease. Journal of Neurochemistry, 0, , .	3.9	1
5383	Antidepressant effect of bright light therapy on patients with Alzheimer's disease and their caregivers. Frontiers in Pharmacology, 0, 14, .	3.5	0
5384	Decoding metabolic signatures in Alzheimer's disease: a mitochondrial perspective. Cell Death Discovery, 2023, 9, .	4.7	1
5385	Norms for the Triana Test: A Story Recall Test Based on Emotional Material. Journal of Alzheimer's Disease Reports, 2023, 7, 1179-1186.	2.2	Ο
5386	Specific serum autoantibodies predict the development and progression of Alzheimer's disease with high accuracy. Brain, Behavior, and Immunity, 2024, 115, 543-554.	4.1	0
5387	Advances in single molecule arrays (SIMOA) for ultra-sensitive detection of biomolecules. Talanta, 2024, 270, 125529.	5.5	1

#	Article	IF	CITATIONS
5388	Longitudinal study of traumatic-stress related cellular and cognitive aging. Brain, Behavior, and Immunity, 2024, 115, 494-504.	4.1	0
5389	Glucose Transport and Utilization in the Hippocampus: From Neurophysiology to Diabetes-Related Development of Dementia. International Journal of Molecular Sciences, 2023, 24, 16480.	4.1	0
5390	The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials. European Journal of Medical Research, 2023, 28, .	2.2	5
5391	Sleep spindle architecture associated with distinct clinical phenotypes in older adults at risk for dementia. Molecular Psychiatry, 0, , .	7.9	0
5392	Brief instrument for direct complex functionality assessment: a new ecological tool. Frontiers in Neuroscience, 0, 17, .	2.8	0
5393	Dementia Speech Dataset Creation and Analysis in Indic Languages—A Pilot Study. IEEE Access, 2023, 11, 130697-130718.	4.2	0
5394	The Role of Insulin-like Growth Factor I in Mechanisms of Resilience and Vulnerability to Sporadic Alzheimer's Disease. International Journal of Molecular Sciences, 2023, 24, 16440.	4.1	0
5395	Predicting neurodegeneration from sleep related biofluid changes. Neurobiology of Disease, 2024, 190, 106369.	4.4	1
5396	Low circulating adropin levels in late-middle aged African Americans with poor cognitive performance. , 2023, 9, .		0
5397	Intérêt du régime cétogène dans la prise en charge de la maladie d'Alzheimer. Biologie Aujourd'hui, 2023, 217, 253-263.	0.1	0
5398	Design, synthesis, and biological evaluation of novel capsaicin-tacrine hybrids as multi-target agents for the treatment of Alzheimer's disease. Bioorganic Chemistry, 2024, 143, 107026.	4.1	0
5399	Cortical thickness modeling and variability in Alzheimer's disease and frontotemporal dementia. Journal of Neurology, 2024, 271, 1428-1438.	3.6	0
5400	High burdens of phosphorylated tau protein and distinct precuneus atrophy in sporadic early-onset Alzheimer's disease. Science Bulletin, 2023, 68, 2817-2826.	9.0	0
5401	Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease. JAMA Neurology, 2023, 80, 1344.	9.0	0
5403	Multipredictor risk models for predicting individual risk of Alzheimer's disease. Journal of Translational Medicine, 2023, 21, .	4.4	1
5404	Incorporating laparoscopic interval cytoreductive surgery for advanced ovarian cancer-lessons learnt. , 2023, 2, 100028.		0
5408	Retina pathology as a target for biomarkers for Alzheimer's disease: Current status, ophthalmopathological background, challenges, and future directions. Alzheimer's and Dementia, 2024, 20, 728-740.	0.8	2
5409	Innovative SALDI mass spectrometry analysis for Alzheimer's disease synthetic peptides detection. Talanta, 2024, 268, 125357.	5.5	1

#	Article	IF	CITATIONS
5410	Lecanemab: A Hopeful Alzheimerâ $\in$ ${}^{ extsf{ms}}$ s Disease Treatment. Annals of Neurosciences, 0, , .	1.7	0
5411	Plasma pTauâ€217 and Nâ€ŧerminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloidâ€Î² positive individuals. Alzheimer's and Dementia, 2024, 20, 1166-1174.	0.8	2
5412	Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease. Alzheimer's Research and Therapy, 2023, 15, .	6.2	1
5415	Alzheimer's Disease Is Associated with Increased Network Assortativity: Evidence from Metabolic Connectivity. Brain Connectivity, 0, , .	1.7	0
5416	ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels. JAMA Neurology, 2023, 80, 1295.	9.0	3
5417	Correlation Studies of Hippocampal Morphometry and Plasma NFL Levels in Cognitively Unimpaired Subjects. IEEE Transactions on Computational Social Systems, 2023, 10, 3602-3608.	4.4	0
5418	sPDGFRÎ <sup>2</sup> and neuroinflammation are associated with AD biomarkers and differ by race: The ASCEND Study. Alzheimer's and Dementia, 2024, 20, 1175-1189.	0.8	2
5419	A hierarchical attention-based multimodal fusion framework for predicting the progression of Alzheimer's disease. Biomedical Signal Processing and Control, 2024, 88, 105669.	5.7	0
5420	Plasma Al̂²42/Al̂²40 and phosphoâ€ŧau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2024, 20, 1214-1224.	0.8	5
5421	Disease trajectories in older adults with non-AD pathologic change and comparison with Alzheimer's disease pathophysiology: A longitudinal study. Neurobiology of Aging, 2024, 134, 106-114.	3.1	0
5424	CSF biomarker analysis of ABCA7 mutation carriers suggests altered APP processing and reduced inflammatory response. Alzheimer's Research and Therapy, 2023, 15, .	6.2	0
5427	Potential Implications of miRNAs in the Pathogenesis, Diagnosis, and Therapeutics of Alzheimer's Disease. International Journal of Molecular Sciences, 2023, 24, 16259.	4.1	2
5428	Association of Tooth Loss with Alzheimer's Disease Tau Pathologies Assessed by Positron Emission Tomography. Journal of Alzheimer's Disease, 2023, 96, 1253-1265.	2.6	0
5429	A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles. Brain Communications, 2023, 6, .	3.3	0
5431	Differential Diagnosis: "What Is the Lesion?― , 2023, , 137-281.		0
5432	Alzheimer's Targeted Treatments: Focus on Amyloid and Inflammation. Journal of Neuroscience, 2023, 43, 7894-7898.	3.6	2
5433	Repetitive transcranial magnetic stimulation for apathy in patients with neurodegenerative conditions, cognitive impairment, stroke, and traumatic brain injury: a systematic review. Frontiers in Psychiatry, 0, 14, .	2.6	0
5434	Alzheimer's Disease CSF Biomarkers as Possible Indicators of Tap-Test Response in Idiopathic Normal Pressure Hydrocephalus. Brain Sciences, 2023, 13, 1593.	2.3	0

#	Article	IF	Citations
5436	Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP. Neurobiology of Disease, 2023, 189, 106356.	4.4	1
5437	Tracking neurodegenerative diseases in biofluids: Combining pathology and pathophysiology markers is the way. Cell Chemical Biology, 2023, 30, 1340-1342.	5.2	0
5438	Metabolic network alterations as a supportive biomarker in dementia with Lewy bodies with preserved dopamine transmission. European Journal of Nuclear Medicine and Molecular Imaging, 2024, 51, 1023-1034.	6.4	0
5439	Associations Between TREML2 Gene Variants and Alzheimer's Disease: Biomarkers, Neuroimage, and Cognition. Journal of Alzheimer's Disease, 2023, 96, 1555-1563.	2.6	0
5441	Gait Domains May Be Used as an Auxiliary Diagnostic Index for Alzheimer's Disease. Brain Sciences, 2023, 13, 1599.	2.3	1
5442	Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2023, 9, .	3.7	1
5444	Cognitive and Neuropsychiatric Features of Idiopathic Normal Pressure Hydrocephalus. , 2023, , 169-195.		0
5445	Understanding factors associated with the trajectory of subjective cognitive complaints in groups with similar objective cognitive trajectories. Alzheimer's Research and Therapy, 2023, 15, .	6.2	0
5446	Meta-analysis and moderator analysis of the prevalence of malnutrition and malnutrition risk among older adults with dementia. International Journal of Nursing Studies, 2024, 150, 104648.	5.6	0
5447	Automated magnetic-bead-assisted sequential extraction technology for simultaneous detection of Aβ1-42 and Aβ1-40 in cerebrospinal fluid: An advance toward fully automated liquid chromatography-tandem mass spectrometry method. Journal of Chromatography A, 2024, 1713, 464531.	3.7	1
5448	Empirically derived psychosocialâ€behavioral phenotypes in Black/African American and Hispanic/Latino older adults enrolled in HABSâ€HD: Associations with AD biomarkers and cognitive outcomes. Alzheimer's and Dementia, 2024, 20, 1360-1373.	0.8	0
5449	Multimodal Neuroimaging for Early Alzheimer's detection: A Deep Learning Approach. , 2023, , .		0
5450	Cell-free RNA signatures predict Alzheimer's disease. IScience, 2023, 26, 108534.	4.1	0
5451	ApoE Mimic Peptide COG1410 Reduces AÎ <sup>2</sup> Deposition and Improves Cognitive Function by Inducing the Transformation of A1/A2 Reactive Astrocytes and Increasing the BDNF Concentration in Brain of APP/PS1 Double Transgenic Mice. Neuroscience, 2024, 537, 116-125.	2.3	0
5452	Clinical Evaluation of Cerebrospinal Fluid p217tau and Neurofilament Light Chain Levels in Patients with Alzheimer's Disease or Other Neurological Diseases. Journal of Alzheimer's Disease, 2023, 96, 1623-1638.	2.6	0
5453	Neuropsychiatric Symptoms and In Vivo Alzheimer's Biomarkers in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2023, 96, 1827-1836.	2.6	0
5454	Online clinical tools to support the use of new plasma biomarker diagnostic technology in the assessment of Alzheimer's disease: a narrative review. Brain Communications, 2023, 5, .	3.3	0
5455	Clinical outcomes up to 9Âyears after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population. Alzheimer's Research and Therapy, 2023, 15, .	6.2	0

#	Article	IF	CITATIONS
5456	Alzheimer disease biomarkers are associated with decline in subjective memory, attention, and spatial navigation ability in clinically normal adults. Journal of the International Neuropsychological Society, 0, , 1-15.	1.8	0
5457	Effects of Neighboring Phosphorylation Events on the Affinities of pT181-Tau Antibodies. Analytical Chemistry, 2023, 95, 18241-18248.	6.5	0
5458	Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer's disease based on the A/T(N) research framework. Clinical Neurology and Neurosurgery, 2024, 236, 108071.	1.4	0
5459	Cortical gray to white matter signal intensity ratio as a sign of neurodegeneration and cognition independent of βâ€amyloid in dementia. Human Brain Mapping, 2024, 45, .	3.6	Ο
5460	How healthy participants value additional diagnostic testing with amyloid-PET in patients diagnosed with mild cognitive impairment — a bidding game experiment. Alzheimer's Research and Therapy, 2023, 15, .	6.2	0
5461	Validating blood tests as a possible routine diagnostic assay of Alzheimer's disease. Expert Review of Molecular Diagnostics, 2023, 23, 1153-1165.	3.1	0
5462	Plasma Biomarkers of Alzheimer Disease in Women With and Without HIV. JAMA Network Open, 2023, 6, e2344194.	5.9	1
5463	Development and validation of a nutrition-related genetic–clinical–radiological nomogram associated with behavioral and psychological symptoms in Alzheimer's disease. Chinese Medical Journal, 0, , .	2.3	0
5464	Neuroimaging Biomarkers in Alzheimer's Disease and Related Disorders. , 2023, , 163-188.		0
5465	Tau Imaging in Late Traumatic Brain Injury: A [ <sup>18</sup> F]MK-6240 Positron Emission Tomography Study. Journal of Neurotrauma, 2024, 41, 420-429.	3.4	0
5466	Design ofÂthe formalized andÂintegrated Alzheimer's Disease Ontology andÂits application inÂretrieving textual data via text mining. Database: the Journal of Biological Databases and Curation, 2023, 2023, .	3.0	0
5468	The German version of the tabletâ€based UCSF Brain Health Assessment is sensitive to early symptoms of neurodegenerative disorders. Brain and Behavior, 0, , .	2.2	Ο
5469	Harnessing cognitive trajectory clusterings to examine subclinical decline risk factors. Brain Communications, 0, , .	3.3	0
5470	Brain-derived neurotrophic factor interplay with oxidative stress: neuropathology approach in potential biomarker of Alzheimer's disease. Dementia E Neuropsychologia, 0, 17, .	0.8	1
5471	Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies. JAMA Neurology, 2024, 81, 69.	9.0	6
5472	Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer's disease. Alzheimer's Research and Therapy, 2023, 15, .	6.2	0
5474	Bloodâ€based biomarkers in Alzheimer's disease: Future directions for implementation. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2023, 15, .	2.4	0
5475	Contextualizing the Role of Osteopontin in the Inflammatory Responses of Alzheimer's Disease. Biomedicines, 2023, 11, 3232.	3.2	0

#	Article	IF	CITATIONS
5476	Health System Change for Alzheimer's Disease-Modifying Therapies in Canada: Beginning the Discussion. Canadian Journal of Neurological Sciences, 0, , 1-29.	0.5	0
5477	Once upon a time, the Amyloid Cascade Hypothesis. Ageing Research Reviews, 2024, 93, 102161.	10.9	3
5478	Physical activity, sleep disorders, and type of work in the prevention of cognitive function decline in patients with hypertension. BMC Public Health, 2023, 23, .	2.9	0
5480	Associations between liver function and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in nonâ€demented adults: The CABLE study. Journal of Neurochemistry, 2024, 168, 39-51.	3.9	0
5481	Exercise-Related Physical Activity Relates to Brain Volumes in 10,125 Individuals. Journal of Alzheimer's Disease, 2023, , 1-11.	2.6	0
5482	Amplified fluorogenic immunoassay for early diagnosis and monitoring of Alzheimer's disease from tear fluid. Nature Communications, 2023, 14, .	12.8	0
5483	Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer's disease pathogenesis. Brain, 2024, 147, 627-636.	7.6	0
5484	Saccadic eye movement variables as biomarkers for cognitive decline in elderly individuals. , 2023, , .		0
5485	Predictive Modeling Of Alzheimer's Disease Prognosis Using Anatomical & Diffusion MRI. , 2023, , .		0
5486	Machine learning analyses identify multi-modal frailty factors that selectively discriminate four cohorts in the Alzheimer's disease spectrum: a COMPASS-ND study. BMC Geriatrics, 2023, 23, .	2.7	0
5487	Reduced tactile sensitivity is associated with mild cognitive impairment. EBioMedicine, 2024, 99, 104896.	6.1	0
5488	Plasma Amyloid-β, Total Tau, and Neurofilament Light Chain Across the Alzheimer's Disease Clinical Spectrum: A Population-Based Study. Journal of Alzheimer's Disease, 2023, 96, 845-858.	2.6	0
5489	Predicting clinical progression trajectories of early Alzheimer's disease patients. Alzheimer's and Dementia, 0, , .	0.8	0
5490	Positive rate and quantification of amyloid pathology with [18F]florbetapir in the urban Chinese population. European Radiology, 0, , .	4.5	0
5491	Cerebrospinal fluid levels of hypothalamic-pituitary-adrenal axis hormones in MCI and dementia due to Alzheimer's disease: a systematic review. Dementia E Neuropsychologia, 0, 17, .	0.8	0
5492	Cortical microstructural associations with CSF amyloid and pTau. Molecular Psychiatry, 0, , .	7.9	0
5493	Contributions of Vascular Burden and Amyloid Abnormality to Cognitive Decline in Memory Clinic Patients. Journal of Alzheimer's Disease Reports, 2023, 7, 1299-1311.	2.2	0
5494	Resting-state EEG signatures of Alzheimer's disease are driven by periodic but not aperiodic changes. Neurobiology of Disease, 2024, 190, 106380.	4.4	1

#	Article	IF	CITATIONS
5495	Fluid-Based Biomarkers of Alzheimer's Disease. , 2023, , 153-161.		0
5496	Human-derived air–liquid interface cultures decipher Alzheimer's disease–SARS-CoV-2 crosstalk in the olfactory mucosa. Journal of Neuroinflammation, 2023, 20, .	7.2	2
5497	Augmented reality versus standard tests to assess cognition and function in early Alzheimer's disease. Npj Digital Medicine, 2023, 6, .	10.9	1
5498	Differential diagnosis of mild cognitive impairment of Alzheimer's disease by Simoa p-tau181 measurements with matching plasma and CSF. Frontiers in Molecular Neuroscience, 0, 16, .	2.9	0
5499	Impact of the MIND Diet on Cognition in Individuals with Dementia. Journal of Alzheimer's Disease, 2023, 96, 967-977.	2.6	1
5503	Brain Connectome Imaging Markers Research of Glucose Metabolism in the Early Stage of Alzheimer's Disease. , 2023, , .		0
5504	Neuropsychological signs of the neurodegenerative process in Alzheimer's disease at the stage of mild cognitive impairment. Vestnik Nevrologii, Psihiatrii I Nejrohirurgii, 2023, , 975-982.	0.1	0
5505	Transgenic amyloid precursor protein mouse models of amyloidosis. Incomplete models for Alzheimer's disease but effective predictors of antiâ€amyloid therapies. Alzheimer's and Dementia, 2024, 20, 1459-1464.	0.8	0
5506	NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer's clinical syndrome: the ATHENEA randomized clinical trial. Alzheimer's Research and Therapy, 2023, 15, .	6.2	1
5507	Association of Sleep Duration and Change Over Time With Imaging Biomarkers of Cerebrovascular, Amyloid, Tau, and Neurodegenerative Pathology. Neurology, 2024, 102, .	1.1	1
5510	Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer's disease. Journal of Neuroinflammation, 2023, 20, .	7.2	0
5511	Alzheimer's disease classification using 3D conditional progressive GAN- and LDA-based data selection. Signal, Image and Video Processing, 2024, 18, 1847-1861.	2.7	0
5513	Serum neurofilament light chain levels in patients with cognitive deficits and movement disorders: comparison of cerebrospinal and serum neurofilament light chain levels with other biomarkers. Frontiers in Human Neuroscience, 0, 17, .	2.0	0
5515	Revision of Alzheimer's diagnostic criteria or relocation of the Potemkin village. Ageing Research Reviews, 2024, 93, 102173.	10.9	0
5516	Identifying the joint signature of brain atrophy and gene variant scores in Alzheimer's Disease. Journal of Biomedical Informatics, 2024, 149, 104569.	4.3	1
5517	People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare. Journal of Internal Medicine, 2024, 295, 281-291.	6.0	1
5518	Early cerebral amyloid-β accumulation and hypermetabolism are associated with subtle cognitive deficits before accelerated cerebral atrophy. GeroScience, 0, , .	4.6	0
5519	Serum proinsulin levels as peripheral blood biomarkers in patients with cognitive impairment. Scientific Reports, 2023, 13, .	3.3	1

		CITATION REF	PORT	
# 5520	ARTICLE The use of inhaled nitric oxide (Tianox device) in patients with moderate cognitive impairment		IF 1.2	CITATIONS
	Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2023, 15, 64-70.			-
5521	Toward a generalizable machine learning workflow for neurodegenerativeAdisease staging wit on neurofibrillary tangles. Acta Neuropathologica Communications, 2023, 11, .	h focus	5.2	0
5522	Comorbidity of cerebral amyloid angiopathy and Alzheimer's disease. Clinical case analysis. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2023, 15, 85-94.		1.2	0
5523	Association Between Hippocampal Volumes and Cognition in Cerebral Amyloid Angiopathy. N 2024, 102, .	eurology,	1.1	0
5524	Neuropsychological, plasma marker, and functional connectivity changes in Alzheimer's di patients infected with COVID-19. Frontiers in Aging Neuroscience, 0, 15, .	sease	3.4	0
5525	Association of plasma biomarkers with cognition, cognitive decline, and daily function across within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Rese Initiative. Alzheimer's and Dementia, O, , .	and arch	0.8	Ο
5526	Amidst an amygdala renaissance in Alzheimer's disease. Brain, 2024, 147, 816-829.		7.6	1
5527	Biological Diagnosis of Alzheimer's Disease Based on Amyloid Status: An Illustration of Co Bias in Medical Research?. International Journal of Molecular Sciences, 2023, 24, 17544.	nfirmation	4.1	0
5528	Blood Markers in Relation to a History of Traumatic Brain Injury Across Stages of Cognitive Impairment in a Diverse Cohort. Journal of Alzheimer's Disease, 2023, , 1-14.		2.6	0
5529	Correlation Between Amyloid PET Imaging and Discordant Cerebrospinal Fluid Biomarkers Res Patients with Suspected Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, , 1-12.	ults in	2.6	Ο
5530	Higher Fat-Related Body Composition Measurement and Lower Resting-State Inter-Network Fi Connectivity of APOE Iµ4 Carrier in Mild Cognitive Impairment Patients With AI2 Deposition. F Investigation, 2023, 20, 1177-1184.	unctional Psychiatry	1.6	0
5531	Medical help-seeking intentions among patients with early Alzheimerâ $\in$ <sup>Ms</sup> disease. Frontiers i 0, 14, .	n Psychiatry,	2.6	0
5532	Mechanisms of Neurocognitive Adaptation during Aging Process. , 2023, , 94-101.			0
5534	Switching On/Off Amyloid Plaque Formation in Transgenic Animal Models of Alzheimer's D International Journal of Molecular Sciences, 2024, 25, 72.	Disease.	4.1	0
5535	Comparison of diagnostic routines for suspected Alzheimer's disease patients in US–Americ German primary care. Neurodegenerative Disease Management, 2023, 13, 269-280.	an and	2.2	0
5536	Efficacy of Probiotic Supplements on Brain-Derived Neurotrophic Factor, Inflammatory Biomar Oxidative Stress and Cognitive Function in Patients with Alzheimer's Dementia: A 12-Wee Double-Blind Active-Controlled Study. Nutrients, 2024, 16, 16.	kers, k Randomized,	4.1	2
5537	High-Performance Plasma Biomarker Panel for Alzheimer's Disease Screening Using a Fem Label-Free Biosensing System. ACS Nano, 2024, 18, 2117-2130.	tomolar-Level	14.6	1
5538	Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer' Brain, 2024, 147, 961-969.	's disease.	7.6	0

		CITATION RE	PORT	
#	Article		IF	CITATIONS
5539	Overcoming Racial/Ethnic Disparities inÂAlzheimer Disease and RelatedÂDementias. , 2	2024, 3, 100778.		0
5540	Is blood pTau a reliable indicator of the CSF status? A narrative review. Neurological Sc	iences, 0, , .	1.9	Ο
5541	Comparison of Commonly Measured Plasma and Cerebrospinal Fluid Proteins and Thei for the Characterization of Cognitive Impairment Status. Journal of Alzheimer's Diseas	r Significance e, 2023, , 1-13.	2.6	0
5542	Uncovering the Impact of Aggrephagy in the Development of Alzheimer's Disease: Insi Diagnostic and Therapeutic Approaches from Machine Learning Analysis. Current Alzho 2023, 20, 618-635.	ghts Into eimer Research,	1.4	0
5543	Individual and dual trajectories of insomnia symptoms and body mass index before and retirement and their associations with changes in subjective cognitive functioning. Pre Medicine, 2023, , 107830.	l after eventive	3.4	0
5544	Data Classification Analysis for Alzheimer Disease Diagnostic. , 2023, , .			0
5547	Cognitive and Functional Change Over Time in Cognitively Healthy Individuals Accordin Disease Biomarker-Defined Subgroups. Neurology, 2024, 102, .	ng to Alzheimer	1.1	1
5548	Postâ€translational modifications linked to preclinical Alzheimer's disease–related p cognitive changes. Alzheimer's and Dementia, 2024, 20, 1851-1867.	athological and	0.8	0
5549	Tau seeds from Alzheimer's disease brains trigger tau spread in macaques while oligon pathology maturation. Alzheimer's and Dementia, 2024, 20, 1894-1912.	1ericâ€Aβ mediates	0.8	1
5551	Enlarged Perivascular Space and Index for Diffusivity Along the Perivascular Space as E Neuroimaging Biomarkers of Neurological Diseases. Cellular and Molecular Neurobiolo	merging gy, 2024, 44, .	3.3	0
5552	Comparing Symmetric Dimethylarginine and Amyloid-β42 as Predictors of Alzheimerâŧ Development. Journal of Alzheimer's Disease Reports, 2023, 7, 1427-1444.	€™s Disease	2.2	0
5553	Effect of Vascular Risk Factors on Blood-Brain Barrier and Cerebrospinal Fluid Biomarke Alzheimer's Disease Continuum: A Retrospective Observational Study. Journal of A 2023, , 1-9.	ers Along the Izheimer's Disease,	2.6	0
5554	Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism me mild cognitive impairment due to Alzheimer's disease. Journal of Neurology, 0, , .	etrics across	3.6	0
5555	Studying the Alzheimer's disease continuum using EEG and fMRI in single-modality settings. Reviews in the Neurosciences, 2024, .	v and multi-modality	2.9	0
5556	A Continuous Extension of Gene Set Enrichment Analysis Using the Likelihood Ratio Te Identifies Vascular Endothelial Growth Factor as a Candidate Pathway for Alzheimerâ€ ITGA5. Journal of Alzheimer's Disease, 2023, , 1-14.	?st Statistics ™s Disease via	2.6	0
5557	Neuropsychiatric symptoms in Alzheimer's continuum and their association with plasm Journal of Affective Disorders, 2024, 348, 200-206.	na biomarkers.	4.1	1
5558	Optimal blood tau species for the detection of Alzheimer's disease neuropatholog immunoprecipitation mass spectrometry and autopsy study. Acta Neuropathologica, 2	y: an 2024, 147, .	7.7	0
5559	Recommendations for reproducibility of cerebrospinal fluid extracellular vesicle studies Extracellular Vesicles, 2024, 13, .	. Journal of	12.2	0

#	Article	IF	CITATIONS
5560	Engineering nanoprobes for magnetic resonance imaging of brain diseases. Chemical Engineering Journal, 2024, 481, 148472.	12.7	0
5561	Significance of a positive tau PET scan with a negative amyloid PET scan. Alzheimer's and Dementia, 0, , .	0.8	Ο
5564	Radiotherapy for non-cancer diseases: benefits and long-term risks. International Journal of Radiation Biology, 2024, 100, 505-526.	1.8	0
5565	Data-driven modelling of neurodegenerative disease progression: thinking outside the black box. Nature Reviews Neuroscience, 2024, 25, 111-130.	10.2	0
5566	Traffic-related air pollution and dementia incidence in the Adult Changes in Thought Study. Environment International, 2024, 183, 108418.	10.0	0
5567	Automating the analysis of eye movement for different neurodegenerative disorders. Computers in Biology and Medicine, 2024, 170, 107951.	7.0	0
5568	Intelligent digital tools for screening of brain connectivity and dementia risk estimation in people affected by mild cognitive impairment: the AI-Mind clinical study protocol. Frontiers in Neurorobotics, 0, 17, .	2.8	0
5569	COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain–Barré syndrome. Neurological Sciences, 2024, 45, 849-859.	1.9	0
5570	CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease. Acta Neuropathologica, 2024, 147, .	7.7	2
5571	Digital Clock and Recall is superior to the Mini-Mental State Examination for the detection of mild cognitive impairment and mild dementia. Alzheimer's Research and Therapy, 2024, 16, .	6.2	0
5572	Depth- and curvature-based quantitative susceptibility mapping analyses of cortical iron in Alzheimer's disease. Cerebral Cortex, 2024, 34, .	2.9	0
5573	A nIR fluorescent single walled carbon nanotube sensor for broad-spectrum diagnostics. Sensors & Diagnostics, 2024, 3, 203-217.	3.8	2
5574	High-Fat Diets in Animal Models of Alzheimer's Disease: How Can Eating Too Much Fat Increase Alzheimer's Disease Risk?. Journal of Alzheimer's Disease, 2024, 97, 977-1005.	2.6	0
5575	Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: The Strong Heart Study. Alzheimer's and Dementia, 2024, 20, 2072-2079.	0.8	0
5576	Dynamic multilayer functional connectivity detects preclinical and clinical Alzheimer's disease. Cerebral Cortex, 2024, 34, .	2.9	0
5577	Associations of cerebrospinal fluid complement proteins with Alzheimer's pathology, cognition, and brain structure in non-dementia elderly. Alzheimer's Research and Therapy, 2024, 16, .	6.2	0
5578	Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology. Molecular Neurodegeneration, 2024, 19, .	10.8	1
5579	Machine Learning-Derived MRI-Based Neurodegeneration Biomarker for Alzheimer's Disease: A Multi-Database Validation Study. Journal of Alzheimer's Disease, 2024, 97, 883-893.	2.6	0

#	Article	IF	CITATIONS
5580	Depression and Agitation Factors Are Related to Regional Brain Atrophy and Faster Longitudinal Cognitive Decline in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2024, 97, 1341-1351.	2.6	1
5581	Symptoms and conventional treatments of Alzheimer's disease. , 2024, , 213-234.		1
5582	Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer's Disease. International Journal of Molecular Sciences, 2024, 25, 1231.	4.1	0
5583	Definition of a Threshold for the Plasma AÎ <sup>2</sup> 42/AÎ <sup>2</sup> 40 Ratio Measured by Single-Molecule Array to Predict the Amyloid Status of Individuals without Dementia. International Journal of Molecular Sciences, 2024, 25, 1173.	4.1	1
5584	Salivary Biomarkers for Alzheimer's Disease: A Systematic Review with Meta-Analysis. International Journal of Molecular Sciences, 2024, 25, 1168.	4.1	2
5585	Alzheimer's disease early diagnostic and staging biomarkers revealed by large-scale cerebrospinal fluid and serum proteomic profiling. Innovation(China), 2024, 5, 100544.	9.1	0
5586	Correlation between serum biomarkers, brain volume, and retinal neuronal loss in early-onset Alzheimer's disease. Neurological Sciences, 0, , .	1.9	0
5587	The Influence of Kynurenine Metabolites on Neurodegenerative Pathologies. International Journal of Molecular Sciences, 2024, 25, 853.	4.1	0
5588	In vivo imaging of synaptic density in neurodegenerative disorders with positron emission tomography: A systematic review. Ageing Research Reviews, 2024, 94, 102197.	10.9	0
5589	Vascular risk burden is a key player in the early progression of Alzheimer's disease. Neurobiology of Aging, 2024, 136, 88-98.	3.1	0
5590	Current status of PET tracers for the early diagnosis of Alzheimer's disease. TrAC - Trends in Analytical Chemistry, 2024, 172, 117546.	11.4	0
5591	Cognitive impairment in multiple sclerosis. , 2024, , 341-375.		0
5592	Predicting Decline in Clinical Assessments of Alzheimer's Disease With Machine Learning and 3D Brain MRI. , 2023, , .		0
5593	CSF 14–3-3 zeta(ζ) isoform is associated with tau pathology and cognitive decline in Alzheimer's disease. Journal of the Neurological Sciences, 2024, 457, 122861.	0.6	0
5594	<sup>18</sup> F-THK5351 Positron Emission Tomography Clearly Depicted Progressive Multifocal Leukoencephalopathy After Mantle Cell Lymphoma Treatment. Internal Medicine, 2024, , .	0.7	0
5595	Relationship between neuroimaging and emotion recognition in mild cognitive impairment patients. Behavioural Brain Research, 2024, 461, 114844.	2.2	0
5596	Exploring Alzheimer's disease: a comprehensive brain connectome-based survey. Psychoradiology, 2024, 4, .	2.3	0
5597	Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer's Disease. New England Journal of Medicine, 2024, 390, 55-62.	27.0	9

#	Article	IF	CITATIONS
5598	Abnormal motor cortical plasticity as a useful neurophysiological biomarker for Alzheimer's disease pathology. Clinical Neurophysiology, 2024, 158, 170-179.	1.5	0
5599	Longitudinal changes in the functional connectivity of individuals at risk of Alzheimer's disease. GeroScience, 2024, 46, 2989-3003.	4.6	1
5600	Associations of liver function with plasma biomarkers for Alzheimer's Disease. Neurological Sciences, 0, , .	1.9	1
5601	Risk of Alzheimer's disease is associated with longitudinal changes in plasma biomarkers in the multiâ€ethnic Washington Heights–Hamilton Heights–Inwood Columbia Aging Project (WHICAP) cohort. Alzheimer's and Dementia, 2024, 20, 1988-1999.	0.8	2
5602	In Silico Identification of a Potential TNF-Alpha Binder Using a Structural Similarity: A Potential Drug Repurposing Approach to the Management of Alzheimer's Disease. BioMed Research International, 2024, 2024, 1-13.	1.9	0
5603	Brain Health and Cognition in Older Adults: Roadmap and Milestones towards the Implementation of Preventive Strategies. Brain Sciences, 2024, 14, 55.	2.3	0
5604	Determinants of physical activity behavior among older adults with subjective cognitive decline based on the capability, opportunity, motivation, and behavior model: mediating and moderating effects. Frontiers in Public Health, 0, 11, .	2.7	0
5605	Age and beta amyloid deposition impact gait speed, stride length, and gait smoothness while transitioning from an even to an uneven walking surface in older adults. Human Movement Science, 2024, 93, 103175.	1.4	0
5606	Unlocking the Potential of XAI for Improved Alzheimer's Disease Detection and Classification Using a ViT-GRU Model. IEEE Access, 2024, 12, 8390-8412.	4.2	0
5608	Agricultural activities and risk of Alzheimer's disease: the TRACTOR project, a nationwide retrospective cohort study. European Journal of Epidemiology, 2024, 39, 271-287.	5.7	1
5609	Distinct tau and alpha-synuclein molecular signatures in Alzheimer's disease with and without Lewy bodies and Parkinson's disease with dementia. Acta Neuropathologica, 2024, 147, .	7.7	0
5610	PET imagining in Alzheimer's disease. UkraÃ⁻nsʹkij žurnal VìjsʹkovoÃ⁻ Medicini, 2023, 4, 45-54.	0.6	0
5613	Blood Biomarkers of Alzheimer's Disease and Cognition: A Literature Review. Biomolecules, 2024, 14, 93.	4.0	0
5614	Diagnostic accuracy of research criteria for prodromal frontotemporal dementia. Alzheimer's Research and Therapy, 2024, 16, .	6.2	0
5615	Relationship between topological efficiency of white matter structural connectome and plasma biomarkers across the Alzheimer's disease continuum. Human Brain Mapping, 2024, 45, .	3.6	0
5616	Metabotropic glutamate receptor 5 (mGluR5) is associated with neurodegeneration and amyloid deposition in Alzheimer's disease: A [18F]PSS232 PET/MRI study. Alzheimer's Research and Therapy, 2024, 16, .	6.2	0
5617	Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial. Neurology: Clinical Practice, 2024, 14, .	1.6	0
5618	Disentangling empathy impairment along Alzheimer's disease continuum: From subjective cognitive decline to Alzheimer's dementia. Cortex, 2024, 172, 125-140.	2.4	0

# 5620	ARTICLE Association of amyloid-beta with depression or depressive symptoms in older adults without	IF 4.8	CITATIONS
5622	Protein levels in cerebrospinal fluid indicate different subtypes in Alzheimer's disease. Nature Aging, 2024, 4, 12-13.	11.6	0
5623	Research Participants' Perspectives on Precision Diagnostics for Alzheimer's Disease. Journal of Alzheimer's Disease, 2024, 97, 1261-1274.	2.6	0
5624	Comparing Cognitive Tests and Smartphoneâ€Based Assessment in 2 US Communityâ€Based Cohorts. Journal of the American Heart Association, 2024, 13, .	3.7	0
5625	Exploring small non-coding RNAs as blood-based biomarkers to predict Alzheimer's disease. Cell and Bioscience, 2024, 14, .	4.8	0
5626	Application of Suggestive Biomarkers in Dementia With Lewy Bodies With Masking of Typical Clinical Symptoms by Alzheimer Disease-type Pathology. Alzheimer Disease and Associated Disorders, 2024, 38, 95-97.	1.3	0
5627	Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History. Journal of Clinical Medicine, 2024, 13, 536.	2.4	0
5629	Impact of Sleep Disorders and Disturbed Sleep on Brain Health: A Scientific Statement From the American Heart Association. Stroke, 2024, 55, .	2.0	2
5630	Individuals with Alzheimer's disease and low tau burden: Characteristics and implications. Alzheimer's and Dementia, 2024, 20, 2113-2127.	0.8	0
5631	Graphene as basis of biological sensors for determining markers of neurodegenerative dementia. Medical Alphabet, 2024, , 28-33.	0.2	0
5632	Demenzen. , 2024, , 90-97.		0
5633	Glucose–oxygen coupling can serve as a biomarker for neuroinflammation-related genetic variants. Cerebral Cortex, 2024, 34, .	2.9	0
5634	A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. Lancet Neurology, The, 2024, 23, 178-190.	10.2	15
5635	Criteria for a biological definition of neuronal α-synuclein disease—a major conceptual step forward. Lancet Neurology, The, 2024, 23, 129-130.	10.2	0
5636	Digging into the intrinsic capacity concept: Can it be applied to Alzheimer's disease?. Progress in Neurobiology, 2024, 234, 102574.	5.7	0
5637	Blood-based biomarkers in Alzheimer's disease– moving towards a new era of diagnostics. Clinical Chemistry and Laboratory Medicine, 2024, 62, 1063-1069	2.3	1
5638	The prevalence of mild cognitive impairment in Gulf War veterans: a follow-up study. Frontiers in Neuroscience, 0, 17, .	2.8	0
5639	Neuroprotection by tetramethylpyrazine and its synthesized analogues for central nervous system diseases: a review. Molecular Biology Reports, 2024, 51, .	2.3	0

#	Article	IF	CITATIONS
5640	Positive affect disrupts neurodegeneration effects on cognitive training plasticity in older adults. Social Cognitive and Affective Neuroscience, 2024, 19, .	3.0	0
5641	Development of Efficient Brain Age Estimation Method Based on Regional Brain Volume From Structural Magnetic Resonance Imaging. Psychiatry Investigation, 2024, 21, 37-43.	1.6	0
5642	Navigating complexities of racial disparities in Alzheimer disease biomarkers. Nature Reviews Neurology, 2024, 20, 205-206.	10.1	0
5643	Small RNA Changes in Plasma Have Potential for Early Diagnosis of Alzheimer's Disease before Symptom Onset. Cells, 2024, 13, 207.	4.1	0
5644	Human whole-exome genotype data for Alzheimerâ $\in$ ${}^{\mathrm{Ms}}$ s disease. Nature Communications, 2024, 15, .	12.8	0
5645	RNA Analysis of Circulating Leukocytes in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2024, 97, 1673-1683.	2.6	0
5647	Early ultrasonic vocalization deficits and related thyroarytenoid muscle pathology in the transgenic TgF344-AD rat model of Alzheimer's disease. Frontiers in Behavioral Neuroscience, 0, 17, .	2.0	0
5649	Cerebrospinal fluid biomarker profiling of diverse pathophysiological domains in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2024, 10, .	3.7	0
5650	Comparing neuropsychological, typical, and ADNI criteria for the diagnosis of mild cognitive impairment in Vietnam-era veterans. Journal of the International Neuropsychological Society, 2024, 30, 439-447.	1.8	0
5651	Influence of Physiological Variables and Comorbidities on Plasma Aβ40, Aβ42, and p-tau181 Levels in Cognitively Unimpaired Individuals. International Journal of Molecular Sciences, 2024, 25, 1481.	4.1	0
5652	Cerebrospinal fluid level of proNGF as potential diagnostic biomarker in patients with frontotemporal dementia. Frontiers in Aging Neuroscience, 0, 15, .	3.4	0
5654	Deep learning method for adult patients with neurological disorders under remote monitoring. , 2024, , 61-82.		0
5655	Comparison of 18F-FDG PET and arterial spin labeling MRI in evaluating Alzheimer's disease and amnestic mild cognitive impairment using integrated PET/MR. EJNMMI Research, 2024, 14, .	2.5	0
5656	Effects of Data Corrections on Image Quality for a Brain Dedicated PET Insert for MRI. , 2022, , .		0
5657	Mild behavioral impairment in early Alzheimer's disease and its association with APOE and BDNF risk genetic polymorphisms. Alzheimer's Research and Therapy, 2024, 16, .	6.2	0
5658	The role of adiponectin in Alzheimer's disease: A translational review. Journal of Nutrition, Health and Aging, 2024, 28, 100166.	3.3	0
5659	Deep Learning Models for the Screening of Cognitive Impairment Using Multimodal Fundus Images. Ophthalmology Retina, 2024, , .	2.4	0
5660	Downregulation of Dickkopf-3, a Wnt antagonist elevated in Alzheimer's disease, restores synapse integrity and memory in a disease mouse model. ELife, 0, 12, .	6.0	0

#	Article	IF	CITATIONS
5661	latrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone. Nature Medicine, 2024, 30, 394-402.	30.7	3
5662	Uptake of 18F-AV45 in the Putamen Provides Additional Insights into Alzheimer's Disease beyond the Cortex. Biomolecules, 2024, 14, 157.	4.0	0
5663	Mild Behavioral Impairment and Cerebrovascular Profiles Are Associated with Early Cognitive Impairment in a Community-Based Southeast Asian Cohort. Journal of Alzheimer's Disease, 2024, 97, 1727-1735.	2.6	0
5664	Association of Plasma YKL-40 With MRI, CSF, and Cognitive Markers of Brain Health and Dementia. Neurology, 2024, 102, .	1.1	1
5665	Evaluation of serum neurofilament light chain and glial fibrillary acidic protein in the diagnosis of Alzheimer's disease. Frontiers in Neurology, 0, 15, .	2.4	0
5666	Retinal Alterations Predict Early Prodromal Signs of Neurodegenerative Disease. International Journal of Molecular Sciences, 2024, 25, 1689.	4.1	0
5667	Elevated Amyloid-β PET Scan and Cognitive and Functional Decline in Mild Cognitive Impairment and Dementia of Uncertain Etiology. Journal of Alzheimer's Disease, 2024, 97, 1161-1171.	2.6	0
5668	An overview on Alzheimer's disease, diagnosis and treatment approach. , 2023, 11, 379-391.		0
5669	ATN Classification and Clinical Progression of the Amyloid-Negative Group in Alzheimer's Disease Neuroimaging Initiative Participants. Chonnam Medical Journal, 2024, 60, 51.	0.9	0
5671	Application of blood-based biomarkers of Alzheimer's disease in clinical practice: Recommendations from Taiwan Dementia Society. Journal of the Formosan Medical Association, 2024, , .	1.7	0
5672	Choriocapillaris and Retinal Vascular Alterations in Presymptomatic Alzheimer's Disease. , 2024, 65, 47.		0
5674	Consensus on rapid screening for prodromal Alzheimer's disease in China. Annals of General Psychiatry, 2024, 37, e101310.	3.1	0
5675	Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2024, 16, .	2.4	0
5676	Cellular junction dynamics and Alzheimer's disease: a comprehensive review. Molecular Biology Reports, 2024, 51, .	2.3	0
5677	A systematic review and meta-analysis of tau phosphorylation in mouse models of familial Alzheimer's disease. Neurobiology of Disease, 2024, 192, 106427.	4.4	0
5678	Microglia measured by TSPO PET are associated with Alzheimer's disease pathology and mediate key steps in a disease progression model. Alzheimer's and Dementia, 2024, 20, 2397-2407.	0.8	1
5679	Resting state electroencephalographic alpha rhythms are sensitive to Alzheimer's disease mild cognitive impairment progression at a 6-month follow-up. Neurobiology of Aging, 2024, 137, 19-37.	3.1	0
5680	Predicting progression of cognitive decline to dementia using dyadic patterns of subjective reporting: evidence from the CompAS longitudinal study. Frontiers in Aging Neuroscience, 0, 16, .	3.4	0

#	Article	IF	CITATIONS
5681	Evaluation of ATN <sub>PD</sub> Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease. Neurology, 2024, 102, .	1.1	0
5682	Blood Pressure Variability and Plasma Alzheimer's Disease Biomarkers in the SPRINT Trial. Journal of Alzheimer's Disease, 2024, 97, 1851-1860.	2.6	0
5683	CoQ10 and Mitochondrial Dysfunction in Alzheimer's Disease. Antioxidants, 2024, 13, 191.	5.1	0
5684	The spatial distribution of coupling between tau and neurodegeneration in amyloid-Î <sup>2</sup> positive mild cognitive impairment. Neurobiology of Aging, 2024, 136, 70-77.	3.1	0
5685	Early onset diagnosis in Alzheimer's disease patients via amyloid-β oligomers-sensing probe in cerebrospinal fluid. Nature Communications, 2024, 15, .	12.8	1
5686	Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer's clinical trial participants. Alzheimer's Research and Therapy, 2024, 16, .	6.2	0
5687	Cost-effectiveness comparison between blood biomarkers and conventional tests in Alzheimer's disease diagnosis. Drug Discovery Today, 2024, 29, 103911.	6.4	0
5688	The relationship between inflammation, impaired glymphatic system, and neurodegenerative disorders: A vicious cycle. Neurobiology of Disease, 2024, 192, 106426.	4.4	0
5689	The associations between synaptic density and "A/T/N―biomarkers in Alzheimer's disease: An <sup>18</sup> F-SynVesT-1 PET/MR study. Journal of Cerebral Blood Flow and Metabolism, 0, , .	4.3	0
5690	The Applications of CircRNA in the Diagnosis and Treatment of Alzheimer's Disease. Molecular Neurobiology, 0, , .	4.0	0
5691	Palladium nanoballs coupled with smartphone-thermal reader for photothermal lateral flow immunoassay of AÎ <sup>2</sup> 1-40. Journal of Materials Chemistry B, 2024, 12, 2610-2617.	5.8	0
5692	Associations between cardiometabolic multimorbidity and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: the CABLE study. Alzheimer's Research and Therapy, 2024, 16, .	6.2	0
5693	Using Discourse as a Measure of Early Cognitive Decline Associated with Alzheimer's Disease Biomarkers. , 2023, , 53-63.		0
5694	Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 0, , .	3.2	0
5695	Nanomodulators That Target Alzheimer's Disease: A Review. ACS Applied Nano Materials, 2024, 7, 3515-3545.	5.0	0
5696	Prediction of clinical progression of subjective cognitive decline through alterations in morphology and structural covariance networks. Brain and Behavior, 2024, 14, .	2.2	0
5697	Modifiable dementia risk factors and AT(N) biomarkers: findings from the EPAD cohort. Frontiers in Aging Neuroscience, 0, 16, .	3.4	0
5698	Investigating alphaâ€synuclein coâ€pathology in Alzheimer's disease by means of cerebrospinal fluid alphaâ€synuclein seed amplification assay. Alzheimer's and Dementia, 2024, 20, 2444-2452. 	0.8	0

#	Article	IF	CITATIONS	
5699	Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024, 13, .	12.2	17	
5700	Altered dynamic amplitude of lowâ€frequency fluctuation in individuals at high risk for Alzheimer's disease. European Journal of Neuroscience, 2024, 59, 2391-2402.	2.6	Ο	
5701	Fully automated measurement of plasma Aβ42/40 and pâ€ŧau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts. Alzheimer's and Dementia, 2024, 20, 2453-2468.	0.8	0	
5702	Advancing Diagnostics and Patient Care: The Role of Biomarkers in Radiology. Seminars in Musculoskeletal Radiology, 2024, 28, 003-013.	0.7	Ο	
5703	Cortical folding correlates to aging and Alzheimer's Disease's cognitive and CSF biomarkers. Scientific Reports, 2024, 14, .	3.3	0	
5704	Incremental value of amyloid PET in a tertiary memory clinic setting in China. Alzheimer's and Dementia, 2024, 20, 2516-2525.	0.8	0	
5706	Alteration of functional connectivity network in population of objectively-defined subtle cognitive decline. Brain Communications, 2023, 6, .	3.3	1	
5707	Clinical and neuroimaging association between neuropsychiatric symptoms and nutritional status across the Alzheimer's disease continuum: a longitudinal cohort study. Journal of Nutrition, Health and Aging, 2024, 28, 100182.	3.3	0	
5708	The Associations of Phosphorylated Tau 181 and Tau 231 Levels in Plasma and Cerebrospinal Fluid with Cognitive Function in Alzheimer's Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2024, 98, 13-32.	2.6	0	
5709	Cognitive Impairment and Early-onset Cerebral Amyloid Angiopathy in a Middle-aged Man with a History of Childhood Traumatic Brain Injury. Internal Medicine, 2024, , .	0.7	0	
5710	Peripapillary Optical Coherence Tomography Angiography in Alzheimer's Disease, Mild Cognitive Impairment, and Normal Cognition. Ophthalmic Surgery Lasers and Imaging Retina, 2024, 55, 78-84.	0.7	0	
5711	Alzheimer's disease detection using data fusion with a deep supervised encoder. , 0, 3, .		Ο	
5715	Cerebrospinal fluid shunt surgery reduces the risk of developing dementia and Alzheimer's disease in patients with idiopathic normal pressure hydrocephalus: a nationwide population-based propensity-weighted cohort study. Fluids and Barriers of the CNS, 2024, 21, .	5.0	0	
5716	Epilepsy and epileptiform activity in late-onset Alzheimer disease: clinical and pathophysiological advances, gaps and conundrums. Nature Reviews Neurology, 2024, 20, 162-182.	10.1	0	
5717	Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's disease pathology. Alzheimer's and Dementia, 2024, 20, 2564-2574.	0.8	0	
5718	European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. Lancet Neurology, The, 2024, 23, 302-312.	10.2	1	
5719	Hippocampal Subregions Volume and Texture for the Diagnosis of Mild Cognitive Impairment. Experimental Aging Research, 0, , 1-12.	1.2	0	
5720	Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	6.4	0	
$\sim$				
----------	------	------	-----	------------
	ΙΤΔΤ	IV F		<b>D</b> T
<u> </u>	IIAI	IVL	. 0	

#	Article	IF	CITATIONS
5721	Early detection of depression through facial expression recognition and electroencephalogram-based artificial intelligence-assisted graphical user interface. Neural Computing and Applications, 2024, 36, 6937-6954.	5.6	0
5722	Tau depletion in human neurons mitigates Al $^2$ -driven toxicity. Molecular Psychiatry, 0, , .	7.9	0
5723	Social activity mediates locus coeruleus tangle-related cognition in older adults. Molecular Psychiatry, 0, , .	7.9	0
5724	A single-domain antibody for the detection of pathological Tau protein in the early stages of oligomerization. Journal of Translational Medicine, 2024, 22, .	4.4	0
5726	Olfactory deficit: a potential functional marker across the Alzheimer's disease continuum. Frontiers in Neuroscience, 0, 18, .	2.8	0
5727	Profiling amyloidâ $\in \hat{I}^2$ peptides as biomarkers for cerebral amyloid angiopathy. Journal of Neurochemistry, 0, , .	3.9	0
5728	The Association Between Positive Amyloid-PET and Cognitive Decline Is Not Always Supportive of Alzheimer's Disease: Suggestions from a Case Report. Journal of Alzheimer's Disease Reports, 2024, 8, 281-288.	2.2	0
5729	Caregivers' attitudes toward bloodâ€based biomarker testing for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2024, 16, .	2.4	0
5730	Tracing synaptic loss in Alzheimer's brain with SV2A PETâ€ŧracer UCBâ€J. Alzheimer's and Dementia, 2024, 20, 2589-2605.	0.8	0
5731	Association of peripheral immunity and cerebral small vessel disease in older adults without dementia: A longitudinal study. Neurobiology of Aging, 2024, 137, 55-61.	3.1	0
5732	The role of perfusion, grey matter volume and behavioural phenotypes in the data-driven classification of cognitive syndromes. Alzheimer's Research and Therapy, 2024, 16, .	6.2	0
5733	Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease. Molecular Neurodegeneration, 2024, 19, .	10.8	0
5734	Anti-amyloid Antibody Therapies for Alzheimer's Disease. Nuclear Medicine and Molecular Imaging, 0, , .	1.0	0
5735	Profiles of subgingival microbiomes and gingival crevicular metabolic signatures in patients with amnestic mild cognitive impairment and Alzheimer's disease. Alzheimer's Research and Therapy, 2024, 16, .	6.2	0
5736	Prognostic and Predictive Factors in Early Alzheimer's Disease: A Systematic Review. Journal of Alzheimer's Disease Reports, 2024, 8, 203-240.	2.2	0
5737	Synthetic β-sheets mimicking fibrillar and oligomeric structures for evaluation of spectral X-ray scattering technique for biomarker quantification. Cell and Bioscience, 2024, 14, .	4.8	0
5738	Linking activity dyshomeostasis and sleep disturbances in Alzheimer disease. Nature Reviews Neuroscience, 2024, 25, 272-284.	10.2	0
5739	Linking dementia pathology and alteration in brain activation to complex daily functional decline during the preclinical dementia stages: A prospective observational cohort study. (Preprint). JMIR Research Protocols, 0, , .	1.0	0

#	Article	IF	CITATIONS
5740	African Ancestry Individuals with Higher Educational Attainment Are Resilient to Alzheimer's Disease Measured by pTau181. Journal of Alzheimer's Disease, 2024, 98, 221-229.	2.6	0
5741	Altered Motor Activity Patterns within 10-Minute Timescale Predict Incident Clinical Alzheimer's Disease. Journal of Alzheimer's Disease, 2024, 98, 209-220.	2.6	0
5742	The decreased astrocyte-microglia interaction reflects the early characteristics of Alzheimer's disease. IScience, 2024, 27, 109281.	4.1	0
5743	Machine Learning Predicts Conversion from Normal Aging to Mild Cognitive Impairment Using Medical History, APOE Genotype, and Neuropsychological Assessment. Journal of Alzheimer's Disease, 2024, 98, 83-94.	2.6	0
5744	Interaction between AÎ <sup>2</sup> and tau on reversion and conversion in mild cognitive impairment patients: After 2-year follow-up. Heliyon, 2024, 10, e26839.	3.2	0
5745	Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort. Journal of Neurology, 2024, 271, 2716-2729.	3.6	Ο
5746	Effect of cerebral small vessel disease on the integrity of cholinergic system in mild cognitive impairment patients: a longitudinal study. Journal of Neurology, 2024, 271, 2704-2715.	3.6	0
5747	Leveraging electronic health records and knowledge networks for Alzheimer's disease prediction and sex-specific biological insights. Nature Aging, 2024, 4, 379-395.	11.6	Ο
5748	Alzheimer's Disease Detection Using Deep Learning on Neuroimaging: A Systematic Review. Machine Learning and Knowledge Extraction, 2024, 6, 464-505.	5.0	0
5749	A network approach to subjective cognitive decline: Exploring multivariate relationships in neuropsychological test performance across Alzheimer's disease risk states. Cortex, 2024, 173, 313-332.	2.4	0
5750	E2F1 Mediates Traumatic Brain Injury and Regulates BDNF-AS to Promote the Progression of Alzheimer's Disease. Neurotoxicity Research, 2024, 42, .	2.7	0
5752	Examining Frontal Lobe Asymmetry and Its Potential Role in Aggressive Behaviors in Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2024, 98, 539-547.	2.6	0
5753	Creating an Unprotected Class: Addressing Legal Risks in the Era of Biologically-Defined Alzheimer's Disease. Journal of Alzheimer's Disease, 2024, 98, 187-195.	2.6	0
5754	Meeting report of the fifth annual workshop on Principles and Techniques for Improving Preclinical to Clinical Translation in Alzheimer's Disease Research. Alzheimer's and Dementia, 0, , .	0.8	0
5755	Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset. Annals of Neurology, 2024, 95, 951-965.	5.3	0
5756	Can motor decline be a modifiable marker of clinical progression in subjective cognitive decline? A national prospective cohort study. Asian Journal of Psychiatry, 2024, 94, 103978.	2.0	0
5757	Comparative analysis of multimodal biomarkers for amyloid-beta positivity detection in Alzheimer's disease cohorts. Frontiers in Aging Neuroscience, 0, 16, .	3.4	0
5758	Hepatopancreatic metabolic disorders and their implications in the development of Alzheimer's disease and vascular dementia. Ageing Research Reviews, 2024, 96, 102250.	10.9	0

#	Article	IF	CITATIONS
5759	Odor identification score as an alternative method for early identification of amyloidogenesis in Alzheimer's disease. Scientific Reports, 2024, 14, .	3.3	0
5760	Upsetting the Balance: How Modifiable Risk Factors Contribute to the Progression of Alzheimer's Disease. Biomolecules, 2024, 14, 274.	4.0	0
5761	Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals. Alzheimer's Research and Therapy, 2024, 16, .	6.2	0
5762	Clinical variables contributing to the identification of biologically defined subgroups within cognitively unimpaired and mild cognitive impairment individuals. European Journal of Neurology, 2024, 31, .	3.3	0
5763	Trends in incidence, mortality, dynamic needs and rapid evolution of healthcare in dementia. Archives of Gerontology and Geriatrics, 2024, 121, 105389.	3.0	0
5764	The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention. International Journal of Molecular Sciences, 2024, 25, 2727.	4.1	0
5765	Atypical clinical variants of Alzheimer's disease: are they really atypical?. Frontiers in Neuroscience, 0, 18, .	2.8	0
5766	Pathophysiology and Management Approaches in Alzheimer's Disease. , 2023, , 77-102.		0
5767	The Bioâ€Hermes Study: Biomarker database developed to investigate bloodâ€based and digital biomarkers in communityâ€based, diverse populations clinically screened for Alzheimer's disease. Alzheimer's and Dementia, 2024, 20, 2752-2765.	0.8	0
5768	IL-6 from cerebrospinal fluid causes widespread pain via STAT3-mediated astrocytosis in chronic constriction injury of the infraorbital nerve. Journal of Neuroinflammation, 2024, 21, .	7.2	0
5769	Is Alzheimer disease a disease?. Nature Reviews Neurology, 2024, 20, 245-251.	10.1	0
5770	Which neuroimaging and fluid biomarkers method is better in theranostic of Alzheimer's disease? An umbrella review. IBRO Neuroscience Reports, 2024, 16, 403-417.	1.6	0
5771	Biomarker-based staging of Alzheimer disease: rationale and clinical applications. Nature Reviews Neurology, 2024, 20, 232-244.	10.1	0
5772	Pharmacotherapy for Disease Modification in Early Parkinson's Disease: How Early Should We Be?. Journal of Parkinson's Disease, 2024, , 1-15.	2.8	0
5773	Increased levels of circulating soluble CD226 in multiple sclerosis. Multiple Sclerosis Journal, 2024, 30, 654-663.	3.0	0
5774	Advances in nanoprobes for molecular <scp>MRI</scp> of Alzheimer's disease. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2024, 16, .	6.1	0
5775	Assessment of Efficacy and Safety of Zagotenemab. Neurology, 2024, 102, .	1.1	0
5776	Biomarkers for Alzheimer's Disease – An Overview. Macromolecular Symposia, 2024, 413, .	0.7	0

#	Article	IF	CITATIONS
5777	STW-MD: a novel spatio-temporal weighting and multi-step decision tree method for considering spatial heterogeneity in brain gene expression data. Briefings in Bioinformatics, 2024, 25, .	6.5	0
5778	Personality traits and cognitive reserve—High openness benefits cognition in the presence of age-related brain changes. Neurobiology of Aging, 2024, 137, 38-46.	3.1	0
5779	Determining optimal cutoff scores of Cognitive Abilities Screening Instrument to identify dementia and mild cognitive impairment in Taiwan. BMC Geriatrics, 2024, 24, .	2.7	0
5780	An EWAS of dementia biomarkers and their associations with age, African ancestry, and PTSD. Clinical Epigenetics, 2024, 16, .	4.1	0
5781	Circulating biomarkers of inflammaging and Alzheimer's disease to track age-related trajectories of dementia: Can we develop a clinically relevant composite combination?. Ageing Research Reviews, 2024, 96, 102257.	10.9	0
5782	Electroencephalography-based classification of Alzheimer's disease spectrum during computer-based cognitive testing. Scientific Reports, 2024, 14, .	3.3	0
5785	Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra. Annals of Clinical and Translational Neurology, 0, , .	3.7	0
5786	Dementia Prevention and Treatment. JAMA Internal Medicine, 2024, 184, 563.	5.1	0
5787	Exosomal Dynamics and Brain Redox Imbalance: Implications in Alzheimer's Disease Pathology and Diagnosis. Antioxidants, 2024, 13, 316.	5.1	0
5788	Blood-based CNS regionally and neuronally enriched extracellular vesicles carrying pTau217 for Alzheimer's disease diagnosis and differential diagnosis. Acta Neuropathologica Communications, 2024, 12, .	5.2	0
5790	Progranulin and neuropathological features of Alzheimer's disease: longitudinal study. Aging Clinical and Experimental Research, 2024, 36, .	2.9	0
5791	CSF Biomarkers in Longitudinal Alzheimer Disease Cohorts: Pre-Analytic Challenges. Clinical Chemistry, 2024, 70, 538-550.	3.2	0
5792	Up-regulation of GPR139 in the medial septum ameliorates cognitive impairment in two mouse models of Alzheimer's disease. International Immunopharmacology, 2024, 130, 111786.	3.8	0
5793	Research hotspots and nursing inspiration in research of older adults with subjective cognitive decline from 2003 to 2023: A bibliometric analysis. International Journal of Nursing Sciences, 2024, 11, 222-232.	1.3	0
5794	Performance on the Latin American version of the Face-Name Associative Memory Exam (LAS-FNAME) distinguishes individuals with Mild Cognitive Impairment from age-matched controls in a sample from Argentina. Applied Neuropsychology Adult, 0, , 1-9.	1.2	0
5795	Preclinical Dementia and Economic Well-Being Trajectories of Racially Diverse Older Adults. Journal of Aging and Health, 0, , .	1.7	0
5796	Diagnosing Alzheimer's disease: Which dementia screening test to use in elderly Puerto Ricans with mild cognitive impairment and early Alzheimer's disease?. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2024, 16, .	2.4	0
5797	Causal association and mediating effect of blood biochemical metabolic traits and brain image-derived endophenotypes on Alzheimer's disease. Heliyon, 2024, 10, e27422.	3.2	0

#	Article	IF	CITATIONS
5798	Missense mutation of angiotensin converting enzyme gene in an Alzheimer's disease patient: a case report. Frontiers in Neuroscience, 0, 18, .	2.8	0
5799	Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer's disease pathology. Alzheimer's Research and Therapy, 2024, 16, .	6.2	0
5800	Mechanisms of Neurocognitive Adaptation during Aging Process. Advances in Gerontology, 2023, 13, 123-129.	0.4	0
5801	Characterization of preclinical Alzheimer's disease model: spontaneous type 2 diabetic cynomolgus monkeys with systemic pro-inflammation, positive biomarkers and developing AD-like pathology. Alzheimer's Research and Therapy, 2024, 16, .	6.2	0
5802	Genetic algorithm-based hybrid deep learning model for explainable Alzheimer's disease prediction using temporal multimodal cognitive data. International Journal of Data Science and Analytics, 0, , .	4.1	0
5803	Putative novel CSF biomarkers of Alzheimer's disease based on the novel concept of generic protein misfolding and proteotoxicity: the PRAMA cohort. Translational Neurodegeneration, 2024, 13, .	8.0	0
5804	Association Between Small Vessel Disease and Financial Capacity: A Study Based on Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2024, 98, 897-906.	2.6	0
5805	The Usefulness of <sup>18</sup> F-FDG PET to Differentiate Subtypes of Dementia: The Systematic Review and Meta-Analysis. Dementia and Neurocognitive Disorders, 2024, 23, 54.	1.4	0
5806	Unraveling diurnal and technical variability in cerebral hemodynamics from neurovascular 4D-Flow MRI. Journal of Cerebral Blood Flow and Metabolism, 0, , .	4.3	0
5809	Predicting early Alzheimer's with blood biomarkers and clinical features. Scientific Reports, 2024, 14, .	3.3	0
5810	Diagnostic and prognostic value of dual-point amyloid PET in Alzheimer's disease (AD) mimickers. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	6.4	0
5811	Preliminary evidence for preserved synaptic density in late-life depression. Translational Psychiatry, 2024, 14, .	4.8	0
5812	Alzheimer's disease heterogeneity revealed by neuroanatomical normative modeling. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2024, 16, .	2.4	0
5813	Comparison of cerebrospinal fluid, plasma and neuroimaging biomarker utility in Alzheimer's disease. Brain Communications, 2024, 6, .	3.3	0
5814	Toward a cross-cultural understanding of intraindividual variability metrics. Journal of Clinical and Experimental Neuropsychology, 0, , 1-11.	1.3	0
5815	Degeneration in Nucleus basalis of Meynert signals earliest stage of Alzheimer's disease progression. Neurobiology of Aging, 2024, 139, 54-63.	3.1	0
5816	Application of a Novel Endpoint Staging Framework: Proof of Concept in the AMBAR Study. Journal of Alzheimer's Disease, 2024, 98, 1079-1094.	2.6	0
5817	Associations of Serum Liver Function with Cerebral Blood Flow in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2024, 8, 437-445.	2.2	0

		CITATION REPORT		
#	Article		IF	CITATIONS
5818	Defining Parkinson's Disease: Past and Future. Journal of Parkinson's Disease, 2024	,,1-15.	2.8	0
5819	Lost in space(s): Multimodal neuroimaging of disorientation along the Alzheimer's dise Human Brain Mapping, 2024, 45, .	ase continuum.	3.6	0
5820	A novel method for PET connectomics guided by fibreâ€ŧracking MRI: Application to Ala Human Brain Mapping, 2024, 45, .	?heimer's disease.	3.6	0
5822	<scp>ER</scp> â€stress response in retinal Müller glia occurs significantly earlier than pathology in the Alzheimer's mouse brain and retina. Glia, 2024, 72, 1067-1081.	n amyloid	4.9	0
5823	Communicative impairment and its neural correlates in Alzheimer's disease and frontot dementia. Brain and Behavior, 2024, 14, .	emporal	2.2	0
5824	Translating NIAâ€AA criteria into usual practice: Report from the ReDeMa Project. Alzhe Dementia: Translational Research and Clinical Interventions, 2024, 10, .	imer's and	3.7	0
5826	Serum NFL and tau, but not serum UCHL-1 and GFAP or CSF SNAP-25, NPTX2, or sTREN delirium in a 3-year retrospective analysis. Frontiers in Neurology, 0, 15, .	12, correlate with	2.4	0
5827	Probable Novel APP Met671Leu Mutation in a Chinese Han Family with Early-Onset Alzł 2024, 26, .	neimer's Disease. ,		0
5828	Plasma biomarkers for Alzheimer's and related dementias: A review and outlook for neuropsychology. Archives of Clinical Neuropsychology, 2024, 39, 313-324.	clinical	0.5	0
5829	Neuropsychological assessment in vascular cognitive impairment: A call to lay the quest test to rest. Cerebral Circulation - Cognition and Behavior, 2024, 6, 100219.	t for the best	0.9	0
5830	Determinants of confrontation naming deficits on the Boston Naming Test associated transactive response DNA-binding protein 43 pathology. Journal of the International Neuropsychological Society, 0, , 1-9.	with	1.8	0
5831	Introduction to Focused Update Vascular Cognitive Impairment and Dementia: Better D Avenues for Prevention. Stroke, 2024, 55, 788-790.	Diagnosis, More	2.0	0
5832	Pharmacotherapy for patients with Alzheimer's disease. Journal of the Korean Medie 2024, 67, 213-220.	cal Association,	0.3	0
5833	Developing blood-brain barrier arterial spin labelling as a non-invasive early biomarker or disease (DEBBIE-AD): a prospective observational multicohort study protocol. BMJ Oper e081635.	f Alzheimer's n, 2024, 14,	1.9	0
5835	Recent Advances in Fluorescent Theranostics for Alzheimer's Disease: A Compreher Design, Synthesis, and Properties. ACS Omega, 2024, 9, 13556-13591.	isive Survey on	3.5	0
5836	Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid of Alzheimer〙s disease spectrum. Alzheimer's Research and Therapy, 2024, 16, .	deposition in	6.2	0
5837	Lifetime Stressful Events Associated with Alzheimer's Pathologies, Neuroinflammation a Structure in a Risk Enriched Cohort. Annals of Neurology, 0, , .	and Brain	5.3	0
5838	Extracellular vesicles in Alzheimer's disease. Arquivos De Neuro-Psiquiatria, 2024, 82, 00	01-008.	0.8	0

#	Article	IF	CITATIONS
5839	Investigating the relationship between sleep disturbances and white matter hyperintensities in older adults on the Alzheimer's disease spectrum. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2024, 16, .	2.4	0
5840	CSF β-Amyloid and Tau Biomarker Changes in Veterans With Mild Traumatic Brain Injury. Neurology, 2024, 102, .	1.1	0
5841	Association of β-Amyloid, Microglial Activation, Cortical Thickness, and Metabolism in Older Adults Without Dementia. Neurology, 2024, 102, .	1.1	0
5843	Plasma Phosphorylated Tau 231 Increases at One-Year Intervals in Cognitively Unimpaired Subjects. Journal of Alzheimer's Disease, 2024, 98, 1029-1042.	2.6	Ο
5845	Altered resting-state functional connectivity and dynamic network properties in cognitive impairment: an independent component and dominant-coactivation pattern analyses study. Frontiers in Aging Neuroscience, 0, 16, .	3.4	0
5846	Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease. Alzheimer's and Dementia, 0, , .	0.8	0
5847	Impaired long-range excitatory time scale predicts abnormal neural oscillations and cognitive deficits in Alzheimer's disease. Alzheimer's Research and Therapy, 2024, 16, .	6.2	0
5848	Quantitative Brain Amyloid PET. Journal of Nuclear Medicine, 2024, 65, 670-678.	5.0	0
5849	Diagnostic Accuracy of Digital Solutions for Screening for Cognitive Impairment: A Systematic Review and Meta-Analysis. Applied Sciences (Switzerland), 2024, 14, 2640.	2.5	0
5850	Disease staging of Alzheimer's disease using a CSF-based biomarker model. Nature Aging, 0, , .	11.6	0
5851	The Contribution of Functional Near-Infrared Spectroscopy (fNIRS) to the Study of Neurodegenerative Disorders: A Narrative Review. Diagnostics, 2024, 14, 663.	2.6	0
5852	Ultrasensitive and Multiple Biomarker Discrimination for Alzheimer's Disease via Plasmonic & Microfluidic Sensing Technologies. Advanced Science, 0, , .	11.2	Ο
5853	The expectations and experiences of patients regarding the diagnostic workup at a specialized memory clinic: An interview study. Health Expectations, 2024, 27, .	2.6	0
5854	Correlation Between Prefrontal Functional Connectivity and the Degree of Cognitive Impairment in Alzheimer's Disease: A Functional Near-Infrared Spectroscopy Study. Journal of Alzheimer's Disease, 2024, 98, 1287-1300.	2.6	0
5855	Neurodegenerative und Demenzielle Erkrankungen. , 2024, , 667-682.		0
5856	The role of 123-I-MIBG cardiac scintigraphy in the differential diagnosis between dementia with Lewy bodies and Alzheimer's disease. Neurological Sciences, 0, , .	1.9	0
5857	Cortical lipid metabolic pathway alteration of early Alzheimer's disease and candidate drugs screen. European Journal of Medical Research, 2024, 29, .	2.2	0
5858	New horizons in the diagnosis and management of Alzheimer's Disease in older adults. Age and Ageing, 2024–53	1.6	0

#	Article	IF	CITATIONS
5859	Impact of Long-Term Dietary High Fat and Eicosapentaenoic Acid on Behavior and Hypothalamic-Pituitary-Adrenal Axis Activity in Amyloidogenic APPswe/PSEN1dE9 Mice. Neuroendocrinology, 0, , 1-24.	2.5	0
5860	Where Should I Draw the Line: PET-Driven, Data-Driven, or Manufacturer Cut-Off?. Journal of Alzheimer's Disease, 2024, 98, 957-967.	2.6	0